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Preface
This book documents the increased number of stem cell related research, basic and clinical
applications as well as views for the future. The book covers a wide range of issues related
to new developments and innovations in cell-based therapies containing basic and clinical
chapters from the respected authors involved in stem cell studies and research around the
world. It thereby complements and extends the basic coverage of stem cells such as immu‐
nogenetics, neuron replacement therapy, cover hematopoietic stem cells, issues related to
clinical problems, advanced HLA typing, alternative donor sources as well as gene therapy
that employs novel methods in this field. Clearly, the treatment of various malignancies and
biomedical engineering will depend heavily on stem cells, and this book is well positioned
to provide comprehensive coverage of these developments.
This book will be the the main source for clinical and preclinical publications for scientists
working toward cell transplantation therapies with the primary goal of replacing diseased
cells with donor cells of various organs and transplanting those cells close to the injured or
diseased target. With the increased number of publications related to stem cells and Cell
Transplantation, we felt it was important to take this opportunity to share these new develop‐
ments and innovations describing stem cell research in the cell transplantation field with our
world-wide readers.
Stem cells have a unique ability; they are able to self renew limitlessly allowing them to re‐
plenish themselves as well as other cells. Another ability of stem cells is that they are able to
differentiate to any cell type. A stem cell does not differentiate directly to a specialized cell,
however. There are often multiple intermediate stages. A stem cell will first differentiate to a
progenitor cell – a progenitor cell is similar to a stem cell, although they are limited in the
number of times they can replicate and they are also restricted in which cells they can fur‐
ther differentiate to. Serving as a sort of repair system for the body, they can theoretically
divide without limit to replenish other cells as long as the person or animal is still alive.
When a stem cell divides, each new cell has the potential to either remain a stem cell or be‐
come another type of cell with a more specialized function, such as a muscle cell, a red
blood cell or a brain cell.
During this last decade, the number of published articles or books investigating the role of
stem cells in cell transplantation or regenerative medicine increased remarkably across all
sections of the stem cell related journals. The largest number of stem cell articles was pub‐
lished mainly in the field of clinical transplantation, neuroscience, followed by the bone,
muscle, and cartilage and hepatocytes. Interestingly, in recent years, the number of stem cell
articles describing the potential use of stem cell therapy and islet transplantation in the dia‐
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divide without limit to replenish other cells as long as the person or animal is still alive.
When a stem cell divides, each new cell has the potential to either remain a stem cell or be‐
come another type of cell with a more specialized function, such as a muscle cell, a red
blood cell or a brain cell.
During this last decade, the number of published articles or books investigating the role of
stem cells in cell transplantation or regenerative medicine increased remarkably across all
sections of the stem cell related journals. The largest number of stem cell articles was pub‐
lished mainly in the field of clinical transplantation, neuroscience, followed by the bone,
muscle, and cartilage and hepatocytes. Interestingly, in recent years, the number of stem cell
articles describing the potential use of stem cell therapy and islet transplantation in the dia‐
betes has also slowly been increasing, even though this field of endeavor could have one of
the greatest clinical and societal impacts.
It will be exciting and interesting for our readers to follow the recent developments in the
field of basic and clinical aspects of stem cells and cell transplantation. Although we are
close to finding pathways for stem cell therapies in many medical conditions, scientists need
to be careful how they use stem cells ethically and should not rush into clinical trials with‐
out carefully investigating the side effects. Focus must be on Good Manufacturing Proce‐
dures (GMP) and careful monitoring of the long-term effects of transplanted stem cells in
the host.
In conclusion, Cell Transplantation is bridging cell transplantation research in a multitude of
disease models as methods and technology continue to be refined. The use of stem cells in
many therapeutic areas will bring hope to many patients awaiting replacement of malfunc‐
tioning organs or repair of damaged tissue. We hope that this book will be an important tool
and reference guide for all scientists worldwide who work in the field of stem cells and cell
transplantation, and that it will shed light upon many important debatable issues in this field.
I would like to thank all authors who contributed to this book with excellent and up-to-
date chapters relaying the recent developments to our readers in the field of stem cell trans‐
plantation. I would like to give a special thanks to Ana Pantar, Publishing Process Manager,
and all InTech staff for their valuable contribution in making this book available.
Taner DEMİRER, MD, FACP
Professor of Medicine, Hematology/Oncology
Dept. of Hematology
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Chapter 1
Immunogenetics of
Hematopoietic Stem Cell Transplantation
Amanda Vansan Marangon, Ana Maria Sell,
Daniela Maira Cardozo and Jeane E. L. Visentainer
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54281
1. Introduction
There are few hematopoietic stem cells (HSCs) in the bone marrow of adult mammals; these
are required throughout life to replenish the short-lived mature blood cells of specific hema‐
topoietic lineages. HSCs have several biological functions including homeostasis control, re‐
generation, immune function and response to microorganisms and inflammation.
The regenerative potential of human HSCs is best illustrated by successful stem cell trans‐
plantation in patients with a variety of genetic disorders, acquired states of bone marrow
failure and cancer [1].
The first bone marrow transplantation took place in 1949 with studies that demonstrated the
protection provided to the spleen of mice given a dose of irradiation that would otherwise
be lethal. In 1960, studies in dogs provided important information about bone marrow
transplantation in exogamic species, results that are applicable to humans. It was demon‐
strated that dogs could bear 2-3 times the lethal dose of total body irradiation with an infu‐
sion of bone marrow cells collected and cryopreserved before irradiation [2,3].
At the same time that animal experiments were being carried out, a number of attempts
were made to treat humans with chemotherapy or irradiation associated with bone mar‐
row infusions [4].
The first  successful  allogeneic bone marrow graft  was achieved in a patient with leuke‐
mia, although the patient died due to the complications of chronic graft-versus-host dis‐
ease (GVHD) [5].
© 2013 Vansan Marangon et al.; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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Currently, bone marrow transplantation is the treatment of choice for many hematologic
diseases with the course of transplant being dependent on several factors, including the
stage of the disease at transplant, the conditioning regimen, source of cells, genetic factors,
and the development of GVHD. The goal to this chapter is to show some genetic factors that
have a strong influence on hematopoietic stem cell transplantation (HSCT) outcomes, such
as the genes of the human leukocyte antigen (HLA) system located in the major histocom‐
patibility complex (MHC), and other genetic factors, including non-HLA genes that seem to
influence transplant outcomes and that are being studied to optimize donor selection. Non-
HLA genes mainly include killer cell immunoglobulin-like receptor (KIR) genes, cytokine
genes and receptors, MHC class I-related chain (MIC) genes and human minor histocompat‐
ibility antigens (mHAgs).
2. HLA immunogenetics and its influence on hematopoietic stem cell
transplantation
Histocompatibility
The immune system is the result of germline selection and thymic education (self vs. non-
self) through contact with pathogenic life and is thus a characteristic that is unique to each
individual and specific to a given point in time; like all other physiological systems, the im‐
mune system is affected by disease, stress, trauma and environmental events [6].
An important cell lineage within this system is represented by T lymphocytes. The main
functions of T lymphocytes are defense against intracellular microorganisms and the activa‐
tion of other cells including macrophages and B lymphocytes.
T lymphocytes are capable of interacting with other cells because the antigen receptors on T
cells recognize antigens that are presented by other cells; presentation is achieved by speci‐
alized proteins that are encoded by genes in a MHC locus [7]. The MHC system has the
greatest diversity of all functional genetic systems at the population level [6]. The MHC gly‐
coprotein family, also referred to as HLAs, presents endogenous and exogenous antigens to
T lymphocytes for recognition and response.
This system was discovered in mice by Peter Gorer and George Snell.  These researchers
discovered  an  antigen  which  was  involved  in  tumour  rejection  and  subsequently  they
showed that  similar  antigens in other strains of  mice were probably alleles  of  the same
“tumour-resistant” gene [8].
Experiments show that transplants of tissue between animals from the same population (en‐
dogamic) were successful, while the consequence of transplants between animals from dif‐
ferent populations (exogamous) was the rejection of tissue. The result of these studies was
the discovery of MHC genes which are capable of recognizing foreign antigens and present‐
ing them to T lymphocytes.
Antibodies induced by transfusions or pregnancy and which react with leukocyte antigens
were first recognized in 1954. Studies showed that kidney transplant patients who suffered
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rejection have circulating antibodies reactive to antigens present in leukocytes; as these anti‐
gens are expressed on leukocytes they were named HLAs [9,7].
Many studies were conducted over the next few years to understand and characterize the
immunogenicity of these antigens.
Structure and function
The MHC, contained within 4.2 Mbp of DNA on the short arm of chromosome 6 at 6p21.3,
has more than 200 genes, most of which have functions related to immunity. It is divided
into three main regions [10].
The HLA-A, -B and -C classic genes and -E, -F and -G non-classic genes, as well as other
genes and pseudogenes are located in the HLA Class I region near to the telomere. The HLA
Class II region, near to the centromere, contains the HLA-DR, -DQ and -DP genes. The
HLA-DR sub-region, includes the DRA gene that encodes the alpha chain is non-polymor‐
phic and can bind with any beta chain to encode for DRB genes [11].
Located between class I and II regions, the class III region has C2, C4A, C4B and B factor,
that encode complement proteins and the tumour necrosis factor (TNF) [10,11].
HLA molecules are polymorphic membrane glycoproteins found on the surface of nearly
all cells. Multiple genetic loci within the MHC encode these proteins with each individu‐
al  simultaneously  expressing  several  polymorphic  forms from a  large  pool  of  alleles  in
the  population.  The  overall  structure  of  HLA  class  I  and  class  II  molecules  is  similar,
with most of the polymorphisms found in the peptide binding groove (PBG) where anti‐
gens are recognized [12].
Class I molecules are made up of one heavy chain (45kD) encoded within the MHC and a
light chain called β2- microglobulin (12kD) whose gene is on chromosome 15. Class II mole‐
cules consist of one α (34kD) and one β chain (30kD) both within the MHC [10]
The class I heavy chain has three domains with the membrane-distal α1 and α2 domains be‐
ing polymorphic. Within these domains, polymorphisms concentrate in three regions: posi‐
tions 62 to 83, 92 to 121, and 135 to 157. These areas are called hypervariable regions. The
two polymorphic domains are encoded by exons 2 and 3 of the class I gene. Diversity in
these domains is very important because these two domains form the antigen binding cleft
or PBG of MHC class I molecules [13,14].
The sides of the antigen binding cleft are formed by α1 and α2, while the floor of the cleft is
comprised of eight anti-parallel β sheets. The antigenic peptides of eight to ten amino acids
(typically nonamers) bind to the cleft with low specificity but high stability. The α3 domain
contains a conserved seven amino acid loop (positions 223 to 229) which serves as a binding
site for CD8 [12,15-17].
Class II molecules consist of two transmembrane glycoproteins, the α and β chains which
are restricted to cells of the immune system (e.g. B cells, dendritic cells - DCs), but can be
induced by other cell types during immune response. The PBG of class II molecules has
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rejection have circulating antibodies reactive to antigens present in leukocytes; as these anti‐
gens are expressed on leukocytes they were named HLAs [9,7].
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immunogenicity of these antigens.
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all cells. Multiple genetic loci within the MHC encode these proteins with each individu‐
al  simultaneously  expressing  several  polymorphic  forms from a  large  pool  of  alleles  in
the  population.  The  overall  structure  of  HLA  class  I  and  class  II  molecules  is  similar,
with most of the polymorphisms found in the peptide binding groove (PBG) where anti‐
gens are recognized [12].
Class I molecules are made up of one heavy chain (45kD) encoded within the MHC and a
light chain called β2- microglobulin (12kD) whose gene is on chromosome 15. Class II mole‐
cules consist of one α (34kD) and one β chain (30kD) both within the MHC [10]
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open ends which allow the peptide to extend beyond the groove at both ends and therefore
to be longer (12-24 amino acids). The peptide is presented to CD4 T cells [10].
Generally both the α and β chains in class II molecules are polymorphic. In these chains, the
α1 and β1 domains are of the PBG and therefore the diversity is found mainly in these do‐
mains. These domains are encoded by exon 2 of their class II A or B genes and the hyper‐
variable regions tend to be found in the walls of the groove [16].
T-cell activation occurs following recognition of peptide/MHC complexes on an antigen-pre‐
senting cell (APC). T-cell activation can be viewed as a series of intertwined steps, ultimately
resulting in the ability to secrete cytokines, replicate and perform various effector functions.
During antigen presentation, CD4 and CD8 are intimately associated with the T-cell receptor
and bind to the MHC molecule. Besides this interaction between T cells and APCs, ligation
between counter-receptors on the T cell and accessory molecules on the APC is required as
additional signals for T-cell activation [18].
Haplotype, Linkage Disequilibrium and Expression of HLA genes
HLA genes are transmitted following Mendel’s  law of segregation,  so the allelic  variant
is codominantly expressed. The set of alleles present in the HLA loci located in a single
chromosome of  a  chromosome pair  is  called a  haplotype.  The probability  that  two sib‐
lings having the same HLA haplotype is 25%; in this situation, it is considered that they
are matching [11].
Moreover, a fact called linkage disequilibrium occurs in HLA genes. This means that certain
alleles occur together at a higher frequency than would normally be expected by chance (ga‐
metic association). Consequently, some combinations of alleles appear more or less com‐
monly in a population than would normally be expected from a random formation of
haplotypes from alleles based on their frequencies [10].
For example, if a determined population has genic frequencies of 14% and 9% for HLA-A*01
and HLA-B*08, respectively, the expected frequency of a haplotype with this combination
would be 1.26% (0.14 x 0.09). However, the true frequency may be 8.8% in this population,
that is, higher than expected, characterizing a positive linkage disequilibrium [11].
Examples can be seen in studies of linkage disequilibrium related to bone marrow donation.
A strong linkage disequilibrium has been reported for HLA-B*39:13 with the DRB1*04:02,
DRB1*08:07 and A*31:12 haplotypes in the Brazilian population [19].
Other  reports  for  unrelated  donors  involved  HLA-A*01  and  HLA-B*08,  HLA-A*03  and
HLA-B*35  and  HLA-A*02  and  HLA-B*12.  This  type  of  results  suggests  that  these  data
have clinical  application,  such as  in  the  selection of  unrelated donors  for  bone marrow
transplantation [20].
HLA compatibility of donors
The genetic origin of patients for whom bone marrow transplantation has been proposed, is
a key determinant in the possibility of identifying compatible unrelated and sibling donors
and consequently in the possibility of performing the procedure.
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The strict HLA compatibility that is required for bone marrow transplantation increases the
difficulties in finding donors. A patient has one chance in four of having a compatible donor
among his brothers and sisters. This chance becomes one in a million, on average, in unrelat‐
ed donors [21].
Different methods are used to identify HLA antigens. In the past, HLA antigens for bone
marrow transplantation were identified by serological  methods based in mixed lympho‐
cyte  culture.  However  this  technique  is  not  as  sensitive  as  molecular  biology  methods
which can define HLA antigens at the allele level.
In molecular analysis,  HLA genes can be identified by polymerase chain reaction (PCR)
using  the  Specific  Sequence  Primers  (SSP),  Specific  Sequence  Oligonucleotides  (SSO)  or
sequencing techniques. These methods are the most commonly used due to its specificity
and  sensibility  that  can  define  HLA  genes  only  (low  resolution)  or  genes  and  alleles
(high resolution).
These results are very important in bone marrow transplantation in order to choose the
best  matched  donor.  The  probability  of  finding  a  well-matched  unrelated  donor  is  im‐
proved if high resolution typing is available for the patient prior to the search. Therefore
typing must ideally be done by DNA methods to avoid hidden mismatches, particularly
in  the  case  of  antigenically  silent  alleles,  and  should  include  the  HLA-A,  -B,  -C  and  -
DRB1 genes at least [10].
Matched or mismatched donors
There are many studies which try to show that better outcomes in bone marrow transplanta‐
tion are linked to full donor matches. In 2004 the National Marrow Donor Program (NMDP)
published the results on the outcomes of 1874 unrelated donor transplants. This study
showed a highly significant survival advantage for 8/8 matched pairs compared to those
with one or two mismatches [22].
Moreover, the study of the Center for International Blood and Marrow Transplant Research
(CIBMTR) examined clinical outcomes in recipients of both sibling and unrelated donors for
chronic myeloid leukemia (CML) in the first chronic phase. There were 1052 recipients of
unrelated transplants; 531 were matched for 8/8 alleles, 252 mismatched for 1 (7/8) allele and
269 mismatched for multiple alleles [22]. The overall survival (OS) at 5 years was 55% for 8/8
matched transplant recipients, 40% for those with a 7/8 matched graft and 21-34% for those
with various multiple mismatched combinations. The recipients of stem cell matched related
donors, predominantly siblings, have lower risk of infections, of the reactivation of cytome‐
galovirus and of mortality than the latter group. Additionally, T-cell immunity reconstitu‐
tion is delayed in mismatched sibling donors and the unrelated group [23, 24].
Graft rejection, GVHD and delayed immune recovery, the major obstacles to successful allo‐
geneic HSCT, are more severe with unrelated donors than in HLA-identical sibling trans‐
plants. Because identical donors are available to only about 30% of patients, the
identification of a suitable unrelated donor by better, more precise HLA matching of donor
and recipient is necessary [25].
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Studies have shown strong negative effects of HLA mismatching of the HLA-A, -B, -C, -
DRB1 or -DQB1 loci on OS. The presence of multiple mismatches was worse for survival
and for severe acute GVHD (grade III-IV). Other trials analyzed the incidence of chronic
GVHD in patients who survived more than 100 days after transplantation. It became evident
that a HLA-A/B mismatch induces a significantly higher incidence of chronic GVHD and
lower OS rate. The same was not confirmed for a HLA-DQ/DR mismatch that showed no
association with the occurrence of chronic GVHD [25;26].
High resolution HLA typing can help in the characterization of donors; there are differences
in the outcomes of bone marrow transplantation if the mismatching of donors was defined
by low or high resolution. Studies show that high resolution matching of HLA-A, -B, -C and
-DRB1 between volunteer HSC donors and recipients is associated with a better survival.
Additionally, single HLA-B and -C mismatches appear to be better tolerated than single
HLA-A or -DRB1 mismatches [27].
Other studies affirm that survival after unrelated HSCT for severe acquired aplastic anemia
has improved significantly over the last 15 years mainly due to better HLA matching at the
allelic level [28].
HLA and bone marrow transplantation
The outcome of transplantation using unrelated donors is highly influenced by HLA match‐
ing between the donor and recipient. Two particular individuals always differ in their ge‐
nome structure in respect to minor histocompatibility antigens, killer cell immunoglobulin-
like receptor (KIR) genes and several other groups of genes.
However, the most potent transplantation antigens are the HLAs encoded by genes located
in the MHC. HLA-C is a class I gene locus, yet its importance in transplantation has been
less validated than the HLA-A and B loci [10].
However, studies that analyzed structure and peptide-binding for HLA-C, show that diver‐
gence in peptide-binding specificity may be a contributor to the risk of mortality after trans‐
plantation perhaps due to the alloreactivity of donor T cells towards peptides presented by
patient HLA molecules but not by donor antigens presenting cells during T-cell develop‐
ment in the thymus [29].
There are two main reasons for the HLA antibodies to result in graft failure and GVHD. The
first is the rapid increase in the number of HLA-mismatched HSCT, including in cord blood
transplantation, haploidentical HSCT and unrelated HSCT. The second is the technical ad‐
vance in the methods of HLA Ab testing, which have attained a rapid, accurate and objec‐
tive identification and qualification of specific HLA antibodies [30].
HLA, sibling and unrelated hematopoietic stem cell transplantation
Matched or mismatched
The use of stem cells from HLA-matched unrelated volunteer donors is an accepted option
for patients without a matching sibling donor providing comparable outcomes to matched
sibling donor HSCT. Many studies have been performed to compare the results between sib‐
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ling and unrelated transplantation. Other studies show single results about sibling and un‐
related transplantation, the importance of HLA compatibility and what effect HLA
mismatches may have on GVHD, graft failure and relapse.
Research has shown that HLA class II  DRB1*15 (*15:01 and *15:02) are important in the
outcome to sibling matched transplants for patients who have aplastic anemia. In multi‐
variate analysis, the secondary graft failure rate at two years was lower in patients who
were HLA-DR15+[31].
Recent studies in a Chinese population show that the outcome of unrelated donor transplan‐
tation matched for HLA-A, HLA-B and HLA-DRB1 but unknown for HLA-C antigens was
associated with a significant risk of mortality and that this risk was higher with HLA-A, B or
DRB1 mismatches compared to an 8/8 match [32].
Other studies confirm that there is no association between HLA mismatching of unrelated
donors with the cumulative incidence of grade II-IV or grade III-IV acute GVHD. Similarly,
there was no association with chronic GVHD, but the incidence of graft failure was higher in
HLA-mismatched unrelated transplants [33]. Trials highlight the importance of defining
HLA by high resolution techniques to improve the outcomes in pediatric transplants using
unrelated donors. The patients that suffered graft failure were mismatched for HLA-C by a
high resolution technique [34].
However, studies show that in unrelated transplantations, the outcome is improved when
the patients are HLA-C and HLA-DPB1 mismatched in some combinations, thus resulting in
lower risk of relapse. Probably some combinations increase the graft-versus-leukemia (GvL)
effect [35].
One study analyzed the impact  of  HLA class  I  and II  high-resolution matching of  1874
unrelated donors and found that HLA-C mismatching was most strongly associated with
graft  failure,  HLA-A  mismatching  was  associated  with  significantly  increased  risk  of
grade III/IV acute and chronic GVHD and mismatches of HLA-A, B, C and DR were as‐
sociated with death [36].
HLA and Haploidentical HSCT
When no matched sibling or unrelated donor exists, the potential curative option is haplo-
HSCT, that is, transplant with a donor who shares only one haplotype with the recipient.
Haploidentical stem cell transplants are increasingly used in the treatment of malignancies,
and immune and hematologic diseases. As multiple mismatched related donors may be
available for transplantation, it is important to select a donor that is most likely to produce a
successful outcome [37].
There are studies that correlate the HLA-B mismatch effect in haplo-HSCT. Studies analyzed
the impact of HLA-A, -B, -DRB1, -DRB3, -DRB4 and -DRB5 and demonstrated that a HLA-B
mismatch not only has a significant effect on GVHD and transplant-related mortality but
was also associated with reduced OS and leukemia-free-survival [38].
There is an important point in haploidentical transplants that should be considered: the con‐
ditioning regimen. Many protocols have been performed to improve the outcomes of trans‐
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plantation and to minimize the effect of HLA incompatibility. For example, studies on
nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose post-
transplant cyclophosphamide. The results showed that HLA mismatch was not associated
with relapse or GVHD [39].
In bone marrow transplantation with mismatch of the HLA-DRB1 antigen in the GVHD di‐
rection and two or more HLA Class I (HLA-A, -B and -Cw) mismatches in either direction
were found to be associated with decreased incidences of relapse without an increased inci‐
dence in nonmyeloablative conditioning with post-transplant cyclophosphamide [40].
HLA and cord blood transplantation
The use of umbilical cord blood transplantation (UCBT) for patients with hematological ma‐
lignances or hereditary diseases is becoming increasingly more common. In October 2006,
the International NETCORD Foundation maintained an inventory of more than 124,000 um‐
bilical cord blood (UCB) units and documented more than 4900 unrelated UCBT [41]. Sever‐
al studies have shown that the number of cells is the most important factor for engraftment,
while some degree of HLA mismatch is acceptable.
For example, studies show that unrelated UCBT is comparable to a 1-antigen mismatch at
the HLA-A, HLA-B or HLA-DR loci in respect to GVHD, relapse and OS [42]. For other
studies on UCBT, HLA-A and -B are defined by low-resolution and HLA-DRB1 by high-res‐
olution, with minimum compatibility of 4/6. It is important to apply the rules of equivalence
of serological groups for HLA-B*14, -B*15, -B*40, and -B*50 as determined by molecular
methods [43].
Clinical comparison studies of UCBT and HLA-A, -B and -DRB1 6/6 allele-matched bone
marrow transplantation or single mismatched for leukemia from unrelated donors in adult
recipients showed similar results. There was no significant increase of relapse rates among
UCB recipients when compared with DRB1 single-mismatched bone marrow recipients. The
OS for UCB recipients was similar too when compared with DRB1 single-mismatched bone
marrow recipients [44].
Korean pediatric studies also show that the results of UCBT are promising. One study com‐
pared the outcomes of acute leukemia children submitted to transplantation using UCB,
bone marrow and peripheral blood stem cells from HLA-matched or unrelated donors. The
results confirm that survival after UCBT was similar to survival after matched related donor
and unrelated donor transplantations. In conclusion, for patients lacking an HLA matched
donor, the use of UCB is a suitable alternative [45].
Additionally,  studies  show  that  recipients  of  UCB  transplants  from  HLA-identical  sib‐
lings have lower incidences of acute and chronic GVHD than recipients of bone marrow
transplants  from HLA-identical  siblings [46].  Hence,  studies  on the distribution of  HLA
alleles and haplotypes in different ethnic populations are also important to find a suita‐
ble unrelated cord blood donor for  a patient.  One study investigated the frequencies of
alleles and HLA-A, -B and -DRB1 haplotypes with high-resolution typing data in a total
of  710  Taiwanese  UCB  units  [47].  The  most  common  alleles  found  for  HLA-A  were
Innovations in Stem Cell Transplantation10
A*11:01,  A*24:02,  A*33:03  and  A*02:01;  for  HLA-B  they  were  B*40:01,  B*46:01,  B*58:01
and  B*13:01  and  for  DRB1  they  were  DRB1*09:01,  DRB1*12:02,  DRB1*15:01  and
DRB1*03:01. Moreover, the five most frequently found haplotypes were A*11:01, B*35:05,
DRB1*11:02; A*24:07, B*35:05, DRB1*12:02; A*01:01, B*5701, DRB1*09:01; A*11:01, B*40:01,
DRB1*09:01  and A*11:01,  B*46:01,  DRB1*09:01.  These  haplotypes  are  common in  Taiwa‐
nese and Asian American populations [47].
Ethnic studies carried out in London showed that the most common alleles in 1500 UCB
units were HLA-A*34, A*36, A*80, HLA-B*75, B*61, B*53, B*78, B*81 and B*82. This kind of
study should help to increase the chances of obtaining acceptably HLA-matched donors for
patients from ethnic minorities [48].
3. Non-HLA immunogenetics and its influence on hematopoietic stem
cell transplantation
Natural killer cells and Killer immunoglobulin-like receptors
Human natural killer (NK) cells are components of the innate immune response that com‐
prise approximately 10-15% of all peripheral blood lymphocytes and play a major role in im‐
munity against viral infections and tumors [49-51]. Years of intensive research in mice and
humans have shown a special importance of NK cells in the hematological diseases and in
mediating favorable HSCT outcomes [52-57]. NK cells were first identified by their in vitro
capacity to kill tumor cells without the requirement of prior immune sensitization of the
host [58-59].
The function of NK cells is regulated by a diverse array of cell-surface receptors includ‐
ing KIR,  NKG2D and DNAM-1.  The KIR receptors,  in  the setting of  HSCT,  seem to be
the most important NK cell receptor family. These receptors can either inhibit or activate
NK cells with the difference between inhibitory and activating KIRs lying mainly in their
intracytoplasmic tail.  Inhibitory KIRs have long cytoplasmic tails  (KIR-L)  and activating
KIRs  have  short  cytoplasmic  tails  (KIR-S)  with  KIRs  having  two  or  three  Ig-domains
(KIR2D or KIR3D) [60-61].
In humans, the gene family encoding the KIR is located in the leukocyte receptor complex
(LRC) on chromosome 19q13.4. To date, 15 genes have been well characterized, of which 9
are NK cell inhibitors (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B,
KIR3DL1, KIR3DL2 and KIR3DL3), 6 are activating (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4,
KIR2DS5 and KIR3DS1), and 2 are pseudogenes (KIR2DP1 and KIR3DP1) [60-61]. An excep‐
tion is KIR2DL4 that although it has long tail it has an amino acid in the transmembrane re‐
gion that allows an association with an accessory protein, FceRI-g, which confers an
activating signal [62].
Individuals differ in the number and type of inherited KIR genes and the KIR haplotypes are
divided into two groups, A and B. The A or AA haplotype has a fixed number of genes, all
of which are inhibitory except for one activating gene (KIR2DS4). Haplotypes with addition‐
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plantation and to minimize the effect of HLA incompatibility. For example, studies on
nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose post-
transplant cyclophosphamide. The results showed that HLA mismatch was not associated
with relapse or GVHD [39].
In bone marrow transplantation with mismatch of the HLA-DRB1 antigen in the GVHD di‐
rection and two or more HLA Class I (HLA-A, -B and -Cw) mismatches in either direction
were found to be associated with decreased incidences of relapse without an increased inci‐
dence in nonmyeloablative conditioning with post-transplant cyclophosphamide [40].
HLA and cord blood transplantation
The use of umbilical cord blood transplantation (UCBT) for patients with hematological ma‐
lignances or hereditary diseases is becoming increasingly more common. In October 2006,
the International NETCORD Foundation maintained an inventory of more than 124,000 um‐
bilical cord blood (UCB) units and documented more than 4900 unrelated UCBT [41]. Sever‐
al studies have shown that the number of cells is the most important factor for engraftment,
while some degree of HLA mismatch is acceptable.
For example, studies show that unrelated UCBT is comparable to a 1-antigen mismatch at
the HLA-A, HLA-B or HLA-DR loci in respect to GVHD, relapse and OS [42]. For other
studies on UCBT, HLA-A and -B are defined by low-resolution and HLA-DRB1 by high-res‐
olution, with minimum compatibility of 4/6. It is important to apply the rules of equivalence
of serological groups for HLA-B*14, -B*15, -B*40, and -B*50 as determined by molecular
methods [43].
Clinical comparison studies of UCBT and HLA-A, -B and -DRB1 6/6 allele-matched bone
marrow transplantation or single mismatched for leukemia from unrelated donors in adult
recipients showed similar results. There was no significant increase of relapse rates among
UCB recipients when compared with DRB1 single-mismatched bone marrow recipients. The
OS for UCB recipients was similar too when compared with DRB1 single-mismatched bone
marrow recipients [44].
Korean pediatric studies also show that the results of UCBT are promising. One study com‐
pared the outcomes of acute leukemia children submitted to transplantation using UCB,
bone marrow and peripheral blood stem cells from HLA-matched or unrelated donors. The
results confirm that survival after UCBT was similar to survival after matched related donor
and unrelated donor transplantations. In conclusion, for patients lacking an HLA matched
donor, the use of UCB is a suitable alternative [45].
Additionally,  studies  show  that  recipients  of  UCB  transplants  from  HLA-identical  sib‐
lings have lower incidences of acute and chronic GVHD than recipients of bone marrow
transplants  from HLA-identical  siblings [46].  Hence,  studies  on the distribution of  HLA
alleles and haplotypes in different ethnic populations are also important to find a suita‐
ble unrelated cord blood donor for  a patient.  One study investigated the frequencies of
alleles and HLA-A, -B and -DRB1 haplotypes with high-resolution typing data in a total
of  710  Taiwanese  UCB  units  [47].  The  most  common  alleles  found  for  HLA-A  were
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prise approximately 10-15% of all peripheral blood lymphocytes and play a major role in im‐
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humans have shown a special importance of NK cells in the hematological diseases and in
mediating favorable HSCT outcomes [52-57]. NK cells were first identified by their in vitro
capacity to kill tumor cells without the requirement of prior immune sensitization of the
host [58-59].
The function of NK cells is regulated by a diverse array of cell-surface receptors includ‐
ing KIR,  NKG2D and DNAM-1.  The KIR receptors,  in  the setting of  HSCT,  seem to be
the most important NK cell receptor family. These receptors can either inhibit or activate
NK cells with the difference between inhibitory and activating KIRs lying mainly in their
intracytoplasmic tail.  Inhibitory KIRs have long cytoplasmic tails  (KIR-L)  and activating
KIRs  have  short  cytoplasmic  tails  (KIR-S)  with  KIRs  having  two  or  three  Ig-domains
(KIR2D or KIR3D) [60-61].
In humans, the gene family encoding the KIR is located in the leukocyte receptor complex
(LRC) on chromosome 19q13.4. To date, 15 genes have been well characterized, of which 9
are NK cell inhibitors (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B,
KIR3DL1, KIR3DL2 and KIR3DL3), 6 are activating (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4,
KIR2DS5 and KIR3DS1), and 2 are pseudogenes (KIR2DP1 and KIR3DP1) [60-61]. An excep‐
tion is KIR2DL4 that although it has long tail it has an amino acid in the transmembrane re‐
gion that allows an association with an accessory protein, FceRI-g, which confers an
activating signal [62].
Individuals differ in the number and type of inherited KIR genes and the KIR haplotypes are
divided into two groups, A and B. The A or AA haplotype has a fixed number of genes, all
of which are inhibitory except for one activating gene (KIR2DS4). Haplotypes with addition‐
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al activating KIR genes (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, KIR3DS1) or with KIR2DL5
are either AB or BB and are grouped together as KIR Bx haplotypes. Often, the KIR2DS4
gene is present in a deleted form and is not believed to be expressed at the cell surface. The
“framework genes”, KIR3DL2, KIR3DP1, KIR2DL4, and KIR3DL3, are common to both
groups of haplotypes [60-61, 63].
The KIRs interact with some HLA class I antigens on target cells. HLA-Bw4 and distinct al‐
lotypes of HLA-C (C1 and C2 groups) are the main ligands for most KIRs [64]. HLA-C al‐
leles are classified as C1 or C2 KIR ligand groups, depending on two amino acid positions
encoded in exon 2. HLA-C1 allotypes have serine at position 77 and asparagine at position
80 and are ligands for the KIR2DL2 and KIR2DL3 inhibitory receptors. HLA-C2 allotypes
have asparagine and lysine at positions 77 and 80, respectively and are ligands for the
KIR2DL1 inhibitory receptor and thought to be the ligand for the KIR2DS1 activating recep‐
tor [65-66]. HLA-Bw4 allotypes are characterized by at least 5 different patterns of amino
acids at positions 77 and 80-83 and are ligands for KIR3DL1. Some HLA-A alleles, namely
23:01, 24:02 and 32:01, are also ligands for KIR3DL1 [67-71]. In addition, HLA-A3 and HLA-
A11 are ligands for KIR3DL2; and HLA-A11 and some C1 and C2 allotypes are ligands for
KIR2DS4 [64, 72-74].The KIR gene and respective ligands are listed in Table 1.
KIR FUNCTION LIGAND
KIR2DL1 Inhibitory HLA-C group 2
KIR2DL2 Inhibitory HLA-C group 1
KIR2DL3 Inhibitory HLA-C group 1
KIR2DL4 Inhibitory, activating HLA-G
KIR2DL5 Inhibitory Unknown
KIR3DL1 Inhibitory HLA-B Bw4 and some HLA-A Bw4*
KIR3DL2 Inhibitory HLA-A3 and HLA-A11
KIR2DS1 Activating HLA-C group 2
KIR2DS2 Activating Unknown
KIR2DS3 Activating Unknown
KIR2DS4 Activating HLA-A11 and subsets of HLA-C group 1 and group 2
KIR2DS5 Activating Unknown
KIR3DS1 Activating Unknown
* HLA-A*23:01, HLA-A*24:02 and HLA-A*32:01
Table 1. KIR receptors and their HLA ligands
The mechanism of recognition of a target cell by NK cells differs from others lymphocytes.
[59] The NK cells are able to recognize a reduction or absence of self HLA class I ligands, as
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a form of distinguishing normal cells from target cells: this is the “missing-self recognition”.
It is well established that cancer cells and some infected cells develop various mechanisms
to escape lysis by T cells [75-76]. An effective mechanism is to decrease or remove complete‐
ly the HLA expression. The downregulation of HLA class I expression leads to resistance to
lysis by T lymphocytes but, as a consequence, can lead to a susceptibility to lysis by NK cells
[77-80]. During development, NK cells become licensed or educated by interaction with self-
HLA molecules to maintain tolerance to normal tissues. NK cells that do not express inhibi‐
tory receptors for self are retained in an anergic or hypofunctional state and those which
express inhibitory KIRs for self-HLA ligands are functionally active and thus can sense the
lack of expression of self HLA molecules on target cells which triggers lysis of these cells.
This is thought to be the main mode of action of NK cells [81-86].
Natural killer cell alloreactivity in hematopoietic stem cell transplantation
The clinical significance of missing-self recognition is especially evident in allogeneic HSCT.
In HSCT the NK cell alloreactivity is determined by an analysis of the donor’s KIR gene pro‐
file and by differences in MHC class I genes between the donor and the recipient. This can
be better explained by the presence in the donor of NK cells expressing inhibitory KIRs that
are not engaged by any of the HLA class I alleles present on the receptor [87]. As a conse‐
quence, donor NK cells become uninhibited and may display alloreactivity against mis‐
matched allogeneic targets [81-86].
Furthermore, NK cells are relevant in the setting of HSCT because they are the first lym‐
phoid cell subset to reconstitute after transplantation at a time when the adaptive immune
system is impaired. They have been detected in vivo in recipients within 1 to 3 months after
transplantation and up to 3 years after [88-91].
KIR model studies
Considering: 1) a strong correlation between the presence of KIR genes and their HLA li‐
gands and cytotoxicity and 2) the advent of methods of precise genetic characterization, it is
possible to determine the contributions of the various inhibitory and activating KIR genes in
HSCT [92]. There are several models to define NK alloreactivity by KIR incompatibility or
KIR mismatching, most of which are based on the analysis of KIR and HLA class I alleles. In
the ligand-ligand model, the KIR expression is assumed following HLA typing. In this mod‐
el, KIR ligands in recipients and donors are analyzed and at least one group of donor KIR
ligands must to be absent in the recipient’s KIR ligand repertoire. In the receptor-ligand
model, the KIR genes are typed for the donor and the HLA alleles are analyzed for recipi‐
ents and at least one of the inhibitory KIRs of the donor is not engaged in the recipient’s li‐
gand repertoire. Moreover some studies perform phenotypic analysis of inhibitory KIRs and
CD94/NKG2A in donor NK cells and also functional assays which can provide more infor‐
mation about the degree of alloreactivity of NK cells [87,93-94]. It is difficult to know which
model is the most adequate to select the KIR mismatch donor. Some authors suggest that an
increasing number of receptor-ligand mismatch pairs increase the potency of the anti-leuke‐
mia effect and also suggest that the receptor-ligand model could improve the accuracy of the
prediction of relapse rather than the ligand-ligand model in patients with lymphoid malig‐
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al activating KIR genes (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, KIR3DS1) or with KIR2DL5
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gene is present in a deleted form and is not believed to be expressed at the cell surface. The
“framework genes”, KIR3DL2, KIR3DP1, KIR2DL4, and KIR3DL3, are common to both
groups of haplotypes [60-61, 63].
The KIRs interact with some HLA class I antigens on target cells. HLA-Bw4 and distinct al‐
lotypes of HLA-C (C1 and C2 groups) are the main ligands for most KIRs [64]. HLA-C al‐
leles are classified as C1 or C2 KIR ligand groups, depending on two amino acid positions
encoded in exon 2. HLA-C1 allotypes have serine at position 77 and asparagine at position
80 and are ligands for the KIR2DL2 and KIR2DL3 inhibitory receptors. HLA-C2 allotypes
have asparagine and lysine at positions 77 and 80, respectively and are ligands for the
KIR2DL1 inhibitory receptor and thought to be the ligand for the KIR2DS1 activating recep‐
tor [65-66]. HLA-Bw4 allotypes are characterized by at least 5 different patterns of amino
acids at positions 77 and 80-83 and are ligands for KIR3DL1. Some HLA-A alleles, namely
23:01, 24:02 and 32:01, are also ligands for KIR3DL1 [67-71]. In addition, HLA-A3 and HLA-
A11 are ligands for KIR3DL2; and HLA-A11 and some C1 and C2 allotypes are ligands for
KIR2DS4 [64, 72-74].The KIR gene and respective ligands are listed in Table 1.
KIR FUNCTION LIGAND
KIR2DL1 Inhibitory HLA-C group 2
KIR2DL2 Inhibitory HLA-C group 1
KIR2DL3 Inhibitory HLA-C group 1
KIR2DL4 Inhibitory, activating HLA-G
KIR2DL5 Inhibitory Unknown
KIR3DL1 Inhibitory HLA-B Bw4 and some HLA-A Bw4*
KIR3DL2 Inhibitory HLA-A3 and HLA-A11
KIR2DS1 Activating HLA-C group 2
KIR2DS2 Activating Unknown
KIR2DS3 Activating Unknown
KIR2DS4 Activating HLA-A11 and subsets of HLA-C group 1 and group 2
KIR2DS5 Activating Unknown
KIR3DS1 Activating Unknown
* HLA-A*23:01, HLA-A*24:02 and HLA-A*32:01
Table 1. KIR receptors and their HLA ligands
The mechanism of recognition of a target cell by NK cells differs from others lymphocytes.
[59] The NK cells are able to recognize a reduction or absence of self HLA class I ligands, as
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a form of distinguishing normal cells from target cells: this is the “missing-self recognition”.
It is well established that cancer cells and some infected cells develop various mechanisms
to escape lysis by T cells [75-76]. An effective mechanism is to decrease or remove complete‐
ly the HLA expression. The downregulation of HLA class I expression leads to resistance to
lysis by T lymphocytes but, as a consequence, can lead to a susceptibility to lysis by NK cells
[77-80]. During development, NK cells become licensed or educated by interaction with self-
HLA molecules to maintain tolerance to normal tissues. NK cells that do not express inhibi‐
tory receptors for self are retained in an anergic or hypofunctional state and those which
express inhibitory KIRs for self-HLA ligands are functionally active and thus can sense the
lack of expression of self HLA molecules on target cells which triggers lysis of these cells.
This is thought to be the main mode of action of NK cells [81-86].
Natural killer cell alloreactivity in hematopoietic stem cell transplantation
The clinical significance of missing-self recognition is especially evident in allogeneic HSCT.
In HSCT the NK cell alloreactivity is determined by an analysis of the donor’s KIR gene pro‐
file and by differences in MHC class I genes between the donor and the recipient. This can
be better explained by the presence in the donor of NK cells expressing inhibitory KIRs that
are not engaged by any of the HLA class I alleles present on the receptor [87]. As a conse‐
quence, donor NK cells become uninhibited and may display alloreactivity against mis‐
matched allogeneic targets [81-86].
Furthermore, NK cells are relevant in the setting of HSCT because they are the first lym‐
phoid cell subset to reconstitute after transplantation at a time when the adaptive immune
system is impaired. They have been detected in vivo in recipients within 1 to 3 months after
transplantation and up to 3 years after [88-91].
KIR model studies
Considering: 1) a strong correlation between the presence of KIR genes and their HLA li‐
gands and cytotoxicity and 2) the advent of methods of precise genetic characterization, it is
possible to determine the contributions of the various inhibitory and activating KIR genes in
HSCT [92]. There are several models to define NK alloreactivity by KIR incompatibility or
KIR mismatching, most of which are based on the analysis of KIR and HLA class I alleles. In
the ligand-ligand model, the KIR expression is assumed following HLA typing. In this mod‐
el, KIR ligands in recipients and donors are analyzed and at least one group of donor KIR
ligands must to be absent in the recipient’s KIR ligand repertoire. In the receptor-ligand
model, the KIR genes are typed for the donor and the HLA alleles are analyzed for recipi‐
ents and at least one of the inhibitory KIRs of the donor is not engaged in the recipient’s li‐
gand repertoire. Moreover some studies perform phenotypic analysis of inhibitory KIRs and
CD94/NKG2A in donor NK cells and also functional assays which can provide more infor‐
mation about the degree of alloreactivity of NK cells [87,93-94]. It is difficult to know which
model is the most adequate to select the KIR mismatch donor. Some authors suggest that an
increasing number of receptor-ligand mismatch pairs increase the potency of the anti-leuke‐
mia effect and also suggest that the receptor-ligand model could improve the accuracy of the
prediction of relapse rather than the ligand-ligand model in patients with lymphoid malig‐
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nancies [94]. However, it has not been well established and further studies are needed to
confirm this hypothesis.
In addition, a novel observation emerged that NK cells of maternal donors of HSCT provid‐
ed better protection from leukemia relapse than other related donors [95]. According to the
authors, the better outcome of mother-to-child transplantation may be the result of the con‐
tact of maternal immune cells with the semi-allogeneic placenta during pregnancy. It was
suggested that if further studies confirm the better outcomes of mother donors, it may be
incorporated as a donor selection criterion.
Another interesting aspect was shown in a recent study with patients that received unrelat‐
ed unmanipulated peripheral blood progenitor cells. The authors indicate that four-digit al‐
lele matching of HLA-C may have effects on the HSCT outcome dependent on the presence
of C1 and C2 KIR epitopes in the patients [96] suggesting the importance of analysis of
HLA-C at allele level for donor selection. While there are no common rules to select the best
donor according KIR compatibilities, all the findings must be analyzed.
KIR genes and haploidentical hematopoietic stem cell transplantation
Full-haplotype mismatched (haploidentical) HSCT is an option to treat patients lacking a
matched donor or a suitable UCB unit. In haploidentical HSCT (haplo-HSCT), the T cells
present  on  allogeneic  hematopoietic  grafts  are  important  to  promote  engraftment  and
mediate the GvL effect.  However,  they can also mediate GVHD [97-98].  These T-cell  re‐
sponses can be controlled by an appropriate intensity of immunosuppression by the con‐
ditioning  regimen.  The  T-cell  depletion  of  the  graft  help  prevent  GVHD  but,  as  a
consequence,  T-cell  depleted haplo-HSCT increases the risk of  graft  rejection and leuke‐
mic relapse.  In this  context,  the presence of  NK cell  alloreactivity in the GVH direction
seems to influence the prevention of leukemia relapse and has been investigated in sev‐
eral  preclinical  and  clinical  trials  [89,99-100].  It  has  been  observed  that  KIR-HLA  mis‐
matches  can  promote  clinical  benefits  in  haplo-HSCT  especially  in  patients  with  acute
myeloid leukemia (AML). In the first studies published by Ruggeri et al. [89,99] and the
more recent updates in 2007 [100] appropriate KIR-Ligand incompatibilities were associ‐
ated with a reduction in the risk of relapse of leukemia and graft rejection, and also pro‐
tection  against  GVHD  in  patients  with  AML.  These  results  were  supported  by  animal
models, in which the presence of NK alloreactivity was suggestive of a low incidence of
acute GVHD due to the killing of host APCs, which are critical for inducing donor T-cell
activation [101].  Similarly,  experimental  data  suggest  that  the  engraftment  rate  was  im‐
proved as a result of the lysis of residual host T lymphocytes by alloreactive donor NK
cells  [89,99,101-102]  and also  that  this  contributed  to  the  eradication  of  leukemia  blasts
that escaped from the conditioning regimen. These studies showed very good results and
led to a novel concept of mismatch to search for a transplant donor.  Since then, several
investigations based on KIR mismatching have been carried out with different outcomes.
In a study of patients that received haplo-HSCT with T-cell depletion [94] KIR incompatibili‐
ty (KIR-mismatch) was related to lower relapse rates in children with AML and also in chil‐
dren with acute lymphoid leukemia (ALL). Interesting, in the studies of Ruggeri et al.,
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patients with ALL were not susceptible to KIR-ligand mismatched haplo-HSCT. The differ‐
ent result in these two groups may be related to the fact that Ruggeri et al. studied only
adult patients. On the other hand, another recent study found no impact of KIR mismatch
on children with chemoresistant ALL that received T-cell depleted Haplo-HSCT [103]. In
general, NK cell alloreactivity seems to positively influence patients with myeloid malignan‐
cies and may benefit childhood ALL patients, but further studies are needed to confirm this.
A positive effect of NK cells on the outcome of haplo-HSCT in paedriatic patients was dem‐
onstrated in another study. The authors analyzed 21 children with different hematologic
malignances and found anti-leukemia activity of alloreactive NK cells in most transplanted
patients. They found that the NK cells derived from the donor were capable to selectively
killing C1/C1 target cells, including the patient’s leukemia blasts. Additionally, KIR2DL2/3+
NK cells that co-expressed KIR2DS1 killed C2/C2 leukemic blasts. These data suggest that
the presence of KIR2DS1 in alloreactive NK cells may mediate potent cytotoxicity [91]. In
agreement, in another study, the KIR2DS1 expression in alloreactive NK cells conferred an
advantage in the ability of NK cells to kill C2/C2 or C1/C2 myelomonocytic DCs and T-cell
blasts [104]. Another recent study examined 86 patients with advanced hematologic malig‐
nancies who received nonmyeloablative, HLA-haploidentical HSCT with high-dose, post-
transplantation cyclophosphamide. The inhibitory KIR gene mismatches between donor and
recipient, or KIR haplotype AA transplant recipients of KIR genotype Bx donors, were asso‐
ciated with lower relapse and non-relapse mortality (NRM) and improved OS and event-
free survival [105].
Nevertheless, other studies failed in find any association with KIR incompatibilities in the
GVHD direction [106], or found worse outcomes of transplantation for donors with the po‐
tential to NK alloreactivity [107]. Using the ligand-ligand model in a study of 62 patients
with ALL, AML and CML, the KIR mismatch was associated to considerably lower OS and a
higher incidence of GVHD [107].
KIR genes and unrelated hematopoietic stem cell transplantation
The impact of KIR-ligand mismatching in HSCT using unrelated donors has been associated
with controversial results. Beneficial outcomes have been shown in some studies. Unrelated
HSCT KIR-ligand incompatibility was associated with a reduced incidence of grade III-IV
acute GVHD and a better OS and disease free survival (DFS) in an analysis of 130 patients with
different  hematological  malignances.  The  conditioning  regimen included  anti-thymocyte
globulin (ATG) for T-cell depletion and the association with DFS remained significant even
when patients with myeloid diseases were analyzed separately [108]. KIR-HLA incompatibili‐
ties were also associated with low rates of leukemic relapse in a study of 374 patients with mye‐
loid malignances submitted to T-cell replete unrelated HSCT [109]. In this study, in spite of this
beneficial result, the rates of graft failure were higher and there were no significant differences
in DFS or transplant-related mortality. A large study described an advantage of donor NK al‐
loreactivity; the authors analyzed 1770 patients of several centers and found that the absence of
HLA-C2 or HLA-Bw4 ligands but not mismatches were associated with a decreased risk of re‐
lapse in recipients receiving unmanipulated grafts from unrelated donors [110].
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nancies [94]. However, it has not been well established and further studies are needed to
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In addition, a novel observation emerged that NK cells of maternal donors of HSCT provid‐
ed better protection from leukemia relapse than other related donors [95]. According to the
authors, the better outcome of mother-to-child transplantation may be the result of the con‐
tact of maternal immune cells with the semi-allogeneic placenta during pregnancy. It was
suggested that if further studies confirm the better outcomes of mother donors, it may be
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ed unmanipulated peripheral blood progenitor cells. The authors indicate that four-digit al‐
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mediate the GvL effect.  However,  they can also mediate GVHD [97-98].  These T-cell  re‐
sponses can be controlled by an appropriate intensity of immunosuppression by the con‐
ditioning  regimen.  The  T-cell  depletion  of  the  graft  help  prevent  GVHD  but,  as  a
consequence,  T-cell  depleted haplo-HSCT increases the risk of  graft  rejection and leuke‐
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Innovations in Stem Cell Transplantation14
patients with ALL were not susceptible to KIR-ligand mismatched haplo-HSCT. The differ‐
ent result in these two groups may be related to the fact that Ruggeri et al. studied only
adult patients. On the other hand, another recent study found no impact of KIR mismatch
on children with chemoresistant ALL that received T-cell depleted Haplo-HSCT [103]. In
general, NK cell alloreactivity seems to positively influence patients with myeloid malignan‐
cies and may benefit childhood ALL patients, but further studies are needed to confirm this.
A positive effect of NK cells on the outcome of haplo-HSCT in paedriatic patients was dem‐
onstrated in another study. The authors analyzed 21 children with different hematologic
malignances and found anti-leukemia activity of alloreactive NK cells in most transplanted
patients. They found that the NK cells derived from the donor were capable to selectively
killing C1/C1 target cells, including the patient’s leukemia blasts. Additionally, KIR2DL2/3+
NK cells that co-expressed KIR2DS1 killed C2/C2 leukemic blasts. These data suggest that
the presence of KIR2DS1 in alloreactive NK cells may mediate potent cytotoxicity [91]. In
agreement, in another study, the KIR2DS1 expression in alloreactive NK cells conferred an
advantage in the ability of NK cells to kill C2/C2 or C1/C2 myelomonocytic DCs and T-cell
blasts [104]. Another recent study examined 86 patients with advanced hematologic malig‐
nancies who received nonmyeloablative, HLA-haploidentical HSCT with high-dose, post-
transplantation cyclophosphamide. The inhibitory KIR gene mismatches between donor and
recipient, or KIR haplotype AA transplant recipients of KIR genotype Bx donors, were asso‐
ciated with lower relapse and non-relapse mortality (NRM) and improved OS and event-
free survival [105].
Nevertheless, other studies failed in find any association with KIR incompatibilities in the
GVHD direction [106], or found worse outcomes of transplantation for donors with the po‐
tential to NK alloreactivity [107]. Using the ligand-ligand model in a study of 62 patients
with ALL, AML and CML, the KIR mismatch was associated to considerably lower OS and a
higher incidence of GVHD [107].
KIR genes and unrelated hematopoietic stem cell transplantation
The impact of KIR-ligand mismatching in HSCT using unrelated donors has been associated
with controversial results. Beneficial outcomes have been shown in some studies. Unrelated
HSCT KIR-ligand incompatibility was associated with a reduced incidence of grade III-IV
acute GVHD and a better OS and disease free survival (DFS) in an analysis of 130 patients with
different  hematological  malignances.  The  conditioning  regimen included  anti-thymocyte
globulin (ATG) for T-cell depletion and the association with DFS remained significant even
when patients with myeloid diseases were analyzed separately [108]. KIR-HLA incompatibili‐
ties were also associated with low rates of leukemic relapse in a study of 374 patients with mye‐
loid malignances submitted to T-cell replete unrelated HSCT [109]. In this study, in spite of this
beneficial result, the rates of graft failure were higher and there were no significant differences
in DFS or transplant-related mortality. A large study described an advantage of donor NK al‐
loreactivity; the authors analyzed 1770 patients of several centers and found that the absence of
HLA-C2 or HLA-Bw4 ligands but not mismatches were associated with a decreased risk of re‐
lapse in recipients receiving unmanipulated grafts from unrelated donors [110].
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Although most studies focus on the effect of the lack of inhibitory KIRs by their HLA class I
pair, some studies have shown interesting results about the role of activating KIRs and KIR
genotypes in unrelated HSCT. Certain B haplotype KIR groups have also been found to favora‐
bly affect the outcome after T-cell depleted HLA-identical sibling transplants [111]. In 2009 a
study showed that donor group B haplotypes significantly improve graft survival in AML pa‐
tients submitted to T-replete unrelated HSCT [112]. The same group in a recent report recon‐
firmed the influence of the B haplotype on transplantation outcome. They published a large
study of 1409 unrelated transplants for AML and ALL and analyzed centromeric and telomeric
gene-content motifs in both group A and B KIR haplotypes. They suggest that centromeric and
telomeric motifs present in B haplotypes could promote protection against leukemic relapse, as
well as, improve survival. Moreover, they found a reduced relapse in those patients whose do‐
nors had 2 or more B gene-content motifs [113]. In addition, in a prospective study, the pres‐
ence of the B KIR genotype in donors was also related to fewer bacterial infections at six months
post transplant in recipients of unrelated HSCT [114]. In fact it has been observed that some ac‐
tivating genes present in Haplotype B may have an influence on unrelated HSCT. The presence
of KIR3DS1 in the donor has been associated with reduced grade II-IV acute GVHD and a low‐
er transplantation-related mortality rate [115-116]. Donor KIR2DS1 in isolation or in associa‐
tion to KIR2DS2 appears to provide protection against relapse in unrelated HSCT [116-117]. On
the other hand, in an analysis of patients and their respective HLA-identical sibling or unrelat‐
ed donors, KIR2DS1 in the donor and the absence of this gene in the receptor was associated
with increased risk of acute GVHD, KIR2DS3 was associated to chronic GVHD and KIR2DS5
was associated to relapse [118]. Another study also demonstrated deleterious effects of activat‐
ing KIRs; an increased number of donor activating KIR genes was suggested to be a significant
factor in the probability of relapse. The KIR-ligand mismatch pairs were a risk factor for trans‐
plant-related mortality [119]. The effect of activating KIRs was mainly found in AML and mye‐
lodysplastic syndrome (MDS) patients. The conditioning regimen included using ATG for in
vivo T-cell depletion.
As discussed above, there are several studies describing improved outcomes based on KIR-
ligand mismatching, however, most studies have reported no advantage [120-123] or worse
outcomes for KIR-ligand mismatch donors in unrelated HSCT. Deleterious results included
lower OS in patients with myeloid malignances submitted to KIR-ligand mismatch HSCT
[120] increased infection rates [124]; increased probability of leukemic relapse [125] in‐
creased rates of rejection and association with acute Grade III and IV GVHD [126].
KIR genes and sibling hematopoietic stem cell transplantation
On applying KIR genotyping, some studies investigated the effect of KIR in sibling HSCT. A
study of 220 donor-recipient pairs in HLA-matched sibling HSCTs found that patients with
myeloid disease who were homozygous for the C2 group had worse OS than patients who
were either homozygous or heterozygous for a C1 group. This effect was seen only in patients
who received a graft from a donor carrying the KIR2DS2 gene and only for patients with mye‐
loid disease (no effect was seen in patients with lymphoid disease) [127]. In another study the
KIR-ligand mismatch was associated to better DFS and OS and lower incidence of relapse in pa‐
tients with AML and MDS that received T-cell depleted HLA-identical sibling transplants.
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AML and MDS patients who lacked two HLA ligands for donor-inhibitory KIR had the highest
DFS and OS. Interesting, these results were found only for AML and MDS patients and not for
CML or ALL patients [128]. Benefits were also described for AML and MDS patients in another
study; the authors found a reduced risk for relapse in patients undergoing HLA-identical sib‐
ling HSCT who both received a high (above-median) NK cell number and lacked at least one
HLA-B or HLA-C ligand of the donor’s inhibitory KIRs. Transplants with more than two differ‐
ent activating donor KIRs were associated with an increased risk for non-relapse mortality
[129]. In another study, KIR-genotyping of 246 T-cell depleted HSCTs with HLA-identical sib‐
ling donors was performed; the 2DL5A, 2DS1, and 3DS1 KIR genes were associated with signif‐
icantly less relapse in patients with AML but not in patients with other myelogenous or
lymphoid malignancies. All these findings suggest that NK cells have implications in donor se‐
lection for myeloid diseases especially for AML patients [130].
Some studies have investigated KIR genes in respect to post-transplant infections in sibling
HSCT. In one study, additional activating KIR genes in the donor compared to the recipi‐
ent's genotype were associated with lower transplant related mortality, better survival, and
a reduced incidence of cytomegalovirus (CMV) reactivation [131]. In another study of T-cell
replete HSCT from matched sibling donors, the presence of donor KIR haplotype B was as‐
sociated with a 65% reduction in CMV reactivation [132]. Moreover, in another the presence
of specific activating KIR haplotypes in the donor was associated with protection from CMV
reactivation in patients submitted to sibling and unrelated HSCT [133]. Other researchers
analyzed patients according to the combination of group A and B KIR haplotypes in the
transplant donor and recipient and found a higher OS when the donor lacked and the recipi‐
ent had group B KIR haplotypes. Moreover, the poorest OS rate and increased relapse and
acute GVHD were recorded when the donor had and the recipient lacked group B KIR hap‐
lotypes and both were homozygous for the C1 KIR ligand. The presence of the Bw4 ligand
was also associated with increased acute GVHD. In contrast, the presence of both KIR3DL1
and its cognate Bw4 ligand was associated with decreased non-relapse mortality. An analy‐
sis of KIR genes individually revealed KIR2DS3 as a protective factor for chronic GVHD
[134]. In another study, 60 AML patients submitted to T-cell replete HLA-matched related
donor allogeneic bone marrow transplants were analyzed. Heterozygous C1/C2 patients
had significantly worse survival than those homozygous for C1 or C2 and the C1/C2 group
had a higher relapse rate. Multivariate analysis found C1/C2 status to be an independent
predictor for mortality. Since C1/C2 heterozygotes have a greater opportunity to engage in‐
hibitory KIRs than C1 or C2 homozygotes, they may more effectively inhibit KIR-positive
NK cell and T cell populations involved in GvL responses [135].
KIR genes and autologous stem cell transplantation
Few research groups have demonstrated the influence of KIR genes in autologous stem cell
transplantation (ASCT). The interest in the role of KIR genes in the setting of ASCT is mainly
related to preventing relapse, the main cause of treatment failure. Some studies have shown
that rapid and early NK cell recovery following ASCT is associated with a better progres‐
sion-free survival (PFS) in some diseases. An analysis of 182 patients with myeloma multi‐
ple submitted to ASCT showed a worse outcome in patients who were KIR3DS1+. The
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KIR3DS1 genotype was associated with a shorter PFS with the effect being more notable in
patients who received a transplant while in complete or partial remission after induction
chemotherapy and those who lacked HLA-Bw4 [136].
Similarly, in a study of 169 neuroblastoma patients treated by ASCT, a survival advantage
was shown in patients lacking HLA class I ligands for autologous inhibitory KIRs. Those
who lacked the HLA-C1 ligand for KIR2DL2/ KIR2DL3 had the highest 3-year survival rate
[137]. Another study analyzed the influence of KIR mismatch in ASCT by the receptor-li‐
gand mismatch model. The study, involving 16 patients who were submitted to ASCT for
non-Hodgkin’s lymphoma and solid tumours, found a reduced relapse rate for patients
with an inhibitory KIR-HLA mismatch [138]. On the other hand, another study of 67 pa‐
tients with solid tumors or lymphomas who were treated with ASCT did not find any effect
of KIR-ligand interactions on the outcomes of ASCT [139].
KIR genes and unrelated umbilical cord blood transplantation
Unrelated UCBT has proved to be a viable treatment option. An advantage of using UCB is the
relatively low risk of acute GVHD due to a lower number of mature donor T cells and thus an
increased possibility of using HLA-mismatched units. Moreover, UCBT, as in haplo-HSCT, is
characterized by a rapid post-transplant recovery of NK cells. An analysis of 218 patients with
AML or ALL showed that patients who received a single UCBT unit from a KIR ligand incom‐
patible donor showed a lower incidence of relapse, and increased DFS and OS [140]. Addition‐
ally, as was seen in the Ruggery studies, the benefits were significantly more marked in
patients with AML. However, another study failed to observe any benefit of KIR-ligand mis‐
match in 155 recipients of UCB after myeloablative conditioning. In fact, in 102 patients who re‐
ceived UCB after nonmyeloablative conditioning, KIR-Ligand mismatch was associated with
an increased rate of acute GVHD and higher treatment-related mortality [141].
Altogether these data show that simple assessments of the KIR genotype might help in the
selection of donors for HSCT. KIR mismatches seem to be effective in haplo-HSCT and
mainly in patients with myeloid diseases. The contradictory results reported about the influ‐
ence of KIR mismatches in the diverse types of HSCT can certainly be explained by differen‐
ces in the transplant protocols employed. Differences like number of patients analyzed, type
of disease studied, stage of the disease, patient age, conditioning regimen, stem cell source,
GVHD prophylaxis and variability in the definition of KIR mismatch can influence trans‐
plant outcomes. Factors like T-cell depletion and no post-transplant immune suppression
seem to be important in maximizing NK cell alloreactivity [142].
Cytokines genes and receptors in HSCT
There are many other genetic factors that influence to outcome of transplant,  independ‐
ent  of  whether  the transplant  is  autologous,  allogeneic,  matched or  mismatched,  sibling
or unrelated donor, or haploidentical and of whether the cell source is bone marrow, pe‐
ripheral blood or UCB.
The goal of the majority to studies is to know what kind of influence these genetic factors
and HLA compatibility have and what effect they have on the course of the transplant: acute
and chronic GVHD, relapse, OS and mortality.
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One important factor is the polymorphisms within the regulatory sequences of cytokine
genes. Proinflammatory cytokines, receptors and related inhibitors have been implicated in
a large number of immune diseases. The main role of cytokine genes is related to the immu‐
nopathogenesis of GVHD [143].
Studies on cytokine genes in the transplant setting involve receptors of the TNF, IL-10, the
IL-1 gene family, IL-2, IL-6, interferon TNF-γ, TGF-β1 and TGF-β1 [28, 144-145].
Tissue injury, including of the mucosa and liver, occurs during the conditioning regimen.
This process causes the secretion of the TNF-α, IL-6 and IL-1 pro-inflammatory cytokines
that increase HLA antigens, thus increasing the antigens recognized by donor T-cell recep‐
tors in allogeneic transplantation. Moreover, during the activation to donor cells, T cells pro‐
duce IL-2 and INF-γ (Th1) that trigger GVHD and are balanced for Th2 cytokines such as
IL-4 and IL-10 [146-147].
Studies on allogeneic HSCT, investigated 16 patients with chronic GVHD by a systematic
clinical examination of the oral cavity, and by biopsies of the buccal mucosa and labial sali‐
vary glands. The findings demonstrated that the mRNA expression of IL-2, INF-γ, IL-4 and
IL-5 in the buccal mucosa of chronic GVHD patients was greater than in control individuals.
A similar result was detected for the labial salivary glands with the addition of IL-10 [148].
Studies show that IL-2 and INF-γ were detected more frequently in patients with acute
GVHD. Additionally, IL-12 and IL-18 were increased while IL-10 was decreased in the same
group, and IL-4 did not present a significant difference between the control and patient
groups [144]. Other studies show high IL-10 gene expression in the recipient that may be re‐
lated to a reduced incidence of grades II to IV acute GVHD and a reduced graft-versus-tu‐
mor effect after HSCT with nonmyeloablative conditioning [145].
On the other hand, studies affirm that IL-4 producing cells inhibit the development of acute
GVHD and the increased percentage of IL-4 secreting cells may be responsible for the unex‐
pected low incidence of acute GVHD after peripheral blood HSCT, despite the presence of
large numbers of mature T cells in the donor infusion [148].
Many studies show that polymorphisms of cytokine genes influence to outcome of trans‐
plants, such as with the development of GVHD. One example is that the IL17+197ª allele was
associated with increased risk of grade III and IV acute and chronic GVHD. Other studies
demonstrate clinically important relationships between genetic polymorphisms in TNF-α
and the severity of acute GVHD [147,149]. There are many other associations of polymor‐
phisms of cytokine genes that course to acute and chronic GVHD.
Major histocompatibility complex class I-related chain genes and HSCT
The MHC class I-related chain (MIC) genes have been the subject of interest in the setting of
HSCT. This family of genes, located in the MHC classical class I region, was first described
in 1994 [150-151]. These genes are very polymorphic, but not as much as the classical HLA
class I genes. Humans have seven MIC genes, named MICA to MICG but only two MIC
genes are functional, the MHC class I-related chain A (MICA) and B (MICB) genes. The MIC
proteins are similar to the HLA class I gene products however they are not associated with
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associated with increased risk of grade III and IV acute and chronic GVHD. Other studies
demonstrate clinically important relationships between genetic polymorphisms in TNF-α
and the severity of acute GVHD [147,149]. There are many other associations of polymor‐
phisms of cytokine genes that course to acute and chronic GVHD.
Major histocompatibility complex class I-related chain genes and HSCT
The MHC class I-related chain (MIC) genes have been the subject of interest in the setting of
HSCT. This family of genes, located in the MHC classical class I region, was first described
in 1994 [150-151]. These genes are very polymorphic, but not as much as the classical HLA
class I genes. Humans have seven MIC genes, named MICA to MICG but only two MIC
genes are functional, the MHC class I-related chain A (MICA) and B (MICB) genes. The MIC
proteins are similar to the HLA class I gene products however they are not associated with
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
19
β-2-microglobulin and also do not bind peptides to present to T cells [150,152]. MIC proteins
appear to be induced by stress [153] and are expressed on the cell surface of fibroblasts and
endothelium cells [154]. They are ligands for NKG2D [155], a receptor present on NK cells
and some T cells, and because of this they can co-stimulate NK cells and T cells and can
therefore determine the outcome of certain effector functions that are related to GVHD. In
fact, MIC genes have been show to be attractive targets in diverse cancers, autoimmune dis‐
eases and in organ rejection after transplantation.
Several studies have demonstrated that the MICA may be a target molecule in allograft re‐
jection because MICA can elicit antibody production after solid organ transplantation
[156-163]. Some studies have reported diverse outcomes in HSCT related to MIC genes. It
was suggested that MIC genes play a role in GVHD in HLA-matched HSCT because a high‐
er rate of grade II-IV acute GVHD was found as was more gastrointestinal GVHD in MICA
mismatched patients [164]. In addition, matches of MICA and MICB loci were shown to in‐
crease patient survival in a study of 44 patients who received unrelated HSCT [165].
Some polymorphisms in MICA genes have also been associated to outcomes in transplants.
A change at position 129 of the α2-heavy chain domain of MICA can denote the strength of
interaction with the NKG2D receptor. The presence of methionine at position 129 of the MI‐
CA gene characterizes a strong binder, and the presence of valine characterizes a weak bind‐
er [166]. Hence, the MICA-129 valine genotype and soluble MICA serum level were
considered risk factors for chronic GVHD in a study of 211 HLA-identical sibling pairs of
HSCT while before transplantation, the presence of anti-MICA antibodies that can neutralize
soluble MICA confers protection [167]. Altogether, these data suggest that MIC genes, in
particular the MICA genes, could be used as biomarkers for chronic GVHD and should be
studied further.
Minor histocompatibility antigens and HSCT
The human minor histocompatibility antigens (mHAgs) are another group of immunogenic
peptides, distinct from the MHC system, which seem to have a role in HSCT outcomes.
They are derived from intracellular polymorphic proteins and are presented by HLA class I
and II restricted T cells [168-170]. Accumulated evidence suggests that they can elicit alloge‐
neic T-cell mediated immune response in HLA-matched allogeneic HSCT and because of
this have been investigated in order to understand their possible role in the control of
GVHD and GvL.
Diverse minor histocompatibility antigens of various genetic and cellular origins have been
described. More than 40 different genes that encode mHAgs recognized by either CD8+ or
CD4+ T cells have been identified [171-174]. Most of the mHAgs are result of non-synony‐
mous single nucleotide polymorphisms in autosomal genes while others are encoded by the
sex chromosomes. At least 6 genes in the Y chromosome encode male-specific MHAgs (so-
called HY antigens). Additionally, mHAgs may also be caused by gene deletions and genet‐
ic variations in non-coding regions affecting gene transcription [175-178].
The best-characterized minor histocompatibility antigen is encoded by the Y chromosome
(HA-1). The mHAgs related to gender seems to be involved in HSCT outcomes because their
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absence in women can lead to a response to male antigens; female-to-male transplants seem
to be more susceptible to GVHD [168-170, 179-180,181-185]. Antibody responses to HY pro‐
teins are also associated with both chronic GVHD and the maintenance of remission [186],
but whether these antibody responses contribute meaningfully to GVHD, or simply serve as
markers for it, remains unclear. In spite of female-to-male immune responses being more
common, the opposite can also happen [187-188].
Some mHAgs are expressed only in the hematopoietic system while others are also ex‐
pressed in normal tissues. mHAgs whose expression is limited to hematopoietic tissue may
be recognized by specific donor T cells and may selectively contribute to a GvL effect and
those with broad tissue expression may mediate GVHD [189].
Several studies have associated the presence of mHAg-specific T cells post-transplantation
with graft rejection [179, 190], GVHD [191-194], and the GVL effect [195-197]. Mismatches
between patient and donor for HA-1, HA-2, HA-4 and HA-5 are associated with an in‐
creased incidence in GVHD [191].
The  role  and  the  mechanisms  of  alloreactions  related  to  mHAgs  are  not  fully  under‐
stood, but these data suggest that they may be relevant in determining post-transplanta‐
tion outcomes.
4. Conclusion
Genetic differences between donor and recipient are crucial factors capable of influencing
transplantation outcomes. Much has been learned about the HLA and non-HLA genes, their
expression, their polymorphisms and their role in mediating GvL and GVHD responses. A
better understanding of these genes may permit more refined donor selection criteria and
consequently a more accurate assessment of transplant-related complications.
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1. Introduction
The occurrence of graft rejection and/or graft-versus-host disease (GVHD) after allogeneic
hematopoietic stem cell transplantation (allo-HSCT) is largely depended on whether the re‐
cipient and the donor have matched HLA types. Under normal circumstances, the individu‐
al with completely matched HLA antigens can be the donor. However, due to the high level
of HLA polymorphism, the major obstacle in the allogeneic hematopoietic stem cell trans‐
plantation is to find a donor with HLA antigens that are a perfect match. This can prove to
be quite problematic.
In 1954, an organ transplantation team led by Dr. Merri at Harvard University successfully
completed a kidney transplantation between identical twins for the first time. From then on, the
importance of histocompatibility in organ transplantation has been well recognized. The first
human bone marrow transplantation between identical twins in 1957 provided a new ap‐
proach for the treatment of leukemia and other hematologic malignancies. As a result, the basic
research on HLA as well as the HLA typing techniques gained much attention over the next 20
years. The short-term survival rate of organ transplantation has been greatly improved since
the 1980s due to the clinical application of immunosuppressive agents such as CsA. These suc‐
cesses,as well as the defects and limitations in serotyping and cellular typing of HLA, the clini‐
cal value of HLA typing has been largely ignored in the medical community.
With the advance of research in immunology and transplantation immunology, particularly
in the structure and function of HLA in the 1990s, new technology for HLA typing has
emerged and continues to improve. Terasaki and Opelz analyzed a large amount of organ
transplantation cases performed in major transplantation centers around the world. The
role, status and importance of HLA typing in hematopoietic stem cell transplantation have
been recognized once again. Overall, HLA typing is required in hematopoietic stem cell
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transplantation. HLA compatibility not only significantly reduces the incidence of acute re‐
jection, but also significantly reduces the incidence of chronic rejection. HLA compatibility is
one of the most critical factors that affect the long-term survival of the graft.
HLA loci are the most genetically variable gene loci in human. Two hundred and twenty
four loci of HLA complex have been identified so far. Among these, 128 are functional loci
that encode proteins, and 39.8% of HLA genes are related to the immune system, particular‐
ly those belong to class II loci. Almost all these genes display immune-related functions. Ap‐
proximately 100 HLA genes loci have been cloned and named, and at least 18 of them have
alleles. Since these loci have various amounts of alleles and each allele encodes a corre‐
sponding HLA antigen, the HLA complex has the most abundant genetic polymorphism in
the human immune system.
Figure 1. Increasing number of HLA alleles from 1987 to July 2012
Systemic investigations of the alleles in HLA loci began in 1987. There were just over 10
identified alleles at that time. The allele numbers in HLA-I and HLA-II loci were increased
to 100 and 50 respectively in 1989. The allele number of HLA-I and HLA-II reached 1028 in
2000. As of July 2012, the total allele number of HLA loci has reached 8016. HLA-A, HLA-B
and HLA-C loci have 2013, 2605 and 1551 alleles respectively. DRA site has 34 and DRB site
has 1260 alleles. DQA1 and DQB1 sites have 47 and 176 alleles respectively, and DPA1 and
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DPB1 sites have 34 and 155 alleles, respectively (Fig 1). Theoretically, it is very difficult to
find an unrelated donor with a perfectly matched HLA genotype (at the allele level) in the
general population.
The polymorphism of HLA makes it difficult to find a match between unrelated donor and
recipient in the allotransplantation. Currently, the most commonly used HLA typing in or‐
gan transplantations around the world is based on HLA-A, B, C and DR genes. There are up
to 7400 alleles in these genes corresponding to more than 100 specific antigens. With the in‐
creasing number of patients who need hematopoietic stem cell transplantation, the lack of
appropriate donors has become a significant challenge. Therefore, there is an urgent need to
develop novel scientific, practical, and feasible HLA typing methods in the field of hemato‐
poietic stem cell transplantation.
2. Principles for HLA typing strategy in allogeneic hematopoietic stem
cell transplantation
The first successful human bone marrow transplantation between identical twins in 1957
has provided a new approach for the treatment of leukemia and other hematologic malig‐
nancies.  After  the  successful  hematopoietic  stem  cell  transplantation  between  unrelated
donor and recipient with matched HLA, a bone marrow donor registry was established in
1988 (National Marrow Donor Program, NMDP) in the USA. Later on, a public cord blood
bank was established. According to the World Marrow Donor Association (WMDA), as of
July 2012, the association has 68 bone marrow banks in 49 countries and regions. It also
has 46 cord blood banks in 30 countries and regions. The registered bone marrow and um‐
bilical  cord blood donors have exceeded 20 million.  Meanwhile,  the technology of  HLA
typing  has  been  transformed from simple  serotyping  to  more  accurate  genotyping.  Al‐
though there are hundreds of reports regarding the effect of HLA matching degree on the
efficacy of hematopoietic stem cell transplantation, these results are not consistent due to
the differences in sample size, disease type and stage, and HLA typing. In addition, the in‐
terpretation of  HLA genotyping results  and their  biological  significance is  becoming in‐
creasingly  complicated.  It  is  challenging  for  the  clinicians  outside  of  the  HLA  field  to
select  an unrelated donor with the best-matched HLA. To meet  this  challenge,  WMDA,
NMDP  of  the  USA  and  European  Federation  of  Immunogenetics  (EFI)  have  provided
guidelines for HLA typing.
2.1. Correlation between HLA allele and HLA antigen specificity
There is a fundamental difference in the result and biological significance between HLA
serotyping and genotyping. In the HLA serotyping, HLA antibodies are used to identify
the HLA antigens on the surface of lymphocytes. HLA antigens are proteins that can be
recognized by the host immune system during blood transfusion, organ transplantation, as
well as pregnancy. Specific antibodies against HLA antigens are the basis of the identifica‐
tion  of  the  HLA antigens.  The  HLA antisera  used in  serotyping,  regardless  of  whether
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guidelines for HLA typing.
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There is a fundamental difference in the result and biological significance between HLA
serotyping and genotyping. In the HLA serotyping, HLA antibodies are used to identify
the HLA antigens on the surface of lymphocytes. HLA antigens are proteins that can be
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they are from the same species or different species, are all produced by immune stimula‐
tion with HLA antigens or peptides. In the HLA genotyping analysis, a specific HLA gene
fragment is amplified in vitro from an individual’s genomic DNA using synthetic oligonu‐
cleotide probes or primers. The genetic difference caused by variant HLA gene alleles is
reflected by the variation in the DNA sequence. Therefore, HLA genotyping can identify
all HLA alleles at the DNA level while HLA serotyping can only detect part of variants.
The  efficacy  of  bone  marrow transplantation  is  closely  related  to  the  matching  level  of
HLA between the donor and recipient. However, the HLA genotyping result does not di‐
rectly reflect the antigen that causes immune rejection after the transplantation. Therefore,
for the purpose of clinical relevance, the result of HLA genotyping should be converted to
the HLA specificity. To this end, the NMPD and the University of California in Los An‐
gels (UCLA) established the International Cell Exchange program, through which correla‐
tions between the HLA alleles and HLA antigen specificities are established by comparing
a large amount of testing results worldwide. The dictionary of HLA alleles and their corre‐
sponding antigen specificities is under constant updating. As of 2008, 70% of HLA alleles
have been correlated to HLA antigen specificities. The rest 30% alleles are rare alleles with
a frequency less than 1 in 10,000.  Therefore,  their  clinical  values are relatively low. The
HLA genotyping result  can be easily converted to the HLA antigen specificity by using
this HLA dictionary.
2.2. The number of donor with matched HLA gene types is much lower than that with
matched HLA antigens
The criteria of matched HLA between the donor and recipient are different for the HLA
genotyping and HLA serotyping in the bone marrow transplantation. From the HLA dic‐
tionary,  one can tell  that  the HLA antigen specificity is  unique,  while  a  unique antigen
may have one or more corresponding HLA alleles. For example, HLA-DR10 antigen only
corresponds to HLA-DRB1*1001 allele, while HLA-DR11 antigen corresponds to 21 alleles
such as HLA-DRB1*1101, 1102 and 1103. Therefore, the choice of donor for bone marrow
transplantation may differ, depending on the method of HLA typing. For example, a do‐
nor and recipient listed in Table 1 may have matched HLA according to antigen specifici‐
ty.  However,  their  HLA genotypes may not  match.  Which method is  more accurate for
bone marrow transplantation is currently under investigation. Statistical analysis indicates
that the chance of finding matched HLA genotypes in a random population is much low‐
er than finding matched HLA antigens. For instance, as of February 2002, HLA-A, B and
DR  have  93  specific  antigens.  HLA-A,  B  and  DR  have  25,  50  and  18  loci  respectively,
which can generate 2.2 x 10 4 haplotypes. The genotype number of these haplotypes can be
up  to  2.5x1013.  Currently,  there  are  2100  alleles  have  been  identified  in  HLA-A,  B  and
DRB1 genes. Their combination will yield 3.4 x10 7 haplotypes. As a result, the number of
HLA-A, B and DRB1 genotypes in a population can be up to 5.78x1015, making it almost
impossible to find the matched HLA genotype in a random population. In other words,
the HLA genotypes of the donor and the recipient are always more or less mismatched in
bone marrow transplantation. Because of this, the concept of permissible HLA mismatch‐
es has been introduced.
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matching status Recipient’s HLA type Donor’s HLA type
antigen gene Antigen gene Antigen gene
matched matched A2 A11 A* 0202 A*1101 A2 A11 A*0202 A*1101
B60 B62 B*4001 B*1501 B60 B62 B*4001 B*1501
DR4 DR8 DRB1*0402 DRB1*0801 DR4 DR8 DRB1*0402 DRB1*0801
matched unmatched A2 A11 A* 0202 A*1101 A2 A11 A*0205 A*1102
B60 B62 B*4001 B*1501 B60 B62 B*4007 B*1504
DR4 DR8 DRB1*0402 DRB1*0801 DR4 DR8 DRB1*0404 DRB1*0803
unmatched unmatched A2 A11 A* 0202 A*1101 A2 A30 A*0201 A*3001
B60 B62 B*4001 B*1501 B61 B62 B*4002 B*1501
DR4 DR8 DRB1*0402 DRB1*0801 DR4 DR11 DRB1*0401 DRB1*1102
Table 1. Examples of HLA antigen matching and allele matching between the recipient and the donor in bone
marrow transplantation
2.3. Permissible HLA mismatches
In the case of permissible HLA mismatches, the donor and the recipient have mismatched
HLA in a bone marrow transplant. However, the mismatch does not cause a significantly
increased rate of GVHD or graft failure, and is acceptable for bone marrow transplantation.
Results from retrospective analyses suggest that mismatched alleles in HLA class I antigens
as well as alleles in HLA-DQ and DP loci have minimal impact on the efficacy of bone mar‐
row transplantation.
2.3.1. HLA class I antigen or allele mismatch
Petersdorf et al had investigated the effect of matching level of HLA class I antigens and alleles
on the success rate of bone marrow transplantation in 471 patients. The transplant failure rate is
0.7% in 280 cases with matched HLA-A, B and C genes, and is 0% in 47 cases with one of mis‐
matched heterozygous HLA-A, B or C gene. However, the failure rate in 51 cases with one of
mismatched HLA-A, B or C antigens is 14%, which is significantly higher than that in the con‐
trol group. In 76 cases with 2 or more mismatched antigens or genes, the transplant failure rate
is 17%. These results indicate that a single mismatched allele in the HLA class I gene does not in‐
crease the transplant failure rate, while a single mismatched antigen, or 2 or more mismatched
antigens or genes can significantly increase the transplant failure rate. These results support Pe‐
tersdorf’s hypothesis that the immune response caused by mismatched HLA class I alleles is
lower than that caused by mismatched antigens. Therefore, mismatched HLA class I genes are
permissible in the bone marrow transplantation, as long as HLA antigens match. Rubinstein et
al also believes that transplantation can be considered if there is only one mismatched allele.
For example, the recipient’s genotype is HLA-A*0202 while the donor’s genotype is HLA-
A*0203. This kind of mismatch does not increase the rate of immune rejection. Further analysis
indicates that whether a single allele mismatch is allowed in the transplantation also depends
on the type of corresponding mismatched amino acid and the position of that amino acid in the
HLA class I antigen. HLA class I molecules consist of a covalently bound heavy chain molecule
and a 2 microglobulin. The extracellular fragment of the heavy chain has 3 activity domains
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they are from the same species or different species, are all produced by immune stimula‐
tion with HLA antigens or peptides. In the HLA genotyping analysis, a specific HLA gene
fragment is amplified in vitro from an individual’s genomic DNA using synthetic oligonu‐
cleotide probes or primers. The genetic difference caused by variant HLA gene alleles is
reflected by the variation in the DNA sequence. Therefore, HLA genotyping can identify
all HLA alleles at the DNA level while HLA serotyping can only detect part of variants.
The  efficacy  of  bone  marrow transplantation  is  closely  related  to  the  matching  level  of
HLA between the donor and recipient. However, the HLA genotyping result does not di‐
rectly reflect the antigen that causes immune rejection after the transplantation. Therefore,
for the purpose of clinical relevance, the result of HLA genotyping should be converted to
the HLA specificity. To this end, the NMPD and the University of California in Los An‐
gels (UCLA) established the International Cell Exchange program, through which correla‐
tions between the HLA alleles and HLA antigen specificities are established by comparing
a large amount of testing results worldwide. The dictionary of HLA alleles and their corre‐
sponding antigen specificities is under constant updating. As of 2008, 70% of HLA alleles
have been correlated to HLA antigen specificities. The rest 30% alleles are rare alleles with
a frequency less than 1 in 10,000.  Therefore,  their  clinical  values are relatively low. The
HLA genotyping result  can be easily converted to the HLA antigen specificity by using
this HLA dictionary.
2.2. The number of donor with matched HLA gene types is much lower than that with
matched HLA antigens
The criteria of matched HLA between the donor and recipient are different for the HLA
genotyping and HLA serotyping in the bone marrow transplantation. From the HLA dic‐
tionary,  one can tell  that  the HLA antigen specificity is  unique,  while  a  unique antigen
may have one or more corresponding HLA alleles. For example, HLA-DR10 antigen only
corresponds to HLA-DRB1*1001 allele, while HLA-DR11 antigen corresponds to 21 alleles
such as HLA-DRB1*1101, 1102 and 1103. Therefore, the choice of donor for bone marrow
transplantation may differ, depending on the method of HLA typing. For example, a do‐
nor and recipient listed in Table 1 may have matched HLA according to antigen specifici‐
ty.  However,  their  HLA genotypes may not  match.  Which method is  more accurate for
bone marrow transplantation is currently under investigation. Statistical analysis indicates
that the chance of finding matched HLA genotypes in a random population is much low‐
er than finding matched HLA antigens. For instance, as of February 2002, HLA-A, B and
DR  have  93  specific  antigens.  HLA-A,  B  and  DR  have  25,  50  and  18  loci  respectively,
which can generate 2.2 x 10 4 haplotypes. The genotype number of these haplotypes can be
up  to  2.5x1013.  Currently,  there  are  2100  alleles  have  been  identified  in  HLA-A,  B  and
DRB1 genes. Their combination will yield 3.4 x10 7 haplotypes. As a result, the number of
HLA-A, B and DRB1 genotypes in a population can be up to 5.78x1015, making it almost
impossible to find the matched HLA genotype in a random population. In other words,
the HLA genotypes of the donor and the recipient are always more or less mismatched in
bone marrow transplantation. Because of this, the concept of permissible HLA mismatch‐
es has been introduced.
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matching status Recipient’s HLA type Donor’s HLA type
antigen gene Antigen gene Antigen gene
matched matched A2 A11 A* 0202 A*1101 A2 A11 A*0202 A*1101
B60 B62 B*4001 B*1501 B60 B62 B*4001 B*1501
DR4 DR8 DRB1*0402 DRB1*0801 DR4 DR8 DRB1*0402 DRB1*0801
matched unmatched A2 A11 A* 0202 A*1101 A2 A11 A*0205 A*1102
B60 B62 B*4001 B*1501 B60 B62 B*4007 B*1504
DR4 DR8 DRB1*0402 DRB1*0801 DR4 DR8 DRB1*0404 DRB1*0803
unmatched unmatched A2 A11 A* 0202 A*1101 A2 A30 A*0201 A*3001
B60 B62 B*4001 B*1501 B61 B62 B*4002 B*1501
DR4 DR8 DRB1*0402 DRB1*0801 DR4 DR11 DRB1*0401 DRB1*1102
Table 1. Examples of HLA antigen matching and allele matching between the recipient and the donor in bone
marrow transplantation
2.3. Permissible HLA mismatches
In the case of permissible HLA mismatches, the donor and the recipient have mismatched
HLA in a bone marrow transplant. However, the mismatch does not cause a significantly
increased rate of GVHD or graft failure, and is acceptable for bone marrow transplantation.
Results from retrospective analyses suggest that mismatched alleles in HLA class I antigens
as well as alleles in HLA-DQ and DP loci have minimal impact on the efficacy of bone mar‐
row transplantation.
2.3.1. HLA class I antigen or allele mismatch
Petersdorf et al had investigated the effect of matching level of HLA class I antigens and alleles
on the success rate of bone marrow transplantation in 471 patients. The transplant failure rate is
0.7% in 280 cases with matched HLA-A, B and C genes, and is 0% in 47 cases with one of mis‐
matched heterozygous HLA-A, B or C gene. However, the failure rate in 51 cases with one of
mismatched HLA-A, B or C antigens is 14%, which is significantly higher than that in the con‐
trol group. In 76 cases with 2 or more mismatched antigens or genes, the transplant failure rate
is 17%. These results indicate that a single mismatched allele in the HLA class I gene does not in‐
crease the transplant failure rate, while a single mismatched antigen, or 2 or more mismatched
antigens or genes can significantly increase the transplant failure rate. These results support Pe‐
tersdorf’s hypothesis that the immune response caused by mismatched HLA class I alleles is
lower than that caused by mismatched antigens. Therefore, mismatched HLA class I genes are
permissible in the bone marrow transplantation, as long as HLA antigens match. Rubinstein et
al also believes that transplantation can be considered if there is only one mismatched allele.
For example, the recipient’s genotype is HLA-A*0202 while the donor’s genotype is HLA-
A*0203. This kind of mismatch does not increase the rate of immune rejection. Further analysis
indicates that whether a single allele mismatch is allowed in the transplantation also depends
on the type of corresponding mismatched amino acid and the position of that amino acid in the
HLA class I antigen. HLA class I molecules consist of a covalently bound heavy chain molecule
and a 2 microglobulin. The extracellular fragment of the heavy chain has 3 activity domains
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(1, 2 and 3), and the 1 and 2 domains form the peptide-binding region. The complex
of HLA and its bound peptide on the cell surface constitutes the ligand for the T-cell receptor
(TCR), thereby inducing an immune response. If there is only one mismatched allele between
the donor and recipient, the number of mismatched amino acids will be much lower, and may
rarely involve the amino acids for TCR binding. On the other hand, if the donor and the recipi‐
ent have a mismatched antigen, it may have many mismatched amino acids, and some of these
amino acids may be involved in peptide binding and TCR binding. This may explain why the
matching of HLA class I antigen is more important than the matching of genotype (Fig 2).
Figure 2. Spatial structure as well as the position and number of mismatched amino acid in the class I HLA with mis‐
matched donor-recipient genotypes (A) or mismatched donor-recipient antigens (B). The position of amino acid resi‐
due is labeled according to its position in the whole protein. Amino acid residues with dark blue color are located in
the -sheet and involved in peptide binding. Amino acid residues located on the  helix are colored with light blue.
Amino acid residues involved in TCR binding are in red. White amino acids are involved in neither TCR binding nor
peptide binding, while gray amino acids are involved in both TCR and peptide binding. Number of mismatched amino
acid involved in peptide binding and TCR binding in the class I HLA with mismatched donor-recipient genotypes (C)
and mismatched antigens (D). In panel D, patients with a transplant failure are in dark gray block.
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Further analysis by Petersdorf et al shows that one mismatched HLA-A, B or C antigen caus‐
es 71% transplant failure in 7 HLA homozygous patients, but causes 7% failure rate in 98
heterozygous patients, suggesting that for HLA homozygous patients, when a matched do‐
nor is not available, the homozygous donor with other matched heterozygous alleles should
be chosen. For example, the recipient’s HLA type is HLA-A2, B44 and DR8/9. Donor 1’s
HLA type is HLA-A2, B51, B46 and DR8/9. Donor 2’s HLA type is HLA-A2/11, B44, B46 and
DR8/9. In this case, donor 1 is preferred.
2.3.2. HLA class II antigen or allele mismatch
HLA class II genes encode antigens such as HLA-DR, DQ and DP. In order to understand
the importance of HLA class II genes in unrelated bone marrow transplantation, McGlave et
al have investigated the effect of mismatched DR, DQ and DP alleles on the result of trans‐
plantation. Data from NMDP that contain 831 chronic myeloid leukemia (CML) patients re‐
ceived bone marrow transplantation between 1988 and 1997 were analyzed. 696 patients
have matched HLA-A and B base on serotyping results. Among them, 565 (81%) have
matched DRB1 genotypes. Data analysis shows that matched HLA-DRB1 alleles can signifi‐
cantly improve graft survival and patient survival. While, mismatched HLA-DQA1, DQB1,
DPA1 and DPB1 genes do not significantly affect the GVHD incidence or transplantation re‐
sult. This result suggests that matching HLA-DRB1 alleles is an important factor in bone
marrow transplantation (Fig 3).
Figure 3. Effect of DRB1 matching level on patient’s survival rate (A) CML patient, (B) Patients with matched HLA-A, B
serotypes
2.4. HLA typing standard for hematopoietic stem cell transplantation
According to the guideline of World Bone Marrow Donor Association (WBDA) and Europe‐
an Federation for Immunogenetics (EFI), HLA typing of the donor in a large-scale bone mar‐
row center is generally limited to 2 digits after the asterisk in the WHO HLA nomenclature,
corresponding to the subtype of a specific HLA antigen. However, high-resolution HLA
typing should be performed for recipients and donors with matched HLA. In addition, the
typing of HLA class I genes should also include the locus C. Due to the increasingly recog‐
nized role of locus C in the immune rejection, the typing of HLA-C should be performed.
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(1, 2 and 3), and the 1 and 2 domains form the peptide-binding region. The complex
of HLA and its bound peptide on the cell surface constitutes the ligand for the T-cell receptor
(TCR), thereby inducing an immune response. If there is only one mismatched allele between
the donor and recipient, the number of mismatched amino acids will be much lower, and may
rarely involve the amino acids for TCR binding. On the other hand, if the donor and the recipi‐
ent have a mismatched antigen, it may have many mismatched amino acids, and some of these
amino acids may be involved in peptide binding and TCR binding. This may explain why the
matching of HLA class I antigen is more important than the matching of genotype (Fig 2).
Figure 2. Spatial structure as well as the position and number of mismatched amino acid in the class I HLA with mis‐
matched donor-recipient genotypes (A) or mismatched donor-recipient antigens (B). The position of amino acid resi‐
due is labeled according to its position in the whole protein. Amino acid residues with dark blue color are located in
the -sheet and involved in peptide binding. Amino acid residues located on the  helix are colored with light blue.
Amino acid residues involved in TCR binding are in red. White amino acids are involved in neither TCR binding nor
peptide binding, while gray amino acids are involved in both TCR and peptide binding. Number of mismatched amino
acid involved in peptide binding and TCR binding in the class I HLA with mismatched donor-recipient genotypes (C)
and mismatched antigens (D). In panel D, patients with a transplant failure are in dark gray block.
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Further analysis by Petersdorf et al shows that one mismatched HLA-A, B or C antigen caus‐
es 71% transplant failure in 7 HLA homozygous patients, but causes 7% failure rate in 98
heterozygous patients, suggesting that for HLA homozygous patients, when a matched do‐
nor is not available, the homozygous donor with other matched heterozygous alleles should
be chosen. For example, the recipient’s HLA type is HLA-A2, B44 and DR8/9. Donor 1’s
HLA type is HLA-A2, B51, B46 and DR8/9. Donor 2’s HLA type is HLA-A2/11, B44, B46 and
DR8/9. In this case, donor 1 is preferred.
2.3.2. HLA class II antigen or allele mismatch
HLA class II genes encode antigens such as HLA-DR, DQ and DP. In order to understand
the importance of HLA class II genes in unrelated bone marrow transplantation, McGlave et
al have investigated the effect of mismatched DR, DQ and DP alleles on the result of trans‐
plantation. Data from NMDP that contain 831 chronic myeloid leukemia (CML) patients re‐
ceived bone marrow transplantation between 1988 and 1997 were analyzed. 696 patients
have matched HLA-A and B base on serotyping results. Among them, 565 (81%) have
matched DRB1 genotypes. Data analysis shows that matched HLA-DRB1 alleles can signifi‐
cantly improve graft survival and patient survival. While, mismatched HLA-DQA1, DQB1,
DPA1 and DPB1 genes do not significantly affect the GVHD incidence or transplantation re‐
sult. This result suggests that matching HLA-DRB1 alleles is an important factor in bone
marrow transplantation (Fig 3).
Figure 3. Effect of DRB1 matching level on patient’s survival rate (A) CML patient, (B) Patients with matched HLA-A, B
serotypes
2.4. HLA typing standard for hematopoietic stem cell transplantation
According to the guideline of World Bone Marrow Donor Association (WBDA) and Europe‐
an Federation for Immunogenetics (EFI), HLA typing of the donor in a large-scale bone mar‐
row center is generally limited to 2 digits after the asterisk in the WHO HLA nomenclature,
corresponding to the subtype of a specific HLA antigen. However, high-resolution HLA
typing should be performed for recipients and donors with matched HLA. In addition, the
typing of HLA class I genes should also include the locus C. Due to the increasingly recog‐
nized role of locus C in the immune rejection, the typing of HLA-C should be performed.
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When choosing a donor, the HLA-DRB1 gene of the donor and the recipient should have 4
identical digits after the asterisk in the WHO HLA nomenclature.
Although most commonly used methods for HLA genotyping cannot cover all genes, it does
not limit their applications in HLA typing for bone marrow transplantation. Among thousands
of identified HLA alleles, most of them are rare alleles. Therefore, it is not necessary to type all
HLA alleles. For instance, 244 expressing genes have been identified in DRB1 loci. Among
them, 148 (60%) alleles have corresponding specific DR antigens, while 96 alleles (40%) do not.
According to the NMDP, result of HLA-DRB1 typing in 65,752 donors shows that 86 alleles
have 0 frequency and the frequency of another 105 alleles is lower than 0.0002. In addition, the
total frequency of 10 alleles without corresponding antigens is 0.000084. Therefore, identifica‐
tion of the rest 43 DRB1 alleles will cover 99.6% of HLA-DR antigen specificities, which is suffi‐
cient for the screen of donor in hematopoietic stem cell transplantation.
3. PCR based HLA genotyping methods
The technology for HLA typing has evolved from the serological level to the cellular level, to
the molecular level. Serotyping was the mainstream method for HLA type and has played a
critical role in organ transplantations before 1990s. However, most HLA antisera are polyclo‐
nal and often have cross-reactions, making it difficult to distinguish antigens with subtle struc‐
tural differences, and leading to misidentifications. Further more, many factors, such as a
prolonged transportation time of the blood sample and excessive amount of immature cells,
may affect the result of serotyping and cellular typing. These are the limitations of traditional
HLA typing methods. The development of polymerase chain reaction (PCR) and its applica‐
tion in biomedical sciences has made the HLA typing at the DNA level possible. Therefore, us‐
ing molecular methods to type HLA at the DNA level has gradually replaced serotyping and
cellular typing. Commonly used DNA based HLA typing methods include PCR based se‐
quence specific primers (PCR-SSP), and PCR based restriction fragment length polymorphism
(PCR-RFLP), single-strand conformation polymorphism (PCR-SSCP), sequence-specific oligo‐
nucleotide (PCR-SSO) and single nucleotide polymorphism (PCR-SNP).
3.1. PCR-SSP (sequence specific primers)
To identify point mutations in a DNA molecule, Newton invented the amplification refrac‐
tory mutation system (ARMS) for in vitro DNA amplification. The technique requires an al‐
lele sequence specific 3’ primer for the PCR amplification. Otherwise the PCR reaction will
not be effective. This is because the Taq DNA polymerase used in the PCR reaction has 5’ to
3’ polymerase activity and 5’ to 3’ exonuclease activity but lacking 3’ to 5’ exonuclease activ‐
ity. Therefore, the enzyme cannot repair the single mismatched nucleotide in the 3’ primer.
In order to amplify the allele with a specific sequence, the primer with the corresponding
sequence is designed. The conditions for PCR reaction are strictly controlled so that the am‐
plification of the fragment with its sequence perfectly matching the primer is much more ef‐
fective than the sequence with one or more mismatched nucleotide. One mismatched
nucleotide between the 3’ primer and the template is sufficient to prevent the amplification.
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The PCR product is further analyzed by electrophoresis to determine whether the amplicon
corresponds to the anticipated primer-specific product. Since the DNA sequence of HLA
class I and class II genes are known, PCR primers can be designed based on the specific se‐
quence of each allele for PCR-SSP genotyping.
The encoding allele sequences of various HLA antigens can be amplified with sequence
specific primers. By controlling the conditions of PCR, a specific primer can only amplify
its corresponding allele,  and not other alleles.  Therefore,  the presence of a PCR product
can be used to determine the presence or  absence of  a  specific  allele.  The specificity  of
PCR product can be further determined by agarose gel  electrophoresis.  Fig 4 shows the
principle of PCR-SSP.
Figure 4. The diagram of PCR reaction
In the first step of PCR reaction, double-stranded DNA is denatured into single-stranded
DNA. In the second step, specific primers anneal to the template DNA. In the third step,
double stranded DNA is generated by TaqDNA polymerase by incorporating 4 types of
dNTP into the newly synthesized DNA strand. After 30-40 cycles of amplification, the target
gene is increased to 108 fold.
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When choosing a donor, the HLA-DRB1 gene of the donor and the recipient should have 4
identical digits after the asterisk in the WHO HLA nomenclature.
Although most commonly used methods for HLA genotyping cannot cover all genes, it does
not limit their applications in HLA typing for bone marrow transplantation. Among thousands
of identified HLA alleles, most of them are rare alleles. Therefore, it is not necessary to type all
HLA alleles. For instance, 244 expressing genes have been identified in DRB1 loci. Among
them, 148 (60%) alleles have corresponding specific DR antigens, while 96 alleles (40%) do not.
According to the NMDP, result of HLA-DRB1 typing in 65,752 donors shows that 86 alleles
have 0 frequency and the frequency of another 105 alleles is lower than 0.0002. In addition, the
total frequency of 10 alleles without corresponding antigens is 0.000084. Therefore, identifica‐
tion of the rest 43 DRB1 alleles will cover 99.6% of HLA-DR antigen specificities, which is suffi‐
cient for the screen of donor in hematopoietic stem cell transplantation.
3. PCR based HLA genotyping methods
The technology for HLA typing has evolved from the serological level to the cellular level, to
the molecular level. Serotyping was the mainstream method for HLA type and has played a
critical role in organ transplantations before 1990s. However, most HLA antisera are polyclo‐
nal and often have cross-reactions, making it difficult to distinguish antigens with subtle struc‐
tural differences, and leading to misidentifications. Further more, many factors, such as a
prolonged transportation time of the blood sample and excessive amount of immature cells,
may affect the result of serotyping and cellular typing. These are the limitations of traditional
HLA typing methods. The development of polymerase chain reaction (PCR) and its applica‐
tion in biomedical sciences has made the HLA typing at the DNA level possible. Therefore, us‐
ing molecular methods to type HLA at the DNA level has gradually replaced serotyping and
cellular typing. Commonly used DNA based HLA typing methods include PCR based se‐
quence specific primers (PCR-SSP), and PCR based restriction fragment length polymorphism
(PCR-RFLP), single-strand conformation polymorphism (PCR-SSCP), sequence-specific oligo‐
nucleotide (PCR-SSO) and single nucleotide polymorphism (PCR-SNP).
3.1. PCR-SSP (sequence specific primers)
To identify point mutations in a DNA molecule, Newton invented the amplification refrac‐
tory mutation system (ARMS) for in vitro DNA amplification. The technique requires an al‐
lele sequence specific 3’ primer for the PCR amplification. Otherwise the PCR reaction will
not be effective. This is because the Taq DNA polymerase used in the PCR reaction has 5’ to
3’ polymerase activity and 5’ to 3’ exonuclease activity but lacking 3’ to 5’ exonuclease activ‐
ity. Therefore, the enzyme cannot repair the single mismatched nucleotide in the 3’ primer.
In order to amplify the allele with a specific sequence, the primer with the corresponding
sequence is designed. The conditions for PCR reaction are strictly controlled so that the am‐
plification of the fragment with its sequence perfectly matching the primer is much more ef‐
fective than the sequence with one or more mismatched nucleotide. One mismatched
nucleotide between the 3’ primer and the template is sufficient to prevent the amplification.
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The PCR product is further analyzed by electrophoresis to determine whether the amplicon
corresponds to the anticipated primer-specific product. Since the DNA sequence of HLA
class I and class II genes are known, PCR primers can be designed based on the specific se‐
quence of each allele for PCR-SSP genotyping.
The encoding allele sequences of various HLA antigens can be amplified with sequence
specific primers. By controlling the conditions of PCR, a specific primer can only amplify
its corresponding allele,  and not other alleles.  Therefore,  the presence of a PCR product
can be used to determine the presence or  absence of  a  specific  allele.  The specificity  of
PCR product can be further determined by agarose gel  electrophoresis.  Fig 4 shows the
principle of PCR-SSP.
Figure 4. The diagram of PCR reaction
In the first step of PCR reaction, double-stranded DNA is denatured into single-stranded
DNA. In the second step, specific primers anneal to the template DNA. In the third step,
double stranded DNA is generated by TaqDNA polymerase by incorporating 4 types of
dNTP into the newly synthesized DNA strand. After 30-40 cycles of amplification, the target
gene is increased to 108 fold.
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The main advantage of this method is that it is simple and fast, and the result is easy to in‐
terpret. The heterozygosity can be easily detected as well. Therefore, PCR-SSP is the current‐
ly most used method for HLA typing. There are several FDA approved high-resolution and
low-resolution detection kits available for HLA class I and class II typing. Many clinical lab‐
oratories in China have been using this method for accurate pre-transplantation HLA typ‐
ing. The procedure of PCR-SSP is shown in Fig 5. One disadvantage of this method is that it
requires multiple primers in order to amply all relevant alleles.
Figure 5. The experimental procedure of PCR-SSP
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3.2. PCR-RFLP (restriction fragment length polymorphism)
Restriction endonucleases have unique recognition sites. Using computer analysis, restriction
endonucleases that can recognize HLA sequence polymorphism are chosen to digest the PCR
product. Because of sequence difference among the alleles, enzyme digestion will yield DNA
fragments with unique patterns of length, which can be distinguished by electrophoresis.
Compared to serotyping, PCR-RFLP method is specific, simple and rapid and does not re‐
quire probes. It can accurately detect single nucleotide difference and two linked polymor‐
phic sites. The disadvantage of this method is that if the enzyme cannot completely digest
the PCR product, the DNA fragments with similar lengths may be difficult to distinguish
after electrophoresis. In addition, alleles need to have endonuclease recognition sites. Fur‐
thermore, PCR-RFLP cannot distinguish certain HLA heterozygosities. It requires multiple
endonucleases for those alleles with high polymorphism such as HLA-DRB1, and may pro‐
duce complicated restriction maps. For these reasons, this method is rarely used for HLA
typing currently.
3.3. PCR-SSCP (single-strand conformation polymorphism)
Suzuki et al in Japan have found that a single-stranded DNA fragment has complex spatial
conformation. The three-dimensional structure is generated by the intramolecular interac‐
tions among the base pairs. The changing of one nucleotide may affect the spatial conforma‐
tion of the DNA strand. Single stranded DNA molecules have their unique size exclusion
characters in polyacrylamide gels due to their molecular weights and three-dimensional
structures. Therefore, they can be separated by non-denature polyacrylamide gel electro‐
phoresis (PAGE). This method is sensitive enough to distinguish molecules with subtle
structural differences, and it is called single-stranded conformation polymorphism (SSCP).
The authors later applied SSCP in the detection of mutations in PCR products and devel‐
oped PCR-SSCP technique, which has further improved the sensitivity and simplicity for
mutation detection.
This method is simple, rapid, sensitive, requiring no special equipment, and is suitable for clin‐
ical applications. However, this method can only detect mutations. The location and the type of
the mutation need to be determined by sequencing. In addition, the conditions of electrophore‐
sis need to be tightly controlled. Furthermore, point mutations in certain locations may have no
to little effect on the DNA conformation. Therefore, different DNA molecules may not be able
to separate by PAGE due to these reasons and other factors. Nevertheless, this method has a rel‐
atively high detection sensitivity compared with other methods. It can detect mutations in un‐
known locations in the DNA molecule. Takao has demonstrated that SSCP can detect 90% of
single nucleotide mutations in a DNA fragment smaller than 300bp. He believes that most
known single nucleotide mutations can be detected by this method. Mutant DNA molecules
can be separated and purified by PAGE due to the different migration rates, and the mutation
can be eventually identified by DNA sequencing.
In SSCP analysis, the separation of single stranded DNA by non denature PAGE is not just
based on their molecular weights and electric charges, but also on the retention force caused
by their spatial conformations. Therefore, the migration rate of a DNA fragment does not
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The main advantage of this method is that it is simple and fast, and the result is easy to in‐
terpret. The heterozygosity can be easily detected as well. Therefore, PCR-SSP is the current‐
ly most used method for HLA typing. There are several FDA approved high-resolution and
low-resolution detection kits available for HLA class I and class II typing. Many clinical lab‐
oratories in China have been using this method for accurate pre-transplantation HLA typ‐
ing. The procedure of PCR-SSP is shown in Fig 5. One disadvantage of this method is that it
requires multiple primers in order to amply all relevant alleles.
Figure 5. The experimental procedure of PCR-SSP
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3.2. PCR-RFLP (restriction fragment length polymorphism)
Restriction endonucleases have unique recognition sites. Using computer analysis, restriction
endonucleases that can recognize HLA sequence polymorphism are chosen to digest the PCR
product. Because of sequence difference among the alleles, enzyme digestion will yield DNA
fragments with unique patterns of length, which can be distinguished by electrophoresis.
Compared to serotyping, PCR-RFLP method is specific, simple and rapid and does not re‐
quire probes. It can accurately detect single nucleotide difference and two linked polymor‐
phic sites. The disadvantage of this method is that if the enzyme cannot completely digest
the PCR product, the DNA fragments with similar lengths may be difficult to distinguish
after electrophoresis. In addition, alleles need to have endonuclease recognition sites. Fur‐
thermore, PCR-RFLP cannot distinguish certain HLA heterozygosities. It requires multiple
endonucleases for those alleles with high polymorphism such as HLA-DRB1, and may pro‐
duce complicated restriction maps. For these reasons, this method is rarely used for HLA
typing currently.
3.3. PCR-SSCP (single-strand conformation polymorphism)
Suzuki et al in Japan have found that a single-stranded DNA fragment has complex spatial
conformation. The three-dimensional structure is generated by the intramolecular interac‐
tions among the base pairs. The changing of one nucleotide may affect the spatial conforma‐
tion of the DNA strand. Single stranded DNA molecules have their unique size exclusion
characters in polyacrylamide gels due to their molecular weights and three-dimensional
structures. Therefore, they can be separated by non-denature polyacrylamide gel electro‐
phoresis (PAGE). This method is sensitive enough to distinguish molecules with subtle
structural differences, and it is called single-stranded conformation polymorphism (SSCP).
The authors later applied SSCP in the detection of mutations in PCR products and devel‐
oped PCR-SSCP technique, which has further improved the sensitivity and simplicity for
mutation detection.
This method is simple, rapid, sensitive, requiring no special equipment, and is suitable for clin‐
ical applications. However, this method can only detect mutations. The location and the type of
the mutation need to be determined by sequencing. In addition, the conditions of electrophore‐
sis need to be tightly controlled. Furthermore, point mutations in certain locations may have no
to little effect on the DNA conformation. Therefore, different DNA molecules may not be able
to separate by PAGE due to these reasons and other factors. Nevertheless, this method has a rel‐
atively high detection sensitivity compared with other methods. It can detect mutations in un‐
known locations in the DNA molecule. Takao has demonstrated that SSCP can detect 90% of
single nucleotide mutations in a DNA fragment smaller than 300bp. He believes that most
known single nucleotide mutations can be detected by this method. Mutant DNA molecules
can be separated and purified by PAGE due to the different migration rates, and the mutation
can be eventually identified by DNA sequencing.
In SSCP analysis, the separation of single stranded DNA by non denature PAGE is not just
based on their molecular weights and electric charges, but also on the retention force caused
by their spatial conformations. Therefore, the migration rate of a DNA fragment does not
The Advanced HLA Typing Strategies for Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/53084
55
reflect its molecular size. Since the wild type and mutant DNA molecules may migrate very
closely and are difficult to distinguish, it is generally required for DNA molecules to migrate
for more than 16-18 cm in the gel. Mobility is calibrated using reference DNA as an internal
control. Because of these reasons, this method cannot clearly determine the HLA genotype.
3.4. PCR-SSO (sequence specific oligonucleotide)
In PCR-SSO, specific probes are synthesized according to the sequence in the HLA polymor‐
phic region. The target DNA fragment is amplified in vitro first. Then a specific probe will be
hybridized to the PCR product under certain conditions based on base pair complements.
The hybridized product can be detected by radioactive or non-radioactive signals. There are
two types of SSOP method, direct hybridization and reverse hybridization. In the direct hy‐
bridization, the PCR product is fixed on the membrane while in the reverse hybridization,
the probe is fixed on membrane. Figure 6 is the diagram of PCR-SSO.
Figure 6. The diagram of PCR-SSO process
In 1986, Saiki et al were the first to report the analysis of DQA1 polymorphism using PCR
and 4 allelic specific oligonucleotide (ASO) probes. MicKelson has typed the DR loci by se‐
rotyping and PCR-SSOP in 268 specimens. The success rate of serotyping is 91.0% while the
success rate of PCR-SSOP is 97.0%. Overall, PCR-SSOP has a high success rate, a wide
source of reagents, a high specificity and resolution. It can detect the difference of one nu‐
cleotide. In addition, PCR-SSOP can be used for a large number of samples with accurate
and reliable results. However, this method is time consuming. It often takes a few days and
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needs a large amount of probes. In addition, it is difficult to detect heterozygous alleles, par‐
ticularly those of the complicated HLA-DRB1 genes.
Overall, PCR-SSO is an accurate HLA genotyping method, and can identify all known HLA
alleles for accurate analysis of HLA polymorphism. HLA is a super gene family and new
alleles are continuously been identified. SSO probes can only be designed based on the se‐
quences of known alleles. Although PCR-SSO may discover new HLA polymorphism
through its hybridization pattern, dot-hybridization often leads to false positives. In addi‐
tion, when an allele is identified in the sample, it is difficult to determine whether the allele
is homozygous or heterozygous. Therefore, the HLA allele frequency and haplotype fre‐
quency cannot be precisely determined by this method.
3.5. PCR-SNP (single nucleotide polymorphism)
Single nucleotide polymorphism (SNP) is the inheritable and stable biallelic single nucleotide
difference. In the human genome, every 1000 base pairs have one to 10 SNPs. SNP may have
some regulatory functions in gene expression and protein activity. High SNP density has been
found in HLA class I genes with one SNP in every 400bp, setting the basis for high-throughput
MHC-SNP analysis. Compared with other methods, SNP is less time consuming and with a
low cost. Gou et al have developed a simple and effective oligonucleotide microarray to detect
SNPs in the coding sequence of HLA-B locus. Based on the known polymorphism in the exon 2
and 3 of HLA-B genes, 137 specific probes were designed. In a double-blind experiment, these
probes were used in the PCR-SNP analysis of 100 specimens from unrelated individuals. The
result showed that this method could explicitly identify all SNPs in the HLA-B locus. Bu Ying et
al have established a rapid, efficient, and cost effective SNP detection method using a single
tube. In this method, 4 primers are used for the PCR amplification. Two primers are used to am‐
plify the DNA fragment containing the SNP region, and the other two primers are SNP specific.
The primer extension error is significantly reduced when 4 primers simultaneously carry out
the PCR reaction, thereby the accuracy of SNP analysis is greatly improved. With the develop‐
ment of third-generation genetic markers, it is expected to find a series of single nucleotide
polymorphisms in the HLA complex, and generate high-density SNP maps. In order to devel‐
op SNP technology into a simple and effective HLA typing method, production of high-density
SNP maps in the HLA regions and development of HLA-SNP genotyping kits have been pro‐
posed in the 13th IHWC conference.
4. Reference-strand-mediated conformation analysis (RSCA)
Arguello et al devised the double-stranded conformation analysis (DSCA) technique in 1998
for the detection and analysis of gene mutations and complex polymorphic loci. Based on
this technique, reference strand mediated conformation analysis (RSCA) has been devel‐
oped. This is a major technical breakthrough in HLA typing. This technique combines se‐
quencing and conformational analysis to overcome the limitations of the methods that just
employ DNA sequencing or conformational analysis. The concept behind RSCA is that a flu‐
orescent labeled reference strand is hybridized with the amplified product of a specific gene
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hybridized to the PCR product under certain conditions based on base pair complements.
The hybridized product can be detected by radioactive or non-radioactive signals. There are
two types of SSOP method, direct hybridization and reverse hybridization. In the direct hy‐
bridization, the PCR product is fixed on the membrane while in the reverse hybridization,
the probe is fixed on membrane. Figure 6 is the diagram of PCR-SSO.
Figure 6. The diagram of PCR-SSO process
In 1986, Saiki et al were the first to report the analysis of DQA1 polymorphism using PCR
and 4 allelic specific oligonucleotide (ASO) probes. MicKelson has typed the DR loci by se‐
rotyping and PCR-SSOP in 268 specimens. The success rate of serotyping is 91.0% while the
success rate of PCR-SSOP is 97.0%. Overall, PCR-SSOP has a high success rate, a wide
source of reagents, a high specificity and resolution. It can detect the difference of one nu‐
cleotide. In addition, PCR-SSOP can be used for a large number of samples with accurate
and reliable results. However, this method is time consuming. It often takes a few days and
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needs a large amount of probes. In addition, it is difficult to detect heterozygous alleles, par‐
ticularly those of the complicated HLA-DRB1 genes.
Overall, PCR-SSO is an accurate HLA genotyping method, and can identify all known HLA
alleles for accurate analysis of HLA polymorphism. HLA is a super gene family and new
alleles are continuously been identified. SSO probes can only be designed based on the se‐
quences of known alleles. Although PCR-SSO may discover new HLA polymorphism
through its hybridization pattern, dot-hybridization often leads to false positives. In addi‐
tion, when an allele is identified in the sample, it is difficult to determine whether the allele
is homozygous or heterozygous. Therefore, the HLA allele frequency and haplotype fre‐
quency cannot be precisely determined by this method.
3.5. PCR-SNP (single nucleotide polymorphism)
Single nucleotide polymorphism (SNP) is the inheritable and stable biallelic single nucleotide
difference. In the human genome, every 1000 base pairs have one to 10 SNPs. SNP may have
some regulatory functions in gene expression and protein activity. High SNP density has been
found in HLA class I genes with one SNP in every 400bp, setting the basis for high-throughput
MHC-SNP analysis. Compared with other methods, SNP is less time consuming and with a
low cost. Gou et al have developed a simple and effective oligonucleotide microarray to detect
SNPs in the coding sequence of HLA-B locus. Based on the known polymorphism in the exon 2
and 3 of HLA-B genes, 137 specific probes were designed. In a double-blind experiment, these
probes were used in the PCR-SNP analysis of 100 specimens from unrelated individuals. The
result showed that this method could explicitly identify all SNPs in the HLA-B locus. Bu Ying et
al have established a rapid, efficient, and cost effective SNP detection method using a single
tube. In this method, 4 primers are used for the PCR amplification. Two primers are used to am‐
plify the DNA fragment containing the SNP region, and the other two primers are SNP specific.
The primer extension error is significantly reduced when 4 primers simultaneously carry out
the PCR reaction, thereby the accuracy of SNP analysis is greatly improved. With the develop‐
ment of third-generation genetic markers, it is expected to find a series of single nucleotide
polymorphisms in the HLA complex, and generate high-density SNP maps. In order to devel‐
op SNP technology into a simple and effective HLA typing method, production of high-density
SNP maps in the HLA regions and development of HLA-SNP genotyping kits have been pro‐
posed in the 13th IHWC conference.
4. Reference-strand-mediated conformation analysis (RSCA)
Arguello et al devised the double-stranded conformation analysis (DSCA) technique in 1998
for the detection and analysis of gene mutations and complex polymorphic loci. Based on
this technique, reference strand mediated conformation analysis (RSCA) has been devel‐
oped. This is a major technical breakthrough in HLA typing. This technique combines se‐
quencing and conformational analysis to overcome the limitations of the methods that just
employ DNA sequencing or conformational analysis. The concept behind RSCA is that a flu‐
orescent labeled reference strand is hybridized with the amplified product of a specific gene
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to form stable double stranded DNA with unique conformation. After non-denature polya‐
crylamide gel electrophoresis or capillary electrophoresis, HLA alleles can be detected by la‐
ser scanning and computer software based analysis. Figure 7 is the basic procedure of
RSCA.
Figure 7. The basic procedure of RSCA
Compared with PCR-SSP, the most commonly used method of HLA genotyping, RSCA has
the following advantages: (1) high resolution and sensitivity. RSCA is based on the differen‐
tial migration rate of fluorescent-labeled double stranded DNA during the electrophoresis.
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Alleles with different sequences will produce DNA duplexes with different spatial struc‐
tures after hybridization with their fluorescent labeled probes. Two alleles with one nucleo‐
tide difference will cause a change in the spatial structure of a hybridized duplex, resulting
in an altered migration rate in electrophoresis. Therefore, RSCA can distinguish the alleles
with a single nucleotide difference. For example, HLA-A*0207 and A*0209 alleles only differ
from one nucleotide at the site 368 of exon 3. In this site, A*0207 has a G while A*0207 has an
A. Likewise, HLA-A*0224 and A*0226 only differ from one nucleotide. These alleles all can
be distinguished by RSCA. (2) high reproducibility. In RSCA, each lane in the non-denature
polyacrylamide gel has markers and each gel has a DNA ladder. Therefore, the alteration
caused by different gels or lanes can be eliminated. (3) new allele or mutation identification.
RSCA is based on the electrophoretic mobility difference caused by different spatial struc‐
ture of the duplexes after allele-FLR hybridization. New alleles or mutations will have elec‐
trophoretic mobility different from that of known alleles. (4) RSCA can be applied at a large
scale with a low cost.
The disadvantages of RSCA are (1) time-consuming for a single sample; (2) requiring high
quality samples; PCR-SSP requires 10-100ng/ml of DNA, which can be obtained with a regu‐
lar DNA purification kit from patients even with a low amount of white blood cells. Howev‐
er, RSCA requires 50-100ng/ml of DNA. It may require an increased amount of blood
sample for patients with low levels of white blood cell in order to obtain sufficient DNA;
and (3) insufficient database.
5. Pyrosequencing: A high-resolution method for HLA typing
Pyrosequencing is a new HLA genotyping technology based on real time sequencing during
DNA amplification. The reaction system contains 4 enzymes (DNA polymerase, ATP sulfur‐
ylase, luciferase and apyrase), a substrate (APS: adenosine 5’ phosphosulfate), fluorescein
(luciferin), primers and the single stranded DNA template. After one type of dNTP (dATP,
dTTP, dCTP and dGTP) is added to the reaction system, it will be incorporated into the
newly synthesized chain if it is complementary to the nucleotide on the template. Incorpora‐
tion of dNTP will generate the same molar amount of pyrophosphate (PPi). ATP sulfurylase
converts APS and PPi into ATP, which provides energy for luciferase to oxidate luciferin
and emit light. The amount of light signal is proportional to the amount of ATP. The optical
signal is detected by a CCD (charge couple device) camera and generates a peak in the pyro‐
gram. The principle of Pyrosequencing is shown in Fig 8.
The height of each signal’s peak is proportional to the number of nucleotides incorperated.
Unincorporated dNTPs and excessive ATP are converted to dNDPs, which are further con‐
verted to dNMPs by apyrase. The optical signal is quenched and the system is regenerated
for the next reaction. The next dNTP can be added to the system to start the next reaction
after the unincorporated dNTPs and excessive ATP are removed. The reaction cycle contin‐
ues until the complementary DNA strand is synthesized. Under the room temperature, it
takes 3-4 seconds from polymerization to light detection. In this system, 1 pmol of DNA will
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to form stable double stranded DNA with unique conformation. After non-denature polya‐
crylamide gel electrophoresis or capillary electrophoresis, HLA alleles can be detected by la‐
ser scanning and computer software based analysis. Figure 7 is the basic procedure of
RSCA.
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A. Likewise, HLA-A*0224 and A*0226 only differ from one nucleotide. These alleles all can
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polyacrylamide gel has markers and each gel has a DNA ladder. Therefore, the alteration
caused by different gels or lanes can be eliminated. (3) new allele or mutation identification.
RSCA is based on the electrophoretic mobility difference caused by different spatial struc‐
ture of the duplexes after allele-FLR hybridization. New alleles or mutations will have elec‐
trophoretic mobility different from that of known alleles. (4) RSCA can be applied at a large
scale with a low cost.
The disadvantages of RSCA are (1) time-consuming for a single sample; (2) requiring high
quality samples; PCR-SSP requires 10-100ng/ml of DNA, which can be obtained with a regu‐
lar DNA purification kit from patients even with a low amount of white blood cells. Howev‐
er, RSCA requires 50-100ng/ml of DNA. It may require an increased amount of blood
sample for patients with low levels of white blood cell in order to obtain sufficient DNA;
and (3) insufficient database.
5. Pyrosequencing: A high-resolution method for HLA typing
Pyrosequencing is a new HLA genotyping technology based on real time sequencing during
DNA amplification. The reaction system contains 4 enzymes (DNA polymerase, ATP sulfur‐
ylase, luciferase and apyrase), a substrate (APS: adenosine 5’ phosphosulfate), fluorescein
(luciferin), primers and the single stranded DNA template. After one type of dNTP (dATP,
dTTP, dCTP and dGTP) is added to the reaction system, it will be incorporated into the
newly synthesized chain if it is complementary to the nucleotide on the template. Incorpora‐
tion of dNTP will generate the same molar amount of pyrophosphate (PPi). ATP sulfurylase
converts APS and PPi into ATP, which provides energy for luciferase to oxidate luciferin
and emit light. The amount of light signal is proportional to the amount of ATP. The optical
signal is detected by a CCD (charge couple device) camera and generates a peak in the pyro‐
gram. The principle of Pyrosequencing is shown in Fig 8.
The height of each signal’s peak is proportional to the number of nucleotides incorperated.
Unincorporated dNTPs and excessive ATP are converted to dNDPs, which are further con‐
verted to dNMPs by apyrase. The optical signal is quenched and the system is regenerated
for the next reaction. The next dNTP can be added to the system to start the next reaction
after the unincorporated dNTPs and excessive ATP are removed. The reaction cycle contin‐
ues until the complementary DNA strand is synthesized. Under the room temperature, it
takes 3-4 seconds from polymerization to light detection. In this system, 1 pmol of DNA will
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generate 6x1011 pmol of ATP, which in turn yields 6x109 pmol of photon with a wavelength
of 560nm. The signal can be easily detected by a CCD camera. For the analysis of DNA with
an unknown sequence by Pyrosequencing, a cyclic nucleotide dispensation order (NDO) is
used. dATP, dGTP, dTTP and dCTP are sequentially added to the reaction. After one nu‐
cleotide is incorporated, the other three will be degraded by the apyrase. For the DNA with
a known sequence, non-cyclic NDO can be used and will yield a predicted pyrogram. The
sequence of the complementary DNA strand can be determined based on the NOD and
peak value in the pyrogram.
Figure 8. The principle of Pyrosequencing
Since nucleotides are differentially incorporated, Pyrosequencing can produce high-resolu‐
tion results. Typing HLA-DRB1*04, 07 and DRB4* in the donor’s DRB genes by Pyrose‐
quencing not only yields the same result as using the SSOP typing kit, but also produces the
result with a higher resolution. Compared with SSP, SSOP, direct or reverse hybridization,
Pyrosequencing can be used to solve ambiguous allele combinations of HLA-DQ and HLA-
A/B in a short time. The types of HLA-DQB1 and HLA-DRB alleles have been accurately de‐
termined by Pyrosequencing.
An inherent problem with this technology is the de novo sequencing of polymorphic region in
heterozygous DNA, although polymorphism can be detected in most cases. When the nucleo‐
tide in the polymorphic region is altered, synchronized extension can be achieved by the addi‐
tion of the substituted nucleotides. If there is a deletion or insertion in the polymorphic region,
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and the deleted or inserted nucleotide is the same as the adjacent nucleotide on the template,
the sequence after the polymorphic region will be synchronized. However, if the deleted or in‐
serted nucleotide is different from the adjacent nucleotide on the template, the sequence reac‐
tion can be out of phase, making the subsequent sequence analysis difficult. Another issue with
this technology is the difficulty in determining the number of incorporated nucleotides at the
homopolymeric region. The light signal will become nonlinear after the incorporation of more
than 5-6 nucleotides. Studies on the polymerization efficiency of the homopolymeric region
have shown that it is possible to incorporate less than 10 identical nucleotides in the presence of
apyrase. However, it needs a specific software algorithm of signal integration to determine the
precise number of incorporated nucleotides. For re-sequencing, the nucleotide is added twice
to ensure complete polymerization in the homopolymeric region. Another limitation of this
technology is the length of the sequencing.
6. Application of flow cytometry in HLA typing
Flow cytometry has failed to become a main method for HLA typing since it was applied to
the field of immunology for the first time in 1977. This is mainly due to the large number of
specific probes required for HLA typing. The flow analyzer LABScan100 that combines the
flow cytometry and reverse SSO technology is trending to replace three conventional meth‐
ods, SSO, SSP and SBT (sequence-based typing, direct sequencing), in HLA typing.
On a suspension platform, multiple types of color-coded beads conjugated with SSO probes
specifically bind to the single stranded DNA. Each type of bead has its unique spectral char‐
acteristics due to the different amount of fluorescent dye conjugated to the beads. When
beads pass through a flow cytometer, the difference in the light scattering pattern from vari‐
ous angles can distinguish HLA genotypes.
Currently, LabType TM SSO is a relatively more mature technique compared with others in
HLA typing. Its unique advantage is that thousands of molecules can be simultaneously an‐
alyzed in a matter of seconds. Therefore, this technique can be used for a large-scale analy‐
sis. Overall, this technique has the following advantages: (1) It has increased accuracy due to
the automated detection system. (2) The workload and reagent consumption are reduced.
One reaction tube can have 100 different SSO probes, thus greatly reducing the workload
and reagent consumption. (3) It produces rapid and objective results. The ambiguous results
can be avoided with Specialty Probe Technology TM (SP Technology). (4) Unlike regular flow
cytometry that requires fresh samples, this technique can examine the sample at any time
upon request or retrospectively. DNA samples can be analyzed right after extraction or stor‐
ed at –20oC for more than 1 year without affecting the results. (5) The technique can analyze
multiple HLA loci with low, medium and high resolutions. (6) It can be used in laboratories
with large or small samples. More than 100 probes can be put in one test tube for one sample
or in a 96-well plate for 96 samples. The analysis of 96 samples takes less than 90 min after
amplification. (7) The pollution to the environment and potential harm to the staff are re‐
duced because electrophoresis is not required in this method.
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generate 6x1011 pmol of ATP, which in turn yields 6x109 pmol of photon with a wavelength
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a known sequence, non-cyclic NDO can be used and will yield a predicted pyrogram. The
sequence of the complementary DNA strand can be determined based on the NOD and
peak value in the pyrogram.
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quencing not only yields the same result as using the SSOP typing kit, but also produces the
result with a higher resolution. Compared with SSP, SSOP, direct or reverse hybridization,
Pyrosequencing can be used to solve ambiguous allele combinations of HLA-DQ and HLA-
A/B in a short time. The types of HLA-DQB1 and HLA-DRB alleles have been accurately de‐
termined by Pyrosequencing.
An inherent problem with this technology is the de novo sequencing of polymorphic region in
heterozygous DNA, although polymorphism can be detected in most cases. When the nucleo‐
tide in the polymorphic region is altered, synchronized extension can be achieved by the addi‐
tion of the substituted nucleotides. If there is a deletion or insertion in the polymorphic region,
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and the deleted or inserted nucleotide is the same as the adjacent nucleotide on the template,
the sequence after the polymorphic region will be synchronized. However, if the deleted or in‐
serted nucleotide is different from the adjacent nucleotide on the template, the sequence reac‐
tion can be out of phase, making the subsequent sequence analysis difficult. Another issue with
this technology is the difficulty in determining the number of incorporated nucleotides at the
homopolymeric region. The light signal will become nonlinear after the incorporation of more
than 5-6 nucleotides. Studies on the polymerization efficiency of the homopolymeric region
have shown that it is possible to incorporate less than 10 identical nucleotides in the presence of
apyrase. However, it needs a specific software algorithm of signal integration to determine the
precise number of incorporated nucleotides. For re-sequencing, the nucleotide is added twice
to ensure complete polymerization in the homopolymeric region. Another limitation of this
technology is the length of the sequencing.
6. Application of flow cytometry in HLA typing
Flow cytometry has failed to become a main method for HLA typing since it was applied to
the field of immunology for the first time in 1977. This is mainly due to the large number of
specific probes required for HLA typing. The flow analyzer LABScan100 that combines the
flow cytometry and reverse SSO technology is trending to replace three conventional meth‐
ods, SSO, SSP and SBT (sequence-based typing, direct sequencing), in HLA typing.
On a suspension platform, multiple types of color-coded beads conjugated with SSO probes
specifically bind to the single stranded DNA. Each type of bead has its unique spectral char‐
acteristics due to the different amount of fluorescent dye conjugated to the beads. When
beads pass through a flow cytometer, the difference in the light scattering pattern from vari‐
ous angles can distinguish HLA genotypes.
Currently, LabType TM SSO is a relatively more mature technique compared with others in
HLA typing. Its unique advantage is that thousands of molecules can be simultaneously an‐
alyzed in a matter of seconds. Therefore, this technique can be used for a large-scale analy‐
sis. Overall, this technique has the following advantages: (1) It has increased accuracy due to
the automated detection system. (2) The workload and reagent consumption are reduced.
One reaction tube can have 100 different SSO probes, thus greatly reducing the workload
and reagent consumption. (3) It produces rapid and objective results. The ambiguous results
can be avoided with Specialty Probe Technology TM (SP Technology). (4) Unlike regular flow
cytometry that requires fresh samples, this technique can examine the sample at any time
upon request or retrospectively. DNA samples can be analyzed right after extraction or stor‐
ed at –20oC for more than 1 year without affecting the results. (5) The technique can analyze
multiple HLA loci with low, medium and high resolutions. (6) It can be used in laboratories
with large or small samples. More than 100 probes can be put in one test tube for one sample
or in a 96-well plate for 96 samples. The analysis of 96 samples takes less than 90 min after
amplification. (7) The pollution to the environment and potential harm to the staff are re‐
duced because electrophoresis is not required in this method.
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7. Gene chip or DNA microarray
In gene chip or DNA microarray, large amount of probe molecules (usually 6x104
molecules/cm2) are attached to a solid surface. Labeled DNA samples are hybridized to the
probes. The amount and sequence information of the target can be determined by the inten‐
sity of the hybridization signal. Gene chip or DNA microarray technology was first devel‐
oped by Affymetrix in the USA, and has been improved significantly within a few years.
The technology is based on the principle of reverse dot hybridization. Thousands of oligo‐
nucleotide probes representing different genes are spotted on a solid surface by a robot.
These probes will bind to radioactive isotope or fluorescent dye labeled DNA or cDNA
through complementary sequences. After autoradiography or fluorescence detection, signals
are processed and analyzed by computer software. The intensity and distribution of hybridi‐
zation signal reflect the expression level of the gene in the sample. The operation process of
microarray is shown in Fig 9. Balazs et al spotted amplified DNA samples on silicon chips
and compared the microarray results with PCR-SSO results in 768 specimens. It has been
found that microarray has a high sensitivity and specificity. The consistent rate of genotyp‐
ing results from microarray and PCR-SSO is 99.9%.
Figure 9. The procedure of gene chip/microarray analysis
Compared with existing genotyping methods, gene chip or microarray has the following ad‐
vantages: (1) High intensity. The dot intensity on a chip can be higher than 6x104/cm2. There‐
fore, probes to thousands of HLA-A, B, C, DR, DQ and DP sequences can be spotted on a
tiny chip of several square centimeters to obtain the information of individual HLA genes
simultaneously. (2) High resolution. It can obtain information at the allele level. (3) Simple
operation. The results are generated by fluorescence scanning instead of gel electrophoresis,
which greatly simplifies the procedure and shortens operation time. (4) High sensitivity.
Signals are amplified twice, first, PCR amplification of the template DNA and second, am‐
plification of fluorescence signal. Therefore, the sensitivity is greatly improved. (5)High ac‐
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curacy. The intensity of the fluorescent signal generated by the perfect pairing of the probe
and the sample is 5 to 35 times higher than the signal generated by the probe and the sample
with one or two mismatched nucleotides. Accurate detection of fluorescent signal intensity
is the basis of the detection specificity. Studies have shown that the consistency between mi‐
croarray and Sanger sequencing in the detection of mutations and polymorphism is 99.9%.
(6) High efficiency. The whole process is highly automatic, which saves manpower and time
for data analysis. Genotyping of genes such as HLA-A, B, DR and DQ in multiple samples
can be done with one PCR reaction and hybridization on one chip. (7) High level of stand‐
ardization. Using a variety of multi-point synchronized hybridization and automated analy‐
sis, the human error is minimized to ensure the specificity and objectivity. (8) Low cost.
Since the chip fabrication and signal detection are all automatic, only a small amount of
probes and samples are required. One chip can be used for the analysis of samples from
multiple individuals, which further reduces the cost. The biggest drawback of microarray
analysis is its expensive equipment, which prevents it from becoming widely used. Only in‐
stitutions with a large program can afford the equipment.
8. DNA sequencing technology
For the analysis of gene structure, sequencing is the most direct and accurate method. In this
case, the DNA fragment is amplified by PCR and followed by sequencing. The basic process
of this method is shown in Figure 10. Since the entire nucleotide sequence of the amplified
fragment is obtained, this is the most reliable and thorough genotyping method. It can not
only identify the sequence and genotype, but also lead to the discovery of new genotypes.
Currently, the newly identified HLA alleles can only be verified by sequencing. It has been
reported that if the HLA type cannot be determined by serotyping or the results from PCR-
SSP and PCR-SSOP are inconsistent, sequence-based typing (SBT) often can yield accurate
and reliable results with a high resolution. Hurley et al have typed HLA alleles by PCR-STB
in 1775 bone marrow transplant patients and unrelated donors in NMDP, USA. The study
has found that the degree of HLA allele mismatching between the recipient and donor of
bone marrow transplantation is much higher than previously thought after examining the
antigen matching results of HLA-A, HLA-B and HLA-DR.
The advantage of SBT over PCR-SSP and PCR-SSOP is its ability to analyze the entire gene
sequence including the non-polymorphic region. SBT can be used not only for DNA se‐
quencing but also for cDNA sequencing to determine gene expression. With increasing pop‐
ularity of DNA sequencing technology, the PCR-SBT method has gained much attention for
genotyping. PCR-SBT has advantages over other typing methods in terms of accuracy, effi‐
ciency and the degree of automation. Specialized software and solid phase sequencing kits
with automatic loading are available for HLA typing. In addition, the cost of DNA sequenc‐
ing has been greatly reduced. Therefore, PCR-SBT is an ideal method for HLA typing in re‐
searches. With further decrease in the cost of automatic sequencing, this genotyping method
will be widely used.
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7. Gene chip or DNA microarray
In gene chip or DNA microarray, large amount of probe molecules (usually 6x104
molecules/cm2) are attached to a solid surface. Labeled DNA samples are hybridized to the
probes. The amount and sequence information of the target can be determined by the inten‐
sity of the hybridization signal. Gene chip or DNA microarray technology was first devel‐
oped by Affymetrix in the USA, and has been improved significantly within a few years.
The technology is based on the principle of reverse dot hybridization. Thousands of oligo‐
nucleotide probes representing different genes are spotted on a solid surface by a robot.
These probes will bind to radioactive isotope or fluorescent dye labeled DNA or cDNA
through complementary sequences. After autoradiography or fluorescence detection, signals
are processed and analyzed by computer software. The intensity and distribution of hybridi‐
zation signal reflect the expression level of the gene in the sample. The operation process of
microarray is shown in Fig 9. Balazs et al spotted amplified DNA samples on silicon chips
and compared the microarray results with PCR-SSO results in 768 specimens. It has been
found that microarray has a high sensitivity and specificity. The consistent rate of genotyp‐
ing results from microarray and PCR-SSO is 99.9%.
Figure 9. The procedure of gene chip/microarray analysis
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vantages: (1) High intensity. The dot intensity on a chip can be higher than 6x104/cm2. There‐
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curacy. The intensity of the fluorescent signal generated by the perfect pairing of the probe
and the sample is 5 to 35 times higher than the signal generated by the probe and the sample
with one or two mismatched nucleotides. Accurate detection of fluorescent signal intensity
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stitutions with a large program can afford the equipment.
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Currently, PCR-SBT is the gold standard of HLA typing. This method has several advantag‐
es: (1) It can accurately determine gene type in the exon 8 by a high-resolution sequencing,
sufficient to meet the need in researches and clinics. (2) It can analyze more than 15,000 sam‐
ples every month with high throughput detection. (3) Automated SOP and advanced data
management system can reduce human error. (4) It has high quality assurance. Ten percent
blind samples are used repeatedly as internal quality control and 100% accuracy is achieved
for 10 consecutive times using UCLA external quality assurance samples. The results are
confirmed by SSP. (5). It may lead to the discovery of new alleles. (6) HLA genotype can be
updated by re-analyzing the sequence after the HLA database is updated.









Figure 10. The diagram of DNA sequencing
9. Conclusion
Hematopoietic stem cell transplantation has become one of the most effective treatments for
a variety of hematologic malignancies. However, graft-versus-host disease (GVHD) is still
inevitable in some cases. This is mainly due to the difference in the major histocompatibility
complex (human leukocyte antigen, HLA) between the recipient and the donor. Other
known and unknown factors that may cause GVHD include minor histocompatibility anti‐
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gen (mHA) and tissue specific antigens. GVHD is the main cause of transplant failure in the
allogeneic transplantation. Therefore, GVHD is the most significant challenge in allogeneic
hematopoietic stem cell transplantation in clinics. It has been proven that whether the graft
can survive largely depends on the degree of HLA matching between the recipient and the
donor. Therefore, HLA typing of the recipient and the donor before the transplantation is
particularly important.
Currently, PCR-SSP genotyping is a commonly used method for HLA typing in clinical lab‐
oratories worldwide. Like SSP method, PCR-SSP method depends on specific primers for
genotyping. Although the process is simple and rapid, high-resolution genotyping requires
a large number of sequence specific primers, which leads to a high cost and prolonged oper‐
ation time. Similarly, SSO technique is based on the sequence-specific oligonucleotide
probes. High-resolution genotyping by SSO significantly increases the cost and complexity.
Therefore, it is rarely used for HLA typing today. PCR-SNP is a simple and fast method
with a high resolution, and PCR-SNP is expected to become more popular in HLA typing as
the technology continues to improve. Although RSCA and Pyrosequencing can achieve
high-resolution results, their applications in HLA typing will be gradually eliminated as the
technology of gene chip and sequencing continues to improve and the cost continues to de‐
crease. HLA-chip genotyping is still largely dependent on the known sequence. It cannot
identify new alleles with unknown sequence. At this moment, PCR-SBT technology has sig‐
nificant advantages over other HLA typing methods in terms of accuracy, efficiency and au‐
tomation. There are specialized software and automatically loaded sequencing reagents for
HLA typing by PCR-SBT. In addition, the operation cost has been greatly reduced. In con‐
clusion, PCR-SBT technology with HLA-chip is the best method for HLA typing in research.
With the reduction in the cost of automated nucleic acid sequencing, this genotyping meth‐
od will be widely used in the field of basic research as well as in clinical transplantation.
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1. Introduction
The brain is one of the main targets of gonadal steroid hormones. In addition, it contains many
of the steroid metabolizing enzymes. The effect of gonadal steroids on brain development and
maturation has been well documented [1,2]. The vast literature on the subject has introduced
the common belief that gonadal steroids may be the only effectors of the brain sexual differ‐
entiation, overshadowing other key elements. Although there is no doubt about its importance,
the dogma of the gonadal origin of somatic differentiation, including neuronal cells, usually
implies that XX and XY cells, accordingly stem cells, are functionally equivalent unless gonadal
secretions act on them in a sex-specific manner. The human Y chromosome encodes 27 different
proteins [3] eight of which are expressed in the male brain and could have a male-specific effect
on the brain, independent of any gonadal hormone influence [4,5]. Furthermore, XX cells
contain an X chromosome that received a paternal genomic imprint, whereas XY cells do not,
a fact that is likely to contribute to autonomous differences between male and female cells. De
Vries and colleagues [6] generated mice in which the testis-determining gene sry was deleted
from the Y chromosome and subsequently inserted onto an autosome. This experiment
resulted in the generation of mice where the development of the testis occurred independently
of the complement of X or Y chromosome. Although most of the sexual dimorphism correlated
with the presence of testis or ovary (and therefore associated with gonadal hormones), XY mice
(with testes or ovaries) were found to be more masculine than the XX mice (with testes or
ovaries) in the density of vasopressin-immunoreactive fibers in the lateral septum, suggesting
that sex chromosome genes contribute to the development of a sex difference in the brain.
These results also suggest that one should not consider that female and male neural stem cells
(NSC) are equal and react in the same manner to a specific environment or pharmacological
agent. Furthermore, there are no data to support the a priori consideration that transplanting
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1. Introduction
The brain is one of the main targets of gonadal steroid hormones. In addition, it contains many
of the steroid metabolizing enzymes. The effect of gonadal steroids on brain development and
maturation has been well documented [1,2]. The vast literature on the subject has introduced
the common belief that gonadal steroids may be the only effectors of the brain sexual differ‐
entiation, overshadowing other key elements. Although there is no doubt about its importance,
the dogma of the gonadal origin of somatic differentiation, including neuronal cells, usually
implies that XX and XY cells, accordingly stem cells, are functionally equivalent unless gonadal
secretions act on them in a sex-specific manner. The human Y chromosome encodes 27 different
proteins [3] eight of which are expressed in the male brain and could have a male-specific effect
on the brain, independent of any gonadal hormone influence [4,5]. Furthermore, XX cells
contain an X chromosome that received a paternal genomic imprint, whereas XY cells do not,
a fact that is likely to contribute to autonomous differences between male and female cells. De
Vries and colleagues [6] generated mice in which the testis-determining gene sry was deleted
from the Y chromosome and subsequently inserted onto an autosome. This experiment
resulted in the generation of mice where the development of the testis occurred independently
of the complement of X or Y chromosome. Although most of the sexual dimorphism correlated
with the presence of testis or ovary (and therefore associated with gonadal hormones), XY mice
(with testes or ovaries) were found to be more masculine than the XX mice (with testes or
ovaries) in the density of vasopressin-immunoreactive fibers in the lateral septum, suggesting
that sex chromosome genes contribute to the development of a sex difference in the brain.
These results also suggest that one should not consider that female and male neural stem cells
(NSC) are equal and react in the same manner to a specific environment or pharmacological
agent. Furthermore, there are no data to support the a priori consideration that transplanting
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young female NSC in an old female brain would result in the same neural differentiation and
functional recovery as transplanting young male NSC in an old male brain. Likewise, there is
no evidence to a priori consider that male and female NSC neurogenic properties would evolve
in a sex-independent manner throughout development and aging. To support this hypothesis,
sexual dimorphism has already been described in various biological aspects of several types
of stem cells [7-13]. In particular, we and others recently reported a sexual dimorphism in the
neurogenic capacity of rat [14,15] and primate [11] NSC. Considering the dramatic and sex-
specific hormonal changes occurring throughout development and aging one might expect a
sex- and sex-through-aging-specific environment to be a prerequisite for successful neuro‐
genesis.
The chapter will first discuss the potential of stem cells for brain repair, tissue regeneration
and function recovery, second the effect of sex on stem cell fate whether neural stem cells or
peripheral stem cells, and third the potential translation in clinics. The goal of the present
proposal is to discuss the therapeutic relevance of the largely under-explored sex- and age-
based differences in the capacity of NSC to engage in neurogenesis programming. Indeed,
beyond understanding the physiology and biochemistry of aging NSC, for both sexes, the
overall objective is to discuss the potential foundation for future studies aimed at tailoring
NSC transplantation strategies for brain repair as a function of sex/age, as well as considering
sex- and age-specific pharmacological approaches towards the development of neurogenesis-
inducing treatments.
2. Stem cells — Hope and hurdles
If one had to explain the excitement and exhilaration stem cell therapy triggers in the field of
tissue repair and the hope it represents, a comparison that would make sense is the new
horizons opened after the first man in flight or the first man in space. The hopes and hypes
reflect the potential offered by stem cell therapy and in that sense, they are completely
justifiable. Probing PubMed with ‘stem cell’ and ‘therapy’ as keywords in certainly the best
way to understand how the interest of research community significantly evolved over 40 years.
Indeed, in 1970, only 13 publications related to stem cell therapy were referenced in PubMed,
compared to 7942 in 2010 (Figure 1). A slightly restricted search for ‘stem cell’, ‘therapy’ and
‘brain’ reveals that the number of publications related to brain repair, although increasing, is
“plateauing” at 10% of the total number of publications focused on stem cell therapy for the
past five years (Figure 1). This status reflects a greater difficulty to generate clear data on
experimental and clinical stem cell therapy for brain repair than with any other organs. This
situation is likely due to the unique architectonic of the brain, the way it interfaces with the
peripheral compartment and the seemingly endless cell phenotypes that compose the brain.
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Figure 1. Number of publications per keyword and per year. Light grey “neural stem cells”; medium grey “stem cells AND therapy AND brain”; 
dark grey “stem cells AND therapy”. 
It is remarkable that the first report using the words ‘neural stem cells’ was published not that long ago in 1992, reaching the 
hundred only in 2001, catching up in 2010 with 714 references with the number of publications that include ‘stem cell’, ‘therapy’ 
and ‘brain’ (Figure 1). Although one cannot deny that the amount of data degenerated nowadays on NSC and brain repair is 
getting more important, the rather slow pace at which progresses are still reported does not prefigure any substantial impact in 
clinics to be made in the near future. Many hurdles lie on the road of brain stem cell therapy. The first one, and not necessarily by 
order of importance, is directly related to the various types of stem cells considered as a potential source for brain transplantation. 
Human embryonic stem cells (hESC) [16,17], fetal NSC [18,19], post-natal or adult NSC [20-25], induced pluripotent stem cells (iPS) 
[26-29], bone marrow stem cells (BMSC) [30-36], mesenchymal stem cells (MSC) [37,38], umbilical cord blood-derived stem cells 
[39-41] and adipose tissue-derived stem cells [42,43]. This luxury of choice turned out to become an increasingly difficult situation 
to handle, generating at best a non-consensual agreement as to which stem cell type should be used for what type of neurological 
disorder. Overall, it seems that potential stem cell sources have been insufficiently characterized, impeding clinical translation. 
Although it sounds like a very easy statement to make, we have to admit that our knowledge in long-term outcome of stem cell 
transplantation in the brain is extremely limited. In example, grafting stem cells not from neurodermal origin in an attempt to 
replace degenerated neurons supposes a transdifferentiation mechanism of the transplanted stem cells prior to undergo successful 
differentiation in the appropriate neuronal phenotype [44-49]. Very little literature is currently available in transdifferentiation 
mechanisms and even more so, recent data reported that transdifferentiation is reversible and may be restricted to certain type of 
stem cells [48,49], raising the question of what would happen in vivo. A major concern is the development of gliomas or other brain 
cancer types secondary to stem cell transplantation. Indeed, the property of stem cells to self-renew is exactly what confer them the 
capacity of being highly tumorigenic [50-53]. It is particularly true for the hESC which tumorigenic properties have been 
extensively studied [52]. In addition, iPS have been developed to exactly mimic embryonic stem cells neurogenic capacity without 
having the capacity to induce brain tumor formation. However, the iPS safety is still being debated [52]. A clinical case has been 
reported very recently regarding a young boy who developed glioneuronal neoplasm four years after having received allogenic 
hESC transplantation in an attempt to improve his ataxia telangiectasia symptomatology [50]. It is remarkable that the tumor cells 
were identified as deriving from at least two of the donors composing the hESC pool from which the young boy received multiple 
transplantations. This specific data points out the possibility that using pool of donors may increase the risk of developing tumor or 
even host-versus-graft reaction [54-57]. Beyond the trivial concern of stem cells tumorigenesis remains the question of inducing the 
proper neural phenotype needed to replace a specific type of neuron. Parkinson’s disease is without any doubt the 
neurodegenerative disease for which brain transplant has been studied the most extensively. A consensual strategy seems to pre-
differentiate the stem cells toward the dopaminergic fate prior to conduct the transplantation [58,59] and as a consequence, many 
studies have been conducted to develop suitable protocols [58-62]. The same question arises to ensure that stem would undergo 
GABAergic differentiation prior to be used in patients suffering from Huntington’s disease [63]. However, despite many efforts to 
establish validated differentiation protocols, the phenotypic fate followed by transplanted stem cells still remain largely 
uncontrolled [64-66] and likely involves stem cells intrinsic properties, i.e. region or context dependency, sex or age [14,67-70]. In a 
medical context of growing interest for global personalized medicine in general [71] and focused on regenerative medicine in 
particular [27,72-74], answering the question “What stem cell for whom?” never appeared as critical. 
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reflect the potential offered by stem cell therapy and in that sense, they are completely
justifiable. Probing PubMed with ‘stem cell’ and ‘therapy’ as keywords in certainly the best
way to understand how the interest of research community significantly evolved over 40 years.
Indeed, in 1970, only 13 publications related to stem cell therapy were referenced in PubMed,
compared to 7942 in 2010 (Figure 1). A slightly restricted search for ‘stem cell’, ‘therapy’ and
‘brain’ reveals that the number of publications related to brain repair, although increasing, is
“plateauing” at 10% of the total number of publications focused on stem cell therapy for the
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peripheral compartment and the seemingly endless cell phenotypes that compose the brain.
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tumorigenic properties have been extensively studied [52]. In addition, iPS have been devel‐
oped to exactly mimic embryonic stem cells neurogenic capacity without having the capacity
to induce brain tumor formation. However, the iPS safety is still being debated [52]. A clinical
case has been reported very recently regarding a young boy who developed glioneuronal
neoplasm four years after having received allogenic hESC transplantation in an attempt to
improve his ataxia telangiectasia symptomatology [50]. It is remarkable that the tumor cells
were identified as deriving from at least two of the donors composing the hESC pool from
which the young boy received multiple transplantations. This specific data points out the
possibility that using pool of donors may increase the risk of developing tumor or even host-
versus-graft reaction [54-57]. Beyond the trivial concern of stem cells tumorigenesis remains
the question of inducing the proper neural phenotype needed to replace a specific type of
neuron. Parkinson’s disease is without any doubt the neurodegenerative disease for which
brain transplant has been studied the most extensively. A consensual strategy seems to pre-
differentiate the stem cells toward the dopaminergic fate prior to conduct the transplantation
[58,59] and as a consequence, many studies have been conducted to develop suitable protocols
[58-62]. The same question arises to ensure that stem would undergo GABAergic differentia‐
tion prior to be used in patients suffering from Huntington’s disease [63]. However, despite
many efforts to establish validated differentiation protocols, the phenotypic fate followed by
transplanted stem cells still remain largely uncontrolled [64-66] and likely involves stem cells
intrinsic properties, i.e. region or context dependency, sex or age [14,67-70]. In a medical
context of growing interest for global personalized medicine in general [71] and focused on
regenerative medicine in particular [27,72-74], answering the question “What stem cell for
whom?” never appeared as critical.
3. Stem cells transplantation in clinics — From hype to disillusion, keeping
the faith alive
The main reason of the arisen interest for stem cell therapy in central and peripheral nervous
system lies in the fact that it addresses neuropathologies and conditions for which neurological
damages are extensive, socially debilitating and irreversible and for which there is no ‘magic
pill’. Stem cell therapy for tissue repair is generating very high expectation to treat neurode‐
generative diseases like Parkinson’s disease [66,75], amyotrophic lateral sclerosis [76-81],
Huntington’s disease [18,19,82-84], Alzheimer’s disease [85-87], multiple sclerosis [88-90],
spinal cord injury [91,92] and retina degeneration [26,31,93]. Clinical translation has been, up
to now and by far, most exclusively conducted in patients suffering from Parkinson’s,
Huntington’s disease or amyotrophic lateral sclerosis and, to our knowledge, there is no data
reported clinical evaluation of stem cell transplantation in Alzheimer’s disease or retina
degeneration.
3.1. Parkinson’s disease
Two groups actively involved in conducting clinical studies assessing the therapeutic effec‐
tiveness of stem cell transplantation to treat Parkinson’s disease reported conflicting results
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[94-97]. In a first study, six Parkinson patients were to received bilateral transplantation of fetal
nigral tissue the post-commissural putamen [95]. The fetal material was obtained from the
mesencephalon of legally aborted fetus and used as solid grafts. Each patient received tissue
pooled from 3 to 4 fetuses. Two years outcome measurement showed an improvement of the
Unified Parkinson’s Disease Rating Scale (UPDRS), and an increase of [18F]-fluorodopa uptake
in the putamen. On the downside, all patients started experience dyskinesia few weeks after
the transplantation. When the same group performed the same type of study on a much larger
cohort, the outcome was much more deceiving [97]. Out of the 34 patients followed up to 2
years, none of them displayed clinically relevant improvement although post-mortem analysis
showed a robust survival of grafted dopaminergic neurons. These results led the authors to
conclude that fetal nigral transplantation could not constitute a therapy for Parkinson’s
disease. One can argue that using solid grafts rather than well characterized stem cell/
neuroblast primary culture might have impaired the capacity of newly formed neurons to
establish connections with the pre-existing network. This point is extensively discussed in a
very recent review [66]. A more striking issue to us is the lack of information related to the sex
of the donor suggesting that the tissue samples were pooled and grafted regardless of a
potential sex-based difference in stem cell biology which could have an impact on the clinical
outcome. In an other study, 40 patients were bilaterally grafted in the putamen with a mixture
of stem cells/dopaminergic neuroblasts obtained from cultured mesencephalic tissue from 4
embryos [94]. Follow-up at one year post-transplantation showed some benefit but only for
the patients 60 years of age or younger. In addition, the benefit was clinically significant only
in some areas of the UPDRS and 15 percent of the patients became dyskinetic. A post-analysis
of the one-year follow-up data revealed a sex-based difference in the graft outcome [96].
Indeed, the male patients displayed more clinical benefit than the female patients after the first
year but the progress rate increased in the female to catch up with the male at the end of the
second year of follow-up [96]. In addition, a follow-up performed over 4 years on 33 patients
out of the 40 initially included showed that the age-based difference observed earlier [94]
disappeared as the oldest patients’ overall UPDRS was catching-up over the 4-years period of
time on the youngest’ one [96]. The authors concluded that some clinical benefit was still clearly
present 4 years after transplantation with however no correlation with the [18F]-fluorodopa
uptake. Although the measured outcome seemed to be more encouraging than in the first series
of experiments, the cell preparation may account for it, the results remain rather inconsistent
and deceiving. On the same line, earlier clinical studies reported a somewhat beneficial effect
of fetal mesencephalic neurons in patients affected by Parkinson’s disease [75,98,99]. Several
reasons have been proposed such inconsistency, among which the number of cells, the grafting
site, the preparation of the cells, the use of immunosuppressant or the lack of functional
rehabilitation associated with the transplantation [66,100] but no consensus has been reached
so far. In addition, a recurrent issue that clinicians and patients are facing is the graft-induced
dyskinesia. This locomotor alteration is a direct consequence of the transplantation and its
causes and possible solutions remain rather elusive [75] and is seen as a permanent drawback
to any progress made in stem cell transplantation to treat Parkinson’s disease. As mentioned
earlier, it is quite interesting that the cells of several donors were pooled with no reference to
their sex as a factor of graft outcome. It is even more surprising since a sexual dimorphism
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tumorigenic properties have been extensively studied [52]. In addition, iPS have been devel‐
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[58,59] and as a consequence, many studies have been conducted to develop suitable protocols
[58-62]. The same question arises to ensure that stem would undergo GABAergic differentia‐
tion prior to be used in patients suffering from Huntington’s disease [63]. However, despite
many efforts to establish validated differentiation protocols, the phenotypic fate followed by
transplanted stem cells still remain largely uncontrolled [64-66] and likely involves stem cells
intrinsic properties, i.e. region or context dependency, sex or age [14,67-70]. In a medical
context of growing interest for global personalized medicine in general [71] and focused on
regenerative medicine in particular [27,72-74], answering the question “What stem cell for
whom?” never appeared as critical.
3. Stem cells transplantation in clinics — From hype to disillusion, keeping
the faith alive
The main reason of the arisen interest for stem cell therapy in central and peripheral nervous
system lies in the fact that it addresses neuropathologies and conditions for which neurological
damages are extensive, socially debilitating and irreversible and for which there is no ‘magic
pill’. Stem cell therapy for tissue repair is generating very high expectation to treat neurode‐
generative diseases like Parkinson’s disease [66,75], amyotrophic lateral sclerosis [76-81],
Huntington’s disease [18,19,82-84], Alzheimer’s disease [85-87], multiple sclerosis [88-90],
spinal cord injury [91,92] and retina degeneration [26,31,93]. Clinical translation has been, up
to now and by far, most exclusively conducted in patients suffering from Parkinson’s,
Huntington’s disease or amyotrophic lateral sclerosis and, to our knowledge, there is no data
reported clinical evaluation of stem cell transplantation in Alzheimer’s disease or retina
degeneration.
3.1. Parkinson’s disease
Two groups actively involved in conducting clinical studies assessing the therapeutic effec‐
tiveness of stem cell transplantation to treat Parkinson’s disease reported conflicting results
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disease. One can argue that using solid grafts rather than well characterized stem cell/
neuroblast primary culture might have impaired the capacity of newly formed neurons to
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of the donor suggesting that the tissue samples were pooled and grafted regardless of a
potential sex-based difference in stem cell biology which could have an impact on the clinical
outcome. In an other study, 40 patients were bilaterally grafted in the putamen with a mixture
of stem cells/dopaminergic neuroblasts obtained from cultured mesencephalic tissue from 4
embryos [94]. Follow-up at one year post-transplantation showed some benefit but only for
the patients 60 years of age or younger. In addition, the benefit was clinically significant only
in some areas of the UPDRS and 15 percent of the patients became dyskinetic. A post-analysis
of the one-year follow-up data revealed a sex-based difference in the graft outcome [96].
Indeed, the male patients displayed more clinical benefit than the female patients after the first
year but the progress rate increased in the female to catch up with the male at the end of the
second year of follow-up [96]. In addition, a follow-up performed over 4 years on 33 patients
out of the 40 initially included showed that the age-based difference observed earlier [94]
disappeared as the oldest patients’ overall UPDRS was catching-up over the 4-years period of
time on the youngest’ one [96]. The authors concluded that some clinical benefit was still clearly
present 4 years after transplantation with however no correlation with the [18F]-fluorodopa
uptake. Although the measured outcome seemed to be more encouraging than in the first series
of experiments, the cell preparation may account for it, the results remain rather inconsistent
and deceiving. On the same line, earlier clinical studies reported a somewhat beneficial effect
of fetal mesencephalic neurons in patients affected by Parkinson’s disease [75,98,99]. Several
reasons have been proposed such inconsistency, among which the number of cells, the grafting
site, the preparation of the cells, the use of immunosuppressant or the lack of functional
rehabilitation associated with the transplantation [66,100] but no consensus has been reached
so far. In addition, a recurrent issue that clinicians and patients are facing is the graft-induced
dyskinesia. This locomotor alteration is a direct consequence of the transplantation and its
causes and possible solutions remain rather elusive [75] and is seen as a permanent drawback
to any progress made in stem cell transplantation to treat Parkinson’s disease. As mentioned
earlier, it is quite interesting that the cells of several donors were pooled with no reference to
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with functional implications has been established for human muscle stem cells [9,12,13] and
monkeys mesenchymal stem cells [11].
3.2. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease that selectively
affects motor neurons in the cortex, brain stem and spinal cord [101] for which there is no
treatment. Several clinical studies have been conducted which results raised some optimism
but, overall, data related to the transplantation outcome remain, as with Parkinson’s disease,
contradictory and inconsistent. A very recent report based on thirteen clinical cases demon‐
strated the feasibility and the therapeutic relevance of performing autologous bone marrow-
derived hematopoietic cell transplantation in patients displaying severe sporadic ALS [76].
One year after receiving CD34+ cells transplantation in the brain stem and the beginning of
the spinal cord, most of the patients displayed an improvement of their status. The majority
of the patients regained neuronal stimulatory capacity of their muscle, as measured by post-
operative electroneuromyogram, and a better bulbar score. Some of them even recovered
walking capacity compatible with a daily life. However, the majority of the patients who
experienced a post-operative gain of function started to see their clinical status decline at one-
year follow-up. This piece of data, rather than suggesting that bone marrow-derived stem cells
cannot be used as a therapeutic tool suggests instead that the transplantation procedure should
be repeated in order to obtain maximum functional recovery. An other study demonstrated
the beneficial effect of stem transplantation as a cytotherapeutic tool for ALS. Thirty-three
patients diagnosed with severe sporadic ALS were to receive autologous transplantation of
peripheral blood mononuclear cells (PBMC) in the motor cortex and followed-up over one
year [78]. All the patients that received CD133+ PBMC transplantation experienced a dramatic
improvement of their clinical status as measured by the ALS Functional Rating Scale-Revised.
The most striking beneficial effect resulting from the transplantation was the increase in the
median survival from 19 months for the patients in the sham group to 66 months in the treated
group. More remarkably, the patients’ quality of life was also dramatically improved. Indeed,
in the sham group, half of the patients had to undergo tracheotomy and gastrostomy at 12-
months follow-up compared to the no tracheotomy and only one gastrostomy performed in
the group of patients who received PBMC transplantation. Taken together, these results show
promises for ALS cytotherapy. However, some more recent clinical studies reported that
transplanting stem cells in ALS patients did not result in any beneficial effect [79,81]. In the
first case, patients received autologous transplantation of mesenchymal stem cells isolated
from bone marrow in the spinal cord at T4-T5 and T5-T6 level and were followed-up for 24
months [79]. Although MRI imaging ascertained graft survival, clinicians did not observe any
clinical improvement. However, it is noteworthy that the patients recruited for this study were
diagnosed with mild to moderate sporadic ALS unlike the two previous studies described
above for which the patients were diagnosed with severe sporadic ALS. This apparent
discrepancy may indicate that the stage of the disease at which the stem cell transplantation
is to be performed has to be cautiously defined as it may critically affect the clinical outcome.
In the second case, patients from 3 different centers received stem cells transplantation and
were then evaluated at 12-months post-transplantation [81]. This study is difficult to interpret
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as it includes a total of 12 patients who received 3 different types of stem cells, depending on
the clinical center of origin, and using intratechal route, intravenous or both. The stem cells
used were embryonic olfactory ensheating stem cells, mesenchymal stem cells or CD34+ stem
cells without further explanation as to how many embryos were used per patients or if the
graft of adult stem cells was autologous or not. However, a common point shared with the
previous reported study, beside its lack of success at restoring the patients’ motor function, is
the fact that most of the patients recruited were diagnosed with a mild to moderate sporadic
ALS supporting the idea 1) that mild to moderate stage of ALS might not be the best moment
to start stem cell therapy, or that 2) the types of stem cells that were proven to be therapeutically
relevant in the severe cases might not be as relevant to treat mild or moderate cases of ALS.
These results certainly advocate for a better personalized therapy to the patient.
3.3. Huntington’s disease
Huntington’s disease is a neurodegenerative condition which is clinically characterized by
cognitive, motor and psychiatric deterioration and leads in 20 years maximum to the death of
the patient. There is currently no treatment for this disease and stem cell therapy is being
extensively investigated as a therapeutic tool. Many attempts of restoring some or all the lost
functions by stem cells transplantation have been made but the long term results have been so
far deceiving. Motor and cognitive functions improvement has been reported in some patients
1 year after the transplantation [82] but these improvements plateaued at 2 years and to finally
completely reverse at 4-6 years [18]. Other studies reported successful engraftment and
neuronal differentiation [19] associated with an improved cortical metabolism [102] unfortu‐
nately not accompanied by any clinical improvement. A major finding that is commonly
reported on long-term post-mortem histological study is the poor survival of the transplanted
stem cells [83,84] which is believed to be due to a reaction of the host immune system against
the grafted cells [54,84]. Interestingly, to our knowledge, all the clinical studies conducted on
Huntington patients reported having used human embryonic stem cells [18,19,54,82-84,102]
which is a quite surprising situation if we compare to the variety of stem cell types used in
Parkinson’s disease and ALS. In addition, one is force to at least acknowledge the fact that the
stem cells used are from embryonic origin may be the factor that triggers the immune response.
Indeed, human embryonic stem cells are not devoid of immunogenicity and are capable of
triggering a significant immune response leading to graft rejection [54,103]. In regard of what
has been accomplished in Parkinson’s disease and ALS, autologous transplantation of PBMC
or bone marrow-derived stem cells seems to be more appropriate and one may wonder why
it has not been tried yet. An other point that raises question is the fact that all the studies
reported, except one [19], transplanted human embryonic stem cells pooled from several
embryos, neither mentioning how many embryos were used per patient nor the sex of the
embryos.
3.4. Other indications for stem cell therapy
Stem cell therapy, beyond the controversy of using embryonic stem cells, is a very seducing
and highly promising therapeutic strategy for repairing the central nervous system. Using
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which is a quite surprising situation if we compare to the variety of stem cell types used in
Parkinson’s disease and ALS. In addition, one is force to at least acknowledge the fact that the
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Indeed, human embryonic stem cells are not devoid of immunogenicity and are capable of
triggering a significant immune response leading to graft rejection [54,103]. In regard of what
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or bone marrow-derived stem cells seems to be more appropriate and one may wonder why
it has not been tried yet. An other point that raises question is the fact that all the studies
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3.4. Other indications for stem cell therapy
Stem cell therapy, beyond the controversy of using embryonic stem cells, is a very seducing
and highly promising therapeutic strategy for repairing the central nervous system. Using
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stem cell transplantation has become a very appealing topic for many researchers and
clinicians around the world. However, developing and implementing such protocols to other
neurological conditions than the ones discussed above reveals to be an even more challenging
endeavor. Among the neurodegenerative disease that would benefit from stem cell therapy,
Alzheimer’s disease evidently represents a major interest. Probably because of the complexity
of the disease and our very limited knowledge about it, stem cell therapy for Alzheimer’s
disease is still in a preclinical stage [85-87]. Stem cell therapy for spinal cord injury is certainly
at the forefront of the preclinical research in order to establish valid therapeutic protocols to
be translated in clinics, but once again translating the knowledge acquired in animal models
facing several hurdles, among which cytotherapy specificity and safety [29,87,91,92,104,105].
Brain stroke is a neurological condition that could require extensive tissue reconstruction and
results obtained in animal models are very encouraging [20,24,106]. So far, only one clinical
study has been conducted in five patients by autologous transplantation of bone marrow-
derived stem cells [36]. One year follow-up showed good safety profile and a trend to clinical
improvement. Retina degeneration, whether idiopathic or post-traumatic, is a major problem
as it is irreversible, without treatment and leads to blindness in most of the case. However, the
retina architectonic and the differentiation process of retina stem cell represent two main
problems to clinical translation. Indeed, many in vivo and in vitro studies have been conducted
in various laboratories [26,30-32,35,37,45,107-117] showing promising results. However,
although the post-transplantation cell survival was excellent in all cases, the retina structure
revealed itself to be an obstacle to stem cell migration. In addition, the differentiation process
that leads to the formation of mature retina cell is by far more complex than in the brain.
4. Looking at the forest instead of the tree — Turning the tide on clinical
setbacks
We have recently published in a recent report that the estrogen receptor ERα is differentially
expressed in male and female NSC. NSC isolated from 3 month-old rats display sexual
dimorphism in the expression of estrogen receptor alpha and beta [14]. Male NSC contain one
third of the ERα levels, whereas ERβ levels were 3 times greater than those expressed NSC
isolated from same age females. Moreover, our data demonstrated that the ERα/ERβ ratio was
close to 1 in the male but 10 fold higher in the female NSC. Interestingly, others previously
reported that the expression of steroid receptors in the fish inner ear varies between sexes [118].
Such sexual dimorphism has been previously described in mature neurons of various brain
structures [119,120] and has been shown to have a role in the differentiation of sexual behavior
and gender identity [121]. Indeed, ERα has been shown to be primarily involved in masculin‐
ization, whereas ERβ is primarily involved in defeminization [122,123]. From birth and
throughout life, sex hormones physiology and homeostasis are different between men and
women which suggest that transplanting the “inadequate” type of NSC to the patient may not
lead to the expected beneficial effect. Indeed, consequences in clinics may run from a lack of
recovery to partial or inadequate recovery. Dissimilarity between NSC and the recipient tissue
may cause these undesirable effects. Interestingly, in the same manner, NSCs isolated from 20
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month old male and female rats displayed a dramatic increase in ERα and ERβ expression that
was equivalent in both sexes, suggesting that male and female NSCs are not equal before aging.
The effect of estrogens on neurogenesis has been extensively studied and it is commonly agreed
that estrogens simultaneously promote NSC proliferation and differentiation [124-129]. There
is increasing evidence on the estrogenic aspect of neurogenesis; however, the differential roles
of ERα and ERβ in this process still remain to be fully characterized. Considering the currently
known role of estrogens in NSC physiology and the regulation of the neurogenesis
[124,126,128-132], the sexual dimorphism we observed in ERα and ERβ expression between
male and female NSC [14] supports a sex-based intrinsic difference in the regulation of
neurogenesis. In addition, ERα genotype has been recently reported to be responsible for the
inter-individual variability of responses to estrogen and testosterone in mesenchymal stem
cell-derived osteoblasts [133]. Moreover, estradiol has been described to alter neurogenesis in
female, but not male rats [134]. We also provided evidence that male NSC expressed a
dramatically higher level of CYP19 than female NSC [135] which supports a capacity for male
NSC, unlike female NSC, to metabolize testosterone and in turn, to produce estradiol. Such
biochemical sexual dimorphism may underlie a steroid-related pharmacological counterpart
as male NSC may therefore have the ability to alter their local environment and modulate
endogenous neurogenesis in a different manner than female NSC may do. Remarkably, an
autocrine control loop in two different systems, the NSC kinin/kallicrein pathway [136] and
the androgenic apparatus of human bone marrow stromal cells [137]. It is noteworthy that the
sex-based differences unveiled in vitro translated in vivo as we recently reported [69]. Indeed,
the outcome of NSC transplantation in brain was shown to tightly depend on the sex of the
donor and the sex of the recipient. Interestingly, in some cases cross-sex grafting provided
better cell survival results than same-sex transplantation. As others also demonstrated the
occurrence of a sexual dimorphism in the neurogenic capacity of rhesus monkeys mesenchy‐
mal stem cells [11], we are the first to have shown a direct impact on the outcome of stem cell
transplantation [69]. Nevertheless, stem cell sexual dimorphism has been previously demon‐
strated by others in various organs [9,12,13,67,134] and organisms [138], and it is our opinion
that sex should be considered as a critical factor and integrated in the development of future
clinical protocol.
There is a consensual agreement that age-associated alterations in the brain play an important
role in the decline of neurogenesis reported in aging [11,139-141]. However, very little work
has been done in defining the age-related alteration of NSC neurogenic properties. Old mice
have been shown to have less NSC in the subventricular zone (SVZ) compared to young ones,
and a similar reduction has been reported in the number of NSC maintained as neurospheres
and recovered in culture in vitro [142]. Aging effect on neurogenesis may also be structure-
specific as revealed by others showing a decrease of NSC proliferation has been described in
the hippocampus of old rats but not in the SVZ of the same animal [143]. On an other hand,
spatial redistribution and a delay in the migratory process seem to affect NSC in the SVZ rather
than a decrease of the proliferation rate [144]. However, although some studies showed that
NSC from old animals retain some or all of their neurogenic properties, to date, studies that
have systematically explored age-based differences of NSC neurogenic properties in terms of
neuronal phenotype and protein marker expression are extremely scarce
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NSC, unlike female NSC, to metabolize testosterone and in turn, to produce estradiol. Such
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as male NSC may therefore have the ability to alter their local environment and modulate
endogenous neurogenesis in a different manner than female NSC may do. Remarkably, an
autocrine control loop in two different systems, the NSC kinin/kallicrein pathway [136] and
the androgenic apparatus of human bone marrow stromal cells [137]. It is noteworthy that the
sex-based differences unveiled in vitro translated in vivo as we recently reported [69]. Indeed,
the outcome of NSC transplantation in brain was shown to tightly depend on the sex of the
donor and the sex of the recipient. Interestingly, in some cases cross-sex grafting provided
better cell survival results than same-sex transplantation. As others also demonstrated the
occurrence of a sexual dimorphism in the neurogenic capacity of rhesus monkeys mesenchy‐
mal stem cells [11], we are the first to have shown a direct impact on the outcome of stem cell
transplantation [69]. Nevertheless, stem cell sexual dimorphism has been previously demon‐
strated by others in various organs [9,12,13,67,134] and organisms [138], and it is our opinion
that sex should be considered as a critical factor and integrated in the development of future
clinical protocol.
There is a consensual agreement that age-associated alterations in the brain play an important
role in the decline of neurogenesis reported in aging [11,139-141]. However, very little work
has been done in defining the age-related alteration of NSC neurogenic properties. Old mice
have been shown to have less NSC in the subventricular zone (SVZ) compared to young ones,
and a similar reduction has been reported in the number of NSC maintained as neurospheres
and recovered in culture in vitro [142]. Aging effect on neurogenesis may also be structure-
specific as revealed by others showing a decrease of NSC proliferation has been described in
the hippocampus of old rats but not in the SVZ of the same animal [143]. On an other hand,
spatial redistribution and a delay in the migratory process seem to affect NSC in the SVZ rather
than a decrease of the proliferation rate [144]. However, although some studies showed that
NSC from old animals retain some or all of their neurogenic properties, to date, studies that
have systematically explored age-based differences of NSC neurogenic properties in terms of
neuronal phenotype and protein marker expression are extremely scarce
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[11,14,69,135,138,145,146]. Surprisingly, NSC isolated from young animals did not perform
better in term of survival rate after brain transplantation when compared to the ones isolated
from old rats [69]. Thus, such a result provocatively raises the question of the rejuvenation
process NSC isolated from old individuals may undergo after being transplanted in a younger
environment as suggested by two recent works [147,148]. Understanding the role of the age
of NSC as a critical factor modulating the neuronal fate specificity and the maturation level
reached by the engrafted NSC is absolutely essential from the perspective of stem cell grafting
into the brain. In addition, in agreement with our previous results showing that NSC age
differently depending on their sex, it appears that sex cannot be dissociated from age as a
determining factor of NSC capacity to lead to functional recovery following transplantation.
5. Conclusion
Stem cell therapy holds a lot of promises for brain repair and the recovery of impaired
neurological functions. However, despite the generation of a large amount of encouraging
results produced on various animal models, the translation at the patient’s bed seems to be
delayed. Facing mitigated results from the few clinical studies that have been conducted so
far, we are constrained to a cautious optimism. Indeed, the low success rate encountered in
clinics questions our knowledge on the topic and suggests that we go back to a more funda‐
mental bench work. Indeed, the high number of stem cell types, to which have to be added the
various engineering counterparts, turn a luxury of choice into a situation where it is extremely,
if not impossible, to determine what cell type or cell line would be the best candidate for tissue
repair. Compelling evidence suggests that sex may be a critical determining factor of stem cell
transplantation outcome in the brain. Surprisingly, none of the clinical studies reported to date
took this parameter into consideration. Furthermore, we foresee that NSC differentiation
induced by neurogenic agents in vitro and in vivo will be an important part of brain repair
procedures as brain repair therapy and optimal neuronal function restoration will likely
require both exogenous NSC grafting and pharmacological stimulation of the endogenous
neurogenesis. However, nothing is currently known about the effect of cell sex on NSC
sensitivity to pharmacologically-induced differentiation, and we therefore strongly believe
that acquiring such knowledge is critical for the development of neurogenic treatments.
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1. Introduction
Heart failure (HF) after myocardial infarction (MI) or the ischemic myocardiopathy (ICM)
continues to be the most prevalent cause of morbidity and mortality worldwide. MI results in
myocardial necrosis, scar formation, ventricular remodeling and eventually HF or death. Faced
with the end stage of ICM, the most of present therapy protocols could only slow worsening
of HF. Cardiac resynchronization therapy may be definite therapeutic effect to those cases with
HF and complete left bundle-branch block. Heart transplantation can more efficiently improve
the cardiac status, but, limited donor supply and organ rejection confine its widespread use.
As a result, a significant proportion of survivors with ICM will still develop HF and have
briefer life-span. Pathologically, HF and myocardial remodeling aggratate each other and a
core pathogenic factor of ICM is loss of massive cardiomyocytes [1]. In fact, the myocardium
itself posseses little capacity for self-regeneration. Although there are still considerable dispute
in the clinical therapeutic effect based on stem cells (SCs), the positive results obtaned in the
repair of damaged myocardium indicated it has become a promising strategy [2-4]. In this
regard, an array of SCs types has been identified and applied, including bon marrow-derived
mononuclear cell (BM-MNCs) [5] and umbilical cord blood-derived stem cells(UCB-SCs). At
the current state of SCs clinical application there is no convincing data showing the superiority
of any tissue committed monopotent stem cells (TCSCs), so heterogenous population of BM-
MNCs is most often used [6]. Some recent studies have showed pluripotent stem cells (PSCs)
are precursors of TCSCs during organ/tissue rejuvenation and a source of these cells in
emergency situations when organs are damaged (e.g., MI or stroke). The application of PSCs
has showed very encouraging results. PSCs includes induced pluripotent stem cells (iPSCs)
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1. Introduction
Heart failure (HF) after myocardial infarction (MI) or the ischemic myocardiopathy (ICM)
continues to be the most prevalent cause of morbidity and mortality worldwide. MI results in
myocardial necrosis, scar formation, ventricular remodeling and eventually HF or death. Faced
with the end stage of ICM, the most of present therapy protocols could only slow worsening
of HF. Cardiac resynchronization therapy may be definite therapeutic effect to those cases with
HF and complete left bundle-branch block. Heart transplantation can more efficiently improve
the cardiac status, but, limited donor supply and organ rejection confine its widespread use.
As a result, a significant proportion of survivors with ICM will still develop HF and have
briefer life-span. Pathologically, HF and myocardial remodeling aggratate each other and a
core pathogenic factor of ICM is loss of massive cardiomyocytes [1]. In fact, the myocardium
itself posseses little capacity for self-regeneration. Although there are still considerable dispute
in the clinical therapeutic effect based on stem cells (SCs), the positive results obtaned in the
repair of damaged myocardium indicated it has become a promising strategy [2-4]. In this
regard, an array of SCs types has been identified and applied, including bon marrow-derived
mononuclear cell (BM-MNCs) [5] and umbilical cord blood-derived stem cells(UCB-SCs). At
the current state of SCs clinical application there is no convincing data showing the superiority
of any tissue committed monopotent stem cells (TCSCs), so heterogenous population of BM-
MNCs is most often used [6]. Some recent studies have showed pluripotent stem cells (PSCs)
are precursors of TCSCs during organ/tissue rejuvenation and a source of these cells in
emergency situations when organs are damaged (e.g., MI or stroke). The application of PSCs
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using gene transfer [7-8] and very small embryonic-like embryonic/epiblast-like stem cells
(VSELs) isolated from the adult tissues or UCB [9]. A rare Sca1+Lin−CD45− SCs population
were initially identified, isolated and named as VSELs in adult mice using fluorescence
activated cell sorting (FACS) [10]. Although VSELs are currently studied in a lot of laboratories
worldwide, the research series of VSELs was mainly contributed by Kucia & Ratajczak and
their colleagues. VSELs possess very primitive morphology and express PSCs markers (e.g.,
Oct4, Nanog, and SSEA-4) as well as the surface phenotype Sca1+/ CD133+Lin−CD45− in mice /
humans. As VSELs can be mobilizated into PB following acute MI [11], improve heart function
and alleviate cardiac remodeling[12,13], these cells seem to possibly become an optimal seed
cells for cardiovascular repair. Recently, employing anti-CD133-conjugated paramagnetic
beads followed by staining with Aldefluor has also been proposed for a faster large-scale
VSELs isolation [14]. More recent evidences demonstrate that VSELs deposited in adults tissue
share several markers with epiblast/germ line cells and play a role in rejuvenation of the TCSCs
responsible for tissue regeneration/repair after organ injuries. Even, VSELs with maximum
regenerative potential are recommended as the true PSCs in adult tissues, whereas the
hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are actually progenitor
SCs arised from asymmetric cell division of VSELs [15]. As a promising candidate, their unique
characteristics and potentiality may have very important pathophysiological and therapeutic
implications for regenerative medicine including myocardial and endothelial repair.
2. Discovered history of VSELs
Small cells able to differentiate into cells from all three germ layers and called “spore-like stem
cells” were isolated from adult mammalian tissues, however, it was not provided for these
small SCs how to be purified and for their surface markers how to be expressed in the original
paper [16]. Afterwords, small SCs expressing CXC chemokine receptor 4 (CXCR4+) and
markers characteristic for embryonic stem cells (ESCs), epiblast stem cells (EPSCs), and
primordial stem cells (PGCs) were purified from the murine BM and several adult organs.
Based on their small size, presence of PSCs markers, distinct morphology (open-type chro‐
matin, large nucleus, narrow rim of cytoplasm with multiple mitochondria) and ability to
differentiate into all three germ layers, including mesoderm-derived cardiomyocytes, these
cells were named as VSELs [9].
3. Found source of VSELs
The rare Sca-1+Lin−CD45−SCs population was initially discovered in mice BM 9. Phenotypi‐
cally similar cells were subsequently identified and purified in murine peripheral blood (PB),
fetal liver, brain, retina, kidneys, pancreas, skeletal muscles spleen, and thymus[17]. In
humans, VSELs were identified in UCB, PB, BM, and cardiac tissue[18]. VSELs deposited in
adult tissues seem to be a reserve pool for TCSCs [19].
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4. Morphology of VSELs
The most common shape feature of VSELs is that they possess very primitive morphology and
relatively small size. The distinctive morphology of VSELs was confirmed using confocal and
transmission electron microscopy [9,10]. Comparison with other populations of cells, murine
VSELs (4-6 µm) are smaller than HSCs, MNCs and granulocytes and erythrocytes, but, larger
than platelets. Human VSELs (6–8 µm) are larger than murine. At the ultramicrostructural
level, they show a very immature morphology, for example, possess a relatively large nucleus
surrounded by a narrow rim of cytoplasm, a few mitochondria, scattered ribosomes, small
profiles of endoplasmatic reticulum and a few vesicles [20].Recently, the high resolution of
ImageStream system (ISS) analysis enables the identification of objects as small as 1 µm in
diameter. Employing ISS analysis, murine VSELs are more precisely confirmed as ~3.6 µm in
diameter [21].
5. Molecular biology and functional features of VSELs
VSELs not only possess the primitive morphology of early developmental cells but also express
typical markers for PSCs
Characteristic  markers  of  VSELs  were  confirmed using  several  complementary  research
tools including flow cytometry (FCM), ISS,  direct  immunofluorescence staining, confocal
microscopy, reverse-transcription polymerase chain reaction (RT-PCR) and etc. Early em‐
bryonic  markers  (Oct-4,  Nanog,  SSEA-1,  Rex1,  Dppa3,  Rif-1)  were  demonstrated  at  the
protein  /mRNA  levels  using  immunofluorescent  staining,  ISS  and  FACS  [21,22].  VSELs
express SSEA-1 antigen on their surface and Oct-4 in their nuclei. Recent study indicates
that  the  promoters  of  Oct4  and  Nanog  contain  transcriptionally  active  chromatin  in
VSELs excluding the possibility of amplification of pseudogenes [23]. CD133+Lin−CD45−
VSELs  identified  in  Human UCB like  their  murine  counterparts,  i)  highly  express  telo‐
merase,  ii)  are  diploid,  and iii)  are  viable,  as  shown by their  ability  to  exclude dye (7-
aminoactinomycin D). Moreover, some of the CD133+Lin−CD45− VSELs, which represent
only a very small subfraction among UCB Lin−CD45−non-hematopoietic cells, may co-ex‐
press  other  stem cell  markers,  including CD34,  CXCR4,  and SSEA-4,  may contain other
stem  cell  types,  including  endothelial  progenitor  cells  (EPCs)  and  mesenchymal  stem
cells  (MSCs),  and may be identified based on very small  size (FSClow/SSClow) and co-
expression of CD133, CD34, and, CXCR4 [23].
Also, there are some differences of the VSELs phenotype between mice and humans. Human
VSELs surface markers consist of lin−CD45−CXCR4+, CD133+ and CD34− as confirmed on the
mRNA level by RQ-PCR and protein level by IF and ISS, whereas Murine VSELs express Sca-1
antigen [24].
VSELs express  chemokine receptor  CXCR4 and are  absent  of  pan-hematopoietic  marker
(CD45−) and hematopoietic lineage markers (Lin−) [9,10,25].  Further study demonstrated
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VSELs isolation [14]. More recent evidences demonstrate that VSELs deposited in adults tissue
share several markers with epiblast/germ line cells and play a role in rejuvenation of the TCSCs
responsible for tissue regeneration/repair after organ injuries. Even, VSELs with maximum
regenerative potential are recommended as the true PSCs in adult tissues, whereas the
hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are actually progenitor
SCs arised from asymmetric cell division of VSELs [15]. As a promising candidate, their unique
characteristics and potentiality may have very important pathophysiological and therapeutic
implications for regenerative medicine including myocardial and endothelial repair.
2. Discovered history of VSELs
Small cells able to differentiate into cells from all three germ layers and called “spore-like stem
cells” were isolated from adult mammalian tissues, however, it was not provided for these
small SCs how to be purified and for their surface markers how to be expressed in the original
paper [16]. Afterwords, small SCs expressing CXC chemokine receptor 4 (CXCR4+) and
markers characteristic for embryonic stem cells (ESCs), epiblast stem cells (EPSCs), and
primordial stem cells (PGCs) were purified from the murine BM and several adult organs.
Based on their small size, presence of PSCs markers, distinct morphology (open-type chro‐
matin, large nucleus, narrow rim of cytoplasm with multiple mitochondria) and ability to
differentiate into all three germ layers, including mesoderm-derived cardiomyocytes, these
cells were named as VSELs [9].
3. Found source of VSELs
The rare Sca-1+Lin−CD45−SCs population was initially discovered in mice BM 9. Phenotypi‐
cally similar cells were subsequently identified and purified in murine peripheral blood (PB),
fetal liver, brain, retina, kidneys, pancreas, skeletal muscles spleen, and thymus[17]. In
humans, VSELs were identified in UCB, PB, BM, and cardiac tissue[18]. VSELs deposited in
adult tissues seem to be a reserve pool for TCSCs [19].
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4. Morphology of VSELs
The most common shape feature of VSELs is that they possess very primitive morphology and
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VSELs excluding the possibility of amplification of pseudogenes [23]. CD133+Lin−CD45−
VSELs  identified  in  Human UCB like  their  murine  counterparts,  i)  highly  express  telo‐
merase,  ii)  are  diploid,  and iii)  are  viable,  as  shown by their  ability  to  exclude dye (7-
aminoactinomycin D). Moreover, some of the CD133+Lin−CD45− VSELs, which represent
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cells  (MSCs),  and may be identified based on very small  size (FSClow/SSClow) and co-
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Also, there are some differences of the VSELs phenotype between mice and humans. Human
VSELs surface markers consist of lin−CD45−CXCR4+, CD133+ and CD34− as confirmed on the
mRNA level by RQ-PCR and protein level by IF and ISS, whereas Murine VSELs express Sca-1
antigen [24].
VSELs express  chemokine receptor  CXCR4 and are  absent  of  pan-hematopoietic  marker
(CD45−) and hematopoietic lineage markers (Lin−) [9,10,25].  Further study demonstrated
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that VSELs can not primarily reveal hematopoietic ability immediately from isolation and
expansion, but may eventually acquire hematopoietic potential following co-culture in hem‐
atopoiesis permissive environment over OP9 stroma feeder layer and reconstitute hemato‐
poiesis in lethally irradiated mice 4–6 weeks after transplantation [26].
Freshly sorted VSELs can be expanded in coculture with C2C12 murine myoblast feeder lay‐
er. After 7 days of co-culture, approximately 5–10% of all VSELs form sphere-like clusters
consisting  of  a  few  hundred  cells  resembling  embryoid  bodies  (VSEL-derived  spheres,
VSEL-DSs). VSEL-DSs express placenta-like alkaline phosphatase. Expanded population of
VSELs isolated from VSEL-DS retain the pluripotent capacity and have ability to differenti‐
ate into all  three germ layers,  including mesodermal cardiomyocytes,  ectodermal neural
cells and endodermal pancreatic cells [27].
The differentiation potency was also documented in circulating murine VSELs after injec‐
tion of G-CSF. Rapidly mobilized VSELs showed up-regulation of PSC markers. These find‐
ings  support  not  only  the  pluripotency  of  VSELs,  but  also  their  tissue  repair
function[10].Study  also  showed that  VSELs  possess  diploid  DNA.  They  do  not  express
MHC-1  and  human  leukocyte  antigen-D  related  (HLA-DR)  antigens  and  are  CD90−
CD105−CD29−.Moreover, if plated over a C2C12 murine sarcoma cell feeder layer, ~5–10%
of  purified  VSELs  are  able  to  form spheres  that  resemble  embryoid  bodies  [9].  Similar
spheres were also formed by VSELs isolated from murine fetal liver, spleen, and thymus
[17].  Interestingly,  VSELs  are  somewhat  heterogenous  developmentally.  Although all  of
VSELs express the Oct-4, some of them express genes that are more closely related to genes
expressed by EP-SCs and others to genes expressed by migrating PGCs [28].
In parallel, VSELs exhibits their potential biologic function. Oct-4+ SSEA-4+ SCs harvested
from BM via elutriation, has been recently shown to give rise into functional insulin-produc‐
ing cells in vivo in induced diabetic mice [29].In another report, VSELs purified from rat BM
successfully repaired damaged myocardium in a model of MI [30].
Similarly, in vivo exposure to hypoxia in mice elicits chemoattractant a gradients that pro‐
mote the mobilization of pluripotent very small embryonic-like stem cells from the bone
marrow to peripheral blood. VSELs in the BM are the primary source of lung epithelial cells
[31-33]. VSELs were also identified in neonatal retina and involved in optic nerve retinal re‐
generation in a rodent model [34]. VSELs may also play a major role as populations of cells
that preferentially give rise to induced pluripotent stem cells (iPSCs) when BM-derived stro‐
mal cells are induced to pluripotency by genetic manipulation [35].In particular, VSELs de‐
rived by parthenogenesis have also been identified successfully [36].
6. Isolation strategies of VSELs
Isolation of VSLEs using FACS is dependent on gating strategy based on their small size,
expression  of  PSC  (Oct4,  Nanog,  and  SSEA-4),  surface  markers  (CXCR4,  CD133  /Sca-1,
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CD34) and absence of hematopoietic lineage markers (lin, CD45). Briefly, the first step is
the lysis of red blood cells to obtain the fraction of nucleated cells. Erythrocyte lysis buf‐
fer is used instead of Ficoll centrifugation because the latter might deplete the population
of very small cells [14]. Subsequently, cells are stained and sorted with antibodies against
Sca-1 (murine VSELs) or CD133 (human VSELs), pan-hematopoietic antigen (CD45), hem‐
atopoietic lineages markers (lin), and CXCR4 [9]. Extended lymphocyte gate was used to
include events with diameter 2–10 µm, approximately consisting of VSELs. The width of
the gate was validated by using synthetic beads of predefined size (1–15 µm) [14]. Sever‐
al  other  approaches  to  define  the  population  of  small  cells  were  used,  including  ISS.
Above standard procedure employing FACS, however, is time consuming, which usually
requires up to 4 days to process and isolate VSELs from UCB MNCs in one entire cord
blood unit (~50–100 ml).  It  is not very difficult for the future clinical application to take
into consideration cell  viability,  the time of sorter usage, and the time commitment of a
sorter operator.
In order to speed up isolation of  VSELs,  a  faster large-scale isolation protocol  based on
anti-CD133-conjugated paramagnetic beads followed by staining with Aldefluor were re‐
cently employed. In this novel approach (i) A UCB research unit is lysed in a hypotonic
ammonium chloride solution for 15 min at room temperature to deplete erythrocytes and
washed twice in phosphate-buffered saline (1st step); (ii) A single-cell suspension of total
nucleated  cells  was  treated  with  antibodies  against  CD133  antigen-coated  immunomag‐
netic  beads and separated by a MACS Separator to obtan CD133+including VSELs (2nd
step);  and subsequently (iii)  The CD133(+)cell  fraction was reacted with the Aldefluor™
Kit  reagent  for  detecting  aldehyde  dehydrogenase  (ALDH).  Cells  were  incubated  with
phycoerythrin  (PE)-conjugated  murine  anti-human CD235a,  PE-CY7-CD45,  and  allophy‐
cocyanin (APC)-conjugated CD133/2.  Cells  were washed and resuspended in cold Alde‐
fluor  buffer  and  sorted  by  FACS  to  obtain  populations  enriched  in  CD45−GlyA
−CD133+ALDHlow VSELs.The whole isolation process takes approximately 2-3 h per UCB
unit  and  these  small  Lin-CD45-CD133+cells  isolated  from  human  UCB  highly  express
Oct-4, Nanog, and SSEA-4 at both the mRNA and protein levels [13,14].
This new isolation protocol was based on the following rationale.(i) Using erythrocytes lysis
buffer was higher yield of VSELs than a Ficoll-Paque gradient centrifugation to remove
erythrocytes [14]. (ii) On the other hand, CD133+ VSELs are highly enriched for PSC tran‐
scription factor expression (e.g., Oct-4 and SSEA-4) [14]. (iii)Small erythroblast GlyA+ that are
present in UCB do not express CD45 antigen. Thus, selection for CD45−cells was used to enrich
for these cells.
The isolation from one entire UCB unit can obtan ~103/100 ml of UCB for CD45−GlyA
−CD133+ALDHlow cells and ~4×103/100 ml of UCB for CD45−GlyA−CD133+ALDHhigh cells.
Freshly isolated CD45-GlyA-CD133+ALDHhigh VSELs express more hematopoietic transcripts
(e.g., c-myb), CD45-GlyA-CD133+ALDH low VSELs exhibit higher levels of PSCs markers (e.g.,
Oct-4) [34,35].
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from BM via elutriation, has been recently shown to give rise into functional insulin-produc‐
ing cells in vivo in induced diabetic mice [29].In another report, VSELs purified from rat BM
successfully repaired damaged myocardium in a model of MI [30].
Similarly, in vivo exposure to hypoxia in mice elicits chemoattractant a gradients that pro‐
mote the mobilization of pluripotent very small embryonic-like stem cells from the bone
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CD34) and absence of hematopoietic lineage markers (lin, CD45). Briefly, the first step is
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7. Special potency and hypothesized role of VSELs
PSCs must correspond to certain in vitro and in vivo conditions. According to these crite‐
ria,  PSCs should be provided with (i)  giving rise to cells from all  three germ layers,  (ii)
completing blastocyst development, and (iii) forming teratomas after inoculation into ex‐
perimental animals. ESCs are generally known as PSCs. However, both VSELs and iPSCs
are not different from ESCs in next two conditions. In special, There are some own unique
superiority that VSELs deposited in various adult organs as a backup for primitive stem
cells share several markers with epiblast/germ line cells, plays a role in rejuvenation of the
pool of TCSCs involved in tissue regeneration, but, not complete blastocyst development
and not form teratomas. During steady-state conditions, VSELs may be responsible for tis‐
sue rejuvenation and for processes of regeneration/repair after organ injuries. VSELs simi‐
larly as epiblast-derived PGCs change the epigenetic signature of some of the imprinted
genes and therefore remain quiescent in adult tissues. This quiescence of VSELs is epige‐
netically regulated by DNA methylation of genomic imprinting [36].VSELs highly express
growth-repressive genes (H19, p57KIP2, Igf2R) and downregulate growth-promoting ones
(Igf2, Rasgrf1). The unique genomic imprinting pattern may explain the quiescent status of
VSELs.  Thus,  VSELs may be progeny of epiblast  cells  to develope tissues and a reserve
pool  of  PSCs to  repair  tissue.  Furthermore,  the  quiescent  state  of  VSELs may also be  a
physiological protective mechanism of preventing uncontrolled proliferation, tumor forma‐
tion [28]. Furthermore, The bone-forming activity of VSELs, exceeded the activity of other
populations of BM-purified cells tested in the same assay if embedded in gelatin sponges
and implanted into living mice. Even, as few as 500 UCB VSELs was capable of forming
bone-like structures in vivo [37]. Based on these finding, VSELs have been described as at
the top of the hierarchy for the mesenchymal and endothelial lineages in BM [38,39]. Inter‐
estingly, the content of VSELs from mice BM at different ages (2 months-3 years) was eval‐
uated  employing  FCM.  the  number  of  these  cells  gradually  decreases  over  time  from
0.052±0.018% to 0.003±0.002% between age of 2-months and 3-years, respectively. In anoth‐
er report, the concentration of VSELs is much higher in BM of long-lived (e.g., C57Bl6) as
compared to  short-lived  (DBA/2J)  mice.  Especially,  not  only  a  number  of  these  cells  in
adult organs decreases with the age but also their ability to form spheres containing VSEL-
DS declaims with time. Whereas, a number of monopotent hemato/lymphopoiesis commit‐
ted HSC increase in older animals [40,41].This age-dependent content and ability of VSELs
in adult organs may explain that these cells could play a pivotal role in the normal cell
turn over and the life span control of mammals.Moreover, a significantly higher number
of VSELs in long-living murine strains (e.g., Laron dwarfs and Ames dwarfs), whose lon‐
gevity is explained by low levels of circulating IGF1 and a decrease in IIS. By contrast, the
number of VSELs is reduced in mice with high levels of circulating IGF1 and enhanced IIS
(e.g., growth hormone-overexpressing transgenic mice) compared to normally aging litter‐
mates [42,43]. There was a envision that in future, VSELs could be isolated from the pa‐
tient  at  young  age  and  than  inject  back  into  same  recipients  several  years  latter  to
regenerate damaged organs and to expand life-span, in case of major health complications
(e.g., heart infarct, stroke) due to aging.
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8. Mobilization and cardiovascular repair of VSELs
VSELs express early cardiac and endothelial lineages markers (GATA-4, Nkx2.5/Csx, VE-
cadherin, and von Willebrand factor), SDF-1 chemokine receptor CXCR4. Under steady-state
conditions, VSELs circulate in PB is very rare, however, undergo rapid mobilization during
acute MI [44].The processes are regulated by SDF-1, and its receptor CXCR4 as well as other
important cytokine-receptor systems of regulating the stem cell mobilization and homing
include leukemia inhibitory factor (LIF) – LIF receptor, hepatocyte growth factor (HGF) – c-
met axis, stem cell factor-CD117 axes [45-48]. Interestingly, the number of these cells in PB is
significantly higher in younger acute MI patients than in older ones. Number of VSELs was
also correlated with left ventricular ejection fraction, troponin I and creatinine kinase-MB levels
[44]. Further studies provided evidence that VSELs can be mobilized into PB in adult patients
injected with granulocyte-colony stimulating factor (G-CSF) and their number could be of
prognostic value [49].Consistently, a protocol which VSELs differentiate into cardiomyocytes
in vitro has been developed. In the first step, VSELs are co-cultured with myoblast line (C2C12)
where the cells expand and form VSEL-DS.Subsequently, VSELs isolated from VSEL-DS by
FACS sorting are plated on cardiac media to differentiate them into cardiomyocytes. The
period over 21 days in expression of early cardiac markers and cardiac structural proteins also
resembles the maturation of cardimyocytes from ESCs [50].
Murin experiments in vivo also showed that expanded and subsequent cardiopoiesis-guided
VSELs were markedly more effective than expanded and non-pre-differentiated cells. Inter‐
estingly, beneficial effects were observed despite use of only small number (104 cells) of VSELs.
At the same time a much higher number of hematopoietic cells (105 cells) was not effective [37].
so far, a cochrane controlled trial called Myocardial Regeneration by Intracoronary Infusion
of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) study are
available.The objective study was to assess the efficacy of intracoronary infusion of autologous
BM-derived CD34+CXCR4+ progenitor cells in comparison to non-selected BMMNC on LVEF
in patients with acute ST-segment elevation MI and reduced below 40% LVEF. CD34+CXCR4+
cells which is enriched for VSELs were isolated by two step immunomagnetic selection using
the magnetic beads. The reslut demonstrated that the use of selected CD34+CXCR4+ cells or
non-selected BMMNCs in patients with significantly reduced LV function is safe, feasible and
not leads to a significant improvement of LVEF, there was however a trend in favour of cell
therapy. In another, athough CD34+CXCR4+ cells were not pure population of VSELs, The use
of a relatively small number of selected CD34+CXCR4+ cells is associated with similar trend
as the use of 100 times higher number of non-selected BMMNCs (1.90 × 106 vs. 1.78 × 108) for
improvement of LVEF. It also further showed which the activity of VSELs is more superior
than that of BMMNC [52].Based on above finding, administration of VSELs after an acute MI
increases LVEF and improves left ventricular structure, and these benefits remain stable during
long-term follow-up. Although the mechanisms remain under investigation, paracrine effects,
regeneration of cellular constituents, and stimulation of endogenous stem/progenitors may
play combinatorial roles [49], because the rare VSEL-derived cardiac myocytes expressing
cardiac markers were present in the recipients myocardium [50,52].
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Thus, VSELs may serve as an ideal SCs source for cardiac repair by their ability to secrete
various cardioprotective growth factors/cytokines, as well as their ability to differentiate into
cardiomyocytes and endothelial cells
9. Remaining challenges of VSELs application
However, there are also some challenges and conflict coming out from recent VSELs’ stud‐
ies.At first, a recent study showed that VSELs from human UCB lack SCs characteristics and
fail to expand in vitro under a wide range of culture conditions [53].We also found that it is
very difficulte for human VSELs to be cultured or expanded in vitro using general culture
conditions. Thus, it has to be further determined whether these cells are merely developmental
remnants found in the adult tissue that cannot be harnessed effectively for regeneration or
whether they are real SCs population for regeneration medicine.
Subsquently, the biological characteristics and role of VSELs were studied mostly in mice and
human. No information of VSELs from large animal close to human has been reported. Future
clinical studies using autologous VSELs are needed to validate those promising large animal
experimental data.
Furthermore, it has seldomly obtained for parallel experiments to compare several populations
of putative SCs to determine the similarities and differences between these cell populations.
10. Summary
Overall, as mentioned above, the importance of SSEA-1+Oct-4+Sca-1+/ CD133+CXCR4+Lin
−CD45− pluripotent VSELs in adult tissue or UCB is now being stressed. New data from Kucia
& Ratajczak group and other groups has provided mounting evidence on the existence and
potential biological role of VSELs mostly in mice. VSELs would very possibly be a promising
PSCs population for cardiac repair in future clinical application of patients with ICM. Their
cardiogenic potential should be confirmed in large animal similar to humans and technical
issues regarding their isolation, expansion and differentiation need to further be addressed.We
also look forward to share how to higher efficiently isolate and expand these rare cells as well
as to know about further information on their biology and in vitro and in vivo differentiation
potential.
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1. Introduction
Hematopoietic stem cell transplantation (HSCT) has a half-century history. It is currently an
indispensable treatment for not only incurable blood diseases such as aplastic anemia and
severe hemolytic anemia, but also malignant hematological diseases such as leukemia and
lymphoma. Although allergenic HSCT is also used to treat hereditary diseases, its indica‐
tions are restricted because of critical complications including regimen-related toxicities in‐
volving conditioning, infection, and graft-versus-host disease.
Studies in recent decades have shown that HSCT can have a long-term effect in the treat‐
ment of hereditary diseases involving a responsible gene in hematogenous cells. Although
the first successful gene therapy using lymphocytes or bone marrow cells for a patient with
adenosine deaminase (ADA) deficiency inspired great hope in the future of gene therapy
[1-3], subsequent gene therapy using HSCs for patients with X-linked severe combined im‐
munodeficiency (SCID-X1) resulted in tumorigenesis [4]. In addition to the self-renewal and
multilineage differentiation capacities of tissue stem cells, HSCs exhibit cell-cycle dormancy,
which complicates their use in gene therapy.
However, as technological advances have increased the safety and efficiency of introduc‐
ing genes into HSCs, gene therapy with HSCs is attracting attention again. In this chapter,
advances in the technology of HSC gene therapy, e.g., vector design to avoid genotoxicity
and  increase  transgenic  efficiency  by  taking  advantage  of  the  special  characteristics  of
HSCs, are reviewed. In addition, recent studies on HSC gene therapy for various heredita‐
ry diseases, such as thalassemia, Fanconi anemia, hemophilia, primary immunodeficiency,
mucopolysaccharidosis,  Gaucher  disease,  and  X-linked  adrenoleukodystrophy  (X-ALD)
are discussed.
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2. Characteristics of HSCs and gene therapy
The concept of the HSC was introduced by Till and McCulloch in 1961 [5]. Although a healthy
adult produces approximately 1 trillion blood cells each day, they are considered to originate
from a single HSC which can potentially be transplanted into a mouse [6, 7]. Generally stem
cells are defined as cells capable of self-renewal and multilineage differentiation. In addition to
these two characteristics, HSCs have the capability of cell-cycle dormancy, i.e. to enter a state of
dormancy (G0 phase) in the cell cycle and can continue blood cell production over a lifetime
while protecting themselves from various kinds of stress [8].
Fig. 1 shows HSC surface markers and the typical cytokines regulating HSCs. Stem cell factor
(SCF) and thrombopoietin (TPO) are important direct cytokine regulators of HSCs. Although
SCF promotes the proliferation and differentiation of hematopoietic progenitor cells, it is
thought to not be essential for the initiation of hematopoiesis and HSC self-renewal [9]. TPO
and its receptor, c-Mpl, are thought to play important roles in early hematopoiesis from HSCs.
In contrast to the CD34+CD38-c-Mpl- population, CD34+CD38-c-Mpl+ cells show significantly
better HSC engraftment [10]. Mice lacking either TPO or c-Mpl have deficiencies in progenitor
cells of multiple hematopoietic lineages [11]. TPO-mediated signal transduction for the self-re‐
newal of HSCs is negatively regulated by the intracellular scaffold protein Lnk [12, 13]. A sig‐
nal from angiopoietin-1 via Tie2 regulates HSC dormancy by promoting the adhesion of HSCs
to osteoblasts in the bone marrow niche and maintains long-term repopulating activity [14].
Although cytokine-induced lipid raft clustering of the HSC membrane is essential for HSC re-
entry into the cell cycle, transforming growth factor-β (TGF-β) inhibits lipid raft clustering and
induces p57Kip2 expression, leading to HSC dormancy [15, 16]. Recently, the hypoxic niche of
HSCs has been demonstrated. It, along with the osteoblastic and vascular niches, are important
for HSC dormancy [17-19]. They are targets in HSC gene therapy [20].
Figure 1. Hematopoietic stem cell (HSC) surface markers and typical cytokines that regulate HSCs. Stem cell fac‐
tor (SCF) promotes the proliferation and differentiation of HSCs. Thrombopoietin (TPO) and its receptor, c-Mpl, play
important roles in early hematopoiesis, especially self-renewal. Signals from angiotensin-1 via Tie2 and transforming
growth factor -β via its receptors regulate HSC dormancy. (This figure is based on the illustration by BioLegend, Inc.
San Diego, CA, U.S.A. http://www.biolegend.com/cell_markers)
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While making a HSC with few opportunities for cell division into a transgenic target, it is
important to design a safe and efficient vector for inserting a gene into the host chromo‐
some. Furthermore, since a hematogenous cell also has many cells which exhibit its function
in the specialization process to a mature effector cell, it is also important to select differentia‐
tion-specific or non-specific promoters or enhancers during the vector design process.
3. Vectors for HSC gene therapy
Vectors derived from the Retroviridae family, RNA viruses with reverse transcriptase activi‐
ty, are widely used for inserting genes in host chromosomes. Although adeno-associated vi‐
rus (AAV) vectors can also insert genes into host chromosomes, this process is inefficient
and partial. Gammaretroviruses and lentiviruses are members of the Retroviridae family
that are commonly used as vectors in HSC gene therapy. Generally, the former is called sim‐
ply a retroviral vector and the latter is called a lentiviral vector. When a gene is inserted in
the chromosome of an HSC with a Retroviridae vector, genotoxicity can occur.
3.1. Gammaretroviral (Retroviral) vectors
Retroviral vectors are commonly constructed from the Moloney murine leukemia virus
(MoMLV) genome. Retroviral genomes have a gag/pol gene that codes for viral structure
proteins, protease and reverse transcriptase, an env gene that codes for the envelope glyco‐
protein and the packaging signal. These genes are flanked by long terminal repeats (LTR)
which contain enhancers and promoters. A retroviral vector consists of a packaging plasmid
that does not have the packaging signal but does include the gag/pol gene, a transfer vector
with the packaging signal, and the target gene cDNA. After transfection of these plasmids
into producer cells (e.g., 297T cells, NIH3T3 cell, etc.), a target vector is obtained by collect‐
ing the culture solution.
Expression of a target gene can be inhibited by mechanisms such as methylation of CpG is‐
lands in the promoter region, insertion of a negative control region (NCR) into the LTR, and
the presence of a repressor binding site (RBS) downstream of the 5′ LTR. Other vectors, such
as the murine stem cell virus (MSCV) vector [21], the myeloproliferative sarcoma virus vec‐
tor, the negative control region deleted (MND) vector [22], and the MFG-S vector [23] were
developed to improve the efficiency of transgene expression; they are widely used in clinical
applications of gene therapy involving HSCs.
Since the retroviral viral genome cannot cross the nuclear membrane, it can be incorporated
into a chromosome only during the phase of mitosis when the nuclear membrane has disas‐
sembled. Since many HSCs are thought to exist in a dormant phase, insertions into the HSC
genome with a retroviral vector require a proliferation stimulus by cytokines. Although var‐
ious combinations of cytokines to suppress the decrease in HSC self-renewal have been
studied, stem cell factor (SCF), fms-related tyrosine kinase-3 (Flt-3) ligand, interleukin-3
(IL-3), TPO, among others, are commonly used [24, 25].
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Human immunodeficiency virus type 1 (HIV-1), the representative lentivirus, differs from
gammaretroviruses in that it can be incorporated during a non-mitotic phase. This is one ad‐
vantage of lentiviral vectors in HSC gene therapy.
Both lentiviruses and gammaretroviruses have gag, pol, and env genes sandwiched between
LTRs with promoter activity at both ends. In addition, lentiviruses have accessory genes (vif,
vpr, vpu, nef) and regulatory genes (tat, rev). Double-stranded cDNA produced from the viral
genome enters the cell, and a pre-integration complex is formed with a host protein. This
complex can pass through the pores of the nuclear membrane during non-mitotic phases, al‐
lowing the viral genome to be inserted into the host cell chromosome.
Figure 2. HIV provirus (A) and the four plasmids of a third-generation lentiviral vector (B). The viral long termi‐
nal repeats (LTRs), reading frames of the viral genes, splice donor site (SD), splicing acceptor site (SA), packaging signal
(Ψ), and rev-responsive element (RRE) are indicated. The packaging plasmid contains the gag and pol genes under the
influence of the CMV promoter, intervening sequences, and the polyadenylation site (polyA) of the human β-globin
gene. As the transcripts of the gag and pol genes contain cis-repressive sequences, they are expressed only if rev pro‐
motes their nuclear export by binding to the RRE. All tat and rev exons have been deleted, and the viral sequences
upstream of the gag gene have been replaced. The rev plasmid expresses rev cDNA. The SIN vector plasmid contains
HIV-1 cis-acting sequences and an expression cassette for the transgene. It is the only portion transferred to the target
cells and does not contain wild-type copies of the HIV LTR. The 5′ LTR is chimeric, with the RSV enhancer and promoter
replacing the U3 region to rescue transcriptional dependence on tat. The 3′ LTR has an almost completely deleted U3
region, which includes the TATA box. As the latter is the template used to generate both copies of the LTR in the inte‐
grated provirus, transduction of this vector results in transcriptional inactivation of both LTRs; thus, it is a self-inactivat‐
ing (SIN) vector. The envelope plasmid encodes a heterologous envelope to pseudotype the vector, here shown
coding for vesicular stomatitis virus (VSV)-G. Only the relevant parts of the constructs are shown (Reproduced with
modifications from [26]).
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Although first-generation lentiviral vectors included modification genes, they were re‐
moved in the second generation because it was discovered that the modification genes are
not required for infection during non-mitotic phases. In the third generation, further modifi‐
cations included the deletion of tat, use of multiple vector plasmids, and introduction of self-
inactivating (SIN) vectors. The structure of HIV-1 and a typical third-generation lentiviral
vector system are shown in Fig. 2 [26]. Approximately one-third of the HIV-1 genome has
been deleted, and the vector system has been divided into four plasmids, namely, the pack‐
aging plasmid, rev plasmid, SIN vector plasmid and envelope plasmid. To prevent produc‐
tion of wild type HIV-1, tat, a regulatory gene indispensable to viral reproduction was
deleted, and the rev gene was moved to a separate plasmid. Moreover, since the HIV-1 LTR
promoter is weak in the absence of tat, it was replaced with the cytomegalovirus (CMV) pro‐
moter in the packaging plasmid. Since an envelope plasmid can only infect CD4 positive
cells with a HIV-1 envelope, the envelope gene was replaced with the vesicular stomatitis
virus G glycoprotein (VSV-G) envelope. The SIN vector further improved safety by replac‐
ing the enhancer / promoter portion of the LTR, suppressing the activation of unnecessary
genes with the integrated gene (Fig. 3) [27].
Figure 3. Mechanism of gene activation induced by vector insertion. The genomic integration site of an MLV-
based retroviral vector is depicted. With this MLV vector design, the enhancer and promoter within the U3 region
(blue rectangle) of the long terminal repeat (LTR) drive transcription of the transgene (indicated by the parallel arrow
arising from the blue rectangle). Vector integration near Gene X is shown in the top panel. The enhancer elements
located in the U3 region (blue rectangle) of the vector can interact with the regulatory elements upstream of Gene X
to increase its basal transcription rate to inappropriately high levels, potentially altering the growth of the cell. Two
alternatives for eliminating the use of the powerful enhancer in the U3 region include (1) middle panel: use of a self-
inactivating (SIN) MLV-based vector in which the U3 region has been deleted. An internal cellular promoter is used to
drive transgene expression and (2) bottom panel: use of a SIN lentiviral vector in which U3 (yellow rectangle) has been
eliminated. This system also uses an internal cellular promoter to drive transgene expression (Reproduced with modifi‐
cation from [27]).
To improve the gene transfer into HSCs, Verhoeyen and colleagues designed lentiviral vec‐
tors displaying “early-acting cytokines” such as TPO and SCF. This vector can promote sur‐
vival of CD34 positive HSCs and achieve selective transduction of long-term repopulating
cells in a humanized mouse model (Fig. 4) [28, 29].
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Figure 4. Lentiviral vector particles (HIV-1) display recombinant membrane envelope proteins such as stem cell factor
(SCF), thrombopoietin (TPO), and vesicular stomatitis virus G glycoprotein (VSV-G). This vector can specifically target
vector particles to hematopoietic stem cells (HSCs) expressing c-kit and c-mpl receptors for SCF and TPO, respectively.
VSV-G envelope protein can bind to phospholipids in the HSC cell membrane. (Karlsson S, Gene therapy: efficient tar‐
geting of hematopoietic stem cells. Blood. 2005;106(10):3333)
3.3. Genotoxicity of viral vectors
The most serious problem with using viral vectors to incorporate a gene into a chromosome
is the potential development of clonal proliferative diseases such as leukemia, which was
observed in clinical trials involving gene therapy for SCID-X1 and chronic granulomatous
disease (CGD). Although this problem of genotoxicity represents a great hurdle in the devel‐
opment of clinical applications for gene therapy, there is promising ongoing research on the
mechanisms underlying genotoxicity and how to avoid it.
The mechanisms of retrovirus-induced oncogenesis are shown in Fig. 5 [30]. In oncogene
capture, an acute transforming replication-competent retrovirus captures a cellular proto-
oncogene and mediates transformation. This mechanism does not occur in replication-in‐
competent vectors. Second, the provirus 3′ LTR can trigger increased transcription of a
cellular proto-oncogene. Third, enhancers in the provirus LTRs can activate transcription
from nearby cellular proto-oncogene promoters. Fourth, a novel isoform can be expressed
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when transcription from the provirus 5′ LTR creates a novel truncated isoform of a cellular
proto-oncogene via splicing. Fifth, an inserted provirus can disrupt transcription by causing
premature polyadenylation. The same mechanisms can occur in cellular oncogenesis when a
gene is inserted by a retroviral vector [30].
Figure 5. Retroviral mechanisms of oncogenesis. The detailed mechanisms are shown in the text. The integrated
provirus is indicated by two LTRs. Cellular proto-oncogene promoter and exons are indicated by black and grey boxes
respectively (Reproduced from [30]).
Even if a gene is inserted into a HSC similarly, it is also known that there are diseases which
may develop a tumor, and diseases a tumor is not accepted to be. Each type of virus has a
unique integration profile, and the following observations have been made [30]: (a) Different
retroviral vectors have distinct integration profiles. (b) The route of entry does not appear to
strongly affect distribution of integration sites. VSV-G–pseudotyped HIV vectors have an in‐
tegration profile similar to HIV virions with the native HIV envelope despite differences in
the route of entry. (c) The integration profile is largely independent of the target cell type,
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disease (CGD). Although this problem of genotoxicity represents a great hurdle in the devel‐
opment of clinical applications for gene therapy, there is promising ongoing research on the
mechanisms underlying genotoxicity and how to avoid it.
The mechanisms of retrovirus-induced oncogenesis are shown in Fig. 5 [30]. In oncogene
capture, an acute transforming replication-competent retrovirus captures a cellular proto-
oncogene and mediates transformation. This mechanism does not occur in replication-in‐
competent vectors. Second, the provirus 3′ LTR can trigger increased transcription of a
cellular proto-oncogene. Third, enhancers in the provirus LTRs can activate transcription
from nearby cellular proto-oncogene promoters. Fourth, a novel isoform can be expressed
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when transcription from the provirus 5′ LTR creates a novel truncated isoform of a cellular
proto-oncogene via splicing. Fifth, an inserted provirus can disrupt transcription by causing
premature polyadenylation. The same mechanisms can occur in cellular oncogenesis when a
gene is inserted by a retroviral vector [30].
Figure 5. Retroviral mechanisms of oncogenesis. The detailed mechanisms are shown in the text. The integrated
provirus is indicated by two LTRs. Cellular proto-oncogene promoter and exons are indicated by black and grey boxes
respectively (Reproduced from [30]).
Even if a gene is inserted into a HSC similarly, it is also known that there are diseases which
may develop a tumor, and diseases a tumor is not accepted to be. Each type of virus has a
unique integration profile, and the following observations have been made [30]: (a) Different
retroviral vectors have distinct integration profiles. (b) The route of entry does not appear to
strongly affect distribution of integration sites. VSV-G–pseudotyped HIV vectors have an in‐
tegration profile similar to HIV virions with the native HIV envelope despite differences in
the route of entry. (c) The integration profile is largely independent of the target cell type,
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although the transcriptional program and epigenetic status of the target cell can influence
integration site selection. (d) For lentiviruses, which can integrate independently of mitosis,
the cell-cycle status of the target cell has only a modest effect on the distribution of integra‐
tion sites.
In order to avoid genotoxicity, various SIN vectors have been developed and improved.
In general, lentiviral vectors are considered to have a lower risk of oncogenesis than ret‐
roviral  vectors  [31].  However,  when a  HSC is  the  target  cell,  more  attention should be
required  because  tumorigenesis  can  occur  when  the  cell  with  the  inserted  gene  under‐
goes differentiation.
4. Clinical applications of HSC gene therapy
Diseases  in  which  gene  therapy  using  HSCs  are  being  studied  are  shown  in  Table  1.
They  are  roughly  divided  into  hematological  disorders,  immunodeficiencies,  and  meta‐
bolic  diseases.  Most  are congenital  or  hereditary diseases.  The characteristic  clinical  fea‐







X-linked severe combined immunodeficiency (SCID-X1)
Adenosine deaminase deficiency (ADA-SCID)
Chronic granulomatous disease (CGD)
Wiskott-Aldrich syndrome (WAS)
Janus kinase 3 (JAK3) deficiency
Purine nucleoside phosphorylase (PNP) deficiency
Leukocyte adhesion deficiency type 1 (LAD-1)
Congenital metabolic diseases
Mucopolysaccharidosis (MPS) types I, II, III, VII
Gaucher disease
X-linked adrenoleukodystrophy (X-ALD)
Table 1. Clinical applications of hematopoietic stem cell gene therapy.
4.1. β-thalassemia
Hemoglobin  A (HbA),  comprising 98% of  adult  human hemoglobin,  is  a  tetramer  with
two α-globin and two β-globin chains combined with a heme group. β-thalassemia is an
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autosomal hemoglobin disorder caused by decreased β-globin chain synthesis.  Although
individuals  with β-thalassemia minor (heterozygote) may be asymptomatic or have mild
to moderate  microcytic  anemia,  β-thalassemia major  (homozygote)  progresses  to  serious
anemia by one or two years of age, and hemosiderosis, iron overload caused by transfu‐
sion or increased iron absorption,  develops.  Since most patients develop life-threatening
complications such as heart failure by adolescence, HSCT has been performed in patients
with advanced disease  [32].  In  recent  years,  gene therapy using a  lentiviral  vector  con‐
taining a functional β-globin gene has been performed in an HbE/ β-thalassemia (βE/ β0)
transfusion-dependent  adult  male,  who  subsequently  did  not  require  transfusions  for
over 21 months [33].
The human β-globin locus is located in a large 70kb area which also contains some β-like
globulin genes (ε, Gγ, Aγ, δ, β). Gene switching takes place according to the development
stage, and the β-globin gene is transcribed and expressed specifically after birth. A powerful
enhancer called the LCR (locus control region) exists on the 5′ side of the promoter. The LCR
contains five DNase I hypersensitive sites, referred to as HS5 to HS1 starting from the 5′
side. Furthermore, HS5 contains CCCTC-binding factor (CTCF)-dependent insulator.
The structure of the lentiviral SIN vector used in gene therapy for β-thalassemia is shown in
Fig. 6. To improve safety, two stop codons were inserted into the packaging signal (ψ) of
GAG, the HS5 portion with insulator activity was deleted, and two copies of the 250 base
pair (bp) core of the cHS4 chromatin insulators (chicken β-globin insulators) were inserted
in the U3 region of the HIV 3′ LTR. Furthermore, the amino acid at the 87th position of β-
globin was changed from threonine to glutamine. This altered β-globin can be distinguished
from normal adult β-globin by high performance liquid chromatography (HPLC) analysis in
individuals receiving red blood cell transfusion and β+-thalassemia patients [33].
Figure 6. Diagram of the human β-globin gene in a lentiviral vector. HIV LTR, human immunodeficiency type-1
virus long terminal repeat; Ψ+, packaging signal; cPPT/flap, central polypurine tract/DNA flap; RRE, rev-responsive ele‐
ment; βp, human β-globin promoter; ppt, polypurine tract; HS, DNase I Hypersensitive Sites (Reproduced with color
modification from [33])
A clinical study using this vector was performed in two β-thalassemia patients. As with au‐
tologous bone marrow transplantation, some of the patients’ marrow cells were cryopre‐
served as a backup. The lentiviral vector particles containing a functional β-globin were
Recent Advances in Hematopoietic Stem Cell Gene Therapy
http://dx.doi.org/10.5772/53587
115
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autosomal hemoglobin disorder caused by decreased β-globin chain synthesis.  Although
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over 21 months [33].
The human β-globin locus is located in a large 70kb area which also contains some β-like
globulin genes (ε, Gγ, Aγ, δ, β). Gene switching takes place according to the development
stage, and the β-globin gene is transcribed and expressed specifically after birth. A powerful
enhancer called the LCR (locus control region) exists on the 5′ side of the promoter. The LCR
contains five DNase I hypersensitive sites, referred to as HS5 to HS1 starting from the 5′
side. Furthermore, HS5 contains CCCTC-binding factor (CTCF)-dependent insulator.
The structure of the lentiviral SIN vector used in gene therapy for β-thalassemia is shown in
Fig. 6. To improve safety, two stop codons were inserted into the packaging signal (ψ) of
GAG, the HS5 portion with insulator activity was deleted, and two copies of the 250 base
pair (bp) core of the cHS4 chromatin insulators (chicken β-globin insulators) were inserted
in the U3 region of the HIV 3′ LTR. Furthermore, the amino acid at the 87th position of β-
globin was changed from threonine to glutamine. This altered β-globin can be distinguished
from normal adult β-globin by high performance liquid chromatography (HPLC) analysis in
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Figure 6. Diagram of the human β-globin gene in a lentiviral vector. HIV LTR, human immunodeficiency type-1
virus long terminal repeat; Ψ+, packaging signal; cPPT/flap, central polypurine tract/DNA flap; RRE, rev-responsive ele‐
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A clinical study using this vector was performed in two β-thalassemia patients. As with au‐
tologous bone marrow transplantation, some of the patients’ marrow cells were cryopre‐
served as a backup. The lentiviral vector particles containing a functional β-globin were
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introduced into the remaining cells. After the transfected cells were cultured for one week ex
vivo, some were also cryopreserved. The patients were conditioned with intravenous busul‐
fan (3.2 mg/kg/day for four days) without the addition of cyclophosphamide, before trans‐
plantation using the autologous gene-modified cryopreserved cells (Fig. 7) [34].
The first patient failed to engraft because the HSCs had been compromised by how they
were handled, not because of any issues with the gene therapy vector, and ultimately used
backup bone marrow. The second patient, as described previously, achieved long-term β-
globin production; one-third of the patient’s hemoglobin was produced by the genetically
modified cells [33].
Furthermore, the detailed examination of the transgenic cells showed significantly increased
expression of high mobility group AT-hook 2 (HMGA2), which interacts with transcription
factors to regulate gene expression, in the clones where gene insertion occurred in the
HMGA2 gene. The proportion of the HMGA2 overexpressing clones increased with time, to
over 50% of transgenic cells at 20 months after gene therapy. In this patient, the HMGA2
overexpressing cells were only 5% of all circulating hematopoietic cells and there was no
evidence of malignant transformation. However, researchers point out that there was ex‐
pressive production of a truncated form of the HMGA2 protein. Since truncated or overex‐
pressed HMGA2 is observed with some blood cancers and non-malignant expansions of
blood cells, caution is recommended with this therapy [34].
Figure 7. Gene-therapy procedure for patient with b-thalassemia. a. Hematopoietic stem cells (HSCs) are collected
from the bone marrow of a patient with β-thalassemia and maintained them in culture. b, Lentiviral-vector particles con‐
taining a functional β-globin gene were then introduced into the cells and allowed them to expand further in culture. c. To
eradicate the patient’s remaining HSCs and make room for the geneticaaly modified cells, the patient underwent chemo‐
therapy. d. The genetically modified HSCs were then transplanted into the patient (Reproduced from [34]).
Recently, researchers generated a LCR-free SIN lentiviral vector that combines two heredita‐
ry persistence of fetal hemoglobin (HPFH)-activating elements, resulting in therapeutic lev‐
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els of Aγ-globin protein produced by erythroid progenitors derived from thalassemic HSCs
[35]. Both lentiviral-mediated γ-globin gene addition and genetic reactivation of endoge‐
nous γ-globin genes are considered potentially capable of providing therapeutic levels of
hemoglobin F to patients with β-globin deficiency [36]. In addition, a trial of γ-globin induc‐
tion with β-globin production using mithramycin, an inducer of γ-globin expression, to re‐
move excess α-globin proteins in β-thalassemic erythroid progenitor cells was reported [37].
4.2. Fanconi anemia
Fanconi anemia is a hereditary disease characterized by cellular hypersensitivity to DNA
crosslinking agents. It leads to bone marrow failure, such as aplastic anemia, by approxi‐
mately eight years of age. Since there is a high risk of developing malignancy, HSCT has
been performed as a curative treatment for bone marrow insufficiency. Although the ten-
year probability of survival after transplant from an Human leukocyte antigen (HLA) -iden‐
tical donor is over 80%, results with other donors are not satisfactory. HSC gene therapy is
considered an alternative in cases where there is no HLA-identical donor available [38-40].
There are currently 13 discovered Fanconi anemia complement groups and 13 distinct genes
(FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ,
FANCL, FANCM, FANCN) have been cloned. Mutations in FANCB are associated with an X-
linked form of Fanconi anemia; mutations in the other genes are associated with autosomal
recessive transmission. Although frequencies vary by geographical region, FANCA gene ab‐
normalities are found in more than half of all Fanconi anemia patients [41]. Although one of
the major hurdles in the development of gene therapy for Fanconi anemia is the increased
sensitivity of Fanconi anemia stem cells to free radical-induced DNA damage during ex vivo
culture and manipulation, retroviral and lentiviral vectors have been successfully employed
to deliver complementing Fanconi anemia cDNA to HSCs with targeted disruptions of the
FANCA and FANCC genes [20, 42-44]. In a phase I trial of FANCA gene therapy, gene trans‐
fer was performed with patient bone marrow-derived CD34+ cells and the MSCV retroviral
vector [38]. Whether sufficient HSCs can be obtained is a potential problem in Fanconi ane‐
mia patients due to possible bone marrow insufficiency, but in this study, sufficient target
CD34+ cells were obtained from most patients. Two patients had FANCA-transduced cells
successfully infused. The procedure was safe, well tolerated, and resulted in transient im‐
provements in hemoglobin and platelet counts [39]. However, transduced cell products
were not obtained in one patient who required cryopreserved bone marrow. The first clini‐
cal study of FANCC gene therapy using a retroviral vector involved four patients. Although
functional FANCC gene expression was observed in peripheral blood and bone marrow
cells, the results were transient [43].
Engraftment efficiency of FANCA-modified cells using a lentiviral vector was studied in a
mouse model. Rapid transduction with four hours of culture using only SCF and megakar‐
yocyte growth and development factor and minimal differentiation of gene-induced cells is
better than standard 96-hour culture using a variety of cytokines, including SCF, interleu‐
kin-11, Flt-3 ligand, and IL-3 [44]. Moreover, a recent trial demonstrated enhanced viability
and engraftment of gene-corrected cells in patients with FANCA abnormalities with short
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introduced into the remaining cells. After the transfected cells were cultured for one week ex
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plantation using the autologous gene-modified cryopreserved cells (Fig. 7) [34].
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globin production; one-third of the patient’s hemoglobin was produced by the genetically
modified cells [33].
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expression of high mobility group AT-hook 2 (HMGA2), which interacts with transcription
factors to regulate gene expression, in the clones where gene insertion occurred in the
HMGA2 gene. The proportion of the HMGA2 overexpressing clones increased with time, to
over 50% of transgenic cells at 20 months after gene therapy. In this patient, the HMGA2
overexpressing cells were only 5% of all circulating hematopoietic cells and there was no
evidence of malignant transformation. However, researchers point out that there was ex‐
pressive production of a truncated form of the HMGA2 protein. Since truncated or overex‐
pressed HMGA2 is observed with some blood cancers and non-malignant expansions of
blood cells, caution is recommended with this therapy [34].
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[35]. Both lentiviral-mediated γ-globin gene addition and genetic reactivation of endoge‐
nous γ-globin genes are considered potentially capable of providing therapeutic levels of
hemoglobin F to patients with β-globin deficiency [36]. In addition, a trial of γ-globin induc‐
tion with β-globin production using mithramycin, an inducer of γ-globin expression, to re‐
move excess α-globin proteins in β-thalassemic erythroid progenitor cells was reported [37].
4.2. Fanconi anemia
Fanconi anemia is a hereditary disease characterized by cellular hypersensitivity to DNA
crosslinking agents. It leads to bone marrow failure, such as aplastic anemia, by approxi‐
mately eight years of age. Since there is a high risk of developing malignancy, HSCT has
been performed as a curative treatment for bone marrow insufficiency. Although the ten-
year probability of survival after transplant from an Human leukocyte antigen (HLA) -iden‐
tical donor is over 80%, results with other donors are not satisfactory. HSC gene therapy is
considered an alternative in cases where there is no HLA-identical donor available [38-40].
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(FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ,
FANCL, FANCM, FANCN) have been cloned. Mutations in FANCB are associated with an X-
linked form of Fanconi anemia; mutations in the other genes are associated with autosomal
recessive transmission. Although frequencies vary by geographical region, FANCA gene ab‐
normalities are found in more than half of all Fanconi anemia patients [41]. Although one of
the major hurdles in the development of gene therapy for Fanconi anemia is the increased
sensitivity of Fanconi anemia stem cells to free radical-induced DNA damage during ex vivo
culture and manipulation, retroviral and lentiviral vectors have been successfully employed
to deliver complementing Fanconi anemia cDNA to HSCs with targeted disruptions of the
FANCA and FANCC genes [20, 42-44]. In a phase I trial of FANCA gene therapy, gene trans‐
fer was performed with patient bone marrow-derived CD34+ cells and the MSCV retroviral
vector [38]. Whether sufficient HSCs can be obtained is a potential problem in Fanconi ane‐
mia patients due to possible bone marrow insufficiency, but in this study, sufficient target
CD34+ cells were obtained from most patients. Two patients had FANCA-transduced cells
successfully infused. The procedure was safe, well tolerated, and resulted in transient im‐
provements in hemoglobin and platelet counts [39]. However, transduced cell products
were not obtained in one patient who required cryopreserved bone marrow. The first clini‐
cal study of FANCC gene therapy using a retroviral vector involved four patients. Although
functional FANCC gene expression was observed in peripheral blood and bone marrow
cells, the results were transient [43].
Engraftment efficiency of FANCA-modified cells using a lentiviral vector was studied in a
mouse model. Rapid transduction with four hours of culture using only SCF and megakar‐
yocyte growth and development factor and minimal differentiation of gene-induced cells is
better than standard 96-hour culture using a variety of cytokines, including SCF, interleu‐
kin-11, Flt-3 ligand, and IL-3 [44]. Moreover, a recent trial demonstrated enhanced viability
and engraftment of gene-corrected cells in patients with FANCA abnormalities with short
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transduction (overnight), low oxidative stress (5% oxygen), and the anti-oxidant N-acetyl-L-
cysteine [20]. Lentiviral transduction of unselected Fanconi anemia bone marrow cells medi‐
ates efficient phenotypic correction of hematopoietic progenitor cells and CD34-
mesenchymal stromal cells, with increased efficacy in hematopoietic engraftment [45]. In
Fancg -/- mice, the wild-type mesenchymal stem and progenitor cells play important roles in
the reconstitution of exogenous HSCs in vitro [46]. Recently, a new approach that directly
injects lentiviral vector particles into the femur for FANCC gene transfer in mice was able to
successfully introduce the FANCC gene to HSCs. This result provides evidence that target‐
ing the HSCs directly in their native environment enables efficient and long-term correction
of bone marrow defects in Fanconi anemia [47].
In recent years, the design of lentiviral vectors used for gene therapy in Fanconi anemia has
improved. Although the vav and phosphoglycerate kinase (PGK) promoters are relatively
weak, physiological levels of FANCA gene expression can be obtained in lymphoblastoid
cells. CMV and spleen focus-forming virus (SFFV) promoters result in overexpression of
FANCA. The PGK-FANCA lentiviral vectors with either a wild-type woodchuck hepatitis vi‐
rus posttranscriptional regulatory element (WPRE) or a mutated WPRE in the 3′ region have
higher levels of FANCA gene expression. In conclusion, lentiviral vectors with a mutated
WPRE and a PGK promoter are considered the most suitable with respect to safety and effi‐
ciency for Fanconi anemia gene therapy [48].
There was a recent interesting report on the use of induced pluripotent stem cells (iPS cell).
Instead of introducing a repaired gene into the HSCs of a patient with a FANCA gene abnor‐
mality, the modified gene was introduced into more stable somatic cells, e.g. fibroblasts, and
iPS cells were derived from the genetically modified somatic cells. If HSCs can be produced
from genetically modified iPS cells, hematological function can be efficiently reconstructed
in patients with hematologic disorders [49].
4.3. Hemophilia
Hemophilia is a common congenital coagulopathy caused by coagulation factor VIII (hemo‐
philia A) or IX (hemophilia B) deficiency. Although the genes encoding both factor VIII
(Xq28) and factor IX (Xq27) are located on the X chromosome and most cases are X-linked,
many sporadic variations have been reported. Factor substitution therapies have been used
to treat hemophilia for many years. However, there is great hope for gene therapy with he‐
mophilia because coagulation factors have short half-lives (factor VIII, 8 to 12 hours; factor
IX, 18 to 24 hours), and an inhibitor is produced in many cases. Furthermore, it is possible
for gene therapy to suppress immunogenicity by introducing a mutant protein that lacks the
domain with which the inhibitor interacts. Since both coagulation factors are usually pro‐
duced in the liver, there are few studies involving HSCs. In addition to hepatocytes, trials
introducing the modified gene directly into splenic cells, endothelial cells, myoblasts, fibro‐
blasts, etc. have been reported [50-52]. Since the factor IX gene (34 kb) is smaller than the
factor VIII gene (186 kb), hemophilia B gene therapy can be possible with an adenovirus vec‐
tor or an AAV vector. Therefore, hemophilia B is progressing more as a field of gene therapy
research even through there are five times more patients with hemophilia A [51-53].
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Recently, human factor VIII variant genes were successfully introduced into the HSCs of a
mouse with hemophilia A resulting in therapeutic levels of factor VIII variant protein ex‐
pression. This variant factor VIII has changes in the B and A2 domain in addition to the A1
domain for improved secretion and reduced immunogenicity (wild-type factor VIII has six
domains, A1, A2, B, A3, C1, and C2) [54]. To ameliorate the symptoms of hemophilia A, par‐
tial replacement of the mutated liver cells by healthy cells in hemophilia A mice was chal‐
lenged with allogeneic bone marrow progenitor cell transplantation. In this study, the bone
marrow progenitor cell-derived hepatocytes and sinusoidal endothelial cells synthesized
factor VIII, showing that autologous gene-modified bone marrow progenitor cells have the
potential to treat hemophilia [55].
4.4. Primary immunodeficiencies
Although HSCT has been widely performed as curative treatment for primary immunodefi‐
ciencies, gene therapy has been considered when there is no HLA-identical donor available.
As previously shown, the first successful gene therapy was performed in a patient with
ADA deficiency in the U.S. in 1990. Since the gene was introduced into T lymphocytes, fre‐
quent treatment was required. However, this treatment was associated with an unacceptable
level of toxicity. Since transfected vector and normal ADA gene expression in T lympho‐
cytes continued for two years after the cessation of treatment [1], gene therapy attracted at‐
tention. With advances in HSC gene-transfer technology, gene therapy for many primary
immunodeficiencies can now be considered [56].
4.4.1. SCID-X1
SCID-X1 is an X-linked disease caused by deficiency of the common γ (γc) chain in the IL-2
receptor. Because the γc chain is common to the IL-4, IL-7, IL-9, IL-15, and IL-21 receptors, in
SCID-X1 patients, there are defects in T and natural killer (NK) cells, and B cell dysfunction
are usually observed [57]. Patients begin suffering from various infections starting several
weeks after birth. Without curative treatment, such as HSCT, patients die in infancy.
In SCID-X1, since T cells are lacking, engraftment of the gene-transduced cells can be ach‐
ieved without pre-conditioning therapy. In the clinical studies of SCID-X1 patients in France
and the U.K., the MFG retroviral vector was used with HSCs obtained from the patient. Af‐
ter gene therapy, many patients had improvements in immune function. However, since the
genes regulating lymphocyte proliferation, such as LIM domain only 2 (LMO2), Bmi1, cyclin
D2 (CCND2) are near the gene insertion region, there was a high frequency of T-cell leuke‐
mia after treatment. Furthermore, in the patients who developed leukemia, additional chro‐
mosomal changes, including activating mutations of Notch1, changes in the T cell receptor β
region, and deletion of tumor suppressor genes, e.g. cyclin-dependent kinase-2A (CDKN2A)
were observed [58]. Almost gene integration sites by the retroviral vector were inside or
near genes that are highly expressed in CD34 positive stem cells. Furthermore, the activity
of protein kinases or transferases coded by these activated genes was stronger in CD3 posi‐
tive T cells than CD34 positive cells [59]. Thus, gene integration mediated by a retrovirus in‐
fluences the target cell’s dormant capacity for survival, engraftment, and proliferation.
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transduction (overnight), low oxidative stress (5% oxygen), and the anti-oxidant N-acetyl-L-
cysteine [20]. Lentiviral transduction of unselected Fanconi anemia bone marrow cells medi‐
ates efficient phenotypic correction of hematopoietic progenitor cells and CD34-
mesenchymal stromal cells, with increased efficacy in hematopoietic engraftment [45]. In
Fancg -/- mice, the wild-type mesenchymal stem and progenitor cells play important roles in
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ing the HSCs directly in their native environment enables efficient and long-term correction
of bone marrow defects in Fanconi anemia [47].
In recent years, the design of lentiviral vectors used for gene therapy in Fanconi anemia has
improved. Although the vav and phosphoglycerate kinase (PGK) promoters are relatively
weak, physiological levels of FANCA gene expression can be obtained in lymphoblastoid
cells. CMV and spleen focus-forming virus (SFFV) promoters result in overexpression of
FANCA. The PGK-FANCA lentiviral vectors with either a wild-type woodchuck hepatitis vi‐
rus posttranscriptional regulatory element (WPRE) or a mutated WPRE in the 3′ region have
higher levels of FANCA gene expression. In conclusion, lentiviral vectors with a mutated
WPRE and a PGK promoter are considered the most suitable with respect to safety and effi‐
ciency for Fanconi anemia gene therapy [48].
There was a recent interesting report on the use of induced pluripotent stem cells (iPS cell).
Instead of introducing a repaired gene into the HSCs of a patient with a FANCA gene abnor‐
mality, the modified gene was introduced into more stable somatic cells, e.g. fibroblasts, and
iPS cells were derived from the genetically modified somatic cells. If HSCs can be produced
from genetically modified iPS cells, hematological function can be efficiently reconstructed
in patients with hematologic disorders [49].
4.3. Hemophilia
Hemophilia is a common congenital coagulopathy caused by coagulation factor VIII (hemo‐
philia A) or IX (hemophilia B) deficiency. Although the genes encoding both factor VIII
(Xq28) and factor IX (Xq27) are located on the X chromosome and most cases are X-linked,
many sporadic variations have been reported. Factor substitution therapies have been used
to treat hemophilia for many years. However, there is great hope for gene therapy with he‐
mophilia because coagulation factors have short half-lives (factor VIII, 8 to 12 hours; factor
IX, 18 to 24 hours), and an inhibitor is produced in many cases. Furthermore, it is possible
for gene therapy to suppress immunogenicity by introducing a mutant protein that lacks the
domain with which the inhibitor interacts. Since both coagulation factors are usually pro‐
duced in the liver, there are few studies involving HSCs. In addition to hepatocytes, trials
introducing the modified gene directly into splenic cells, endothelial cells, myoblasts, fibro‐
blasts, etc. have been reported [50-52]. Since the factor IX gene (34 kb) is smaller than the
factor VIII gene (186 kb), hemophilia B gene therapy can be possible with an adenovirus vec‐
tor or an AAV vector. Therefore, hemophilia B is progressing more as a field of gene therapy
research even through there are five times more patients with hemophilia A [51-53].
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Recently, human factor VIII variant genes were successfully introduced into the HSCs of a
mouse with hemophilia A resulting in therapeutic levels of factor VIII variant protein ex‐
pression. This variant factor VIII has changes in the B and A2 domain in addition to the A1
domain for improved secretion and reduced immunogenicity (wild-type factor VIII has six
domains, A1, A2, B, A3, C1, and C2) [54]. To ameliorate the symptoms of hemophilia A, par‐
tial replacement of the mutated liver cells by healthy cells in hemophilia A mice was chal‐
lenged with allogeneic bone marrow progenitor cell transplantation. In this study, the bone
marrow progenitor cell-derived hepatocytes and sinusoidal endothelial cells synthesized
factor VIII, showing that autologous gene-modified bone marrow progenitor cells have the
potential to treat hemophilia [55].
4.4. Primary immunodeficiencies
Although HSCT has been widely performed as curative treatment for primary immunodefi‐
ciencies, gene therapy has been considered when there is no HLA-identical donor available.
As previously shown, the first successful gene therapy was performed in a patient with
ADA deficiency in the U.S. in 1990. Since the gene was introduced into T lymphocytes, fre‐
quent treatment was required. However, this treatment was associated with an unacceptable
level of toxicity. Since transfected vector and normal ADA gene expression in T lympho‐
cytes continued for two years after the cessation of treatment [1], gene therapy attracted at‐
tention. With advances in HSC gene-transfer technology, gene therapy for many primary
immunodeficiencies can now be considered [56].
4.4.1. SCID-X1
SCID-X1 is an X-linked disease caused by deficiency of the common γ (γc) chain in the IL-2
receptor. Because the γc chain is common to the IL-4, IL-7, IL-9, IL-15, and IL-21 receptors, in
SCID-X1 patients, there are defects in T and natural killer (NK) cells, and B cell dysfunction
are usually observed [57]. Patients begin suffering from various infections starting several
weeks after birth. Without curative treatment, such as HSCT, patients die in infancy.
In SCID-X1, since T cells are lacking, engraftment of the gene-transduced cells can be ach‐
ieved without pre-conditioning therapy. In the clinical studies of SCID-X1 patients in France
and the U.K., the MFG retroviral vector was used with HSCs obtained from the patient. Af‐
ter gene therapy, many patients had improvements in immune function. However, since the
genes regulating lymphocyte proliferation, such as LIM domain only 2 (LMO2), Bmi1, cyclin
D2 (CCND2) are near the gene insertion region, there was a high frequency of T-cell leuke‐
mia after treatment. Furthermore, in the patients who developed leukemia, additional chro‐
mosomal changes, including activating mutations of Notch1, changes in the T cell receptor β
region, and deletion of tumor suppressor genes, e.g. cyclin-dependent kinase-2A (CDKN2A)
were observed [58]. Almost gene integration sites by the retroviral vector were inside or
near genes that are highly expressed in CD34 positive stem cells. Furthermore, the activity
of protein kinases or transferases coded by these activated genes was stronger in CD3 posi‐
tive T cells than CD34 positive cells [59]. Thus, gene integration mediated by a retrovirus in‐
fluences the target cell’s dormant capacity for survival, engraftment, and proliferation.
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Although continuous T cell production was founded in many cases, there was little recon‐
struction of myeloid cells and B cells, and some patients required continuous immunoglobu‐
lin substitution therapy. The use of conditioning therapy is also related to immunological
reconstruction after γc chain gene therapy. There is decreased NK cell reconstruction with‐
out conditioning therapy, so conditioning chemotherapy is required for the engraftment of
undifferentiated stem cells [58]. A trial of SCID-X1 gene therapy in the U.S. involved three
patients ranging from 10 to 14 years of age. They had poor immunological recovery after al‐
lergenic HSCT and T cell recovery was only observed in the youngest patient, suggesting
there is a limit to the recovery of the function of the thymus in older children [60].
To study whether activation of genes near the region of gene insertion or inserted γc chain
gene expression itself induces oncogenicity during SCID-X1 gene therapy, a study of the hu‐
man γc chain gene being expressed under the control of the human CD2 promoter and LTR
(CD2- γc chain gene) was performed in mice. When the CD2- γc chain gene was expressed
in transgenic mice, a few abnormalities involving T cells were observed, but tumorigenesis
was not observed and T and B cell functions were recovered in γc chain-gene deficient mice.
This study demonstrated that when the γc c chain gene is expressed externally, SCID-X1
may be treated safely [61].
Although SIN vectors were developed from earlier retroviral [62] or lentiviral vectors [63] to
reduce the risk of oncogenicity in SCID-X1 gene therapy, genotoxicity unrelated to muta‐
tions in gene insertion regions or γc chain gene overexpression have been reported with len‐
tiviral vectors in recent years, and it seems that more sophisticated vector development is
required [64].
4.4.2. ADA-SCID
ADA is an enzyme that catalyzes the conversion of purine metabolism products adenosine
and deoxyadenosine into inosine or deoxyinosine. ADA-SCID is an autosomal recessive dis‐
ease that results in the accumulation of adenosine, deoxyadenosine, and deoxyadenosinetri‐
phosphate (dATP). Accumulated phosphorylated purine metabolism products act on the
thymus and cause the maturational or functional disorder of lymphocytes. Because ADA-
SCID patients have both T and B cell production fail, patients have a severe combined im‐
munodeficiency disease with a clinical presentation similar to SCID-X1 results, but unlike
SCID-X1, many patients have a low level of T cells. Although enzyme replacement therapy
with polyethylene glycol–modified bovine ADA (PEG-ADA) was developed to treat ADA-
SCID, it is limited by the development of neutralizing antibodies and the cost of lifelong
treatment.
In ADA-SCID, since T cell counts are increased by PEG-ADA, gene therapy to increase pe‐
ripheral T cell counts was attempted during the early stages of gene therapy. Although ad‐
verse events were not observed and continuous expression of ADA was achieved in many
patients, reconstruction of immune function was not obtained and substitution therapy with
PEG-ADA remained necessary. Therefore, HSCs were no longer the target of gene therapy
for ADA-SCID. Since ADA-SCID patients have T cells, nonmyeloablative conditioning was
performed to achieve gene-transduced HSC engraftment [25, 65].
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In a joint Italian-Israeli study started in 2000, ten ADA-SCID children were infused with
CD34 positive cells transduced with a MoMLV retroviral vector containing the ADA gene
after  nonmyeloablative  conditioning  with  busulfan  (2mg/kg/day  for  two  days).  T  cell
counts or function were improved in nine out of the ten patients, and PEG-ADA was dis‐
continued in eight.  Many patients also had improvements in B or NK cell  function, and
immunoglobulin  substitution therapy was discontinued in  five  patients.  Although some
patients  had serious adverse events  including prolonged neutropenia,  hypertension,  Ep‐
stein-Barr virus infection, and autoimmune hepatitis, there were no cases of treatment-in‐
duced leukemia [25].
As with SCID-X1, the retroviral vector gene insertion region is also near genes that control
cell proliferation or self-duplication, such as LMO2, or proto-oncogenes [66]. In clinical stud‐
ies performed in France, the U.S., and the U.K., none of the ADA-SCID patients had adverse
events related to insertional mutagenesis, such as leukemia [67, 68]. Thus, HSC gene therapy
for ADA-SCID using a lentiviral vector [69] is expected to become the alternative therapy in
cases without a suitable donor for HSCT [70]. As an alternative to HSC-based gene therapy,
a study using an AAV vector has reported ADA gene expression in various tissues, includ‐
ing heart, skeletal muscle, and kidney [71].
4.4.3. CGD
CGD is a disease caused by an abnormality in nicotinamide dinucleotide phosphate
(NADPH) oxidase expressed in phagocytes, resulting in failure to produce reactive oxygen
species and decreased ability to kill bacteria or fungi after phagocytosis. NADPH oxidase
consists of gp91phox (Nox2) and p22 phox which together constitute the membrane-spanning
component flavocytochrome b558 (CYBB), and the cytosolic components p47phox, p67phox,
p40phox, and Rac. CGD is caused by a functional abnormality in any of these components.
Mutations in gp91phox on the X chromosome account for approximately 70% of CGD cases.
CGD patients are afflicted with recurrent opportunistic bacterial and fungal infections, lead‐
ing to the formation of chronic granulomas. Although lifelong antibiotic prophylaxis re‐
duces the incidence of infections, the overall annual mortality rate remains high (2%–5%)
and the success rate of HSCT is limited by graft-versus-host-disease and inflammatory flare-
ups at infected sites [56].
In the initial trials of CGD gene therapy without any conditioning therapy, p47phox or gp91phox
gene was inserted using a retroviral vector. The inserted gene was expressed in peripheral
blood granulocytes three to six weeks after re-infusion and mobilization by granulocyte col‐
ony-stimulating factor (G-CSF), but there was no clinical effect within six months [72-74].
In a German study where gp91phox was inserted with busulfan conditioning (8mg/kg), there
were fewer infections after gene therapy. Gene expression was observed in 20% of leuko‐
cytes in the first month, rising to 80% at one year. However, in the gene insertion region
there are genes related to myeloid cell proliferation, such as myelodysplastic syndrome 1-eco‐
tropic virus integration site 1 (MDS1/EVI1), PR domain containing protein 16 (PRDM16), SET
binding protein 1 (SETBP1). Two patients developed myelodysplasia [75]. These two patients
had monosomy 7, considered to be related to EVI1 activation. One died of severe sepsis 27
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man γc chain gene being expressed under the control of the human CD2 promoter and LTR
(CD2- γc chain gene) was performed in mice. When the CD2- γc chain gene was expressed
in transgenic mice, a few abnormalities involving T cells were observed, but tumorigenesis
was not observed and T and B cell functions were recovered in γc chain-gene deficient mice.
This study demonstrated that when the γc c chain gene is expressed externally, SCID-X1
may be treated safely [61].
Although SIN vectors were developed from earlier retroviral [62] or lentiviral vectors [63] to
reduce the risk of oncogenicity in SCID-X1 gene therapy, genotoxicity unrelated to muta‐
tions in gene insertion regions or γc chain gene overexpression have been reported with len‐
tiviral vectors in recent years, and it seems that more sophisticated vector development is
required [64].
4.4.2. ADA-SCID
ADA is an enzyme that catalyzes the conversion of purine metabolism products adenosine
and deoxyadenosine into inosine or deoxyinosine. ADA-SCID is an autosomal recessive dis‐
ease that results in the accumulation of adenosine, deoxyadenosine, and deoxyadenosinetri‐
phosphate (dATP). Accumulated phosphorylated purine metabolism products act on the
thymus and cause the maturational or functional disorder of lymphocytes. Because ADA-
SCID patients have both T and B cell production fail, patients have a severe combined im‐
munodeficiency disease with a clinical presentation similar to SCID-X1 results, but unlike
SCID-X1, many patients have a low level of T cells. Although enzyme replacement therapy
with polyethylene glycol–modified bovine ADA (PEG-ADA) was developed to treat ADA-
SCID, it is limited by the development of neutralizing antibodies and the cost of lifelong
treatment.
In ADA-SCID, since T cell counts are increased by PEG-ADA, gene therapy to increase pe‐
ripheral T cell counts was attempted during the early stages of gene therapy. Although ad‐
verse events were not observed and continuous expression of ADA was achieved in many
patients, reconstruction of immune function was not obtained and substitution therapy with
PEG-ADA remained necessary. Therefore, HSCs were no longer the target of gene therapy
for ADA-SCID. Since ADA-SCID patients have T cells, nonmyeloablative conditioning was
performed to achieve gene-transduced HSC engraftment [25, 65].
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CD34 positive cells transduced with a MoMLV retroviral vector containing the ADA gene
after  nonmyeloablative  conditioning  with  busulfan  (2mg/kg/day  for  two  days).  T  cell
counts or function were improved in nine out of the ten patients, and PEG-ADA was dis‐
continued in eight.  Many patients also had improvements in B or NK cell  function, and
immunoglobulin  substitution therapy was discontinued in  five  patients.  Although some
patients  had serious adverse events  including prolonged neutropenia,  hypertension,  Ep‐
stein-Barr virus infection, and autoimmune hepatitis, there were no cases of treatment-in‐
duced leukemia [25].
As with SCID-X1, the retroviral vector gene insertion region is also near genes that control
cell proliferation or self-duplication, such as LMO2, or proto-oncogenes [66]. In clinical stud‐
ies performed in France, the U.S., and the U.K., none of the ADA-SCID patients had adverse
events related to insertional mutagenesis, such as leukemia [67, 68]. Thus, HSC gene therapy
for ADA-SCID using a lentiviral vector [69] is expected to become the alternative therapy in
cases without a suitable donor for HSCT [70]. As an alternative to HSC-based gene therapy,
a study using an AAV vector has reported ADA gene expression in various tissues, includ‐
ing heart, skeletal muscle, and kidney [71].
4.4.3. CGD
CGD is a disease caused by an abnormality in nicotinamide dinucleotide phosphate
(NADPH) oxidase expressed in phagocytes, resulting in failure to produce reactive oxygen
species and decreased ability to kill bacteria or fungi after phagocytosis. NADPH oxidase
consists of gp91phox (Nox2) and p22 phox which together constitute the membrane-spanning
component flavocytochrome b558 (CYBB), and the cytosolic components p47phox, p67phox,
p40phox, and Rac. CGD is caused by a functional abnormality in any of these components.
Mutations in gp91phox on the X chromosome account for approximately 70% of CGD cases.
CGD patients are afflicted with recurrent opportunistic bacterial and fungal infections, lead‐
ing to the formation of chronic granulomas. Although lifelong antibiotic prophylaxis re‐
duces the incidence of infections, the overall annual mortality rate remains high (2%–5%)
and the success rate of HSCT is limited by graft-versus-host-disease and inflammatory flare-
ups at infected sites [56].
In the initial trials of CGD gene therapy without any conditioning therapy, p47phox or gp91phox
gene was inserted using a retroviral vector. The inserted gene was expressed in peripheral
blood granulocytes three to six weeks after re-infusion and mobilization by granulocyte col‐
ony-stimulating factor (G-CSF), but there was no clinical effect within six months [72-74].
In a German study where gp91phox was inserted with busulfan conditioning (8mg/kg), there
were fewer infections after gene therapy. Gene expression was observed in 20% of leuko‐
cytes in the first month, rising to 80% at one year. However, in the gene insertion region
there are genes related to myeloid cell proliferation, such as myelodysplastic syndrome 1-eco‐
tropic virus integration site 1 (MDS1/EVI1), PR domain containing protein 16 (PRDM16), SET
binding protein 1 (SETBP1). Two patients developed myelodysplasia [75]. These two patients
had monosomy 7, considered to be related to EVI1 activation. One died of severe sepsis 27
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months after gene therapy. Although the gene-inserted cells remained expressed in this pa‐
tient, methylation of the CpG site in the LTR of the viral vector was observed and the ex‐
pression of the inserted gp91phox gene was decreased. Interestingly, methylation was
restricted to the promoter region of the LTR; the enhancer region was not methylated.
Therefore, although gp91phox gene expression was decreased, the activation of EVI1 near the
inserted region occurred, leading to clonal proliferation [76]. Since there is a possibility that
the transcription activity of genes related to myeloid cell proliferation near the gene inser‐
tion site will be increased, there remains a concern about tumorigenesis with peripheral
stem cells mobilization by G-CSF in CGD patients, as with X-SCID [74].
Recently, next-generation gene therapy for CGD using lineage- and stage-restricted lenti‐
viral  vectors  to  avoid  tumorigenesis  [77]  and  novel  approaches  involving  iPSs  derived
from CGD patients using zinc finger nuclease (ZFN)-mediated gene targeting were stud‐
ied [78]. Specific gene targeting can be performed in human iPSs using ZFNs to induce se‐
quence-specific  double-strand  DNA  breaks  that  enhance  site-specific  homologous
recombination. A single-copy of gp91phox  was targeted into one allele of the "safe harbor"
AAVS1 locus in iPSs [79].
4.4.4. Wiskott-Aldrich Syndrome (WAS)
WAS is  a  severe X-linked immunodeficiency caused by mutations in the gene encoding
the WAS protein (WASP), a key regulator of signaling and cytoskeletal reorganization in
hematopoietic cells. Mutations in WAS gene result in a wide spectrum of clinical manifes‐
tations ranging from relatively mild X-linked thrombocytopenia to the classic WAS pheno‐
type characterized by thrombocytopenia, immunodeficiency, eczema, high susceptibility to
developing tumors, and autoimmune manifestations [80]. Preclinical and clinical evidence
suggest  that  WASP-expressing  cells  have  a  proliferative  or  survival  advantage  over
WASP-deficient cells, supporting the development of gene therapy [56]. Furthermore, up
to 11% of WAS patients have somatic mosaicism due to spontaneous in vivo reversion to
the normal genotype, and in WAS patients, accumulation of normal T-cell precursors are
sometimes seen [81].
In one preclinical study introducing the WAS gene into human T and B cells or mouse HSCs
using a retroviral vector, recovery of T cell function and immune reactions to infection were
observed [82, 83]. The first clinical study of WAS using HSCs involved two young boys in
Germany. The WASP-expressing retroviral vector was transfected into CD34 positive cells
obtained by apheresis of peripheral blood. Busulfan was used for conditioning therapy
(4mg/kg/day for two days). Over two years, WASP gene expression by HSCs, lymphoid and
myeloid cells, and platelets was sustained, and the number and function of monocytes, T, B,
and NK cells normalized. Clinically, hemorrhagic diathesis, eczema, autoimmunity, and the
predisposition to severe infections were diminished. Since comprehensive insertion-site
analysis showed vector integration near multiple genes controlling growth and immunolog‐
ic responses in a persistently polyclonal hematopoiesis, careful monitoring for tumorigene‐
sis is necessary, as with SCID-X1 and CGD [84, 85].
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SIN lentiviral vectors using the minimal domain of the WAS promoter or other ubiquitous
promoters, such as the PGK promoter, are currently being developed for WAS gene therapy.
Preclinical studies using the HSCs obtained from mice or human patients have yield good
results in terms of gene expression and genotoxicity [86-90].
Since a study using human embryonic stem cells (hESCs) and WAS-promoter–driven lenti‐
viral vectors labeled by green fluorescent protein (GFP) showed highly specific gene expres‐
sion in hESCs-derived HSCs, the WAS promoter will be used specifically in the generation
of hESC-derived HSCs [91].
4.4.5. Janus Kinase 3 (JAK3) deficiency
JAK3 deficiency is characterized by the absence of T and NK cells and impaired function of
B cells, similar to SCID-X1. Treatment consists of HSCT with an HLA-identical or HLA-hap‐
lo-identical donor, often the parents of the patient, with T cell depletion. Engraftment is suc‐
cessful in most cases.
Although the recovery of T cell function is usually observed after HSCT, there are usually
no improvements in B or NK cell function [92]. One case report involved introduction of
JAK3 into the patient’s bone marrow CD34 positive cells using the MSCV retroviral vector.
In this study, immunological recovery was not achieved although gene expression was ob‐
served for seven months [93]. Since JAK activation can cause T-cell lymphoma, tumorigene‐
sis remains a concern with JAK gene therapy [92].
4.4.6. Purine Nucleoside Phosphorylase (PNP) deficiency
PNP metabolizes adenosine into adenine, inosine into hypoxanthine, and guanosine into
guanine. PNP deficiency is an autosomal recessive metabolic disorder characterized by le‐
thal T cell defects resulting from the accumulation of products from purine metabolism.
In PNP-deficient mice, transplantation of bone marrow cells transduced with a lentiviral
vector containing human PNP resulted in human PNP expression, improved thymocyte ma‐
turation, increased weight gain, and extended survival. However, 12 weeks after transplant,
the benefit of PNP-transduced cells and the percentage of engrafted cells decreased [94].
4.4.7. Leukocyte Adhesion Deficiency type 1 (LAD-1)
LAD-1 is a primary immunodeficiency disease caused by abnormalities in the leukocyte in‐
tegrin CD11/CD18 heterodimer due to mutations in the CD18 gene. It is similar to canine
leukocyte adhesion deficiency (CLAD). LAD-1 patients begin experiencing repeated serious
bacterial infections immediately after birth.
In order to suppress gene activation near the gene insertion region in CLAD and to obtain
the sufficient expression of the CD18 gene, researches have used various promoters with a
lentiviral vector or foamy virus, a retroviral vector. In vivo animal experiments using a PGK
or an elongation factor 1α promoter did not lead to symptom improvement [95-97], but im‐
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months after gene therapy. Although the gene-inserted cells remained expressed in this pa‐
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pression of the inserted gp91phox gene was decreased. Interestingly, methylation was
restricted to the promoter region of the LTR; the enhancer region was not methylated.
Therefore, although gp91phox gene expression was decreased, the activation of EVI1 near the
inserted region occurred, leading to clonal proliferation [76]. Since there is a possibility that
the transcription activity of genes related to myeloid cell proliferation near the gene inser‐
tion site will be increased, there remains a concern about tumorigenesis with peripheral
stem cells mobilization by G-CSF in CGD patients, as with X-SCID [74].
Recently, next-generation gene therapy for CGD using lineage- and stage-restricted lenti‐
viral  vectors  to  avoid  tumorigenesis  [77]  and  novel  approaches  involving  iPSs  derived
from CGD patients using zinc finger nuclease (ZFN)-mediated gene targeting were stud‐
ied [78]. Specific gene targeting can be performed in human iPSs using ZFNs to induce se‐
quence-specific  double-strand  DNA  breaks  that  enhance  site-specific  homologous
recombination. A single-copy of gp91phox  was targeted into one allele of the "safe harbor"
AAVS1 locus in iPSs [79].
4.4.4. Wiskott-Aldrich Syndrome (WAS)
WAS is  a  severe X-linked immunodeficiency caused by mutations in the gene encoding
the WAS protein (WASP), a key regulator of signaling and cytoskeletal reorganization in
hematopoietic cells. Mutations in WAS gene result in a wide spectrum of clinical manifes‐
tations ranging from relatively mild X-linked thrombocytopenia to the classic WAS pheno‐
type characterized by thrombocytopenia, immunodeficiency, eczema, high susceptibility to
developing tumors, and autoimmune manifestations [80]. Preclinical and clinical evidence
suggest  that  WASP-expressing  cells  have  a  proliferative  or  survival  advantage  over
WASP-deficient cells, supporting the development of gene therapy [56]. Furthermore, up
to 11% of WAS patients have somatic mosaicism due to spontaneous in vivo reversion to
the normal genotype, and in WAS patients, accumulation of normal T-cell precursors are
sometimes seen [81].
In one preclinical study introducing the WAS gene into human T and B cells or mouse HSCs
using a retroviral vector, recovery of T cell function and immune reactions to infection were
observed [82, 83]. The first clinical study of WAS using HSCs involved two young boys in
Germany. The WASP-expressing retroviral vector was transfected into CD34 positive cells
obtained by apheresis of peripheral blood. Busulfan was used for conditioning therapy
(4mg/kg/day for two days). Over two years, WASP gene expression by HSCs, lymphoid and
myeloid cells, and platelets was sustained, and the number and function of monocytes, T, B,
and NK cells normalized. Clinically, hemorrhagic diathesis, eczema, autoimmunity, and the
predisposition to severe infections were diminished. Since comprehensive insertion-site
analysis showed vector integration near multiple genes controlling growth and immunolog‐
ic responses in a persistently polyclonal hematopoiesis, careful monitoring for tumorigene‐
sis is necessary, as with SCID-X1 and CGD [84, 85].
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results in terms of gene expression and genotoxicity [86-90].
Since a study using human embryonic stem cells (hESCs) and WAS-promoter–driven lenti‐
viral vectors labeled by green fluorescent protein (GFP) showed highly specific gene expres‐
sion in hESCs-derived HSCs, the WAS promoter will be used specifically in the generation
of hESC-derived HSCs [91].
4.4.5. Janus Kinase 3 (JAK3) deficiency
JAK3 deficiency is characterized by the absence of T and NK cells and impaired function of
B cells, similar to SCID-X1. Treatment consists of HSCT with an HLA-identical or HLA-hap‐
lo-identical donor, often the parents of the patient, with T cell depletion. Engraftment is suc‐
cessful in most cases.
Although the recovery of T cell function is usually observed after HSCT, there are usually
no improvements in B or NK cell function [92]. One case report involved introduction of
JAK3 into the patient’s bone marrow CD34 positive cells using the MSCV retroviral vector.
In this study, immunological recovery was not achieved although gene expression was ob‐
served for seven months [93]. Since JAK activation can cause T-cell lymphoma, tumorigene‐
sis remains a concern with JAK gene therapy [92].
4.4.6. Purine Nucleoside Phosphorylase (PNP) deficiency
PNP metabolizes adenosine into adenine, inosine into hypoxanthine, and guanosine into
guanine. PNP deficiency is an autosomal recessive metabolic disorder characterized by le‐
thal T cell defects resulting from the accumulation of products from purine metabolism.
In PNP-deficient mice, transplantation of bone marrow cells transduced with a lentiviral
vector containing human PNP resulted in human PNP expression, improved thymocyte ma‐
turation, increased weight gain, and extended survival. However, 12 weeks after transplant,
the benefit of PNP-transduced cells and the percentage of engrafted cells decreased [94].
4.4.7. Leukocyte Adhesion Deficiency type 1 (LAD-1)
LAD-1 is a primary immunodeficiency disease caused by abnormalities in the leukocyte in‐
tegrin CD11/CD18 heterodimer due to mutations in the CD18 gene. It is similar to canine
leukocyte adhesion deficiency (CLAD). LAD-1 patients begin experiencing repeated serious
bacterial infections immediately after birth.
In order to suppress gene activation near the gene insertion region in CLAD and to obtain
the sufficient expression of the CD18 gene, researches have used various promoters with a
lentiviral vector or foamy virus, a retroviral vector. In vivo animal experiments using a PGK
or an elongation factor 1α promoter did not lead to symptom improvement [95-97], but im‐
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provement was seen with CD11b and CD18 promoters, respectively, with a SIN lentiviral
vector in one animal study [98].
4.5. Mucopolysaccharidosis (MPS)
MPS is a general term for diseases characterized by glycosaminoglycan (GAG) accumula‐
tion into lysosomes as a result  of  deficiencies in lysosomal enzymes that degrade GAG.
Although there are more than ten enzymes that are known to degrade GAG, MPS is div‐
ided  into  seven  types:  type  I  (α-L-iduronidase  deficiency,  Hurler  syndrome,  Sheie  syn‐
drome,  Hurler-Sheie  syndrome),  type  II  (iduronate  sulfatase  deficiency,  Hunter
syndrome),  type III  (heparan N-sulfatase deficiency,  α-N-acetylglucosaminidase deficien‐
cy,  α-glucosaminidase  acetyltransferase  deficiency,  N-acetylglucosamine  6-sulfatase  defi‐
ciency,  Sanfilippo  syndrome),  type  IV  (galactose  6-sulfatase  deficiency,  Morquio
syndrome),  type  VI  (N-acetylgalactosamine  4-sulfatase  deficiency,  Maroteaux-Lamy syn‐
drome), type VII (β-glucuronidase deficiency, Sly syndrome), and type IX (hyaluronidase
deficiency).  Type II  is  X-linked;  the other types are autosomal recessive.  Although lyso‐
somes are found in almost all cells, MPS mainly affects internal organs such as the brain,
heart, bones, joints, eyes, liver, and spleen. The extent of disease, including mental retar‐
dation, varies with MPS type.
In types I, II, and VI, enzyme replacement therapy is performed. HSCT is performed in
types I, II, IV, and VII. Gene therapy for types I, II, III, and VII type have been investigated.
There are trials using an AAV or adenovirus vector to insert the modified gene into various
cell types, including hepatocytes, muscle cells, myoblasts, and fibroblasts [99].
The first study of HSC gene therapy for MPS using a retroviral vector was performed on
type VII mice in 1992, resulting in decreased accumulation of GAG in the liver and spleen
but not in the brain and eyes [100]. Subsequent studies in type I and III animal models
showed decreases in GAG accumulation in the kidneys and brain. Introductory efficiency
and immunological reactions are considered challenges in HSC gene therapy for MPS [99].
Restoring or preserving central nervous system (CNS) function is one of the major chal‐
lenges  in  the  treatment  of  MPS.  Since  replaced  enzymes  easily  cannot  pass  the  blood-
brain  barrier  (BBB),  a  high  dose  of  enzyme  is  needed  to  improve  CNS  function.  Gene
therapy  faces  the  same  challenge.  Even  with  high  expression  of  enzyme by,  for  exam‐
ple,  hepatocytes,  the  BBB  prevents  efficient  delivery  into  the  CNS.  When  a  lentiviral
vector is  directly injected into the body,  gene expression in brain tissue is  observed,  al‐
though  the  underlying  mechanism  is  unknown.  There  are  also  trials  where  AAV  vec‐
tors  are  directly  injected  into  the  CNS  of  mice  or  dogs  and  gene  expression  was
observed in brain tissue [99].
Recently, a lentiviral vector using an ankyrin-1-based erythroid-specific hybrid promoter/
enhancer (IHK) was used with HSCs to obtain gene expression only in erythroblasts for type
I MPS. This approach resulted in decreased accumulation of GAG in the liver, spleen, heart,
and CNS via enzyme expression in erythroblasts [101].
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4.6. Gaucher disease
Gaucher disease is the most common lysosomal storage disorder. It is caused by deficiency of
glucocerebroside-cleaving enzyme (β-glucocerebrosidase), resulting in the accumulation of
glucocerebroside in the reticuloendothelial system [102]. This autosomal recessive disease
presents with hepatosplenomegaly, anemia, thrombocytopenia, and convulsions with or with‐
out mental retardation. It is classified into three types based on the clinical course or existence
of neurological symptoms: type I (non-neuropathic, adult type), type II (acute neuropathic, in‐
fantile type), and type III (chronic neuropathic, juvenile type). Enzyme replacement therapy
has been established in type I. As with MPS, since it is difficult to improve CNS symptoms with
enzyme replacement therapy, HSCT is used, especially with type III. Gene therapy is consid‐
ered in cases with little improvement with enzyme replacement therapy [103].
For Gaucher disease without CNS symptoms, a animal model using an AAV vector to pro‐
duce enzyme in hepatocytes yielded good results [103]. HSC gene therapy using a retroviral
vector was attempted in type I mice. The treated cells had higher β-glucocerebrosidase activ‐
ity than the HSCs from wild-type mice. Glucocerebroside levels normalized five to six
months after treatment and no infiltration of Gaucher cells could be observed in the bone
marrow, spleen, and liver [104]. In recent years, development of lentiviral vectors including
the human glucocerebrosidase gene [105] and low-risk HSCT with nonmyeloablative doses
of busulfan (25mg/kg) and no radiation therapy have been attempted in mice [106].
4.7. X-ALD
X-ALD is a peroxisomal disease in which a lipid metabolism abnormality causes demyelina‐
tion of CNS tissues and dysfunction of the adrenal gland. It results from mutations in the
ATP-binding cassette sub-family D (ABCD1) gene that codes for the adrenoleukodystrophy
(ALD) protein. Behavioral disorders, mental retardation, or both occur by the age of five or
six. Once symptoms appear, they progress to gait disorder and visual impairment within
several months and the prognosis is poor. Increased levels of very long chain fatty acids
(VLCFA), such as C25:0 or C26:0, are observed in the CNS, plasma, erythrocytes, leucocytes,
etc. If the neurological defects are not severe, arrest of or improvement in symptoms can be
obtained with HSCT [107].
One study has reported the introduction of wild-type ABCD1 using a lentiviral vector into pe‐
ripheral blood CD34 positive cells of two patients with no HLA-identical donor. The patients
received a transfusion of autologous gene-modified cells after myeloablative conditioning
therapy. At three years of follow-up, ALD proteins were expressed in approximately 7–14% of
neutrophils, monocytes, and T cells. Clinically, cerebral demyelination stopped 14 and 16
months after gene therapy, respectively, similar to results with allergenic HSCT [108, 109].
5. Conclusion
Gene therapy using HSCs was outlined. HSCT with HSCs can replace all of the patient’s
original HSCs with donor HSCs. Therefore, gene therapy using HSCs is an alternative if the
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provement was seen with CD11b and CD18 promoters, respectively, with a SIN lentiviral
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patient does not have an HLA-identical donor or cannot tolerate the conditioning regimen
or other HSCT-related side effects. Fully myeloablative or nonmyeloablative conditioning
regimens are still necessary to eliminate potential competition within the bone marrow com‐
partment, in an attempt to increase the number of gene-modified HSCs or progenitors that
produce the therapeutic enzyme or protein. With gene therapy, eliminating the risk of im‐
mune reactions against the transgene is necessary. Lentiviral vectors in clinical use must not
be contaminated by replication-competent recombinant vectors related to the parent HIV-1
virus. The main risk of retrovirus- or lentivirus-mediated gene therapy may prove to be in‐
sertional mutagenesis caused by random retroviral integration leading to activation of pro‐
to-oncogenes or inactivation of tumor-suppressor genes, ultimately leading to malignancy
[107]. However, with advances in gene introduction technology, such as the development of
the SIN vector and advances in cell or gene-region targeting, gene therapy can be done more
safely and efficiently. Furthermore, since cells more immature than HSCs, i.e., iPS cells, are
available, further advances in HSC gene therapy are expected in the future.
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1. Introduction
Transplantation of autologous or allogeneic hematopoietic stem cells is a method currently
used to treat many malignant and nonmalignant hematological diseases. The indications,
methods, goals of therapy have evolved since the introduction of transplantation to the clini‐
cal practice. Progress that has been achieved allowed for the improvement of results. Thanks
to the availability of various conditioning regimens, various hematopoietic cells sources as
well as variable possibilities of anti-GvHD prophylaxis the individualization of the trans‐
plantation procedure has been more and more widely used in the recent years. This chapter
summarizes current clinical practices and presents major clinical problems that have to be
optimally managed in order to improve the outcomes of transplantation.
2. Autologous hematopoietic stem cells transplantation
Autologous peripheral hematopoietic stem cells transplantation (auto-HSCT) was for the
first time performed at Hammersmith Hospital in London in 1981 to treat the patient in ac‐
celerated phase of CML. Although auto-HSCT does not play any role in the treatment of
CML nowadays, indications for this valuable therapeutic method have evolved for many
years. In acute leukemia auto-HSCT should be recommended only in the context of clinical
studies. Auto-HSCT after myeloablative chemotherapy or radiotherapy has originally been
developed as an alternative to allogeneic hematopoietic stem cell transplantation for pa‐
tients with AML with no suitable donor. Several randomized studies in patients with AML
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in first complete remission (CR1) subsequently suggested reduced relapse rates after auto-
HSCT [1]. Auto-HSCT is also widely used to consolidate first remission in AML. The novel
molecular and cytogenetic stratification methods may allow the identification of AML enti‐
ties which could benefit from autografting. The overall survival of patients receiving auto-
HSCT in ALL in first remission is around 40%. The high-dose therapy followed by auto-
HSCT can be an alternative treatment in patients in whom allo-HSCT is precluded.
The results of a large European study showed that auto-HSCT can be recommended in pa‐
tients with good-risk cytogenetic characteristics of myelodysplastic syndrome [2]. Auto-
HSCT can be recommended as post-remission therapy to reduce the risk of relapse. The
longer remission was observed in patients who undergo auto-HSCT.
In myeloproliferative disorders auto-HSCT can induce responses in patients with primary
myelofibrosis, but this procedure cannot be recommended out of clinical protocols.
In chronic lymphocytic leukemia auto-HSCT can be considered for patients with poor-risk
disease in complete or good partial remission able to withstand high-dose therapy, but it
should be performed preferably in the context of clinical protocols.
Auto-HSCT is the standard therapy for patients with Hodgkin’s lymphoma (HL) in first che‐
mosensitive relapse or second complete remission as shown by two prospective randomized
clinical trials [3,4]. There is no indication for auto-HSCT in first remission, even in patients
with poor prognosis at diagnosis [5,6]. Patients refractory to first-line therapy but sensitive
to salvage therapy might benefit from auto-HSCT [7]. Auto-HCT might be considered as a
part of a clinical protocol for patients with resistant Hodgkin’s lymphoma, as an initial de‐
bulking therapy to be followed by an allo-HSCT as consolidation therapy [8].
In many non-Hodgkin’s lymphomas auto-HSCT is a standard therapy. In diffuse large B-cell
lymphoma (DLBCL) auto-HSCT is a standard therapy for patients with chemosensitive re‐
lapse [9]. The role of auto-HSCT is being re-evaluated with the advance of monoclonal anti‐
bodies and use of chemo-immunotherapy as first-line treatment. Auto-HSCT remains also
the standard approach for early relapsing patients with follicular lymphoma (FL) [10]. In
both DLBCL and FL, auto-HSCT does not provide any clinical benefit in patients with re‐
fractory disease. Otherwise, most patients with mantle cell lymphoma are being offered an
early intensification with an auto-HSCT, owing it to the inherent poor prognosis of the dis‐
ease. The retrospective analysis indicates that the results of auto-HSCT performed beyond
the first remission are inferior [11]. Few studies showed an improved survival in patients
with T-cell non-Hodgkin’s lymphoma (NHL) who received auto-HSCT as a first line treat‐
ment, compared to those who did not.
Patients with multiple myeloma form a large group of patients being transplanted. Auto-
HSCT is clearly indicated for patients <70 years of age with satisfactory general health and
fitness who respond to the first-line treatment. Although new agents change the place of au‐
to-HSCT in MM, this procedure still has an established position in treatment. Best results are
observed in patients achieving good response before the auto-HSCT, but some non-respond‐
ing patients also may benefit from this approach. Double auto-HSCT (or tandem auto-
HSCT) has been shown to be superior to consolidation and maintenance with agents such as
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thalidomide in patients not achieving the remission or a very good partial response after the
first transplant [12].
Auto-HSCT constitutes an important treatment option for patients with solid tumors. Select‐
ed subgroups of oncological patients may benefit from high-dose chemotherapy supported
by auto-HSCT. High-dose chemotherapy for refractory germ cell tumors is considered a
standard therapy. Conditioning regimen in this case incorporates carboplatin and etoposide.
Auto-HSCT after conditioning regimen aimed to increase the immunosuppression is being
considered in clinical protocols for selected patients with severe multiple sclerosis [13],
rheumatoid arthritis [14], systemic lupus erythromatous [15], systemic sclerosis [16], im‐
mune cytopenias and Crohn’s disease [17]. Auto-HSCT for other autoimmune disorders is
being considered on a developmental basis. Steroid dependency with Cushing threshold
and skeletal damage could be an indication.
3. Allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) constitutes a standard treat‐
ment of hematological malignant and nonmalignant disorders. The possibility of finding a
donor has been increased by use of unrelated donors, with similar results of transplantation
when compared to results of sibling donor transplants. The use of peripheral blood stem
cells, instead of bone marrow, results in faster engraftment, but also in the increased risk of
chronic GvHD (Graft versus Host Disease). Reduced-intensity conditioning is used instead
of high–dose myeloablative conditioning for older patients and those with comorbidities.
Disease relapse is a major problem and thus it should be detected as early as possible, at the
stage of the minimal residual disease or recurrent recipient chimerism and managed by im‐
munotherapy with donor lymphocyte infusions. Novel diagnostic tools and anti-microbial
drugs have reduced the morbidity and mortality from infections.
Allogeneic hematopoietic stem cell transplantation connected with application of high-dose
chemo- and radiotherapy was first carried out by Thomas et al. in 1957 to treat leukemia pa‐
tient in advanced stage [18]. The concept of treatment at that time was based on the previous
observations conducted during the second world war, referring to destructive activity of ra‐
diation on the function of bone marrow, as well as further research conducted in the 1950’s,
which showed that it was possible to avoid irreversible pancytopenia thanks to the bone
marrow cells transplantation in the irradiated animals. The discovery of Human Leucocyte
Antigen (HLA) enabled to match appropriately the donor and the recipient, what contribut‐
ed to the significant increase in overall survival after transplantation which has been ob‐
served since 1968 [19]. The improvement of the results was undoubtedly also influenced by
other factors: performing the transplantation in the optimal phase- remission of the disease,
GvHD prevention, the improvement of adjunctive treatment. Nowadays more that 25.000
allo-HSCTs are being performed each year.
The main indication for allo-HSCT is acute myeloblastic leukemia (AML) and acute lympho‐
blastic leukemia (ALL). In high risk ALL and AML, when favorable prognostic genetic
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drugs have reduced the morbidity and mortality from infections.
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chemo- and radiotherapy was first carried out by Thomas et al. in 1957 to treat leukemia pa‐
tient in advanced stage [18]. The concept of treatment at that time was based on the previous
observations conducted during the second world war, referring to destructive activity of ra‐
diation on the function of bone marrow, as well as further research conducted in the 1950’s,
which showed that it was possible to avoid irreversible pancytopenia thanks to the bone
marrow cells transplantation in the irradiated animals. The discovery of Human Leucocyte
Antigen (HLA) enabled to match appropriately the donor and the recipient, what contribut‐
ed to the significant increase in overall survival after transplantation which has been ob‐
served since 1968 [19]. The improvement of the results was undoubtedly also influenced by
other factors: performing the transplantation in the optimal phase- remission of the disease,
GvHD prevention, the improvement of adjunctive treatment. Nowadays more that 25.000
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blastic leukemia (ALL). In high risk ALL and AML, when favorable prognostic genetic
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changes are lacking, the allo-HSCT is recommended in the first remission of the disease. The
transplantation in more advanced stages of the disease leads to the higher relapse rate, as
well as to the increased incidence of transplantation complications.
Despite the introduction of tyrosine kinase inhibitors (TKIs) into the treatment of chronic
myeloid leukemia (CML) over ten years ago, allo-HSCT still remains the only way of treat‐
ment capable to provide the complete recovery. The standard indication for allo-HSCT is re‐
sistance to TKIs treatment, especially in young patients. Other indications for allo-HSCT are
myelodysplastic syndrome, high-risk chronic lymphocytic leukemia, selected patients with
high-risk lymphoma, patients with myelofibrosis and other myeloproliferative neoplasms of
unfavorable prognosis. The results of multiple myeloma treatment with the use alloHSCT
are encouraging. AlloHSCT with the reduced conditioning regimen after previous auto-
HSCT constitutes an interesting alternative in patients with multiple myeloma patients, who
undergo single or tandem autologous transplantation [20].
Allo-HSCT is also the standard treatment in nonmalignant diseases of hematopoietic system
such as severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH) and he‐
moglobinopathies. In some cases of inborn metabolic defects, allogeneic transplantation of
donor’s cells can restore the production of the deficient or lacking enzyme and eliminate the
disease [21].
4. Hematopoietic stem cell donors
The optimal donors are siblings possessing both haplotypes identical with the recipient. The
syngeneic transplantation, i.e. from monozygotic twins, is the safest from the immunological
point of view, however it is connected with the increased risk of the relapse of the disease
resulting from the lack of immunological interaction between the donor cells and the recipi‐
ent cells [22].
Probability of possessing matched sibling donor is defined by the formula: 1–(0.75)n, were n
indicates the number of siblings. The observed decrease in the number of newly born chil‐
dren causes problems in finding matched family donors for many patients. In rare cases
with no matched sibling donor, matching donor could be found among other members of
the family. In the vast majority of patients without matched sibling donor, transplantation
from unrelated donor is the most frequently chosen option. The number of such transplanta‐
tions has increased considerably in the last 20 years [23]. It has been made possible thanks to
dynamic development of bone marrow donors’ registries, whose number of potential do‐
nors exceeded 20 million in the current year 2012. Alternatively, for those patients who are
unlikely to find a matched donor, partial incompatibility could be accepted.
The most desirable model of the donors’ registry organization is the development of nation‐
al ones which, for many reasons (safety of donors, clearness of procedures and financial rea‐
sons), according to WMDA’s (World Marrow Donors Association) recommendations should
control and supervise the recruitment of the donors within the country. The chance to find
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the matched donor depends on the frequency of occurrence of HLA-haplotypes in the whole
population and the race of recipient – most donors recruited by registries worldwide belong
to Caucasian race. The efforts are being made, especially in the USA, aiming to recruit high‐
er number of donors of other races.
Phenotypic HLA-matching involving the testing of HLA-antigens by means of specific sera
has been replaced by more precise molecular testing enabling the precise identification of
HLA allelic determinants.
The question of accepting a mismatched donor for a patients, who didn’t find a fully match‐
ed donor has not been finally solved. With the increasing number of observations there are
recommendations concerning optimal matching not only in HLA-A, B and DR, but also in C,
DQ and even DP. Many centers aim to transplant patients only from donors fully matched
in 10/10 alleles of HLA-A, B, C, DR and DQ. The improved methods of typing enabling
more precise molecular donor matching has improved the results of allo-HSCT from unre‐
lated donors, which are now similar to those of allo-HSCT from siblings [24]. As the allo-
HSCT from an unrelated donor has to be preceded by often time-consuming search for a
donor, it is important to plan the transplantation carefully in advance.
5. The sources of hematopoietic stem cells
The choice of the cells source depends of diagnosis and the type of conditioning treatment
applied. Collection of bone marrow is preferred in nonmalignant diseases in order to avoid
chronic GvHD. Transplantation of hematopoietic cells from peripheral blood is preferred
when reduced intensity conditioning regimen is used, with regard to the fact that transplan‐
tation of larger number of hematopoietic cells is able to break the resistance of the recipient
and to result in the engraftment.
The bone marrow aspirated in general anesthesia from iliac spine was for many years the
main source of cells for transplantation. Except of hematopoietic cells, the bone marrow also
consists of multipotential mesenchymal cells which, although are not hematopoietic cells,
have a potential to differentiate in vitro and in vivo into various mesenchymal tissues, such
as bone, cartilage, fat tissue, tendons and bone matrix. Mesenchymal stem cells can reduce
the alloreactivity, they inhibit lymphocytes T proliferation and act immunosuppressively,
what has been implemented in the form of unrelated or haploidentical mesenchymal cells
infusion into the treatment of acute GvHD.
During the 1990’s the cells collected in apheresis from peripheral blood after their previous
stimulation with granulocytic stimulating factor (G-CSF) completely superseded the bone
marrow aspiration in autologous transplantations. In the beginning of 21st century, the simi‐
lar trend occurred also in allo-HSCT. The apheresis of cells from peripheral blood usually
results in collection of higher number of nucleated cells, CD34+ cells, lymphocytes CD3+
and NK cells when compared with cells aspiration from the bone marrow; it enables faster
regeneration of granulocytes and platelets. It translates into the smaller risk of infections and
smaller demand for transfusions of blood derivatives.
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changes are lacking, the allo-HSCT is recommended in the first remission of the disease. The
transplantation in more advanced stages of the disease leads to the higher relapse rate, as
well as to the increased incidence of transplantation complications.
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high-risk lymphoma, patients with myelofibrosis and other myeloproliferative neoplasms of
unfavorable prognosis. The results of multiple myeloma treatment with the use alloHSCT
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Allo-HSCT is also the standard treatment in nonmalignant diseases of hematopoietic system
such as severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH) and he‐
moglobinopathies. In some cases of inborn metabolic defects, allogeneic transplantation of
donor’s cells can restore the production of the deficient or lacking enzyme and eliminate the
disease [21].
4. Hematopoietic stem cell donors
The optimal donors are siblings possessing both haplotypes identical with the recipient. The
syngeneic transplantation, i.e. from monozygotic twins, is the safest from the immunological
point of view, however it is connected with the increased risk of the relapse of the disease
resulting from the lack of immunological interaction between the donor cells and the recipi‐
ent cells [22].
Probability of possessing matched sibling donor is defined by the formula: 1–(0.75)n, were n
indicates the number of siblings. The observed decrease in the number of newly born chil‐
dren causes problems in finding matched family donors for many patients. In rare cases
with no matched sibling donor, matching donor could be found among other members of
the family. In the vast majority of patients without matched sibling donor, transplantation
from unrelated donor is the most frequently chosen option. The number of such transplanta‐
tions has increased considerably in the last 20 years [23]. It has been made possible thanks to
dynamic development of bone marrow donors’ registries, whose number of potential do‐
nors exceeded 20 million in the current year 2012. Alternatively, for those patients who are
unlikely to find a matched donor, partial incompatibility could be accepted.
The most desirable model of the donors’ registry organization is the development of nation‐
al ones which, for many reasons (safety of donors, clearness of procedures and financial rea‐
sons), according to WMDA’s (World Marrow Donors Association) recommendations should
control and supervise the recruitment of the donors within the country. The chance to find
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the matched donor depends on the frequency of occurrence of HLA-haplotypes in the whole
population and the race of recipient – most donors recruited by registries worldwide belong
to Caucasian race. The efforts are being made, especially in the USA, aiming to recruit high‐
er number of donors of other races.
Phenotypic HLA-matching involving the testing of HLA-antigens by means of specific sera
has been replaced by more precise molecular testing enabling the precise identification of
HLA allelic determinants.
The question of accepting a mismatched donor for a patients, who didn’t find a fully match‐
ed donor has not been finally solved. With the increasing number of observations there are
recommendations concerning optimal matching not only in HLA-A, B and DR, but also in C,
DQ and even DP. Many centers aim to transplant patients only from donors fully matched
in 10/10 alleles of HLA-A, B, C, DR and DQ. The improved methods of typing enabling
more precise molecular donor matching has improved the results of allo-HSCT from unre‐
lated donors, which are now similar to those of allo-HSCT from siblings [24]. As the allo-
HSCT from an unrelated donor has to be preceded by often time-consuming search for a
donor, it is important to plan the transplantation carefully in advance.
5. The sources of hematopoietic stem cells
The choice of the cells source depends of diagnosis and the type of conditioning treatment
applied. Collection of bone marrow is preferred in nonmalignant diseases in order to avoid
chronic GvHD. Transplantation of hematopoietic cells from peripheral blood is preferred
when reduced intensity conditioning regimen is used, with regard to the fact that transplan‐
tation of larger number of hematopoietic cells is able to break the resistance of the recipient
and to result in the engraftment.
The bone marrow aspirated in general anesthesia from iliac spine was for many years the
main source of cells for transplantation. Except of hematopoietic cells, the bone marrow also
consists of multipotential mesenchymal cells which, although are not hematopoietic cells,
have a potential to differentiate in vitro and in vivo into various mesenchymal tissues, such
as bone, cartilage, fat tissue, tendons and bone matrix. Mesenchymal stem cells can reduce
the alloreactivity, they inhibit lymphocytes T proliferation and act immunosuppressively,
what has been implemented in the form of unrelated or haploidentical mesenchymal cells
infusion into the treatment of acute GvHD.
During the 1990’s the cells collected in apheresis from peripheral blood after their previous
stimulation with granulocytic stimulating factor (G-CSF) completely superseded the bone
marrow aspiration in autologous transplantations. In the beginning of 21st century, the simi‐
lar trend occurred also in allo-HSCT. The apheresis of cells from peripheral blood usually
results in collection of higher number of nucleated cells, CD34+ cells, lymphocytes CD3+
and NK cells when compared with cells aspiration from the bone marrow; it enables faster
regeneration of granulocytes and platelets. It translates into the smaller risk of infections and
smaller demand for transfusions of blood derivatives.
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In the beginning allo-HSCT in the form of PBSCT (Peripheral Blood Stem Cells Transplanta‐
tion) was applied only in sibling transplantations due to the anxiety of acute GvHD occur‐
rence, however, the frequency of GvHD is similar to the one after bone marrow
transplantation, despite greater number of T-lymphocytes in the transplantation material
collected from peripheral blood, as it was shown in the number of studies. Thus allo-PBSCT
has been successfully applied also in allo-HSCT from unrelated donors. However, the fre‐
quency of chronic GvHD is higher, and thus allo-PBSCT is applied seldom in patients with
nonmalignant disease, who do not benefit from Graft versus Leukemia (GvL) effect, which
is usually connected with chronic GvHD [25].
The important source of hematopoietic stem cells for allo-HSCT is a cord blood (CB), usually
intended to be discarded. In many countries there are banks of frozen CB units where there
are over 0,5 million units ready to be transplanted. The advantage of applying CB cells is
their immediate availability and a reduced risk of GvHD, related to a relative shortage of
mature T-lymphocytes in the CB. Therefore the higher level of HLA-mismatching between
the donor and the the recipient is more acceptable in CB transplantation than in traditional
transplantations. The unfavorable factors are a more frequent occurrence of graft failure and
a slower regeneration responsible for higher risk of infections. The number of necessary
nucleated cells and CD34+ cells calculated per kilogram of the recipient’s body mass is lower
by about one logarithm when compared to the bone marrow. A number of studies showed
the importance of sufficient number of cord blood nucleated cells, for this reason it is recom‐
mended to transplant more than 2x10^7 nucleated cells per kilogram of recipient’s body
mass. It constitutes limitation in CB application in adults due to the small volume of cord
blood and small total number of cells. Simultaneous transplantation of two CB units is suc‐
cessfully applied to solve this problem [26,27]. In vitro cells expansion to increase the num‐
ber of CB cells has not been widely used. Because of the limited, usually small number of
cord blood cells, it is most often applied as the source of cells for transplantation in children.
6. Preparative treatment before transplantation
The preparative treatment before transplantation (or conditioning regimen) aims to eradi‐
cate the remains of the disease and to make immunological system of recipient weaker in
order to enable the acceptance of the graft by the recipient. The preparative treatment is con‐
nected with toxicities which turned out to be impossible to eliminate so far.
The choice of conditioning treatment depends of the patient’s age, the main disease and co‐
existing diseases. Myeloablative conditioning regimens are characterized by strong cytotox‐
icity as well as strong immunosuppressive potential, while reduced intensity conditioning
regimens differ in cytotoxic activity and immunosuppressive potential. They are chosen de‐
pending on the main disease and evaluation of the risk of graft failure.
The combination of radiotherapy (TBI- total body irradiation- at total dose of 12 Gy, deliv‐
ered in fractions) and cyclophosphamide (Cy, at total dose of 120 mg/kg administered with‐
in 2 days) has been used for over 40 years for conditioning [28]. TBI treatment is
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recommended as a standard in ALL. In order to avoid potential TBI consequences, such as
bronchiolitis obliterans, cataract, secondary malignancy, endocrinological disorders, inhibi‐
tion of the growing process in children, TBI in AML and MDS has been replaced by busul‐
fan given at 16 mg/kg dose within 4 consecutive days before Cy [29]. The BuCy treatment
has higher risk of SOS (sinusoidal obstruction syndrome), hemorrhagic cystitis and chronic
GvHD. The high serum concentration of Bu (Busulfan) occurring during its oral treatment
has influenced considerably its toxic complications. It is difficult to avoid it because of vari‐
ous degree of absorption from digestive tract. Thus the intravenous use of busulfan is more
favorable. The reduction of SOS incidence and decrease of transplant related mortality
(TRM) after intravenous use of Bu has been reported [30]. In order to further limit the toxici‐
ty, treosulfan is used instead of Bu in modern treatment programs nowadays, and addition‐
al immunosuppressive effect is obtained by parallel application of purine analoque, e.g.
fludarabine.
The standard preparative treatment applied in SAA comprises of Cy 200 mg/kg and antithy‐
mocyte globulin (ATG).
Although the intensive conditioning treatment decreases the risk of relapse after transplan‐
tation, it does not prolong the overall survival because greater toxicity leads to increased
transplant related mortality [31].
The concept of so-called RIC (reduced intensity conditioning) incorporates the advantage of
anti-leukemic effect of donor T-lymphocytes while cytotoxic effect of conditioning regimen
is decreased. The main result of RIC treatment is immunosuppressive therapy aiming to en‐
able the acceptance of the transplant by braking the immunological defence of the recipient.
The anti-leukemic effect can be escalated after transplantation by means of DLI (Donor Lym‐
phocyte Infusion), whenever it is required. DLI was first used with success in CML patients,
in whom the disease relapsed after conventional allo-HSCT [32]. Since then it has been used
in many other diseases, including many clonal diseases of hematopoietic system, most often
lymphomas and chronic lymphocytic leukemia (CLL). RIC treatment has lower toxicity
when compared to conventional conditioning treatment, thus it is suitable for transplanta‐
tion in older patients and in patients with coexisting diseases in whom the application of
myeloablative treatment is contraindicated. RIC treatment consists most often of purine ana‐
loque. The example of RIC treatment reduced to the minimum, after which graft occurs, is
the combination of TBI dose 2Gy with fludarabine. Other exemplary RIC protocols are the
combination of fludarabine with Bu at dose 8 mg/kg and ATG with Cy or with melphalan.
The important element of RIC treatment is the use of immunosuppressive therapy after
transplantation e.g. cyclosporine A and mycophenolate mofetil. The reduced intensity of
conditioning enables the immunocompetent recipient cells to survive until the moment of
transplantation, what leads to the higher risk of graft failure or incomplete graft. In some
centers transplantation with RIC are performed in ambulatory, however patients often re‐
quire further hospitalization due to infections or GvHD [33].
Allo-HSCT with use of RIC can be applied when autologous transplantation is ineffective.
Other possibility is to apply the tandem transplantation: at first autologous one and then the
allogeneic one, with use of RIC in order to reduce the TRM by separation of high-dosed cy‐
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In the beginning allo-HSCT in the form of PBSCT (Peripheral Blood Stem Cells Transplanta‐
tion) was applied only in sibling transplantations due to the anxiety of acute GvHD occur‐
rence, however, the frequency of GvHD is similar to the one after bone marrow
transplantation, despite greater number of T-lymphocytes in the transplantation material
collected from peripheral blood, as it was shown in the number of studies. Thus allo-PBSCT
has been successfully applied also in allo-HSCT from unrelated donors. However, the fre‐
quency of chronic GvHD is higher, and thus allo-PBSCT is applied seldom in patients with
nonmalignant disease, who do not benefit from Graft versus Leukemia (GvL) effect, which
is usually connected with chronic GvHD [25].
The important source of hematopoietic stem cells for allo-HSCT is a cord blood (CB), usually
intended to be discarded. In many countries there are banks of frozen CB units where there
are over 0,5 million units ready to be transplanted. The advantage of applying CB cells is
their immediate availability and a reduced risk of GvHD, related to a relative shortage of
mature T-lymphocytes in the CB. Therefore the higher level of HLA-mismatching between
the donor and the the recipient is more acceptable in CB transplantation than in traditional
transplantations. The unfavorable factors are a more frequent occurrence of graft failure and
a slower regeneration responsible for higher risk of infections. The number of necessary
nucleated cells and CD34+ cells calculated per kilogram of the recipient’s body mass is lower
by about one logarithm when compared to the bone marrow. A number of studies showed
the importance of sufficient number of cord blood nucleated cells, for this reason it is recom‐
mended to transplant more than 2x10^7 nucleated cells per kilogram of recipient’s body
mass. It constitutes limitation in CB application in adults due to the small volume of cord
blood and small total number of cells. Simultaneous transplantation of two CB units is suc‐
cessfully applied to solve this problem [26,27]. In vitro cells expansion to increase the num‐
ber of CB cells has not been widely used. Because of the limited, usually small number of
cord blood cells, it is most often applied as the source of cells for transplantation in children.
6. Preparative treatment before transplantation
The preparative treatment before transplantation (or conditioning regimen) aims to eradi‐
cate the remains of the disease and to make immunological system of recipient weaker in
order to enable the acceptance of the graft by the recipient. The preparative treatment is con‐
nected with toxicities which turned out to be impossible to eliminate so far.
The choice of conditioning treatment depends of the patient’s age, the main disease and co‐
existing diseases. Myeloablative conditioning regimens are characterized by strong cytotox‐
icity as well as strong immunosuppressive potential, while reduced intensity conditioning
regimens differ in cytotoxic activity and immunosuppressive potential. They are chosen de‐
pending on the main disease and evaluation of the risk of graft failure.
The combination of radiotherapy (TBI- total body irradiation- at total dose of 12 Gy, deliv‐
ered in fractions) and cyclophosphamide (Cy, at total dose of 120 mg/kg administered with‐
in 2 days) has been used for over 40 years for conditioning [28]. TBI treatment is
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recommended as a standard in ALL. In order to avoid potential TBI consequences, such as
bronchiolitis obliterans, cataract, secondary malignancy, endocrinological disorders, inhibi‐
tion of the growing process in children, TBI in AML and MDS has been replaced by busul‐
fan given at 16 mg/kg dose within 4 consecutive days before Cy [29]. The BuCy treatment
has higher risk of SOS (sinusoidal obstruction syndrome), hemorrhagic cystitis and chronic
GvHD. The high serum concentration of Bu (Busulfan) occurring during its oral treatment
has influenced considerably its toxic complications. It is difficult to avoid it because of vari‐
ous degree of absorption from digestive tract. Thus the intravenous use of busulfan is more
favorable. The reduction of SOS incidence and decrease of transplant related mortality
(TRM) after intravenous use of Bu has been reported [30]. In order to further limit the toxici‐
ty, treosulfan is used instead of Bu in modern treatment programs nowadays, and addition‐
al immunosuppressive effect is obtained by parallel application of purine analoque, e.g.
fludarabine.
The standard preparative treatment applied in SAA comprises of Cy 200 mg/kg and antithy‐
mocyte globulin (ATG).
Although the intensive conditioning treatment decreases the risk of relapse after transplan‐
tation, it does not prolong the overall survival because greater toxicity leads to increased
transplant related mortality [31].
The concept of so-called RIC (reduced intensity conditioning) incorporates the advantage of
anti-leukemic effect of donor T-lymphocytes while cytotoxic effect of conditioning regimen
is decreased. The main result of RIC treatment is immunosuppressive therapy aiming to en‐
able the acceptance of the transplant by braking the immunological defence of the recipient.
The anti-leukemic effect can be escalated after transplantation by means of DLI (Donor Lym‐
phocyte Infusion), whenever it is required. DLI was first used with success in CML patients,
in whom the disease relapsed after conventional allo-HSCT [32]. Since then it has been used
in many other diseases, including many clonal diseases of hematopoietic system, most often
lymphomas and chronic lymphocytic leukemia (CLL). RIC treatment has lower toxicity
when compared to conventional conditioning treatment, thus it is suitable for transplanta‐
tion in older patients and in patients with coexisting diseases in whom the application of
myeloablative treatment is contraindicated. RIC treatment consists most often of purine ana‐
loque. The example of RIC treatment reduced to the minimum, after which graft occurs, is
the combination of TBI dose 2Gy with fludarabine. Other exemplary RIC protocols are the
combination of fludarabine with Bu at dose 8 mg/kg and ATG with Cy or with melphalan.
The important element of RIC treatment is the use of immunosuppressive therapy after
transplantation e.g. cyclosporine A and mycophenolate mofetil. The reduced intensity of
conditioning enables the immunocompetent recipient cells to survive until the moment of
transplantation, what leads to the higher risk of graft failure or incomplete graft. In some
centers transplantation with RIC are performed in ambulatory, however patients often re‐
quire further hospitalization due to infections or GvHD [33].
Allo-HSCT with use of RIC can be applied when autologous transplantation is ineffective.
Other possibility is to apply the tandem transplantation: at first autologous one and then the
allogeneic one, with use of RIC in order to reduce the TRM by separation of high-dosed cy‐
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totoxic treatment from immunotherapy related to allogeneic HSCT, which has been applied
for the first time in patients with multiple myeloma (MM).
7. Adjunctive treatment
During the phase of pancytopenia after myeloablative conditioning patients are usually sus‐
ceptible to infections and thus they have to stay in a sterile environment, e.g. in HEPA-fil‐
tered rooms with reversed isolation. They routinely receive preventive treatment against
bacteria, viruses, fungi. Moreover, the substitution treatment is applied with the use of irra‐
diated, CMV-negative red blood cells and single donor platelets concentrates. Analgetic
drugs and parenteral nutrition are applied when needed. Ursodeoxycholic acid is used in
order to avoid hepatic complications. G-CSF is applied to accelerate the regeneration of
granulocytes, however it can delay the recovery of platelets and can increase the risk of
GvHD. Erythropoietin accelerates the recovery of red blood cells system and thus it reduces
the need for transfusions, but it increases the cost of the transplant procedure and it is not
used on a regular basis.
8. Post-transplant complications
8.1. Graft versus host disease
Acute and chronic graft versus host disease are the main complications of allo-HSCT. In
pathophysiology of acute and chronic GvHD, T-lymphocytes of the donor recognize HLA-
molecules of the recipient presented by the antigen presenting cells. It results in the release
of interleukin-2 and activation of cytotoxic T-lymphocytes, NK-cells and macrophages. The
main targets of the attack are skin, gut and liver. The most important risk factor is the HLA-
incompatibility between the donor and the recipient, but also minor histocompatibility anti‐
gens are responsible for the risk of GvHD, especially HY mismatch in case when the donor
is female and the recipient is male [34]. Chronic GvHD occurs most often from 100 days to
one year after allo-HSCT. It resembles autoimmunological diseases, e.g. systemic scleroder‐
mia and Sjoegren syndrome. Symptoms such as lichen and sclerodermic skin changes, mu‐
cositis, kserostomia, keratoconjunctivitis sicca, stricture of esophagus and vagina, cholestatic
liver failure, bronchiolitis obliterans and musculitis also occur. Cachexia, immunological de‐
ficiency, additionally increasing the risk of infections especially caused by gram-plus bacte‐
ria can be also observed. The initial stage of chronic GvHD is usually more progressive
when it is preceded by the acute form of the disease. It can also occurr after nonsymptomatic
(quiescent) period or de-novo, without any preceding symptoms of acute GvHD. The chron‐
ic progressive GvHD has the worst prognosis.
In order to decrease the risk of GvHD a preventive immunosuppression, usually with the
use of cyclosporine A (CsA) and methotrexate is applied. The removal of T-lymphocytes
from the transplanted cells (T-depletion) constitutes the effective form of prevention, how‐
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ever, it is connected with the higher risk of the graft failure and relapse of the disease. In
cord blood transplantations, instead of methotrexate which prolonges the regeneration peri‐
od, prednisolon is used. New immunosuppressive protocols include calcineurin-inhibitors
other than cyclosporine A – tacrolimus, macrolid immunosuppressant– syrolimus and my‐
cophenolan mofetil. The administration of ATG before transplantation is an important im‐
munosuppressive element used in allo-HSCT from unrelated donors. As the effective serum
concentration of ATG is maintained for many weeks after infusion, it effects not only T-lym‐
phocytes of the recipient but also those of the donor [35]. The increased risk of infections is
an undesirable side effect of ATG.
The type of GvHD prevention depends of the diagnosis, the type of conditioning treatment
and the applied cell source. The GvHD prevention should be more effective in nonmalig‐
nant disease and less intensive when lower number of cells have been transplanted.
When symptoms of acute GvHD develop despite its prophylaxis, methylprednisolone at the
dose of 2-5 mg per kilogram of body weight per day is used on the standard basis, usually
effectively. In case of steroid resistance the risk of failure is high. The second line treatment
consists of ATG, anti-IL-2 antibodies, anti-IL-2 receptor antibodies and antibodies against
TNF-alpha. Photosensitizing psolarens and ultraviolet radiation in a form of extracorporal
photopheresis and transplantation of mesenchymal stem cells can be also applied, but are
not everywhere available. Mesenchymal stem cells have strong immunosuppressive effect,
they can be obtained from the primitive connective tissue of the umbilical cord, called the
Wharton’s jelly, and they do not require any matching due to low levels of HLA-ABC and
lack of HLA-DR antigens.
The treatment of chronic GvHD consists of CsA and steroids. In patients not responding to
the treatment tacrolimus, thalidomide, mycophenolan mofetil, sirolimus and irradiation of
lymphatic system with dose of 1 Gy can be applied.
8.2. Infections
Immunological  reconstitution  is  of  a  primary  importance  to  avoid  infections  after  allo-
HSCT. The highest risk of the infection occurs in patients with GvHD, but also in the re‐
maining patients with no GvHD it is 20 times higher than in the whole population. From
20% up to 50% of patients still require immunosuppressive treatment after 3 years from al‐
lo-HSCT, what considerably increases the risk of infectious complications in this group of
patients [36].
Normal endogenous Gram-negative flora from the gastrointestinal tract and exogenous
catheter-related Gram-positive bacteria constitute the most frequent cause of infections in
the early stage after allo-HSCT. In this stage fungal infections are also the problem, especial‐
ly other than Candida albicans, which are usually recognized with the delay. Although my‐
cological diagnosis based on PCR method is available, it has not been introduced into
practice yet. Galactomannan testing and detection of specific fungal antigens in the blood
are sometimes helpful. In the treatment we already administer not only conventional am‐
photericine B with considerable side effects, but also its lipid-based preparations (Abelcet,
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totoxic treatment from immunotherapy related to allogeneic HSCT, which has been applied
for the first time in patients with multiple myeloma (MM).
7. Adjunctive treatment
During the phase of pancytopenia after myeloablative conditioning patients are usually sus‐
ceptible to infections and thus they have to stay in a sterile environment, e.g. in HEPA-fil‐
tered rooms with reversed isolation. They routinely receive preventive treatment against
bacteria, viruses, fungi. Moreover, the substitution treatment is applied with the use of irra‐
diated, CMV-negative red blood cells and single donor platelets concentrates. Analgetic
drugs and parenteral nutrition are applied when needed. Ursodeoxycholic acid is used in
order to avoid hepatic complications. G-CSF is applied to accelerate the regeneration of
granulocytes, however it can delay the recovery of platelets and can increase the risk of
GvHD. Erythropoietin accelerates the recovery of red blood cells system and thus it reduces
the need for transfusions, but it increases the cost of the transplant procedure and it is not
used on a regular basis.
8. Post-transplant complications
8.1. Graft versus host disease
Acute and chronic graft versus host disease are the main complications of allo-HSCT. In
pathophysiology of acute and chronic GvHD, T-lymphocytes of the donor recognize HLA-
molecules of the recipient presented by the antigen presenting cells. It results in the release
of interleukin-2 and activation of cytotoxic T-lymphocytes, NK-cells and macrophages. The
main targets of the attack are skin, gut and liver. The most important risk factor is the HLA-
incompatibility between the donor and the recipient, but also minor histocompatibility anti‐
gens are responsible for the risk of GvHD, especially HY mismatch in case when the donor
is female and the recipient is male [34]. Chronic GvHD occurs most often from 100 days to
one year after allo-HSCT. It resembles autoimmunological diseases, e.g. systemic scleroder‐
mia and Sjoegren syndrome. Symptoms such as lichen and sclerodermic skin changes, mu‐
cositis, kserostomia, keratoconjunctivitis sicca, stricture of esophagus and vagina, cholestatic
liver failure, bronchiolitis obliterans and musculitis also occur. Cachexia, immunological de‐
ficiency, additionally increasing the risk of infections especially caused by gram-plus bacte‐
ria can be also observed. The initial stage of chronic GvHD is usually more progressive
when it is preceded by the acute form of the disease. It can also occurr after nonsymptomatic
(quiescent) period or de-novo, without any preceding symptoms of acute GvHD. The chron‐
ic progressive GvHD has the worst prognosis.
In order to decrease the risk of GvHD a preventive immunosuppression, usually with the
use of cyclosporine A (CsA) and methotrexate is applied. The removal of T-lymphocytes
from the transplanted cells (T-depletion) constitutes the effective form of prevention, how‐
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ever, it is connected with the higher risk of the graft failure and relapse of the disease. In
cord blood transplantations, instead of methotrexate which prolonges the regeneration peri‐
od, prednisolon is used. New immunosuppressive protocols include calcineurin-inhibitors
other than cyclosporine A – tacrolimus, macrolid immunosuppressant– syrolimus and my‐
cophenolan mofetil. The administration of ATG before transplantation is an important im‐
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8.2. Infections
Immunological  reconstitution  is  of  a  primary  importance  to  avoid  infections  after  allo-
HSCT. The highest risk of the infection occurs in patients with GvHD, but also in the re‐
maining patients with no GvHD it is 20 times higher than in the whole population. From
20% up to 50% of patients still require immunosuppressive treatment after 3 years from al‐
lo-HSCT, what considerably increases the risk of infectious complications in this group of
patients [36].
Normal endogenous Gram-negative flora from the gastrointestinal tract and exogenous
catheter-related Gram-positive bacteria constitute the most frequent cause of infections in
the early stage after allo-HSCT. In this stage fungal infections are also the problem, especial‐
ly other than Candida albicans, which are usually recognized with the delay. Although my‐
cological diagnosis based on PCR method is available, it has not been introduced into
practice yet. Galactomannan testing and detection of specific fungal antigens in the blood
are sometimes helpful. In the treatment we already administer not only conventional am‐
photericine B with considerable side effects, but also its lipid-based preparations (Abelcet,
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AmBisome, Amphocil) being better tolerated, but unfortunately expensive. New antifungal
drugs such as echinocandins (caspofungin, anidulafungin, micafungin) and newer azole
drugs (voriconazole, posaconazole) are also currently available.
After  resolution  of  pancytopenia  cytomegalovirus  infection  is  a  most  frequent  problem.
Thanks  to  a  modern  diagnostic  approach  based  on  early  CMV  antigen  detection  by
means of  PCR methods,  CMV reactivation can be  detected and cured before  CMV dis‐
ease is developed. The most common cause of CMV infection is latent virus reactivation
in  CMV-seropositive  patient  or  CMV-transmission  from a  seropositive  donor  to  a  sero‐
negative  recipient.  Therefore  the  optimal  situation  is  when the  serological  status  of  the
donor and the recipient is identical. The antiviral prevention includes the substitution of
blood  products  from  CMV-seronegative  donors,  transfusion  of  immunoglobulines  and
administration  of  antiviral  drugs  such  as  gancyclovir,  foscavir,  cydofovir  and  oral  val‐
gancyclovir.  Polyoma- BK virus and adenovirus are common causes of  dysuria,  urinary
tract  infections and haemorrhagic  cystitis  in immunocompromised patients.  Epstein-Barr
virus can cause post-transplant  lymphoproliferative disease (PTLD).  The risk factors  are
the use of  anti-thymocyte globulin and transplantation from unrelated donors.  Monitor‐
ing of  EBV-viremia by means of  PCR methods enables  to start  the treatment early –  to
reduce  the  immunosuppression  and  to  use  rituximab  (anti-CD20  antibody)  and  donor
lymphocyte infusion (DLI).
8.3. Relapse of the disease
Having better adjunctive treatment and more effective GvHD prevention, the relapse of ba‐
sic disease constitutes the main cause of allo-HSCT failure. The risk of the relapse depends
on the type of the disease, its stage at the moment of transplantation and the GvHD preven‐
tion applied (the more effective immunosuppression, the higher risk of the relapse). The lon‐
gest survival time is observed in patients with moderate acute or limited chronic GvHD,
because of the lowest risk of the relapse.
Although the relapse after allo-HSCT can be treated by means by DLI, good prognosis refers
usually to the patients with CML. In acute leukemia relapsing after allo-HSCT the tempora‐
ry response can be also achieved, but it is usually not stable.
Patients with molecular CML relapse, i.e. with reappearance of bcr/abl transcript in PCR
tests, have better prognosis than those with hematological relapse. The prognosis in patients
with more advanced stages of CML- relapse, acceleration phase or blastic transformation- is
much worse. The relapse should by detected as soon as possible, when there is still a chance
for effective immunotherapy after allo-HSCT.
The alternative to specific disease markers determination is post-transplant chimerism test‐
ing. The PCR short tandem repeats (STR) method is used. The goal of allo-HSCT is to obtain
the full donor’s chimerism. Detection of returning or increasing recipient’s chimerism can be
a sign of the relapse of the disease, similarly to the re-occurrence of minimal residual disease
[37]. In such case it is recommended to use adoptive immunotherapy by reduction of immu‐
nosuppressive treatment and DLI application. The chimerism testing is important also for
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prediction and analysis of the graft failure and GvHD risks. GvHD and pancytopenia can
develop as the side effects of DLI. The use of T-lymphocytes in escalating doses is equally
effective as high DLI dose, but it decreases the risk of GvHD [38].
9. New indications for transplantation of hematopoietic stem cells
Allo-HSCT with subsequent immunotherapy can be applied in patients with metastatic sol‐
id tumors. The presence of graft versus tumor effect has been shown in kidney cancer, colon
adenoma, metastatic breast, ovarian, prostate and pancreas cancers. RIC treatment has been
used in these conditions in order to reduce TRM while enabling to achieve the response,
which was complete in some cases [39]. The presence of fewer than 3 metastases and Kar‐
nofsky scale ≥70 constitutes beneficial prognostic factors [40]. The survival is longer in pa‐
tients who develop chronic GvHD after DLI.
Allo-HSCT is currently tested in animal models and in experimental clinical applications.
Hematopoietic stem cells are characterized by plasticity, which means that they can form
not only blood cells. Hematopoietic stem cells can be forced to transform into the cells of
various tissues such as heart muscle, bone or blood vessels in suitable conditions [41]. The
science dealing with plasticity of stem cells is just developing, but it arises hope for revolu‐
tion in the way of thinking about transplantation and organ regeneration.
10. Conclusion
Allo-HSCT procedure has transformed from the experimental method of treatment of leuke‐
mia in its final stage into routine procedure applied in patients with various hematological
diseases. The ability to collect and to transplant hematopoietic cells makes it possible to cure
many patients with malignant and nonmalignant diseases incurable with other methods.
Thanks to development of unrelated donor registries the treatment with allo-HSCT can be
currently offered not only to the patients having HLA-matched sibling donor but to almost
every patient in need. The observed increase of transplantations of peripheral hematopoietic
stem cells results from observed faster regeneration of hematopoietic system than after bone
marrow transplantation and from beneficial GvL effect in clonal diseases, although it coin‐
cides with more frequent occurrence of GvHD.
The patients in the older age group and those with comorbidities can be treated with allo-
HSCT after preparation with RIC. Still, the main problem is the relapse of the disease, how‐
ever when it is detected early basing on chimerism analysis and minimal residual disease
evaluation, it can be successfully treated with immunological intervention with DLI. Recent
and current studies indicate that hematopoietic stem cells will be used for new clinical appli‐
cations in the near future.
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1. Introduction
1.1. Aims of chapter
In this Chapter we will discuss the indications for allogeneic hematopoietic stem cell trans‐
plantation (HCT). We will focus on the appropriate timing of this procedure for the different
hematologic malignancies. We reviewed past approaches using myeloablative conditioning
and present some of the newer reduced intensity therapies. Allogeneic transplantation is one
of the first known uses of stem cells. Born from the need to rescue damaged bone marrow, it
was first used in the setting of aplastic anemia and acute leukemia. Over the years, the
technique has changed steadily and support for this procedure has improved immensely.
Today this procedure is used to treat multiple malignant blood disorders, bone marrow failure
syndromes, immune deficiency syndromes, and hemoglobinopathies. This chapter will focus
on the malignant hematopathies. Another aspect of this Chapter will be to review the condi‐
tioning regimens used in allogeneic HCT.
2. Indications for transplantation
2.1. Acute myeloid leukemia
Acute myeloid leukemia (AML) Is heterogeneous group of clonal disorders. The disease can
present at all ages, but this disorder is most commonly seen in older patients, with a median
age at presentation of 67 years. [1] AML can present in a de novo fashion or can progress from
antecedent hematological disorders, including myelodysplasia and myeloproliferative
neoplasms (secondary AML), or after prior exposure to chemotherapy and/or radiation
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therapy (treatment-related AML). Patients who are deemed fit enough to receive therapy can
be given various combinations of chemotherapy to induce a remission of the disease. The most
common induction therapy is that of cytarabine given as a continuous infusion for 7 days in
combination with an anthracycline for 3 days (the 7+3 regimen). This approach has been used
for over 40 years with very good results [2-6]. Attempts to improve on this by adding other
therapies have not resulted in improved outcomes. More recently, dose intensification of the
anthracycline has resulted in improved complete remission (CR) rates and more importantly
overall survival (OS) for patients below the age of 65 years [7-10]. Although current induction
chemotherapy regimens are successful in obtaining a CR with rates approaching 70-80%;
without consolidation chemotherapy, most patients will relapse and die of the disease. Because
of the high risk of relapse, AML is the leading indication for allogeneic transplant.
There are several significant prognostic factors that will affect the patient's ability to achieve a
CR. The most important is that of age. Other recognized factors are cytogenetic risk profile, mo‐
lecular mutations, prior exposures to chemotherapy and radiation therapy, and antecedent
hematological disorders. [11] These factors also impact on the patient's ability to maintain long-
term remission and be cured of the disease. More recently, molecular mutations have come to the
forefront in determining overall prognosis. These mutations include nucleophosmin-1 (NPM1),
fms-like tyrosine kinase-3 (FLT3), CAAT enhancer binding protein alpha (CEBPA), and c-KIT.
Retrospective analyses have shown that, in cytogenetically normal individuals, NPM-1and
CEBPA have improved survival in comparison to those with other mutations [12]. FLT3-ITD
negatively impacts all cytogenetic and molecular risk groups [12-14]. The European Leukemia
Network proposed a new prognostic designation based on both accepted cytogenetic and mo‐
lecular abnormalities [15]. More recently, newer molecular mutations have been described
which in the future may help further delineate the prognostic risk [14]. A recent retrospective
study from the Center for International Blood and Marrow Transplantation Research has also re‐
classified the cytogenetic risk for those patients proceeding to transplantation. [16]
The potential for relapse and the patient’s clinical status are factors that determine the consoli‐
dation approach. Currently, prognostic factors are used to decide on the most appropriate con‐
solidation therapy for patients with this disease. Multiple studies have demonstrated that
patients with the core binding factor AML (AML/ETO and RUNX/RUNX1] have an excellent re‐
sponse to induction and consolidation chemotherapy. [17] For these patients, allogeneic hema‐
topoietic cell transplantation (HCT) should be reserved for relapse of the disease. Contrary to
this, an unfavorable risk profile usually portends a very poor prognosis. Patients with unfavor‐
able  cytogenetics  (complex  cytogenetics,  single  or  multiple  monosomal  karyotype,  MLL
(11q23) [18]) respond very poorly to induction chemotherapy, and remissions are usually short‐
er. In patients with cytogenetically normal AML, the presence of FLT3, MLL, DNMT3A, and oth‐
ers have also demonstrated shorter disease-free survival (DFS) and OS [12, 19-21].
For more than 15 years, the standard of consolidation therapy for patients with AML in first CR
(CR1) has been intensive chemotherapy using high-dose cytarabine. However, this approach is
only effective in patients who are below the age of 60 years and have favorable risk cytogenetics
[22]. Initially, allogeneic HCT was used as salvage therapy for patients who failed conventional
chemotherapy. The sentinel paper was published by Thomas et al., who used allogeneic HCT as
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salvage therapy for 100 patients who had relapsed or refractory AML. The 13% OS gave great
hope to the use of this modality [23] Subsequent reports from the same group promoted the use
of allogeneic HCT as front-line consolidation therapy [24-27]. Randomized trials using genetic
randomization demonstrated an improved DFS in patients receiving allogeneic transplanta‐
tion [28]. Although the US Intergroup trial demonstrated there was no advantage to allogeneic
transplantation compared to intensive chemotherapy in patients with de novo AML below the
age of 60in CR1[29], more recent studies have demonstrated effectiveness of this approach. The
US Intergroup trial had a significant flaw in that a large number of patients allocated to trans‐
plantation did not receive the intended therapy. However, retrospective subset analysis did
note a significant improvement in patients with unfavorable-risk cytogenetics [30]. A meta-
analysis of five trials performed by Yanada et al. (3100 patients) demonstrated an improved OS
for patients with unfavorable-risk cytogenetic profiles. Until recently, there was no consensus
as to how to treat patients with intermediate risk AML in CR1. Meta-analyses by the HOVON-
SAKK group (925 patients) and a systematic review by Koreth et al. (6007 patients) all showed
an improved OS for patients with intermediate- and unfavorable-risk cytogenetic profiles.
These analyses were limited to related donor transplantations and to younger patients. [31-33]
A Markov analysis of 2090 Japanese patients with de novo AML in CR1 confirmed the appropri‐
ateness of a related or alternative donor HCT over chemotherapy in this setting but not for pa‐
tients  without  a  matched donor  [34].  A recent  evaluation of  patients  with  AML with  a
monosomal karyotype also demonstrated a benefit of allogeneic HCT in this group. [35] The ap‐
propriate intensity of the conditioning regimen for patients with myeloid malignancies in first
CR is currently being evaluated by the Bone Marrow Transplant Clinical Trials Network (BMT-
CTN) in a prospective randomized multi-center trial (0901).
About two-thirds of the patients with AML will not have a matched related donor (MRD). For
these patients, matched unrelated donor (MUD) transplantation is an option particularly for
those patients with unfavorable-risk profiles. A retrospective study from the CIBMTR
reviewed MRD, MUD and partial MUD transplantation in patients with unfavorable-risk
cytogenetics. Here the investigators found that MRD and MSD had similar leukemia-free
survival and OS. The benefit was not seen in partially MUD or those over the age of 50 years.
Other studies have demonstrated the similarities in outcomes compared to sibling transplants.
[36-39] The trade-off is an increase in graft versus host disease (GVHD) and its associated
mortality for increased disease control (graft versus leukemia effect). The only randomized
trial using MUD was a German AML 01/99 trial. Here patients < 60 years of age with high-risk
features (non CBF AML and > 5% blasts on the day 15 bone marrow biopsy) who did not have
a MRD were randomized to a MUD allogeneic versus autologous HCT. The patients who had
a MUD HCT had a superior OS to those treated with an autograft. [36]
Improvements in human leukocyte antigen (HLA) sequencing and selection of donors have
reduced the effect of GVHD in this setting. [40] Better treatment options for the conditioning
regimen and preventing and treating acute GVHD have provided more confidence in the
procedure. [41] Tacrolimus and methotrexate are widely used as GVHD prophylaxis with or
without anti-thymocyte globulin (ATG). Newer GVHD prophylaxis combinations such as si‐
rolimus and tacrolimus [42-44], and ATG-Fresenius have reduced the incidence of both
acute and chronic GVHD without impacting relapse or OS. [45]
Current Approach to Allogeneic Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/53488
157
therapy (treatment-related AML). Patients who are deemed fit enough to receive therapy can
be given various combinations of chemotherapy to induce a remission of the disease. The most
common induction therapy is that of cytarabine given as a continuous infusion for 7 days in
combination with an anthracycline for 3 days (the 7+3 regimen). This approach has been used
for over 40 years with very good results [2-6]. Attempts to improve on this by adding other
therapies have not resulted in improved outcomes. More recently, dose intensification of the
anthracycline has resulted in improved complete remission (CR) rates and more importantly
overall survival (OS) for patients below the age of 65 years [7-10]. Although current induction
chemotherapy regimens are successful in obtaining a CR with rates approaching 70-80%;
without consolidation chemotherapy, most patients will relapse and die of the disease. Because
of the high risk of relapse, AML is the leading indication for allogeneic transplant.
There are several significant prognostic factors that will affect the patient's ability to achieve a
CR. The most important is that of age. Other recognized factors are cytogenetic risk profile, mo‐
lecular mutations, prior exposures to chemotherapy and radiation therapy, and antecedent
hematological disorders. [11] These factors also impact on the patient's ability to maintain long-
term remission and be cured of the disease. More recently, molecular mutations have come to the
forefront in determining overall prognosis. These mutations include nucleophosmin-1 (NPM1),
fms-like tyrosine kinase-3 (FLT3), CAAT enhancer binding protein alpha (CEBPA), and c-KIT.
Retrospective analyses have shown that, in cytogenetically normal individuals, NPM-1and
CEBPA have improved survival in comparison to those with other mutations [12]. FLT3-ITD
negatively impacts all cytogenetic and molecular risk groups [12-14]. The European Leukemia
Network proposed a new prognostic designation based on both accepted cytogenetic and mo‐
lecular abnormalities [15]. More recently, newer molecular mutations have been described
which in the future may help further delineate the prognostic risk [14]. A recent retrospective
study from the Center for International Blood and Marrow Transplantation Research has also re‐
classified the cytogenetic risk for those patients proceeding to transplantation. [16]
The potential for relapse and the patient’s clinical status are factors that determine the consoli‐
dation approach. Currently, prognostic factors are used to decide on the most appropriate con‐
solidation therapy for patients with this disease. Multiple studies have demonstrated that
patients with the core binding factor AML (AML/ETO and RUNX/RUNX1] have an excellent re‐
sponse to induction and consolidation chemotherapy. [17] For these patients, allogeneic hema‐
topoietic cell transplantation (HCT) should be reserved for relapse of the disease. Contrary to
this, an unfavorable risk profile usually portends a very poor prognosis. Patients with unfavor‐
able  cytogenetics  (complex  cytogenetics,  single  or  multiple  monosomal  karyotype,  MLL
(11q23) [18]) respond very poorly to induction chemotherapy, and remissions are usually short‐
er. In patients with cytogenetically normal AML, the presence of FLT3, MLL, DNMT3A, and oth‐
ers have also demonstrated shorter disease-free survival (DFS) and OS [12, 19-21].
For more than 15 years, the standard of consolidation therapy for patients with AML in first CR
(CR1) has been intensive chemotherapy using high-dose cytarabine. However, this approach is
only effective in patients who are below the age of 60 years and have favorable risk cytogenetics
[22]. Initially, allogeneic HCT was used as salvage therapy for patients who failed conventional
chemotherapy. The sentinel paper was published by Thomas et al., who used allogeneic HCT as
Innovations in Stem Cell Transplantation156
salvage therapy for 100 patients who had relapsed or refractory AML. The 13% OS gave great
hope to the use of this modality [23] Subsequent reports from the same group promoted the use
of allogeneic HCT as front-line consolidation therapy [24-27]. Randomized trials using genetic
randomization demonstrated an improved DFS in patients receiving allogeneic transplanta‐
tion [28]. Although the US Intergroup trial demonstrated there was no advantage to allogeneic
transplantation compared to intensive chemotherapy in patients with de novo AML below the
age of 60in CR1[29], more recent studies have demonstrated effectiveness of this approach. The
US Intergroup trial had a significant flaw in that a large number of patients allocated to trans‐
plantation did not receive the intended therapy. However, retrospective subset analysis did
note a significant improvement in patients with unfavorable-risk cytogenetics [30]. A meta-
analysis of five trials performed by Yanada et al. (3100 patients) demonstrated an improved OS
for patients with unfavorable-risk cytogenetic profiles. Until recently, there was no consensus
as to how to treat patients with intermediate risk AML in CR1. Meta-analyses by the HOVON-
SAKK group (925 patients) and a systematic review by Koreth et al. (6007 patients) all showed
an improved OS for patients with intermediate- and unfavorable-risk cytogenetic profiles.
These analyses were limited to related donor transplantations and to younger patients. [31-33]
A Markov analysis of 2090 Japanese patients with de novo AML in CR1 confirmed the appropri‐
ateness of a related or alternative donor HCT over chemotherapy in this setting but not for pa‐
tients  without  a  matched donor  [34].  A recent  evaluation of  patients  with  AML with  a
monosomal karyotype also demonstrated a benefit of allogeneic HCT in this group. [35] The ap‐
propriate intensity of the conditioning regimen for patients with myeloid malignancies in first
CR is currently being evaluated by the Bone Marrow Transplant Clinical Trials Network (BMT-
CTN) in a prospective randomized multi-center trial (0901).
About two-thirds of the patients with AML will not have a matched related donor (MRD). For
these patients, matched unrelated donor (MUD) transplantation is an option particularly for
those patients with unfavorable-risk profiles. A retrospective study from the CIBMTR
reviewed MRD, MUD and partial MUD transplantation in patients with unfavorable-risk
cytogenetics. Here the investigators found that MRD and MSD had similar leukemia-free
survival and OS. The benefit was not seen in partially MUD or those over the age of 50 years.
Other studies have demonstrated the similarities in outcomes compared to sibling transplants.
[36-39] The trade-off is an increase in graft versus host disease (GVHD) and its associated
mortality for increased disease control (graft versus leukemia effect). The only randomized
trial using MUD was a German AML 01/99 trial. Here patients < 60 years of age with high-risk
features (non CBF AML and > 5% blasts on the day 15 bone marrow biopsy) who did not have
a MRD were randomized to a MUD allogeneic versus autologous HCT. The patients who had
a MUD HCT had a superior OS to those treated with an autograft. [36]
Improvements in human leukocyte antigen (HLA) sequencing and selection of donors have
reduced the effect of GVHD in this setting. [40] Better treatment options for the conditioning
regimen and preventing and treating acute GVHD have provided more confidence in the
procedure. [41] Tacrolimus and methotrexate are widely used as GVHD prophylaxis with or
without anti-thymocyte globulin (ATG). Newer GVHD prophylaxis combinations such as si‐
rolimus and tacrolimus [42-44], and ATG-Fresenius have reduced the incidence of both
acute and chronic GVHD without impacting relapse or OS. [45]
Current Approach to Allogeneic Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/53488
157
A major challenge which remains is the older patient conventionally described as older than
60 years of age. [46] Interestingly in the case of allogeneic transplantation the threshold for the
older patient is closer to 50 years. These patients are affected by worse prognostic factors,
comorbidities, and intolerance to therapy. [47] However, multiple reports have demonstrated
that transplant is possible with the appropriate conditioning regimen utilizing a non-myeloa‐
blative or reduced intensity dosing of therapy. [48]Although no randomized trial between
conventional therapy and HCT has been reported to date, results suggest that outcomes are
better than conventional chemotherapy for this group of patients. [49, 50] More on this will be
discussed later in this chapter.
3. Chronic myeloid leukemia
Translocation between chromosomes 9 and 22 (t(9;22) or Philadelphia chromosome (Ph+) leads
to an abnormal fusion protein (BCR-ABL) with dysregulated tyrosine kinase activity resulting
in a myeloproliferative disorder characterized by abnormal white cell production known as
chronic myeloid leukemia (CML). Without therapy, CML has a predictable progression from
a chronic phase (CP) to the more advanced accelerated (AP) and/or blast (BP) phases.Since the
introduction of tyrosine kinase inhibitors (TKIs) in October 2001, allogeneic hematopoietic
stem cell transplant (HCT) has shifted from a first-line treatment option and to a second-, third-,
or even a fourth-line option [51, 52]. The number of allogeneic transplantations in the post-TKI
era has significantly decreased in CP CML patients; however, the number of patients trans‐
planted in AP or BP remains the same [53].
Given the excellent results of studies using TKIs as upfront treatment for CP CML, a random‐
ized trial to compare HCT to TKIs has not been performed and has not been justified. The use of
TKIs as standard front-line therapy has been supported by few retrospective and/or genetically
randomized studies [54, 55]. Imatinib mesylate has activity against progenitors and mature
cells but has limited activity against leukemia stem cells [56, 57]. Unfortunately, the majority of
patients achieving remission with imatinib mesylate continue to have molecular evidence of
persistent disease [58]. Even in those patients who are treated for over 4 years with imatinib me‐
sylate and in remission, BCR-ABL + stem cells are still detected in bone marrow [59].
Allogeneic HCT remains a curative approach with long-term molecular remissions, seen only
rarely with TKIs, as the mechanism of the graft versus leukemia effect relies on the presence
of antigens on leukemia stem cells [60]. Current indications of transplant are reserved,
according to the European leukemia net [61], to the following CML subjects:
• At diagnosis for patients presenting in AP or BP
• Imatinib failure (after second-generation TKI pretreatment) progressing to AP or BP
• Patients with TKI resistant mutations such us T315I
• All patients failing second-generation TKI treatment.
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Definitions of imatinib mesylate failure are: 1) a lack to achieve complete hematological
remission at 3 months; 2) failure to achieve any cytogenetic response at 6 months; 3) persistence
of more than 35% Ph+ metaphases at 12 months; or 4) less than complete cytogenetic response
at 18 months. Resistance to imatinib mesylate is defined as loss of complete hematological
response or complete cytogenetic response or development during imatinib mesylate treat‐
ment of an ABL kinase mutation leading to its resistance.
In summary, the present use of allogeneic HCT is reserved for patients with poor response to
TKIs and/or those with advanced disease. Saussele et al. reported an interim analysis from the
German CML Study group IV in patients who underwent a 5-arm randomization where 84
patients underwent allogeneic HCT as second-line therapy after imatinib mesylate failure
[62].The 3-year survival in CP was 91%, with 59% in AP. The majority of patients (88%)
achieved a molecular remission and reported a very low treatment-related mortality (TRM)
(8%).The authors at that time concluded that allogeneic HCT could become the preferred
second-line option after imatinib mesylate failure for suitable patients with a donor.
Because most patients are treated with TKI before transplant, it is important to understand
whether this strategy could potentially jeopardize HCT results. Retrospective comparison of
patients treated with imatinib mesylate pre-HCT compared with historical controls showed
no effect on OS, progression-free survival, and non-relapse mortality [63]. Based on a Center
for International Blood and Marrow Transplant Research (CIBMTR) study reported by Lee et
al., imatinib mesylate before HCT in patients with CP CML leads to a better survival but no
statistically significant difference in TRM, relapse, and leukemia-free survival and no differ‐
ences reported in advanced CML. These results are re-assuring for the majority of patients that
today are treated with TKIs prior to allogeneic HCT [64]. In summary, imatinib mesylate use
before HCT has been shown to not increase toxicity and/or engraftment of subsequent
allogeneic HCT [65-68]. Interestingly, risk of chronic GVHD may be decreased with the use of
imatinib mesylate pre-HCT [67] and may potentially target GVHD-related fibrotic features if
they developed post-HCT[69, 70]. In addition, the use of TKIs before HCT has been shown to
improve outcomes if a patient achieves major cytogenetic remission compared to those who
do not [67].
Imatinib mesylate as frontline for CP patients leads to a major cytogenetic response rate
of 89% and OS of 86% at 7 years. Unfortunately, secondary resistance develops at a rate
of 4% per year for CP [71] and 70-90% in AP/BP phases [72-74].With the development of
second-generation TKIs  (dasatinib  and nilotinib)  and the  compelling results  shown of  a
major  cytogenetic  response of  up to  45% for  imatinib  mesylate  failure  patients  [75,  76],
recommendations  for  HCT are  reserved for  patients  who have  failed  not  only  imatinib
but  also second-generation TKIs[61].  Front-line therapy with second-generation TKIs  for
CP CML it is now warranted [77, 78].
The majority of mutations are susceptible to second-generation TKIs, but some are resistant
not only to first-generation but also to all second-generation TKIs. Threonine-to-isoleucine
substitution at position 315 of Bcr-Abl fusion protein (T315I mutation) is well established to
confer resistance to most TKIs [61]. Multiple reports have shown encouraging results with
allogeneic HCT in patients for whom allogeneic HCT is recommended earlier in the disease
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course [79-82]. The results from efforts to develop third-line TKIs to target resistant mutations
are encouraging. On September 4, 2012, the U.S. Food and Drug Administration approved
bosutinib tablets (Bosulif®, Pfizer, Inc.) for the treatment of CP, AP, and BP Ph+ CML in adult
patients with imatinib-resistant mutants of Abl or intolerance to prior therapy (http://
www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm318203.htm). The pivotal
PACE trial data have shown robust anti-leukemic activity of ponatinib in patients with CML
at all stages, who are either resistant or intolerant to dasatinib or nilotinib or who have the
T315I mutation [83].
For advanced patients, TKIs have facilitated a bridge to the HCT procedure. Long-term
outcomes with imatinib mesylate for AP CML are only up to 47 months and 7 months for BP
CML[84-86] with a 2-year OS of only 47% and 16% for patients in AP and BP, respectively [87].
The goal for advanced disease patients is to achieve a second CP in order to proceed with
allogeneic HCT. Because the rate of mutations is highly increased for these patients, assessment
of mutation profile is quite vital to guide TKI selection. Allogeneic HCT represents the best
chance for long-term success or even cure in AP/BP CML [88]. Given selection bias, only
unfavorable risk CML patients should proceed to allogeneic HCT these days. Reduced
intensity conditioning (RIC) regimens have facilitated transplant access to more frail popula‐
tions; unfortunately a higher relapse risk remains due to aggressive disease and reduced
chemotherapy [89-92]. Therefore, there is a need for strategies to improve current leukemia-
free survival post-allogeneic HCT.Measurement of minimal residual disease has become
particularly important as it has been shown that patients who have increased BCR-ABL
expression levels (more than 10-4) experience higher relapses rates [93-95]. Serial BCR-ABL RT-
PCR is considered a standard practice and can be used to guide clinical interventions. It is not
unusual to decect low level molecular disease; however treatment should be reserved for those
patients whose markers increase over time or remain persistently positive. Maintenance
therapy with TKIs post-transplant has proven to be tolerable [96]. Carpenter et al. reported
that prophylactic use of imatinib mesylate for 1 year in Ph+ acute lymphoblastic leukemia
(ALL) and CML lead to a low risk of relapse (18%) [97]. Other groups have also shown that
use of TKIs post-HCT can help to minimize relapse risk [98, 99] and/or effectively control
relapse post-HCT [100]. Experience of second-generation TKIs in the post-HCT setting are
currently being explored in clinical trials (http://clinicaltrials.gov/ct2/show/NCT00702403). An
early approach is to consider maintenance with a TKI in those who have shown activity prior
to transplant, and BCR-ABL mutation analysis should guide TKI selection. Role of TKIs in the
post-HCT setting should also be studied in the context of donor lymphocyte infusions (DLI)
as immunotherapy, as it has been shown to be effective for management of early relapse in the
pre-TKI era. The synergistic role of TKI with DLI should be further explored [101].
In conclusion, several effective drugs are available today to treat CML upfront during the
chronic phase of the disease. Careful monitoring for BCR/ABL and mutation analysis are
warranted to determine which patients will be in need of second- or third-line therapies. For
patients with advanced-phase disease, HCT remains the option of choice, using a TKI to bridge
to allogeneic HCT.
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4. Myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a clonal stem cell disorder that results in a heterogeneous
group of disorders characterized by excessive apoptosis of bone marrow cells. It is character‐
ized by low peripheral counts, marrow dysplasia, proliferation and loss of differentiation of
hematopoietic progenitors with a median age of 60-70 years at presentation. Mortality is
related to bone marrow failure and evolution to secondary AML [102]. Despite development
of novel therapeutic agents over the past decades, allogeneic HCT remains the only curative
option in this disease. To date, HCT indications, timing, and incorporation of novel drugs
before and/or after HCT remains a challenge. Additionally, whether novel treatment agents
for elderly MDS patients should be pursued instead of allogeneic HCT remains unanswered.
A recent retrospective cohort analysis suggested a survival advantage for allogeneic HCT
(39%) compared with azacytidine (23%) therapy in medically fit patients with high-risk MDS
of 60-70 years of age [103]. The German MDS study group is testing 5-azacytidine compared
to allogeneic HCT in a prospective study for patients with International Prognostic Scoring
System (IPSS) intermediate II or high-risk up to age 70 years (NCT01404741).
The IPSS system is based on peripheral blood cytopenias, cytogenetics, and marrow myeloblast
percentages and is generally used to identify HCT candidates [104]. A limitation of the IPSS
score is that it does not take into account patient age; therefore, development of other scoring
system has been proposed. The World Health Organization classification and the World
Health Organization classification–based Prognostic Scoring System have both shown relevant
prognostic values in post-HCT MDS outcome for OS and relapse [105, 106]. In a recent analysis
of 1915 patients with MDS, only 26% had primary MDS without prior therapy that could be
classified with the IPSS system. A multivariate analysis of prognostic factors determined worst
outcome for poor performance, older age, thrombocytopenia, anemia, increased bone marrow
blasts, leukocytosis, chromosome 7 or complex (≥3) abnormalities, and prior transfusions. This
new MDS prognostic model divided patients into 4 prognostic groups with significantly
different outcomes with the advantage that it accounts for duration of MDS and prior therapy
and is applicable to any patient with MDS at any time during the course of MDS [107].
A Markov decision analysis model designed by Cutler et al. showed that for low and inter‐
mediate-1 IPSS groups, delayed transplantation maximized OS; for intermediate-2 and high
IPSS groups, HCT at diagnosis maximized OS and was associated with maximal life expect‐
ancy [108]. In contrast, other studies have suggested that younger patients with less advanced
disease have a better transplantation outcome [105, 109]. An evidence-based review consensus
by the American Society of Blood and Marrow Transplantation recommended early HCT for
patients with IPSS intermediate-2 or high-risk at diagnosis and selected patients with lower
risk disease at diagnosis who have poor prognostic features (such as older age, refractory
cytopenias, and/or transfusion dependence) [110]. The American Society of Blood and Marrow
Transplantation recommendations are limited as they are based on studies using IPSS score
instead of more comprehensive ones; in addition, it only applies to newly diagnosed patients
and excludes MDS subjects with treatment-related MDS/t-AML and chronic myelomonocytic
leukemia subtype [111].
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Factors that determine risk of progression from MDS to t-AML and that more accurately
predict disease progression and HCT indication have been studied in the context of MDS
phenotype and/or disease biology. With a patient group of 692 MDS patients, a European
group analyzed outcome and reported worse OS and relapse rates based on poor cytogenetics
[112]. In a multivariate analysis by Chang et al. comparing patients with secondary MDS or
transformed to AML(t-AML) to de novo MDS, no significant differences in outcome were
shown between the 2 cohorts and overall inferior outcome was shown in patients with
secondary MDS/tAML, as the majority of advanced patients has increased frequency of high-
risk cytogenetics [113]. Flow cytometric scoring system is predictive of post-HCT outcomes
even after adjusting for risk factors such as marrow myeloblast percentage and IPSS score
[114]. Cases of MDS classified as AML by microarray-based GEP assays had more aggressive
disease and more rapid progression to AML, whereas MDS cases classified as “none-of-the-
targets” had a more indolent clinical course [115]. Tumor necrosis factor-α polymorphisms
affect HCT outcome in a disease-dependent manner [116]. There are many others risk catego‐
rization factors in MDS like FISH, spectral karyotyping, and mutation or deletion analyses
[117-119], although clinical significance remains controversial [120]. Development of a revised
scoring system is warranted to guide the decision-making process to recommend HCT for such
a diverse and heterogeneous clonal condition.
Clinical evolution of disease such us increased transfusion, recurrent infections or bleeding
may also precipitate the decision to proceed with HCT. Elevated serum ferritin levels, as
reflection of increased body iron storage, have been showed to be associated with decreased
OS and DFS, acute GVHD, and infections with myeloablative HCT [121, 122]. Ferritin levels
should guide the need of chelation therapy prior to HCT and/or may guide conditioning
regimen selection [123]. Co-morbidity as a determinant of HCT outcomes has been elegantly
studied by Sorror et al. [124] and applied in the context of AML-MDS [125]. This group
investigated the role of comorbidities, among other risk factors, in stratifying and comparing
patients conditioned with non-myeloablative or myeloablative regimens. Patients with low
HCT-CI scores and either low or high disease risks had probabilities of OS at 2 years of 70%
and 57% after nonmyeloablative conditioning compared to 78% and 50% after myeloablative
conditioning, respectively. Patients with higher HCT-CI scores ( ≥ 3) and either low or high
disease risks had probabilities of OS of 41% and 29% with nonmyeloablative conditioning
compared with 45% and 24% with myeloablative regimens, respectively. After adjusting for
pretransplantation differences, stratified outcomes were not significantly different among
patients receiving nonmyeloablative compared with myeloablative conditioning, with the
exception of lessened nonrelapse mortality (hazard ratio, 0.50; P =.05) in the highest risk group.
This group concluded that patients with low comorbidity scores could be candidates for
prospective randomized trials comparing nonmyeloablative and myeloablative conditioning
regardless of disease status [125]. An additional scoring system has also emphasized the
negative influence of comorbidities on HCT outcomes [126].
Based on published literature, patients up to 70 years of age can tolerate allogeneic HCT and
age per se should not be a criterion for patient selection and/or intensity of the conditioning
regimen rather than performance status, comorbidity, and disease status [127].Results from a
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European Group for Blood and Marrow Transplantation (EBMT) report suggested that age is
not a contraindication to HCT; the cumulative incidence of non-relapse mortality at 4 years
was 36% in the 50- to 60-year-old patient group and 39% for the group 60 years or older (P =.
39], with OS not differing between the groups (34% versus 27%, P =.2). In a multivariate analysis
for OS, only advanced stage of the disease at time of transplantation (hazard ratio = 1.55] was
associated with inferior survival [128]. Similar results were reported by the CIBMTR; in a
multivariate analysis, they showed that OS was inferior with low performance status, mis‐
matched unrelated donors, and unfavorable cytogenetic, but age had no impact [129].
To facilitate HCT access to the majority of MDS patients, a RIC regimen has been developed.
The rationale for RIC is to promote graft-versus-leukemia effect without excessive toxicity to
minimize TRM. Many RIC regimens have been developed using combinations of busulfan
with cyclophosphamide or fludarabine, fludarabine with cyclophosphamide, or low-dose total
body irradiation (TBI) (200cG) among others versus the more intense or conventional regimens
based on TBI or busulfan/cyclophosphomide-based regimens. Unfortunately, due to the lack
randomized prospective trials, it remains unknown which conditioning regimen should be
chosen and how “intense and/or reduced” the conditioning should be. In general, the highest
tolerable regimen should be chosen since reduced intensity is associated with a higher relapse
rate, as suggested in multiple retrospective studies [130-136]. RIC HCT with fludarabine/
melphalan and tacrolimus/sirolimus-based GVHD prophylaxis resulted in a relapse incidence
of 20.9% with low-grade acute GVHD [137]. An ongoing prospective randomized trial
comparing RIC versus myeloablative conditioning has been developed to address selection
bias for allogeneic HCT by the EBMT group (NCT00682396).
Disease relapse post-HCT remains a critical issue as long-term outcome is compromised.
Approaches to tackle this issue include pre-HCT induction chemotherapy and/or novel agents
for high-risk patients or drug maintenance to prevent relapse pre-emptively post-HCT, as
opposed to strategies for relapse treatment. Still debatable to date is whether pre-HCT
induction chemotherapy has a role to minimize relapse post-HCT for patients with advanced
MDS. Unfortunately, this remains unanswered due to lack of randomized and/or definitive
data [138-141]. Introduction of novel agents in the pre-HCT setting seems feasible, associated
with less toxicity, and may allow for similar post-HCT outcomes when compared to chemo‐
therapy [142].Another approach is to use low-dose 5-azacytidine as maintenance post-HCT.
De Lima et al. determined that the optimal combination was 32 mg/m2 given for at least 4
cycles, with reversible thrombocytopenia as the dose-limiting toxicity. The authors suggested
that this treatment prolonged event-free survival (EFS) and OS [143]. In the event of disease
relapse post-HCT, azacytidine administration is feasible and may induce durable remissions
[144]. DLIs can result in complete remission in some patients, but long-term survival is
infrequent [145]. The Azarela trial, a prospective multicenter phase II trial, was developed to
test whether a combination of 5-azacytidine and DLI would benefit patients with relapsed
MDS post-HCT. Overall response rate was 64% with 20% achieving and staying in CR, 12%
achieved partial response, and 32% showed stable disease with low incidence of acute GVHD
occurring (24%). These data suggest that salvage therapy with combination azacytidine + DLI
is feasible and has significant anti-leukemic activity in relapsed MDS post-HCT [146].
Current Approach to Allogeneic Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/53488
163
Factors that determine risk of progression from MDS to t-AML and that more accurately
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HCT-CI scores and either low or high disease risks had probabilities of OS at 2 years of 70%
and 57% after nonmyeloablative conditioning compared to 78% and 50% after myeloablative
conditioning, respectively. Patients with higher HCT-CI scores ( ≥ 3) and either low or high
disease risks had probabilities of OS of 41% and 29% with nonmyeloablative conditioning
compared with 45% and 24% with myeloablative regimens, respectively. After adjusting for
pretransplantation differences, stratified outcomes were not significantly different among
patients receiving nonmyeloablative compared with myeloablative conditioning, with the
exception of lessened nonrelapse mortality (hazard ratio, 0.50; P =.05) in the highest risk group.
This group concluded that patients with low comorbidity scores could be candidates for
prospective randomized trials comparing nonmyeloablative and myeloablative conditioning
regardless of disease status [125]. An additional scoring system has also emphasized the
negative influence of comorbidities on HCT outcomes [126].
Based on published literature, patients up to 70 years of age can tolerate allogeneic HCT and
age per se should not be a criterion for patient selection and/or intensity of the conditioning
regimen rather than performance status, comorbidity, and disease status [127].Results from a
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multivariate analysis, they showed that OS was inferior with low performance status, mis‐
matched unrelated donors, and unfavorable cytogenetic, but age had no impact [129].
To facilitate HCT access to the majority of MDS patients, a RIC regimen has been developed.
The rationale for RIC is to promote graft-versus-leukemia effect without excessive toxicity to
minimize TRM. Many RIC regimens have been developed using combinations of busulfan
with cyclophosphamide or fludarabine, fludarabine with cyclophosphamide, or low-dose total
body irradiation (TBI) (200cG) among others versus the more intense or conventional regimens
based on TBI or busulfan/cyclophosphomide-based regimens. Unfortunately, due to the lack
randomized prospective trials, it remains unknown which conditioning regimen should be
chosen and how “intense and/or reduced” the conditioning should be. In general, the highest
tolerable regimen should be chosen since reduced intensity is associated with a higher relapse
rate, as suggested in multiple retrospective studies [130-136]. RIC HCT with fludarabine/
melphalan and tacrolimus/sirolimus-based GVHD prophylaxis resulted in a relapse incidence
of 20.9% with low-grade acute GVHD [137]. An ongoing prospective randomized trial
comparing RIC versus myeloablative conditioning has been developed to address selection
bias for allogeneic HCT by the EBMT group (NCT00682396).
Disease relapse post-HCT remains a critical issue as long-term outcome is compromised.
Approaches to tackle this issue include pre-HCT induction chemotherapy and/or novel agents
for high-risk patients or drug maintenance to prevent relapse pre-emptively post-HCT, as
opposed to strategies for relapse treatment. Still debatable to date is whether pre-HCT
induction chemotherapy has a role to minimize relapse post-HCT for patients with advanced
MDS. Unfortunately, this remains unanswered due to lack of randomized and/or definitive
data [138-141]. Introduction of novel agents in the pre-HCT setting seems feasible, associated
with less toxicity, and may allow for similar post-HCT outcomes when compared to chemo‐
therapy [142].Another approach is to use low-dose 5-azacytidine as maintenance post-HCT.
De Lima et al. determined that the optimal combination was 32 mg/m2 given for at least 4
cycles, with reversible thrombocytopenia as the dose-limiting toxicity. The authors suggested
that this treatment prolonged event-free survival (EFS) and OS [143]. In the event of disease
relapse post-HCT, azacytidine administration is feasible and may induce durable remissions
[144]. DLIs can result in complete remission in some patients, but long-term survival is
infrequent [145]. The Azarela trial, a prospective multicenter phase II trial, was developed to
test whether a combination of 5-azacytidine and DLI would benefit patients with relapsed
MDS post-HCT. Overall response rate was 64% with 20% achieving and staying in CR, 12%
achieved partial response, and 32% showed stable disease with low incidence of acute GVHD
occurring (24%). These data suggest that salvage therapy with combination azacytidine + DLI
is feasible and has significant anti-leukemic activity in relapsed MDS post-HCT [146].
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In conclusion, several factors influence HCT indication and timing for MDS patients. Incor‐
poration of evolving prognostic indicators might help to develop treatment algorithms to
decide the appropriate timing for allogeneic HCT. The ultimate objective is to proceed with
HCT when non-transplantation approaches would result in outcomes lower than those that
would result with allogeneic HCT. Currently, novel HCT approaches are allowing the
consideration of older patients and/or the use of alternative donors to treat MDS. A remaining
question is how to incorporate HCT for those patients that are achieving a CR with hypome‐
thylating agents and/or other novel agents. Development of prospective clinical trial may help
to elucidate these questions within a fast evolving field.
5. Acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is a bone marrow clonal disease characterized by the
rapid proliferation of immature lymphoblasts. Despite initial control of the disease, the
majority of adult patients will relapse with poor long-term outcomes. Allogeneic HCT has been
used as a salvage therapy for both relapsed patient and high-risk patients with ALL early in
the disease process. The availability of unrelated donors and/or alternative stem cell sources
and the development of RIC transplants have resulted in far more allogeneic transplants being
performed for this rare disease. For adults with ALL, indication and timing of allogeneic HCT
remains debatable as defining the optimal role for allogeneic HCT has been limited by the lack
of prospective data that can only be gained by large multicenter-national trials.
Historically, allogeneic HCT was reserved for high-risk patients, especially for those with Ph
+ ALL. Patients with high-risk features benefit from upfront HCT, including those with
increased white blood count at presentation (>25,000/µL), chromosomal translocations [t(9;22),
t(4;11), t(8;14)], older age (≥30 years), extra-medullary disease at diagnosis, and/or requiring
more than 4 weeks to achieve CR [147]. Strategy to take ALL patients in CR1 for t(9;22) and
t(1;19) have been supported by a trial by the French Group of Therapy for adult ALL (LALA-94)
in a subgroup analysis [148]. Improvement in detection of minimal residual disease has also
helped to assess disease risk, as 10% of patients with a rapid MRD decline to lower than 10(-4)
or below detection limits at day 11 and day 24 were classified as low risk as their 3-year relapse
rate was 0% [149]. Testing MRD with flow cytometry and/or molecular analysis for gene
rearrangements may help to guide transplant decisions.
The largest prospective study of HCT in adult ALL was conducted by the Medical Research
Council in Great Britain (UKALL XII) and the Eastern Cooperative Oncology Group in the
United States (ECOG 2993). In this trial, allogeneic HCT resulted in improved disease control
in all adult patients with ALL, with younger patients with low-risk disease benefiting the most
with allogeneic HCT [150]. This international collaboration prospectively evaluated the role
of allogeneic HCT for adults with ALL and compared autologous HCT with standard chemo‐
therapy. Patients received 2 phases of induction and, if in remission, were assigned to
allogeneic HCT if they had a compatible sibling donor. Patients without a donor were
randomized to chemotherapy for 2.5 years versus an autologous HCT. A donor versus no-
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donor analysis showed that Ph- ALL patients (standard risk) with a donor had a 5-year
improved OS of 53% versus 45% for no donor (P =.01). The relapse rate was significantly lower
(P ≤.001) with HCT in the standard-risk ALL patients. The survival difference was significant
only in standard-risk patients, but not in high-risk patients, who had an impressive reduction
in relapse rate but increased non-relapse mortality that abrogated the OS benefit of allogeneic
HCT. For the no donor group, patients randomized to chemotherapy had a higher 5-year OS
(46%) than those randomized to autologous transplantation (37%; P =.03). In conclusion, MRD
allogeneic HCT for ALL in CR1 provide the most potent anti-leukemic therapy and consider‐
able survival benefit for standard-risk patients. We may also conclude that there is no role for
a single autologous HCT to replace consolidation/maintenance in any risk group.
For high-risk patients, results are conflicting with a recent large meta-analysis from seven
studies of adult high-risk ALL (n=1274) using natural randomization based on donor availa‐
bility combined with intent-to-treat analyses. This study demonstrated that patients in the
donor groups had significantly better survival than patients in the no-donor groups (hazard
ratio, 1.29; 95% confidence interval [95% CI], 1.02-1.63 [P =.037]). When only high-risk patients
were included in the analysis, the superiority of the survival advantage was even greater
(hazard ratio, 1.42; 95% CI, 1.06-1.90 [P =.019]) [151]. In addition, a recent systematic review
and meta-analysis supported MRD HCT as the optimal post-remission therapy in ALL patients
aged 15 years or over, resulting in improved OS and DFS with a significant reduction of disease
relapse but with increased non-relapse mortality[152]. Interpretation of the results of the
multicenter international trial has led to advocating early allogeneic HCT for patients with
standard risk for some transplantation teams while others have preferred a more personalized
approach as reports from various study groups differ and are often contradictory, leading to
difficulty in interpreting the data [153, 154].
Historically, allogeneic HCT has been the standard of care for patients with high-risk Ph+ ALL
in CR1. With the introduction of TKIs over the past decade, a treatment algorithm introducing
TKIs in combination with allogeneic HCT for adult patients with Ph+ ALL is mandated. TKIs
have been used in the upfront induction/maintenance chemotherapy setting and as mainte‐
nance post-HCT to prevent disease relapse in Ph+ ALL patients. Whether use of TKIs has an
impact on OS when combined with HCT or whether TKIs will replace the use of allogeneic
HCT remains unanswered to date. Multiple studies have shown the advantage of using
imatinib mesylate in the induction/consolidation phase, allowing better remission rates and
durable response with minimal toxicity as well as facilitating access and planning for an
allogeneic HCT [154-159]. Review of these trials has suggested that over 90% of patients
achieved a complete response as previously reviewed [154, 160]. Dasatinib, a multi-target
kinase inhibitor of BCR-ABL and SRC family kinases, has been shown to induce responses in
patients with imatinib-resistant or intolerant Ph+ ALL. In the START-L trial, major hematologic
responses were achieved in 42%(15/36) of patients, 67% of whom remained progression-free
when used at a dose of 140 mg. Complete cytogenetic responses were attained by 58% (21/36)
of patients. The presence of BCR-ABL mutations conferring imatinib resistance did not
preclude a response to dasatinib in this trial [161], suggesting a role for dasatinib to manage
Ph+ ALL upfront [161]. Ravandi et al. examined the efficacy and safety of combining chemo‐
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In conclusion, several factors influence HCT indication and timing for MDS patients. Incor‐
poration of evolving prognostic indicators might help to develop treatment algorithms to
decide the appropriate timing for allogeneic HCT. The ultimate objective is to proceed with
HCT when non-transplantation approaches would result in outcomes lower than those that
would result with allogeneic HCT. Currently, novel HCT approaches are allowing the
consideration of older patients and/or the use of alternative donors to treat MDS. A remaining
question is how to incorporate HCT for those patients that are achieving a CR with hypome‐
thylating agents and/or other novel agents. Development of prospective clinical trial may help
to elucidate these questions within a fast evolving field.
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rapid proliferation of immature lymphoblasts. Despite initial control of the disease, the
majority of adult patients will relapse with poor long-term outcomes. Allogeneic HCT has been
used as a salvage therapy for both relapsed patient and high-risk patients with ALL early in
the disease process. The availability of unrelated donors and/or alternative stem cell sources
and the development of RIC transplants have resulted in far more allogeneic transplants being
performed for this rare disease. For adults with ALL, indication and timing of allogeneic HCT
remains debatable as defining the optimal role for allogeneic HCT has been limited by the lack
of prospective data that can only be gained by large multicenter-national trials.
Historically, allogeneic HCT was reserved for high-risk patients, especially for those with Ph
+ ALL. Patients with high-risk features benefit from upfront HCT, including those with
increased white blood count at presentation (>25,000/µL), chromosomal translocations [t(9;22),
t(4;11), t(8;14)], older age (≥30 years), extra-medullary disease at diagnosis, and/or requiring
more than 4 weeks to achieve CR [147]. Strategy to take ALL patients in CR1 for t(9;22) and
t(1;19) have been supported by a trial by the French Group of Therapy for adult ALL (LALA-94)
in a subgroup analysis [148]. Improvement in detection of minimal residual disease has also
helped to assess disease risk, as 10% of patients with a rapid MRD decline to lower than 10(-4)
or below detection limits at day 11 and day 24 were classified as low risk as their 3-year relapse
rate was 0% [149]. Testing MRD with flow cytometry and/or molecular analysis for gene
rearrangements may help to guide transplant decisions.
The largest prospective study of HCT in adult ALL was conducted by the Medical Research
Council in Great Britain (UKALL XII) and the Eastern Cooperative Oncology Group in the
United States (ECOG 2993). In this trial, allogeneic HCT resulted in improved disease control
in all adult patients with ALL, with younger patients with low-risk disease benefiting the most
with allogeneic HCT [150]. This international collaboration prospectively evaluated the role
of allogeneic HCT for adults with ALL and compared autologous HCT with standard chemo‐
therapy. Patients received 2 phases of induction and, if in remission, were assigned to
allogeneic HCT if they had a compatible sibling donor. Patients without a donor were
randomized to chemotherapy for 2.5 years versus an autologous HCT. A donor versus no-
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donor analysis showed that Ph- ALL patients (standard risk) with a donor had a 5-year
improved OS of 53% versus 45% for no donor (P =.01). The relapse rate was significantly lower
(P ≤.001) with HCT in the standard-risk ALL patients. The survival difference was significant
only in standard-risk patients, but not in high-risk patients, who had an impressive reduction
in relapse rate but increased non-relapse mortality that abrogated the OS benefit of allogeneic
HCT. For the no donor group, patients randomized to chemotherapy had a higher 5-year OS
(46%) than those randomized to autologous transplantation (37%; P =.03). In conclusion, MRD
allogeneic HCT for ALL in CR1 provide the most potent anti-leukemic therapy and consider‐
able survival benefit for standard-risk patients. We may also conclude that there is no role for
a single autologous HCT to replace consolidation/maintenance in any risk group.
For high-risk patients, results are conflicting with a recent large meta-analysis from seven
studies of adult high-risk ALL (n=1274) using natural randomization based on donor availa‐
bility combined with intent-to-treat analyses. This study demonstrated that patients in the
donor groups had significantly better survival than patients in the no-donor groups (hazard
ratio, 1.29; 95% confidence interval [95% CI], 1.02-1.63 [P =.037]). When only high-risk patients
were included in the analysis, the superiority of the survival advantage was even greater
(hazard ratio, 1.42; 95% CI, 1.06-1.90 [P =.019]) [151]. In addition, a recent systematic review
and meta-analysis supported MRD HCT as the optimal post-remission therapy in ALL patients
aged 15 years or over, resulting in improved OS and DFS with a significant reduction of disease
relapse but with increased non-relapse mortality[152]. Interpretation of the results of the
multicenter international trial has led to advocating early allogeneic HCT for patients with
standard risk for some transplantation teams while others have preferred a more personalized
approach as reports from various study groups differ and are often contradictory, leading to
difficulty in interpreting the data [153, 154].
Historically, allogeneic HCT has been the standard of care for patients with high-risk Ph+ ALL
in CR1. With the introduction of TKIs over the past decade, a treatment algorithm introducing
TKIs in combination with allogeneic HCT for adult patients with Ph+ ALL is mandated. TKIs
have been used in the upfront induction/maintenance chemotherapy setting and as mainte‐
nance post-HCT to prevent disease relapse in Ph+ ALL patients. Whether use of TKIs has an
impact on OS when combined with HCT or whether TKIs will replace the use of allogeneic
HCT remains unanswered to date. Multiple studies have shown the advantage of using
imatinib mesylate in the induction/consolidation phase, allowing better remission rates and
durable response with minimal toxicity as well as facilitating access and planning for an
allogeneic HCT [154-159]. Review of these trials has suggested that over 90% of patients
achieved a complete response as previously reviewed [154, 160]. Dasatinib, a multi-target
kinase inhibitor of BCR-ABL and SRC family kinases, has been shown to induce responses in
patients with imatinib-resistant or intolerant Ph+ ALL. In the START-L trial, major hematologic
responses were achieved in 42%(15/36) of patients, 67% of whom remained progression-free
when used at a dose of 140 mg. Complete cytogenetic responses were attained by 58% (21/36)
of patients. The presence of BCR-ABL mutations conferring imatinib resistance did not
preclude a response to dasatinib in this trial [161], suggesting a role for dasatinib to manage
Ph+ ALL upfront [161]. Ravandi et al. examined the efficacy and safety of combining chemo‐
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therapy with dasatinib in patients with Ph+ ALL and determined that 94% achieved CR with
an estimated 2-year survival of 64%. The combination of chemotherapy with dasatinib is
effective in achieving long-term remissions in patients with newly diagnosed Ph+ ALL[162].
Nilotinib has also been tested for the management of relapsed/refractory Ph+ ALL with
encouraging results[163].
TKI treatment is  also a promising strategy when used as a consolidation strategy to in‐
duce and/or maintain molecular responses to decrease relapse rate after allogeneic HCT.
Carpenter el al. reported safety data in 15 patients with Ph+ ALL who were enrolled in a
prospective  study and given imatinib  from the  time of  engraftment  until  day  265  after
HCT [97].  A clinical trial is currently ongoing to determine the safety of the administra‐
tion of  nilotinib between day 81 and day 365 after  HCT in patients  with Ph+ leukemia
(http://clinicaltrials.gov/show/NCT00702403).  Lastly,  TKIs  have  been  shown  to  be  effec‐
tive for management of relapse in Ph+ ALL in the post-HCT setting, although these data
are based on few reports [160].  In summary, TKIs should be incorporated as a pre-HCT
strategy to facilitate higher response rate and to improve both quality and durability of
responses  prior  to  allografting.  TKIs  are  also  a  reasonable  and promising strategy after
allogeneic HCT to consolidate and maintain molecular responses that may ultimately im‐
prove  survival  for  patients  with  Ph+  ALL.  The  optimal  duration  of  therapy  post-HCT,
particularly  in  patients  with  sustained  molecular  response,  remains  to  be  determined.
Whether TKI incorporation in the treatment strategy would impact OS is still unclear. In
the  absence  of  large  prospective  randomized  trials  comparing  imatinib-chemotherapy
regimens  versus  allo-HCT as  a  consolidative  strategy,  allo-HCT remains  the  best  thera‐
peutic approach that offers a possibility of cure in Ph+ ALL [160].
There  is  increased interest  in  developing strategies  to  minimize toxicity  associated with
allogeneic HCT, especially after the results of the UK ALL XII ECOG 2993 study, which
showed a significant  TRM in patients  over the age of  35 years despite  better  control  of
disease  [150].  Several  groups  have  sought  to  minimize  morbidity  and  mortality  in  this
group of  patents  through reduced intensity  approaches,  allowing for  access  to  HCT for
majority  of  Ph+  ALL  subjects  [164].  Unfortunately,  there  is  no  prospective  trials  using
RIC  for  this  disease  published  in  the  literature.  Few  recent  retrospective  series  have
been  reported  with  2-year  OS  and  DFS  between  50  and  61.5%  [165].  We  previously
published our initial experience with FLU and BU in adult ALL patients, which showed
a 2-year  cumulative  incidence  of  relapse  of  19% (95% CI  8%-41%)  for  those  transplant‐
ed in  CR1 and 48% (29%-80%) in  those with more advanced disease,  with a  2-year  OS
of  54% (95% CI 39%-69%).  Relapse-free  survival  at  2  years  was 63% (95% CI 45%-81%)
for  patients  transplanted  in  CR1  and  34%  (95%  CI  11%-57%)  for  patients  transplanted
in  more  advanced disease.  We concluded that,  compared to  irradiation-containing  regi‐
mens,  FLU and PK-targeted BU appear safer  and similarly effective in controlling ALL,
providing a  treatment  option for  adult  patients  with ALL [166].  Nonmyeloablative allo‐
geneic  HCT  approach  is  promising  but  its  role  for  management  of  Ph+  ALL  requires
further investigations [154].
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6. Lymphoma
Both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) represent a large group
of diverse diseases. They are characterized by enlarged lymph nodes, splenomegaly, and
constitutional symptoms. These disorders can present with bone marrow and extramedullary
consequences. As a whole, they respond to combination chemotherapy. For patients who have
relapsed or are refractory to initial therapy autologous HCT is the treatment of choice. The
Parma group study, established the superiority of high-dose chemotherapy and autologous
HCT over conventional salvage chemotherapy in a randomized multi-center trial for relapsed
aggressive NHL [167]. Based on this study, autologous HCT became the standard of care for
chemotherapy-sensitive relapsed or primary refractory aggressive NHL. There are instances
where allogeneic HCT is the preferred approach for lymphoma.
6.1. Non-hodgkin lymphoma
6.1.1. Diffuse large B cell lymphoma (DLBCL)
The number of published studies using allogeneic HCT in DLBCL are limited and do not allow
definitive conclusions. Allogeneic HCT has generally been used as treatment for patients who
have relapsed after autologous HCT and on occasion for relapsed high-risk or refractory
disease. No prospective comparative studies are available in this setting. A retrospective study
by the CIBMTR compared the outcomes of DLBCL patients undergoing first autologous HCT
(n = 837) or HLA-identical MSD allogeneic HCT with myeloablative conditioning (n =79).
Allogeneic HCT was associated with higher TRM but with a similar risk of disease progression
compared with lower-risk patients who received autologus HCT. [168] The European Group
for Blood and Marrow Transplantation (EBMT) registry published a retrospective analysis of
101 patients. Approximately two-thirds of the patients received a reduced-intensity condi‐
tioning (RIC) regimen and 70% had an MSD. Non relapse mortality (NRM) was low with a
rate of 28.2%, a relapse rate of 30% and an OS rate of 53%. Patients with a long remission after
autologous HCT and with sensitive disease at allogeneic HCT appear to be the best candidates
for this approach. [169] Thus, the use of allogeneic transplantation should be reserved for
relapsed and refractory DLBCL that is responsive to the last line of therapy.
6.2. Follicular lymphoma (FL)
FL comprises approximately 25% of all newly diagnosed NHL cases. As an indolent lympho‐
ma, the disease course is one of remissions and relapses with chemotherapy, followed
inevitably by resistance and transformation to a more aggressive NHL histology. Trials from
the several European Groups compared consolidative autologous HCT to chemotherapy ±
interferon alfa (IFN-α) maintenance therapy or rituximab. [170-173] As autologous HCT
provides no benefit in OS in FL it is currently not recommended as consolidation therapy.
The graft-vs-lymphoma effect afforded by allogeneic HCT is appealing as a potential curative
approach in FL. Myeloablative conditioning allogeneic HCT, due to high TRM has not resulted
in an improved OS in this disease. [174, 175] RIC allogeneic HCT is associated with a lower
Current Approach to Allogeneic Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/53488
167
therapy with dasatinib in patients with Ph+ ALL and determined that 94% achieved CR with
an estimated 2-year survival of 64%. The combination of chemotherapy with dasatinib is
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Nilotinib has also been tested for the management of relapsed/refractory Ph+ ALL with
encouraging results[163].
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duce and/or maintain molecular responses to decrease relapse rate after allogeneic HCT.
Carpenter el al. reported safety data in 15 patients with Ph+ ALL who were enrolled in a
prospective  study and given imatinib  from the  time of  engraftment  until  day  265  after
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tion of  nilotinib between day 81 and day 365 after  HCT in patients  with Ph+ leukemia
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mens,  FLU and PK-targeted BU appear safer  and similarly effective in controlling ALL,
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6. Lymphoma
Both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) represent a large group
of diverse diseases. They are characterized by enlarged lymph nodes, splenomegaly, and
constitutional symptoms. These disorders can present with bone marrow and extramedullary
consequences. As a whole, they respond to combination chemotherapy. For patients who have
relapsed or are refractory to initial therapy autologous HCT is the treatment of choice. The
Parma group study, established the superiority of high-dose chemotherapy and autologous
HCT over conventional salvage chemotherapy in a randomized multi-center trial for relapsed
aggressive NHL [167]. Based on this study, autologous HCT became the standard of care for
chemotherapy-sensitive relapsed or primary refractory aggressive NHL. There are instances
where allogeneic HCT is the preferred approach for lymphoma.
6.1. Non-hodgkin lymphoma
6.1.1. Diffuse large B cell lymphoma (DLBCL)
The number of published studies using allogeneic HCT in DLBCL are limited and do not allow
definitive conclusions. Allogeneic HCT has generally been used as treatment for patients who
have relapsed after autologous HCT and on occasion for relapsed high-risk or refractory
disease. No prospective comparative studies are available in this setting. A retrospective study
by the CIBMTR compared the outcomes of DLBCL patients undergoing first autologous HCT
(n = 837) or HLA-identical MSD allogeneic HCT with myeloablative conditioning (n =79).
Allogeneic HCT was associated with higher TRM but with a similar risk of disease progression
compared with lower-risk patients who received autologus HCT. [168] The European Group
for Blood and Marrow Transplantation (EBMT) registry published a retrospective analysis of
101 patients. Approximately two-thirds of the patients received a reduced-intensity condi‐
tioning (RIC) regimen and 70% had an MSD. Non relapse mortality (NRM) was low with a
rate of 28.2%, a relapse rate of 30% and an OS rate of 53%. Patients with a long remission after
autologous HCT and with sensitive disease at allogeneic HCT appear to be the best candidates
for this approach. [169] Thus, the use of allogeneic transplantation should be reserved for
relapsed and refractory DLBCL that is responsive to the last line of therapy.
6.2. Follicular lymphoma (FL)
FL comprises approximately 25% of all newly diagnosed NHL cases. As an indolent lympho‐
ma, the disease course is one of remissions and relapses with chemotherapy, followed
inevitably by resistance and transformation to a more aggressive NHL histology. Trials from
the several European Groups compared consolidative autologous HCT to chemotherapy ±
interferon alfa (IFN-α) maintenance therapy or rituximab. [170-173] As autologous HCT
provides no benefit in OS in FL it is currently not recommended as consolidation therapy.
The graft-vs-lymphoma effect afforded by allogeneic HCT is appealing as a potential curative
approach in FL. Myeloablative conditioning allogeneic HCT, due to high TRM has not resulted
in an improved OS in this disease. [174, 175] RIC allogeneic HCT is associated with a lower
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TRM and the graft-vs-lymphoma effect may be beneficial in this indolent disease. Several
studies have been published using this approach. The MD Anderson BMT program published
results of their single institution trial of 43 patients with relapsed/refractory FL receiving a RIC
allogeneic HCT with high doses of rituximab during and after conditioning. The PFS and OS
rates were robust at 83% and 85%, respectively. [176] Currently, the BMT-CTN (0701) is
confirming these results in a multi-institution trial.
6.3. Mantle cell lymphoma (MCL)
MCL is an aggressive NHL that often is responsive to initial chemotherapy but has a very high
relapse rate and is incurable with conventional chemotherapy. With intensified induction
regimens and the addition of rituximab, a higher proportion of patients achieve complete
remission; however, long term cures are rare. [177] Autologous HCT provides very good
control of the disease particularly in patients who received transplants in CR1. [178, 179] The
Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted good outcomes for
patients in the good- and intermediate-risk. Unfortunately the poor-risk group had a disap‐
pointing survival, suggesting that these patients may be better suited for allogeneic HCT. [180]
To reduce toxicity and mortality in these heavily pretreated and older patients, RIC allogeneic
HCT has been proposed with promising results. Treatment with a nonmyeloablative condi‐
tioning regimen and allogeneic HCT in 33 patients with relapsed and refractory MCL resulted
in an OS rate of 65%. None of the patients transplanted in CR had relapsed after a median
follow-up of 2 years. [181] Long term follow upof RIC allogeneic HCT in 35 patients with
relapsed or refractory MCL demonstrated a low TRM rate and outcomes in which median OS
had not been reached. [182] Finally, The British Society for Blood and Marrow Transplantation
published the results of a retrospective analysis of 70 heavily pretreated patients with relapsed/
refractory MCL who received RIC allogeneic HCT with or without alemtuzumab with or
without DLI to boost the graft vs-lymphoma effect. The 3-year OS rate for patients who
received donor lymphocyte infusions for relapse was 79%. [183] All of these studies demon‐
strated a plateau on the survival curves. Based on these reports, allogeneic HCT appears to be
effective therapy for relapsed and refractory MCL and the only one associated with long-term
remission. It will be necessary to complete a prospective, randomized study to define the role
of upfront allogeneic HCT in MCL patients.
6.4. T-cell lymphoma
T-cell NHL (Peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell
lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)) are a heterogeneous group
of lymphomas which for the most part have an inferior prognosis when compared to B-cell
NHL after CHOP therapy. With the exception of anaplastic large-cell kinase-positive (ALK)
positive anaplastic large-cell lymphoma, T-cell NHL Carries a poor prognosis with low DFS
and OS with standard chemotherapy. Several studies have demonstrated the use of autologous
HCT in T-cell lymphoma has similar results to DLBCL. [184-189].
Innovations in Stem Cell Transplantation168
Allogeneic HCT has been proposed for the treatment of T-cell Lymphoma because of the
potential graft-vs-lymphoma effect. There are limited studies in this field but the results have
been promising. A retrospective analysis from France on 77 patients who underwent allogeneic
HCT for PTCL resulted in a 5-year OS rates of 57%. Myeloablative conditioning was used in
the majority of the patients. Patients with AITL had the best outcome, with a 5-year OS rate of
80%. Risk of relapse was low; however, the high TRM limited the benefit of the myeloablative
approach. [190] RIC allogeneic HCT was published a prospective phase II trial using a reduced
intensity regimen in 17 patients with PTCL. As expected TRM was low and the estimated 3-
year OS was 81%. [191] In summary, the use of RIC allogeneic HCT through a lower TRM and
allows transplant in older and heavily pretreated patients with reasonable OS. Certain T-cell
entities such as hepatosplenic T-cell lymphoma, adult T-cell leukemia/ lymphoma, and
systemic extranodal NK/T-cell lymphoma carry such a poor prognosis that allogeneic HCT is
justified as part of the initial treatment. The use of prognostic indexes such help identify
patients with extremely high risk of relapse who may also benefit from an allograft. Only
prospective multicenter trials will define the role of allogeneic HCT in these aggressive
lymphomas.
6.5. Hodgkin lymphoma
Combination chemotherapy with or without radiation therapy results in long-term DFS and
OS for about 80% of newly diagnosed patients with HL. [192] As in NHL autologous HCT is
well established for the treatment of disease. [193] An approach to minimize relapse after
autologous HCT for high-risk patients using the anti-CD30 antibody (brentuximab) conjugat‐
ed to an anti-tubulin drug (vedotin) [SGN-35][194] is currently being studied in a randomized
phase III placebo-controlled trial as maintenance therapy following autologous HCT.
Because of prior intensive therapy, RIC allogeneic HCT is an appropriate option in candidates
for patients with HL. [195-198] Recent retrospective analyses demonstrate improved PFS and
OS compared to additional salvage therapy for patients treated with this approach after relapse
following autologous HCT. [197, 199] More importantly, outcomes with MRD vs MUD do not
appear to be different. [196, 198]
7. Conditioning regimens
7.1. Myeloablative conditioning
Allogeneic bone marrow transplantation is the most intensive post-remission therapy used for
management of malignant disorders over the past decades. Toxicity of a conditioning regimen
can impact on overall morbidity, including interstitial pneumonitis, sinusoidal obstruction
syndrome/veno-occlusive disease, and may lead to an increased incidence of GVHD. Despite
current understanding of the transplantation process, the optimal chemotherapy and/or
radiation conditioning regimen remains unknown. Few data from comparative or randomized
studies are available to address this issue. Allogeneic hematopoietic cells serve a dual purpose,
not only to restore hematopoiesis but also to impose immunologic effects against malignant
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received donor lymphocyte infusions for relapse was 79%. [183] All of these studies demon‐
strated a plateau on the survival curves. Based on these reports, allogeneic HCT appears to be
effective therapy for relapsed and refractory MCL and the only one associated with long-term
remission. It will be necessary to complete a prospective, randomized study to define the role
of upfront allogeneic HCT in MCL patients.
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T-cell NHL (Peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell
lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)) are a heterogeneous group
of lymphomas which for the most part have an inferior prognosis when compared to B-cell
NHL after CHOP therapy. With the exception of anaplastic large-cell kinase-positive (ALK)
positive anaplastic large-cell lymphoma, T-cell NHL Carries a poor prognosis with low DFS
and OS with standard chemotherapy. Several studies have demonstrated the use of autologous
HCT in T-cell lymphoma has similar results to DLBCL. [184-189].
Innovations in Stem Cell Transplantation168
Allogeneic HCT has been proposed for the treatment of T-cell Lymphoma because of the
potential graft-vs-lymphoma effect. There are limited studies in this field but the results have
been promising. A retrospective analysis from France on 77 patients who underwent allogeneic
HCT for PTCL resulted in a 5-year OS rates of 57%. Myeloablative conditioning was used in
the majority of the patients. Patients with AITL had the best outcome, with a 5-year OS rate of
80%. Risk of relapse was low; however, the high TRM limited the benefit of the myeloablative
approach. [190] RIC allogeneic HCT was published a prospective phase II trial using a reduced
intensity regimen in 17 patients with PTCL. As expected TRM was low and the estimated 3-
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systemic extranodal NK/T-cell lymphoma carry such a poor prognosis that allogeneic HCT is
justified as part of the initial treatment. The use of prognostic indexes such help identify
patients with extremely high risk of relapse who may also benefit from an allograft. Only
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Combination chemotherapy with or without radiation therapy results in long-term DFS and
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well established for the treatment of disease. [193] An approach to minimize relapse after
autologous HCT for high-risk patients using the anti-CD30 antibody (brentuximab) conjugat‐
ed to an anti-tubulin drug (vedotin) [SGN-35][194] is currently being studied in a randomized
phase III placebo-controlled trial as maintenance therapy following autologous HCT.
Because of prior intensive therapy, RIC allogeneic HCT is an appropriate option in candidates
for patients with HL. [195-198] Recent retrospective analyses demonstrate improved PFS and
OS compared to additional salvage therapy for patients treated with this approach after relapse
following autologous HCT. [197, 199] More importantly, outcomes with MRD vs MUD do not
appear to be different. [196, 198]
7. Conditioning regimens
7.1. Myeloablative conditioning
Allogeneic bone marrow transplantation is the most intensive post-remission therapy used for
management of malignant disorders over the past decades. Toxicity of a conditioning regimen
can impact on overall morbidity, including interstitial pneumonitis, sinusoidal obstruction
syndrome/veno-occlusive disease, and may lead to an increased incidence of GVHD. Despite
current understanding of the transplantation process, the optimal chemotherapy and/or
radiation conditioning regimen remains unknown. Few data from comparative or randomized
studies are available to address this issue. Allogeneic hematopoietic cells serve a dual purpose,
not only to restore hematopoiesis but also to impose immunologic effects against malignant
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clones, a process known as graft versus leukemia. This has led to the development of a
conditioning regimen that will minimize toxicity with preservation of graft versus leukemia
effect as the main mechanism of action to eradicate disease.
The spectrum of conditioning intensity has been defined in three categories: 1) myeloablative,
which causes irreversible marrow aplasia if transplantation is not performed; 2) nonmyeloa‐
blative, which cause minimal marrow suppression; and 3) RIC, which causes cytopenias of
intermediate duration [200]. Assignment to these categories is based on the duration of
cytopenia and on the requirement for stem cell support. Myeloablative regimens cause
irreversible cytopenia, and stem cell support is mandatory. Nonmyeloablative regimens cause
minimal cytopenia and can be given also without stem cell support. RIC causes cytopenias of
variable duration and should be given with stem cell support, although cytopenia may not be
irreversible. Compared with high-dose MA preparative regimens, NMA or RIC regimens are
associated with shorter inpatient hospital stays, reduced need for transfusions [201], and a
shorter duration of neutropenia with fewer bacterial infections [202-204]. There is current trend
to adopt less-toxic conditioning regimens to allow access for patients to undergo HCT who
has been previously been excluded because of age or comorbidities. Standardized classification
of conditioning regimen intensities will allow comparisons across studies and interpretation
of study results [200].
Myeloablative regimens, a combination of agents expected to produce profound pancytopenia
and myeloablation within 1-3 weeks from administration, have caused pancytopenia that is
long lasting, usually irreversible, and in most instances fatal, unless hematopoiesis is restored
by hemopoietic stem cell infusion [200]. Early use of this approached invested on the theory
of dose intensity to eradicate disease. [205]. The two most commonly used myeloablative
conditioning regimens for allografts for leukemia/lymphoma use a combination of high-dose
busulfan combined with cyclophosphamide and cyclophosphamide in combination with TBI.
The Cyclophosphamide-TBI regimen uses a cyclophosphamide dose of 120 mg/kg and 10–15
Gy TBI [23] and busulfan-cyclophosphamide uses a busulfan dose of 16 mg/kg orally and Cy
120 mg/kg [206]. From the available data, there are no significant differences in survival with
these two regimens. There is also no evidence that intensified conditioning improves survival,
as a higher dose of TBI is associated with increased toxicity [205]. Cyclophosphamide or TBI
has also been tested in addition to other chemotherapy agents like melphalan, thiotepa,
etoposide, and dimethylbusulfan. The problem with myeloablative conditioning is the high
TRM that ultimately jeopardizes overall success. The risk of TRM after a myeloablative
regimen has decreased over time, attributed to improved HLA-typing and better supportive
care [207]. Neither regimen explored in the myeloablative setting is suitable for all the
situations and a particular regimen should be selected depending on the clinical situations if
myeloablative approaches are still an option nowadays [208] with the introduction of less toxic
transplantation approaches.
Several  attempts  have been made in the past  30 years  to  limit  early transplant  toxicity,
by  reducing  the  intensity  of  the  conditioning  regimen  as  previously  reviewed  [200].
Within  the  past  20  years,  the  introduction  of  fludarabine  (Flu)  [209,  210]  and  further
dose  reductions  of  alkylating  agents  [211,  212]  or  TBI  has  led  to  minimized  toxicity.
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These regimens were  designed to  allow access  to  HCT for  older  patients  or  because  of
comorbidities  that  would  preclude  HCT.  Enthusiasm  in  the  transplant  community  has
led to adoption of these reduced toxicity modalities [213].  A workshop convened by the
CIBMTR addressed the dose spectrum, which defines a RIC regimen [214]. A total of 56
participants were surveyed, and 67% agreed that a RIC regimen should cause reversible
myelosuppression when administered without stem cell support, result in low nonhema‐
tologic  toxicity,  and,  after  transplantation,  result  in  mixed donor–recipient  chimerism at
the  time  of  first  assessment  in  most  patients.  Likewise,  the  majority  (71%)  agreed  or
strongly agreed that regimens including <500 cGy of TBI as a single fraction or 800 cGy
in fractionated doses, busulfan dose <9 mg/kg, melphalan dose <140 mg/m2, and thiotepa
dose  <  10  mg/kg  should  be  considered  RIC  regimens.  However,  only  32%  agreed  or
strongly  agreed that  the  combination of  carmustine,  etoposide,  cytarabine,  and melpha‐
lan  (BEAM)  should  be  considered  a  RIC  regimen.  These  results  demonstrate  that,  al‐
though  HCT  professionals  have  not  reached  a  consensus  on  what  constitutes  a  RIC
regimen, most accept currently used criteria and operational definitions [214].
RIC is an intermediate category of regimens that causes pancytopenia and requires stem cell
support if prolonged and autologous recovery is possible. An improved rate of toxicity is
achieved by reducing the dose of alkylating agents or TBI by at least 30%. Most often, these
regimens combine Flu with an alkylating agent, melphalan [215],Bu [211],thiotepa[212] in
reduced doses, or Flu with reduced-dose TBI [216]. Decreased TRM has been successfully
achieved with this approach [217, 218] Among the published phase II trials, leukemia relapse
remained consistently the main cause of treatment failure after RIC or nonmyeloablative
conditioning, with 2- to 4-year relapse rates ranging from 30% to 61%. Mohty et al.recently
updated results of the first prospective trial directly comparing RIC allogeneic HCT versus
consolidation chemotherapy in patients with AML using “genetic allocation.” In an intent-to-
treat analysis, leukemia-free survival was superior in the donor group (60% versus 23% at 7
years; P =.003) but with a significant relapse risk [219]. Recent retrospective analysis demon‐
strated that RIC has similar outcomes to MAC in patients with AML or MDS. [217, 220] Because
of prior therapy and older age, as described above in the Lymphoma section RIC allogeneic
HCT is appropriate for most those patients. Allogeneic transplantation has evolved signifi‐
cantly in the last 40 plus years of use as stem cell therapy. To further improve its outcomes
patients should be selected early and the appropriate regimen should be used to optimize the
anti-malignancy effect.
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updated results of the first prospective trial directly comparing RIC allogeneic HCT versus
consolidation chemotherapy in patients with AML using “genetic allocation.” In an intent-to-
treat analysis, leukemia-free survival was superior in the donor group (60% versus 23% at 7
years; P =.003) but with a significant relapse risk [219]. Recent retrospective analysis demon‐
strated that RIC has similar outcomes to MAC in patients with AML or MDS. [217, 220] Because
of prior therapy and older age, as described above in the Lymphoma section RIC allogeneic
HCT is appropriate for most those patients. Allogeneic transplantation has evolved signifi‐
cantly in the last 40 plus years of use as stem cell therapy. To further improve its outcomes
patients should be selected early and the appropriate regimen should be used to optimize the
anti-malignancy effect.
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1. Introduction
The treatment paradigm for multiple myeloma has evolved considerably over the past three
decades with the incorporation of autologous stem cell transplantation (ASCT) in upfront
therapy for eligible patients, and the use of novel agents. As a result, although multiple
myeloma remains an incurable disease, clinical outcomes have significantly improved. In
this chapter we will review the seminal studies that established the role of ASCT in multiple
myeloma and as well as the current controversies with regard to the role of ASCT in the
management of myeloma in the era of novel agents. We will review conditioning regimens,
post-transplant maintenance strategies with novel agents and immune modulation. We will
summarize the current data on early versus late ASCT, single versus tandem transplant and
the role of ASCT in patients with relapsed or progressive disease.
2. The role of autologous stem cell transplantation in multiple myeloma
The advent of autologous stem cell transplantation has changed the therapeutic landscape
for the management of multiple myeloma and has been the standard frontline therapy for
younger patients with normal renal function since the 1990’s. The standard of care for multi‐
ple myeloma patients prior to the incorporation of ASCT was conventional chemotherapy
using melphalan and prednisone with the primary goals of treatment being achievement of
partial response or disease stabilization. Treatment complications and later resistance were
associated with poor outcomes with median overall survival ranged between two and three
years.
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decades with the incorporation of autologous stem cell transplantation (ASCT) in upfront
therapy for eligible patients, and the use of novel agents. As a result, although multiple
myeloma remains an incurable disease, clinical outcomes have significantly improved. In
this chapter we will review the seminal studies that established the role of ASCT in multiple
myeloma and as well as the current controversies with regard to the role of ASCT in the
management of myeloma in the era of novel agents. We will review conditioning regimens,
post-transplant maintenance strategies with novel agents and immune modulation. We will
summarize the current data on early versus late ASCT, single versus tandem transplant and
the role of ASCT in patients with relapsed or progressive disease.
2. The role of autologous stem cell transplantation in multiple myeloma
The advent of autologous stem cell transplantation has changed the therapeutic landscape
for the management of multiple myeloma and has been the standard frontline therapy for
younger patients with normal renal function since the 1990’s. The standard of care for multi‐
ple myeloma patients prior to the incorporation of ASCT was conventional chemotherapy
using melphalan and prednisone with the primary goals of treatment being achievement of
partial response or disease stabilization. Treatment complications and later resistance were
associated with poor outcomes with median overall survival ranged between two and three
years.
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High-dose chemotherapy was initially explored as a therapeutic approach in the 1980’s after
a landmark study demonstrated its effectiveness in inducing 100-percent complete remis‐
sion rates in nine high-risk multiple myeloma and plasma cell leukemia patients after pre‐
conditioning with high-dose melphalan. The observation that high-dose melphalan had
significant anti-tumor activity and could overcome primary drug resistance was confirmed
in a later study.
Since its initial description, there have been seven randomized clinical trials comparing
high-dose ASCT to conventional chemotherapy (Table 1). The first of these trials was con‐
ducted by the Intergroupe Français du Myélome (IFM) in which 200 untreated multiple
myeloma patients under 65 years of age were randomized to receive either conventional
chemotherapy or high dose chemotherapy in combination with ASCT. Response rates were
significantly higher in patients receiving high-dose chemotherapy and ASCT compared to
those who received conventional chemotherapy alone (81% vs 57%, p<0.001). Furthermore,
patients who received high-dose therapy had a higher probability of 5-year event-free sur‐
vival (28% vs 10%, p = 0.01) and estimated 5-year rate of overall survival (52% vs 12%, p
=0.03). Seven years later, the findings from the IFM study were corroborated by the British
Medical Research Council Myeloma VII Trial (MRCM-VII) in a larger 407 patient multicen‐
ter study.
These findings prompted modifications to the disease response criteria as proposed by the
International Myeloma Working Group as the achievement of complete responses (CRs),
which were rare using conventional chemotherapy, became more achievable and, most im‐
portantly, were found to correlate with survival endpoints.
An additional five prospective randomized trials comparing ASCT to conventional chemo‐
therapy followed. Most, but not all, demonstrated superiority of ASCT to conventional che‐
motherapy with respect to higher rates of CR and very good partial responses (VGPR)
which ultimately translated into longer progression-free survival (PFS). An overall survival
(OS) benefit was reported in three of the seven studies [5,6,12]. Differences in methodology
and trial design between studies may account for some of the discordance in results. A sys‐
tematic review and meta-analysis of these randomized trials reported improved overall me‐
dian PFS with no significant improvement in OS following ASCT when compared to
conventional chemotherapy .
In summary, high dose chemotherapy and ASCT has markedly improved the depth of re‐
sponse, overall response rates, and length of progression-free survival in multiple myeloma
patients. Most importantly, ASCT has improved overall survival from a median of 36
months to 50-55 months, thereby establishing it as the standard of care for multiple myelo‐
ma patients under the age of 65 with normal renal function. However, there remains consid‐
erable heterogeneity between myeloma patients with regard to underlying disease
characteristics and post-ASCT clinical responses. A number of prognostic markers have
been identified that influence disease response to chemotherapy, ASCT and survival, specif‐
ically age, elevated β-2-microglobulin levels, LDH and serum free light chain ratio. Addi‐
tionally, the recognition of recurrent chromosomal abnormalities, which have been reported
in as many as 90% of patients has allowed myeloma patients to be categorized into low, in‐
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termediate and high risk groups on the basis of these aberrations. Translocation (4;14),
t(14;20), deletion 17p and gain of 1q have been well associated with poor disease responses
and negatively impact overall survival. A recent update from the IFM group have demon‐
strated a 75% 8-year survival rate in patients who did not have these chromosomal abnor‐
















IFM, (1996) 200 <65 7 years
ORR: 57 vs 81
18 vs 28 44 vs 57CR: 5 vs 22
VGPR: 9 vs 16
MAG91 (1998) 185 55-65 58 mos
ORR: 62 vs 86
19 vs 24 50 vs 55
CR: 5 vs 19
BMRC VII, (2003) 407 <65 42 mos
ORR: 67 vs 90
19 vs 31 42 vs 54CR: 8 vs 44
PR: 40 vs 42
Italian MMSG
M97G(2004)
194 50-70 39 mos
ORR: 42 vs 73
15.6 vs 28 42 vs 58+
nCR: 6 vs 25
MAG95 (2005) 190 55-65 120 mos
ORR: 77 vs 70
19 vs 31 42 vs 54
CR +MRD: 20 vs 36
PR: 38.5 vs 26
MR: 18 vs 7
PETHEMA, (2005) 164 <65 44 mos CR: 11 vs 30 33 vs 42 66 vs 61
US Intergroup
9321 (2006)
516 ≤70 76 mos CR: 15 vs 17 14% vs 17%** 38% vs 38%**
Abbreviations: IFM:,Intergroupe Français du Myélome, MAG: Myélome Autogreffe, BMRC: British Medical Research
Council, MMSG: Multiple Myeloma Study Group, PETHEMA: Programa para el Estudio de la Terapéutica en Hemaopa‐
tia Maligna, ORR: Overall response rate, CR: Complete remission, nCR: Near complete remission, VGPR: Very good par‐
tial response, PR: Partial response, MRD: Minimal residual disease, MR: Minimal response
** 7-year estimated EFS and OS rate
Table 1. Randomized trials comparing ASCT to conventional chemotherapy (CCT)
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While clinical outcomes have improved significantly since the widespread implementation
of ASCT, there are several unanswered questions relating to the use of ASCT in multiple
myeloma, particularly in the era of novel therapies, which remain as areas of active investi‐
gation. However, before these controversies can be fully addressed, it is important to under‐
stand the role of novel agents and their impact on myeloma management before discussing
their current use in the context of ASCT.
3. Immune modulation and the advent of novel agents
The concept of immune modulation was formulated and developed after a greater under‐
standing of the complex interaction between myeloma cells and their microenvironment as
well as the discovery that myeloma cells, through a variety of mechanisms, are inherently
able to evade host natural immune defenses, thereby potentiating their own survival. The
immune dysregulation that is known to accompany multiple myeloma is believed to be the
result of multiple biological pathways and mechanisms including excess production of mye‐
loma–derived cytokines, inadequate antigen presentation, resistance to NK-cell lysis and im‐
paired activity of B, T and NK cells. Additionally, multiple myeloma is also associated with
defective humoral and cellular immunity leading to abnormal B-cell differentiation and
function. Reduced numbers of CD4+ T cells, abnormal Th1/Th2 CD4+ T-cell ratios, impaired
cytotoxic T-cell responses, dysfunction of NK and NK T-cells and abnormal dendritic cell
function further compound the immune dysfunction associated with multiple myeloma.
The immunomodulatory drugs (IMiDs), lenalidomide and pomalidomide are thalidomide
analogs that were specifically developed in response to the resurgence of interest in thalido‐
mide after it was incidentally discovered to be an effective treatment in patients with cuta‐
neous leprosy presumably through inhibition of TNFα. Subsequent preclinical trials
revealed that thalidomide, in fact, had several favorable properties that would optimize its
use as an anti-cancer agent.
The IMiDs, were created with the intent to maximize the pleiotropic activity directed against
myeloma cells that was demonstrated by thalidomide, and, in fact are 50,000 times more po‐
tent than thalidomide in their immunomodulatory properties, including CD4+ and CD8+ T-
cell costimulation, Th1 cytokine production, NK and NK T-cell activation, and antibody-
dependent cellular cytotoxicity. Furthermore, they also disrupt the interaction between
myeloma cells and the tumor microenvironment through potent inhibition of angiogenesis
and downregulation of inflammatory cytokines, specifically TNFα, from peripheral blood
mononuclear cells. The IMiDs also directly exert anti-tumor proliferation effects. Additional‐
ly the IMiDs are more capable of stimulating T-cells with without incurring the same degree
of toxicity as thalidomide. The manipulation of the immune system by IMiDs has establish‐
ed their efficacy in the management of multiple myeloma. Lenalidomide and thalidomide,
in addition to the proteasome inhibitor, bortezomib, are considered the main novel agents,
and, in light of their significant disease activity, are now routinely integrated into multiple
myeloma management in ASCT eligible and ineligible patients.
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4. The impact of novel agents on induction and stem cell mobilization
Prior to the widespread use and incorporation of novel agents, the standard induction regi‐
men was vincristine, doxorubicin and dexamethasone (VAD). Dexamethasone was the most
active drug in this regimen and has long since remained the cornerstone of upfront treat‐
ment for multiple myeloma,. The investigation and incorporation of novel agents into induc‐
tion chemotherapy regimens was prompted by the discovery that the quality of disease
response following induction therapy, preceding ASCT, corresponded to better clinical out‐
comes, including subsequent response to ASCT, PFS and OS. Novel agents were initially in‐
vestigated to determine whether the rates of these responses could be improved. Table 3
summarizes the results of published studies using novel agents as part of induction therapy
prior to ASCT.
Thalidomide-based induction regimens were initially compared to VAD and were found to
produce higher VGPR, but not CR, rates prior to transplant.. However, the increased inci‐
dence of thromboembolic complications and drug toxicity rendered the overall benefit of
thalidomide containing regimens somewhat modest. A 10-year clinical follow-up study of
169 myeloma with advanced or refractory disease who were initially treated with thalido‐
mide demonstrated remarkably improved event-free survival and OS in patients with nor‐
mal cytogenetics and non-lambda light chain isotype.
Lenalidomide  and  high-dose  dexamethasone  (RD)  was  compared  to  lenalidomide  and
low-dose  dexamethasone (Rd)  as  initial  therapy in  transplant  eligible  and ineligible  pa‐
tients  and,  while  improved response rates (≥  VGPR) were significantly improved in pa‐
tients  receiving RD,  increased toxicities  and mortality  were also  more pronounced with
this  regimen,  especially  in  patients  older  than  65  years  of  age.  Furthermore,  ASCT  in
combination with RD or Rd improved 3-year OS rates compared to patients who did not
undergo ASCT [92% vs  79%].  Three  drug-combinations  using  lenalidomide,  bortezomib
and dexamethasone  (RVD)  have  also  been  investigated  in  a  few phase  I/II  studies  and
have shown even greater improvements in response rates pre and post-transplant.
The proteasome inhibitor, bortezomib, in combination with dexamethasone was initially
discovered to significantly improve near complete remission (nCR) and CR rates in the land‐
mark IFM2005-1 trial when it was compared to VAD, VAD and dexamethasone, cyclophos‐
phamide, etoposide and cisplatin (DCEP) consolidation, and bortezomib and
dexamethasone followed by DCEP consolidation followed by ASCT. Bortezomib-containing
regimens resulted in higher CR/nCR rates irrespective of disease stage or cytogenetic risk.
Post-transplant, these improved response rates were associated with improved CR, nCR and
VGPR rates as well as improved PFS after a median follow-up of 32 months compared to
patients treated with VAD alone (36 mos vs 30 mos). In the VISTA trial, the addition of bor‐
tezomib to melphalan and prednisone also produced longer OS, and was not found to incur
more resistant relapses in a long term follow-up study. The IFM 2005-1 and VISTA trials
were critical in establishing the role of bortezomib in induction therapy for myeloma. To
further improve the depth of disease response several phase II and III clinical trials have
evaluated the efficacy of adding a third novel agent, either lenalidomide or thalidomide, to
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analogs that were specifically developed in response to the resurgence of interest in thalido‐
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have shown even greater improvements in response rates pre and post-transplant.
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discovered to significantly improve near complete remission (nCR) and CR rates in the land‐
mark IFM2005-1 trial when it was compared to VAD, VAD and dexamethasone, cyclophos‐
phamide, etoposide and cisplatin (DCEP) consolidation, and bortezomib and
dexamethasone followed by DCEP consolidation followed by ASCT. Bortezomib-containing
regimens resulted in higher CR/nCR rates irrespective of disease stage or cytogenetic risk.
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VGPR rates as well as improved PFS after a median follow-up of 32 months compared to
patients treated with VAD alone (36 mos vs 30 mos). In the VISTA trial, the addition of bor‐
tezomib to melphalan and prednisone also produced longer OS, and was not found to incur
more resistant relapses in a long term follow-up study. The IFM 2005-1 and VISTA trials
were critical in establishing the role of bortezomib in induction therapy for myeloma. To
further improve the depth of disease response several phase II and III clinical trials have
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the bortezomib and dexamethasone backbone, and have demonstrated improved responses
following the addition of a third agent.
Although novel agents have vastly improved the quality of disease response as well as over‐
all response rates in the pre- and post-transplant settings, the use of these agents as part of
induction therapy has resulted in greater difficulties with stem cell collection prior to autolo‐
gous transplant, particularly with the use of lenalidomide and, to a lesser extent, bortezomib
although the exact mechanisms by which stem cell collection is hindered has not yet been
fully elucidated. To address this issue, the International Myeloma Working Group has rec‐
ommended early stem cell mobilization, following 3-4 cycles of induction therapy. Mobiliza‐
tion using G-CSF alone or in combination with cyclophosphamide is typically considered
adequate; and while a large multi-center randomized phase III trial demonstrated a signifi‐
cant improvement in the number of CD34+ cells/kg collected in patients receiving G-CSF
and the CXCR4 inhibitor, plerixafor (AMD3100) compared to G-CSF and placebo, the rou‐
tine use of plerixafor upfront for mobilization remains controversial.
5. The importance of pre-transplant disease response
Complete remissions in the pre-ASCT era were rare, but have now become a very attainable
and desirable treatment goal in the pre and post-transplant settings, especially as they are
considered to be strong surrogate markers for progression-free and survival overall survival
in several studies. The prognostic impact of CR was not fully appreciated until ASCT was
adopted as frontline therapy in the management of multiple myeloma, and this is reflected
in the International Myeloma Working Group response criteria by the introduction of strin‐
gent CRs to further qualify the depth of response [Table 2]. Furthermore, the duration of CR
is also described as a favorable prognostic variable ; however, in several patient subgroups,
including those with a prior history of monoclonal gammopathy of undetermined signifi‐
cance and smoldering myeloma or with low-risk disease achievement of CR appears to be of
less importance.
sCR: Meets criteria for CR plus normal FLC ratio and no clonal cells bone marrow IHC or immunofluorescence
CR: Absence of M protein in serum and urine by immunofixation, < 5% bone marrow plasma cells, no increase of lytic
bone lesions, disappearance of soft tissue plasmacytomas
VGPR: Serum and urine M protein detectable by immunofixation but not on electrophoresis OR ≤ 90% reduction in
serum M-protein plus urine M-protein <100mg/24hr
Abbreviations: IMWG: International Myeloma Working Group, sCR: stringent complete remission, CR: Complete Re‐
mission, VGPR: Very Good Partial Response, FLC: Free Light Chains, IHC: Immunohistochemistry
Table 2. IMWG Complete Response Criteria (Durie et al, Leukemia 2006)














Rajkumar, 2006 207 TD vs Dex 207 CR: 4 vs 0
≥ VGPR: ---





Lokhorst, 2010 536 VAD vs TAD 52 mos CR: 2 vs 3
≥ VGPR: 18 vs 37
≥ PR: 57 vs 71
CR: 12 vs 14
≥ VGPR: 44 vs 54
≥ PR: 76 vs 84
22 vs 34 mos 60 vs 73 mos
Harousseau,
2010
482 VAD vs VD 31.2 mos CR/nCR: 6.4 vs
14.8
≥ VGPR: 15.1 vs
37.7
≥ PR: 62.8 vs 72.5
CR/nCR: 18.4 vs
35
≥ VGPR: 37.2 vs
54.3






Cavo, 2010 480 VTD vs TD 36 mos CR/nCR: 31 vs 11
≥ VGPR: 62 vs 28
≥ PR: 93 vs 79
CR/nCR: 55 vs 41
≥ VGPR: 82 vs 64





Rajkumar, 2010 445 RD vs Rd 35.8 mos CR: 5 vs 4
≥ VGPR: 71vs 26




19 vs 25 mos 2yr OS 87%
vs 75%
Moreau, 2011 199 VD vs vtD 32 mos CR: 22 vs 31
≥ VGPR: 36 vs 49
≥ PR: 81 vs 88
CR: 52 vs 61
≥ VGPR: 58 vs 74
≥ PR: 86 vs 89
30 vs 26 mos ---
Rosinol, 2012 386 VTD vs TD vs
VBMCP/
VBAD/B
35.2 mos CR: 35 vs 14 vs 21
≥ VGPR: 25 vs 15
vs 15
≥ PR: 25 vs 33 vs
39










833 VAD vs PAD 41 mos CR/nCR: 15 vs 11
≥ VGPR: 14 vs 42
≥ PR: 54 vs 78
CR/nCR: 15 vs 31
≥ VGPR: 36 vs 62
≥ PR: 75 vs 88
28 vs 35 mos 5 yr OS, 55%
vs 65%
Abbreviations: TD: Thalidomide and Dexamethasone,Dex: Dexamethasone VAD: Vincristine, Adriamycin and Dexame‐
thasone, TAD: Thalidomide, Adriamycin and Dexamethasone, VD: Bortezomib and Dexamethasone, VTD: Bortezomib,
Thalidomide and Dexamethasone, RD: Lenalidomide and high-dose dexamethasone, Rd: Lenalidomide and low-dose
dexamethasone, PAD: Bortezomib, Adriamycin and Dexamethasone, vtD: reduced dose bortezomib, thalidomide and
Dexamethasone
Table 3. Published phase III studies using novel agents as part of induction therapy prior to ASCT
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the bortezomib and dexamethasone backbone, and have demonstrated improved responses
following the addition of a third agent.
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all response rates in the pre- and post-transplant settings, the use of these agents as part of
induction therapy has resulted in greater difficulties with stem cell collection prior to autolo‐
gous transplant, particularly with the use of lenalidomide and, to a lesser extent, bortezomib
although the exact mechanisms by which stem cell collection is hindered has not yet been
fully elucidated. To address this issue, the International Myeloma Working Group has rec‐
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tion using G-CSF alone or in combination with cyclophosphamide is typically considered
adequate; and while a large multi-center randomized phase III trial demonstrated a signifi‐
cant improvement in the number of CD34+ cells/kg collected in patients receiving G-CSF
and the CXCR4 inhibitor, plerixafor (AMD3100) compared to G-CSF and placebo, the rou‐
tine use of plerixafor upfront for mobilization remains controversial.
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Complete remissions in the pre-ASCT era were rare, but have now become a very attainable
and desirable treatment goal in the pre and post-transplant settings, especially as they are
considered to be strong surrogate markers for progression-free and survival overall survival
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bone lesions, disappearance of soft tissue plasmacytomas
VGPR: Serum and urine M protein detectable by immunofixation but not on electrophoresis OR ≤ 90% reduction in
serum M-protein plus urine M-protein <100mg/24hr
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Table 2. IMWG Complete Response Criteria (Durie et al, Leukemia 2006)














Rajkumar, 2006 207 TD vs Dex 207 CR: 4 vs 0
≥ VGPR: ---





Lokhorst, 2010 536 VAD vs TAD 52 mos CR: 2 vs 3
≥ VGPR: 18 vs 37
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Abbreviations: TD: Thalidomide and Dexamethasone,Dex: Dexamethasone VAD: Vincristine, Adriamycin and Dexame‐
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Table 3. Published phase III studies using novel agents as part of induction therapy prior to ASCT
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6. Early versus late transplant
Only one randomized trial has compared upfront ASCT to late ASCT at the time of relapse.
Upfront ASCT improved event-free survival and quality of life compared to patients treated
with conventional chemotherapy and who underwent ASCT as rescue treatment at the time
of relapse; interestingly there was no appreciable difference in 5-year overall survival be‐
tween the arms . However, in the era of novel agents and resultant improvements in com‐
plete remission rates, the question as to whether ASCT could potentially be delayed until
disease relapse or progression has, again, resurfaced. The International Myeloma Working
Group recommends that all eligible patients be offered ASCT at some point in their disease
course and while there are no published randomized phase III trials incorporating the use of
novel agents in induction therapy to support the use of ASCT upon disease relapse, many
clinicians opt to collect stem cells early and preserve them for use following disease relapse.
We believe that upfront ASCT should be the standard of care until ongoing trials establish
that delayed ASCT after novel agents has a role.
7. Single ASCT versus tandem transplant
Tandem ASCT, as part of a more intensified treatment strategy (“total therapy”) was initial‐
ly shown to improve CR rates, EFS and OS in comparison to standard therapy. The superi‐
ority of double ASCT was later appreciated in a landmark randomized clinical trial which
demonstrated significantly improved OS, particularly in patients who had not achieved
VGPR following transplant. Several other randomized trials have also attempted to compare
single versus double ASCT and have reported conflicting results regarding the superiority
of one approach over the other. A recent meta-analysis attempted to answer this question
and concluded that tandem transplant offered no benefit in terms of disease outcomes and
was, in fact, associated with greater morbidity; however, this analysis has received criticism
due to the heterogeneity of the selected studies which were evaluated as well as variability
in treatment methodology. A more recent analysis suggests that tandem ASCT does offer a
survival benefit. Most clinicians speculate that tandem and single transplants are equivocal,
however, there have been no definitive trials evaluating this issue and it remains an area of
considerable debate.
8. Methods to improve conditioning regimens: The addition of total body
irradiation or other agents to high-dose melphalan
The quality of disease response following pre-transplant conditioning is critical to the suc‐
cess of ASCT. High dose melphalan 200mg/m2 is the standard conditioning chemotherapy
regimen prior to autologous HSCT in multiple myeloma as this approach has demonstrated
superior overall survival rates in comparison to chemotherapy alone. Various approaches to
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improve responses to this conditioning regimen while minimizing toxicities have been eval‐
uated in a number of studies.
Total body irradiation (TBI) in combination with melphalan demonstrated improved CR
rates, relapse and progression rates and five year OS rates when compared to TBI and cyclo‐
phosphamide as a myeloablative conditioning regimen in myeloma patients undergoing al‐
logeneic HSCT. A landmark study, however, in which melphalan and TBI was compared
with high-dose melphalan 200mg/m2 demonstrated more rapid hematologic recovery, re‐
duced transfusion requirements, shorter hospitalization and improved survival in patients
receiving high-dose melphalan alone. As such, the routine use of TBI in conjunction with
melphalan is not widely used.
The alkylating agent, busulfan, has been used in several studies in combination melpha‐
lan with promising outcomes,  particularly  in patients  with non-remission disease at  the
time of transplant.  A recent analysis of multiple myeloma patients treated with oral bu‐
sulfan and melphalan 140mg/m2 compared to standard melphalan 200mg/m2 did demon‐
strate  improved  median  PFS  (41  mos  vs  31  mos,  p=0.009),  however,  the  increased
incidence  of  veno-occlusive  disease  and  transplant  related  mortality  counteracted  the
benefits; additionally, patients who received busulfan had less access to salvage therapies
using novel agents than patients who had relapsed following treatment with melphalan
200mg/m2.
The  Intergroupe  Francophone  du  Myelome  study  group  also  evaluated  the  efficacy  of
adding bortezomib to high-dose melphalan in a recent phase II  study and were able to
demonstrate, that, in comparison to historical controls, patients treated with the bortezo‐
mib and melphalan achieved higher  CR rates  (35% vs 11%, p=.001)  with no increase in
hematologic toxicity.
9. Novel agents as post-transplant maintenance therapy
Maintenance with interferon, steroids, and chemotherapy has been tried in many centers
for  over  30  years  with  no  clear  benefit.  Maintenance  interferon  frequently  resulted  in
worsened quality  of  life;  furthermore,  future  development  of  therapy-related myelodys‐
plastic syndrome following chemotherapy led to these maintenance treatments to fall out
of favor. The availability of novel agents and their tolerable toxicity profiles has renewed
interest in post-transplant maintenance treatment. The results of this approach have, thus
far,  been  encouraging,  including  upgrades  in  disease  responses  and  improvements  in
PFS/EFS, and OS in many studies; however, none of these agents are currently approved
in the post-transplant  setting.  The recently released consensus statement from the Inter‐
national Myeloma Working Group does not advocate for or against maintenance therapy
and recommends that the decision to use maintenance therapy be made on an individu‐
alized basis. In the following paragraph we will review various agents with a brief sum‐
mary of the randomized trials data.
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Thalidomide maintenance therapy following ASCT has been evaluated in six randomized
clinical  trials  all  of  which  have  reported  a  significant  improvement  in  progression  free
survival  in  patients  receiving  thalidomide  maintenance  versus  the  comparator  arm,  but
only  3  had  shown  improvement  in  OS  by  6-9  months.  Two  meta-analyses  have  con‐
firmed  improved  OS  with  thalidomide  maintenance.  However,  most  patients  (>  50%)
eventually discontinued thalidomide, between 7 months and 2 years of treatment, due to
side  effects,  particularly  development  of  peripheral  neuropathy.  Interestingly,  thalido‐
mide maintenance does not benefit patients with poor-risk cytogenetics, and, in fact, this
patient  subset  was  shown to  have  a  shorter  survival  duration.  Similar  results  from the
Total Therapy 2 study were reported although a longer follow up showed improvement
in long-term survival in high risk disease, although the main impact was most apprecia‐
ble in patients with favorable cytogenetics.
9.2. Lenalidomide
Lenalidomide has a favorable toxicity profile,  and its  efficacy extends beyond inhibition
of the growth of myeloma cells as the drug also causes alterations within the bone mar‐
row microenvironment leading to an enhancement of immune responses, thereby making
it an ideal drug for post-transplant maintenance. Two very recently published trials from
the Cancer and Leukemia Group B (CALGB) and IFM evaluated the efficacy of lenalido‐
mide following transplant and demonstrated that lenalidomide maintenance therapy was
associated with a significant improvement in PFS compared to placebo (48 vs 30.9 mos,
and 41 vs 24 mos in the CALGB and IFM studies, respectively). The benefits of lenalido‐
mide  maintenance  were  appreciated  across  all  patient  subgroups,  including  those  with
high-risk cytogenetics,  although the data is limited to a small number pf patients in the
IFM study, β2-microglobulin and response following transplant. In the IFM-2005-02 trial,
patients were given two courses of lenalidomide as consolidation treatment which led to
an upgrade in the number of disease response with rates of CR increasing from 14% to
20%  and  responses  higher  than  or  equal  to  VGPR  from  58%  to  67%.  The  side  effects
were tolerable, mostly hematologic, and responded well to dose adjustments, supportive
growth  factor  injections  and  transfusion  support.  A  meta-analysis  by  the  International
Myeloma Working Group,  which included a  total  of  1380 patients  demonstrated a  65%
reduction  in  risk  of  disease  progression  for  patients  treated  with  lenalidomide  mainte‐
nance  therapy.  There  is  a  notable  increased  risk  of  second  cancers  in  association  with
this drug as noted by both IFM and CALGB. The IFM reported the incidence of second
cancers as 3.1 per 100 patient years, compared to 1.2 per 100 patient years in the placebo
group (p = 0.002).  In the CALGB study, 8% of patients treated with lenalidomide devel‐
oped second cancers, compared to 3% in the control arm.
9.3. Bortezomib
An interesting study to evaluate the effect of minimal residual disease, by qualitative and
real-time quantitative polymerase chain reaction (RQ-PCR) after ASCT showed that a con‐
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solidation regimen comprised of bortezomib, thalidomide, and dexamethasone (VTD) in‐
creased CRs from 15% after ASCT to 49% after VTD. Most importantly, molecular
remissions increased from 3% after ASCT to 18% after VTD. No patients had relapsed at the
time of reporting (median follow-up, 42 months). These unprecedented levels of tumor cell
reduction are very encouraging and have laid the foundation for a new area of investigation
to better evaluate the depth of treatment response in myeloma.
A subsequent randomized phase 3 study specifically assessed the efficacy and safety of con‐
solidation therapy using bortezomib, thalidomide and dexamethasone (VTD) versus thali‐
domide and dexamethasone (TD). Before starting consolidation, CR/nCR rates were not
significantly different in the VTD and TD arms (63.1% 54.7%, respectively). However, after
consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly
higher for VTD-treated versus TD-treated patients. With a median follow-up of 30.4 months
from start of consolidation, 3-year PFS was significantly longer for the VTD group compared
to TD (60% vs 48%). The VTD consolidation therapy was shown to significantly improve
clinical outcomes after ASCT.
The evaluation of novel agents in the post-transplant setting has resulted in significant im‐
provements in disease responses and survival endpoints. Moreover combination regimens
in the form of consolidation and/or long term maintenance are well tolerated with further
improvements and achievement of molecular remissions. Future studies to determine the
optimal duration of maintenance therapy are urgently needed.
10. Combined ASCT/Allogeneic Hematopoeitic Stem Cell Transplant
approaches
Early trials evaluating myeloablative allogeneic stem cell transplantation in the treatment of
multiple myeloma demonstrated improvements in relapse and progression rates attributed
to graft versus myeloma effects; however, development of graft versus host disease and in‐
fectious complications resulted in high transplant-related mortality [TRM]. A critical ad‐
vantage of allogeneic transplantation was the development of reduced intensity
conditioning (RIC) regimens that were associated with decreased toxicities and profound
graft versus tumor effects as demonstrated in early trials evaluating the efficacy of RIC in
relapsed and refractory myeloma patients. However, higher rates of disease progression and
relapse, were noted and attributed to the late use of this modality underscoring the impor‐
tance of using effective regimens early before the disease becomes refractory especially since
the goals of allogeneic transplant are curative in intent.
Combined  sequential  therapy  utilizing  ASCT for  cytoreduction  followed RIC allogeneic
transplant  (i.e.  the  auto-allo  approach)  to  exploit  the  graft  versus  myeloma  effect  has
been compared to tandem ASCT in several studies; randomization in these trials was bi‐
ological;  i.e.  patients  with  an  HLA-matched  sibling  received  RIC  allogeneic  transplant
and all  others  underwent  tandem ASCT.  The  first  published study from the  IFM com‐
pared  tandem ASCT in  219  patients  to  auto-allo  in  65  patients  with  high-risk  multiple
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myeloma and reported no significant  difference in  response rates  or  event-free  survival
between groups; however, there was an observed trend toward better overall survival in
patients  treated with tandem ASCT;  these  findings remained unchanged in  a  long-term
follow-analysis  from the  same group.  Subsequent  comparisons  have  reported improved
CR rates and PFS durations and only one has shown superior OS in auto-allo treated pa‐
tients.  However a  recently published large multi-center  phase 3 study reported that  the
auto-allo  approach  was  not  superior  to  auto-auto  in  terms  of  progression-free  survival
(43 % vs 46% at 3 years) or 3-year OS (77% vs 80%). Additionally, there was no signifi‐
cant difference in the development of grade 3-5 adverse events between groups by three
years (46% vs 42%). Further modifications to allogeneic transplantation would be needed
to  offset  the  graft  versus  myeloma  effect  as  well  as  the  increase  in  transplant-related
mortality. The Eastern Cooperative Oncology Group conducted a small trial in which 32
patients  received  non-myeloablative  matched  sibling  donor  transplant  following  ASCT
and reported a  78% ORR (30% CR and 48% PR)  with  low TRM; however  over  half  of
patients developed chronic GVHD. A recent Swedish study compared auto-allo approach
to single ASCT in 357 previously untreated multiple myeloma patients and was demon‐
strated  that  the  auto-allo  approach  was  superior  in  terms  of  PFS,  OS  and  relapse  rate
with a 12% nonrelapse mortality rate. The data remain conflicting; however, a meta-anal‐
ysis reviewing outcomes on 7 published and unpublished studies concluded that the au‐
to-allo approach offers  no benefit  compared to autologous transplant  approaches and is
associated  with  higher  TRM.  The  International  Myeloma Working  Group does  not  rec‐
ommend the routine use of allogeneic transplantation,  and, in fact,  recommends consid‐
eration of RIC transplant only in the setting of a clinical trial.
11. Novel immunotherapy strategies
The post-transplant period is the ideal time point for immunotherapy as the disease bur‐
den is, theoretically, low. Immune function remains depressed following high-dose thera‐
py  for  many  months.  Ex  vivo  expansion  and  subsequent  transfer  of  autologous
stimulated  T  cells  may  enhance  host  antitumor  immunity  and  may  also  allow  for  en‐
hancement of a post-transplant vaccination strategy against tumor-directed antigens. Ear‐
ly trials  focused on the generation of  antibodies against  myeloma specific  antigens.  The
idiotype [Id] protein has, in a number of pre-clinical studies, demonstrated powerful an‐
tibody responses that, in vitro, resulted in apoptosis of myeloma cells. However, durable
clinical responses were not seen in subsequent clinical studies.  Idiotype-pulsed dendritic
cell vaccinations following ASCT have also demonstrated that cellular immune responses
can be elicited in the context of minimal residual disease following transplantation; how‐
ever,  again,  there  is  no  definitive  evidence  that  these  vaccination  strategies  alter  the
course  of  disease.  It  has  been  suggested  that  the  immune  dysfunction  in  myeloma pa‐
tients is the primary barrier to successful vaccination strategies. A low number of T-cells
with activity against myeloma have been detected in multiple myeloma patients . Several
attempts to expand T cells,  collected from the peripheral blood of affected patients,  and
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infused after  ASCT, have shown that  rapid recovery of  T-cell  numbers can be achieved
but,  unfortunately,  with  no  clear  anti-myeloma  benefits.  The  results  of  one  interesting
study in  which myeloma patients  received the  conjugated pneumococcal  vaccine before
T-cell collection and after ASCT showed profound antibody responses, suggesting that T
cells may improve immune responses to vaccination. A subsequent study in which adop‐
tive transfer of vaccine primed autologous T-cells to the htert/survivin multipeptide vac‐
cine,  a  target  in  myeloma  cells,  corroborated  these  findings  and  demonstrated  that
vaccination  was  associated  with  robust  antibody  responses  in  most  patients;  however,
again,  there was no definitive activity directed against  myeloma cells  specifically.  Clini‐
cal  trials  building  on  the  expansion  of  T  cells  and  targeting  various  myeloma  antigen
such as MAGE A3 and NYESO1 are ongoing. Of important note, several studies focusing
on expansion of  marrow infiltrating lymphocytes  (MILs)  had yielded interesting results
with regards to antimyeloma activities, but, again, the clinical benefit was quite limited.
Several antibody trials in myeloma are ongoing. A recently published phase 1 study has
provided encouraging evidence that elotuzumab in combination with lenalidomide yields
impressive responses in relapsed and refractory myeloma; whether the responses seen in the
relapsed setting can be confirmed and implemented in patients with minimal disease states
would require further investigation. In light of these findings, it is suggested that enhance‐
ment of T-cell function could potentially lay the groundwork for subsequent trials aimed to
improve immune function, and by extension, clinical outcomes following ASCT in myeloma
patients.
12. Salvage ASCT for relapsed disease
At present, the optimal treatment approach for patients with relapsed disease following ini‐
tial ASCT has not yet been defined. Potential options include treatment with novel agents,
conventional chemotherapy or a second salvage ASCT. While the data evaluating the role of
a second ASCT are limited, several small retrospective analyses have demonstrated that it is
an effective and well tolerated treatment option with overall response rates reported be‐
tween 55-90%. Overall survival and progression free survival is significantly improved for
patients who have received fewer lines of therapy prior to transplant and for those who
have experienced a late disease relapse. However, the length of time which constitutes a late
relapse has varied between studies, ranging between 12 months and > 36 months. A recently
published retrospective review suggested a time-dependent association between remission
duration following initial ASCT and PFS following transplant. Patients who relapsed within
18 months of initial ASCT had significantly shorter PFS compared to those who relapsed be‐
tween 18 and 36 months and those who relapsed 36 months or more (4.2 mos vs 13.8 mos vs
49.1 mos) [111]. Although larger studies would provide greater insight regarding the opti‐
mal timing of a second transplant, consideration of salvage ASCT is generally regarded as
feasible approach which offers the greatest benefit in select patients who have relapsed at
least more than 12 months after their initial ASCT. Salvage allogeneic transplant following
failure of initial autografting has also been compared to salvage ASCT in a limited number
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myeloma and reported no significant  difference in  response rates  or  event-free  survival
between groups; however, there was an observed trend toward better overall survival in
patients  treated with tandem ASCT;  these  findings remained unchanged in  a  long-term
follow-analysis  from the  same group.  Subsequent  comparisons  have  reported improved
CR rates and PFS durations and only one has shown superior OS in auto-allo treated pa‐
tients.  However a  recently published large multi-center  phase 3 study reported that  the
auto-allo  approach  was  not  superior  to  auto-auto  in  terms  of  progression-free  survival
(43 % vs 46% at 3 years) or 3-year OS (77% vs 80%). Additionally, there was no signifi‐
cant difference in the development of grade 3-5 adverse events between groups by three
years (46% vs 42%). Further modifications to allogeneic transplantation would be needed
to  offset  the  graft  versus  myeloma  effect  as  well  as  the  increase  in  transplant-related
mortality. The Eastern Cooperative Oncology Group conducted a small trial in which 32
patients  received  non-myeloablative  matched  sibling  donor  transplant  following  ASCT
and reported a  78% ORR (30% CR and 48% PR)  with  low TRM; however  over  half  of
patients developed chronic GVHD. A recent Swedish study compared auto-allo approach
to single ASCT in 357 previously untreated multiple myeloma patients and was demon‐
strated  that  the  auto-allo  approach  was  superior  in  terms  of  PFS,  OS  and  relapse  rate
with a 12% nonrelapse mortality rate. The data remain conflicting; however, a meta-anal‐
ysis reviewing outcomes on 7 published and unpublished studies concluded that the au‐
to-allo approach offers  no benefit  compared to autologous transplant  approaches and is
associated  with  higher  TRM.  The  International  Myeloma Working  Group does  not  rec‐
ommend the routine use of allogeneic transplantation,  and, in fact,  recommends consid‐
eration of RIC transplant only in the setting of a clinical trial.
11. Novel immunotherapy strategies
The post-transplant period is the ideal time point for immunotherapy as the disease bur‐
den is, theoretically, low. Immune function remains depressed following high-dose thera‐
py  for  many  months.  Ex  vivo  expansion  and  subsequent  transfer  of  autologous
stimulated  T  cells  may  enhance  host  antitumor  immunity  and  may  also  allow  for  en‐
hancement of a post-transplant vaccination strategy against tumor-directed antigens. Ear‐
ly trials  focused on the generation of  antibodies against  myeloma specific  antigens.  The
idiotype [Id] protein has, in a number of pre-clinical studies, demonstrated powerful an‐
tibody responses that, in vitro, resulted in apoptosis of myeloma cells. However, durable
clinical responses were not seen in subsequent clinical studies.  Idiotype-pulsed dendritic
cell vaccinations following ASCT have also demonstrated that cellular immune responses
can be elicited in the context of minimal residual disease following transplantation; how‐
ever,  again,  there  is  no  definitive  evidence  that  these  vaccination  strategies  alter  the
course  of  disease.  It  has  been  suggested  that  the  immune  dysfunction  in  myeloma pa‐
tients is the primary barrier to successful vaccination strategies. A low number of T-cells
with activity against myeloma have been detected in multiple myeloma patients . Several
attempts to expand T cells,  collected from the peripheral blood of affected patients,  and
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study in  which myeloma patients  received the  conjugated pneumococcal  vaccine before
T-cell collection and after ASCT showed profound antibody responses, suggesting that T
cells may improve immune responses to vaccination. A subsequent study in which adop‐
tive transfer of vaccine primed autologous T-cells to the htert/survivin multipeptide vac‐
cine,  a  target  in  myeloma  cells,  corroborated  these  findings  and  demonstrated  that
vaccination  was  associated  with  robust  antibody  responses  in  most  patients;  however,
again,  there was no definitive activity directed against  myeloma cells  specifically.  Clini‐
cal  trials  building  on  the  expansion  of  T  cells  and  targeting  various  myeloma  antigen
such as MAGE A3 and NYESO1 are ongoing. Of important note, several studies focusing
on expansion of  marrow infiltrating lymphocytes  (MILs)  had yielded interesting results
with regards to antimyeloma activities, but, again, the clinical benefit was quite limited.
Several antibody trials in myeloma are ongoing. A recently published phase 1 study has
provided encouraging evidence that elotuzumab in combination with lenalidomide yields
impressive responses in relapsed and refractory myeloma; whether the responses seen in the
relapsed setting can be confirmed and implemented in patients with minimal disease states
would require further investigation. In light of these findings, it is suggested that enhance‐
ment of T-cell function could potentially lay the groundwork for subsequent trials aimed to
improve immune function, and by extension, clinical outcomes following ASCT in myeloma
patients.
12. Salvage ASCT for relapsed disease
At present, the optimal treatment approach for patients with relapsed disease following ini‐
tial ASCT has not yet been defined. Potential options include treatment with novel agents,
conventional chemotherapy or a second salvage ASCT. While the data evaluating the role of
a second ASCT are limited, several small retrospective analyses have demonstrated that it is
an effective and well tolerated treatment option with overall response rates reported be‐
tween 55-90%. Overall survival and progression free survival is significantly improved for
patients who have received fewer lines of therapy prior to transplant and for those who
have experienced a late disease relapse. However, the length of time which constitutes a late
relapse has varied between studies, ranging between 12 months and > 36 months. A recently
published retrospective review suggested a time-dependent association between remission
duration following initial ASCT and PFS following transplant. Patients who relapsed within
18 months of initial ASCT had significantly shorter PFS compared to those who relapsed be‐
tween 18 and 36 months and those who relapsed 36 months or more (4.2 mos vs 13.8 mos vs
49.1 mos) [111]. Although larger studies would provide greater insight regarding the opti‐
mal timing of a second transplant, consideration of salvage ASCT is generally regarded as
feasible approach which offers the greatest benefit in select patients who have relapsed at
least more than 12 months after their initial ASCT. Salvage allogeneic transplant following
failure of initial autografting has also been compared to salvage ASCT in a limited number
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of studies and has been reported to have comparable PFS due to lower rates of disease pro‐
gression following allogeneic transplant, but superior OS in autografted patients; further‐
more, the increased incidence of graft versus host disease in allografted patients has
rendered this approach less preferable. Refinements in allogeneic transplant techniques may
potentially generate renewed interest in this treatment approach.
13. Conclusion
The widespread implementation of autologous stem cell transplantation, in conjunction
with novel agents, has revolutionized the management of multiple myeloma and has mark‐
edly altered the natural history of the disease by improving disease responses and response
duration, which, by extension, have led to significant improvements in overall survival.
While treatment options for multiple myeloma have expanded considerably over the past
several decades, long-term survivorship remains low. Continued investigative efforts are
targeted towards refining our current treatment modalities with the hope of ultimately de‐
veloping a treatment approach which results in cure.
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1. Introduction
Multiple myeloma is a malignant plasma cell disorder in which the proliferation of the ma‐
lignant plasma cells leads to anemia, infections, bone fractures, hypercalcemia and renal
dysfunction [1]. Affecting approximately 32,000 people each year worldwide, with a median
age of onset of approximately 68 years, it is the second most common hematological malig‐
nancy after non-Hodgkin’s lymphoma (NHL). Two major advances have occurred in the
treatment of multiple myeloma in the last two decades: the introduction of high-dose che‐
motherapy with autologous stem cell transplantation (ASCT), and the development of active
drugs with a novel mechanism of action (proteasome inhibition and immunomodulation).
Both advances have led to significant improvements in overall survival in this disease.
The superiority of ASCT over conventional chemotherapy treatment in younger subjects
with newly diagnosed multiple myeloma was first established in a French IFM Phase 3
study in the 1990s [2]. The ASCT approach led to higher tumor response rates, better event-
free survival (EFS) and overall survival (OS). This superiority of ASCT over conventional
treatment was later confirmed in a British phase 3 study [3]. Both EFS and OS appear direct‐
ly related to the depth of the tumor response to treatment [4]. Due to this correlation achiev‐
ing complete response (CR) or at least very good partial response (VGPR) has become an
important goal of the ASCT approach. ASCT can be complicated by severe myelosuppres‐
sion and infections and has therefore been reserved for patients who are <65-70 years old
without significant comorbidities [5].
ASCT is  preceded  by  an  induction  regimen  the  primary  objective  of  which  is  to  debulk
the tumor without causing damage to the hematopoietic progenitor cells.  Until  recently,
the standard induction regimens in myeloma were vincristine, doxorubicin and dexame‐
thasone (VAD),  which has 5-7% CR rate post  induction [6],  or Thalidomide-Dexametha‐
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dysfunction [1]. Affecting approximately 32,000 people each year worldwide, with a median
age of onset of approximately 68 years, it is the second most common hematological malig‐
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study in the 1990s [2]. The ASCT approach led to higher tumor response rates, better event-
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treatment was later confirmed in a British phase 3 study [3]. Both EFS and OS appear direct‐
ly related to the depth of the tumor response to treatment [4]. Due to this correlation achiev‐
ing complete response (CR) or at least very good partial response (VGPR) has become an
important goal of the ASCT approach. ASCT can be complicated by severe myelosuppres‐
sion and infections and has therefore been reserved for patients who are <65-70 years old
without significant comorbidities [5].
ASCT is  preceded  by  an  induction  regimen  the  primary  objective  of  which  is  to  debulk
the tumor without causing damage to the hematopoietic progenitor cells.  Until  recently,
the standard induction regimens in myeloma were vincristine, doxorubicin and dexame‐
thasone (VAD),  which has 5-7% CR rate post  induction [6],  or Thalidomide-Dexametha‐
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sone  (Thal-Dex),  which  has  a  4%  CR  rate  post  induction  [7].  After  induction  therapy
autologous  CD34+  hematopoietic  stem  cells  are  harvested  from  peripheral  blood,  and
less  often collected as  part  of  bone marrow cells,  and reinfused after  conditioning with
high-dose  chemotherapy  regimen  with  high-dose  melphalan  (conditioning  regimen).  The
conditioning  and  reinfusion  of  CD34+  stem  cells  can  be  done  once  or  twice  (single  or
double ASCT). The addition of a limited number of cycles of standard dose chemothera‐
py (consolidation treatment)  or of  a prolonged exposure to low dose therapy (maintenance
treatment)  after the ASCT is increasingly being used to further improve EFS and OS, al‐
though their value has not been fully established [5]
If the ASCT approach is not used in the treatment of a newly diagnosed patient with multi‐
ple myeloma, it can still be applied upon relapse. A randomized study by the French GMA
group indicated that a second-line rescue with high dose therapy and ASCT resulted in sim‐
ilar overall survival as compared to initial treatment with this approach [8].
The value of allogeneic bone marrow transplantation (Allo-SCT) in multiple myeloma is
controversial [9]. The high treatment related mortality associated with myeloablative condi‐
tioning in allo-SCT has led to the development of reduced-intensity conditioning (Allo-RIC).
Convincing evidence is sofar lacking that Allo-RIC can improve the survival compared with
autologous stem-cell transplantation. For this reason, allo-RIC in myeloma is currently only
recommended in the context of clinical trials.
It  is  still  unclear  whether  any of  these treatment  approaches can be curative,  even in a
subset  of  patients,  although they have extended the median overall  survival  of  patients
with  newly  diagnosed  multiple  myeloma  beyond  5-6  years  [10].  Improvement  of  out‐
comes by incorporation of the proteasome inhibitor bortezomib into autologous stem cell
transplantation approaches has been an area of intense clinical research over the last dec‐
ade and is the topic of this review.
Bortezomib is a first-in-class proteasome inhibitor which was originally approved for the
treatment of relapsed or refractory multiple myeloma by the US Food and Drug Administra‐
tion (FDA) in 2003 and by the European Agency for the Evaluation of Medicinal Products
(EMEA) in 2004 [11,12]. Bortezomib is a reversible inhibitor of the 26S proteasome which is a
large protein complex that degrades ubiquitinated proteins. Regulatory proteins relevant to
the initiation and progression of cancers including multiple myeloma are known to be de‐
graded during the cell cycle by the ubiquitin-proteasome pathway [13]. Binding of bortezo‐
mib to the 20S β5 subunit of the proteasome results in a reversible inhibition of the
chymotrypsin-like protease in the proteasome. In multiple myeloma cells, this results in in‐
hibition of NF-kB activation, in attenuation of interleukin-6-mediated cell growth, and direct
apoptotic and anti-angiogenic effects [14,15].
In relapsed multiple myeloma, single agent bortezomib was shown to improve time to pro‐
gression, response rate and overall survival as compared to high-dose dexamethasone [16].
Median survival of patients treated with bortezomib was 29.9 months as compared to 23.7
months in the dexamethasone control group (p=0.027) [17]. In patients with newly diag‐
nosed multiple myeloma who were not candidate for ASCT, the addition of bortezomib to
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standard chemotherapy with melphalan-prednisone also resulted in improvement in time to
progression, response rate and complete rate, and overall survival. Complete response rate
of patients treated with the bortezomib-melphalan-prednisone combination was 30% as
compared to 4% in the melphalan-prednisone control group (p<0.001) [18]. Median survival
of patients treated with the bortezomib-melphalan-prednisone combination was 56.4
months as compared to 43.1 months in the melphalan-prednisone control group (p=0.0004)
[19]. Based on these significant improvements in outcomes in other settings in multiple mye‐
loma, the introduction of bortezomib in autologous stem cell transplant approaches in mye‐
loma has been an area of intense clinical study activity.
The approved single agent bortezomib dose and schedule in multiple myeloma is 1.3
mg/m2, on days 1, 4, 8, and 11, followed by a 10-day rest period (21 day cycle). The most
clinically significant side-effect is a cumulative dose-related peripheral neuropathy which is
managed by treatment interruptions and dose modifications [20]. Other common adverse
events include lower grade gastro-intestinal adverse events and thrombocytopenia [16]. In
most clinical studies, including those reviewed in this chapter, bortezomib has been given
intravenously. Recent data in relapsed multiple myeloma have indicated that the subcutane‐
ous administration of bortezomib is as efficacious and results in less neurotoxicity [21].
However, data on subcutaneous administration of bortezomib as part of transplant regi‐
mens in myeloma are currently still lacking.
2. Methodology
We followed published guidelines for medical literature reviews [22,23,24]. The medical lit‐
erature was searched in the OVID database (Medline; Derwent Drug File; Your journals @
Ovid; Biosis Previews; and Embase). The search was limited to the English language and ar‐
ticles published without a data range limit to August 1, 2012. The following search strategy
was used with the following words being entered in the basic search section of OVID:
1. randomized AND phase AND 3 AND bortezomib OR velcade AND stem AND cell
AND transplantation.
2. the second phase of searching showed the addition of ‘myeloma AND proteosome in‐
hibitor’ with ‘autologous’
3. the  third  phase  of  searching  substituted  ‘bone  AND  marrow’  for  the  words  ‘stem
AND cell
Further selection of the identified studies included in this review was based on following
criteria: (1) prospective study design; (2) publication in peer-reviewed journals; (3) random‐
ized phase 3 or phase 2 design, or single arm phase 2 design with sample size >25 patients.
These criteria were chosen to increase likelihood of scientific quality and interpretability of
the selected studies. Twenty-nine studies were initially retained in the search and 16 studies
were subsequently selected based on these criteria.
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VELCADE (Bortezomib for Injection) is a small molecule proteasome inhibitor being code‐
veloped by Millennium Pharmaceuticals, Inc. (Millennium) and Janssen Research & Devel‐
opment. The selection of the identified was solely based on the criteria indicated above and
no studies were de-selected due a conflict-of-interest.
3. Results
3.1. Bortezomib in induction therapy
The search of an optimal induction regimen prior to high-dose therapy and ASCT in multi‐
ple myeloma is still ongoing. An ideal induction regimen should, among others, have the
following characteristics:
1. Able to give the optimum post induction tumor response, since better response is asso‐
ciated with better long-term outcomes;
2. Able to act quickly to debulk the tumor, as often the patients present with advanced
disease and complicated presentations;
3. Able to work even in renal failure, since this is a common feature of multiple myeloma;
4. Allowing collection of an adequate of viable hematopoietic stem cells necessary for suc‐
cessful bone marrow rescue and engraftment.
All randomized studies published in peer reviewed journals and investigating the role of
bortezomib in induction therapy have been analyzed in this section. Some of the random‐
ized phase 2 and 3 studies compare a bortezomib containing regimen with a non-bortezo‐
mib containing regimen, while other studies investigate various combinations and doses
with all treatment groups containing bortezomib. Further, all single arm phase 2 studies
with more than 25 patients are also included in this review.
Early studies started soon after the introduction of bortezomib into the treatment of relapsed
myeloma compared the role of a bortezomib-containing induction regimen against VAD,
the standard regimen at that time.
A first phase 3 study by the French IFM group provided evidence that the combination of
bortezomib plus dexamethasone was superior to VAD as induction regimen [25]. In this
IFM2005-01 study 481 patients who were eligible for autologous stem cell transplantation
(≤65 years) were randomized to receive VAD (n = 121); VAD plus DCEP (n=121); bortezomib
plus dexamethasone (n = 121) or bortezomib plus dexamethasone plus DCEP (n = 119).
DCEP (dexamethasone, cyclophosphamide, etoposide and cisplatin) were given as a consoli‐
dation course, soon after 4 induction cycles and before the high dose melphalan for condi‐
tioning. The study allowed a second high-dose therapy and stem cell transplant procedure
for patients failing to attain at least a VGPR after first transplant. The primary endpoint was
post induction CR/nCR rate. Patients in the VAD group were treated with four 4-week cy‐
cles of vincristine 0.4 mg/d and doxorubicin 9 mg/m2/d by continuous infusion on days 1 to
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4, and dexamethasone 40 mg daily po on days 1 to 4 (all cycles) and days 9 to 12 and days 17
to 20 (cycles 1 and 2 only). Bortezomib plus dexamethasone comprised four 3 week cycles of
bortezomib 1.3 mg/m2 iv days 1, 4, 8 and 11 plus dexamethasone po 40 mg/d on days 1 to 4
(all cycles) and days 9 to 12 (cycles 1 and 2 only). DCEP comprised two 4-week cycles of
dexamethasone 40 mg/daily on days 1 to 4; plus cyclophosphamide 400 mg/m2, etoposide 40
mg/m2 and cisplatin 15 mg/m2 by continuous iv infusion day 1 to 4. Stem cells were collected
after priming with granulocyte stimulating factor alone or cyclophosphamide for those who
mobilize poorly. The CR/nCR rate was significantly higher (14.8%) for patients receiving
bortezomib plus dexamethasone compared to patients receiving VAD (6.4%, p-value=0.004).
ORR was 78.5% vs 62.8% (p=<0.001). Patients with del13, a negative prognostic cytogenetic
abnormality in multiple myeloma, also reported higher response rates in the bortezomib
containing arm : ORR was 78.2% vs 65.1% (p=0.037); and CR/nCR was 20.8% compared to
5.8%( p=0.002). The study showed that the addition of DCEP did not further improve the
outcomes wither either regimen. The PFS for the bortezomib group was 36 months vs 29.7
months in the VAD arm after 32.2 months follow-up (p=0.064 unadjusted). Median OS was
not yet reached but the 3 year OS rate was 81.4% compared to 77.4% in favor of the bortezo‐
mib-dexamethasone combination. Stem cell collection was adequate in both arms. The safety
profile was similar between the groups for most adverse events except for all grade periph‐
eral neuropathy (45.6% for bortezomib and dexamethasone and 28% for VAD) and grade 3/4
neuropathy (7.1% and 2.1%, respectively).
A second phase 3 study by the Dutch-German HOVON-GMMG groups randomized 827 pa‐
tients to receive 3 cycles of either bortezomib combined with adriamycin and dexametha‐
sone (PAD) or VAD during induction given every 28 days [26,26,27]. This HOVON-65/
GMMG-HD4 study had a maintenance part post ASCT in which patients on VAD further
received thalidomide 50 mg po daily for a further 2 years while those on PAD received bor‐
tezomib 1.3 mg/m2 iv every two weeks for 2 years. The primary objective of the study was to
compare PFS of the two arms. Response rates post induction were analyzed as secondary
objectives. The CR/nCR rate post induction was 5% in patients who were randomized to
VAD and 11% in patients who received PAD (P <.001). The post transplant response rate for
nCR/CR was 15% (VAD) versus 31% (PAD), (P <.001). Overall nCR/CR rates were 34% ver‐
sus 49%, (P <.001) for patients on VAD and PAD respectively. The median PFS was 28
months for the VAD arm and 35 months for the PAD arm (p=0.002). Median OS was not
reached after 66 months of follow-up, with 5-year OS of 55% (VAD) versus 61% (PAD). In
patients with del17p, the worst prognostic cytogenetic abnormality in multiple myeloma,
both PFS (median PFS, 12 vs 22 months, p=0.01) and OS (median OS, 24 vs > 54 months,
p=0.003) were significantly better in the PAD arm. In patients with del13, a negative impact
on PFS was observed in both treatment arms. OS in patients with this deletion was similar to
the OS in patients with no del13 in the PAD arm and significantly better than OS in the VAD
arm (median OS for VAD 49 vs 59 months for the PAD arm, p=0.007). Stem cell collection
was adequate in both treatment arms. In patients presenting with a baseline serum creati‐
nine of more than 2 mg/dL, bortezomib significantly improved CR/nCR rates which were
27% (VAD) compared to 53% (PAD) (p=0.02). The PFS in the same population improved
from a median of 13 months to 30 months (p= 0.004) and OS from a median of 21 months to
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myeloma compared the role of a bortezomib-containing induction regimen against VAD,
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A first phase 3 study by the French IFM group provided evidence that the combination of
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dation course, soon after 4 induction cycles and before the high dose melphalan for condi‐
tioning. The study allowed a second high-dose therapy and stem cell transplant procedure
for patients failing to attain at least a VGPR after first transplant. The primary endpoint was
post induction CR/nCR rate. Patients in the VAD group were treated with four 4-week cy‐
cles of vincristine 0.4 mg/d and doxorubicin 9 mg/m2/d by continuous infusion on days 1 to
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4, and dexamethasone 40 mg daily po on days 1 to 4 (all cycles) and days 9 to 12 and days 17
to 20 (cycles 1 and 2 only). Bortezomib plus dexamethasone comprised four 3 week cycles of
bortezomib 1.3 mg/m2 iv days 1, 4, 8 and 11 plus dexamethasone po 40 mg/d on days 1 to 4
(all cycles) and days 9 to 12 (cycles 1 and 2 only). DCEP comprised two 4-week cycles of
dexamethasone 40 mg/daily on days 1 to 4; plus cyclophosphamide 400 mg/m2, etoposide 40
mg/m2 and cisplatin 15 mg/m2 by continuous iv infusion day 1 to 4. Stem cells were collected
after priming with granulocyte stimulating factor alone or cyclophosphamide for those who
mobilize poorly. The CR/nCR rate was significantly higher (14.8%) for patients receiving
bortezomib plus dexamethasone compared to patients receiving VAD (6.4%, p-value=0.004).
ORR was 78.5% vs 62.8% (p=<0.001). Patients with del13, a negative prognostic cytogenetic
abnormality in multiple myeloma, also reported higher response rates in the bortezomib
containing arm : ORR was 78.2% vs 65.1% (p=0.037); and CR/nCR was 20.8% compared to
5.8%( p=0.002). The study showed that the addition of DCEP did not further improve the
outcomes wither either regimen. The PFS for the bortezomib group was 36 months vs 29.7
months in the VAD arm after 32.2 months follow-up (p=0.064 unadjusted). Median OS was
not yet reached but the 3 year OS rate was 81.4% compared to 77.4% in favor of the bortezo‐
mib-dexamethasone combination. Stem cell collection was adequate in both arms. The safety
profile was similar between the groups for most adverse events except for all grade periph‐
eral neuropathy (45.6% for bortezomib and dexamethasone and 28% for VAD) and grade 3/4
neuropathy (7.1% and 2.1%, respectively).
A second phase 3 study by the Dutch-German HOVON-GMMG groups randomized 827 pa‐
tients to receive 3 cycles of either bortezomib combined with adriamycin and dexametha‐
sone (PAD) or VAD during induction given every 28 days [26,26,27]. This HOVON-65/
GMMG-HD4 study had a maintenance part post ASCT in which patients on VAD further
received thalidomide 50 mg po daily for a further 2 years while those on PAD received bor‐
tezomib 1.3 mg/m2 iv every two weeks for 2 years. The primary objective of the study was to
compare PFS of the two arms. Response rates post induction were analyzed as secondary
objectives. The CR/nCR rate post induction was 5% in patients who were randomized to
VAD and 11% in patients who received PAD (P <.001). The post transplant response rate for
nCR/CR was 15% (VAD) versus 31% (PAD), (P <.001). Overall nCR/CR rates were 34% ver‐
sus 49%, (P <.001) for patients on VAD and PAD respectively. The median PFS was 28
months for the VAD arm and 35 months for the PAD arm (p=0.002). Median OS was not
reached after 66 months of follow-up, with 5-year OS of 55% (VAD) versus 61% (PAD). In
patients with del17p, the worst prognostic cytogenetic abnormality in multiple myeloma,
both PFS (median PFS, 12 vs 22 months, p=0.01) and OS (median OS, 24 vs > 54 months,
p=0.003) were significantly better in the PAD arm. In patients with del13, a negative impact
on PFS was observed in both treatment arms. OS in patients with this deletion was similar to
the OS in patients with no del13 in the PAD arm and significantly better than OS in the VAD
arm (median OS for VAD 49 vs 59 months for the PAD arm, p=0.007). Stem cell collection
was adequate in both treatment arms. In patients presenting with a baseline serum creati‐
nine of more than 2 mg/dL, bortezomib significantly improved CR/nCR rates which were
27% (VAD) compared to 53% (PAD) (p=0.02). The PFS in the same population improved
from a median of 13 months to 30 months (p= 0.004) and OS from a median of 21 months to
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54 months (HR, 0.33; p < 0.001) respectively. There was more neuropathy in the PAD arm
(40% grades 2 to 4) compared to the VAD arm (18%, p<0.001). The contribution of the main‐
tenance regimens in this study is discussed later in this chapter.
The above two large studies showed significant improvement of bortezomib-containing reg‐
imens as compared to VAD in terms of post-induction response and PFS, with a positive
trend on overall survival. Later studies focused on comparing bortezomib-containing regi‐
mens against non-bortezomib containing regimens other than VAD.
The bortezomib-thalidomide-dexamethasone (VTD) regimen was compared to the thalido‐
mide-dexamethasone (TD) regimen in a Phase 3 study randomizing 480 patients over four
21-day cycles [28,29]. The patients received thalidomide 100 mg po daily for the first 14 days
and 200 mg daily thereafter, plus dexamethasone (40 mg po daily on 8 of the first 12 days,
but not consecutively; total of 320 mg per cycle), either alone or with bortezomib (1 3 mg/m2
iv on days 1, 4, 8, and 11). Post double ASCT the patients received two 35-day cycles of their
assigned drug regimen, VTD or TD, as consolidation therapy (see below). The primary end‐
point was the CR/nCR rate to induction therapy. After induction therapy, complete or near
complete response was achieved in 31% patients receiving VTD compared to 11% for those
on TD (p<0 0001). Rates of complete or near complete response continued to be significantly
higher in the VTD group than in the TD group after the first and second autologous stem-
cell transplantations (55% vs 41%, p=0.0024). Median time to best complete or near complete
response was significantly shorter for patients receiving VTD (9 months) than in those on
TD (14 months). The contribution of the consolidation therapy is discussed below. The esti‐
mated 3-year PFS was 60% in the VTD arm compared to 48% in the TD arm. Overall, PFS
was significantly longer with VTD compared to TD (median not reached vs 32 months,
p=0.0061). The estimated 3-year probability of progression or relapse was 29% in the VTD
group versus 39% in the TD group (p=0 0061 by Kaplan-Meier analysis with an HR of 0 61.
In the VTD group, the PFS of subjects with or without high-risk cytogenetic abnormalities
[del13q, or del17p or t(4;14)] were similar (59% with abnormalities and 60% without). This
contrasted with the TD group in which a much lower PFS of 19% for patients with high-risk
cytogenetics was observed as compared to the 48% attained by patients without high-risk
cytogenetics in the same TD group. Stem cell collection was adequate in both arms. Grade 3
or 4 adverse events were more frequent on VTD (56%) than on TD (33%), with a higher oc‐
currence of grade 3 or higher peripheral neuropathy in patients on VTD (10%) than on TD
(2%).
A further phase 3 study (GEM05-MENOS65) performed by the Spanish GIMEMA group
randomized 390 patients in a three arm study to receive VTD versus TD versus a regimen
called VBMCP/VBAD with bortezomib [30]. Combination chemotherapy with VBMCP/
VBAD and bortezomib consisted of a total of 4 cycles of alternating VBMCP (vincristine,
BCNU, melphalan, cyclophosphamide, prednisone) and VBAD (vincristine, BCNU, doxor‐
rubicine, dexamethasone ) followed by 2 cycles of bortezomib (1.3 mg/m2 iv on days 1, 4, 8
and 11 at 3 weeks intervals), TD consisted of thalidomide 200 mg po daily (escalating doses
in the first cycle: 50 mg on days 1 to 14 and 100 mg on days 15 to 28) and dexamethasone 40
mg po on days 1-4 and 9-12 at 4-week intervals for 6 cycles and the VTD arm was identical
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to TD plus bortezomib 1.3 mg/m2 iv on days 1, 4, 8 and 11 of each cycle. The duration of the
induction therapy was 24 weeks in all arms. Three months after ASCT patients were
randomized to receive maintenance therapy with interferon alfa-2b subcutaneously versus
thalidomide 100 mg po daily versus thalidomide 100 mg/day po daily plus one cycle of bor‐
tezomib iv on days 1, 4, 8 and 11 every three months (see below). The CR rate after induc‐
tion was significantly higher with VTD (35%) compared to TD (14%) and VBMCP/VBAD/B
(21%) (p=0.0001 and p=0.01, respectively). Of significance in the VBMCP/VBAD/Bortezomib
arm, the CR rate increased from 8% after the 4 cycles of VBMCP/VBAD to 21% after the
completion of the 2 bortezomib courses. The progressive disease (PD) rate during induction
was significantly lower with VTD than with TD (7% vs. 23%, p= 0.0004). In patients with ex‐
tramedullary soft-tissue plasmacytomas the CR rate after induction was significantly higher
with VTD as compared with TD (42% vs. 14%, p=0.02). In all the above analysis the VBMCP/
VBAD/Bortezomib arm showed an intermediate efficacy between VTD and TD. In this study
VTD also had superior CR rates in the subgroup of patients with high-risk cytogenetic ab‐
normalities as compared to the two other regimens. After a median duration of follow-up of
35.2 months, the median PFS was significantly higher for VTD (56.2m) than with VBMCP/
VBAD/Bortezomib (35.3m) or with TD (28.2 m, p=0.01). The difference in the four-year sur‐
vival rates between VTD (74%), VPMCP/VVBAD/bortezomib (70%) and TD (65%) is not
statistically significant at this point. There were two stem cell mobilization failures in the
VBMCP/VBAD/Bortezomib group. Peripheral neuropathy grade ≥ 3 with VTD (14%) was
significantly higher than with TD (5%) (p=0.01) but not significantly different from VBMCP/
VBAD/B (9%). An additional 46% of patients in the VTD arm developed grade 2 peripheral
neuropathy compared with 8% and 15% in the TD and VBMCP/VBAD/B arms, respectively
(p<0.001). Grade 3 and 4 neutropenia was significantly higher with VBMCP/VBAD/B (22%)
than with remaining two arms TD (14%) and VTD (10%). There were no significant differ‐
ence in incidence of all grade ≥ 3 adverse events between the three treatment groups.
In conclusion, all currently published phase 3 studies indicate that induction regimens con‐
taining bortezomib lead to improvements in CR/nCR rates after induction which are main‐
tained after ASCT, and also lead to improved PFS as compared to standard regimens. Where
reported, the time to response appear shorter, and the regimens have important activity in
poor prognosis situations such as high-risk cytogenetic disease and renal insufficiency. After
a relatively short duration of follow-up, a trend towards improved overall survival with the
bortezomib regimens has been noted in several studies. All phase 3 studies also provide evi‐
dence of good hematopoietic stem cell collection but indicate a higher incidence of neuropa‐
thy in patients treated with a bortezomib combination. This phase 3 evidence is further
supported by a plethora of randomized and non-randomized phase 2 studies which have in‐
corporated bortezomib in the induction regimens.
In a randomized phase 2 study by the French IFM (IFM2007-02) a lower dose of bortezomib
was investigated in combination with thalidomide and dexamethasone in order to reduce
the peripheral neuropathy risk. One hundred ninety-nine patients were randomized to re‐
ceive VD or vTD over four 3 week cycles prior to ASCT [31]. vtD was composed of reduced
bortezomib at 1 mg/m2 iv on days 1, 4, 8, and 11, thalidomide 100 mg/day po, and dexame‐
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54 months (HR, 0.33; p < 0.001) respectively. There was more neuropathy in the PAD arm
(40% grades 2 to 4) compared to the VAD arm (18%, p<0.001). The contribution of the main‐
tenance regimens in this study is discussed later in this chapter.
The above two large studies showed significant improvement of bortezomib-containing reg‐
imens as compared to VAD in terms of post-induction response and PFS, with a positive
trend on overall survival. Later studies focused on comparing bortezomib-containing regi‐
mens against non-bortezomib containing regimens other than VAD.
The bortezomib-thalidomide-dexamethasone (VTD) regimen was compared to the thalido‐
mide-dexamethasone (TD) regimen in a Phase 3 study randomizing 480 patients over four
21-day cycles [28,29]. The patients received thalidomide 100 mg po daily for the first 14 days
and 200 mg daily thereafter, plus dexamethasone (40 mg po daily on 8 of the first 12 days,
but not consecutively; total of 320 mg per cycle), either alone or with bortezomib (1 3 mg/m2
iv on days 1, 4, 8, and 11). Post double ASCT the patients received two 35-day cycles of their
assigned drug regimen, VTD or TD, as consolidation therapy (see below). The primary end‐
point was the CR/nCR rate to induction therapy. After induction therapy, complete or near
complete response was achieved in 31% patients receiving VTD compared to 11% for those
on TD (p<0 0001). Rates of complete or near complete response continued to be significantly
higher in the VTD group than in the TD group after the first and second autologous stem-
cell transplantations (55% vs 41%, p=0.0024). Median time to best complete or near complete
response was significantly shorter for patients receiving VTD (9 months) than in those on
TD (14 months). The contribution of the consolidation therapy is discussed below. The esti‐
mated 3-year PFS was 60% in the VTD arm compared to 48% in the TD arm. Overall, PFS
was significantly longer with VTD compared to TD (median not reached vs 32 months,
p=0.0061). The estimated 3-year probability of progression or relapse was 29% in the VTD
group versus 39% in the TD group (p=0 0061 by Kaplan-Meier analysis with an HR of 0 61.
In the VTD group, the PFS of subjects with or without high-risk cytogenetic abnormalities
[del13q, or del17p or t(4;14)] were similar (59% with abnormalities and 60% without). This
contrasted with the TD group in which a much lower PFS of 19% for patients with high-risk
cytogenetics was observed as compared to the 48% attained by patients without high-risk
cytogenetics in the same TD group. Stem cell collection was adequate in both arms. Grade 3
or 4 adverse events were more frequent on VTD (56%) than on TD (33%), with a higher oc‐
currence of grade 3 or higher peripheral neuropathy in patients on VTD (10%) than on TD
(2%).
A further phase 3 study (GEM05-MENOS65) performed by the Spanish GIMEMA group
randomized 390 patients in a three arm study to receive VTD versus TD versus a regimen
called VBMCP/VBAD with bortezomib [30]. Combination chemotherapy with VBMCP/
VBAD and bortezomib consisted of a total of 4 cycles of alternating VBMCP (vincristine,
BCNU, melphalan, cyclophosphamide, prednisone) and VBAD (vincristine, BCNU, doxor‐
rubicine, dexamethasone ) followed by 2 cycles of bortezomib (1.3 mg/m2 iv on days 1, 4, 8
and 11 at 3 weeks intervals), TD consisted of thalidomide 200 mg po daily (escalating doses
in the first cycle: 50 mg on days 1 to 14 and 100 mg on days 15 to 28) and dexamethasone 40
mg po on days 1-4 and 9-12 at 4-week intervals for 6 cycles and the VTD arm was identical
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to TD plus bortezomib 1.3 mg/m2 iv on days 1, 4, 8 and 11 of each cycle. The duration of the
induction therapy was 24 weeks in all arms. Three months after ASCT patients were
randomized to receive maintenance therapy with interferon alfa-2b subcutaneously versus
thalidomide 100 mg po daily versus thalidomide 100 mg/day po daily plus one cycle of bor‐
tezomib iv on days 1, 4, 8 and 11 every three months (see below). The CR rate after induc‐
tion was significantly higher with VTD (35%) compared to TD (14%) and VBMCP/VBAD/B
(21%) (p=0.0001 and p=0.01, respectively). Of significance in the VBMCP/VBAD/Bortezomib
arm, the CR rate increased from 8% after the 4 cycles of VBMCP/VBAD to 21% after the
completion of the 2 bortezomib courses. The progressive disease (PD) rate during induction
was significantly lower with VTD than with TD (7% vs. 23%, p= 0.0004). In patients with ex‐
tramedullary soft-tissue plasmacytomas the CR rate after induction was significantly higher
with VTD as compared with TD (42% vs. 14%, p=0.02). In all the above analysis the VBMCP/
VBAD/Bortezomib arm showed an intermediate efficacy between VTD and TD. In this study
VTD also had superior CR rates in the subgroup of patients with high-risk cytogenetic ab‐
normalities as compared to the two other regimens. After a median duration of follow-up of
35.2 months, the median PFS was significantly higher for VTD (56.2m) than with VBMCP/
VBAD/Bortezomib (35.3m) or with TD (28.2 m, p=0.01). The difference in the four-year sur‐
vival rates between VTD (74%), VPMCP/VVBAD/bortezomib (70%) and TD (65%) is not
statistically significant at this point. There were two stem cell mobilization failures in the
VBMCP/VBAD/Bortezomib group. Peripheral neuropathy grade ≥ 3 with VTD (14%) was
significantly higher than with TD (5%) (p=0.01) but not significantly different from VBMCP/
VBAD/B (9%). An additional 46% of patients in the VTD arm developed grade 2 peripheral
neuropathy compared with 8% and 15% in the TD and VBMCP/VBAD/B arms, respectively
(p<0.001). Grade 3 and 4 neutropenia was significantly higher with VBMCP/VBAD/B (22%)
than with remaining two arms TD (14%) and VTD (10%). There were no significant differ‐
ence in incidence of all grade ≥ 3 adverse events between the three treatment groups.
In conclusion, all currently published phase 3 studies indicate that induction regimens con‐
taining bortezomib lead to improvements in CR/nCR rates after induction which are main‐
tained after ASCT, and also lead to improved PFS as compared to standard regimens. Where
reported, the time to response appear shorter, and the regimens have important activity in
poor prognosis situations such as high-risk cytogenetic disease and renal insufficiency. After
a relatively short duration of follow-up, a trend towards improved overall survival with the
bortezomib regimens has been noted in several studies. All phase 3 studies also provide evi‐
dence of good hematopoietic stem cell collection but indicate a higher incidence of neuropa‐
thy in patients treated with a bortezomib combination. This phase 3 evidence is further
supported by a plethora of randomized and non-randomized phase 2 studies which have in‐
corporated bortezomib in the induction regimens.
In a randomized phase 2 study by the French IFM (IFM2007-02) a lower dose of bortezomib
was investigated in combination with thalidomide and dexamethasone in order to reduce
the peripheral neuropathy risk. One hundred ninety-nine patients were randomized to re‐
ceive VD or vTD over four 3 week cycles prior to ASCT [31]. vtD was composed of reduced
bortezomib at 1 mg/m2 iv on days 1, 4, 8, and 11, thalidomide 100 mg/day po, and dexame‐
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thasone while VD consisted of bortezomib 1.3 mg/m2 iv on days 1, 4, 8, and 11 plus the same
dexamethasone regimen. In case of less than partial response (PR) after cycle 2, the dose of
bortezomib was increased to 1.3 mg/m2 and the dose of thalidomide to 200 mg/day in the
vTD arm. The primary endpoint of this study was post induction CR rate. The CR rate be‐
tween the groups was the same after 4 cycles, 13% in the vTD arm and 12% in the VD arm.
However, both the bortezomib and thalidomide dose had to be increased in 7 patients in the
vTD arm. The ORR was 88% in the vTD arm versus 81% in the VD arm, the difference not
reaching statistical significance. Further, there was no difference in CR rate post transplant
(29% in vTD arm and 31% in VD arm). The target stem cell collection yield of 2 × 106 CD34+
cells/kg was achieved in 93% and 80% of VD and vTD patients, respectively (P =.01). While
the overall safety profile was similar between the two arms, there was less peripheral neuro‐
pathy in the vTD arm (53% all grade vs 70% on VD, 11% grade 3 or higher vs 11% on VD).
Results of the VD control group were consistent with prior observations from the IFM group
on this VD induction regimen, both in a single arm phase 2 study [32] and in the random‐
ized phase 3 study (see above).
Efficacy of VD in induction was also assessed in another phase 2 study with 57 patients, giv‐
en over 4 cycles followed by 2 cycles of DCEP consolidation [33]. The median CR34+ cells
collected were 7.5 x 106/kg and in 86% of these patients the amount was more than twice the
minimum required for transplantation. The ORR was 87% and CR 30%. Univariate analysis
found no difference between response and cytogenetic abnormalities.
Efficacy of VTD was further confirmed in a single arm phase 2 study of 44 patients treated
with bortezomib combined with thalidomide and dexamethasone, administered over eight
3-week cycles [34]. The patient enrolment included both frontline and recurrent disease as
long as the patients were eligible for ASCT. Thirty four patients were frontline, 8 with recur‐
rent disease in second line and a further 2 had a third line recurrence. The ORR was 91%
with CR/sCR rate of 20%. Post transplant these response rates increased to ORR of 100% and
CR/sCR rate of 53%. All 44 patients had successful stem cell collection. Fifty-five percent of
the subjects developed neuropathy of all grades, though grade 3 neuropathy was reported
in 9%. DVT occurred in 5% of the patients.
Other multidrug combination induction regimens including bortezomib were also investi‐
gated in phase 2:
• In a randomized phase 2 study, 140 patients were initially randomized to VDCR, VDR, or
VDC to receive eight 3-week cycles of induction therapy followed by four 6-week cycles
of bortezomib maintenance therapy [35]. The VDC arm was modified after an interim
analysis to add a third dose of cyclophosphamide at 500 mg/m2 on day 15 (VDC-mod).
Bortezomib was given in standard doses. Patients could undergo stem cell mobilization
any time after 2 cycles and undergo ASCT any time after 4 cycles. After 4 cycles of induc‐
tion therapy, the confirmed ORR was 80%, 73%, 63%, and 82% of patients in the VDCR,
VDR, VDC, and VDC-mod arms including VGPR or better in 33%, 32%, 13%, and 41%,
respectively. After ASCT, the ORR was 88%, 85%, 75%, and 100% for the VDCR, VDR,
VDC, and VDC-mod arms including VGPR or better in 58%, 51%, 41%, and 53%, respec‐
tively. The 1-year PFS was 100%, 100%, 88%, and 100% for the VDCR, VDR, VDC, and
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VDC-mod arms, respectively. The 1-year OS estimate was 100% for all 4 arms. In addition
the 1-year PFS for the high-risk patients (n = 24) was 100% and 85% for the standard-risk
patients, and was similar across the study arms. The median CD34+ cell yield was 6.8 x
106/kg (VDCR); 7.8 (VDR); 7.95 (VDC) and 7.75 (VDC modified). At least one grade ≥ 3 AE
was seen in ~ 80% of patients in each arm. AEs leading to discontinuation were seen in
21%, 19%, 12%, and 6% in the VDCR, VDR, VDC, and VDC-mod arms, respectively. The
most common adverse event of grade 3 or higher was neutropenia occurring in 44%
(VDCR), 10% (VDR), 30% (VDC) and 24% (VDC modified). Neuropathy grade 3 or higher
occurred in 13%, 17%, 9% and 18% respectively.
• In two single arm phase 2 studies, bortezomib was combined with cyclophosphamide
and dexamethasone (CyBorD) [36,37]. In one study, 33 patients were treated with four 3
weekly cycles with cyclophosphamide 300 mg/m2 given orally and once weekly, while
bortezomib and dexamethasone were given in standard doses. ORR was 88%, and 39%
were CR/nCR. Responses were rapid with a mean 80% decline in the monoclonal protein
at the end of two cycles. All patients undergoing stem cell harvest had a successful collec‐
tion. The most common grade 3-4 adverse events were hematological (anemia in 12%,
neutropenia in 13%, thrombocytopenia in 25%) and hyperglycemia (13%). All grade pe‐
ripheral neuropathy adverse events occurred in 66% of the patients while grade 3 occur‐
red in 7%. In the second study, 30 patients were treated with different IV
cyclophosphamide dose levels in combination with bortezomib and dexamethasone for 3
cycles [37]. The recommended dose of IV cyclophosphamide was 900 mg/m2 on day 1.
The CR rate after induction therapy was 10% and the overall response rate was 90% at the
end of the induction therapy. Most frequent adverse events were again hematologic and
neuropathy as well as gastro-intestinal.
• The most  intense bortezomib-containing induction regimen of  VTD-PACE is  included
in a high-dose therapy approach called Total Therapy 3 and has been investigated in a
large  cohort  of  303  patients  [38].  The  regimen  consists  of  two  cycles  of  VTD-PACE
(bortezomib,  thalidomide,  dexamethasone  and  4-d  continuous  infusions  of  cis-platin,
doxorubicin, cyclophosphamide, etoposide) during induction and then another two cy‐
cles during consolidation after the ASCT. The patients are then maintained for 3 years
on monthly  cycles  of  VTD in  the  first  and TD in  the  remaining years.  The  response
rates  of  this  Total  Therapy  3  approach  are  among  the  highest  reported  in  multiple
myeloma. The 2 year CR rate was 56% whilst the nCR rate was as high as 83%. Two
year  OS estimates  were  also  high at  82.9% and EFS of  79.9%.  Although no  random‐
ized comparison was performed, the investigators consider those results better than a
similar approach (Total therapy 2) which did not include bortezomib. Stem cell collec‐
tion  was  successful.  Adverse  events  grade  3  or  higher  included  thrombo-embolic
events in 27% and peripheral neuropathy in 12% of the patients.
In conclusion, these studies have provided evidence of the important role of bortezomib in
induction therapy pre-ASCT. Randomized phase 3 studies indicate that induction regimens
containing bortezomib lead to improvements in CR/nCR rates after induction which are
maintained after ASCT, and also lead to improved PFS as compared to standard non-borte‐
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thasone while VD consisted of bortezomib 1.3 mg/m2 iv on days 1, 4, 8, and 11 plus the same
dexamethasone regimen. In case of less than partial response (PR) after cycle 2, the dose of
bortezomib was increased to 1.3 mg/m2 and the dose of thalidomide to 200 mg/day in the
vTD arm. The primary endpoint of this study was post induction CR rate. The CR rate be‐
tween the groups was the same after 4 cycles, 13% in the vTD arm and 12% in the VD arm.
However, both the bortezomib and thalidomide dose had to be increased in 7 patients in the
vTD arm. The ORR was 88% in the vTD arm versus 81% in the VD arm, the difference not
reaching statistical significance. Further, there was no difference in CR rate post transplant
(29% in vTD arm and 31% in VD arm). The target stem cell collection yield of 2 × 106 CD34+
cells/kg was achieved in 93% and 80% of VD and vTD patients, respectively (P =.01). While
the overall safety profile was similar between the two arms, there was less peripheral neuro‐
pathy in the vTD arm (53% all grade vs 70% on VD, 11% grade 3 or higher vs 11% on VD).
Results of the VD control group were consistent with prior observations from the IFM group
on this VD induction regimen, both in a single arm phase 2 study [32] and in the random‐
ized phase 3 study (see above).
Efficacy of VD in induction was also assessed in another phase 2 study with 57 patients, giv‐
en over 4 cycles followed by 2 cycles of DCEP consolidation [33]. The median CR34+ cells
collected were 7.5 x 106/kg and in 86% of these patients the amount was more than twice the
minimum required for transplantation. The ORR was 87% and CR 30%. Univariate analysis
found no difference between response and cytogenetic abnormalities.
Efficacy of VTD was further confirmed in a single arm phase 2 study of 44 patients treated
with bortezomib combined with thalidomide and dexamethasone, administered over eight
3-week cycles [34]. The patient enrolment included both frontline and recurrent disease as
long as the patients were eligible for ASCT. Thirty four patients were frontline, 8 with recur‐
rent disease in second line and a further 2 had a third line recurrence. The ORR was 91%
with CR/sCR rate of 20%. Post transplant these response rates increased to ORR of 100% and
CR/sCR rate of 53%. All 44 patients had successful stem cell collection. Fifty-five percent of
the subjects developed neuropathy of all grades, though grade 3 neuropathy was reported
in 9%. DVT occurred in 5% of the patients.
Other multidrug combination induction regimens including bortezomib were also investi‐
gated in phase 2:
• In a randomized phase 2 study, 140 patients were initially randomized to VDCR, VDR, or
VDC to receive eight 3-week cycles of induction therapy followed by four 6-week cycles
of bortezomib maintenance therapy [35]. The VDC arm was modified after an interim
analysis to add a third dose of cyclophosphamide at 500 mg/m2 on day 15 (VDC-mod).
Bortezomib was given in standard doses. Patients could undergo stem cell mobilization
any time after 2 cycles and undergo ASCT any time after 4 cycles. After 4 cycles of induc‐
tion therapy, the confirmed ORR was 80%, 73%, 63%, and 82% of patients in the VDCR,
VDR, VDC, and VDC-mod arms including VGPR or better in 33%, 32%, 13%, and 41%,
respectively. After ASCT, the ORR was 88%, 85%, 75%, and 100% for the VDCR, VDR,
VDC, and VDC-mod arms including VGPR or better in 58%, 51%, 41%, and 53%, respec‐
tively. The 1-year PFS was 100%, 100%, 88%, and 100% for the VDCR, VDR, VDC, and
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VDC-mod arms, respectively. The 1-year OS estimate was 100% for all 4 arms. In addition
the 1-year PFS for the high-risk patients (n = 24) was 100% and 85% for the standard-risk
patients, and was similar across the study arms. The median CD34+ cell yield was 6.8 x
106/kg (VDCR); 7.8 (VDR); 7.95 (VDC) and 7.75 (VDC modified). At least one grade ≥ 3 AE
was seen in ~ 80% of patients in each arm. AEs leading to discontinuation were seen in
21%, 19%, 12%, and 6% in the VDCR, VDR, VDC, and VDC-mod arms, respectively. The
most common adverse event of grade 3 or higher was neutropenia occurring in 44%
(VDCR), 10% (VDR), 30% (VDC) and 24% (VDC modified). Neuropathy grade 3 or higher
occurred in 13%, 17%, 9% and 18% respectively.
• In two single arm phase 2 studies, bortezomib was combined with cyclophosphamide
and dexamethasone (CyBorD) [36,37]. In one study, 33 patients were treated with four 3
weekly cycles with cyclophosphamide 300 mg/m2 given orally and once weekly, while
bortezomib and dexamethasone were given in standard doses. ORR was 88%, and 39%
were CR/nCR. Responses were rapid with a mean 80% decline in the monoclonal protein
at the end of two cycles. All patients undergoing stem cell harvest had a successful collec‐
tion. The most common grade 3-4 adverse events were hematological (anemia in 12%,
neutropenia in 13%, thrombocytopenia in 25%) and hyperglycemia (13%). All grade pe‐
ripheral neuropathy adverse events occurred in 66% of the patients while grade 3 occur‐
red in 7%. In the second study, 30 patients were treated with different IV
cyclophosphamide dose levels in combination with bortezomib and dexamethasone for 3
cycles [37]. The recommended dose of IV cyclophosphamide was 900 mg/m2 on day 1.
The CR rate after induction therapy was 10% and the overall response rate was 90% at the
end of the induction therapy. Most frequent adverse events were again hematologic and
neuropathy as well as gastro-intestinal.
• The most  intense bortezomib-containing induction regimen of  VTD-PACE is  included
in a high-dose therapy approach called Total Therapy 3 and has been investigated in a
large  cohort  of  303  patients  [38].  The  regimen  consists  of  two  cycles  of  VTD-PACE
(bortezomib,  thalidomide,  dexamethasone  and  4-d  continuous  infusions  of  cis-platin,
doxorubicin, cyclophosphamide, etoposide) during induction and then another two cy‐
cles during consolidation after the ASCT. The patients are then maintained for 3 years
on monthly  cycles  of  VTD in  the  first  and TD in  the  remaining years.  The  response
rates  of  this  Total  Therapy  3  approach  are  among  the  highest  reported  in  multiple
myeloma. The 2 year CR rate was 56% whilst the nCR rate was as high as 83%. Two
year  OS estimates  were  also  high at  82.9% and EFS of  79.9%.  Although no  random‐
ized comparison was performed, the investigators consider those results better than a
similar approach (Total therapy 2) which did not include bortezomib. Stem cell collec‐
tion  was  successful.  Adverse  events  grade  3  or  higher  included  thrombo-embolic
events in 27% and peripheral neuropathy in 12% of the patients.
In conclusion, these studies have provided evidence of the important role of bortezomib in
induction therapy pre-ASCT. Randomized phase 3 studies indicate that induction regimens
containing bortezomib lead to improvements in CR/nCR rates after induction which are
maintained after ASCT, and also lead to improved PFS as compared to standard non-borte‐
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zomib containing regimens. After a relatively short duration of follow-up, a trend towards
improved overall survival with the bortezomib regimens has been noted. Particularly in pa‐
tients with high-risk cytogenetic abnormalities, such as del17p and del13, the addition of
bortezomib to induction therapy has improved outcomes. All phase 3 studies also provide
evidence of good hematopoietic stem cell collection. While bortezomib can safely be com‐
bined with several induction regimens, a higher incidence of neuropathy in patients treated
with a bortezomib combination is generally noted. Other toxicities of the induction regimens
appear related to the combination partner (such as neutropenia for cyclophosphamide,
thrombo-embolic events for thalidomide, hyperglycemia for high-dose dexamethasone) and
the optimal combination regimen, as well as the optimal number of induction cycles has not
been identified yet. One phase 2 study provided evidence of a lower incidence of neuropa‐
thy with a lower dose of bortezomib.
3.2. Bortezomib during conditioning
The high-dose chemotherapy regimen which immediately precedes the autologous stem cell
transplantation is referred to as the ‘conditioning regimen’. Melphalan is the most frequent‐
ly used conditioning agent in multiple myeloma and is given at the high-dose of 200 mg/m2
or at a reduced dose in case of renal function impairment [39].
Two single arm studies have investigated the addition of bortezomib to the high-dose mel‐
phalan conditioning regimen. The rationale to combine the two agents in this setting was
based on (1) the synergy between bortezomib and melphalan reported both in vitro and in
vivo [14,40], as well as on (2) the lack of overlapping toxicities between the two agents
(mainly neurologic for bortezomib and hematologic for melphalan).
In a dose and schedule-finding phase ½ study, 39 patients with newly diagnosed multi‐
ple  myeloma who achieved less  than VGPR following induction therapy were  random‐
ized to receive a single escalating dose of bortezomib (1 mg, 1.3 mg or 1.6 mg/m2) either
24 hours before or  24 hours after  melphalan (given 100 mg/m2/d for  2  days)  [41].  Stem
cells were reinfused 2 days after the last melphalan dose. Median time to neutrophil re‐
covery and platelet  recovery was 12 days and 16 days,  respectively,  for both schedules.
Transplant-related  toxicities  (gastro-intestinal  and  mucositis)  were  also  similar  for  the
two schedules. No peripheral neuropathy was reported. In the treatment group receiving
bortezomib  prior  to  melphalan  (n=19)  47%  had  at  least  VGPR  and  11%  had  CR  post-
transplant,  while  in  the  treatment  group  receiving  bortezomib  after  melphalan  (n=20)
55%  had  at  least  VGPR  and  30%  had  CR.  The  investigators  that  the  combination  was
safe with data suggesting improved efficacy and recommend the administration of borte‐
zomib after high-dose melphalan as the preferred schedule.
In  a  phase  2  study  conducted  by  the  French  IFM group,  54  patients  with  newly  diag‐
nosed  multiple  myeloma  received  melphalan  200  mg/m2  in  combination  with  four  ad‐
ministrations of bortezomib at a dose 1 mg/m2 (1 and 4 days prior to melphalan, and 3
and 6 days after melphalan) [42].  The autologous peripheral blood stem cells were rein‐
fused 2 days after melphalan administration. While 4% of patients had CR and 28% had
PR  at  the  end  of  the  induction  therapy,  32%  had  CR  and  68%  had  at  least  VGPR  3
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months after  this  conditioning regimen.  The median time to  neutrophil  and platelet  re‐
covery  was  7  days  and  3  days  after  stem  cell  reinfusion  respectively.  No  engraftment
failure or treatment-related death was reported. Three patients developed de novo neuro‐
pathy, while the severity of pre-existing neuropathy was not affected. In a matched con‐
trol analysis, only 11% of CR post-conditioning were reported.
In  a  randomized  phase  2  study,  60  patients  not  in  CR  after  induction  therapy  were
randomized  to  receive  an  unconventional  conditioning  regimen  with  melphalan  200
mg/m2 in combination with arsenic trioxide and ascorbic acid either without (group 1) or
with  bortezomib  at  either  1mg/m2  (group 2)  or  1.3  mg/m2  for  3  doses  (group 3).  Fifty-
eight patients were randomized between the 3 treatment groups. Addition of bortezomib
to this regimen was found safe with no apparent increase in time to neutrophil or plate‐
let  engraftment,  in  grade  ¾  non-hematologic  toxicity  or  in  treatment-related  mortality.
However, there was no significant improvement in the CR rate, PFS and OS rates in the
bortezomib groups. The reason for this lack of improvement was interpreted by the au‐
thors  as  related  to  the  high  proportion  of  patients  with  relapsed  disease  (25%)  and by
the concomitant administration of ascorbic acid [43].
In conclusion, these studies have provided evidence that the addition of bortezomib to the
conditioning regimen is feasible with no negative impact on hematopoietic recovery or treat‐
ment-related mortality after ASCT. From the two phase 2 studies adding bortezomib to
high-dose melphalan, high CR rates post-ASCT were noted which appeared superior to his‐
toric data. A small randomized phase 2 study was not able to confirm improved efficacy
outcomes when bortezomib was added to a multi-drug conditioning evidence.
3.3. Bortezomib in consolidation treatment
At the moment of our search, the results of only one randomized study incorporating borte‐
zomib in consolidation therapy has been published in a peer-reviewed paper.
In the GIMEMA phase 3 study investigating bortezomib-thalidomide-dexamethasone (VTD)
vs thalidomide-dexamethasone (TD), the combination regimens were given both in induc‐
tion therapy pre-ASCT and in consolidation therapy post-ASCT[29]. Patients initially
randomized to VTD received 2 post-ASCT consolidation cycles of bortezomib 1.3 mg/m2 iv
on d1,8,15,22 every 5 weeks in combination with thalidomide 100 mg/d po and dexametha‐
sone, patients initially randomized to TD received 2 post-ASCT consolidation cycles without
bortezomib. Of the 236 patients initially randomized to VTD induction, 160 patients (68%)
continued with VTD consolidation, while of the 238 patients initially randomized to TD in‐
duction, 161 patients (68%) continued with TD consolidation. VTD consolidation significant‐
ly improved the CR and CR/nCR rates post-ASCT, while the TD consolidation did not. After
a median follow-up of 30.4 months from start of consolidation, 3-year PFS was significantly
longer for the VTD group (60% vs 48%, p=0.042) but sofar no difference in overall survival
from this landmark has been seen (3-year survival rates 90% for VTD and 88% for TD).
Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD versus TD
consolidation. The authors conclude that VTD consolidation therapy significantly contribut‐
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zomib containing regimens. After a relatively short duration of follow-up, a trend towards
improved overall survival with the bortezomib regimens has been noted. Particularly in pa‐
tients with high-risk cytogenetic abnormalities, such as del17p and del13, the addition of
bortezomib to induction therapy has improved outcomes. All phase 3 studies also provide
evidence of good hematopoietic stem cell collection. While bortezomib can safely be com‐
bined with several induction regimens, a higher incidence of neuropathy in patients treated
with a bortezomib combination is generally noted. Other toxicities of the induction regimens
appear related to the combination partner (such as neutropenia for cyclophosphamide,
thrombo-embolic events for thalidomide, hyperglycemia for high-dose dexamethasone) and
the optimal combination regimen, as well as the optimal number of induction cycles has not
been identified yet. One phase 2 study provided evidence of a lower incidence of neuropa‐
thy with a lower dose of bortezomib.
3.2. Bortezomib during conditioning
The high-dose chemotherapy regimen which immediately precedes the autologous stem cell
transplantation is referred to as the ‘conditioning regimen’. Melphalan is the most frequent‐
ly used conditioning agent in multiple myeloma and is given at the high-dose of 200 mg/m2
or at a reduced dose in case of renal function impairment [39].
Two single arm studies have investigated the addition of bortezomib to the high-dose mel‐
phalan conditioning regimen. The rationale to combine the two agents in this setting was
based on (1) the synergy between bortezomib and melphalan reported both in vitro and in
vivo [14,40], as well as on (2) the lack of overlapping toxicities between the two agents
(mainly neurologic for bortezomib and hematologic for melphalan).
In a dose and schedule-finding phase ½ study, 39 patients with newly diagnosed multi‐
ple  myeloma who achieved less  than VGPR following induction therapy were  random‐
ized to receive a single escalating dose of bortezomib (1 mg, 1.3 mg or 1.6 mg/m2) either
24 hours before or  24 hours after  melphalan (given 100 mg/m2/d for  2  days)  [41].  Stem
cells were reinfused 2 days after the last melphalan dose. Median time to neutrophil re‐
covery and platelet  recovery was 12 days and 16 days,  respectively,  for both schedules.
Transplant-related  toxicities  (gastro-intestinal  and  mucositis)  were  also  similar  for  the
two schedules. No peripheral neuropathy was reported. In the treatment group receiving
bortezomib  prior  to  melphalan  (n=19)  47%  had  at  least  VGPR  and  11%  had  CR  post-
transplant,  while  in  the  treatment  group  receiving  bortezomib  after  melphalan  (n=20)
55%  had  at  least  VGPR  and  30%  had  CR.  The  investigators  that  the  combination  was
safe with data suggesting improved efficacy and recommend the administration of borte‐
zomib after high-dose melphalan as the preferred schedule.
In  a  phase  2  study  conducted  by  the  French  IFM group,  54  patients  with  newly  diag‐
nosed  multiple  myeloma  received  melphalan  200  mg/m2  in  combination  with  four  ad‐
ministrations of bortezomib at a dose 1 mg/m2 (1 and 4 days prior to melphalan, and 3
and 6 days after melphalan) [42].  The autologous peripheral blood stem cells were rein‐
fused 2 days after melphalan administration. While 4% of patients had CR and 28% had
PR  at  the  end  of  the  induction  therapy,  32%  had  CR  and  68%  had  at  least  VGPR  3
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months after  this  conditioning regimen.  The median time to  neutrophil  and platelet  re‐
covery  was  7  days  and  3  days  after  stem  cell  reinfusion  respectively.  No  engraftment
failure or treatment-related death was reported. Three patients developed de novo neuro‐
pathy, while the severity of pre-existing neuropathy was not affected. In a matched con‐
trol analysis, only 11% of CR post-conditioning were reported.
In  a  randomized  phase  2  study,  60  patients  not  in  CR  after  induction  therapy  were
randomized  to  receive  an  unconventional  conditioning  regimen  with  melphalan  200
mg/m2 in combination with arsenic trioxide and ascorbic acid either without (group 1) or
with  bortezomib  at  either  1mg/m2  (group 2)  or  1.3  mg/m2  for  3  doses  (group 3).  Fifty-
eight patients were randomized between the 3 treatment groups. Addition of bortezomib
to this regimen was found safe with no apparent increase in time to neutrophil or plate‐
let  engraftment,  in  grade  ¾  non-hematologic  toxicity  or  in  treatment-related  mortality.
However, there was no significant improvement in the CR rate, PFS and OS rates in the
bortezomib groups. The reason for this lack of improvement was interpreted by the au‐
thors  as  related  to  the  high  proportion  of  patients  with  relapsed  disease  (25%)  and by
the concomitant administration of ascorbic acid [43].
In conclusion, these studies have provided evidence that the addition of bortezomib to the
conditioning regimen is feasible with no negative impact on hematopoietic recovery or treat‐
ment-related mortality after ASCT. From the two phase 2 studies adding bortezomib to
high-dose melphalan, high CR rates post-ASCT were noted which appeared superior to his‐
toric data. A small randomized phase 2 study was not able to confirm improved efficacy
outcomes when bortezomib was added to a multi-drug conditioning evidence.
3.3. Bortezomib in consolidation treatment
At the moment of our search, the results of only one randomized study incorporating borte‐
zomib in consolidation therapy has been published in a peer-reviewed paper.
In the GIMEMA phase 3 study investigating bortezomib-thalidomide-dexamethasone (VTD)
vs thalidomide-dexamethasone (TD), the combination regimens were given both in induc‐
tion therapy pre-ASCT and in consolidation therapy post-ASCT[29]. Patients initially
randomized to VTD received 2 post-ASCT consolidation cycles of bortezomib 1.3 mg/m2 iv
on d1,8,15,22 every 5 weeks in combination with thalidomide 100 mg/d po and dexametha‐
sone, patients initially randomized to TD received 2 post-ASCT consolidation cycles without
bortezomib. Of the 236 patients initially randomized to VTD induction, 160 patients (68%)
continued with VTD consolidation, while of the 238 patients initially randomized to TD in‐
duction, 161 patients (68%) continued with TD consolidation. VTD consolidation significant‐
ly improved the CR and CR/nCR rates post-ASCT, while the TD consolidation did not. After
a median follow-up of 30.4 months from start of consolidation, 3-year PFS was significantly
longer for the VTD group (60% vs 48%, p=0.042) but sofar no difference in overall survival
from this landmark has been seen (3-year survival rates 90% for VTD and 88% for TD).
Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD versus TD
consolidation. The authors conclude that VTD consolidation therapy significantly contribut‐
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ed to the improved clinical outcomes observed for patients randomly assigned to the VTD
arm of the study.
3.4. Bortezomib in maintenance treatment
There were no studies identified which in a randomized fashion have investigated the role
of single agent bortezomib as prolonged maintenance therapy post-ASCT. However, a lot of
information on single agent bortezomib maintenance therapy can be derived from the HOV‐
ON-65/GMMG-HD4 study, the largest phase 3 study ever conducted in ASCT in newly di‐
agnosed multiple myeloma. In addition, preliminary data are available from a randomized
phase 3 study investigating the bortezomib-thalidomide combination in maintenance thera‐
py (GEM05-MENOS65) and from a phase 2 study investigating a bortezomib-thalidomide-
dexamethasone combination in maintenance therapy post-ASCT [44].
In the HOVON-65/GMMG-HD4 study, as discussed above, patients randomized to the bor‐
tezomib-doxorubicin-dexamethasone (PAD) induction treatment group continued bortezo‐
mib maintenance 1.3 mg/m2 iv every 2 weeks for 2 years post-ASCT, whereas the control
treatment group of vincristine-doxorubicin-dexamethasone (VAD) induction continued to
be treated with thalidomide 50 mg/d po for the same treatment duration [26]. In this study,
833 patients were randomized between the PAD and the VAD induction regimens. After
ASCT, 229 patients from the PAD treatment group (55%) continued with bortezomib main‐
tenance, while in the VAD treatment group 270 patients (65%) continued with thalidomide
maintenance. Of the 229 patients starting bortezomib maintenance, 109 (48%) completed the
2-year maintenance, while 26 (11%) discontinued because of toxicity and 74 (32%) discontin‐
ued earlier because of progression. Of the 270 patients starting thalidomide maintenance,
only 73 (27%) completed the 2-year maintenance, while more patients (82 or 30%) discontin‐
ued because of toxicity and a similar percentage (86 or 32%) discontinued because of pro‐
gression. Because of the sequential study design a direct comparison between the two
maintenance regimens should be interpreted with caution. However, the main study publi‐
cation indicates a statistically significantly higher incidence of serious adverse events (34%
vs 23%, p<0.01) during bortezomib maintenance, mainly related to infection, while on the
other hand more peripheral neuropathy was reported during thalidomide maintenance (5%
vs 8%, p<0.001). The sequential design also limits the interpretation of the efficacy data of
the maintenance regimens. Although in the bortezomib maintenance all patients had al‐
ready been exposed to bortezomib during induction therapy, a similar percentage of pa‐
tients (23%) had an upgrade of their tumor response post-ASCT as compared to the
thalidomide maintenance which introduced a new agent (24%). An analysis of progression-
free survival calculated from the last ASCT indicates that bortezomib contributed more to
improvement of progression-free survival than thalidomide (31 months vs 26 months). Also,
a landmark analysis starting at month 12 shows an improvement in progression-free surviv‐
al (p=0.04) and overall survival (p=0.05) in the bortezomib-containing arm.
In phase 3 study GEM05-MENOS65 performed by the Spanish PETHEMA/GEM group, pa‐
tients initially randomized to answer the induction regimen question of bortezomib-thal-dex
vs thal-dex vs VBMCP/VBAD/bortezomib (discussed above) were rerandomized after ASCT
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between different maintenance regimens: interferon alfa-2b versus thalidomide 100 mg/d vs
thalidomide 100 mg/d plus bortezomib (1.3 mg/m2 d1,4,8,11 q3 month) until progression
and for a maximum of 3 years [30]. Three-hundred ninety patients were initially random‐
ized between the three induction arms; the initial study publication does not report how
many patients were rerandomized between the 3 maintenance arms nor does it address the
toxicities observed. However, the publication states that after a median follow-up of 24
months from initiation of maintenance, the PFS is significantly longer with thalidomide/
bortezomib compared with thalidomide alone and with alfa2-interferon (78% vs 63% vs 49%
at 2 years, p=0.01). However, at this early analysis, the overall survival is not significantly
different between the 3 maintenance groups.
In a small phase 2 study of 40 patients post-ASCT, a sequential maintenance therapy includ‐
ing bortezomib was investigated [44]. In this study, 6 4-week cycles of weekly bortezomib at
a dose of 1.3 mg/m2 was given in combination with dexamethasone, followed by 6 cycles of
thalidomide and dexamethasone and then followed by thalidomide single agent until pro‐
gression. Of the 40 patients, 32 (80%) completed the bortezomib therapy and in 9 patients
the bortezomib-dexamethasone combination upgraded the response from less than CR to
CR. The combination regimen was feasible, with peripheral neuropathy grade 1-2 being re‐
ported in 27 patients. The authors concluded that this bortezomib maintenance regimen was
able to upgrade post-ASCT CR responses with no severe grade ¾ peripheral neuropathy.
In  conclusion,  currently  available  data  suggest  that  maintenance  therapy  with  bortezo‐
mib,  either  as  single  agent  or  in  combination with  thalidomide,  improves  the  PFS over
thalidomide alone. Prolonged maintenance therapy with bortezomib at lower dose inten‐
sity  than  in  the  induction  setting  (either  one  dose  weekly  or  every  2  weeks,  or  four
doses every 3 months) appears feasible and is able to further improve the CR rate post-
ASCT.  More  follow-up is  needed on  the  impact  of  these  bortezomib  maintenance  regi‐
mens on overall survival.
3.5. Bortezomib during or after ASCT procedure for relapsed myeloma
There were no studies identified which specifically looked into the use of bortezomib as part
of an ASCT procedure for relapsed multiple myeloma.
However, one large randomized phase 3 study by the EBMT group (European Group for
Blood and Marrow Transplantation) investigated the use of a bortezomib containing regi‐
men to rescue patients with multiple myeloma progressing or relapsing after ASCT [45]. In
this study, 269 patients were randomly assigned to receive bortezomib or no bortezomib for
one year, in combination with thalidomide (200mg/d) and dexamethasone. Almost half of
the patients (47%) had two prior ASCTs. The triplet combination of VTD resulted in a signif‐
icantly longer time to progression (19.5 m vs 13.8 m, p=0.001) and a significantly better
CR/nCR rate (45% vs 25%, p=0.001) with a trend towards improved overall survival (71% vs
65% 24-month survival rate, p=0.093) as compared to the TD control group. On the other
hand, the triplet combination had a higher incidence of grade 3 peripheral sensory neuropa‐
thy (29% vs 12%, p=0.001) and a higher incidence of grade >=3 thrombocytopenia (17% vs
7%, p=0.016) not associated with serious bleeding complications. The neurotoxicity was at‐
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ed to the improved clinical outcomes observed for patients randomly assigned to the VTD
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information on single agent bortezomib maintenance therapy can be derived from the HOV‐
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py (GEM05-MENOS65) and from a phase 2 study investigating a bortezomib-thalidomide-
dexamethasone combination in maintenance therapy post-ASCT [44].
In the HOVON-65/GMMG-HD4 study, as discussed above, patients randomized to the bor‐
tezomib-doxorubicin-dexamethasone (PAD) induction treatment group continued bortezo‐
mib maintenance 1.3 mg/m2 iv every 2 weeks for 2 years post-ASCT, whereas the control
treatment group of vincristine-doxorubicin-dexamethasone (VAD) induction continued to
be treated with thalidomide 50 mg/d po for the same treatment duration [26]. In this study,
833 patients were randomized between the PAD and the VAD induction regimens. After
ASCT, 229 patients from the PAD treatment group (55%) continued with bortezomib main‐
tenance, while in the VAD treatment group 270 patients (65%) continued with thalidomide
maintenance. Of the 229 patients starting bortezomib maintenance, 109 (48%) completed the
2-year maintenance, while 26 (11%) discontinued because of toxicity and 74 (32%) discontin‐
ued earlier because of progression. Of the 270 patients starting thalidomide maintenance,
only 73 (27%) completed the 2-year maintenance, while more patients (82 or 30%) discontin‐
ued because of toxicity and a similar percentage (86 or 32%) discontinued because of pro‐
gression. Because of the sequential study design a direct comparison between the two
maintenance regimens should be interpreted with caution. However, the main study publi‐
cation indicates a statistically significantly higher incidence of serious adverse events (34%
vs 23%, p<0.01) during bortezomib maintenance, mainly related to infection, while on the
other hand more peripheral neuropathy was reported during thalidomide maintenance (5%
vs 8%, p<0.001). The sequential design also limits the interpretation of the efficacy data of
the maintenance regimens. Although in the bortezomib maintenance all patients had al‐
ready been exposed to bortezomib during induction therapy, a similar percentage of pa‐
tients (23%) had an upgrade of their tumor response post-ASCT as compared to the
thalidomide maintenance which introduced a new agent (24%). An analysis of progression-
free survival calculated from the last ASCT indicates that bortezomib contributed more to
improvement of progression-free survival than thalidomide (31 months vs 26 months). Also,
a landmark analysis starting at month 12 shows an improvement in progression-free surviv‐
al (p=0.04) and overall survival (p=0.05) in the bortezomib-containing arm.
In phase 3 study GEM05-MENOS65 performed by the Spanish PETHEMA/GEM group, pa‐
tients initially randomized to answer the induction regimen question of bortezomib-thal-dex
vs thal-dex vs VBMCP/VBAD/bortezomib (discussed above) were rerandomized after ASCT
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between different maintenance regimens: interferon alfa-2b versus thalidomide 100 mg/d vs
thalidomide 100 mg/d plus bortezomib (1.3 mg/m2 d1,4,8,11 q3 month) until progression
and for a maximum of 3 years [30]. Three-hundred ninety patients were initially random‐
ized between the three induction arms; the initial study publication does not report how
many patients were rerandomized between the 3 maintenance arms nor does it address the
toxicities observed. However, the publication states that after a median follow-up of 24
months from initiation of maintenance, the PFS is significantly longer with thalidomide/
bortezomib compared with thalidomide alone and with alfa2-interferon (78% vs 63% vs 49%
at 2 years, p=0.01). However, at this early analysis, the overall survival is not significantly
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CR/nCR rate (45% vs 25%, p=0.001) with a trend towards improved overall survival (71% vs
65% 24-month survival rate, p=0.093) as compared to the TD control group. On the other
hand, the triplet combination had a higher incidence of grade 3 peripheral sensory neuropa‐
thy (29% vs 12%, p=0.001) and a higher incidence of grade >=3 thrombocytopenia (17% vs
7%, p=0.016) not associated with serious bleeding complications. The neurotoxicity was at‐
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tributed by the investigators as due to the combination of the two neurotoxic agents bortezo‐
mib and thalidomide given for a prolonged period of time (1 year) and at higher dose levels
(200 mg/d thalidomide). The investigators concluded that the VTD combination may be con‐
sidered as a standard of care for patients relapsing after ASCT, but that the risk for neuro‐
toxicity should be decreased by using lower doses of thalidomide and appropriate dose
reductions of bortezomib.
4. Conclusions and future directions
There is an increasing body of literature on the incorporation of bortezomib in the different
treatment phases of the autologous stem cell transplantation approach in multiple myeloma.
The highest level of evidence on the benefit of bortezomib-containing regimens is available
from multiple phase 3 studies in the induction treatment phase. In other treatment phases,
the current experimental clinical evidence is more limited. In the conditioning phase, only
phase 2 data are available on the addition of bortezomib and comparisons with historic data
should be made with caution. In consolidation, only limited phase 3 information is currently
available but phase 3 studies comparing bortezomib consolidation versus no consolidation
are ongoing or awaiting final publication [46]. In the maintenance phase, randomized phase
3 studies have been published but did not directly test the value of bortezomib maintenance
over no maintenance. Despite these limitations some common themes on the incorporation
of bortezomib can be observed across the different treatment phases:
• The addition of bortezomib increased the quality of the response (higher complete and
near-complete response rates) as compared to control groups or to historic data
• The addition of bortezomb improved the progression-free survival post-ASCT as com‐
pared to control groups or to historic data
• Where analyzed, the addition of bortezomib improved the outcomes of patients with
poor prognostic features, such as high-risk cytogenetics and renal function impairment
• The addition of bortezomib had no negative impact on hematopoietic stem cell collection
or engraftment
• The addition of bortezomib resulted in a higher incidence of peripheral neuropathy
The effect of the addition of bortezomib on the overall survival post-ASCT were variable
across studies. While several studies appear to report a favorable survival trend, only in the
largest phase 3 study (HOVON-65/GMMG-HD4) the survival improvement reached statisti‐
cal significance. Potentially contributing to this could be the short duration of follow-up in
the initial study publications, the effect of subsequent therapy (and in particular of cross-
over use of bortezomib in subsequent therapy lines) and the sample size limitation of the
individual studies. An argument for the latter could be found in a recent meta-analysis indi‐
cating a survival benefit of bortezomib-containing induction therapy if the different phase 3
study results are combined [47].
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Which future research directions can be expected on this topic in the next decade?
First, given the high response rates and complete response rates observed with bortezomib
containing regimens, the question will be asked whether in this younger population with
newly diagnosed multiple myeloma a non-transplant approach incorporating bortezomib
and immunomodulatory agents can delay or prevent the need for a high-dose therapy and
autologous transplant approach. Several randomized phase 3 studies are currently under‐
way to test this hypothesis.
Second, if  the ultimate goal of the autologous transplant approach is disease eradication
and cure,  more rigorous definitions of  complete response and more sensitive diagnostic
techniques  will  be  required  to  optimize  individual  therapy  decisions.  A  stringent  CR
(sCR)  category  has  already  been  defined  by  the  IMWG  criteria  [48].  This  stringent  CR
(sCR) category requires a normalization of  the free κ/λ ratio in serum and an immuno‐
phenotypic  normalization  of  the  κ/λ  ratio  in  the  bone  marrow,  but  sofar  has  not  been
routinely reported in high-dose therapy studies.  By the most recent criteria,  also an im‐
munophenotypic  CR  category  has  been  defined  to  exclude  minimal  residual  disease
based on a more extensive immunophenotypic analysis of the bone marrow [49]. Charac‐
terization of minimal residual disease by immunophenotyping has only been reported in
selected studies [50]. Alternative techniques such as magnetic resonance imaging or posi‐
tron  emission  tomography  have  also  been  reported  but  require  further  characterization
before incorporation in routine ASCT procedures. [51,52].
Third, second-generation proteasome inhibitors, such as carfilzomib, marizomib and
MLN-9708, are currently in development in multiple myeloma [53]. These agents are also
potent inhibitors of proteasome activity in vitro but show differences in enzyme binding ki‐
netics which might affect their pharmacology and result in different efficacy and safety pro‐
files [54]. Most data with the second generation proteasome inhibitors have been generated
in the relapsed or refractory myeloma setting. As there are no full publications in peer-re‐
viewed journals available addressing the incorporation of such agents in autologous stem
cell transplant approaches, these agents were not included in this review. However, data of
early studies combining carfilzomib with either thalidomide-dexamethasone or lenalido‐
mide-dexamethasone as induction treatment prior to ASCT have already been reported at
international conferences [55,56]. Further research on the incorporation of second-generation
proteasome inhibitors in autologous stem cell transplant approaches in myeloma can there‐
fore definitely be expected.
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1. Introduction
In the majority of patients, the therapy of acute myeloid leukemia (AML) has a curative in‐
tent and includes two phases, i.e. induction and consolidation. The former aims at complete
remission (CR) achievement, the latter at the eradication of residual leukemic cells, which
are undetectable at morphologic examination of bone marrow after induction therapy in pa‐
tients in CR. Current induction regimens, conventionally based on the combination of dau‐
norubicin and cytarabine result in CR rates of 60 – 70% of AML patients younger than 65
years; in order to improve both CR rate and quality, different studies tested alternative an‐
thracyclines [1]-[5], higher schedules of Ara-C[6]-[10], the addition of a third cytotoxic drug
[11]-[16] and, more recently, the combination with new agents. Overall, results have been
disappointing even though the addition of gemtuzumab ozogamycin (GO), an antiCD33
monoclonal antibody conjugated with the cytotoxic agents chalicheamycin, has been report‐
ed to confer a significant advantage in selected patients with AML [17]-[21]. Notwithstand‐
ing, in absence of intensive post-induction therapy virtually all patients will ultimately
relapse, therefore consolidation therapy is strictly needed. At present, after CR achievement
all patients receive a consolidation chemotherapy based on intermediate or high dose ARA-
C and then in young adult patients three options can be considered, i.e. allogeneic stem cell
transplantation (allo-SCT), autologous SCT (ASCT) or repetitive intensive consolidation che‐
motherapy cycles (ICC) with high or intermediate dose ARA-C [22]-[37], depending on age,
disease risk and donor availability. In particular, it is widely accepted that ICC and ASCT
would be limited to patients with favorable risk, such as AML with t(8;21), AML with
inv(16) or t(16;16) and AML with normal karyotype with NPM1 mutation in absence of mu‐
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tations of FLT3/ITD gene [38], [39]. In the remaining patient population, allo-SCT must be
considered when age and performance status result in an acceptable risk/benefit ratio. In
this regard, it should be considered that in the last years morbidity and mortality from allo-
SCT have been considerably reduced; in addition, the introduction into daily practice of re‐
duced intensity conditioning (RIC) has allowed to offer the procedure to selected old and/or
previously not eligible patient population.
Currently, even in patients with favourable prognostic factors at diagnosis, the role of ASCT
remains unclear although most studies that have compared ASCT with ICC demonstrated a
significantly lower rate of relapse following ASCT (5,6). Results in terms of survival were,
however, less encouraging because of transplant-related deaths and the low rate of second
CR in patients who relapsed after ASCT, therefore in the last year ASCT has become less
popular, mainly in USA. Notwithstanding, different considerations should be made: first,
both the occurrence of toxicity and mortality related to ASCT have greatly decreased since
use of peripheral-blood stem cells was introduced, even in older patients. Second, reduction
of relapse rate would represent a main therapeutic objective in the therapy of AML, just as it
is any malignant disorder. Finally, consolidation therapy based on repeated courses of high-
dose or intermediate-dose cytarabine is probably more toxic and costly than ASCT and is
poorly feasible in patients aged over 55-60 years. In elderly patients, particularly, the dose
intensification by either ASCT or ICC has failed so far to induce a significant benefit [40]-
[42]. Therefore, novel more rational targeted agents are particularly warranted in this set‐
ting. On the other hand, two important conditions are necessary in order to perform ASCT:
CR achievement and collection of an adequate number of CD34+ cells (> 2 x 106/Kg). As the
latter aspect is concerned, it should be mentioned that a previous history of myeloid disor‐
der (especially myelodysplastic syndrome), advanced age and the use of certain drugs dur‐
ing the induction and consolidation phases (e.g. fludarabine [43]) can significantly impair
the possibility to collect an adequate number of cells.
Overall, data from the literature are controversial, but it has been definitively demonstrated
that ASCT provides better results in patients with favorable risk diseases and low amount of
minimal residual disease after induction/consolidation therapy. In the last years, a few com‐
plete meta-analyses and extensive reviews tried to draw some conclusions but were not able
to indicate definite guidelines [44]-[46].
In this chapter, the authors review the current knowledge on the use of SCT in post-consoli‐
dation therapy of AML, based on their own experience and the most recent literature data,
by mainly focusing on randomized clinical trials (RCT).
2. Randomized clinical trials comparing autologous stem cell
transplantation and chemotherapy or no further therapy
In  1995  Zittoun  et  al.  for  the  EORTC-GIMEMA  groups  reported  on  941  AML  patients
treated with one or two cycles of standard Daunorubicine/Cytarabine schedule (3/7).  Pa‐
tients obtaining CR were submitted to one consolidation cycle including high-dose cytar‐
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abine  (HD-AC)  and  Amsacrine.  Subsequently,  patients  with  HLA  identical  donor  were
allo-transplanted, whereas patients without HLA identical donor were randomized to re‐
ceive  ASCT  or  a  second  consolidation  (ICC)  with  daunorubicine  and  HD-AC.  The  CR
rate after induction therapy was 66%. The relapse rate were 40% in the two arms (ASCT)
and 57% (ICC),  respectively;  DFS was longer for  patients  submitted to ASCT compared
to patients submitted to ICC (48% vs 30%; p=0.05). However the OS was not significant‐
ly superior in the ASCT group, due to the greater ability of ASCT to rescue relapsed pa‐
tients in the ICC arm [24].
In 1997 Harousseau and Colleagues reported data on 517 eligible patients (15-50 years of
age) affected by previously untreated AML. Patients received 3 - 4 courses of conventional
induction treatment (Ara-C: 200 mg/sqm/day for 7 consecutive days with either idarubicin
administered intravenously on days 1 - 5 at a daily dose of 8 mg/sqm or rubidazone admin‐
istered intravenously on days 1 - 4 at a daily dose of 200 mg/sqm). Patients aged 40 year or
younger, in CR after induction therapy, were assigned to SCT if an HLA identical donor was
available. All other patients received a first course of HD-Ara-C (3 gr/sqm) administered ev‐
ery 12 hours along 4 days (ICC) and then were randomized to receive either a second course
of ICC or an ASCT. Eighty-eight patients out of 517 received an SCT, while 164 out of 517
were eligible for randomization (75 received ASCT, 71 received ICC). No differences in
terms of OS and DFS were observed between the two arms: the 4 years DFS was 44 +/- 5.5%
in ASCT group and 40.5 +/- 5.5% in ICC group (p value 0.41); the 4 years OS was 50 +/- 6% in
ASCT group and 54.5 +/- 6% in ICC group (p value 0.72). The retrospective analysis of DFS
and OS based on the cytogenetic risk could not detect any differences between the ASCT
group and the ICC group [28].
In 1998 Cassileth et al. reported on 740 AML patients treated with standard 3/7 – 3/5 induc‐
tion – consolidation chemotherapy cycles. Patients without an HLA identical donor were
randomized between ASCT and HD-AC. The overall CR rate was 70%; the 4-years-DFS was
35% in both groups; the 4 years OS was 43% in ASCT group and 52% in ICC group respec‐
tively (p= 0.05) [25].
The first report on the MRC AML 10 trial was published in 1998 [29]. Patients were firstly
randomly assigned to different induction chemotherapy regimens (DAT vs. ADE); all pa‐
tients achieving CR after two induction courses received a third consolidation chemothera‐
py course (MACE). Patients who lacked an HLA-matched sibling donor were randomized
to receive one more chemotherapy course (MidAC) followed by either ASCT or no further
therapy; patients with an HLA-matched sibling donor were assigned to receive an SCT. Ba‐
sis on the intention to treat analysis the number of relapses was significantly lower in the
ASCT group than in the group assigned no further treatment (37% vs. 58%; p= 0.0007), re‐
sulting in superior DFS at 7 years (53% vs. 40%; p=0.04). No difference in terms of OS was
observed. Of note, however, in this trial only 38% of patients available for randomization
were randomized [29].
Tsimberidou et al. then reported data on 120 patients with de novo AML in 2003. All pa‐
tients were treated with standard 3/7 regimen (2 courses) and if in CR underwent a first HD-
AC course. All patients aged less than 50 years and with an HLA compatible donor received
Autologous Stem Cell Transplantation for Acute Myeloid Leukemia
http://dx.doi.org/10.5772/54280
243
tations of FLT3/ITD gene [38], [39]. In the remaining patient population, allo-SCT must be
considered when age and performance status result in an acceptable risk/benefit ratio. In
this regard, it should be considered that in the last years morbidity and mortality from allo-
SCT have been considerably reduced; in addition, the introduction into daily practice of re‐
duced intensity conditioning (RIC) has allowed to offer the procedure to selected old and/or
previously not eligible patient population.
Currently, even in patients with favourable prognostic factors at diagnosis, the role of ASCT
remains unclear although most studies that have compared ASCT with ICC demonstrated a
significantly lower rate of relapse following ASCT (5,6). Results in terms of survival were,
however, less encouraging because of transplant-related deaths and the low rate of second
CR in patients who relapsed after ASCT, therefore in the last year ASCT has become less
popular, mainly in USA. Notwithstanding, different considerations should be made: first,
both the occurrence of toxicity and mortality related to ASCT have greatly decreased since
use of peripheral-blood stem cells was introduced, even in older patients. Second, reduction
of relapse rate would represent a main therapeutic objective in the therapy of AML, just as it
is any malignant disorder. Finally, consolidation therapy based on repeated courses of high-
dose or intermediate-dose cytarabine is probably more toxic and costly than ASCT and is
poorly feasible in patients aged over 55-60 years. In elderly patients, particularly, the dose
intensification by either ASCT or ICC has failed so far to induce a significant benefit [40]-
[42]. Therefore, novel more rational targeted agents are particularly warranted in this set‐
ting. On the other hand, two important conditions are necessary in order to perform ASCT:
CR achievement and collection of an adequate number of CD34+ cells (> 2 x 106/Kg). As the
latter aspect is concerned, it should be mentioned that a previous history of myeloid disor‐
der (especially myelodysplastic syndrome), advanced age and the use of certain drugs dur‐
ing the induction and consolidation phases (e.g. fludarabine [43]) can significantly impair
the possibility to collect an adequate number of cells.
Overall, data from the literature are controversial, but it has been definitively demonstrated
that ASCT provides better results in patients with favorable risk diseases and low amount of
minimal residual disease after induction/consolidation therapy. In the last years, a few com‐
plete meta-analyses and extensive reviews tried to draw some conclusions but were not able
to indicate definite guidelines [44]-[46].
In this chapter, the authors review the current knowledge on the use of SCT in post-consoli‐
dation therapy of AML, based on their own experience and the most recent literature data,
by mainly focusing on randomized clinical trials (RCT).
2. Randomized clinical trials comparing autologous stem cell
transplantation and chemotherapy or no further therapy
In  1995  Zittoun  et  al.  for  the  EORTC-GIMEMA  groups  reported  on  941  AML  patients
treated with one or two cycles of standard Daunorubicine/Cytarabine schedule (3/7).  Pa‐
tients obtaining CR were submitted to one consolidation cycle including high-dose cytar‐
Innovations in Stem Cell Transplantation242
abine  (HD-AC)  and  Amsacrine.  Subsequently,  patients  with  HLA  identical  donor  were
allo-transplanted, whereas patients without HLA identical donor were randomized to re‐
ceive  ASCT  or  a  second  consolidation  (ICC)  with  daunorubicine  and  HD-AC.  The  CR
rate after induction therapy was 66%. The relapse rate were 40% in the two arms (ASCT)
and 57% (ICC),  respectively;  DFS was longer for  patients  submitted to ASCT compared
to patients submitted to ICC (48% vs 30%; p=0.05). However the OS was not significant‐
ly superior in the ASCT group, due to the greater ability of ASCT to rescue relapsed pa‐
tients in the ICC arm [24].
In 1997 Harousseau and Colleagues reported data on 517 eligible patients (15-50 years of
age) affected by previously untreated AML. Patients received 3 - 4 courses of conventional
induction treatment (Ara-C: 200 mg/sqm/day for 7 consecutive days with either idarubicin
administered intravenously on days 1 - 5 at a daily dose of 8 mg/sqm or rubidazone admin‐
istered intravenously on days 1 - 4 at a daily dose of 200 mg/sqm). Patients aged 40 year or
younger, in CR after induction therapy, were assigned to SCT if an HLA identical donor was
available. All other patients received a first course of HD-Ara-C (3 gr/sqm) administered ev‐
ery 12 hours along 4 days (ICC) and then were randomized to receive either a second course
of ICC or an ASCT. Eighty-eight patients out of 517 received an SCT, while 164 out of 517
were eligible for randomization (75 received ASCT, 71 received ICC). No differences in
terms of OS and DFS were observed between the two arms: the 4 years DFS was 44 +/- 5.5%
in ASCT group and 40.5 +/- 5.5% in ICC group (p value 0.41); the 4 years OS was 50 +/- 6% in
ASCT group and 54.5 +/- 6% in ICC group (p value 0.72). The retrospective analysis of DFS
and OS based on the cytogenetic risk could not detect any differences between the ASCT
group and the ICC group [28].
In 1998 Cassileth et al. reported on 740 AML patients treated with standard 3/7 – 3/5 induc‐
tion – consolidation chemotherapy cycles. Patients without an HLA identical donor were
randomized between ASCT and HD-AC. The overall CR rate was 70%; the 4-years-DFS was
35% in both groups; the 4 years OS was 43% in ASCT group and 52% in ICC group respec‐
tively (p= 0.05) [25].
The first report on the MRC AML 10 trial was published in 1998 [29]. Patients were firstly
randomly assigned to different induction chemotherapy regimens (DAT vs. ADE); all pa‐
tients achieving CR after two induction courses received a third consolidation chemothera‐
py course (MACE). Patients who lacked an HLA-matched sibling donor were randomized
to receive one more chemotherapy course (MidAC) followed by either ASCT or no further
therapy; patients with an HLA-matched sibling donor were assigned to receive an SCT. Ba‐
sis on the intention to treat analysis the number of relapses was significantly lower in the
ASCT group than in the group assigned no further treatment (37% vs. 58%; p= 0.0007), re‐
sulting in superior DFS at 7 years (53% vs. 40%; p=0.04). No difference in terms of OS was
observed. Of note, however, in this trial only 38% of patients available for randomization
were randomized [29].
Tsimberidou et al. then reported data on 120 patients with de novo AML in 2003. All pa‐
tients were treated with standard 3/7 regimen (2 courses) and if in CR underwent a first HD-
AC course. All patients aged less than 50 years and with an HLA compatible donor received
Autologous Stem Cell Transplantation for Acute Myeloid Leukemia
http://dx.doi.org/10.5772/54280
243
an SCT; patient aged more than 50 years or without an HLA-matched sibling donor were
randomly assigned to receive a second HD-Ara course or an ASCT. With a median follow-
up of 43 months the 3-year failure free survival rates was 42% for patients receiving ASCT
and 33% for patients receiving conventional chemotherapy [33].
Subsequently, Breems et al in 2005 reported data on 646 patients enrolled in the HOVO/
SAKK AML4 trial. After two cycle of induction therapy combining cytarabine with daunor‐
ubicine (first course) and amsacrine (second course), CR patients (75%) were addressed to a
consolidation therapy with mitoxantrone and VP16. Eighty-one patients received SCT. Pa‐
tients non eligible for SCT were randomized between ASCT (66 patients) and no further
therapy (46 patients). After a median follow up of 154 months, there were no statistically
significant differences concerning DFS, OS and relapse rate within the two randomization
arms. There was a trend towards a better OS of the non-autografted patients. This was asso‐
ciated with a higher, though non significant, incidence of death in CR within the auto-trans‐
planted group with respect to the no treatment group. The 5 years OS after relapse for
patients previously auto-grafted was significantly shorter with respect to patients who re‐
ceived no further treatment [34].
A large European intergroup trial [47] later evaluated HD-AC induction and escalation of
post-remission therapy in a 2-stage RCT. Patients under the age of 60 years were random‐
ized to 1 of 2 induction courses (double HD-AC vs. standard cytarabine/HD-AC). Patients in
remission received a third cycle of chemotherapy followed by a second randomization to
ASCT or maintenance chemotherapy. Fifty-one percent assigned to maintenance received
the assigned therapy, while only 24% received the assigned ASCT. Three-year remission du‐
ration was 50% versus 44%, 3-year relapse-free survival was 48% versus 43% for mainte‐
nance and ASCT, respectively, and there was no significant difference between the 2 arms
when stratified according to cytogenetic risk profile [47].
An update of the AML10 study was then reported in 2006 [35]. Briefly, The overall survival
of patients allocated to autologous transplantation was better than for those in the no-fur‐
ther-therapy arm (53% vs. 45%) at 10 years, with 165 patients at risk at that time point. Of
note, although this difference was not statistically significant on a log-rank analysis (P=.09),
the Kaplan-Meier plots clearly diverged after the first 3 years, the difference becoming sig‐
nificant. This was related to a highly significant reduction in relapse risk in the autograft
arm (40% vs. 58%; P=.0005), with consequent improved DFS in the ASCT arm (50% vs. 39%;
P=.03), a data which was partially obscured by a higher risk of death in remission (16% vs.
6%; P=.02). Overall, the study suggested a survival benefit with ASCT in patients in the
good- and standard-risk groups but not in the poor-risk group. Conversely, it was unclear if
any specific age group benefited [35].
Based on these studies, a couple of systematic meta-analyses and reviews, tried to delineate
some possible indications. However, many data were conflicting a definitive recommenda‐
tions appeared difficult. Particularly, Nathan and Colleagues performed a comprehensive
meta-analysis on consolidation therapy for AML. In particular, they analyzed 6 studies in‐
cluding 1044 patients randomly assigned t receive ASCT vs. ICC (5 studies), or ASCT vs. no
further treatment (1 study). Patients receiving ASCT had a better disease free but not differ‐
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ent overall survival. Thus, they did not recommend ASCT as routine options for AML pa‐
tients in first CR [45]. Thereafter, Visani and Colleagues, based on evidence based medicine
(EBM) criteria, considered 6 RCT evaluating the role of ASCT and concluded that due to the
heterogeneity of AML biology (i.e. molecular genetics), further studies specifically dedicated
to the different entities were probably necessary to build robust recommendation according
to EBM rules [46].
More recently, the HOVON Group reported the results of a prospective, randomized phase
3 trial evaluating ASCT vs. ICC in newly diagnosed AML patients in first CR (CR1) [48]. Pa‐
tients with AML (16-60 years) in CR1 after 2 cycles of intensive chemotherapy and not eligi‐
ble for allogeneic SCT were randomized between ICC (including etoposide and
mitoxantrone) or ASCT (Bu/Cy). More than 90% of randomized patients received their as‐
signed treatment (ICC, n = 259; ASCT, n = 258),. The 2 groups were comparable with regard
to prognostic factors. The ASCT group showed a markedly reduced relapse rate (58% vs.
70%, P = 0.02) and better relapse-free survival at 5 years (38% vs. 29%,P =0.065) with non-
relapse mortality of 4% vs. 1% in the chemotherapy arm (P =0.02). OS was similar (44% vs.
41% at 5 years, P =0.86), possibly because of more opportunities for salvage with second-line
chemotherapy and SCT in patients relapsing on the chemotherapy arm. [48].
Finally, Pfirman et al reported the results of the AML96 trial [49], aiming to differentiate
groups of patients according to the treatments that would provide them optimum benefit.
Five hundred eighty six AML patients (aged below 60 years) - excluding those with t(8;21) –
in CR1 after double induction treatment were consolidated with SCT or ASCT, or ICC con‐
taining HD-AC, in a priority-based and risk-adapted manner. The association between po‐
tentially prognostic variables and OS was assessed and a post-remission treatment (PRT)
score was developed in 452 patients with a complete dataset. This score was then validated
in additional 407 patients from the AML2003 trial. Age, percentage of CD34-positive blasts,
FLT3-ITD mutant-to-wild-type ratio, cytogenetic risk, and de-novo or secondary AML were
identified as independent prognostic factors, and included in the PRT score. Accordingly,
patients were separated into three groups: favorable (N=190; 3-year survival 68%), inter‐
mediate (N=198; 49%), and unfavorable (n=64; 20%). These results were confirmed in the
AML2003 trial dataset: 3-year survival for the favorable group (n=265) was 69%, for the in‐
termediate group (n=114) it was 61%, and for the unfavorable group (n=28) it was 46%.
Therefore, the 3 groups presented with significantly different survival probabilities
(p=0.015). Additionally, the Authors found that in the favorable group, patients who re‐
ceived SCT (n=60) had higher survival probabilities (82%) than did those given chemothera‐
py (n=56, 55%; p=0.0012) or ASCT (n=74, 66%; p=0.044). In the intermediate PRT score group,
patients receiving ASCT (n=69) had the best survival probabilities (62%) compared with
those given chemotherapy (n=72, 41%; p=0.0006) or SCT (n=57, 44%; p=0.0045).
Overall, the study thus supported the use of autologous HSCT in patients aged 60 years or
younger with an intermediate PRT score.
Results of the above mentioned studies on ASCT are summarized in Table 1.
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990 patients (< 59 y) previously untreated AML.
(941 evaluable)
4 yrs DFS: 48 ± 5% 4 yrs DFS: 30 ± 5% 0.05
Study design: 4 yrs OS : 56 ± 5% 4 yrs OS : 56 ± 5% NS
- Induction: cytarabine + doxorubicine
If PR: 2nd course of induction therapy
Consolidation: HDAC+amsacrine
If CR, age<45 yrs and HLA compatible donor: allo-
SCT (N= 144)
- If > 45 yrs and/or no HLA compatible donor: ran‐
domization (auto-SCT, N= 95 vs. 2nd course of in‐
tensive therapy, N=104)
Harousseau et al
517 previously untreated AML patients (15-50 yrs) 4 yrs DFS: 44 ± 5.5% 4 y DFS: 40.5 ± 5.5% NS
Study design: 4 yrs OS: 50 ± 6% 4 y OS: 54.5 ± 6%
- Induction: cytarabine and idarubicine or rubida‐
zone. If no CR: 2nd cycle
Low risk group
- Consolidation: HD-AC + Idarubicine or Rubida‐
zone
4 yrs DFS: 50 ± 9% 4 yrs DFS : 56 ± 11% NS
If CR, age <40 yrs and HLA compatible donor: allo-
SCT (N=88)
4 yrs OS: 59 ± 9% 4 yrs OS: 71 ± 8% NS
- If > 40 yrs and/or no HLA compatible donor: ran‐
domization (auto-SCT, N= 75 vs. ICC, N=71)
Intermediate risk group
- 4 yrs DFS: 38.5 ±
9%
- 4 yrs DFS: 31 ±
8.5%
NS
- 4 yrs OS: 42.5 ± 9% - 4 yrs OS: 55 ± 9% NS
High risk group
- 4 yrs DFS: 38 ±
10%
- 4 yrs DFS: 28.5 ±
10%
NS
- 4 yrs OS: 46.5 ±
11%




772 previously untreated AML patients 4 yrs DFS: 35±9 % 4 yrs DFS: 35±9 % NS
(16-55 yrs)
Study design: 4 yrs OS: 43±9 % 4 yrs OS: 52±9 % P=0.05
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Induction: 2 cycles of idarubicine and cytarabine
Consolidation: idarubicine and cytarabine
- If CR and HLA compatible donor: allo-SCT
(N=113)
- If not HLA compatible donor: randomization au‐
to-SCT (N =116) vs. HD-Cytarabine (N = 117)
Burnett et al
1509 previously untreated AML patients aged less
than < 56 yrs
10 yrs DFS: 50% 10 yrs DFS: 39% 0.03
Study design:
- 2 Induction: Daunorubicine, Cytarabine, Thio‐
guanine vs Daunorubicine, Cytarabine, VP-16
10 yrs OS: 53% 10 yrs OS : 45% 0.009
- 1st Consolidation: Amsacrine, Cytarabine, VP-16
- Pts with HLA identical donor: 2nd consolidation
(Mitoxantrone, Cytarabine) and allo-SCT
Relapse rate at 10
yrs: 40%
Relapse rate at 10
yrs: 58%
0.0005
- Pts lacking HLA identical donor: 2nd consolida‐
tion (Mitozantrone, Cytarabine) and randomiza‐
tion to auto-SCT (N =190) vs. no further therapy
(N =191)
Tsimberidou et al
120 previously untreated AML patients (<60 yrs) 3 yrs OS: 58% 3 yrs OS: 46% NS
Study design: 3 yrs FFS: 42% 3 yrs FFS: 33% NS
- 2 Induction: Idarubicine, Cytarabine (3+7)
- Consolidation: HD-AC
- If < 50 y and HLA compatible donor :
allo-SCT (N = 21)
- If > 50 y and/or no HLA compatible donor: ran‐
domization (auto-SCT, N = 19 vs. 2nd HD-AC, N=
15)
Breems et al
646 previously untreated AML patients (< 60
years)
5 yrs DFS: about
35%




5 yrs OS : about
45%
5 yrs OS : about 55% NS
- Induction 1: Daunorubicine, Cytarabine (3+7)
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- Induction 2: Amsacrine, Cytarabine
7 pts died in CR
within 9 months
1 pts died in CR
within 9 months
NS
- Consolidation: Mitoxantrone, VP16
- If eligible and compatible donor : allo-SCT (N =
81)
5 yrs OS after re‐
lapse: about 5%
5 yrs OS after re‐
lapse: about 25%
0.003
- If non eligible: randomization (auto-SCT, N =66
vs. no therapy, N = 64)
Buchner et al.
840 AML/high-risk MDS patients (age ≤ 60 years) 3 yrs DFS: 48% 3 yrs DFS: 46% 0.65
Study design:
1st Randomization at induction: TAM-HAM vs.
HAM-HAM
3 yrs OS : 43% 3 yrs OS : 41% 0.52
TAD: thioguanine, cytarabine, and daunorubicin
HAM: cytarabine and mitoxantrone
Consolidation: TAD
2nd Randomization (auto-SCT, N=429 vs. mantei‐
nance, N = 411)
If eligible and compatible donor : allo-SCT (N=
128)
Vellenga 2011
2,017 AML patients (age ≤ 60 years)
Induction 1: cytarabine and idarubicinInduction 2:
cytarabine and amsacrine
5 yrs DFS: 38% 5 yrs DFS: 29% 0.065
Consolidation: etoposide and mitoxantrone 5 yrs OS: 44% 5 yrs OS : 41% 0.86
Randomization to ASCT (N=258) vs. Chemothera‐
py (N=259)
Relapse rate: 58% Relapse rate: 70% 0.02
Pfirman 2012
1,151 AML patients (age ≤ 60 years) Favorable PRT:
Assigment to ASCT (N=191) vs. Chemotherapy
(N=223)
3 yrs OS: 66% 3 yrs OS : 55%
Assigment to SCT (N=172) Intermediate PRT:
3 yrs OS: 62% 3 yrs OS : 41% 0.0006
Adverse PRT:
3 yrs OS: 7% 3 yrs OS : 19%
Table 1. Summary of the most relevant randomized clinical trials evaluating the role of ASCT in AML
Innovations in Stem Cell Transplantation248
3. Discussion and perspectives
Current intensive induction chemotherapy for patients with AML produces CR rates higher
than 60-65 %; however, less than 30% of patients still survive for more 5 years free of disease. In
this context, the aim of post-remission treatment is to eradicate clonogenic leukemic cells,
which persists after induction and are ultimately able to induce disease relapse. Nonetheless,
the optimal form of treatment is still under debate. As discussed, three main strategies are used
to prevent relapse in patients with AML in first CR, including intensive chemotherapy based on
intermediate-dose or high-dose cytarabine, and allogeneic and autologous hemopoietic stem
cell transplantation. The choice among these approaches for an individual patient relies on two
main factors, namely the expected risk of relapse as determined by biological features of leuke‐
mic cells and expected morbidity and mortality associated with a specific option, according to
age and comorbidities [50].
Intensive chemotherapy (ICC) proved to be useful for improving AML patients outcome
[17], [19]-[21], [51]-[55].
On the other hand, allogeneic SCT was demonstrated to be the most effective strategy to re‐
duce the relapse risk [24], [25], [28], [29]. However, it is associated with a high-risk of treat‐
ment-related morbidity and mortality (TRM), and it is conventionally offered to younger
patients with a HLA-matched sibling or unrelated donor. Of note, in the last years several
evidences emerged that allogeneic SCT should not be offered as first option to patients with
relatively favorable biological characteristics. The latter include a few genetic abnormalities
– t(8;21)(q23;q22), inv(16)(p13q22), and t(15;17)(q22;q21) – as well as the presence of somatic
mutations of NMP1 and/or CEBPA genes in absence of other abnormalities. Therefore, for
these patients, with the exception of M3 patients that can benefit from specific targeted
agents, once achieved CR, the most suitable therapeutic options remain intensive chemo‐
therapy and ASCT.
ASCT is an alternative approach to deliver an effective anti-leukemic myeloablative thera‐
py to AML patients in CR, when a donor is not available. It has been demonstrated that
ASCT is  feasible  and effective  in  AML,  provided that  an  adequate  induction/consolida‐
tion treatment has previously determined an effective in vivo purging. In fact, the results
obtained with ASCT can be significantly affected by other relevant factors,  including in‐
tensity  of  induction  and  consolidation  chemotherapy  as  well  as  conditioning  regimens,
which strongly influencing the MRD burden before the procedure is performed [50]. Bear‐
ing  this  in  mind,  it  is  not  surprising  that  the  several  RCT trying  to  define  the  role  of
ASCT as post-remission therapy in AML ended up with discrepant result.  In particular,
the nine largest studies, though considering 2,894 patients assigned to either ASCT or che‐
motherapy/no further therapy (among more than 8,000 enrolled ones) did not reach defin‐
itive  conclusions (Table  1).  In  fact,  although a  reduced relapse risk was often recorded,
only one study provided evidences  of  survival  advantages for  patients  receiving ASCT,
considering the whole population [35], while one assessed a significant advantage only in
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mutations of NMP1 and/or CEBPA genes in absence of other abnormalities. Therefore, for
these patients, with the exception of M3 patients that can benefit from specific targeted
agents, once achieved CR, the most suitable therapeutic options remain intensive chemo‐
therapy and ASCT.
ASCT is an alternative approach to deliver an effective anti-leukemic myeloablative thera‐
py to AML patients in CR, when a donor is not available. It has been demonstrated that
ASCT is  feasible  and effective  in  AML,  provided that  an  adequate  induction/consolida‐
tion treatment has previously determined an effective in vivo purging. In fact, the results
obtained with ASCT can be significantly affected by other relevant factors,  including in‐
tensity  of  induction  and  consolidation  chemotherapy  as  well  as  conditioning  regimens,
which strongly influencing the MRD burden before the procedure is performed [50]. Bear‐
ing  this  in  mind,  it  is  not  surprising  that  the  several  RCT trying  to  define  the  role  of
ASCT as post-remission therapy in AML ended up with discrepant result.  In particular,
the nine largest studies, though considering 2,894 patients assigned to either ASCT or che‐
motherapy/no further therapy (among more than 8,000 enrolled ones) did not reach defin‐
itive  conclusions (Table  1).  In  fact,  although a  reduced relapse risk was often recorded,
only one study provided evidences  of  survival  advantages for  patients  receiving ASCT,
considering the whole population [35], while one assessed a significant advantage only in
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patients  with  an  intermediate  prognostic  score  [49].  Indeed,  in  most  instances,  the  re‐
duced leukemia recurrence was balanced by an increase TRM. In this regard, however, it
should be mentioned that in the last years the mortality of ASCT has definitely declined,
possibly challenging some of the results published so far. Moreover, reduction of the re‐
lapse rate is a pivotal objective in the treatment of AML, as the only way toward the cure.
In addition, the continuous and very fast improvement in our knowledge of the biology
of the disease on one hand clearly established that AML is not a unique disease, provid‐
ing the basis for future more rationale therapies based on the specific molecular features,
while on the other hand made more difficult to be interpreted results from most clinical
trials, that were initiated when a comprehensive molecular characterization was not avail‐
able.  Accordingly,  a  modern  view of  the  problem should  consider  these  new elements
and rather than debating whether ASCT is superior to SCT or ICC in AML, it would be
more useful to identify those patients who would more benefit from the procedure.
Of note, one study (actually the most recently published) tried to identify the optimal post-
remission strategy according to both clinical and biological features of the single case, recog‐
nizing three different groups based on an original post-remission treatment (PRT) score.
Indeed, ASCT turned out to be the treatment of choice for the intermediate class, the out‐
come being quite favourable (Table 1). Therefore, although the proposed scoring systems
will be probably modified/updated in the future, following, for example, the knowledge de‐
rived fro the most recent massive parallel sequencing studies [56] and the introduction of
novel anti-leukemic compounds, an interesting scenario has probably (re)opened for ASCT.
Finally, future research should focus on designing better ways to do autografts rather than
conducting more trials comparing chemotherapy with the same autograft procedures cur‐
rently in use, including the adoption of immunotherapy, the selection of patients based on
the absence of a minimal residual disease [57] and/or of new biologic molecularly targeted
compounds in the post-ASCT phase.
In conclusion, although evidence based indication cannot be offered for ASCT in AML, it is
reasonable to consider it as a valid therapeutic option for AML patients at low-intermediate
risk in CR1. Indeed, a main goal should be having optimal frontline genetic characterization,
as well as MRD evaluation on the harvested cells. For high risk patients, unfortunately, SCT
can be an option, if they achieve a good quality CR; otherwise, experimental procedures are
mandatory.
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1. Introduction
The substance of bone marrow transplantation is the organ transplantation. Accurately, it is
the grafting of hematopoietic and immunologic system. Comparing to the transplantation of
solid organ, in the hematopoietic stem cell transplantation (HSCT), the ill organ, id est. hem‐
atopoietic and immunology system, is ablated by high-dose chemotherapy and total body
irradiation(TBI) (conditioning regime). Thus, the normal hematopoietic stem cells could be
engrafted and normal function of hematopoietic and immune system could be reconstituted.
The standard myeloablative conditioning regimen would be reasonable or enough for the
non-malignances of marrow, which needed by replacing therapy, such as marrow failure.
However, for treatment of hematopoietic malignances, it maybe not cure the malignance
diseases to ablate the normal hematopoietic, immune system and reconstitute the normal
function of allogeneic hematopoietic and immune system of patients. Because the leukemic
stem cells (LSC) are not only existence in the bone marrow, it might be occurrence in any
site of body. For instance, the traditional myeloablative conditioning regimen to treat leuke‐
mia could have striking killing effects of leukemic cells, and residual leukemic cells further
eradicated by effect of the graft versus leukemia (GVL), but the malignant cells are not al‐
ways removed at all in the all patients, therefore, relapse post transplantation could be oc‐
curred in the some patients. In fact, the traditional allogeneic myeloablative HSCT could
cure or improve outcome of acute leukemic patients with standard risk, however, the dis‐
ease relapse after transplant for acute leukemia with high risk and refractory is 40% to 80%
[1-4]. Moreover, the leukemic cells in the majority of relapsed cases originate from inceptive
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leukemic cells at initial diagnosis [5-7], which strongly indicated that the standard myeloa‐
blative conditioning regimen could remove the normal lymphohematopoietic system of the
recipients and make grafts successfully ecize and proliferate, but could not always kill the
residual leukemic stem cells in vivo, particularly the those in extramedullary sites. Those re‐
sidual leukemic stem cells are the crime for the disease recurrence. We pioneered the tumor‐
ablative allogeneic hematopoietic stem cell transplantation (TAHSCT) for treatment of those
patients with high-risk, refractory, even advanced-stage acute leukemia. The TAHSCT in‐
volve all parts in procedure of transplantation, the principal contents include two elements
that are using the individual tumorablative conditioning regimen and enhancing the immu‐
notherapy post-transplantation.
2. Indication of TAHSCT
The indication of TAHSCT is the patients with high-risk, relapsed, refractory, even ad‐
vanced leukemia. On the one hand, the recurrence of disease post-transplantation in these
patients is very high by standard myeloablative transplantation. In the recent years, with the
development of immunosuppressant, antibiotic agents and effective supportive therapy, it
makes significant improvement to reduce the morbidity and mortality of non-relapse, such
as GVHD, infections and multiple organ failure, post allogeneic HSCT, how to prevention
and treatment of relapse after allogeneic HSCT in these acute leukemia is the key point to
increase the long-term survival. In a recent retrospective cohort from the Center for Interna‐
tional Blood and Marrow Transplant Research, the 3-year overall survival rate only was 16%
in patients who underwent allo-HSCT in relapse or primary induction failure of acute lym‐
phoblastic leukemia (ALL) [4], for acute non-lymphoblastic leukemia (ANLL) with High-
risk, refractory and relapsed, it could be up to 20%-40%. On the other hand, we are faced
with more and more of those patients in the clinical transplantation. It is necessary to im‐
prove and optimize traditional procedure of HSCT.
3. Rationale of TAHSCT
The leukemia is the malignant clone disease derived from hematopoietic cell. The leukemic
stem cell is quite different from the normal hematopoietic stem cell in the biocharacteristics
[8]. Comparing to the latter, the former has strong growth vigor and tolerance in some de‐
gree to chemotherapy or radiotherapy. Furthermore, the leukemic stem cell is not only in
marrow, but also infiltrates to any sites or organs besides hematopoietic system, including
some sites in which the anti-leukemia drugs could but achieved to the treating concentra‐
tion, such as central nerve system, skin and lung and so on. On account of the insight in bio‐
nomics of leukemic stem cell, and the results in clinical transplantation, it is demonstrated
that standard myeloablative HSCT could not enough to root out of leukemic or leukemic
stem cells, particularly the in extramedullary sites. Therefore, the myeloablative HSCT is not
equal to TAHSCT, the residual leukemic or leukemic stem cell is the convict for relapse [9].
Innovations in Stem Cell Transplantation258
Although GVL effect after transplantation produces a marked effect, it is always later after
transplant. Eventually, the residual leukemic stem cell could be proliferation and disease re‐
lapse occurrences [10].
The purpose of tumorablative tailored conditioning regimen is not only to suppress or de‐
stroy the immune and hematopoietic system to make space for engraftment, but also to
ablate leukemic stem cell, especially the leukemic stem cells in the “asylum” of extramedul‐
lary sites, and to induce or enhance the GVL effect as far as possible [11].
Compared with myeloablative transplantation, besides removal of normal hematopoietic tis‐
sue, TAHSCT focuses more on killing residual tumor cells, especially elimination of extrame‐
dullary residual tumor cells. In the selection of drugs, it puts more emphasis on the killing
intensity of drugs on leukemic cells, the maintenance effective concentration and enough time
of killing effect, and reduction of post-transplant leukemia relapse to minimum [11]. Com‐
pared with non-myeloablative transplantation or reduced toxicity transplantation, the latter
still retains hematopoietic stem cells of recipient, in some extent, for autologous hematopoiet‐
ic reconstruction, but also residue a certain amount of leukemic stem cells which might cause
relapse, therefore the reconstructed mixed hematopoietic chimerism often requires donor
lymphocyte infusion (DLI) to ensure the possibility of a successful engraftment, and the pre‐
vention and treatment of relapse are also dependent on DLI and subsequent immunotherapy
or targeted therapy[11]. Their comparison is showed in Figure 1.
Figure 1. Comparison of tumorablative to myeloablative and non-myeloablative transplantation
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4. Strategy for TAHSCT
Based on the regularity and characteristics of disease relapse after transplantation, we pro‐
posed a preventive pathway for leukemic recurrence post-transplantation in the early of
2007 years [12]. They are general prophylaxis, early intervention and clinical therapy. The
general prophylaxis means to avoid the selection of high risks (shown in table 1) during the
grafting procedure, the key points in early intervention are to institute a reasonable individ‐
ual tumorablative conditioning regimen. The clinical therapy is to treat the leukemia in the
early or frank relapse, including immunotherapy post transplantation. In the clinical prac‐
tice for 5 years, the relapse rate of 85 and 83 cases with high risk, refractory or relapse re‐
ceived TAHSCT in 2008 and 2009 year was 2.3% and 5%, respectively [11]. It was strikingly
advance; however, the challenge is still presence. Obviously, among the risks associated to
relapse, the conditioning regimen and immunotherapy are more important.
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conditioning regimen non myeloablative myeloablative
GVHD Prophylaxis strong fairly
immunosuppressive agent
interfere by immunotherapy
reduce or stop early
yes
Table 1. The risks associated to relapse in the transplantation
5. Approach to tumorablative conditioning regimen
Theoretically, the tumorablative conditioning regimen should contain drugs or TBI to ablate
normal hematopoietic and immunologic tissue, also drugs or agents to get rid of leukemic or
leukemic stem cell, particularly, those in the extramedullary sites. The ideal drugs should be
high effective and targeted on the leukemic or leukemic stem cell, however, these special
target agents have not been successfully used in clinical, and it should be exploited in the
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future. According to the clinical experiences for successful treatment of refractory or re‐
lapsed leukemia, and combining with standard myeloablative regimen, we selected some
regimen with high effective and less toxicity, and establish a tumorablative conditioning
regimens (shown in table 2).
Regimen content indication
HDAra-C+Bu/Cy Ara-C 2.5g/m2 IV, -11d- -9d
Bu 1mg/kg.6hrs, -8d- -6d
MCCNU 250mg/ m2 (ANLL) or
Vm26 300mg/ m2 (ALL), -5d
CY 50mg/kg.d IV, -3- -4d
rest, -2 - -1d,
HSCT d 0
High risk in CR
G-CSF primed
HDAra-C+Bu/Cy
G-CSF 5µg/kg.d sc, -12- -9d
Ara-C 3 g/ m2 IV, -11d- -9d
Bu 1mg/kg.6hrs, -8d- -6d
MCCNU 250mg/ m2 (ANLL) or
Vm26 300mg/ m2 (ALL), -5d
CY 50mg/kg.d IV, -3- -4d
Rest, -2 - -1d,
HSCT d 0
Remission or early relapse in high risk
patients with bone marrow hypoplasia
or leukopenia
FLAG/RIT G-CSF 5µg/kg.d sc, -14- -9d
Ara-C 2 g/ m2.d CI, -13- -9d
FDL 30mg/ m2.d IV, -13 --9d
BSF 0.8mg/kg.6hr IV, -8 - -6d
CY 50 mg/m2.d IV, -5 - -4d
MCCNU 250mg/m2.d, -3d
Rest, -2 - -1d,
HSCT d 0
Progressive or advanced patients with
ANLL
TBI/FLAG/CY TBI 1.5 - 2 Gy, Bid, -13- -11d
Vm26 300 mg/m 2. IV, -10d
G-CSF 5µg/kg.d sc, -10- -5d
Ara-C 2 g/ m2.d CI, -9- -5d
FDL 30mg/ m2.d, IV, -9 --5d
CY 30 mg/kg.d IV, -4 - -3d
Rest, -2 - -1d,
HSCT d 0
Progressive or advanced patients with
ALL
* All regimens can be used in transplantation of HLA matched unrelated and halo-identical HSCT, but ATG must be
added. ATG, antithymocyte globulin; Ara-C, cytarabine; Bu, busulfan; BSF, busulfex; Vm26, teniposide; CY, cyclophos‐
phamide; FDL, fludarabine; MCCNU, semustine; RIT, reduced intensive transplantation; TBI, total body irradiation.
Table 2. Some tumorablative conditioning regimen*
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patients with bone marrow hypoplasia
or leukopenia
FLAG/RIT G-CSF 5µg/kg.d sc, -14- -9d
Ara-C 2 g/ m2.d CI, -13- -9d
FDL 30mg/ m2.d IV, -13 --9d
BSF 0.8mg/kg.6hr IV, -8 - -6d
CY 50 mg/m2.d IV, -5 - -4d
MCCNU 250mg/m2.d, -3d
Rest, -2 - -1d,
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Progressive or advanced patients with
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TBI/FLAG/CY TBI 1.5 - 2 Gy, Bid, -13- -11d
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FLAG/reduced intensive transplantation (FLAG/RIT regimen) A large number of clinical
practice confirmed that intravenous infusion of high-dose cytosine (Ara-C) was an effective
rescue measure for the treatment of refractory or relapsed leukemia, about 40% refractory
acute myeloid leukemia (AML) could achieve remission. Pharmacokinetic study on high-
dose Ara-C intravenous infusion revealed that intravenous infusion of Ara-C (1.8-32.0) g/m2
for 2 hours, every 12 hours, the plasma concentrations could reach (8-24) µg/ml, cerebrospi‐
nal fluid concentrations was about (10-15)% of plasma concentration. This high concentra‐
tion of this drug in blood and cerebrospinal fluid was thought to be the pharmacological
basis of significantly increased efficacy [13-15]. Ara-C combined with anthracycline (uniqui‐
none) or acridines drugs could further improve the CR rate to 50 % [16, 17].
FLAG protocol consisting of fludarabine combined with Ara-C plus recombinant human
granulocyte-stimulating factor (G-CSF) is currently a potent and well-tolerated treatment for
refractory and relapsed AML. Fludarabine is a nucleotide analogue, acts as a ribonucleic
acid inhibitor by phosphorylation to active triphosphate form F-ara-ATP. As a substrate for
DNA synthesis in leukemic cells, F-ara-ATP has anti-leukemia activity by inhibition of DNA
polymerase and ribose reductase, especially has a strong effect on quiescent cells. In vitro
and in vivo studies proved that addition of fludarabine before Ara-C administration might
increase the intracellular concentration of Ara-CTP, enhance the cytotoxicity and clinical ef‐
ficacy of Ara-C, so that the CR rate of refractory and relapsed AML reaching 50% - 75%, CR
period reaching 9 months and above [18]. Schmid et al [19] used combination chemotherapy
with fludarabine and Ara-C for 4 days followed by reduced-toxicity allogeneic hematopoiet‐
ic cell transplantation and post-transplant donor lymphocyte infusion in 103 refractory acute
myeloid leukemia patients, followed up for a median period of 25 months. It was found that
1, 2 and 4-year overall survival rates were 54%, 40% and 32%, respectively. Therefore, the
FLAG/RIT regimen is mainly used in treatment of ANLL with progressive or advanced pa‐
tients with ANLL.
TBI/FLAG/CY regimen It consists of total body irradiation, FLAG and reduced cyclophos‐
phamide, and always utilized to treat ALL in progressive or advanced phase. Because, TBI
was more effectiveness in allo-HSCT for ALL.
G-CST priming regimen It is usually to treat the ANLL at remission or early relapse in high
risk with bone marrow hypoplasia or leucopenia. Granulocyte-stimulating factor can induce
the proliferation of AML cells and increase the proportion of S phase cells in vitro or in vivo,
thereby enhancing cell sensitivity to chemotherapeutic drugs. Reasonable and sequential ap‐
plication of G-CSF and chemotherapeutics is another effective option for the treatment of re‐
fractory AML, such as the above-mentioned FLAG protocol and CAG protocol composed of
low-dose Ara-C (LD-Ara-C), aclacinomycin and G-CSF. In fact a large number of experi‐
mental and clinical studies confirmed that pre-transplant application of G-CSF not only pro‐
moted the differentiation of T cells to TH2 and enhanced the function of regulatory T cells,
but also amplified immature antigen-presenting cells and plasmacytoid dendritic cells,
which was beneficial for maintenance of post-transplant T cells function and reduction the
incidence of GVHD. Morris ES, et al. also confirmed that through modification of pegylation
and combination with Flt-3L, G-CS might lead to activation and amplification of donor in‐
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variant NKT (iNKT) cells, a marked increase of post-transplant cell mediated CD8+ T cyto‐
toxicity, and enhancement of GVL effect [20]. Takahashi et al. had proved that application of
G-CS together with conditioning regimen could reduce the post-transplantation relapse in
refractory myeloid leukemia [21]. Ooi et al. used G-CSF + Ara-C or + total body irradiation
and fludarabine as a conditioning regimen, and performed unrelated cord blood transplan‐
tation in adult AML patients, the results showed that 2-year disease-free survival was
76%[22]. Rational application of G-CSF in tumorablative conditioning regimen not only aug‐
mented anti-leukemia effect, but also separated GVHD and GVL effect to a certain degree,
improved the safety of transplantation and reduced the relapse [23].
Regimen containing high Ara-C For the transplantation of ANLL with high risk in the com‐
plete remission, we used the regimen containing high Ara-C as tumorablative conditioning.
As early as 2004, Lu DP et al. reported the application of GIAC protocol (Ara-C, busulfan,
cyclophosphamide, MCCNU and G-CSF activated bone marrow and peripheral blood) in‐
cluding high-dose Ara-C, MCCNU and G-CSF for mobility of peripheral blood stem cells in
donor-recipients HLA-unmatched or haploidentical hematopoietic stem cell transplantation.
Post-transplant observation confirmed this protocol resulted in a higher disease-free surviv‐
al rate (70%) and lower relapse rate (13%), further suggesting the necessity of intensified
measures with direct anti-leukemic cell effects in the conditioning regimen [24].
Based on the above theory and the specific situation of individual patient, we have modified
GIAC protocol and designed the HDAra-C+Bu/Cy. Preliminary clinical attempts have yield‐
ed encouraging results (Table 2).
In clinical practice, about one-third of AML and more than half of ALL patients relapsed
firstly manifested as extramedullary relapse, such as leukemic sarcoma or infiltration into
the central nervous system. So that, drugs with good liposolubility and ability to penetrate
blood-brain barrier, such as Carmustine (BCNU), methyl cyclohexyl nitrosourea (MCCNU),
teniposide (VM26) as well as high-dose Ara-C or MTX, should be chosen as a part of tumor‐
ablative regimen.
Our tumorablative conditioning regimen possess following features: The first, it could en‐
hance the intensity of anti-leukemia chemotherapy. All regimens included continuous infu‐
sion of medium dose Ara-C for 72 hours, meanwhile drugs with good liposolubility were
added such as MCCNU (acute myeloid leukemia) and teniposide (acute lymphocyte leuke‐
mia). The duration of the regimen extended to 11-14 days, which not only enhanced the anti-
leukemia effects on leukemic (stem) cells in hematopoietic tissue, but also ensured a longer
maintaining period of effective drug concentration in extramedullary tissue including cen‐
tral nervous system, and further depletion of leukemic (stem) cells in all tissues. Secondly,
granulocyte-stimulating factor was added in some regimes. It not only recruited quiescent
leukemic (stem) cells into proliferation cycle, increased the sensitivity to the killing effects of
drugs, but also reduced or alleviates the incidence of post-transplant GVHD through regula‐
tion of immune cells, or might induce GVL effects. Third, the reduction of the dosage of al‐
kylating agent decreased or alleviated the toxic and side effects, under the circumstances of
depletion of normal hematopoietic tissue and effective immunosuppressant. Fourth, indi‐
vidualization was emphasized. In clinical, application of these regimens should focus on in‐
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tion of this drug in blood and cerebrospinal fluid was thought to be the pharmacological
basis of significantly increased efficacy [13-15]. Ara-C combined with anthracycline (uniqui‐
none) or acridines drugs could further improve the CR rate to 50 % [16, 17].
FLAG protocol consisting of fludarabine combined with Ara-C plus recombinant human
granulocyte-stimulating factor (G-CSF) is currently a potent and well-tolerated treatment for
refractory and relapsed AML. Fludarabine is a nucleotide analogue, acts as a ribonucleic
acid inhibitor by phosphorylation to active triphosphate form F-ara-ATP. As a substrate for
DNA synthesis in leukemic cells, F-ara-ATP has anti-leukemia activity by inhibition of DNA
polymerase and ribose reductase, especially has a strong effect on quiescent cells. In vitro
and in vivo studies proved that addition of fludarabine before Ara-C administration might
increase the intracellular concentration of Ara-CTP, enhance the cytotoxicity and clinical ef‐
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myeloid leukemia patients, followed up for a median period of 25 months. It was found that
1, 2 and 4-year overall survival rates were 54%, 40% and 32%, respectively. Therefore, the
FLAG/RIT regimen is mainly used in treatment of ANLL with progressive or advanced pa‐
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TBI/FLAG/CY regimen It consists of total body irradiation, FLAG and reduced cyclophos‐
phamide, and always utilized to treat ALL in progressive or advanced phase. Because, TBI
was more effectiveness in allo-HSCT for ALL.
G-CST priming regimen It is usually to treat the ANLL at remission or early relapse in high
risk with bone marrow hypoplasia or leucopenia. Granulocyte-stimulating factor can induce
the proliferation of AML cells and increase the proportion of S phase cells in vitro or in vivo,
thereby enhancing cell sensitivity to chemotherapeutic drugs. Reasonable and sequential ap‐
plication of G-CSF and chemotherapeutics is another effective option for the treatment of re‐
fractory AML, such as the above-mentioned FLAG protocol and CAG protocol composed of
low-dose Ara-C (LD-Ara-C), aclacinomycin and G-CSF. In fact a large number of experi‐
mental and clinical studies confirmed that pre-transplant application of G-CSF not only pro‐
moted the differentiation of T cells to TH2 and enhanced the function of regulatory T cells,
but also amplified immature antigen-presenting cells and plasmacytoid dendritic cells,
which was beneficial for maintenance of post-transplant T cells function and reduction the
incidence of GVHD. Morris ES, et al. also confirmed that through modification of pegylation
and combination with Flt-3L, G-CS might lead to activation and amplification of donor in‐
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toxicity, and enhancement of GVL effect [20]. Takahashi et al. had proved that application of
G-CS together with conditioning regimen could reduce the post-transplantation relapse in
refractory myeloid leukemia [21]. Ooi et al. used G-CSF + Ara-C or + total body irradiation
and fludarabine as a conditioning regimen, and performed unrelated cord blood transplan‐
tation in adult AML patients, the results showed that 2-year disease-free survival was
76%[22]. Rational application of G-CSF in tumorablative conditioning regimen not only aug‐
mented anti-leukemia effect, but also separated GVHD and GVL effect to a certain degree,
improved the safety of transplantation and reduced the relapse [23].
Regimen containing high Ara-C For the transplantation of ANLL with high risk in the com‐
plete remission, we used the regimen containing high Ara-C as tumorablative conditioning.
As early as 2004, Lu DP et al. reported the application of GIAC protocol (Ara-C, busulfan,
cyclophosphamide, MCCNU and G-CSF activated bone marrow and peripheral blood) in‐
cluding high-dose Ara-C, MCCNU and G-CSF for mobility of peripheral blood stem cells in
donor-recipients HLA-unmatched or haploidentical hematopoietic stem cell transplantation.
Post-transplant observation confirmed this protocol resulted in a higher disease-free surviv‐
al rate (70%) and lower relapse rate (13%), further suggesting the necessity of intensified
measures with direct anti-leukemic cell effects in the conditioning regimen [24].
Based on the above theory and the specific situation of individual patient, we have modified
GIAC protocol and designed the HDAra-C+Bu/Cy. Preliminary clinical attempts have yield‐
ed encouraging results (Table 2).
In clinical practice, about one-third of AML and more than half of ALL patients relapsed
firstly manifested as extramedullary relapse, such as leukemic sarcoma or infiltration into
the central nervous system. So that, drugs with good liposolubility and ability to penetrate
blood-brain barrier, such as Carmustine (BCNU), methyl cyclohexyl nitrosourea (MCCNU),
teniposide (VM26) as well as high-dose Ara-C or MTX, should be chosen as a part of tumor‐
ablative regimen.
Our tumorablative conditioning regimen possess following features: The first, it could en‐
hance the intensity of anti-leukemia chemotherapy. All regimens included continuous infu‐
sion of medium dose Ara-C for 72 hours, meanwhile drugs with good liposolubility were
added such as MCCNU (acute myeloid leukemia) and teniposide (acute lymphocyte leuke‐
mia). The duration of the regimen extended to 11-14 days, which not only enhanced the anti-
leukemia effects on leukemic (stem) cells in hematopoietic tissue, but also ensured a longer
maintaining period of effective drug concentration in extramedullary tissue including cen‐
tral nervous system, and further depletion of leukemic (stem) cells in all tissues. Secondly,
granulocyte-stimulating factor was added in some regimes. It not only recruited quiescent
leukemic (stem) cells into proliferation cycle, increased the sensitivity to the killing effects of
drugs, but also reduced or alleviates the incidence of post-transplant GVHD through regula‐
tion of immune cells, or might induce GVL effects. Third, the reduction of the dosage of al‐
kylating agent decreased or alleviated the toxic and side effects, under the circumstances of
depletion of normal hematopoietic tissue and effective immunosuppressant. Fourth, indi‐
vidualization was emphasized. In clinical, application of these regimens should focus on in‐
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dividualization, in view of the differences of cytogenetics and gene alterations in the
pathogenesis of leukemic cell, clinical manifestations and prognosis, or pre-transplant dis‐
ease, performance status and drug tolerance of patients. In addition, the regimens should al‐
so be adjusted in accordance with the donor source, for example, the transplantation of
unrelated or haploididential donor, anti-lymphocyte globulin (ATG) should be included in
the corresponding conditioning regimen [25]. We met a case of AML-M5 with primary re‐
sistance to chemotherapy, the blasts remain more than 50% in marrow after induction by
daunomycin plus Ara-C (DA), idarubicin plus Ara-C (IA), mitoxantrone plus Ara-C and eto‐
poside (MAE), CAG and FLAG regimen, but, after AE (amsacrine + Vm26) regimen, near CR
was achieved. Then he received haplo-identical transplantation using TBI/FLAG/CY regi‐
men in February, 2012, in which amsacrine + Vm26 instead of FLAG, because his leukemic
cell is sensitive to amsacrine and Vm26. After successful engraftment, he is still alive in con‐
tinual CR up to now.
6. Detection of minimal residual disease and immunotherapy post
TAHSCT
Detection of minimal residual disease (MRD) and immunotherapy post transplantation are
very impotent principle in the TAHSCT [25]. Although it is almost specific method to detect
the marrow morphology, clone culture, immunophenotype, and abnormal gene or protein
of leukemic cell, clinically, the flow cytometry (FCM) and polymerase chain reaction (PCR)
are the more convenience, fast and sensitive. It should be routinely done post transplanta‐
tion. In some patients, relapse proceeded in extramedullary sites, even sarcoma, especially,
CNS, subperiosteum, skin, serous cavity, lung and intestinal tract, so image analysis also is
necessity, such as, CT, MIR, PET or PET-CT. We had used a PET-CT to detect proceed re‐
lapse in extramedullary sites in an advanced case with ANLL after underwent unrelated
HSCT, and successful pinpoint treated by the cyberknife.
With regard to immunotherapy, firstly, immunosuppressive agents should be decreased or
even stopped as quickly as possible, when GVHD was strictly controlled. Then, if necessary,
some immune modulators should be given, such as interferon, IL2 and thymopeptides. For
the two latter, which should not use in T cell malignances. Finally, it is the cell therapy [25, 26].
Donor lymphocyte or G-CSF mobilized peripheral blood stem cell infusion (DLI/DSI) for
treatment of leukemia relapse after allo-HSCT was introduced in early 1990s, being extreme‐
ly effective in chronic myeloid leukemia. The DLI for AML relapse post-transplant has been
questioned in general. Recently, Schmid C, et al retrospectively analyzed the data of 399 pa‐
tients with AML in first hematological relapse after HSCT whose treatment did or did not
include DLI. After correction for imbalances and established risk factors, the two groups
were compared with respect to overall survival. Further, a detailed analysis of risk factors
for survival among DLI recipients was performed. The results confirm a role for an allogene‐
ic GVL effect in AML [27]. Various modifications of DLI have been investigated. These in‐
cluded the systematical use of mobilized donor PBSC concentrates instead of lymphocytes,
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or the systemic application of cytokine induced killer cells (CIK) for additional immunosti‐
mulation to increase GVL efficacy. In addition, infusion of allogeneic natural killer (NK)
cells is also a promising innovative immunotherapy, being alloreactive NK cells reported to
produce a strong GVL effect after haploidentical HSCT in patients with advanced AML,
without causing GVHD [28]. In vitro studies have suggested the possibility to create specific
antileukemic cytotoxicity by stimulation of donor lymphocytes using AML-derived dendrit‐
ic cells. Porter and colleagues reported encouraging results from a phase I trial using con‐
ventional DLI, followed by an additional infusion of ex vivo activated donor T cells.
Therefore, we used DLC, DSI or CIK as maintenance therapy after HSCT for patients in re‐
mission or in a minimal residual disease situation in our program to exploit the GVL effica‐
cy, and got a ducky result. Recently, we treated 18 cases in relapse after allogeneic HSCT,
including 11 of HLA matched sibling, 5 of haploidentical and 2 of matched unrelated donor
by donor’s dendritic cell-primed CIK (DC-CIK). After the median number of 3.6 X 109 DC-
CIK infused, molecule complete remission was obtained in 12 cases (68%), and 11 of 12 cases
are survival with a median follow-up of 12 (range 6-41) months, except 1 died of treatment
related complication. It confirms that donor derived DC-CIK infusion is efficacious and safe‐
ty in this setting [29]. However, DLI or CIK infusion was often associated with a considera‐
ble risk of GVHD, and clinically, we should be careful to assay and prevent from GVHD.
Along with screening and identification of new immunogenic tumor protein or peptides, an‐
ti-tumor specific functional T cells could be produced in vitro, the anti-leukemia specific im‐
munotherapy would have more definite position in treatment of relapse post
transplantation. Further experimental and clinical research are required to overcome the ob‐
viously high burden of leukemia blasts to escape from an allogeneic immunereaction in re‐
lapsing patients after allogeneic HSCT for refractory acute leukemia.
7. Clinical practice of TAHSCT
In fact, the first TAHSCT with HLA identical donor we preformed was in 2007 for a 54 years
old female with resistant relapse, She was diagnosed as AML in July 2004 and obtained CR
after 3 courses of chemotherapy by daunomycin plus Ara-C (DA), idarubicin plus Ara-C
(IA) and mitoxantrone plus Ara-C (MA), and then received 13 courses of intensive consoli‐
dation chemotherapy including high dose of Ara-C, and autologous CIK infusion for 3
times. Her leukemia relapsed in the end of Dec 2006, and could not response to the several
courses of reinduction chemotherapy. Before she received tumorablative allo-HSCT, there
were 27% of leukemic blasts in marrow. The FLAG/RIT regimen was conditioned for HLA-
identical sibling HSCT on February 22nd 2007. Her neutrophil and platelet were successful‐
ly engraftment on +18 days, chimerism analyses shown that full donor chimerism achieved
by +30 days. Assay of MRD periodically by FCM monitoring after TAHSCT was zero. Grade
I aGVHD of intestinal tract and liver was happened on +51 days, and thereafter invasive
fungal infections in sinusitis, lung, liver on right-sidedness (pathological culture supported
mucor infection) were happened, The Aspergillus was detected in sputum culture. All the
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even stopped as quickly as possible, when GVHD was strictly controlled. Then, if necessary,
some immune modulators should be given, such as interferon, IL2 and thymopeptides. For
the two latter, which should not use in T cell malignances. Finally, it is the cell therapy [25, 26].
Donor lymphocyte or G-CSF mobilized peripheral blood stem cell infusion (DLI/DSI) for
treatment of leukemia relapse after allo-HSCT was introduced in early 1990s, being extreme‐
ly effective in chronic myeloid leukemia. The DLI for AML relapse post-transplant has been
questioned in general. Recently, Schmid C, et al retrospectively analyzed the data of 399 pa‐
tients with AML in first hematological relapse after HSCT whose treatment did or did not
include DLI. After correction for imbalances and established risk factors, the two groups
were compared with respect to overall survival. Further, a detailed analysis of risk factors
for survival among DLI recipients was performed. The results confirm a role for an allogene‐
ic GVL effect in AML [27]. Various modifications of DLI have been investigated. These in‐
cluded the systematical use of mobilized donor PBSC concentrates instead of lymphocytes,
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Therefore, we used DLC, DSI or CIK as maintenance therapy after HSCT for patients in re‐
mission or in a minimal residual disease situation in our program to exploit the GVL effica‐
cy, and got a ducky result. Recently, we treated 18 cases in relapse after allogeneic HSCT,
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by donor’s dendritic cell-primed CIK (DC-CIK). After the median number of 3.6 X 109 DC-
CIK infused, molecule complete remission was obtained in 12 cases (68%), and 11 of 12 cases
are survival with a median follow-up of 12 (range 6-41) months, except 1 died of treatment
related complication. It confirms that donor derived DC-CIK infusion is efficacious and safe‐
ty in this setting [29]. However, DLI or CIK infusion was often associated with a considera‐
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ti-tumor specific functional T cells could be produced in vitro, the anti-leukemia specific im‐
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lapsing patients after allogeneic HSCT for refractory acute leukemia.
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In fact, the first TAHSCT with HLA identical donor we preformed was in 2007 for a 54 years
old female with resistant relapse, She was diagnosed as AML in July 2004 and obtained CR
after 3 courses of chemotherapy by daunomycin plus Ara-C (DA), idarubicin plus Ara-C
(IA) and mitoxantrone plus Ara-C (MA), and then received 13 courses of intensive consoli‐
dation chemotherapy including high dose of Ara-C, and autologous CIK infusion for 3
times. Her leukemia relapsed in the end of Dec 2006, and could not response to the several
courses of reinduction chemotherapy. Before she received tumorablative allo-HSCT, there
were 27% of leukemic blasts in marrow. The FLAG/RIT regimen was conditioned for HLA-
identical sibling HSCT on February 22nd 2007. Her neutrophil and platelet were successful‐
ly engraftment on +18 days, chimerism analyses shown that full donor chimerism achieved
by +30 days. Assay of MRD periodically by FCM monitoring after TAHSCT was zero. Grade
I aGVHD of intestinal tract and liver was happened on +51 days, and thereafter invasive
fungal infections in sinusitis, lung, liver on right-sidedness (pathological culture supported
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complications above were controlled and cured after symptomatic treatment. She is still
alive in continue complete remission up to now (more than 78 months).
The first TAHSCT with haploidentical donor we did was in 2008. The case with 22 years old
male was diagnosed as AML with t (8; 21), AML1/ETO positive in August 2005. He had re‐
ceived several courses of intensive consolidation, and maintenance chemotherapy including
high dose Ara-C. Three years later, he had leukemia relapse, and not obtained CR again af‐
ter reinduction chemotherapy. Before transplantation, there were 75% of leukemic blasts in
marrow. The patient received the FLAG/RIC/ATG conditioning regimen for HLA haploi‐
dentical TAHSCT from his sibling. On January 1st 2008, after TAHSCT, engraftment was
durable with full donor chimerism, and detection of non MDR by FCM, chromosome, and
realtime PCR for AML1/ETO fused gene monitoring. Limited cGVHD was controlled by
CSA and prednisone in fewer months. The patient is still alive in disease-free survival (DFS)
until now.
Between August 2006 and march 2007, a total of 57 patients with high risk/refractory leuke‐
mia were received tumorablative individualized conditioning regiments, included HDAra-C
+Bu/Cy, G-CSF primed HDAra-C+Bu/Cy, and FLAG/RIT. Among 57, 20 patients of acute
lymphoblast leukemia (ALL), 23 patients of acute myelogenous leukemia (AML), and 12 pa‐
tients of chronic myeloid leukemia (CML) in accelerate or blast crises phase, and 2 patients
of myelodysplastic syndrome–refractory anemia with excess of blasts (MDS-RAEB). 28 pa‐
tients received haplo-identical transplantation, 17 patients HLA-identical unrelated donor
transplantation and 12 patients HLA-identical sibling transplantation. The results showed
that 56 patients, but one recovered with autologous hematopoiesis, attained durable engraft‐
ment. The median time to an absolute neutrophil count >0.5x109/L was 16 (range: 12-21)
days. The median time to a platelet count >20x109/L was 18 (range: 12–32) days..With a me‐
dian follow-up of 17.5 (2-34)months, the probabilities of OS and DFS were (74.7±6.1) % and
(62.4±6.7) %, respectively. The incidence rate of aGVHD in grades II-IV and III-IV were
(19.3±5.2)% and (12.3±4.3)% respectively. Extensive chronic GVHD was observed in 36
(64.3%) patients. Cytomegaloviremia (CMV) was observed in 39 (68.42%) patients. Hemor‐
rhagic cystitis was observed in 13 (22.8%) patients. Fungous and bacterial infection occurred
in 16 (28.07%) and 38 (66.67%) patients, respectively. The relapse in all patients occurred in
14 (24.6%). Among them, relapse rate in high risk and advanced group (blast cells were
more than 20% in bone marrow) were 28.1% and 15.6%, respectively. 11 of 14 patients re‐
lapsed in marrow, 3 of 14 relapsed in extramedullary sites, 15 patients died (6 from hemato‐
logical relapse, 5 from infection of bacterial and fungous, 4 from chronic GVHD) after 100
days. The toxicity in this TAHSCT could be tolerance, and overcame [30,31].
Recently, we reported forty-nine patients, from first affiliated hospital, Chinese PLA General
Hospital, of hematological malignancy with high risk or refractory, including 24 AML, 14
ALL, 9 non-Hodgkin lymphoma (NHL), and 2 CML in blast crisis. All patients received hap‐
loidentical TAHSCT, in which umbilical cord mesenchymal stem cells were added. All pa‐
tients achieved engraftment and complete remission after TAHSCT. Regimen-related
toxicities were tolerable. Only five patients (10.2%) experienced relapse at a median time of
192 days after transplantation. The probability of 2 year leukemia free survival (LFS) in
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AML and CML patients was 83.3%, which was significant higher than that in the ALL and
NHL patients (40.0%, P<0.05) [32]. Our another 45 patients, form Beijing Dao-pei hospital,
with refractory recurrent AML treated by TAHSCT [33]. The median blasts in marrow were
36% (20% to 92%) before transplantation, including 6 of HLA identical sibling, 9 of unrelated
and 30 of haploindentical transplantation. All but 2 patients attained durable engraftment.
The incidence of grade II to IV aGVHD and cGVHD were 34% and 59.1%, respectively. With
median follow-up 30 (0.5 to 57) months, the relapse rate was 29.2%. Twenty nine (60.2%) pa‐
tients remained CR since transplantation. Three years DFS and Overall survival (OS) were
60.2% and 62.6%, respectively. These data confirmed that the individualized tumorablative
allogeneic hematopoietic stem cell transplantation is a promising and safety choice for treat‐
ment of high risk, refractory or relapse leukemia, even with high leukemia burden.
In the recent, these TAHSCT have being carried out in many hospitals in China. A total of
250 patients from 5 hospitals enrolled, the all patients with high-risk, resistant or relapse,
even advanced hematological malignances, including leukemia and lymphoma [32,33-34].
The primary clinical observation revealed that the results are the similar to that above (data
not published). Obviously, its efficacy must be confirmed by randomized, prospective clini‐
cal trials on a large population.
Actually, many investigators have being devoted to prevent from and treat recurrence post
transplantation in refractory leukemia, including Schmid C, et al, who used a sequential
treatment with chemotherapy and reduced-intensity conditioning for allogenic stem cell
transplantation [19], and Takahashi S. et al, which used GCS-F combined regimen for alloge‐
neic bone marrow transplantation shown above [21]. Recently, Eom KS, et al. reported that
FLANG salvage chemotherapy as a safe bridge to transplantation for patients with relapsed
or refractory acute myeloid leukemia is an effective regimen [35]. Arita K, et al. described
that a sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell trans‐
plantation for refractory acute lymphoblastic leukemia [36], and so on. All of them have ob‐
tained encouraging results. Comparing to them, our TAHSCT strategy emphasizes more
entirety, individual and tumorablative efficacy in the sitting of tolerated toxicity.
8. Conclusion
In summary, the TAHSCT strategy is a primary entirety approach for treatment of hemato‐
poietic malignances with high-risk, refractory or resistant relapse, based on the successful
experiences either standard HSCT or chemotherapy for these patients. It is true, there were
still some relapse post TAHSCT strategy, however, and it has reduced the relapse rate to
about 20% in these patients, so it also highlights the need to improve. Theoretically, the re‐
sidual leukemic stem cell is the chief offender in relapse post transplantation. We can utilize
the differences in the biocharacteristics between normal and leukemic stem cells, which re‐
sult of regulating disorder in proliferation, differentiation, apoptosis and ecize, signaling
pathways, and so on [8,37,38], to exploit the targeted drugs with specific killing effects on
LSC and niches for LSC, apoptosis-promoting and differentiation-inducing effects, such as
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(62.4±6.7) %, respectively. The incidence rate of aGVHD in grades II-IV and III-IV were
(19.3±5.2)% and (12.3±4.3)% respectively. Extensive chronic GVHD was observed in 36
(64.3%) patients. Cytomegaloviremia (CMV) was observed in 39 (68.42%) patients. Hemor‐
rhagic cystitis was observed in 13 (22.8%) patients. Fungous and bacterial infection occurred
in 16 (28.07%) and 38 (66.67%) patients, respectively. The relapse in all patients occurred in
14 (24.6%). Among them, relapse rate in high risk and advanced group (blast cells were
more than 20% in bone marrow) were 28.1% and 15.6%, respectively. 11 of 14 patients re‐
lapsed in marrow, 3 of 14 relapsed in extramedullary sites, 15 patients died (6 from hemato‐
logical relapse, 5 from infection of bacterial and fungous, 4 from chronic GVHD) after 100
days. The toxicity in this TAHSCT could be tolerance, and overcame [30,31].
Recently, we reported forty-nine patients, from first affiliated hospital, Chinese PLA General
Hospital, of hematological malignancy with high risk or refractory, including 24 AML, 14
ALL, 9 non-Hodgkin lymphoma (NHL), and 2 CML in blast crisis. All patients received hap‐
loidentical TAHSCT, in which umbilical cord mesenchymal stem cells were added. All pa‐
tients achieved engraftment and complete remission after TAHSCT. Regimen-related
toxicities were tolerable. Only five patients (10.2%) experienced relapse at a median time of
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Innovations in Stem Cell Transplantation266
AML and CML patients was 83.3%, which was significant higher than that in the ALL and
NHL patients (40.0%, P<0.05) [32]. Our another 45 patients, form Beijing Dao-pei hospital,
with refractory recurrent AML treated by TAHSCT [33]. The median blasts in marrow were
36% (20% to 92%) before transplantation, including 6 of HLA identical sibling, 9 of unrelated
and 30 of haploindentical transplantation. All but 2 patients attained durable engraftment.
The incidence of grade II to IV aGVHD and cGVHD were 34% and 59.1%, respectively. With
median follow-up 30 (0.5 to 57) months, the relapse rate was 29.2%. Twenty nine (60.2%) pa‐
tients remained CR since transplantation. Three years DFS and Overall survival (OS) were
60.2% and 62.6%, respectively. These data confirmed that the individualized tumorablative
allogeneic hematopoietic stem cell transplantation is a promising and safety choice for treat‐
ment of high risk, refractory or relapse leukemia, even with high leukemia burden.
In the recent, these TAHSCT have being carried out in many hospitals in China. A total of
250 patients from 5 hospitals enrolled, the all patients with high-risk, resistant or relapse,
even advanced hematological malignances, including leukemia and lymphoma [32,33-34].
The primary clinical observation revealed that the results are the similar to that above (data
not published). Obviously, its efficacy must be confirmed by randomized, prospective clini‐
cal trials on a large population.
Actually, many investigators have being devoted to prevent from and treat recurrence post
transplantation in refractory leukemia, including Schmid C, et al, who used a sequential
treatment with chemotherapy and reduced-intensity conditioning for allogenic stem cell
transplantation [19], and Takahashi S. et al, which used GCS-F combined regimen for alloge‐
neic bone marrow transplantation shown above [21]. Recently, Eom KS, et al. reported that
FLANG salvage chemotherapy as a safe bridge to transplantation for patients with relapsed
or refractory acute myeloid leukemia is an effective regimen [35]. Arita K, et al. described
that a sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell trans‐
plantation for refractory acute lymphoblastic leukemia [36], and so on. All of them have ob‐
tained encouraging results. Comparing to them, our TAHSCT strategy emphasizes more
entirety, individual and tumorablative efficacy in the sitting of tolerated toxicity.
8. Conclusion
In summary, the TAHSCT strategy is a primary entirety approach for treatment of hemato‐
poietic malignances with high-risk, refractory or resistant relapse, based on the successful
experiences either standard HSCT or chemotherapy for these patients. It is true, there were
still some relapse post TAHSCT strategy, however, and it has reduced the relapse rate to
about 20% in these patients, so it also highlights the need to improve. Theoretically, the re‐
sidual leukemic stem cell is the chief offender in relapse post transplantation. We can utilize
the differences in the biocharacteristics between normal and leukemic stem cells, which re‐
sult of regulating disorder in proliferation, differentiation, apoptosis and ecize, signaling
pathways, and so on [8,37,38], to exploit the targeted drugs with specific killing effects on
LSC and niches for LSC, apoptosis-promoting and differentiation-inducing effects, such as
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tyrosine kinase inhibitor, FLT3 inhibitor [39], hypomethylating agent, and so on, together
with the specific functional T cell adoptive immunotherapy. It should provide a broad pros‐
pect for the prevention and radical cure of relapse after TAHSCT in patients with refractory
and relapsed leukemia.
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1. Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia diagnosed in Western
world, with an incidence of 3–6/105 per year, that increase to 12.8/105 at the age of 65 [1-3].
This disease is characterized by an extremely heterogeneous behavior, with the clinical
course varying from patients who never require therapy to patients with a rapid disease
progression and early resistance to treatment. In fact, about 20% of the patients show an ag‐
gressive course and die within few years from diagnosis [3, 4].
Molecular markers, such as cytogenetic alteration [5], immunoglobulin heavy chain (IGH)
and TP53 genes mutational status [6, 7], zeta associated protein 70 (ZAP70) expression [8]
and CD38 expression [9], help to predict outcomes in CLL. However, their presence in the
absence of clinical symptomatology is not a sufficient criterium to initiate therapy. Further,
even in the absence of these factors, resistance to purine-analogue treatment can occur. This
suggests that additional molecular mechanisms, which confer drug refractoriness in poor-
risk CLL, do exist. In this regard, based on next generation sequencing studies, it was recent‐
ly shown that additional genetic events can predict CLL patients outcome, including
NOTCH1, SF3B1, and BIRC3 mutations [10-15].
A major issue in CLL is the identification of the optimal timing and type of first-line treat‐
ment. In the current recommendation of International Workshop on CLL (IWCLL) updated
guidelines for the diagnosis and treatment of CLL the therapy is reserved for advanced,
symptomatic or progressive disease [16]. Numerous studies showed that, either as first-line
therapy or in relapsed/refractory settings, treatment with new agents, such as alemuzumab,
ofatumumab, lenalidomide, and flavoperidole [17-22] or combination of conventional che‐
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motherapy to target immunotherapy lead to a better response in these patients [23-29].
These approaches significantly reduce the tumor load in refractory patients, even if the ulti‐
mate cure of disease has not yet been achieved. Therefore, CLL remains incurable outside
the setting of allogeneic stem cell transplant (allo-SCT). In fact, up to date this is the only
therapeutical approach that can potentially offer a curable solution to this disease [9]. The
indications for SCT in CLL were established by European Bone Marrow Transplant (EBMT)
[30]. Specifically, based on the evidence of efficacy and potential toxicity of SCT in CLL,
these procedure is designated for high-risk CLL patents. These include: a) patients with
TP53 abnormalities, who fail to achieve complete remission (CR) or who progress within 12
months after purine analogues, b) those who relapse within 24 months after having ach‐
ieved a response with purine-analogue-based combination therapy, c) those who relapsed
after prior autologous SCT and d) patients who are fludarabine refractory [31, 32]. It should
be noted that none of these categories requires assessment of biologic risk factors except cy‐
togenetic detection of TP53 deletions. Ongoing prospective clinical studies will determine
the impact of biomarkers such as IGH mutational status and other cytogenetic abnormalities
in identification of patients at sufficiently high risk for allogeneic SCT use at first CR. Several
groups agree that allogeneic transplant early in the disease course is the best strategy for pa‐
tients with high-risk or poor response to initial therapy. For those with durable first remis‐
sions, the timing of transplant is more controversial. The debate in “when to proceed to a more
aggressive treatment approach?” in CLL is in part driven by the presence of new therapeutic
strategies available for these patients. However, it is unknown how these therapies will
change the indications for or the outcome following transplant in CLL. Nevertheless, these
promising results have already started to impact the transplant recommendations in CLL
patients in a similar manner to chronic myeloid leukemia (CML) patients in imatinib era.
In this chapter the Authors, based on their own experience as well as on the most updated
literature, discuss the usage of autologous and allogeneic SCT in the clinical setting of CLL,
also in the light of the novel biological prognostic indicators.
2. Autologous hematopoietic stem cell transplantation
Autologous stem cell transplantation (ASCT) has been extensively investigated as a treat‐
ment option for CLL patients during the last years.
Evidences from clinical and minimal residual disease (MRD) studies have suggested that
ASCT has curative potential in only few patients. Nevertheless, ASCT might be capable of
prolonged disease control even in CLL with poor-risk features.
Autologous transplantation consists in the collection of stem cells from the patient’s marrow or
peripheral blood before high-dose irradiation or chemotherapy and their subsequent reinfu‐
sion to guarantee a new blood production. The main problems with this procedure are the risk
of re-infusion of leukemic cells that could potentially contaminate the stem cell population and
the difficulty in mobilizing progenitor cell in patients who have received multiple previous
treatments [33, 34]; particularly if purine analogs, have been administrated [35]. In addition,
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the outcome of ASCT is strongly correlated with the status of the disease: patients transplant‐
ed in CR have a much better outcome than those transplanted with active disease [36]. There‐
fore, optimal disease control prior to transplantation is mandatory [33, 34, 37].
Other factors that negatively influence the transplantation outcome and correlate with early
relapse are: the interval between the diagnosis and the transplant, the number of prior lines
of therapy, the presence of adverse cytogenetic abnormalities and of unmutated IGH genes
[36, 38]. In addition, the detection of MRD by either polymerase chain reaction (PCR) or
flow cytometry after transplantation anticipates clinical relapse [39, 40].
As mentioned above, different studies have investigated the role of ASCT in patients with
CLL and the results were controversial. A retrospective matched-pair analysis suggested a
survival advantage for ASCT in 66 patients who had undergone a uniform high dose thera‐
py and transplantation over conventional therapy in 291 patients. With an overall median
follow-up time of 70 and 86 months, survival was significantly longer for the patients who
had undergone ASCT compared with conventionally treated patients [41]. However, in
2011, several prospective studies have failed to confirm the survival advantage of ASCT in
advanced CLL patients [42, 43]. Brion et al. [43] published the results of a prospective multi‐
center randomized trial on the benefit of ASCT using a cyclophosphamide/TBI preparative
regimen in advanced clinical-stage untreated CLL compared to conventional treatment. The
conventional treatment was represented by 6 cicles of miniCHOP; for the ASCT cohort the
scheduled therapy consisted of 3 miniCHOP cicles followed by immediate ASCT for pa‐
tients with a very good partial remission (VGPR) or CR. This study highlights the absence of
differences in median overall survival (OS) between the two groups thus denying the supe‐
riority of ASCT over conventional therapy.
The necessity of additional randomized studies to better clarify the role of ASCT in the man‐
agement of patients with CLL was further emphasized by a comparative study conducted
by the EBMT group in which 621 autografted patients were compared to 630 non-autograft‐
ed patients. Patients autografted within 18 months of diagnosis had a better outcome that
those treated with chemotherapy, but this was offset by an inferior outcome of patients au‐
tografted after 18 months [44]. In addition it was found a promising benefit by the T-cell
mediated cytotoxicity via autologous transplantation in the high-risk CLL population.
Interestingly, Porter et al. [45] reported on the management of a chemo-refractory, CLL pa‐
tient with del(17p) treated with autologous T-cells genetically modified to express anti-
CD19; although the long-term disease control and late toxicities are not yet known, the
patient was in remission [45].
Most of the studies published have relatively short follow up and therefore only focus on
treatment related mortality (TRM) early after transplant, but the late consequences, particu‐
larly the development of secondary myelodysplasia and acute myeloid leukaemia (MDS/
AML), deserve some concern [37]. In fact, among 65 patients treated with fludarabine fol‐
lowed by ASCT, 8 developed MDS/ AML [37, 46]. Of note, in most studies, despite a high
initial CR rate, relapse is common, suggesting that autologous transplant is unlikely to be
curative in CLL [37]. However, based on the present literature, although ASCT cannot be
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considered as a standard treatment it should be considered in the context of clinical trials or
as an innovative therapy to prolong survival in selected patients (i.e. those with chemosensi‐
tivity, absence of unfavorable factors, and transplanted early in the course of the disease).
3. Allogeneic hematopoietic stem cell transplantation
In recent years, allogeneic hematopoietic stem cell transplant (allo-SCT) was visibly
emerged as the favorite treatment option for patients with high-risk CLL. In fact, in contrast
with ASCT, allo-SCT can induce durable responses even in patients refractory to therapy
[47-49]. Studies on the outcomes post ASCT failed to show a plateau effect on survival
curves and resulted in a remarkably high incidence of secondary myelodysplastic syn‐
dromes (9% to 12%) [50]. On the contrary, in most series where allo-SCT has been carried
out, a plateau is observed, with 40–60% of the patients remaining alive and free of disease 5–
6 years after transplantation [39, 44, 46, 48, 49, 51-55]. Therefore, allo-SCT become, in the last
two decades, the first treatment approach with curative potential in CLL.
The crucial anti-leukemic principle of allo-SCT in CLL appears to be the graft-versus-leuke‐
mia effect (GVL). The resultant GVL effect derived from alloreactive donor T cells is the key
mechanism responsible for lowering relapse rates after allo-SCT. There is evidence that the
GVL effect plays an essential role in controlling the disease and reverts poor prognostic bio‐
logical variables such as unmutated IGH genes [56, 57]. In addition, one of the most impor‐
tant advantage of allo-SCT includes infusion of tumor-free hematopoietic progenitor and
effector cells from healthy donors. Of note, it is important to exclude the presence in donor
peripheral blood of a monoclonal population immunophenotypically identical to that of pa‐
tients with CLL; in fact it was demonstrated that CLL clones were found in around 12% of
the first-degree relatives of patients with CLL and in up to 3% of the general population [58].
Nevertheless, the use of allo-SCT is limited due to the advanced age of most patients with
CLL and the high mortality associated with the procedure (in the range 24–47%), main caus‐
es for death being graft-vs host disease (GVHD) and infections.
At present, ongoing prospective clinical studies will determine the impact of biomarkers in‐
cluding IGH mutational status and other cytogenetic abnormalities in identification of pa‐
tients with sufficiently high risk to deserve use of allo-SCT in first CR.
4. Myeloablative allogeneic stem cell transplantation
In myeloablative allo-SCT, patients are given extremely high doses of chemotherapy, with
or without radiation, to wipe out, or “ablate,” the marrow. Then they are given an infusion
of donor stem cells to revive blood cell production and immunity.
Several theoretical advantages of myeloablative allo-SCT over ASCT are: a) none tumor con‐
tamination of the stem cell b) GVL effect to eliminate chemotherapy-resistant leukaemia
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cells by immune mechanisms c) better survival curves. In fact, studies from MD Anderson
Cancer Center demonstrate improved outcome after allogeneic compared to ASCT [59] sug‐
gesting that myeloablative allo-SCT can induce durable remission even in patients with re‐
fractory disease. However, the major limitation of using myeloablative allo-SCT is the
increased risk of transplant-associated morbidity and mortality, mostly from organ failure
due to direct toxicity of the preparative regimen and/or development of GVHD [48, 60, 61].
Registry data from the International Bone Marrow Transplant Research (IBMTR) group and
the EBMT group reported a transplant-related mortality (TRM) of 46% with mortality from
GVHD of 20% [60]. These published data showed that approximately two-thirds of allo‐
transplanted CLL patients will succumb either to TRM or to recurrent disease, and approxi‐
mately one-third will be cured of their disease [54, 60].
Active chronic GVHD is principal determinant of long-term morbidity and significantly re‐
duced long-term health status in patients allografted for various hematological malignancies
[62]. Indeed, transplant-related long-term morbidity after allo-SCT for CLL can be signifi‐
cant but is mainly restricted to those patients who have ongoing active chronic GVHD.
However, in the majority of affected patients clinical symptoms of chronic GVHD resolved
over time, allowing discontinuation of systemic therapeutic immunosuppression after a me‐
dian of 25 months [63]. Further, a high graft rejection rates remain a relevant complication in
myeloablative allo-SCT; a possible explanations could be the significant marrow infiltration
in CLL patients at the time of transplantation, inversely correlated with outcome [64], and
the role played by host dendritic cells, which are seriously defective in CLL patients [65].
Another problem is represented by the high infection rates, that correlated with preexisting
immunosuppression. Infections are the cause of about 50% of all CLL-related deaths [62, 66]
primarily in fludarabine and/or alemtuzumab-refractory patients [16, 67]. Moreover in re‐
cent reports the risk of infections has been clearly correlated with presence of GVHD [57, 63,
65, 68] and refractory disease [67, 69]. In addition, it is important to note that patients with
chemosensitive disease have significantly better outcomes than patients with refractory dis‐
ease, suggesting that an earlier application of allo-SCT may further improve transplantation
outcomes [60, 70, 71].
In conclusion, allo-SCT is a therapy with curative potential in CLL and, in contrast to con‐
ventional treatment, with an high potential of providing long-term disease control even in
patients with a very unfavorable biological and clinical risk profile. However, in addition to
the disease risk, it is necessary to consider patient-related risk factors, such as age and co‐
morbidity, when allo-SCT is performed [63].
5. Reduced-intensity conditioning stem cell transplantation
(nonmyeloablative allo-SCT)
Although myeloablative allo-SCT in CLL can result in durable remissions, rates of TRM are
after unacceptably and greatly reduced its application, even in the most refractory and high-
risk individuals.
Stem Cell Transplantation in Chronic Lymphocytic Leukemia
http://dx.doi.org/10.5772/53085
277
considered as a standard treatment it should be considered in the context of clinical trials or
as an innovative therapy to prolong survival in selected patients (i.e. those with chemosensi‐
tivity, absence of unfavorable factors, and transplanted early in the course of the disease).
3. Allogeneic hematopoietic stem cell transplantation
In recent years, allogeneic hematopoietic stem cell transplant (allo-SCT) was visibly
emerged as the favorite treatment option for patients with high-risk CLL. In fact, in contrast
with ASCT, allo-SCT can induce durable responses even in patients refractory to therapy
[47-49]. Studies on the outcomes post ASCT failed to show a plateau effect on survival
curves and resulted in a remarkably high incidence of secondary myelodysplastic syn‐
dromes (9% to 12%) [50]. On the contrary, in most series where allo-SCT has been carried
out, a plateau is observed, with 40–60% of the patients remaining alive and free of disease 5–
6 years after transplantation [39, 44, 46, 48, 49, 51-55]. Therefore, allo-SCT become, in the last
two decades, the first treatment approach with curative potential in CLL.
The crucial anti-leukemic principle of allo-SCT in CLL appears to be the graft-versus-leuke‐
mia effect (GVL). The resultant GVL effect derived from alloreactive donor T cells is the key
mechanism responsible for lowering relapse rates after allo-SCT. There is evidence that the
GVL effect plays an essential role in controlling the disease and reverts poor prognostic bio‐
logical variables such as unmutated IGH genes [56, 57]. In addition, one of the most impor‐
tant advantage of allo-SCT includes infusion of tumor-free hematopoietic progenitor and
effector cells from healthy donors. Of note, it is important to exclude the presence in donor
peripheral blood of a monoclonal population immunophenotypically identical to that of pa‐
tients with CLL; in fact it was demonstrated that CLL clones were found in around 12% of
the first-degree relatives of patients with CLL and in up to 3% of the general population [58].
Nevertheless, the use of allo-SCT is limited due to the advanced age of most patients with
CLL and the high mortality associated with the procedure (in the range 24–47%), main caus‐
es for death being graft-vs host disease (GVHD) and infections.
At present, ongoing prospective clinical studies will determine the impact of biomarkers in‐
cluding IGH mutational status and other cytogenetic abnormalities in identification of pa‐
tients with sufficiently high risk to deserve use of allo-SCT in first CR.
4. Myeloablative allogeneic stem cell transplantation
In myeloablative allo-SCT, patients are given extremely high doses of chemotherapy, with
or without radiation, to wipe out, or “ablate,” the marrow. Then they are given an infusion
of donor stem cells to revive blood cell production and immunity.
Several theoretical advantages of myeloablative allo-SCT over ASCT are: a) none tumor con‐
tamination of the stem cell b) GVL effect to eliminate chemotherapy-resistant leukaemia
Innovations in Stem Cell Transplantation276
cells by immune mechanisms c) better survival curves. In fact, studies from MD Anderson
Cancer Center demonstrate improved outcome after allogeneic compared to ASCT [59] sug‐
gesting that myeloablative allo-SCT can induce durable remission even in patients with re‐
fractory disease. However, the major limitation of using myeloablative allo-SCT is the
increased risk of transplant-associated morbidity and mortality, mostly from organ failure
due to direct toxicity of the preparative regimen and/or development of GVHD [48, 60, 61].
Registry data from the International Bone Marrow Transplant Research (IBMTR) group and
the EBMT group reported a transplant-related mortality (TRM) of 46% with mortality from
GVHD of 20% [60]. These published data showed that approximately two-thirds of allo‐
transplanted CLL patients will succumb either to TRM or to recurrent disease, and approxi‐
mately one-third will be cured of their disease [54, 60].
Active chronic GVHD is principal determinant of long-term morbidity and significantly re‐
duced long-term health status in patients allografted for various hematological malignancies
[62]. Indeed, transplant-related long-term morbidity after allo-SCT for CLL can be signifi‐
cant but is mainly restricted to those patients who have ongoing active chronic GVHD.
However, in the majority of affected patients clinical symptoms of chronic GVHD resolved
over time, allowing discontinuation of systemic therapeutic immunosuppression after a me‐
dian of 25 months [63]. Further, a high graft rejection rates remain a relevant complication in
myeloablative allo-SCT; a possible explanations could be the significant marrow infiltration
in CLL patients at the time of transplantation, inversely correlated with outcome [64], and
the role played by host dendritic cells, which are seriously defective in CLL patients [65].
Another problem is represented by the high infection rates, that correlated with preexisting
immunosuppression. Infections are the cause of about 50% of all CLL-related deaths [62, 66]
primarily in fludarabine and/or alemtuzumab-refractory patients [16, 67]. Moreover in re‐
cent reports the risk of infections has been clearly correlated with presence of GVHD [57, 63,
65, 68] and refractory disease [67, 69]. In addition, it is important to note that patients with
chemosensitive disease have significantly better outcomes than patients with refractory dis‐
ease, suggesting that an earlier application of allo-SCT may further improve transplantation
outcomes [60, 70, 71].
In conclusion, allo-SCT is a therapy with curative potential in CLL and, in contrast to con‐
ventional treatment, with an high potential of providing long-term disease control even in
patients with a very unfavorable biological and clinical risk profile. However, in addition to
the disease risk, it is necessary to consider patient-related risk factors, such as age and co‐
morbidity, when allo-SCT is performed [63].
5. Reduced-intensity conditioning stem cell transplantation
(nonmyeloablative allo-SCT)
Although myeloablative allo-SCT in CLL can result in durable remissions, rates of TRM are
after unacceptably and greatly reduced its application, even in the most refractory and high-
risk individuals.
Stem Cell Transplantation in Chronic Lymphocytic Leukemia
http://dx.doi.org/10.5772/53085
277
Reduced-intensity conditioning (RIC) regimens were introduced as a way to take advantage
of GVL effect, reducing TRM and making transplant more approachable also in older or
younger patients with comorbidities [72, 73]. These reduced regimens, are associated with
improved TRM; in fact, in 2003, the EBMT reported outcomes of 77 CLL patients who re‐
ceived an allo-SCT [74]. The authors described an encouraging TRM rate of 18%, an impres‐
sive overall response rate of 91%, as well as a 69% complete response rate and a 22% partial
response rate, associated with reduction in the ablative intensity of the preparative regimen.
This lower TRM (18%), when compared with that linked to a myeloablative conditioning
(46%), turned out to be extremely promising [74].
On the contrary, there were no significant differences in terms of OS or progression free sur‐
vival (PFS) between these two groups [74]. In fact, although nonmyeloablative transplants
may carry a stronger safety profile, the rate of relapse was higher than that associated with
traditional myeloablative treatment [74]. Interestingly, instead, Sorror et al. have recently
published data indicating that non-myeloablative transplants can provide a lower risk of re‐
lapse [63]. They reported encouraging long-term outcomes in 82 CLL patients who received
RIC allo-SCT. In this study, at a median follow-up of 5 years, TRM, PFS, and OS were 23%,
39%, and 50%, respectively, suggesting a curative potential for RIC allo-SCT in patients with
relapsed CLL, with a more favorable toxicity profile particularly in older patients who
would not have been eligible to receive myeloablative conditioning regimens [63].
In contrast to ASCT where the efficacy relies exclusively on the cytotoxicity administered
with the high-dose regimen, and in agreement to myeloablative allo-SCT, nonmyeloablative
allo-SCT adds the immune-mediated anti-host activities conferred with the graft as a second
fundamental principle of antileukemic efficacy: the GVL effect.
There is no doubt that the main therapeutic principle of allo-SCT in CLL is GVL activity and
this evidence derives from some remarkable observations such as: 1) decreasing relapse inci‐
dence over time even in RIC allo-SCT, in contrast to ASCT or other intensive therapies [56,
60, 63, 70, 71, 75, 76], 2) durable clinical and molecular responses due to antitumor activity
[77], 3) reduced relapse rates in patients with chronic GVHD [78], 4) increased relapse rates
associated with T cell–depleted grafts [79, 80], 5) high efficacy of donor lymphocyte infu‐
sions (DLIs) in the post-transplant relapse [65, 80].
This finging supports alloreactivity as the principal mechanism responsible for GVL.
On the other hand, the most important cause of RIC allo-SCT failure in CLL patients is the
disease relapse. Early relapses are correlated with chemorefractory disease at the time of
transplantation, the most of time due to the unsuccessfulness of RIC regimens in controlling
the disease before the GVL effect. The late relapse, instead, derives from different mecha‐
nism including: CLL clonal evolution, development of tolerance [80], presence of tumor cells
in “GVCLL sanctuary sites”[63] and an insufficient GVL effect to produce a complete dis‐
ease eradication. Interestingly, an high percentage of these late relapses occurred in lymph
nodes without bone marrow or peripheral blood involvement, or even in patients with MRD
negative status [40, 53, 55, 81, 82].
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Quantitative MRD monitoring by RQ-PCR or flowcytometry is an essential tool to establish
the clinical benefit of allo-SCT in CLL; in fact, the absence of detectable MRD, one year after
allo-SCT, was strongly associated with a reduced risk of clinical relapse. In addition, there
are evidences of a powerful correlation between MRD status and GVL activity, while its di‐
rect involvement for guiding GVL-inducing immunomodulation needs further evaluation
[83]. Therefore quantitative MRD monitoring seems to be mandatory to assure safe and ef‐
fective immunotherapy in the context of allo-SCT [83].
The best approach to post transplant immunotherapy in CLL includes monoclonal antibody
(MoAbs). Some of them, although a still short follow-up, show very promising results and
the use of MoAbs in the conditioning or just after transplant, could improve the results of
allo-SCT. Initially, RIC allo-SCT was associated with the use of only fludarabine and cyclo‐
phosphamide. The CLL3X trial from the German CLL Study Group evaluated the long-term
outcome of RIC allo-SCT in patients with poor-risk CLL who received allogeneic transplant
following fludarabine and cyclophosphamide-based conditioning. The 4-year non relapse
mortality (NRM), event-free survival (EFS), and OS were 23%, 42%, and 65%, respectively.
To improve relapse-free survival following transplant and to modulate the impact of
GVHD, MoAbs have been incorporated into transplant regimens [84]. Alemtuzumab, Ritux‐
imab are the most used MoAbs with recognized clinical activity in CLL. Alemtuzumab is a
humanized anti-CD52 IgG1 MoAb with an activity in reducing the incidence of GVHD but,
also, associated with an high risk of death from opportunistic infections [85]. Rituximab (an‐
ti-CD20 MoAb), instead, used in tandem with RIC preparative regimens, can induce re‐
sponse and help in disease control, decreasing the incidence of acute GVHD and
modulating the GVL effect. [59]. However, there is no clear consensus concerning the opti‐
mal conditioning regimen to be used prior to allo-HCT. Using RIC regimens may reduce
toxic deaths, but the success of non-myeloablative allo-SCT is highly dependent on the che‐
mosensitivity of the disease.
6. Conclusion and future directions
Despite much progress in its treatment, CLL continues to be an incurable disease with
standard treatments. SCT cell transplantation has changed the management of CLL patients
with refractory disease or younger patients with aggressive disease. In particular, ASCT has
partially failed in the treatment of advanced CLL: it prolongs survival in selected patients,
but unfortunately do not cure the disease. In addition, secondary MDS/AML is one of major
complication in autografted patients.
Allo-SCT, conversely, may be an acceptable option: myeloablative allo-SCT is an opportuni‐
ty for younger patients with bulky, refractory, or aggressive disease; RIC allo-SCT, instead,
is an emerging curative possibility for older patients with high-risk disease.
Although allo-SCT appears to result in high response rates and eradication of PCR detectable
MRD, the follow up of most clinical trials is too short to assess whether allo-SCT can cure CLL.
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Future approaches in menagment of CLL must take in consideration the balance between in‐
creased morbidity and mortality of SCT in CLL with the potentiality of new therapy in the
setting of the improvements in outcome.
In the absence of any other treatment modalities currently capable of improving outcome in
CLL, SCT should be considered the main option for patients with high-risk, refractory to
standard therapy or with relapsed after prior ASCT.
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1. Introduction
1.1. Current status of hematopoietic stem cell transplantation in patients with refractory or
relapse hodgkin lymphoma
Although the high response rates, approximately 10% of patients with early-stage Hodgkin
Lymphoma (HL) and 20% with advanced disease will be refractory to initial treatment or
relapse after a first complete response [1-3]. The strategy for management of relapsed or
refractory disease is to deliver salvage chemotherapy, followed by high-dose chemotherapy
and autologous stem-cell transplantation (AutoSCT) in responding patients [4,5].
2. Autologous stem cell transplantation for Hodgkin lymphoma
2.1. Autologous stem cell transplantation at first-line therapy
The use of autoSCT for HL in first remission was wondered. There are only a few prospective
randomized clinical trials focusing in this issue. Although historically controlled studies are
promising, prospective controlled studies showed different results [6].
The HD01 trial included 163 patients achieving complete remission (CR) or partial remission
(PR) with advanced HL after four cycles of ABVD (ABVD; doxorubicin, bleomycin, vinblastine,
and dacarbazine) or other doxorubicin-containing regimens who had an unfavorable risk
profile (at least two factors: high lactate dehydrogenase level, large mediastinal mass, more
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than one extranodal site of disease, low hematocrit, or inguinal involvement). The patients
were randomly divided into two groups; AutoSCT and four additional cycles of conventional
chemotherapy. There was no significant difference regarding complete remission rates, and
the 5-year failure-free survival, overall survival and relapse-free survival rates between the
groups [7]. Similarly, the recently published 10-year follow-up results could not demonstrate
an advantage of the high dose therapy in terms of failure-free survival, overall survival and
relapse-free survival rates between the groups [8]. The HD01 trial suggested that patients
responding to an anthracycline- based regimen do not benefit from autoSCT at first line
therapy.
In the GOELAMS Group’s (Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du
Sang) randomized phase 2 study, H97-HR trial, the authors tested 2 intensive chemotherapy
regimens in 158 patients with stage IIB - IV HL accompanied by high-risk factors. High-risk
were defined by the presence of >5 involved lymphoid areas, and/or a mediastinal mass ratio
> 0.45, and/or >2 extra lymph node sites affected by the disease. This study examined an early
intensive chemotherapy and ABVD for 4 cycles followed by delayed myeloablative intensifi‐
cation. In one of the arms, patients received 3 courses of combined vindesine, doxorubicin,
carmustine, etoposide, and methylprednisolone (VABEM) followed by low-dose lymph node
irradiation. In the other arm, patients received 4 cycles of ABVD followed by myeloablative
regimen containing carmustine, etoposide, cytarabine, and melphalan and underwent
autoSCT. After the completion of treatment, the CR rates for both of arms were similar. The 5-
year freedom from treatment failure and 5-year overall survival rates also were similar
between the arms. Consequently, the authors recommended that conventional chemotherapy
should remain the reference treatment in advanced and high risk HL [9].
In considering all these results, autoSCT for HL does not take place as a part of first line therapy
even for high-risk patients.
2.2. Autologous stem cell transplantation for relapsed/refractory HL
Because conventional salvage chemotherapy and/or radiotherapy have poor results in first
relapsed or progressive HL, autoSCT was evaluated as a curative approach for patients with
relapsed or progressive disease. There were two prospective randomized clinical trials in the
last twenty years. Firstly the British National Lymphoma Investigation performed a random‐
ized smaller prospective study in 40 patients. The aim of the study was comparison of high-
dose chemotherapy (BEAM = carmustine, etoposide, cytarabine, and melphalan) plus autoSCT
(n=20) with the same drugs at lower doses (mini-BEAM) (n=20) in patients with primary
refractory disease, early relapse, or prior failure of conventional therapy. All patients have
been followed up for at least one year. Although there was no difference in overall survival
(OS), both event-free survival and progression-free survival showed statistical significant
differences in favour of BEAM plus autoSCT (p = 0.025 and p = 0.005, respectively) [10]. This
study suggested that High-dose chemotherapy with autoSCT could provide better disease-
free survival but not overall survival.
The second randomized multicenter trial (HD-R1) was performed by investigators of the
German Hodgkin’s disease Study Group and the Lymphoma Working Party (LWP) of the
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EBMT to determine the benefit of HDCT in relapsed HL. Patients were randomly assigned to
either four cycles of conventional chemotherapy (Dexa-BEAM: dexamethasone and carmus‐
tine, etoposide, cytarabine, and melphalan) or two cycles of Dexa-BEAM followed by autoSCT
(n=73, n=88). After two cycles Dexa-BEAM chemotherapy, only 117 patients with chemosen‐
sitive disease proceeded to further treatment. Median follow-up was 39 months (IQR 3–78).
Freedom from treatment failure at 3 years was significantly better for autoSCT patients (55%)
than for those on Dexa-BEAM (34%; difference –21%, 95% CI –39 87 to –2 13; p=0 019), although
OS was not different [11].
Data  from  randomized  trials  established  autoSCT  as  standard  therapy  in  relapsing  HL
patients responding to salvage therapy [11,12,13]. Moskowitz et al reported retrospective
analysis  of  75  consecutive patients  with primary refractory HD,  who were  treated with
high  dose  chemoradiotherapy  and  autoSCT.  Median  follow-up  was  10  years.  Only
chemosensitivity  to  second-line  chemotherapy  predicted  for  a  better  survival,  thus
responding patients had an event-free survival (EFS), progression-free survival (PFS) and
OS of 60%, 62% and 66%, respectively, versus 19%, 23% and 17% for patients who had a
poor response to second-line chemotherapy (P < 0.001). Patients with disease refractory to
first-line  therapy  but  chemosensitive  to  standard-dose  second-line  therapy  might  have
better  outcome  after  an  autoSCT  [14].  Primary  refractory  patients  or  for  patients  in
chemorefractory relapse, autoSCT has only a small likelihood to induce long-term remis‐
sion.  For  these  patients,  autoSCT  can  be  clinical  option  [13].  Patients  with  progressive
disease after  autoSCT have a poor outcome,  and either allogeneic stem cell  transplanta‐
tion or other investigative approaches are necessary [14,15].
Nodular lymphocyte predominant HL (LPNHL) has to be accepted a complete different entity.
There is almost no information in the literature about the impact of autoSCT in those groups
of patients. Nevertheless, autoSCT can be considered a therapeutic option for LPNHL patients
in advanced stages and relapsing after standard treatment [13].
2.3. High dose conditioning regimens for autologous stem cell transplantation
There is no randomized clinical trial comparing different high dose conditioning regimes
for autoSCT. In retrospective analyses, the superiority of a specific regimen has not been
demonstrated.  Total  body  irradiation  (TBI)-based  regimens  as  high  dose  conditioning
regimens  were  compared  to  chemotherapy  combinations.  There  was  no  difference  in
efficacy  and  toxicity  between  the  regimens  [16,17,18].  German  Hodgkin  Study  Group
evaluated the impact of sequential high-dose therapy to increase the intensity of condition‐
ing  before  autoSCT.  Additional  high-dose  therapy  did  not  improve  the  prognosis  of
patients with relapsed HL compared with the standard BEAM regimen and autoSCT, and
was  associated with  increased toxic  effects  [19].  There  was  no  benefit  of  increasing  the
intensity of conditioning regimen. Most of randomized trials of autoSCT in HL used BEAM
regimen and this  regimen is  regarded,  by most transplant centers,  as the standard high
dose-conditioning regimen [20].
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There is almost no information in the literature about the impact of autoSCT in those groups
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2.4. Prognostic factors associated with outcome in relapse and refractor Hodgkin lymphoma
before autologous stem cell transplantation
Several trials have identified prognostic factors in patients with RR-HL who have undergone
subsequent salvage chemotherapy and autoSCT. These prognostic factors are summarized in
table-I. Extra nodal disease, B symptoms at relapse and short remission duration after initial
therapy have consistently been demonstrated to be predictors of poor outcome. Chemotherapy
resistance prior to autoSCT is generally associated with poor outcome [21].
The depth of response to salvage chemotherapy before autoSCT is important. Detectable
disease with functional imaging has predictive value for an unfavorable outcome [21, 22].
Jabbour et al suggested that positive functional pretransplant imaging (either gallium or
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography; FDG-PET scan) can be
predictive of poor outcome. The 3-year OS rates for patients with negative functional imaging
were 87% but this was 58% in patients with positive functional imaging [22]. Moskowitz et al
demonstrated that patients with negative functional imaging (either gallium or FDG-PET scan)
had 75% EFS compared to 31% for patients with positive functional imaging [21]. Recently,
Moskowitz et al reported a prospective phase 2 study. They used a risk-adapted approach to
improve PFS after high-dose radio chemotherapy and autoSCT. First salvage chemotherapies
were 2 cycles of ICE (ICE; ifosfamide, carboplatin, etoposide) in a standard or augmented dose,
followed by restaging FDG-PET scan. Patients with a negative scan received a transplant. If
the FDG-PET scan was still positive, patients received again chemotherapy (GVD; gemcita‐
bine, vinorelbine, and liposomal doxorubicin). Patients without evidence of disease progres‐
sion proceeded to high-dose chemotherapy (HDT)/ autoSCT. Patients transplanted with
negative FDG-PET had an EFS of > 80%, versus 28.6% for patients with a positive scan (P <.
001). In that study, FDG-PET–negative status is a major factor in the determination of outcome.
The finding that the outcome for patients receiving GVD and having a FDG-PET–negative
result is indistinguishable from patients with ICE-based therapy induced FDG-PET–negative
response argues that quality of response is an important determinant of outcome. The authors
suggested that the goal of salvage chemotherapy in patients with HL should be a negative
FDG-PET scan before HDT/AutoSCT [23].
3. Allogeneic stem cell transplantation
Although allogeneic stem cell transplantation (alloSCT) historically associated with signifi‐
cantly greater treatment-related mortality (TRM) than autologous stem cell transplantation
(autoSCT), Because of the potential for graft versus lymphoma (GVHL) effects and the
assurance of a tumor-free graft, alloSCT is carrying curative potential especially in patients
with Hodgkin lymphoma (HL) who are younger than other lymphoma patients. Nevertheless,
comparative studies between myeloablative alloSCT and autoSCT in refractory and relapsed
HL patients provided evidence of GVHL effect. The widespread use of alloSCT in HL patients
is still a matter of controversy because of the TRM and was quite limited until the advent of
reduced intensity conditioning (RIC). Nowadays, increasing numbers of studies have been
Innovations in Stem Cell Transplantation292
Prognostic factors Effects of prognostic factories Reference
B symptoms at relapse,
Extranodal disease at relapse,
Initial remission duration of < 1 year
3-year PFS: 24
No risk factor: 100%,
1 risk factor: 81%,
2 risk factors: 40%
3 risk factors: 0%
>2 prior chemotherapy regimens, Patients who had received >2 chemotherapy regimens had a
poorer DFS
17
Performance status; ECOG: 1-3
>1 chemotherapy regimens failed,
The presence of mediastinal disease
at AutoSCT
These factors significantly associated with FFS,
Patients with >2 failed chemotherapy regimens have an
estimated 4 year FFS of 10%.
25
Systemic symptoms at relapse,
Disseminated pulmonary or bone
marrow disease at relapse,
More than minimal disease at
AutoSCT
4-year FFP:
No risk factor: 85%
>1 risk factors: 41%
18
End-of-treatment to relapse
interval < 12 months
Presence of extranodal disease at
relapse
4-year survival: 26
No risk factor: 93%,
1 risk factor: 59%,
2 risk factors: 43%
Chemotherapy resistance prior to
AutoSCT,
Advanced disease stage at
diagnosis (stage ≥III)





Complete remission duration of less
than 1 year
EFS:
0-1 risk factor: 83%
2 risk factors: 27%
3 risk factors: 10%
28
Advanced stage at diagnosis,
Radiotherapy before AutoSCT,
A short first CR,
Detectable disease at AutoSCT
5-year TTF:
No risk factor: 71%±4%
3 or more risk factors: 18%±5%
29
Pre-autoSCT positive functional
imaging (FDG-PET or gallium scan)
In this trial, the only factor that predicted an unfavorable
outcome in the transplanted patients was a pre-HDT/AutoSCT–
positive functional imaging
30
Pre-autoSCT, FDG-PET status Persistent FDG-PET positivity after salvage therapy have a poor
outcome with HDT/ AutoSCT
31
EFS: Event-free survival, FFP: Freedom from progression, FFS: Failure-free survival, PFS: Progression-free survival, TTF: Time
to treatment failure, FDG-PET: Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography, HDT: High-dose
chemotherapy
Table 1. Prognostic factors in relapse and refractory HL
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investigating the role of especially RIC-alloSCT in patients with refractory or relapsed HL,
most of whom have previously received autoSCT. [32]
3.1. Myeloablative conditioning regimens
Myeloablative Conditioning (MAC) alloSCT derives its benefit from both the high-dose
conditioning regimen and the GVHL effect. To determine whether this approach would benefit
patients with advanced HL, proof of concept was reported by Appelbaum et al. in Seattle [33].
Eight patients with disseminated HL resistant to MOPP chemotherapy were treated with high-
dose chemoradiotherapy and marrow transplantation from an HLA-match sibling donor
(MSD). Two patients remain alive in unmaintained complete remission (CR) at 38 and 39
months after transplant. In the other six patients, reasons for failure included relapse of
lymphoma (two patients), or death due to complications of the transplant procedure. They
suggest that some patients with MOPP-resistant HL can obtain prolonged CR following
intensive chemoradiotherapy followed by alloSCT.
In Johns Hopkins Oncology Center, the first prospective study to compare autoSCT with
allogeneic marrow transplantation (alloBMT) was done by Jines RJ. et al. [34]. Patients with
HL who have failed two or more chemotherapy regimens or who have relapsed after an initial
chemotherapy-induced remission of less than 12 months are seldom cured with conventional
salvage therapies. They studied the effect of high-dose cytoreductive therapy followed by
alloBMT in 50 patients with relapsed HL. Twenty-one patients with HLA-matched donors had
alloBMT, one patient received marrow from an identical twin, and 28 patients received
autologous grafts. The authors demonstrated that autoSCT and alloSCT yield similar EFS.
However, they did see a difference in relapse rates between recipients of alloSCT (17%) and
autoSCT recipients with chemosensitive disease (34%), which indicated the possibility of a
GVHL effect [34]. In another study Anderson et al. reported from Seattle, between 1970 and
1991, 127 patients (median age, 29 years) with relapsed or refractory HL received high-dose
chemotherapy with or without irradiation, followed by autoSCT (n=68), alloSCT (n=53), or
syngeneic transplantation (n=6) [35]. The 5-year actuarial probabilities of OS, EFS, relapse, and
nonrelapse mortality (NRM) for the entire group were 21%, 18%, 65%, and 49%, respectively.
HLA-match allogeneic marrow recipients had a statistically lower relapse rate compared with
recipients of autologous marrow, but OS, EFS, and NRM rates were not significantly different.
They described that the use of HLA-MSD marrow results in a lower relapse rate and, thus, for
some individuals, may be preferable to the use of autologous marrow. The European Group
for Blood and Marrow Transplantation (EBMT) directed a retrospective study of 45 patients
(median age, 29 years) with refractory or relapsed HL, who received matched sibling allogeneic
versus autoSCT [36]. The 4-year actuarial probabilities of OS, PFS, relapse, and NRM were
25%, 15%, 61%, and 48% and 37%, 24%, 61%, and 27% after alloBMT and autoBMT, respec‐
tively. The 4-year actuarial probability of survival was 30% after alloBMT and 64% after
autoBMT (P =.007). This difference is mainly due to a higher TRM rate after alloBMT (65% v
12%, P =.005). The authors suggested that patients with relapsed or resistant HL derive no
benefit from alloSCT over autoSCT. However, lower relapse rate (13%) among patients with
acute GVHD, supporting a substantial GVHL effect with alloSCT. The second EBMT registry
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reported by Peniket et al. in 2003, One-hundred-sixty-seven poor-prognosis HL patients who
underwent myeloablative transplantation (77% with stage III or IV at diagnosis and 42% with
chemoresistant disease) were assessed. [37] These patients received allogeneic transplants as
their first transplant procedure. Actuarial OS at 4 years from transplantation was 24.7% years.
These outcomes are relatively poor because of the high TRM associated with these procedures
in patients with HL (51.7% actuarial procedure-related mortality at 4 years). The authors
concluded that the high TRM was probably a reflection of the large percentage of patients with
resistant disease. Gajewski et al. reviewed IBMTR data on 100 consecutive patients with HL
who received HLA-match sibling BMT between 1982 and 1992. All patients had advanced
disease [38]. Eighty-nine of 100 patients were not in remission at the time of transplant. Fifty
had pretransplant Karnofsky scores less than 90% and 27 had active infection in the week
before transplant. The 3-year probability of relapse and the probability of OS were 65% and
15, respectively. They concluded that the role of HLA-identical sibling BMTs have a limited
therapeutic effect in advanced HL. Akpek et al. evaluated the long-term outcome after
allogeneic and autologous blood or marrow transplantation in patients with relapsed or
refractory HL [39]. They analyzed the outcome of 157 consecutive patients with relapsed or
refractory HL, who underwent BMT between 1985 and 1998. There was a trend for probability
of relapse in sensitive patients to be less after alloBMT at 34% (range, 8% to 59%) versus 51%
(range, 36% to 67%) for the auto patients (HR = 0.51, P =.17). There seems to be a clinical GVHL
effect associated with alloBMT. Allogeneic BMT for HL also seems to have a lower risk of
secondary AML/MDS than autoBMT. Thus, alloBMT warrants continued study in HL.
Actually, comparisons of MAC versus autologous transplantation are problematic, because
MAC regimens are favored in patients with extensive prior therapy or comorbidities. In
general, higher NRM has been associated with myeloablative regimens and a greater risk of
relapse associated with autologous approaches, leading to similar long-term outcomes for
patients treated with each approach. The poor outcomes for allogeneic stem cell transplanta‐
tion in HL reported by the IBMTR and the EBMT may result from the selection of patients with
unfavorable risk for these studies. At that point, however, high rate of the TRM with MAC in
Hodgkin lymphoma is considered is rarely pursued [ 40]. Because of the most of this studies
have been reported at least couple decade ago, the effect of myeloablative transplantation in
HL may reevaluate with the developed supportive treatment modalities and new drugs.
3.2. Reduced-intensity conditioning
Last decade has seen a radical change in the approach to alloSCT. Previously, MAC regimens
were thought to be necessary for preventing graft rejection, making marrow space, and
providing antitumor activity. Interest in exploring transplantation with RIC in relapsed or
refractory HL arise from evidence of GVHL effect in these studies comparing allogeneic with
autologous transplantation. In an attempt to decrease TRM, authors increasingly have been
using alloSCT with RIC to patients with HL. Reduced-intensity conditioning could be
sufficient to restore allogeneic engraftment, and allow graft versus host reactions could
eliminate host hematopoiesis and provide antitumor effects. This has allowed treatment to be
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investigating the role of especially RIC-alloSCT in patients with refractory or relapsed HL,
most of whom have previously received autoSCT. [32]
3.1. Myeloablative conditioning regimens
Myeloablative Conditioning (MAC) alloSCT derives its benefit from both the high-dose
conditioning regimen and the GVHL effect. To determine whether this approach would benefit
patients with advanced HL, proof of concept was reported by Appelbaum et al. in Seattle [33].
Eight patients with disseminated HL resistant to MOPP chemotherapy were treated with high-
dose chemoradiotherapy and marrow transplantation from an HLA-match sibling donor
(MSD). Two patients remain alive in unmaintained complete remission (CR) at 38 and 39
months after transplant. In the other six patients, reasons for failure included relapse of
lymphoma (two patients), or death due to complications of the transplant procedure. They
suggest that some patients with MOPP-resistant HL can obtain prolonged CR following
intensive chemoradiotherapy followed by alloSCT.
In Johns Hopkins Oncology Center, the first prospective study to compare autoSCT with
allogeneic marrow transplantation (alloBMT) was done by Jines RJ. et al. [34]. Patients with
HL who have failed two or more chemotherapy regimens or who have relapsed after an initial
chemotherapy-induced remission of less than 12 months are seldom cured with conventional
salvage therapies. They studied the effect of high-dose cytoreductive therapy followed by
alloBMT in 50 patients with relapsed HL. Twenty-one patients with HLA-matched donors had
alloBMT, one patient received marrow from an identical twin, and 28 patients received
autologous grafts. The authors demonstrated that autoSCT and alloSCT yield similar EFS.
However, they did see a difference in relapse rates between recipients of alloSCT (17%) and
autoSCT recipients with chemosensitive disease (34%), which indicated the possibility of a
GVHL effect [34]. In another study Anderson et al. reported from Seattle, between 1970 and
1991, 127 patients (median age, 29 years) with relapsed or refractory HL received high-dose
chemotherapy with or without irradiation, followed by autoSCT (n=68), alloSCT (n=53), or
syngeneic transplantation (n=6) [35]. The 5-year actuarial probabilities of OS, EFS, relapse, and
nonrelapse mortality (NRM) for the entire group were 21%, 18%, 65%, and 49%, respectively.
HLA-match allogeneic marrow recipients had a statistically lower relapse rate compared with
recipients of autologous marrow, but OS, EFS, and NRM rates were not significantly different.
They described that the use of HLA-MSD marrow results in a lower relapse rate and, thus, for
some individuals, may be preferable to the use of autologous marrow. The European Group
for Blood and Marrow Transplantation (EBMT) directed a retrospective study of 45 patients
(median age, 29 years) with refractory or relapsed HL, who received matched sibling allogeneic
versus autoSCT [36]. The 4-year actuarial probabilities of OS, PFS, relapse, and NRM were
25%, 15%, 61%, and 48% and 37%, 24%, 61%, and 27% after alloBMT and autoBMT, respec‐
tively. The 4-year actuarial probability of survival was 30% after alloBMT and 64% after
autoBMT (P =.007). This difference is mainly due to a higher TRM rate after alloBMT (65% v
12%, P =.005). The authors suggested that patients with relapsed or resistant HL derive no
benefit from alloSCT over autoSCT. However, lower relapse rate (13%) among patients with
acute GVHD, supporting a substantial GVHL effect with alloSCT. The second EBMT registry
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reported by Peniket et al. in 2003, One-hundred-sixty-seven poor-prognosis HL patients who
underwent myeloablative transplantation (77% with stage III or IV at diagnosis and 42% with
chemoresistant disease) were assessed. [37] These patients received allogeneic transplants as
their first transplant procedure. Actuarial OS at 4 years from transplantation was 24.7% years.
These outcomes are relatively poor because of the high TRM associated with these procedures
in patients with HL (51.7% actuarial procedure-related mortality at 4 years). The authors
concluded that the high TRM was probably a reflection of the large percentage of patients with
resistant disease. Gajewski et al. reviewed IBMTR data on 100 consecutive patients with HL
who received HLA-match sibling BMT between 1982 and 1992. All patients had advanced
disease [38]. Eighty-nine of 100 patients were not in remission at the time of transplant. Fifty
had pretransplant Karnofsky scores less than 90% and 27 had active infection in the week
before transplant. The 3-year probability of relapse and the probability of OS were 65% and
15, respectively. They concluded that the role of HLA-identical sibling BMTs have a limited
therapeutic effect in advanced HL. Akpek et al. evaluated the long-term outcome after
allogeneic and autologous blood or marrow transplantation in patients with relapsed or
refractory HL [39]. They analyzed the outcome of 157 consecutive patients with relapsed or
refractory HL, who underwent BMT between 1985 and 1998. There was a trend for probability
of relapse in sensitive patients to be less after alloBMT at 34% (range, 8% to 59%) versus 51%
(range, 36% to 67%) for the auto patients (HR = 0.51, P =.17). There seems to be a clinical GVHL
effect associated with alloBMT. Allogeneic BMT for HL also seems to have a lower risk of
secondary AML/MDS than autoBMT. Thus, alloBMT warrants continued study in HL.
Actually, comparisons of MAC versus autologous transplantation are problematic, because
MAC regimens are favored in patients with extensive prior therapy or comorbidities. In
general, higher NRM has been associated with myeloablative regimens and a greater risk of
relapse associated with autologous approaches, leading to similar long-term outcomes for
patients treated with each approach. The poor outcomes for allogeneic stem cell transplanta‐
tion in HL reported by the IBMTR and the EBMT may result from the selection of patients with
unfavorable risk for these studies. At that point, however, high rate of the TRM with MAC in
Hodgkin lymphoma is considered is rarely pursued [ 40]. Because of the most of this studies
have been reported at least couple decade ago, the effect of myeloablative transplantation in
HL may reevaluate with the developed supportive treatment modalities and new drugs.
3.2. Reduced-intensity conditioning
Last decade has seen a radical change in the approach to alloSCT. Previously, MAC regimens
were thought to be necessary for preventing graft rejection, making marrow space, and
providing antitumor activity. Interest in exploring transplantation with RIC in relapsed or
refractory HL arise from evidence of GVHL effect in these studies comparing allogeneic with
autologous transplantation. In an attempt to decrease TRM, authors increasingly have been
using alloSCT with RIC to patients with HL. Reduced-intensity conditioning could be
sufficient to restore allogeneic engraftment, and allow graft versus host reactions could
eliminate host hematopoiesis and provide antitumor effects. This has allowed treatment to be
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considered in older patients, or patients with co-morbidities, including those with HL for
whom prior autoSCT failed.
The EBMT analyzed the first retrospective analysis comparing RIC-alloSCT (n=89) with MAC-
alloSCT (n=79) in patients with relapsed or refractory HL [41]. In the RIC group NRM was
significantly decreased, OS was better and there was a trend for better PFS. Results demon‐
strated nearly twice the relapse incidence in the RIC group (57% vs. 30%), but the 5-year OS
was significantly higher in the RIC group (28% vs. 22%, P=0.003). They also indicate that the
existence of a GVHL effect correlated to the development of GVHD and additional efforts to
reduce the high relaps rate seen in both groups of patients. The centers reported the outcomes
of 143 patients undergoing unrelated donor reduced-intensity and nonmyeloablative (RIC/
NST) SCT for relapsed and refractory HL between 1999 and 2004 reported to the CIBMTR [42].
They analyzed Patients were heavily pretreated, including autoSCT in 89%. With a median
follow-up of 25 months, the probability of TRM at day 100 and 2 years was 15% and 33%,
respectively. The probabilities of PFS and OS were 30% and 56% at 1 year and 20% and 37%
at 2 years. The presence of extranodal disease and the Karnofsky Performance Scale (KPS) <90
were significant risk factors for TRM, PFS, and OS, whereas chemosensitivity at transplanta‐
tion was not. Dose intensity of the conditioning regimen (RIC versus NST) did not impact
outcomes.
Peggs et al. undertook RIC-alloSCT in 49 patients with multiply relapsed HL, 44 (90%) of whom
had progression of disease after previous autoSCT, number of previous treatment courses was
five [range 3-8], and time from diagnosis 4.8 years [range 0.6-4.8]) [43]. Thirty-one patients had
HLA matched donors who were related and 18 had donors who were unrelated. All patients
engrafted. Eight of 49 (16%) had grade II-IV acute GVHD and seven (14%) had chronic GVHD
before DLIs. Sixteen (33%) patients had DLI from 3 months after transplantation for residual
disease or progression. Six (38%) of the 16 developed grade II-IV acute GVHD and five
developed chronic GVHD. Nine (56%) showed disease responses after infusion (eight com‐
plete, one partial). Non-relapse-related mortality was 16.3% at 730 days (7.2% for patients who
had related donors vs. 34.1% for those with unrelated donors, p=0.0206). Projected 4 year OS
and PFS was 55.7% and 39.0%, respectively (62.0% and 41.5% for related donors). In this
prospectively study, authors showed that the potential for durable responses in patients who
have previously had substantial treatment for HL. In another prospective study, Alvarez et al.
described the results of RIC-alloSCT in patients with advanced HL. Forty patients with
relapsed or refractory HL were homogeneously treated with an RIC protocol (fludarabine 150
mg/m(2) intravenously plus melphalan 140 mg/m(2) intravenously) and cyclosporin A and
methotrexate as GVHD prophylaxis [44]. Twenty patients (50%) were allografted in resistant
relapse, and 38 patients received hematopoietic cells from an HLA-match sibling. Five patients
(12%) died from early TRM (before day +100 after allo-RIC). One-year TRM was 25%. Acute
GVHD developed in 18 patients (45%). Chronic GVHD developed in 17 (45%) of the 31
evaluable patients. The response rate 3 months after the allo-RIC was 67% (21 [52%] CRs and
6 [15%] partial remissions). Eleven patients received DLIs for disease relapse. The response
rate after DLI was 54% (3 complete remissions and 3 partial remissions). Overall survival and
PFS were 48% +/- 10% and 32% +/- 10% at 2 years, respectively. They suggest that RIC-alloSCT
Innovations in Stem Cell Transplantation296
is feasible in heavily pretreated HL patients and has an acceptable early TRM. Results are better
in patients allografted in sensitive disease. Both responses observed after the development of
GVHD and DLI may suggest a GVHL effect. Allogeneic RIC has to be considered an effective
therapeutic approach for patients who have had treatment failure with previous autoSCT.
Anderlini et al. reported that a total of 40 patients with relapsed/refractory HL underwent RIC-
alloSCT [45]. Disease status at alloSCT was refractory relapse (n=14) or sensitive relapse (n=26).
The conditioning regimens were fludarabine-cyclophosphamide+/-antithymocyte globulin
(n=14), a less intensive regimen, and fludarabine-melphalan (FM) (n=26), a more intensive one.
The two groups had similar prognostic factors. Day 100 and cumulative TRMs (18-month)
were 5 and 22%. Twenty-four patients (60%) are alive (14 in CR or CR-unconfirmed) with a
median follow-up of 13 months (4-78). In all, 16 patients expired (TRM n=8, disease progression
n=8). FM patients had better OS (73 vs. 39% at 18 months; P=0.03), and a trend towards better
PFS (37 vs 21% at 18 months; P=0.2). Reduced intensity alloSCT is feasible in relapsed/refractory
HL patients with a low TRM. This group updated the results comparing outcomes of 58
patients with HL underwent RIC-alloSCT from a MRD (n=25) or a MUD (n=33) [46]. Forty-
eight (83%) had undergone prior autoSCT. Disease status at transplant was refractory relapse
(n=28) or sensitive relapse (n=30). Cumulative day 100 and 2-year TRM rates were 7% and 15%,
respectively (day 100 transplant-related mortality MRD vs. MUD 8% vs. 6%, p=ns; 2-year MRD
vs. MUD 13% vs. 16%, p=ns). Projected 2-year overall and progression-free survival rates are
64% (49-76%) and 32% (20-45%), with 2-year disease progression/relapse at 55% (43-70%).
There was no statistically significant difference in OS, PFS, and disease progression/relapse
between MRD and MUD transplants. They also suggested that FM as a preparative regimen
for RIC-alloSCT in progression-free survival HL is associated with a significant reduction in
TRM, with comparable results in MRD and MUD allograft.
In a recent study, Sarina et al., using RIC as a salvage option, to evaluate the role of alloSCT
in patients HL relapsing after autoSCT [47]. In this retrospective study based on the commit‐
ment of attending physicians to perform a salvage alloSCT; thus, only HL patients having
human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185
patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical
sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did
not differ. Two-year PFS and OS were better in the donor group (39.3% vs 14.2%, and 66% vs
42%, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis,
having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete
remission showed a better PFS and OS. They concluded that, that: (1) HL patients relapsing
after an autoSCT have a survival advantage if they undergo RIC alloSCT; (2) CR achievement
before RIC alloSCT is very important and influences patients’ clinical outcome; and (3) NRM
after RIC alloSCT is rather low; therefore, this procedure can be considered a feasible option
in the clinical setting. Stephen et al. [48] investigated the role of RIC-alloSCT in the management
of patients with HL. To further define its role they conducted a retrospective analysis of 285
patients with HL who underwent a RIC-alloSCT in order to identify prognostic factors that
predict outcome. Eighty percent of patients had undergone a prior autoSCT and 25% had
refractory disease at transplant. Non-relapse mortality was associated with chemorefractory
disease, poor performance status, age >45 and transplantation before 2002. For patients with
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considered in older patients, or patients with co-morbidities, including those with HL for
whom prior autoSCT failed.
The EBMT analyzed the first retrospective analysis comparing RIC-alloSCT (n=89) with MAC-
alloSCT (n=79) in patients with relapsed or refractory HL [41]. In the RIC group NRM was
significantly decreased, OS was better and there was a trend for better PFS. Results demon‐
strated nearly twice the relapse incidence in the RIC group (57% vs. 30%), but the 5-year OS
was significantly higher in the RIC group (28% vs. 22%, P=0.003). They also indicate that the
existence of a GVHL effect correlated to the development of GVHD and additional efforts to
reduce the high relaps rate seen in both groups of patients. The centers reported the outcomes
of 143 patients undergoing unrelated donor reduced-intensity and nonmyeloablative (RIC/
NST) SCT for relapsed and refractory HL between 1999 and 2004 reported to the CIBMTR [42].
They analyzed Patients were heavily pretreated, including autoSCT in 89%. With a median
follow-up of 25 months, the probability of TRM at day 100 and 2 years was 15% and 33%,
respectively. The probabilities of PFS and OS were 30% and 56% at 1 year and 20% and 37%
at 2 years. The presence of extranodal disease and the Karnofsky Performance Scale (KPS) <90
were significant risk factors for TRM, PFS, and OS, whereas chemosensitivity at transplanta‐
tion was not. Dose intensity of the conditioning regimen (RIC versus NST) did not impact
outcomes.
Peggs et al. undertook RIC-alloSCT in 49 patients with multiply relapsed HL, 44 (90%) of whom
had progression of disease after previous autoSCT, number of previous treatment courses was
five [range 3-8], and time from diagnosis 4.8 years [range 0.6-4.8]) [43]. Thirty-one patients had
HLA matched donors who were related and 18 had donors who were unrelated. All patients
engrafted. Eight of 49 (16%) had grade II-IV acute GVHD and seven (14%) had chronic GVHD
before DLIs. Sixteen (33%) patients had DLI from 3 months after transplantation for residual
disease or progression. Six (38%) of the 16 developed grade II-IV acute GVHD and five
developed chronic GVHD. Nine (56%) showed disease responses after infusion (eight com‐
plete, one partial). Non-relapse-related mortality was 16.3% at 730 days (7.2% for patients who
had related donors vs. 34.1% for those with unrelated donors, p=0.0206). Projected 4 year OS
and PFS was 55.7% and 39.0%, respectively (62.0% and 41.5% for related donors). In this
prospectively study, authors showed that the potential for durable responses in patients who
have previously had substantial treatment for HL. In another prospective study, Alvarez et al.
described the results of RIC-alloSCT in patients with advanced HL. Forty patients with
relapsed or refractory HL were homogeneously treated with an RIC protocol (fludarabine 150
mg/m(2) intravenously plus melphalan 140 mg/m(2) intravenously) and cyclosporin A and
methotrexate as GVHD prophylaxis [44]. Twenty patients (50%) were allografted in resistant
relapse, and 38 patients received hematopoietic cells from an HLA-match sibling. Five patients
(12%) died from early TRM (before day +100 after allo-RIC). One-year TRM was 25%. Acute
GVHD developed in 18 patients (45%). Chronic GVHD developed in 17 (45%) of the 31
evaluable patients. The response rate 3 months after the allo-RIC was 67% (21 [52%] CRs and
6 [15%] partial remissions). Eleven patients received DLIs for disease relapse. The response
rate after DLI was 54% (3 complete remissions and 3 partial remissions). Overall survival and
PFS were 48% +/- 10% and 32% +/- 10% at 2 years, respectively. They suggest that RIC-alloSCT
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is feasible in heavily pretreated HL patients and has an acceptable early TRM. Results are better
in patients allografted in sensitive disease. Both responses observed after the development of
GVHD and DLI may suggest a GVHL effect. Allogeneic RIC has to be considered an effective
therapeutic approach for patients who have had treatment failure with previous autoSCT.
Anderlini et al. reported that a total of 40 patients with relapsed/refractory HL underwent RIC-
alloSCT [45]. Disease status at alloSCT was refractory relapse (n=14) or sensitive relapse (n=26).
The conditioning regimens were fludarabine-cyclophosphamide+/-antithymocyte globulin
(n=14), a less intensive regimen, and fludarabine-melphalan (FM) (n=26), a more intensive one.
The two groups had similar prognostic factors. Day 100 and cumulative TRMs (18-month)
were 5 and 22%. Twenty-four patients (60%) are alive (14 in CR or CR-unconfirmed) with a
median follow-up of 13 months (4-78). In all, 16 patients expired (TRM n=8, disease progression
n=8). FM patients had better OS (73 vs. 39% at 18 months; P=0.03), and a trend towards better
PFS (37 vs 21% at 18 months; P=0.2). Reduced intensity alloSCT is feasible in relapsed/refractory
HL patients with a low TRM. This group updated the results comparing outcomes of 58
patients with HL underwent RIC-alloSCT from a MRD (n=25) or a MUD (n=33) [46]. Forty-
eight (83%) had undergone prior autoSCT. Disease status at transplant was refractory relapse
(n=28) or sensitive relapse (n=30). Cumulative day 100 and 2-year TRM rates were 7% and 15%,
respectively (day 100 transplant-related mortality MRD vs. MUD 8% vs. 6%, p=ns; 2-year MRD
vs. MUD 13% vs. 16%, p=ns). Projected 2-year overall and progression-free survival rates are
64% (49-76%) and 32% (20-45%), with 2-year disease progression/relapse at 55% (43-70%).
There was no statistically significant difference in OS, PFS, and disease progression/relapse
between MRD and MUD transplants. They also suggested that FM as a preparative regimen
for RIC-alloSCT in progression-free survival HL is associated with a significant reduction in
TRM, with comparable results in MRD and MUD allograft.
In a recent study, Sarina et al., using RIC as a salvage option, to evaluate the role of alloSCT
in patients HL relapsing after autoSCT [47]. In this retrospective study based on the commit‐
ment of attending physicians to perform a salvage alloSCT; thus, only HL patients having
human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185
patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical
sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did
not differ. Two-year PFS and OS were better in the donor group (39.3% vs 14.2%, and 66% vs
42%, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis,
having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete
remission showed a better PFS and OS. They concluded that, that: (1) HL patients relapsing
after an autoSCT have a survival advantage if they undergo RIC alloSCT; (2) CR achievement
before RIC alloSCT is very important and influences patients’ clinical outcome; and (3) NRM
after RIC alloSCT is rather low; therefore, this procedure can be considered a feasible option
in the clinical setting. Stephen et al. [48] investigated the role of RIC-alloSCT in the management
of patients with HL. To further define its role they conducted a retrospective analysis of 285
patients with HL who underwent a RIC-alloSCT in order to identify prognostic factors that
predict outcome. Eighty percent of patients had undergone a prior autoSCT and 25% had
refractory disease at transplant. Non-relapse mortality was associated with chemorefractory
disease, poor performance status, age >45 and transplantation before 2002. For patients with
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no risk factors the 3-year non-relapse mortality rate was 12.5% compared to 46.2% for patients
with 2 or more risk factors. The use of an unrelated donor had no adverse effect on the non-
relapse mortality. Acute GVHD grades II-IV developed in 30% and chronic GVHD in 42%. The
development of chronic GVHD was associated with a lower relapse rate. The disease progres‐
sion rate at one and five years was 41% and 58.7% respectively and was associated with
chemorefractory disease and extent of prior therapy. Donor lymphocyte infusions were
administered to 64 patients for active disease of whom 32% showed a clinical response. Eight
out of 18 patients receiving DLIs alone had clinical responses. Progression-free and OS were
both associated with performance status and disease status at transplant. Patients with neither
risk factor had a 3- year PFS and OS of 42% and 56% respectively compared to 8% and 25% for
patients with one or more risk factors. Relapse within six months of a prior autologous
transplant was associated with a higher relapse rate and a lower progression-free. They
recommend that for patients deemed to be at high risk of failing an autologous transplant a
RIC-alloSCT may represent a more effective therapy and prospective comparative studies in
this setting should be considered.
On the basis of current data, some authors recommend RIC-allo for HL only in the context
of prospective clinical trials because allo-SCT trials continue to report disappointing relapse
rates. However, if clinicians feel strongly about proceeding with this strategy, patients with
refractory disease should be excluded and opportunities to exploit the GVHL effect should
be used [20].
3.3. The role of functional imaging in response assessment before RIC allo-SCT
Dodero et al. investigated the prognostic value of PET scanning in 80 patients who had
chemosensitive disease (34 patients with HG-NHL and 46 patients with HL before undergoing
to RIC and followed by alloSCT [49]. Positron emission tomography was used to assess before
they underwent alloSCT: 42 patients had negative PET studies, and 38 patients had positive
PET studies. Patients underwent allograft from MSD (n = 41) or alternative donors (n = 39). At
the time of the last follow-up, 48 patients were alive (60%), and 32 had died. The 3-year
cumulative incidence of nonrecurrence mortality and disease recurrence was 17% and 40%,
respectively. The cumulative incidence of disease recurrence was significantly lower in the
PET-negative patients (25% vs. 56%; P =.007), but there was no significant difference between
the patients with or without chronic GVHD (P =.400). The patients who had negative PET
studies before undergoing alloSCT also had significantly better outcomes in terms of 3-year
OS (76% vs. 33%; P =.001) and 3-year PFS (73% vs. 31%; P =.001). On multivariate analysis, OS
was influenced by PET status (hazard ratio [HR], 3.35), performance status (HR, 5.15), and type
of donor (HR, 6.26 for haploidentical vs. MSD; HR, 1.94 for MUD vs. MSD)l. The current results
indicated that PET scanning appears to be an accurate tool for assessing prognosis in patients
who are eligible for RIC allografting.
In summary, autoSCT and alloSCT may be curative therapy options for patients with relapse/
refractory HL. AutoSCT is a standard therapy in relapsing HL patients especially responding
to salvage therapy. However, there is no place of autoSCT even in high-risk patients with first
remission. If patients with refractory disease after first-line treatment respond second line
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standard-dose therapy, these patients can benefit from an autoSCT. BEAM regimen is used as
the standard high dose-conditioning regimen. Detectable disease with functional imaging
before autoSCT can be an indicator of poor prognosis. Patients with relaps or progressive
disease after autoSCT need either alloSCT or other investigative approaches. The review of the
literature of alloSCT in HL patients has showed that in the last decade an increasing interest
has been raised on this topic. The results that are now available allow the following consider‐
ations: (i) Although myeloablative allogeneic SCT has lower relaps rate still has been associated
high non relaps mortality; (ii) The effect of myeloablative transplantation in HL may reevaluate
with the developed supportive treatment modalities and future studies should be aimed at
integrating intensified therapies and/or new drugs into the treatment plan to pursue the best
response before allografting; (iii) RIC alloSCT is a feasible option in relapsed/refractory HL
patients even if they were heavily pretreated; (iv) 20–30% of the allografted patients can be
long-term survivors after RIC alloSCT; (v) Complete response is the most important predictor
of a favorable outcome; (vi) PET scanning appears to be an accurate tool for assessing prognosis
in patients who are eligible for RIC allografting; thus (vii) Since the relapse risk after RIC-
alloSCT is still high maintenance treatment or immunological methods should be explored in
prospective clinical trials.
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no risk factors the 3-year non-relapse mortality rate was 12.5% compared to 46.2% for patients
with 2 or more risk factors. The use of an unrelated donor had no adverse effect on the non-
relapse mortality. Acute GVHD grades II-IV developed in 30% and chronic GVHD in 42%. The
development of chronic GVHD was associated with a lower relapse rate. The disease progres‐
sion rate at one and five years was 41% and 58.7% respectively and was associated with
chemorefractory disease and extent of prior therapy. Donor lymphocyte infusions were
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transplant was associated with a higher relapse rate and a lower progression-free. They
recommend that for patients deemed to be at high risk of failing an autologous transplant a
RIC-alloSCT may represent a more effective therapy and prospective comparative studies in
this setting should be considered.
On the basis of current data, some authors recommend RIC-allo for HL only in the context
of prospective clinical trials because allo-SCT trials continue to report disappointing relapse
rates. However, if clinicians feel strongly about proceeding with this strategy, patients with
refractory disease should be excluded and opportunities to exploit the GVHL effect should
be used [20].
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Dodero et al. investigated the prognostic value of PET scanning in 80 patients who had
chemosensitive disease (34 patients with HG-NHL and 46 patients with HL before undergoing
to RIC and followed by alloSCT [49]. Positron emission tomography was used to assess before
they underwent alloSCT: 42 patients had negative PET studies, and 38 patients had positive
PET studies. Patients underwent allograft from MSD (n = 41) or alternative donors (n = 39). At
the time of the last follow-up, 48 patients were alive (60%), and 32 had died. The 3-year
cumulative incidence of nonrecurrence mortality and disease recurrence was 17% and 40%,
respectively. The cumulative incidence of disease recurrence was significantly lower in the
PET-negative patients (25% vs. 56%; P =.007), but there was no significant difference between
the patients with or without chronic GVHD (P =.400). The patients who had negative PET
studies before undergoing alloSCT also had significantly better outcomes in terms of 3-year
OS (76% vs. 33%; P =.001) and 3-year PFS (73% vs. 31%; P =.001). On multivariate analysis, OS
was influenced by PET status (hazard ratio [HR], 3.35), performance status (HR, 5.15), and type
of donor (HR, 6.26 for haploidentical vs. MSD; HR, 1.94 for MUD vs. MSD)l. The current results
indicated that PET scanning appears to be an accurate tool for assessing prognosis in patients
who are eligible for RIC allografting.
In summary, autoSCT and alloSCT may be curative therapy options for patients with relapse/
refractory HL. AutoSCT is a standard therapy in relapsing HL patients especially responding
to salvage therapy. However, there is no place of autoSCT even in high-risk patients with first
remission. If patients with refractory disease after first-line treatment respond second line
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standard-dose therapy, these patients can benefit from an autoSCT. BEAM regimen is used as
the standard high dose-conditioning regimen. Detectable disease with functional imaging
before autoSCT can be an indicator of poor prognosis. Patients with relaps or progressive
disease after autoSCT need either alloSCT or other investigative approaches. The review of the
literature of alloSCT in HL patients has showed that in the last decade an increasing interest
has been raised on this topic. The results that are now available allow the following consider‐
ations: (i) Although myeloablative allogeneic SCT has lower relaps rate still has been associated
high non relaps mortality; (ii) The effect of myeloablative transplantation in HL may reevaluate
with the developed supportive treatment modalities and future studies should be aimed at
integrating intensified therapies and/or new drugs into the treatment plan to pursue the best
response before allografting; (iii) RIC alloSCT is a feasible option in relapsed/refractory HL
patients even if they were heavily pretreated; (iv) 20–30% of the allografted patients can be
long-term survivors after RIC alloSCT; (v) Complete response is the most important predictor
of a favorable outcome; (vi) PET scanning appears to be an accurate tool for assessing prognosis
in patients who are eligible for RIC allografting; thus (vii) Since the relapse risk after RIC-
alloSCT is still high maintenance treatment or immunological methods should be explored in
prospective clinical trials.
Author details
Leylagül Kaynar1*, Mustafa Çetin2, Ali Ünal3 and Taner Demirer4
*Address all correspondence to: drleylagul@gmail.com
1 Erciyes University, Faculty of Medicine, Deparment of Hematology, Erciyes Transplant
Center, Kayseri, Turkey
2 Erciyes University, Faculty of Medicine, Deparment of Hematology, Erciyes Transplant
Center, Kayseri, Turkey
3 Erciyes University, Faculty of Medicine, Deparment of Hematology, Erciyes Transplant
Center, Kayseri, Turkey
4 Ankara University, Medical School, Deparment of Hematology, Ankara, Turkey
References
[1] Engert, A, Plütschow, A, Eich, H. T, Lohri, A, Dörken, B, Borchmann, P, et al. Re‐
duced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl
J Med. (2010). , 363, 640-652.
Current Status of Hematopoietic Stem Cell Transplantation in Patients with Refractory or Relapse Hodgkin Lymphoma
http://dx.doi.org/10.5772/55106
299
[2] Diehl, V, Franklin, J, Pfreundschuh, M, Lathan, B, Paulus, U, Hasenclever, D, et al.
Standard and increased-dose BEACOPP chemotherapy compared with COPP-
ABVD for advanced Hodgkin’s disease. N Engl J Med. (2003). , 348, 2386-2395.
[3] Eich, H. T, Diehl, V, Görgen, H, Pabst, T, Markova, J, Debus, J, et al. Intensified che‐
motherapy and dose-reduced involved-field radiotherapy in patients with early un‐
favorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group
HD11 trial. J Clin Oncol. (2010). , 28, 4199-4206.
[4] Linch, D. C, Winfield, D, Goldstone, A. H, Moir, D, Hancock, B, Mcmillan, A, et al.
Dose intensification with autologous bone-marrow transplantation in relapsed and
resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet (1993). , 341,
1051-1054.
[5] Schmitz, N, Pfistner, B, Sextro, M, Sieber, M, Carella, A. M, Haenel, M, et al. Aggres‐
sive conventional chemotherapy compared with high-dose chemotherapy with au‐
tologous haemopoietic stem-cell transplantation for relapsed chemosensitive
Hodgkin’s disease: a randomized trial. Lancet (2002). , 359, 2065-2071.
[6] Nademanee, A, Molina, A, Fung, H, Stein, A, Parker, P, Planas, I, et al. High-dose
chemo/radiotherapy and autologous bone marrow or stem cell transplantation for
poor-risk advanced-stage Hodgkin’s disease during first partial or complete remis‐
sion. Biol Blood Marrow Transplant. (1999). , 5(5), 292-298.
[7] Federico, M, Bellei, M, Brice, P, Brugiatelli, M, Nagler, A, Gisselbrecht, C, et al. High-
dose therapy and autologous stem-cell transplantation versus conventional therapy
for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J
Clin Oncol. (2003). , 21(12), 2320-2325.
[8] Carella, A. M, Bellei, M, Brice, P, Gisselbrecht, C, Visani, G, Colombat, P, et al. High-
dose therapy and autologous stem cell transplantation versus conventional therapy
for patients with advanced Hodgkin’s lymphoma responding to front-line therapy:
long-term results. Haematologica. (2009). , 94(1), 146-148.
[9] Arakelyan, N, Berthou, C, Desablens, B, De Guibert, S, Delwail, V, Moles, M. P, et al.
Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cy‐
cles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4
cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus mye‐
loablative chemotherapy with autologous stem cell transplantation: five-year results
of a randomized trial on behalf of the GOELAMS Group Cancer. (2008). , 113,
3323-3330.
[10] Linch, D. C, Winfield, D, Goldstone, A. H, Moir, D, Hancock, B, Mcmillan, A, et al.
Dose intensification with autologous bone-marrow transplantation in relapsed and
resistant Hodgkin’s disease: Results of a BNLI randomized trial. Lancet (1993). , 341,
1051-1054.
[11] Schmitz, N, Pfistner, B, Sextro, M, Sieber, M, Carella, A. M, Haenel, M, et al. Aggres‐
sive conventional chemotherapy compared with high-dose chemotherapy with au‐
Innovations in Stem Cell Transplantation300
tologous haemopoietic stem-cell transplantation for relapsed chemosensitive
Hodgkin’s disease: a randomised trial. Lancet. (2002). Jun 15;, 359(9323), 2065-2071.
[12] Linch, D. C, Winfield, D, Goldstone, A. H, Moir, D, Hancock, B, et al. Dose intensifi‐
cation with autologous bone- marrow transplantation in relapsed and resistant
Hodgkin’s disease: Results of a BNLI randomized trial. Lancet (1993). , 341,
1051-1054.
[13] Ljungman, P, Bregni, M, Brune, M, Cornelissen, J, De Witte, T, Dini, G, et al. Alloge‐
neic and autologous transplantation for haematological diseases, solid tumours and
immune disorders: current practice in Europe 2009. Bone Marrow Transplanst.
(2010). , 45(2), 219-234.
[14] Moskowitz, C. H, Kewalramani, T, Nimer, S. D, Gonzalez, M, Zelenetz, A. D, & Ya‐
halom, J. Effectiveness of high dose chemoradiotherapy and autologous stem cell
transplantation for patients with biopsy-proven primary refractory Hodgkin’s dis‐
ease. Br J Haematol (2004). , 124, 645-652.
[15] Kewalramani, T, Nimer, S. D, Zelenetz, A. D, Malhotra, S, Qin, J, Yahalom, J, et al.
Progressive disease following autologous transplantation in patients with chemosen‐
sitive relapsed or primary refractory Hodgkin’s disease or aggressive non- Hodg‐
kin’s lymphoma. Bone Marrow Transplant (2003). , 32, 673-679.
[16] Gutierrez-delgado, F, Holmberg, L, Hooper, H, Petersdorf, S, Press, O, Maziarz, R, et
al. Autologous stem cell transplantation for Hodgkin’s disease: busulfan, melphalan
and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant.
(2003). , 32(3), 279-285.
[17] Nademanee, A, Donnell, O, Snyder, M. R, Schmidt, D. S, Parker, G. M, & Stein, P. M.
AS, et al. High-dose chemotherapy with or without total body irradiation followed
by autologous bone marrow and/or peripheral blood stem cell transplantation for pa‐
tients with relapsed and refractory Hodkin’s disease: results in 85 patients with anal‐
ysis of prognostic factors. Blood (1995). , 85, 1381-1390.
[18] Horning, S. J, Chao, N. J, Negrin, R. S, Hoppe, R. T, Long, G. D, Hu, W. W, et al.
High-dose therapy and autologous hematopoietic progenitor cell transplantation for
recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results
and prognostic indices. Blood (1997). , 89, 801-813.
[19] Josting, A, Müller, H, Borchmann, P, Baars, J. W, Metzner, B, Döhner, H, Aurer, I, et
al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J
Clin Oncol. (2010). Dec 1;, 28(34), 5074-5080.
[20] Kuruvilla, J, Keating, A, & Crump, M. How I treat relapsed and refractory Hodgkin
lymphoma. Blood. (2011). Apr 21;, 117(16), 4208-4217.
[21] Moskowitz, C. H, Yahalom, J, Zelenetz, A. D, Zhang, Z, Filippa, D, Teruya-feldstein,
J, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lympho‐
Current Status of Hematopoietic Stem Cell Transplantation in Patients with Refractory or Relapse Hodgkin Lymphoma
http://dx.doi.org/10.5772/55106
301
[2] Diehl, V, Franklin, J, Pfreundschuh, M, Lathan, B, Paulus, U, Hasenclever, D, et al.
Standard and increased-dose BEACOPP chemotherapy compared with COPP-
ABVD for advanced Hodgkin’s disease. N Engl J Med. (2003). , 348, 2386-2395.
[3] Eich, H. T, Diehl, V, Görgen, H, Pabst, T, Markova, J, Debus, J, et al. Intensified che‐
motherapy and dose-reduced involved-field radiotherapy in patients with early un‐
favorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group
HD11 trial. J Clin Oncol. (2010). , 28, 4199-4206.
[4] Linch, D. C, Winfield, D, Goldstone, A. H, Moir, D, Hancock, B, Mcmillan, A, et al.
Dose intensification with autologous bone-marrow transplantation in relapsed and
resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet (1993). , 341,
1051-1054.
[5] Schmitz, N, Pfistner, B, Sextro, M, Sieber, M, Carella, A. M, Haenel, M, et al. Aggres‐
sive conventional chemotherapy compared with high-dose chemotherapy with au‐
tologous haemopoietic stem-cell transplantation for relapsed chemosensitive
Hodgkin’s disease: a randomized trial. Lancet (2002). , 359, 2065-2071.
[6] Nademanee, A, Molina, A, Fung, H, Stein, A, Parker, P, Planas, I, et al. High-dose
chemo/radiotherapy and autologous bone marrow or stem cell transplantation for
poor-risk advanced-stage Hodgkin’s disease during first partial or complete remis‐
sion. Biol Blood Marrow Transplant. (1999). , 5(5), 292-298.
[7] Federico, M, Bellei, M, Brice, P, Brugiatelli, M, Nagler, A, Gisselbrecht, C, et al. High-
dose therapy and autologous stem-cell transplantation versus conventional therapy
for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J
Clin Oncol. (2003). , 21(12), 2320-2325.
[8] Carella, A. M, Bellei, M, Brice, P, Gisselbrecht, C, Visani, G, Colombat, P, et al. High-
dose therapy and autologous stem cell transplantation versus conventional therapy
for patients with advanced Hodgkin’s lymphoma responding to front-line therapy:
long-term results. Haematologica. (2009). , 94(1), 146-148.
[9] Arakelyan, N, Berthou, C, Desablens, B, De Guibert, S, Delwail, V, Moles, M. P, et al.
Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cy‐
cles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4
cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus mye‐
loablative chemotherapy with autologous stem cell transplantation: five-year results
of a randomized trial on behalf of the GOELAMS Group Cancer. (2008). , 113,
3323-3330.
[10] Linch, D. C, Winfield, D, Goldstone, A. H, Moir, D, Hancock, B, Mcmillan, A, et al.
Dose intensification with autologous bone-marrow transplantation in relapsed and
resistant Hodgkin’s disease: Results of a BNLI randomized trial. Lancet (1993). , 341,
1051-1054.
[11] Schmitz, N, Pfistner, B, Sextro, M, Sieber, M, Carella, A. M, Haenel, M, et al. Aggres‐
sive conventional chemotherapy compared with high-dose chemotherapy with au‐
Innovations in Stem Cell Transplantation300
tologous haemopoietic stem-cell transplantation for relapsed chemosensitive
Hodgkin’s disease: a randomised trial. Lancet. (2002). Jun 15;, 359(9323), 2065-2071.
[12] Linch, D. C, Winfield, D, Goldstone, A. H, Moir, D, Hancock, B, et al. Dose intensifi‐
cation with autologous bone- marrow transplantation in relapsed and resistant
Hodgkin’s disease: Results of a BNLI randomized trial. Lancet (1993). , 341,
1051-1054.
[13] Ljungman, P, Bregni, M, Brune, M, Cornelissen, J, De Witte, T, Dini, G, et al. Alloge‐
neic and autologous transplantation for haematological diseases, solid tumours and
immune disorders: current practice in Europe 2009. Bone Marrow Transplanst.
(2010). , 45(2), 219-234.
[14] Moskowitz, C. H, Kewalramani, T, Nimer, S. D, Gonzalez, M, Zelenetz, A. D, & Ya‐
halom, J. Effectiveness of high dose chemoradiotherapy and autologous stem cell
transplantation for patients with biopsy-proven primary refractory Hodgkin’s dis‐
ease. Br J Haematol (2004). , 124, 645-652.
[15] Kewalramani, T, Nimer, S. D, Zelenetz, A. D, Malhotra, S, Qin, J, Yahalom, J, et al.
Progressive disease following autologous transplantation in patients with chemosen‐
sitive relapsed or primary refractory Hodgkin’s disease or aggressive non- Hodg‐
kin’s lymphoma. Bone Marrow Transplant (2003). , 32, 673-679.
[16] Gutierrez-delgado, F, Holmberg, L, Hooper, H, Petersdorf, S, Press, O, Maziarz, R, et
al. Autologous stem cell transplantation for Hodgkin’s disease: busulfan, melphalan
and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant.
(2003). , 32(3), 279-285.
[17] Nademanee, A, Donnell, O, Snyder, M. R, Schmidt, D. S, Parker, G. M, & Stein, P. M.
AS, et al. High-dose chemotherapy with or without total body irradiation followed
by autologous bone marrow and/or peripheral blood stem cell transplantation for pa‐
tients with relapsed and refractory Hodkin’s disease: results in 85 patients with anal‐
ysis of prognostic factors. Blood (1995). , 85, 1381-1390.
[18] Horning, S. J, Chao, N. J, Negrin, R. S, Hoppe, R. T, Long, G. D, Hu, W. W, et al.
High-dose therapy and autologous hematopoietic progenitor cell transplantation for
recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results
and prognostic indices. Blood (1997). , 89, 801-813.
[19] Josting, A, Müller, H, Borchmann, P, Baars, J. W, Metzner, B, Döhner, H, Aurer, I, et
al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J
Clin Oncol. (2010). Dec 1;, 28(34), 5074-5080.
[20] Kuruvilla, J, Keating, A, & Crump, M. How I treat relapsed and refractory Hodgkin
lymphoma. Blood. (2011). Apr 21;, 117(16), 4208-4217.
[21] Moskowitz, C. H, Yahalom, J, Zelenetz, A. D, Zhang, Z, Filippa, D, Teruya-feldstein,
J, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lympho‐
Current Status of Hematopoietic Stem Cell Transplantation in Patients with Refractory or Relapse Hodgkin Lymphoma
http://dx.doi.org/10.5772/55106
301
ma and the signifi- cance of pre-transplant functional imaging. Br J Haematol.
(2010). , 148(6), 890-897.
[22] Jabbour, E, Hosing, C, Ayers, G, Nunez, R, Anderlini, P, Pro, B, et al. Pretransplant
positive positron emission tomography/gallium scans predict poor outcome in pa‐
tients with recurrent/refractory Hodgkin lymphoma. Cancer. (2007). , 109(12),
2481-2489.
[23] Moskowitz, C. H, Matasar, M. J, Zelenetz, A. D, Nimer, S. D, Gerecitano, J, Hamlin,
P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-
resistant, chemotherapy programs improves event-free survival in patients with
Hodgkin lymphoma. Blood. (2012). , 119(7), 1665-1670.
[24] Reece, D. E, Connors, J. M, Spinelli, J. J, Barnett, M. J, Fairey, R. N, Klingemann, H. G,
et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin,
and autologous bone marrow transplantation for Hodgkin’s disease in first relapse
after combination chemotherapy. Blood (1995). , 83, 1193-1119.
[25] Bierman, P. J, Bagin, R. G, Jagannath, S, Vose, J. M, Spitzer, G, Kessinger, A, et al.
High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s
disease: long term follow-up in 128 patients. Ann Oncol (1993). , 4, 767-773.
[26] Brice, P, Bouabdallah, R, Moreau, P, Divine, M, André, M, Aoudjane, M, et al. Prog‐
nostic factors for survival after HDT and ASCT for patients with relapsed HD: analy‐
sis of 280 patients from the French Registry. Bone Marrow Transplant (1997). , 20,
21-26.
[27] Popat, U, Hosing, C, Saliba, R. M, Anderlini, P, Van Besien, K, Przepiorka, D, et al.
Prognostic factors for disease progression after high-dose chemotherapy and autolo‐
gous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin’s
lymphoma. Bone Marrow Transplant. (2004). , 33(10), 1015-23.
[28] Moskowitz, C. H, Nimer, S. D, Zelenetz, A. D, Trippett, T, Hedrick, E. E, Filippa, D.
A, et al. A 2-step comprehensive high-dose chemotherapy second-line program for
relapsed and refractory Hodgkin disease: analysis by intent to treat and development
of a prognostic model. Blood (2001). , 97, 616-623.
[29] Sureda, A, Constans, M, Iriondo, A, Arranz, R, Caballero, M. D, Vidal, M. J, et al.
Prognostic factors affecting long-term outcome after stem cell transplantation in
Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol (2005). , 16,
625-633.
[30] Moskowitz, A. J, Yahalom, J, & Kewalramani, T. Pretransplantation functional imag‐
ing predicts outcome following autologous stem cell transplantation for relapsed and
refractory Hodgkin lymphoma. Blood (2010). , 116(23), 4934-4937.
[31] Moskowitz, C. H, Matasar, M. J, Zelenetz, A. D, Nimer, S. D, Gerecitano, J, Hamlin,
P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-
Innovations in Stem Cell Transplantation302
resistant, chemotherapy programs improves event-free survival in patients with
Hodgkin lymphoma. Blood. (2012). , 119(7), 1665-70.
[32] Salit, R. B, Bishop, M. R, & Pavletic, S. Z. Allogeneic Hematopoietic Stem Cell Trans‐
plantation: Does It Have a Place in Treating Hodgkin Lymphoma? Curr Hematol
Malig Rep (2010). , 5, 229-238.
[33] Appelbaum, F. R, Sullivan, K. M, Thomas, E. D, Buckner, C. D, Clift, R. A, et al. Allo‐
geneic marrow transplantation in the treatment of MOPP-resistant Hodgkin’s dis‐
ease. J Clin Oncol (1985). , 3, 1490-1494.
[34] Jones, R. J, Piantadosi, S, Mann, R. B, Ambinder, R. F, Seifter, E. J, Vriesendorp, H. M,
et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed
Hodgkin’s disease. J Clin Oncol (1990). , 8, 527-537.
[35] Anderson, J. E, Litzow, M. R, Appelbaum, F. R, Schoch, G, Fisher, L. D, Buckner, C.
D, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodg‐
kin’s disease: the year Seattle experience. J Clin Oncol (1993). , 21.
[36] Milpied, N, Fielding, A. K, Pearce, R. M, Ernst, P, & Goldstone, A. H. Allogeneic
bone marrow transplant is not better than autologous transplant for patients with re‐
lapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplan‐
tation. J Clin Oncol (1996). , 14, 1291-1296.
[37] Peniket, A. J. Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, et al. An
EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allo‐
geneic transplantation is associated with a lower relapse rate but a higher procedure-
related mortality rate than autologous transplantation. Bone Marrow Transplant
(2003). , 31, 667-678.
[38] Gajewski, J. L, Phillips, G. L, Sobocinski, K. A, Armitage, J. O, Gale, R. P, Champlin,
R. E, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodg‐
kin’s disease. J Clin Oncol (1996). , 14, 572-578.
[39] Akpek, G, Ambinder, R. F, Piantadosi, S, Abrams, R. A, Brodsky, R. A, Vogelsang, G.
B, et al. Long-term results of blood and marrow transplantation for Hodgkin’s lym‐
phoma. J Clin Oncol (2001). , 19, 4314-4321.
[40] Corradini, P, Sarina, B, & Farina, L. Allogeneic transplantation for Hodgkin’s lym‐
phoma. Br J Haematol. (2011). , 152(3), 261-272.
[41] Sureda, A, Robinson, S, Canals, C, Carella, A. M, Boogaerts, M. A, Caballero, D, et al.
Reduced-intensity conditioning compared with conventional allogeneic stem-cell
transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the
Lymphoma Working Party of the European Group for Blood and Marrow Transplan‐
tation. J Clin Oncol (2008). , 26, 455-462.
[42] Devetten, M. P, Hari, P. N, Carreras, J, Logan, B. R, Van Besien, K, et al. Unrelated
donor reduced-intensity allogeneic hematopoietic stem cell transplantation for re‐
Current Status of Hematopoietic Stem Cell Transplantation in Patients with Refractory or Relapse Hodgkin Lymphoma
http://dx.doi.org/10.5772/55106
303
ma and the signifi- cance of pre-transplant functional imaging. Br J Haematol.
(2010). , 148(6), 890-897.
[22] Jabbour, E, Hosing, C, Ayers, G, Nunez, R, Anderlini, P, Pro, B, et al. Pretransplant
positive positron emission tomography/gallium scans predict poor outcome in pa‐
tients with recurrent/refractory Hodgkin lymphoma. Cancer. (2007). , 109(12),
2481-2489.
[23] Moskowitz, C. H, Matasar, M. J, Zelenetz, A. D, Nimer, S. D, Gerecitano, J, Hamlin,
P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-
resistant, chemotherapy programs improves event-free survival in patients with
Hodgkin lymphoma. Blood. (2012). , 119(7), 1665-1670.
[24] Reece, D. E, Connors, J. M, Spinelli, J. J, Barnett, M. J, Fairey, R. N, Klingemann, H. G,
et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin,
and autologous bone marrow transplantation for Hodgkin’s disease in first relapse
after combination chemotherapy. Blood (1995). , 83, 1193-1119.
[25] Bierman, P. J, Bagin, R. G, Jagannath, S, Vose, J. M, Spitzer, G, Kessinger, A, et al.
High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s
disease: long term follow-up in 128 patients. Ann Oncol (1993). , 4, 767-773.
[26] Brice, P, Bouabdallah, R, Moreau, P, Divine, M, André, M, Aoudjane, M, et al. Prog‐
nostic factors for survival after HDT and ASCT for patients with relapsed HD: analy‐
sis of 280 patients from the French Registry. Bone Marrow Transplant (1997). , 20,
21-26.
[27] Popat, U, Hosing, C, Saliba, R. M, Anderlini, P, Van Besien, K, Przepiorka, D, et al.
Prognostic factors for disease progression after high-dose chemotherapy and autolo‐
gous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin’s
lymphoma. Bone Marrow Transplant. (2004). , 33(10), 1015-23.
[28] Moskowitz, C. H, Nimer, S. D, Zelenetz, A. D, Trippett, T, Hedrick, E. E, Filippa, D.
A, et al. A 2-step comprehensive high-dose chemotherapy second-line program for
relapsed and refractory Hodgkin disease: analysis by intent to treat and development
of a prognostic model. Blood (2001). , 97, 616-623.
[29] Sureda, A, Constans, M, Iriondo, A, Arranz, R, Caballero, M. D, Vidal, M. J, et al.
Prognostic factors affecting long-term outcome after stem cell transplantation in
Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol (2005). , 16,
625-633.
[30] Moskowitz, A. J, Yahalom, J, & Kewalramani, T. Pretransplantation functional imag‐
ing predicts outcome following autologous stem cell transplantation for relapsed and
refractory Hodgkin lymphoma. Blood (2010). , 116(23), 4934-4937.
[31] Moskowitz, C. H, Matasar, M. J, Zelenetz, A. D, Nimer, S. D, Gerecitano, J, Hamlin,
P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-
Innovations in Stem Cell Transplantation302
resistant, chemotherapy programs improves event-free survival in patients with
Hodgkin lymphoma. Blood. (2012). , 119(7), 1665-70.
[32] Salit, R. B, Bishop, M. R, & Pavletic, S. Z. Allogeneic Hematopoietic Stem Cell Trans‐
plantation: Does It Have a Place in Treating Hodgkin Lymphoma? Curr Hematol
Malig Rep (2010). , 5, 229-238.
[33] Appelbaum, F. R, Sullivan, K. M, Thomas, E. D, Buckner, C. D, Clift, R. A, et al. Allo‐
geneic marrow transplantation in the treatment of MOPP-resistant Hodgkin’s dis‐
ease. J Clin Oncol (1985). , 3, 1490-1494.
[34] Jones, R. J, Piantadosi, S, Mann, R. B, Ambinder, R. F, Seifter, E. J, Vriesendorp, H. M,
et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed
Hodgkin’s disease. J Clin Oncol (1990). , 8, 527-537.
[35] Anderson, J. E, Litzow, M. R, Appelbaum, F. R, Schoch, G, Fisher, L. D, Buckner, C.
D, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodg‐
kin’s disease: the year Seattle experience. J Clin Oncol (1993). , 21.
[36] Milpied, N, Fielding, A. K, Pearce, R. M, Ernst, P, & Goldstone, A. H. Allogeneic
bone marrow transplant is not better than autologous transplant for patients with re‐
lapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplan‐
tation. J Clin Oncol (1996). , 14, 1291-1296.
[37] Peniket, A. J. Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, et al. An
EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allo‐
geneic transplantation is associated with a lower relapse rate but a higher procedure-
related mortality rate than autologous transplantation. Bone Marrow Transplant
(2003). , 31, 667-678.
[38] Gajewski, J. L, Phillips, G. L, Sobocinski, K. A, Armitage, J. O, Gale, R. P, Champlin,
R. E, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodg‐
kin’s disease. J Clin Oncol (1996). , 14, 572-578.
[39] Akpek, G, Ambinder, R. F, Piantadosi, S, Abrams, R. A, Brodsky, R. A, Vogelsang, G.
B, et al. Long-term results of blood and marrow transplantation for Hodgkin’s lym‐
phoma. J Clin Oncol (2001). , 19, 4314-4321.
[40] Corradini, P, Sarina, B, & Farina, L. Allogeneic transplantation for Hodgkin’s lym‐
phoma. Br J Haematol. (2011). , 152(3), 261-272.
[41] Sureda, A, Robinson, S, Canals, C, Carella, A. M, Boogaerts, M. A, Caballero, D, et al.
Reduced-intensity conditioning compared with conventional allogeneic stem-cell
transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the
Lymphoma Working Party of the European Group for Blood and Marrow Transplan‐
tation. J Clin Oncol (2008). , 26, 455-462.
[42] Devetten, M. P, Hari, P. N, Carreras, J, Logan, B. R, Van Besien, K, et al. Unrelated
donor reduced-intensity allogeneic hematopoietic stem cell transplantation for re‐
Current Status of Hematopoietic Stem Cell Transplantation in Patients with Refractory or Relapse Hodgkin Lymphoma
http://dx.doi.org/10.5772/55106
303
lapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant (2009). ,
15, 109-117.
[43] Peggs, K. S, Hunter, A, Chopra, R, Parker, A, Mahendra, P, Milligan, D, et al. Clinical
evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced intensity alloge‐
neic transplantation. Lancet (2005). , 365, 1934-1941.
[44] Alvarez, I, Sureda, A, Caballero, M. D, Urbano-ispizua, A, Ribera, J. M, et al. Non‐
myeloablative stem cell transplantation is an effective therapy for refractory or re‐
lapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol.
Biol Blood Marrow Transplant (2006). , 12, 172-183.
[45] Anderlini, P, Saliba, R, Acholonu, S, Okoroji, G. J, Donato, M, et al. Reduced-intensity
allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease:
low transplant-related mortality and impact of intensity of conditioning regimen.
Bone Marrow Transplant (2005). , 35, 943-951.
[46] Anderlini, P, Saliba, R, Acholonu, S, Giralt, S. A, Andersson, B, et al. Fludarabine-
melphalan as a preparative regimen for reduced-intensity conditioning allogeneic
stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updat‐
ed M.D. Anderson Cancer Center experience. Haematologica (2008). , 93, 257-264.
[47] Sarina, B, Castagna, L, Farina, L, Patriarca, F, Benedetti, F, Carella, A. M, et al. Allo‐
geneic transplantation improves the overall and progression-free survival of Hodg‐
kin lymphoma patients relapsing after autologous transplantation: a retrospective
study based on the time of HLAtyping and donor availability. Blood. (2010). ,
115(18), 3671-3677.
[48] Robinson, S. P, Sureda, A, Canals, C, Russell, N, Caballero, D, Bacigalupo, A, et al.
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s
lymphoma: identification of prognostic factors predicting outcome. Haematologica
(2009). , 94, 230-238.
[49] Dodero, A, Crocchiolo, R, Patriarca, F, Miceli, R, Castagna, L, Ciceri, F, et al. Pre‐
transplantation [18 F]Fluorodeoxyglucose Positron Emission Tomography Scan Pre‐
dicts Outcome in Patients With Recurrent Hodgkin Lymphoma or Aggressive Non-
Hodgkin Lymphoma Undergoing Reduced-Intensity Conditioning Followed by
Allogeneic Stem Cell Transplantation. Cancer (2010). , 116, 5001-5011.
Innovations in Stem Cell Transplantation304
Chapter 14
Iron Overload and
Hematopoetic Stem Cell Transplantation
Zeynep Arzu Yegin, Gülsan Türköz Sucak and
Taner Demirer
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53819
1. Introduction
Hematopoietic stem cell transplantation (HSCT) is an established treatment modality with a
curative potential in a variety of hematological disorders. Although remarkable advances in
transplant immunology and supportive care allowed widespread use of HSCT, transplant
related morbidity and mortality remain as a problem [1-7]. Early complications including si‐
nusoidal obstruction syndrome (SOS), hemorrhagic cystitis, engraftment syndrome, idio‐
pathic pneumonia syndrome (IPS), infections and graft versus host disease (GVHD) are the
major causes of morbidity and non relapse mortality (NRM). High doses of radiotherapy
and chemotherapy of the conditioning regimen have adverse effects on all organs and tis‐
sues of the recipient, which also triggers several early and late effects of variable intensity [1,
3, 5-8]. Iron overload (IO) is a relatively common condition in patients with hematological
malignacies and HSCT recipients. Free iron which accompanies IO might contribute to the
already existing prooxidant state in HSCT recipients by inducing the formation of reactive
oxygen species (ROS). Tissue peroxidation and organ damage, as a consequence, contribute
to the development of some early transplant complications [2, 4, 5, 9]. Increasing number of
transplants performed each year and improved transplant techniques result in a rise in the
number of long term survivors. The primary goal of HSCT is to cure the primary disease.
However long term transplant related morbidity might be very challenging and might sig‐
nificantly impair the quality of life. Late effects might be the consequence of the direct toxici‐
ty of chemoradiotherapy and/or the immunologic complications mainly consisting of
GVHD. Besides the secondary late effects including osteoporosis and dental caries, very late
effects, namely cardiovascular toxicity considered as tertiary late effect may also occur.
Among this wide spectrum of complications, IO has a substantial role as a contributor to liv‐
© 2013 Yegin et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
lapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant (2009). ,
15, 109-117.
[43] Peggs, K. S, Hunter, A, Chopra, R, Parker, A, Mahendra, P, Milligan, D, et al. Clinical
evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced intensity alloge‐
neic transplantation. Lancet (2005). , 365, 1934-1941.
[44] Alvarez, I, Sureda, A, Caballero, M. D, Urbano-ispizua, A, Ribera, J. M, et al. Non‐
myeloablative stem cell transplantation is an effective therapy for refractory or re‐
lapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol.
Biol Blood Marrow Transplant (2006). , 12, 172-183.
[45] Anderlini, P, Saliba, R, Acholonu, S, Okoroji, G. J, Donato, M, et al. Reduced-intensity
allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease:
low transplant-related mortality and impact of intensity of conditioning regimen.
Bone Marrow Transplant (2005). , 35, 943-951.
[46] Anderlini, P, Saliba, R, Acholonu, S, Giralt, S. A, Andersson, B, et al. Fludarabine-
melphalan as a preparative regimen for reduced-intensity conditioning allogeneic
stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updat‐
ed M.D. Anderson Cancer Center experience. Haematologica (2008). , 93, 257-264.
[47] Sarina, B, Castagna, L, Farina, L, Patriarca, F, Benedetti, F, Carella, A. M, et al. Allo‐
geneic transplantation improves the overall and progression-free survival of Hodg‐
kin lymphoma patients relapsing after autologous transplantation: a retrospective
study based on the time of HLAtyping and donor availability. Blood. (2010). ,
115(18), 3671-3677.
[48] Robinson, S. P, Sureda, A, Canals, C, Russell, N, Caballero, D, Bacigalupo, A, et al.
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s
lymphoma: identification of prognostic factors predicting outcome. Haematologica
(2009). , 94, 230-238.
[49] Dodero, A, Crocchiolo, R, Patriarca, F, Miceli, R, Castagna, L, Ciceri, F, et al. Pre‐
transplantation [18 F]Fluorodeoxyglucose Positron Emission Tomography Scan Pre‐
dicts Outcome in Patients With Recurrent Hodgkin Lymphoma or Aggressive Non-
Hodgkin Lymphoma Undergoing Reduced-Intensity Conditioning Followed by
Allogeneic Stem Cell Transplantation. Cancer (2010). , 116, 5001-5011.
Innovations in Stem Cell Transplantation304
Chapter 14
Iron Overload and
Hematopoetic Stem Cell Transplantation
Zeynep Arzu Yegin, Gülsan Türköz Sucak and
Taner Demirer
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53819
1. Introduction
Hematopoietic stem cell transplantation (HSCT) is an established treatment modality with a
curative potential in a variety of hematological disorders. Although remarkable advances in
transplant immunology and supportive care allowed widespread use of HSCT, transplant
related morbidity and mortality remain as a problem [1-7]. Early complications including si‐
nusoidal obstruction syndrome (SOS), hemorrhagic cystitis, engraftment syndrome, idio‐
pathic pneumonia syndrome (IPS), infections and graft versus host disease (GVHD) are the
major causes of morbidity and non relapse mortality (NRM). High doses of radiotherapy
and chemotherapy of the conditioning regimen have adverse effects on all organs and tis‐
sues of the recipient, which also triggers several early and late effects of variable intensity [1,
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malignacies and HSCT recipients. Free iron which accompanies IO might contribute to the
already existing prooxidant state in HSCT recipients by inducing the formation of reactive
oxygen species (ROS). Tissue peroxidation and organ damage, as a consequence, contribute
to the development of some early transplant complications [2, 4, 5, 9]. Increasing number of
transplants performed each year and improved transplant techniques result in a rise in the
number of long term survivors. The primary goal of HSCT is to cure the primary disease.
However long term transplant related morbidity might be very challenging and might sig‐
nificantly impair the quality of life. Late effects might be the consequence of the direct toxici‐
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er toxicity, infections and SOS and as a predictor of transplant outcome. Hematopoietic SCT
recipients have been demonstrated to have a high degree of liver iron content (LIC) almost
in the range of hereditary hemochromatosis (HH) and IO was shown to cause liver fibrosis,
heart failure, hypogonadism, diabetes and endocrinopathy in HSCT recipients in the long
run [4, 6, 7, 10]. 
Iron is an essential element which plays a key role in several biochemical reactions including
oxygen transport and electron transfer. It mediates the conversion of hydrogen peroxyde
(H2O2) to highly toxic free radicals leading to tissue damage by oxidation of proteins, per‐
oxidation of membrane lipids and modification of nucleic acids [4]. Under normal circum‐
stances, an appreciable concentration of free iron does not exist outside physiological sinks.
Any released ferrous iron (Fe+2) is immediately chelated in cells by compounds such as cit‐
rate or adenosine diphosphate. Thus, labile iron could not participate in the Haber–Weiss
reaction, which catalyses the formation of ROS. Free iron may directly initiate lipid peroxi‐
dation which destroys membrane structure resulting in increased oxidative stress and cellu‐
lar damage. Excess iron accumulation causes chronic free radical induced tissue damage in
multiple organs and leads to progressive organ dysfunction, which results in significant
morbidity and mortality. In this respect, IO should be prevented in order to preclude the ad‐
verse impact of free iron on natural homeostasis [9, 11].
This chapter will focus on iron balance and the course of excess iron in HSCT recipients. The ad‐
verse impact of IO on transplant outcome and the preventive strategies will also be discussed.
2. Body
2.1. Iron homeostasis
Iron is vital for all living organisms and takes part in several metabolic processes, including
DNA synthesis, oxygen and electron transport. Although iron is a critical element in cell
growth and multiplication, it is potentially toxic in excess amounts by generating ROS [5,
11-13]. Reactive oxygen species have a potential to damage DNA and proteins by lipid per‐
oxidation. Labile iron participates in free radical formation via Fenton reaction which was
first recognized in 1894. Namely, trace amounts of iron as Fe+2 could catalyze the oxidation
of tartrate by H2O2. Consequently, superoxide anion (O2-) or H2O2 is converted to toxic free
radicals such as hydroxyl radical (OH-). This process is mediated by the Fenton reaction cat‐
alyzed by iron, where O2- reduces ferric iron (Fe+3) to produce oxygen and Fe+2. This reduced
iron becomes reoxidized by H2O2 to produce OH- [5, 11].
Figure 1. a. Fenton reaction; b. Iron catalyzed Haber–Weiss reaction or the superoxide driven Fenton reaction [5].
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There are no physiological mechanisms in humans to excrete excess iron and iron homeosta‐
sis is primarily regulated at the level of absorbtion [4, 9, 11, 14-16]. The majority of iron ab‐
sorbtion occurs via enterocytes in the proximal small intestine. The conversion of dietary
inorganic non–heme iron to Fe+2 is facilitated by the brush border ferri reductases. Iron is
transported across the cellular membrane by the divalent metal transporter 1 (DMT1) which
transfers Fe+2 across the apical membrane and into the cell through a proton coupled process
[9, 15, 16]. Ferroportin is an iron efflux pump that mediates the export of Fe+3 from the enter‐
ocyte. Prior to transport, Fe+2 is converted to Fe+3 by either hephaestin or ceruloplasmin both
of which have ferroxidase activity. Subsequently, iron is uploaded to transferrin which is the
primary iron transporter in the circulation. Ferric iron bound to transferrin is soluble and
non reactive. The majority of iron (60–70%) is incorporated into hemoglobin while the rest is
stored in hepatocytes, myoglobin and reticuloendothelial macrophages [9]. Hepcidin, the
main regulator of iron absorbtion, inhibits intestinal absorbtion and release of storage iron in
iron-overloaded states, whereas its expression is markedly decreased in iron deficiency
states. Hepcidin interacts directly with ferroportin, causing its internalization, degradation
and blocking iron release from cells to plasma. Hepcidin acts as an acute phase reactant
which is responsible for the anemia of inflammation. Its production is upregulated by body
iron excess and inflammation whereas downregulated by anemia and hypoxia [9, 14, 16].
Cell survival depends on the balance between the destructive and beneficial effects of iron
[9, 12]. Natural iron homeostasis comprises regulation mechanisms to control iron excess.
The primary protective pathway is the sequestration of iron in ferritin or transferrin. Ferritin
is the chief storage molecule while transferrin is functionary for the transport of iron. Ferri‐
tin captures and buffers the intracellular iron pool, thus it makes iron available for critical
cellular processes while protecting lipids, DNA and proteins from potentially toxic effects of
iron. Iron stored in ferritin is not capable of catalyzing radical reactions and is considered as
safe. It is well known that serum ferritin concentration closely parallels body iron reserves.
However, as free iron is the main form of iron which can precipitate in oxidative stress, any
measure of unbound iron will result in deleterious effects. The balance of free iron to bound
iron changes and free iron becomes available to catalyze free radical reactions in iron over‐
loaded states [5, 9]. Large amounts of excess iron in the circulation are likely to exceed the
serum iron binding capacity (SIBC) and non transferrin bound iron (NTBI) will emerge
eventually. Non transferrin bound iron bypasses the normal regulatory mechanism of recep‐
tor mediated iron uptake and is able to stimulate the peroxidation of membrane lipids and
the formation of ROS. The intracellular counterpart of NTBI is considered as labile iron pool
(LIP) which is bound mainly to low molecular weight compounds. Labile iron pool is cata‐
lytically active and capable of initiating free radical reactions. The expansion of the LIP and
simultaneously increased NTBI may trigger cell toxicity. Generation of LIP leads to unregu‐
lated iron uptake and subsequent intracellular storage either within ferritin molecules or as
hemosiderin. The adverse effects of IO can arise from the elevation of NTBI and LIP in plas‐
ma and might as well cause organ damage mediated by the accumulation of tissue iron in
target organs. The equilibrium between the LIP and iron locked in the ferritin shell is critical
to maintain the normal function of cellular iron enzymes. Imbalance in this equilibrium re‐
sults in the uncontrolled loading of organs, such as the liver, heart and endocrine glands,
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recipients have been demonstrated to have a high degree of liver iron content (LIC) almost
in the range of hereditary hemochromatosis (HH) and IO was shown to cause liver fibrosis,
heart failure, hypogonadism, diabetes and endocrinopathy in HSCT recipients in the long
run [4, 6, 7, 10]. 
Iron is an essential element which plays a key role in several biochemical reactions including
oxygen transport and electron transfer. It mediates the conversion of hydrogen peroxyde
(H2O2) to highly toxic free radicals leading to tissue damage by oxidation of proteins, per‐
oxidation of membrane lipids and modification of nucleic acids [4]. Under normal circum‐
stances, an appreciable concentration of free iron does not exist outside physiological sinks.
Any released ferrous iron (Fe+2) is immediately chelated in cells by compounds such as cit‐
rate or adenosine diphosphate. Thus, labile iron could not participate in the Haber–Weiss
reaction, which catalyses the formation of ROS. Free iron may directly initiate lipid peroxi‐
dation which destroys membrane structure resulting in increased oxidative stress and cellu‐
lar damage. Excess iron accumulation causes chronic free radical induced tissue damage in
multiple organs and leads to progressive organ dysfunction, which results in significant
morbidity and mortality. In this respect, IO should be prevented in order to preclude the ad‐
verse impact of free iron on natural homeostasis [9, 11].
This chapter will focus on iron balance and the course of excess iron in HSCT recipients. The ad‐
verse impact of IO on transplant outcome and the preventive strategies will also be discussed.
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DNA synthesis, oxygen and electron transport. Although iron is a critical element in cell
growth and multiplication, it is potentially toxic in excess amounts by generating ROS [5,
11-13]. Reactive oxygen species have a potential to damage DNA and proteins by lipid per‐
oxidation. Labile iron participates in free radical formation via Fenton reaction which was
first recognized in 1894. Namely, trace amounts of iron as Fe+2 could catalyze the oxidation
of tartrate by H2O2. Consequently, superoxide anion (O2-) or H2O2 is converted to toxic free
radicals such as hydroxyl radical (OH-). This process is mediated by the Fenton reaction cat‐
alyzed by iron, where O2- reduces ferric iron (Fe+3) to produce oxygen and Fe+2. This reduced
iron becomes reoxidized by H2O2 to produce OH- [5, 11].
Figure 1. a. Fenton reaction; b. Iron catalyzed Haber–Weiss reaction or the superoxide driven Fenton reaction [5].
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There are no physiological mechanisms in humans to excrete excess iron and iron homeosta‐
sis is primarily regulated at the level of absorbtion [4, 9, 11, 14-16]. The majority of iron ab‐
sorbtion occurs via enterocytes in the proximal small intestine. The conversion of dietary
inorganic non–heme iron to Fe+2 is facilitated by the brush border ferri reductases. Iron is
transported across the cellular membrane by the divalent metal transporter 1 (DMT1) which
transfers Fe+2 across the apical membrane and into the cell through a proton coupled process
[9, 15, 16]. Ferroportin is an iron efflux pump that mediates the export of Fe+3 from the enter‐
ocyte. Prior to transport, Fe+2 is converted to Fe+3 by either hephaestin or ceruloplasmin both
of which have ferroxidase activity. Subsequently, iron is uploaded to transferrin which is the
primary iron transporter in the circulation. Ferric iron bound to transferrin is soluble and
non reactive. The majority of iron (60–70%) is incorporated into hemoglobin while the rest is
stored in hepatocytes, myoglobin and reticuloendothelial macrophages [9]. Hepcidin, the
main regulator of iron absorbtion, inhibits intestinal absorbtion and release of storage iron in
iron-overloaded states, whereas its expression is markedly decreased in iron deficiency
states. Hepcidin interacts directly with ferroportin, causing its internalization, degradation
and blocking iron release from cells to plasma. Hepcidin acts as an acute phase reactant
which is responsible for the anemia of inflammation. Its production is upregulated by body
iron excess and inflammation whereas downregulated by anemia and hypoxia [9, 14, 16].
Cell survival depends on the balance between the destructive and beneficial effects of iron
[9, 12]. Natural iron homeostasis comprises regulation mechanisms to control iron excess.
The primary protective pathway is the sequestration of iron in ferritin or transferrin. Ferritin
is the chief storage molecule while transferrin is functionary for the transport of iron. Ferri‐
tin captures and buffers the intracellular iron pool, thus it makes iron available for critical
cellular processes while protecting lipids, DNA and proteins from potentially toxic effects of
iron. Iron stored in ferritin is not capable of catalyzing radical reactions and is considered as
safe. It is well known that serum ferritin concentration closely parallels body iron reserves.
However, as free iron is the main form of iron which can precipitate in oxidative stress, any
measure of unbound iron will result in deleterious effects. The balance of free iron to bound
iron changes and free iron becomes available to catalyze free radical reactions in iron over‐
loaded states [5, 9]. Large amounts of excess iron in the circulation are likely to exceed the
serum iron binding capacity (SIBC) and non transferrin bound iron (NTBI) will emerge
eventually. Non transferrin bound iron bypasses the normal regulatory mechanism of recep‐
tor mediated iron uptake and is able to stimulate the peroxidation of membrane lipids and
the formation of ROS. The intracellular counterpart of NTBI is considered as labile iron pool
(LIP) which is bound mainly to low molecular weight compounds. Labile iron pool is cata‐
lytically active and capable of initiating free radical reactions. The expansion of the LIP and
simultaneously increased NTBI may trigger cell toxicity. Generation of LIP leads to unregu‐
lated iron uptake and subsequent intracellular storage either within ferritin molecules or as
hemosiderin. The adverse effects of IO can arise from the elevation of NTBI and LIP in plas‐
ma and might as well cause organ damage mediated by the accumulation of tissue iron in
target organs. The equilibrium between the LIP and iron locked in the ferritin shell is critical
to maintain the normal function of cellular iron enzymes. Imbalance in this equilibrium re‐
sults in the uncontrolled loading of organs, such as the liver, heart and endocrine glands,
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with free iron which generates free radicals and causes cell damage [12, 17]. Eventually,
NTBI and LIP may be more relevant iron markers than serum ferritin and transferrin as a
predictor of IO induced tissue damage. Alterations in ferritin levels are seen commonly in
clinical practice often reflecting perturbations in iron homeostasis or metabolism. Serum fer‐
ritin differs markedly from tissue ferritin in molecular weight, iron and carbonhydrate con‐
tent, subunit size and amino acid sequence. The extracellular form of ferritin, termed as
serum ferritin, is used as a clinical marker of iron status. Tissue ferritin is the more efficient
storage form of iron than is serum ferritin and the function of serum ferritin has to be clari‐
fied in these circumstances [9, 12]. Serum ferritin is usually correlated with NTBI, whereas
inflammation, acute and chronic liver diseases and malignancies may also cause elevated se‐
rum ferritin levels regardless of the iron stores [12].
2.2. Iron overload and stem cell transplantation
Iron overload is a significant problem in autologous (auto) and allogeneic (allo) HSCT recip‐
ients and may adversely affect transplant outcome [4, 18]. The diagnosis of IO has been re‐
ported in up to 88% of long term survivors of HSCT on the basis of serum ferritin levels [19].
Iron overloaded state may last for a long time after transplantation. In a cross sectional
study by Majhail et al, in which LIC on MRI was used for diagnosis, the prevalence of IO
was reported to be 32% in allo-HSCT recipients who had survived 1 year or more following
HSCT [20]. In another study by the same group, serum ferritin levels were found to be
above 1000 ng/ml in 34% of allo-HSCT and 13% of auto-HSCT recipients. Thus, IO may be
less prevalent among recipients of auto-HSCT compared to allo-HSCT as expected [21].
The main causes of IO in HSCT are prolonged dyserythropoiesis, increased intestinal iron
absorbtion due to anemia and chemotherapy associated mucositis which leads to increased
iron absorbtion, transfusion burden and release of iron from injured tissues [8, 22].
Iron overload is particularly common in HSCT recipients with hemoglobinopathies and
hematological malignancies which require frequent transfusions and is associated with inef‐
fective erythropoesis such as acute leukemia and myelodysplastic syndrome (MDS). Trans‐
fusion load is considered to be the principal cause of IO in this group, as each unit of packed
red blood cells (PRBC) contains approximately 200–250 mg iron. Since there is no physiolog‐
ical mechanism for excreting excess iron, iron accumulation is inevitable after 10–20 transfu‐
sions [22-24]. Ineffective erythropoiesis might be a contributing factor leading to excessive
iron absorbtion particularly in MDS and thalassemia which is mediated by erythroid regula‐
tors of iron metabolism which suppress hepcidin and result in increased iron absorbtion.
Elevated growth differentiation factor 15 (GDF–15) levels are considered to be the initiating
event in this context. Ineffective erythropoiesis either as a feature of the underlying disease
or a consequence of intensive treatment leads to inhibition of hepcidin possibly due to over‐
expression of GDF–15 and thus increases iron absorbtion and toxicity. Hematopoietic SCT
recipients are at risk of IO due to prior transfusion load, increased iron absorbtion related to
elevated GDF–15 levels and peri–tansplant transfusions [22, 24, 25].
Bone marrow (BM) and tumor cell destruction which occurs as a consequence of high dose
therapy and release of iron from damaged cells as well as underutilization of iron due to the
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inhibition of erythropoiesis as a result of cytotoxic therapy are important factors in the etiol‐
ogy of IO. Erythropoiesis, which is the main route of iron utilization, is temporarily halted
by the conditioning regimen [8, 22, 23, 26]. Conditioning treatment with chemo/radiothera‐
py during HSCT causes toxicity and immunosuppression leading to organ damage and in‐
fectious complications mainly in the first 3 months of the procedure [27]. Free iron, which
acts as a free radical catalyser, might increase the toxicity of the conditioning regimen dur‐
ing HSCT. Serum iron parameters were demonstrated to be elevated 2–3 days during condi‐
tioning chemotherapy prior to stem cell infusion in a report by Gordon et al [13]. Non
transferrin bound iron appears shortly after conditioning regimen and remains detectable in
most patients throughout the peri–transplant period. Transferrin saturation (TS) increases
during the conditioning regimen, often reaching to levels above 80% with the consequent
emergence of NTBI [28]. The ability of ferritin to sequestrate iron and binding of iron to
transferrin is exhausted in HSCT recipients receiving conditioning regimen, thus leading to
excess NTBI formation. The extent of BM suppression caused by the conditioning regimen is
correlated with the elevation of NTBI [27]. A substantial decrease in plasma anti-oxidant de‐
fense has also been demonstrated in HSCT recipients, and NTBI levels were found to be in‐
versely correlated with plasma antioxidant capacity in a report by Yegin et al [29]. A
derangementof the prooxidative/antioxidative balance was demonstrated as antioxidants
only partially recover to baseline values until day 14 after HSCT [30, 31].
Hepatic toxicity due to chemotherapy and radiation might lead to hepatocellular damage
with subsequent further release of hepatic iron stores. Liver damage may also disturb trans‐
ferrin synthesis [28, 30]. A decrease in transferrin due to hepatic toxicity, stored iron leaking
from injured liver to blood and a suppression of erythropoietic activity during treatment
may causes elevated TS levels. Thus, increasing TS succeeds and contributes to the appear‐
ance of potentially toxic NTBI in the circulation. Iron in its NTBI form is a potent catalyst in
Fenton’s reaction which produces ROS capable of causing cellular damage through various
mechanisms. Tissue damage such as mucositis and liver injury is common after HSCT and
may be partly mediated by NTBI during cytotoxic chemoradiotherapy [28, 29, 32]. It is indi‐
cated that increased NTBI levels may contribute to organ toxicity and infectious complica‐
tions in the early post–transplant period [29].
Complication Incidence Mechanism of Injury
Infection Variable Immune dysregulation, mediated in part by IO, iron-rich
microbial environment
Chronic liver disease Common Multifactorial, including IO
SOS Common (up to 54%) Conditioning regimen, prior irradiation, possibly IO
IPS Uncommon (2-8%) Pro-inflammatory events and increased ROS (mediated by
IO)
Table 1. Complications of IO in patients undergoing HSCT [24]
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with free iron which generates free radicals and causes cell damage [12, 17]. Eventually,
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inhibition of erythropoiesis as a result of cytotoxic therapy are important factors in the etiol‐
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cated that increased NTBI levels may contribute to organ toxicity and infectious complica‐
tions in the early post–transplant period [29].
Complication Incidence Mechanism of Injury
Infection Variable Immune dysregulation, mediated in part by IO, iron-rich
microbial environment
Chronic liver disease Common Multifactorial, including IO
SOS Common (up to 54%) Conditioning regimen, prior irradiation, possibly IO
IPS Uncommon (2-8%) Pro-inflammatory events and increased ROS (mediated by
IO)
Table 1. Complications of IO in patients undergoing HSCT [24]





Infections Mucormycosis, invasive aspergillosis, listeria monocytogenes and other
infections
Acute GVHD No clear evidence available, elevated ferritin might increase risk
SOS Iron overload might increase risk
NRM Elevated ferritin associated with increased risk in allo and auto-HSCT recipients
Late ("/>1 year)
Infections Mucormycosis, invasive aspergillosis and other infections
Chronic GVHD No clear evidence available, decreased risk reported with elevated ferritin
Liver Function Abnormalities Iron overload increases risk
Cardiac Late Effects Iron overload might increase risk
NRM No clear evidence available
Table 2. The Role of IO in Early and Late Complications of HSCT [4]
Iron toxicity may play an important role in the pathogenesis of transplant related complica‐
tions [Table 1, 2]. In a series of 25 patients who underwent HSCT, very high levels of ferritin
(>3000 ng/ml) and TS (>100%) dramatically increased transplant related mortality (TRM)
and decreased overall survival (OS) which was particularly attributed to infections [32]. As
iron is an essential element for all pathological microorganisms, excess amounts of free iron
might increase microbial growth and the probability of severe infections [33]. The coexis‐
tence of excess plasma iron with the damage to the mucosal barrier may also predispose to
infectious events with bacterial translocation. Hypoferraemia is a normal response to infec‐
tion and appears to be a part of a natural resistance mechanism whereas hyperferremia can
predispose to bacterial and fungal infections. In this context, elevated TS and ferritin levels
are proven risk factors for the development of systemic fungal infections in patients with
hematological malignancies [1, 33, 34]. Furthermore, an increase in late fungal infections, es‐
pecially mucormycosis, has been reported in iron loaded patients after HSCT [35]. Elevated
pre–transplant ferritin levels seem to effect prognosis adversely in myeloablative HSCT pri‐
marily due to increased NRM. On the other hand, elevated iron stores apart from providing
a milieu for infection and organ toxicity, may also be in relevance to tumor growth. Thus
elevated ferritin levels might be in association with relapse and relapse mortality [36]. Ma‐
hindra et al reported that elevated pre–transplant serum ferritin level was an independent
adverse risk factor for OS in patients undergoing non myeloablative HSCT. Inferior survival
in patients with elevated ferritin was related to both higher rates of treatment related mor‐
tality and relapse mortality [37]. On the other hand it should also be noted that ferritin is an
acute phase reactant and a marker of inflammation besides its role as a surrogate marker of
iron status. Thus, elevated ferritin levels might as well indicate a group of patients with
more agressive primary disease biology and a subgroup of patients who are already more
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likely to experience disease relapse. Thus the association of elevated ferritin levels with re‐
lapse might be unrelated to IO.
The adverse impact of IO on transplant outcome has been demonstrated most convincingly
in patients with thalassemia where class III patients with extensive liver damage had higher
TRM [38]. Besides increased TRM, other complications attributed to IO includes fungal in‐
fections, hepatic dysfunction and hepatic SOS/Veno occlusive disease (VOD) [4, 27, 38, 39].
In fact, thalassemia is a benign disorder and ferritin is directly a marker of excess iron and
elevated levels could not be attributed to the biology of an underlying malignant pathology.
As a result of the above mentioned data, pre–transplant serum ferritin was included in a
prognostic scoring system for acute leukemia and MDS patients undergoing allo–HSCT [40].
The late morbidity of IO is primarily due to the involvement of heart and liver. Although
iron related liver function test (LFT) abnormalities have been reported, there are no studies
that describe the role of IO in late onset cardiomyopathy and hepatic fibrosis/cirrhosis in pa‐
tients transplanted for diseases other than thalassemia. Post–transplant iron depletion thera‐
py has been shown to reverse hepatic fibrosis and cardiomyopathy in children with
thalassemia who have undergone allo–HSCT [4].
2.3. Iron overload and transplant complications
2.3.1. Liver complications
Liver disease is a frequent cause of morbidity and mortality following allo–HSCT and af‐
fects 90% of recipients and up to 5–10% of toxic deaths are liver related. Liver injury in the
early post–transplant period may be secondary to drug toxicity, SOS, acute GVHD, oppor‐
tunistic infections, total parenteral nutrition, tumor invasion and cholestatic disorders [3,
41]. Long term liver disease is also a common complication of HSCT, as 57, 5% of survivors
developed chronic liver disease (CLD) at 2 years after transplantation in a retrospective ser‐
ies of 106 patients reported by Tomas et al. In this retrospective study, the combination of
chronic hepatitis C and IO was presented as the most frequent cause of CLD [41]. On the
other hand, chronic GVHD also contributes to liver toxicity. The timing and pattern of LFT
abnormalities, history of pre or post transplantation hepatitis, presence of GVHD at other
sites and transfusion burden might be helpful in determining the etiology of liver disease.
Accurate diagnosis of the etiology of liver dysfunction is generally problematic even though
the patterns of biochemical, clinical and histological abnormalities can aid diagnosis. Liver
biopsy in patients following HSCT is not without risks, particularly due to thrombocytope‐
nia during the early post–transplant period. The most common indication for liver biopsy is
to assess the possibility of GVHD in allo–HSCT in the late post–transplant period with per‐
sistently abnormal LFTs and no evidence of GVHD on other sites. In this clinical setting, the
sensitivity and specifity of serum ferritin as a marker of IO is not well defined due to its con‐
comittant role as an acute phase reactant [3, 5, 8, 24, 41-43]. Liver biopsy may be performed
when atypical clinical features are present or multiple disease processes are likely to occur
simultaneously or when there is poor response to therapy that has been instituted [44]. The
management of liver dysfunction under these conditions may be complicated as overlap‐
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adverse risk factor for OS in patients undergoing non myeloablative HSCT. Inferior survival
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likely to experience disease relapse. Thus the association of elevated ferritin levels with re‐
lapse might be unrelated to IO.
The adverse impact of IO on transplant outcome has been demonstrated most convincingly
in patients with thalassemia where class III patients with extensive liver damage had higher
TRM [38]. Besides increased TRM, other complications attributed to IO includes fungal in‐
fections, hepatic dysfunction and hepatic SOS/Veno occlusive disease (VOD) [4, 27, 38, 39].
In fact, thalassemia is a benign disorder and ferritin is directly a marker of excess iron and
elevated levels could not be attributed to the biology of an underlying malignant pathology.
As a result of the above mentioned data, pre–transplant serum ferritin was included in a
prognostic scoring system for acute leukemia and MDS patients undergoing allo–HSCT [40].
The late morbidity of IO is primarily due to the involvement of heart and liver. Although
iron related liver function test (LFT) abnormalities have been reported, there are no studies
that describe the role of IO in late onset cardiomyopathy and hepatic fibrosis/cirrhosis in pa‐
tients transplanted for diseases other than thalassemia. Post–transplant iron depletion thera‐
py has been shown to reverse hepatic fibrosis and cardiomyopathy in children with
thalassemia who have undergone allo–HSCT [4].
2.3. Iron overload and transplant complications
2.3.1. Liver complications
Liver disease is a frequent cause of morbidity and mortality following allo–HSCT and af‐
fects 90% of recipients and up to 5–10% of toxic deaths are liver related. Liver injury in the
early post–transplant period may be secondary to drug toxicity, SOS, acute GVHD, oppor‐
tunistic infections, total parenteral nutrition, tumor invasion and cholestatic disorders [3,
41]. Long term liver disease is also a common complication of HSCT, as 57, 5% of survivors
developed chronic liver disease (CLD) at 2 years after transplantation in a retrospective ser‐
ies of 106 patients reported by Tomas et al. In this retrospective study, the combination of
chronic hepatitis C and IO was presented as the most frequent cause of CLD [41]. On the
other hand, chronic GVHD also contributes to liver toxicity. The timing and pattern of LFT
abnormalities, history of pre or post transplantation hepatitis, presence of GVHD at other
sites and transfusion burden might be helpful in determining the etiology of liver disease.
Accurate diagnosis of the etiology of liver dysfunction is generally problematic even though
the patterns of biochemical, clinical and histological abnormalities can aid diagnosis. Liver
biopsy in patients following HSCT is not without risks, particularly due to thrombocytope‐
nia during the early post–transplant period. The most common indication for liver biopsy is
to assess the possibility of GVHD in allo–HSCT in the late post–transplant period with per‐
sistently abnormal LFTs and no evidence of GVHD on other sites. In this clinical setting, the
sensitivity and specifity of serum ferritin as a marker of IO is not well defined due to its con‐
comittant role as an acute phase reactant [3, 5, 8, 24, 41-43]. Liver biopsy may be performed
when atypical clinical features are present or multiple disease processes are likely to occur
simultaneously or when there is poor response to therapy that has been instituted [44]. The
management of liver dysfunction under these conditions may be complicated as overlap‐
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ping features often complicate the diagnosis and establishing the correct diagnosis is crucial
to institute disease specific therapy. Autopsies performed in 10 patients who died early after
HSCT showed iron accumulation in a range equivalent to that of patients suffering from HH
[26]. A cumulative cirrhosis incidence of 3, 8% by 20 years after HSCT has been reported
previously [8]. This rate seems to be an underestimation as the majority of long term survi‐
vors have not been subjected to liver biopsy. In a retrospective study by Sucak et al, severe
IO was demonstrated in 75% of 24 liver biopsies which were performed with the presump‐
tive diagnosis of hepatic GVHD in 20 patients with persistent elevation of liver enzymes in
the post–transplant setting. The initial clinical diagnosis of GVHD was refuted in 43, 5% of
the patients. Median number of post–transplant transfusions, TS and ferritin levels were
found to be significantly higher in patients who had histologically proven hepatic IO. A sig‐
nificant correlation between serum ferritin levels and histological grade of iron in the hepa‐
tocytes was also demonstrated [10]. In another study by Iqbal et al, the diagnosis obtained at
laparoscopic liver biopsies altered targeted therapy in 31% of patients. Iron overload was
found in 81, 25% of a total of 32 biopsies [45]. A diagnosis of IO after HSCT was demonstrat‐
ed based on histological evidence of siderosis found in 52, 4% of liver biopsies performed at
15–110 days post-transplant in another study. Liver biopsies were performed for diagnostic
purposes in patients with chronic liver dysfunction. An improvement in LFT was observed
in 21 of the 23 patients (91%) with IO who underwent phlebotomy [41]. Namely, IO seems to
be underestimated as a cause of liver dysfunction in HSCT setting and liver biopsy which
allows disease specific therapy could be life saving.
Hepatic IO may also worsen the natural course of chronic viral hepatitis and the response to
antiviral therapy. Fujita et al demonstrated that liver iron deposition was more common in
chronic hepatitis C compared to hepatitis B and was associated with liver disease progres‐
sion. Increased hepatic iron stores in chronic hepatitis C were related to resistance to Inter‐
feron/Ribavirin treatment [46]. Thalassemic patients with liver fibrosis and hepatomegaly
who undergo HSCT, have a markedly reduced OS and event free survival compared to pa‐
tients without evidence of liver disease. The liver disease in these patients is due to a combi‐
nation of severe IO and chronic viral hepatitis both of which improve with effective iron
chelation therapy [19, 26, 47]. Iron is also deposited in other tissues such as myocardium or
BM. Slow and spontaneous decrease in iron stores has been reported in thalassemic children
in the years following HSCT. This natural iron depletion could normalize iron stores in indi‐
viduals with mild siderosis. However, in patients with moderate to severe IO this slow de‐
pletion could not prevent the development of liver dysfunction. For this reason, iron
depletion protocols have been developed for patients with severe IO [19, 23, 26, 47].
2.3.2. Sinusoidal obstruction syndrome (veno occlusive disease)
Sinosoidal obstruction syndrome is a treatment related toxicity associated with auto and al‐
lo–HSCT which is seen in 6–54 % of the recipients. The severity of SOS ranges from a mild
reversible to a progressive course with a mortality rate close to 100% [5, 24].
The role of pre–transplant hyperferritinemia in the development of SOS was first demon‐
strated  by  Morado  et  al  in  a  cohort  of  180  auto–HSCT  recipients.  In  this  prospective
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study, SOS was defined in 12, 2% of patients based on McDonald criteria.  Patients with
pre–transplant ferritin levels above 300 mg/dl were shown to have a higher risk of devel‐
oping SOS [48]. In a recent report by Maradei et al, a pre–transplant serum ferritin level
above  1000  ng/dl  was  identified  as  an  independent  risk  factor  for  the  development  of
SOS [39]. A retrospective study of 250 HSCT recipients by Sucak et al, in which SOS in‐
cidence was reported to be 29,  7%,  demonstrated significantly higher  pre–transplant  se‐
rum ferritin  levels  in  patients  with SOS [49].  In  another  study reported by Sucak et  al,
pre–transplant ferritin levels were found to be higher in HSCT recipients who developed
SOS  in  the  post–transplant  setting  [50].  Serum  ferritin  may  be  increased  in  conditions
other than IO in this particular group of patients, including chronic inflammation and in‐
fection.  Nevertheless,  values  higher  than  1000  ng/ml  were  rarely  reported  in  these  in‐
flammatory conditions [1, 25, 29, 39, 48-51].
Iron induced hepatotoxicity is multifactorial which involves oxidative stress and modula‐
tion of gene expression of Kuppfer cells. Cellular injury is induced by iron generated ROS
and peroxidation of lipid membranes [39]. Risk factors associated with the development of
SOS are defined as preexisting liver dysfunction, previous abdominal irradiation, high dose
total body irradiation, high dose preperative regimens, advanced disease and HLA mis‐
match or unrelated HSCT. The typical hepatocellular lesion of SOS mainly occurs in zone 3
of hepatic acines including a characteristic endothelial lesion which is shown to be associat‐
ed with hypercoagulability. The oxidant effect of iron on endothelial and and hepatocyte
membranes mediated by ROS contributes to the development of these typical lesions of SOS
[48, 50]. The risk of SOS is higher in carriers of at least one allele of the hemochromatosis
gene, HFE, which predisposes to iron deposition in the liver [24].
2.3.3. Infections
Patients with HH and other diseases with IO are considered to be more susceptible to infec‐
tions, as iron adversely affects the phagocytic, chemotactic and bactericidal capacity of gran‐
ulocytes and monocytes and inhibits the activity of natural killer cells and macrophages [35,
52]. A number of studies have demonstrated the adverse impact of IO on the development
infections in HSCT recipients. Tachibana et al observed an association between IO and blood
stream infections (BSI) in 114 patients who underwent allo–HSCT. They found that pre–
transplant serum ferritin levels significantly predicted BSI within the 100–day period after
allo–HSCT [1]. A direct correlation between hepatic IO and BSI was demonstrated in a retro‐
spective cohort of 154 allo – HSCT recipients, as patients with hepatic IO tended to experi‐
ence more frequent and prolonged episodes of lethal BSI [53]. Altes et al reported a ferritin
level above 1500 µg/l was associated with the occurence of bacteremia and febrile days in
first 3 months after auto–HSCT [27]. A prospective study investigated the risk factors for 140
early infection episodes which occured in 367 multiple myeloma (MM) patients undergoing
auto–HSCT. Bone marrow iron stores were identified as significant risk factors for early se‐
vere infections [54]. Pre–transplant serum ferritin levels were demonstrated to be associated
with fungal infections after allo–HSCT in several studies [33-35, 49, 55, 56]. Tunçcan et al
identified the predictive role of pre–transplant serum ferritin level in the development of
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tions, as iron adversely affects the phagocytic, chemotactic and bactericidal capacity of gran‐
ulocytes and monocytes and inhibits the activity of natural killer cells and macrophages [35,
52]. A number of studies have demonstrated the adverse impact of IO on the development
infections in HSCT recipients. Tachibana et al observed an association between IO and blood
stream infections (BSI) in 114 patients who underwent allo–HSCT. They found that pre–
transplant serum ferritin levels significantly predicted BSI within the 100–day period after
allo–HSCT [1]. A direct correlation between hepatic IO and BSI was demonstrated in a retro‐
spective cohort of 154 allo – HSCT recipients, as patients with hepatic IO tended to experi‐
ence more frequent and prolonged episodes of lethal BSI [53]. Altes et al reported a ferritin
level above 1500 µg/l was associated with the occurence of bacteremia and febrile days in
first 3 months after auto–HSCT [27]. A prospective study investigated the risk factors for 140
early infection episodes which occured in 367 multiple myeloma (MM) patients undergoing
auto–HSCT. Bone marrow iron stores were identified as significant risk factors for early se‐
vere infections [54]. Pre–transplant serum ferritin levels were demonstrated to be associated
with fungal infections after allo–HSCT in several studies [33-35, 49, 55, 56]. Tunçcan et al
identified the predictive role of pre–transplant serum ferritin level in the development of
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hepatosplenic candidiasis among 255 HSCT recipients. Hepatosplenic candidiasis was diag‐
nosed in 6 (2, 3%) patients. Pre–transplant serum ferritin levels were significantly higher in
patients with hepatosplenic candidiasis [55]. Özyilmaz et al studied the relationship be‐
tween serum ferritin level and pulmonary fungal infections in 148 allo – HSCT recipients. In
this study, the sensitivity and specifity of ferritin > 1000 ng/ml for the prediction of fungal
pulmonary infections were found to be 67% and 70%, respectively [56].
2.3.4. Idiopathic Pneumonia Syndrome (IPS)
Idiopathic pneumonia syndrome comprises a group of disorders that result in interstitial
pneumonitis and/or widespread alveolar injury with an incidence of 2–8 % and a mortality
of up to 70% in the HSCT setting. There is increasing evidence implicating ROS and pro–
inflammatory events as major contributing factors to IPS [5, 24]. The mechanism of iron in‐
duced IPS probably involves endothelial injury by catalytically active iron released from
heme groups, which can trigger a cascade of events leading to acute lung injury and pulmo‐
nary fibrosis [24]. Currently, there are no studies regarding the direct association of IO and
IPS, except the oxidative milieu, which is partly a consequence of IO.
2.3.5. Graft-versus-host disease (GVHD)
The role of IO in the pathogenesis of GVHD has been evaluated in a number of studies.
There are conflicting results regarding the relationship between IO and GVHD in HSCT
recipients. In a prospective cohort of 190 allo – HSCT recipients reported by Pullarkat et
al, the effect of elevated pre–transplant ferritin on acute GVHD was assessed. Grade 2 or
above acute GVHD was diagnosed in 48% of patients.  Acute GVHD was more frequent
in  patients  with  high  ferritin  levels  (≥1000  ng/ml).  This  was  attributed  to  the  increased
ROS  mediated  injury  on  exposure  to  the  conditioning  regimen  in  iron  overloaded  pa‐
tients,  as  antigen  exposition  following  tissue  injury  was  indicated  to  be  the  initiating
event in the pathogenesis of GVHD [38]. Similarly in a report by Platzbecker et al, which
was performed in 172 patients with MDS, transfusion burden reflected by ferritin levels,
was found to be correlated with a higher probability of acute GVHD [57].  On the other
hand, Mahindra et al investigated 222 patients who underwent myeloablative allo–HSCT
and  demonstrated  that  pre–transplant  ferritin  level  >1910  µg/l  was  associated  with  de‐
creased  incidence  of  chronic  GVHD  [58].  Furthermore,  in  a  study  of  264  patients  who
underwent  allo–HSCT  for  various  hematological  malignancies,  no  significant  difference
in the cumulative incidence of acute and chronic GVHD was demonstrated in high (≥599
ng/ml) and low (<599 ng/ml) ferritin groups [59].  Alessandrino et al reported that trans‐
fusion dependency was an independent risk factor for the development of acute GVHD,
but not  for chronic GVHD [60].  On the other hand, IO might as well  mimic GVHD re‐
sulting in unnecessary continuation or intensification of  immunosuppressive therapy for
GVHD  [18].  Apart  from  hepatocellular,  cardiac  and  other  organ  dysfunction,  IO  may
worsen the natural course of liver GVHD, similar to the status with chronic hepatitis and
its response to therapy [3, 18, 23, 51, 57]. It is speculated that intestinal iron absorbtion is
increased as  a  result  of  epithelial  injury related to  chemotherapy or  GVHD. Suggesting
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that  IO might  be the consequence rather  than being the cause of  intestinal  GVHD [23].
The liver and the intestinal mucosa, which express essential iron regulatory genes includ‐
ing hepatic antimicrobial protein (HAMP), the gene that encodes hepcidin and ferropor‐
tin  1,  are  targets  of  conditioning  related  toxicity  as  well  as  GVHD,  initiated  by  donor
derived T  lymphocytes.  The  ensuing  release  of  cytokines  including  IL-6,  might  directly
affect the expression of hepcidin as IL-6 is a potent inducer of hepcidin via STAT3 [61].
Graft versus host disease also involves the interaction of Fas ligand expressed on activat‐
ed donor T lymphocytes with host tissue including enterocytes and hepatocytes.  T lym‐
phocyte  induced  tissue  damage  disrupts  iron  homeostasis  leading  to  uncontrolled  iron
accumulation which may aggravate tissue damage related to the development of GVHD
and infections [15]. The pattern of the relationship between IO and GVHD remains to be
confirmed in future studies.
2.4. Prognostic role of iron overload in stem cell transplantation
Several recent reports demonstrated that IO is an adverse prognostic factor for patients un‐
dergoing allo–HSCT [1, 17, 22, 36, 59, 62-66]. In a retrospective cohort of 114 AML and MDS
patients, the OS rate at 5 years was found to be significantly better in patients with ferritin
levels < 1000 ng/ml [1]. Tanaka et al evaluated the outcome of 47 patients with acute leuke‐
mia or MDS who underwent reduced intensity HSCT. High ferritin level which was defined
as >1000 ng/ml was associated with worse 2 year OS on multivariate analysis [62]. Another
study by the same group demonstrated the adverse impact of elevated ferritin levels on 5
year OS in a cohort of 143 patients with acute lymphoblastic leukemia (ALL) and acute mye‐
loblastic leukemia (AML) who received allo–HSCT with myeloablative and non myeloabla‐
tive conditioning regimens [63]. Transfusion dependency, predicted by serum ferritin levels,
was found to be independently associated with reduced OS and increased NRM in a retro‐
spective cohort of 357 MDS patients undergoing allo–HSCT [60]. The transplant iron score
which included serum ferritin level above 1000 ng/ml was tested in 78 patients who received
allo or auto–HSCT. The independent impact of IO on transplant survival was indicated with
the most pronounced predictive power of the iron score restricted to allo–HSCT recipients.
A high iron score (≥2) was associated with 50% absolute decrease in OS at 1 year [67]. Lim et
al reported the adverse impact of elevated serum ferritin on OS in 99 MDS patients who un‐
derwent reduced intensity HSCT [64]. Altes et al demonstrated that serum ferritin levels
≥3000 µg/l and TS ≥100% were associated with a decreased OS and increased TRM, which
was attributed to a high infectious mortality [32]. On the other hand Pullarkat et al analyzed
190 patients and demonstrated that elevated pre–transplant ferritin levels were associated
with increased risk of death and day 100 mortality, mainly due to acute GVHD and infec‐
tions [38]. Mahindra et al demonstrated a pre–transplant serum ferritin > 685 ng/ml was as‐
sociated with lower OS and relapse free survival in 315 patients with Hodgkin and non
Hodgkin lymphoma who received auto–HSCT, whereas same ferritin level exhibited a high‐
er incidence of relapse and relapse mortality. They identified the baseline ferritin level was
best correlated with poor survival. They concluded that elevated iron stores may also in‐
crease tumor growth, as tumor cells require more iron for DNA synthesis due to rapid pro‐
liferation [36]. Same group confirmed their results in a study of 222 allo–HSCT recipients
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hepatosplenic candidiasis among 255 HSCT recipients. Hepatosplenic candidiasis was diag‐
nosed in 6 (2, 3%) patients. Pre–transplant serum ferritin levels were significantly higher in
patients with hepatosplenic candidiasis [55]. Özyilmaz et al studied the relationship be‐
tween serum ferritin level and pulmonary fungal infections in 148 allo – HSCT recipients. In
this study, the sensitivity and specifity of ferritin > 1000 ng/ml for the prediction of fungal
pulmonary infections were found to be 67% and 70%, respectively [56].
2.3.4. Idiopathic Pneumonia Syndrome (IPS)
Idiopathic pneumonia syndrome comprises a group of disorders that result in interstitial
pneumonitis and/or widespread alveolar injury with an incidence of 2–8 % and a mortality
of up to 70% in the HSCT setting. There is increasing evidence implicating ROS and pro–
inflammatory events as major contributing factors to IPS [5, 24]. The mechanism of iron in‐
duced IPS probably involves endothelial injury by catalytically active iron released from
heme groups, which can trigger a cascade of events leading to acute lung injury and pulmo‐
nary fibrosis [24]. Currently, there are no studies regarding the direct association of IO and
IPS, except the oxidative milieu, which is partly a consequence of IO.
2.3.5. Graft-versus-host disease (GVHD)
The role of IO in the pathogenesis of GVHD has been evaluated in a number of studies.
There are conflicting results regarding the relationship between IO and GVHD in HSCT
recipients. In a prospective cohort of 190 allo – HSCT recipients reported by Pullarkat et
al, the effect of elevated pre–transplant ferritin on acute GVHD was assessed. Grade 2 or
above acute GVHD was diagnosed in 48% of patients.  Acute GVHD was more frequent
in  patients  with  high  ferritin  levels  (≥1000  ng/ml).  This  was  attributed  to  the  increased
ROS  mediated  injury  on  exposure  to  the  conditioning  regimen  in  iron  overloaded  pa‐
tients,  as  antigen  exposition  following  tissue  injury  was  indicated  to  be  the  initiating
event in the pathogenesis of GVHD [38]. Similarly in a report by Platzbecker et al, which
was performed in 172 patients with MDS, transfusion burden reflected by ferritin levels,
was found to be correlated with a higher probability of acute GVHD [57].  On the other
hand, Mahindra et al investigated 222 patients who underwent myeloablative allo–HSCT
and  demonstrated  that  pre–transplant  ferritin  level  >1910  µg/l  was  associated  with  de‐
creased  incidence  of  chronic  GVHD  [58].  Furthermore,  in  a  study  of  264  patients  who
underwent  allo–HSCT  for  various  hematological  malignancies,  no  significant  difference
in the cumulative incidence of acute and chronic GVHD was demonstrated in high (≥599
ng/ml) and low (<599 ng/ml) ferritin groups [59].  Alessandrino et al reported that trans‐
fusion dependency was an independent risk factor for the development of acute GVHD,
but not  for chronic GVHD [60].  On the other hand, IO might as well  mimic GVHD re‐
sulting in unnecessary continuation or intensification of  immunosuppressive therapy for
GVHD  [18].  Apart  from  hepatocellular,  cardiac  and  other  organ  dysfunction,  IO  may
worsen the natural course of liver GVHD, similar to the status with chronic hepatitis and
its response to therapy [3, 18, 23, 51, 57]. It is speculated that intestinal iron absorbtion is
increased as  a  result  of  epithelial  injury related to  chemotherapy or  GVHD. Suggesting
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that  IO might  be the consequence rather  than being the cause of  intestinal  GVHD [23].
The liver and the intestinal mucosa, which express essential iron regulatory genes includ‐
ing hepatic antimicrobial protein (HAMP), the gene that encodes hepcidin and ferropor‐
tin  1,  are  targets  of  conditioning  related  toxicity  as  well  as  GVHD,  initiated  by  donor
derived T  lymphocytes.  The  ensuing  release  of  cytokines  including  IL-6,  might  directly
affect the expression of hepcidin as IL-6 is a potent inducer of hepcidin via STAT3 [61].
Graft versus host disease also involves the interaction of Fas ligand expressed on activat‐
ed donor T lymphocytes with host tissue including enterocytes and hepatocytes.  T lym‐
phocyte  induced  tissue  damage  disrupts  iron  homeostasis  leading  to  uncontrolled  iron
accumulation which may aggravate tissue damage related to the development of GVHD
and infections [15]. The pattern of the relationship between IO and GVHD remains to be
confirmed in future studies.
2.4. Prognostic role of iron overload in stem cell transplantation
Several recent reports demonstrated that IO is an adverse prognostic factor for patients un‐
dergoing allo–HSCT [1, 17, 22, 36, 59, 62-66]. In a retrospective cohort of 114 AML and MDS
patients, the OS rate at 5 years was found to be significantly better in patients with ferritin
levels < 1000 ng/ml [1]. Tanaka et al evaluated the outcome of 47 patients with acute leuke‐
mia or MDS who underwent reduced intensity HSCT. High ferritin level which was defined
as >1000 ng/ml was associated with worse 2 year OS on multivariate analysis [62]. Another
study by the same group demonstrated the adverse impact of elevated ferritin levels on 5
year OS in a cohort of 143 patients with acute lymphoblastic leukemia (ALL) and acute mye‐
loblastic leukemia (AML) who received allo–HSCT with myeloablative and non myeloabla‐
tive conditioning regimens [63]. Transfusion dependency, predicted by serum ferritin levels,
was found to be independently associated with reduced OS and increased NRM in a retro‐
spective cohort of 357 MDS patients undergoing allo–HSCT [60]. The transplant iron score
which included serum ferritin level above 1000 ng/ml was tested in 78 patients who received
allo or auto–HSCT. The independent impact of IO on transplant survival was indicated with
the most pronounced predictive power of the iron score restricted to allo–HSCT recipients.
A high iron score (≥2) was associated with 50% absolute decrease in OS at 1 year [67]. Lim et
al reported the adverse impact of elevated serum ferritin on OS in 99 MDS patients who un‐
derwent reduced intensity HSCT [64]. Altes et al demonstrated that serum ferritin levels
≥3000 µg/l and TS ≥100% were associated with a decreased OS and increased TRM, which
was attributed to a high infectious mortality [32]. On the other hand Pullarkat et al analyzed
190 patients and demonstrated that elevated pre–transplant ferritin levels were associated
with increased risk of death and day 100 mortality, mainly due to acute GVHD and infec‐
tions [38]. Mahindra et al demonstrated a pre–transplant serum ferritin > 685 ng/ml was as‐
sociated with lower OS and relapse free survival in 315 patients with Hodgkin and non
Hodgkin lymphoma who received auto–HSCT, whereas same ferritin level exhibited a high‐
er incidence of relapse and relapse mortality. They identified the baseline ferritin level was
best correlated with poor survival. They concluded that elevated iron stores may also in‐
crease tumor growth, as tumor cells require more iron for DNA synthesis due to rapid pro‐
liferation [36]. Same group confirmed their results in a study of 222 allo–HSCT recipients
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with a serum ferritin level >1910 µg/l associated with lower OS, lower relapse free survival
and higher NRM rates [58]. Furthermore they demonstrated inferior survival rates related to
higher rates of TRM and relapse mortality in patients with elevated ferritin levels who re‐
ceived non myeloablative conditioning [37]. In a large retrospective study by Armand et al,
an elevated pre–transplant serum ferritin level was significantly associated with lower OS
and disease free survival. This association was particularly restricted to patients with acute
leukemia and MDS which was particularly attributed to transfusion load. They suggested a
possible role of iron chelation therapy in the pre and post – transplant setting, as they
showed an absolute difference of 37% in 5–year OS for patients with MDS between the high‐
est and lowest ferritin quartiles [66]. Sucak et al demonstrated an adverse impact of a pre–
transplant serum ferritin level >500 ng/ml on OS and TRM in 250 patients who received auto
and allo–HSCT, underscoring the prognostic effect of IO in auto transplants [49]. The same
group confirmed their results with a more toxic form of iron, NTBI, in a retrospective cohort
of 149 patients. In concordance with the previous report, a significant impact of NTBI on
day 30 and day 100 survival was shown in auto–transplanted patients for the first time in
iron and transplant connection [29]. Notwithstanding, in a prospective study by Armand et
al, pre–transplant IO predicted by LIC which is considered to be the gold standard indicator
of IO, was not found to be associated with increased mortality, relapse, SOS or GVHD [68].
Therefore, they assumed that the adverse prognostic impact of pre–transplant hyperferriti‐
nemia may be related to factors independent of IO. Taken together, it is speculated that fer‐
ritin may be prognostic not because it reflects iron stores but because it is an acute phase
reactant [68, 69].
2.5. Diagnosis of iron overload
2.5.1. Liver biopsy
Liver remains to be the most accessible parenchymal organ that can be used to estimate tis‐
sue iron load after HSCT. Iron overload is not uncommonly seen in various other primary
liver diseases such as alcoholic liver disease, chronic viral hepatitis, non alcoholic steatohe‐
patitis, liver cirrhosis and HH. Histological evaluation of liver specimens is essential in the
management of these disorders. The reported incidence of significant liver fibrosis in HSCT
recipients varies from 5% to 80% and LIC has been demonstrated to have a particular role in
the progression of fibrosis [26, 41, 70]. Though ferritin continues to be the mainstay for the
initial clinical evaluation of IO, liver biopsy is still the gold standard for quantifying iron.
Measurement of hepatic iron stores provides the most reliable estimate of body iron burden.
Liver iron content exceeding 80 mcmol/g of liver dry weight was found to be consistent with
IO with a hepatic index greater than 1, 9 mmol/kg/year. However, the need for a relatively
large volume of tissue as well as its invasive nature has made this procedure less appealing
to most clinicians and patients [4, 9, 53]. Although liver biopsy is an invasive procedure and
can not be safely administered in patients with very low platelet counts, a liver biopsy can
be advantageous in some HSCT recipients as it can also exclude alternative causes of hepatic
dysfunction, such as infections and GVHD. In high risk patients, liver biopsy using a trans‐
juguler approach may be a feasible alternative to percutaneous biopsy [4, 17].
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2.5.2. Non-invasive procedures
Superconducting quantum interference device (SQUID) assesses total body iron by using bi‐
omagnetic susceptometry. Ferritin and hemosiderin are the only paramagnetic materials in
the human body, thus the magnitude of these parameters is directly related to the amount of
iron in a certain volume of tissue. The device utilizes the magnetic property of iron in ferri‐
tin and hemosiderin to estimate hepatic iron stores. Furthermore, it is considered to be the
non invasive reference standard for estimation of LIC as it has an excellent correlation with
liver biopsy. However, widespread clinical use is limited by its cost, complexity and very
limited availability [4, 9, 17].
Liver iron content measurement has limited predictive value for extrahepatic iron deposi‐
tion. The liver is the dominant iron reservoir for the body, accounting for more than 80% of
the total body iron and has high capacity mechanisms for clearing both transferrin and NTBI
species from the circulation. The heart and endocrine tissues have tightly regulated transfer‐
rin uptake and develop IO only when there is circulating NTBI. High liver iron (15-20 mg/g
dry weight) damages liver parenchyma and increases circulating NTBI levels dramatically.
As no liver iron can be considered safe from a cardiac and endocrinological perspective, ex‐
trahepatic monitoring by magnetic resonance imaging (MRI) is essential [71]. Magnetic reso‐
nance imaging becomes increasingly important in the evaluation of iron status as it is non
invasive, more rapidly and widely available. Designating liver iron by older MRI techniques
and equipment showed variable correlation with the biopsy estimates of LIC. More recent
MRI techniques T2* and R2* MRI are reproducible methods for non invasive estimation of
LIC with reported sensitivity and specifity of 89% and 80%, respectively [4, 17, 72-74]. It has
the additional benefit of identifying relatively early IO within organs prior to the onset of
dysfunction. Magnetic resonance imaging can be used to co-measure iron deposition within
the heart, liver and pituitary gland as it does not appear that a single organ gives the full
picture of total body IO. In fact, patients can accumulate cardiac iron, despite apparently
normal hepatic iron levels and thus be at risk for arrhythmia or congestive heart failure. The
discordance of values in two tissues can be resolved with the use of MRI to detect cardiac
iron. Cardiovascular MRI could potentially be used not only to determine myocardial iron
content but also cardiac function and therefore could be used to investigate the effects of
iron mediated organ damage. Non invasive measurement of LIC has also been achieved us‐
ing an MRI technique based on the proton transverse relaxation rates within the liver. The
technique can be implemented on, most clinical 1, 5–T MRI measurements, making it readily
available to the clinical community. This technique resulted in a high specifity and sensitivi‐
ty over a greater range of LIC than any other MRI–based method of LIC assessment [9].
2.5.3. Ferritin
High prevalence of IO in long term survivors of HSCT emphasizes the need for routine
screening for IO in this population. Ferritin is a cellular iron storage protein that buffers
iron in a  soluble and non toxic  form. Under normal conditions ferritin levels  in the se‐
rum  are  low  but  steadily  increase  in  conditions  of  IO.  Therefore,  assessment  of  serum
ferritin levels serves as a simple and widely used surrogate marker for IO. Serum ferri‐
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with a serum ferritin level >1910 µg/l associated with lower OS, lower relapse free survival
and higher NRM rates [58]. Furthermore they demonstrated inferior survival rates related to
higher rates of TRM and relapse mortality in patients with elevated ferritin levels who re‐
ceived non myeloablative conditioning [37]. In a large retrospective study by Armand et al,
an elevated pre–transplant serum ferritin level was significantly associated with lower OS
and disease free survival. This association was particularly restricted to patients with acute
leukemia and MDS which was particularly attributed to transfusion load. They suggested a
possible role of iron chelation therapy in the pre and post – transplant setting, as they
showed an absolute difference of 37% in 5–year OS for patients with MDS between the high‐
est and lowest ferritin quartiles [66]. Sucak et al demonstrated an adverse impact of a pre–
transplant serum ferritin level >500 ng/ml on OS and TRM in 250 patients who received auto
and allo–HSCT, underscoring the prognostic effect of IO in auto transplants [49]. The same
group confirmed their results with a more toxic form of iron, NTBI, in a retrospective cohort
of 149 patients. In concordance with the previous report, a significant impact of NTBI on
day 30 and day 100 survival was shown in auto–transplanted patients for the first time in
iron and transplant connection [29]. Notwithstanding, in a prospective study by Armand et
al, pre–transplant IO predicted by LIC which is considered to be the gold standard indicator
of IO, was not found to be associated with increased mortality, relapse, SOS or GVHD [68].
Therefore, they assumed that the adverse prognostic impact of pre–transplant hyperferriti‐
nemia may be related to factors independent of IO. Taken together, it is speculated that fer‐
ritin may be prognostic not because it reflects iron stores but because it is an acute phase
reactant [68, 69].
2.5. Diagnosis of iron overload
2.5.1. Liver biopsy
Liver remains to be the most accessible parenchymal organ that can be used to estimate tis‐
sue iron load after HSCT. Iron overload is not uncommonly seen in various other primary
liver diseases such as alcoholic liver disease, chronic viral hepatitis, non alcoholic steatohe‐
patitis, liver cirrhosis and HH. Histological evaluation of liver specimens is essential in the
management of these disorders. The reported incidence of significant liver fibrosis in HSCT
recipients varies from 5% to 80% and LIC has been demonstrated to have a particular role in
the progression of fibrosis [26, 41, 70]. Though ferritin continues to be the mainstay for the
initial clinical evaluation of IO, liver biopsy is still the gold standard for quantifying iron.
Measurement of hepatic iron stores provides the most reliable estimate of body iron burden.
Liver iron content exceeding 80 mcmol/g of liver dry weight was found to be consistent with
IO with a hepatic index greater than 1, 9 mmol/kg/year. However, the need for a relatively
large volume of tissue as well as its invasive nature has made this procedure less appealing
to most clinicians and patients [4, 9, 53]. Although liver biopsy is an invasive procedure and
can not be safely administered in patients with very low platelet counts, a liver biopsy can
be advantageous in some HSCT recipients as it can also exclude alternative causes of hepatic
dysfunction, such as infections and GVHD. In high risk patients, liver biopsy using a trans‐
juguler approach may be a feasible alternative to percutaneous biopsy [4, 17].
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2.5.2. Non-invasive procedures
Superconducting quantum interference device (SQUID) assesses total body iron by using bi‐
omagnetic susceptometry. Ferritin and hemosiderin are the only paramagnetic materials in
the human body, thus the magnitude of these parameters is directly related to the amount of
iron in a certain volume of tissue. The device utilizes the magnetic property of iron in ferri‐
tin and hemosiderin to estimate hepatic iron stores. Furthermore, it is considered to be the
non invasive reference standard for estimation of LIC as it has an excellent correlation with
liver biopsy. However, widespread clinical use is limited by its cost, complexity and very
limited availability [4, 9, 17].
Liver iron content measurement has limited predictive value for extrahepatic iron deposi‐
tion. The liver is the dominant iron reservoir for the body, accounting for more than 80% of
the total body iron and has high capacity mechanisms for clearing both transferrin and NTBI
species from the circulation. The heart and endocrine tissues have tightly regulated transfer‐
rin uptake and develop IO only when there is circulating NTBI. High liver iron (15-20 mg/g
dry weight) damages liver parenchyma and increases circulating NTBI levels dramatically.
As no liver iron can be considered safe from a cardiac and endocrinological perspective, ex‐
trahepatic monitoring by magnetic resonance imaging (MRI) is essential [71]. Magnetic reso‐
nance imaging becomes increasingly important in the evaluation of iron status as it is non
invasive, more rapidly and widely available. Designating liver iron by older MRI techniques
and equipment showed variable correlation with the biopsy estimates of LIC. More recent
MRI techniques T2* and R2* MRI are reproducible methods for non invasive estimation of
LIC with reported sensitivity and specifity of 89% and 80%, respectively [4, 17, 72-74]. It has
the additional benefit of identifying relatively early IO within organs prior to the onset of
dysfunction. Magnetic resonance imaging can be used to co-measure iron deposition within
the heart, liver and pituitary gland as it does not appear that a single organ gives the full
picture of total body IO. In fact, patients can accumulate cardiac iron, despite apparently
normal hepatic iron levels and thus be at risk for arrhythmia or congestive heart failure. The
discordance of values in two tissues can be resolved with the use of MRI to detect cardiac
iron. Cardiovascular MRI could potentially be used not only to determine myocardial iron
content but also cardiac function and therefore could be used to investigate the effects of
iron mediated organ damage. Non invasive measurement of LIC has also been achieved us‐
ing an MRI technique based on the proton transverse relaxation rates within the liver. The
technique can be implemented on, most clinical 1, 5–T MRI measurements, making it readily
available to the clinical community. This technique resulted in a high specifity and sensitivi‐
ty over a greater range of LIC than any other MRI–based method of LIC assessment [9].
2.5.3. Ferritin
High prevalence of IO in long term survivors of HSCT emphasizes the need for routine
screening for IO in this population. Ferritin is a cellular iron storage protein that buffers
iron in a  soluble and non toxic  form. Under normal conditions ferritin levels  in the se‐
rum  are  low  but  steadily  increase  in  conditions  of  IO.  Therefore,  assessment  of  serum
ferritin levels serves as a simple and widely used surrogate marker for IO. Serum ferri‐
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tin levels are however subject to natural fluctuation and can also be greatly affected by a
range  of  inflammatory  conditions  that  are  particularly  relevant  in  HSCT recipients.  Al‐
though being a useful test for initial screening of IO in HSCT recipients, serum ferritin is
not a reliable indicator of total body iron burden particularly in patients who have ongo‐
ing acute infections or inflammatory diseases [2, 4, 17, 20, 22, 23, 38, 75, 76]. Serial serum
ferritin  measurements  can compensate  the  potential  fluctuations  and help to  establish a
general  picture  of  IO  over  time.  Nevertheless,  at  1  year  after–transplantation  when  in‐
flammatory  stress  has  largely  subsided,  most  patients  have  a  serum  ferritin  of  <1000
ng/ml and no clinical evidence of IO; serum ferritin in these patients decline slowly with
time [23].  Unlike tissue ferritin a substantial  proportion of serum ferritin is glycosylated
which  suggests  that  plasma ferritin  is  actively  secreted  from reticuloendothelial  system
or  parencymal  cells.  Serum ferritin  in  contrast  to  tissue  ferritin  was  claimed to  have  a
low  iron  content  even  in  iron  loaded  patients  in  some  earlier  studies.  It  is  therefore
claimed that serum ferritin does not provide a major source of hepatic iron either in nor‐
mal individuals or in patients with IO diseases [4,  20,  22,  23,  75].  On the contrary a di‐
rect correlation between serum ferritin levels and transfusion burden has been observed
with a level of 1000 ng/ml after a median of 21 PRBC transfusions. Thus repeated meas‐
urement of serum ferritin levels seems to be a valid method to monitor secondary IO in
patients  with  transfusion  dependent  anemias  and  MDS  [17].  Majhail  et  al  studied  the
prevalence of IO in 56 allo–HSCT recipients and demonstrated the poor predictive value
of  ferritin  for  estimating  LIC.  The  overall  prevalence  of  IO was  32%.  Clinically  signifi‐
cant  IO  (LIC>7  mg/g)  was  uncommon  in  patients  with  serum  ferritin  levels  less  than
1000 ng/ml. However, the LIC on MRI was moderately correlated with serum ferritin. As
a result, they indicated ferritin to be a good screening test but a poor predictor of tissue
IO and recommended estimation of LIC before initiating chelation therapy. They consid‐
ered that this lack of association between ferritin and LIC might be related to the varia‐
bility  in  ferritin  levels  because  of  ineffective  erythropoiesis  or  underlying  inflammation
or  infection  [20].  Whereas  in  a  study  by  Bazuave  et  al,  serum  ferritin,  transferrin,  TS,
iron, soluble transferrin receptor (sTfR) and C reactive protein levels in 230 HSCT recipi‐
ents were measured.  All  iron parameters were found to be significantly associated with
survival.  A  combination  of  ferritin  and  TS  was  shown  to  have  the  highest  prognostic
power. They concluded that the predictive power of ferritin was derived from its associ‐
ation with IO rather than inflammation. Inferior survival in patients with IO was related
to both TRM and relapse. As sTfR and TS were found to have superior prognostic value
when compared to ferritin, they suggested to combine serum ferritin with TS for predic‐
tion of IO [2].
Recent evidence suggests that the determination of iron status before HSCT has important
prognostic implications. There is a gap between the time that patients are identified for
HSCT and the time that actual transplant takes place. During this period, most patients stay
transfusion dependent. After patients are exposed to conditioning regimen and stem cell in‐
fusion, serum ferritin levels are prone to a false elevation due to its role as an acute phase
reactant. Thus, accurate evaluation and diagnosis of iron toxicity after HSCT remains as a
challenge [53, 67] [Table 3].
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Diagnostic Test Advantages Disadvantages
Liver Biopsy Reference method, can assess degree of
hepatic fibrosis, can evaluate other causes of
hepatic dysfunction (GVHD)
Invasive procedure, not feasible in patients with
thrombocytopenia or coagulopathy
SQUID Good correlation with liver biopsy,
noninvasive
Very limited availability
MRI Good correlation with liver biopsy (T2 or R2
MRI), noninvasive, widely available
Variety of MRI techniqueshave not been validated




Noninvasive, widely available Sensitive but not specific for IO, poor correlation
with liver biopsy
Table 3. Diagnostic Tests for Assessment of Body Iron Stores in HSCT Recipients [4]
2.5.4. Non Transferrin Bound Iron (NTBI)
Non transferrin bound iron is toxic to living systems because it can act as a catalyst in the
formation of ROS which in turn stimulate lipid peroxidation in membranes. In iron-over‐
loaded states when SIBC becomes fully saturated, NTBI complexes appear in the serum. In a
study by Harrison et al, serum ferritin was raised in 21 of 28 patients following treatment for
hematological malignancy, whereas only 16% of them had LFT abnormalities. However,
NTBI was detected in 4 of 6 patients with an unexplained elevated LFTs. Therefore, they
considered that NTBI might be a more specific indicator of IO than the serum ferritin con‐
centrations [77]. Assessment of NTBI is a potentially useful approach that allows the estima‐
tion of toxic iron levels. However, the methods for determining this free fraction of body
iron and its precise prognostic significance require fine tuning [17].
2.6. Treatment of iron overload
The current paradigm of managing post–transplant IO is based on extensive experience in
children with transfusion dependent anemias [4]. Post–transplant iron depletion therapy has
been shown to reverse hepatic fibrosis and cardiomyopathy in patients with thalassemia [4,
78]. However, there is no published data indicating the benefit of iron removal therapy on
long term morbidity and mortality in HSCT recipients, especially for diseases other than
thalassemia [4].
Decisions regarding the management of IO should be individualized and based on a review
of several factors including the need for ongoing PRBC transfusion therapy, time since
transplantation, ability to tolerate iron depleting therapy and urgency to reduce body iron
stores [Table 4]. For instance, coexisting anemia can preclude the use of phlebotomy where‐
as renal impairment might increase the risk of toxicity from iron chelating drugs. Also de‐
pletion of iron stores would be more imperative in patients with IO related liver test
abnormalities or cardiac dysfunction compared to those without end organ toxicites [4].
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abnormalities or cardiac dysfunction compared to those without end organ toxicites [4].




Phlebotomy Extensive experience with proven efficacy,
no significant side effects
Not feasible in patients with anemia or poor venous
access
Deferoxamine Extensive experience with proven efficacy Inconvenient administration route and schedule,
side effects (ototoxicity, growth retardation)
Deferiprone Oral iron chelator Unproven efficacy, side effects (neutropenia,
hepatic fibrosis)
Deferasirox Oral iron chelator, efficacy similar to
deferoxamine
Long term toxicity profile not established, side
effects (nephrotoxicity)
Table 4. Treatment Options for Iron Overload after HSCT [4]
Iron overload may be a cause of persistent hepatic dysfunction after HSCT. Patients with
LIC>15 mg/g dry weight should be treated aggresively with both phlebotomy and chelation;
when LIC is 7–15 mg/g dry weight, phlebotomy is indicated; when LIC is under 7 mg/g dry
weight treatment is indicated only if there is evidence of liver disease. Mobilization of iron
from heavily overloaded patients improves cardiac function, normalizes serum alanine
transaminase levels and results in improved liver histology [24, 79].
In patients with extreme IO, effective pre–transplant chelation therapy is suggested to im‐
prove post–transplant survival, as IO is clearly related to treatment related morbidity and
mortality after HSCT [4, 24, 67, 79]. In the pre–transplant period vigorous iron chelation may
be important but prospective studies are required to prove a survival benefit after HSCT. In
the post–transplant period phlebotomy sometimes combined with erythropoiesis stimulat‐
ing agents (ESA) may be successfully applied in thalassemia. For those patients who can not
be phlebotomized iron chelation can be considered. Prospective studies of the impact of iron
chelation therapy before and after HSCT on post–transplant morbidity and mortality are
mandatory [4, 24].
The American Society for Blood and Marrow Transplantation (ASBMT) 2012 guidelines rec‐
ommend annual serum ferritin measurement in patients who received PRBC transfusions
pre or post–transplantation. Subsequent monitoring with serum ferritin should be consid‐
ered among patients with elevated levels, especially in the presence of abnormal LFTs,
PRBC transfusions or HCV infection. Additional diagnosting testing including liver biopsy,
MRI or SQUID may be indicated if therapy is intended for presumptive IO. Current pre‐
scribing guidelines recommend continuation of iron reduction till ferritin levels are below
500 ng/ml [3, 9, 51, 60, 72].
2.6.1. Phlebotomy
Phlebotomy is a feasible option for the treatment of IO following HSCT. Many studies have
documented its efficacy in early and late post–transplant setting. It has been shown that sub‐
clinical left ventricular diastolic dysfunction and impaired left ventricular contractility in pa‐
tients with thalassemia may be reversed by phlebotomy initiated after HSCT [51]. Iron
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overload should be treated by means of phlebotomy and/or chelation therapy especially
when IO coexists with chronic viral hepatitis. Phlebotomy has the advantage over chelation
of better compliance, fewer side effects and lower costs. The use of ESA may facilitate the
success of this strategy in patients with low hemoglobin levels [4, 19, 22, 26, 70].
After normalization of transaminases and serum ferritin with aggressive phlebotomy, main‐
tenance phlebotomy is required every 3-6 months to prevent iron reaccumulation and keep
serum ferritin in a low normal range. The gradual rise in ferritin after successful iron deple‐
tion suggests that there is a signal for increased iron absorbtion and the signal persists well
beyond the peri–transplant period. It may be that post–transplant immunosuppressants re‐
duce the level of cytokines that normally stimulate hepcidin production and allow increased
absorbtion of dietary iron. In addition hepatic GVHD may result in disordered hepcidin reg‐
ulation, as it likely does in chronic viral hepatitis and might explain increased risk of IO and
the need for maintenance phlebotomy after successful iron depletion [23].
2.6.2. Iron chelation
Treatment with phlebotomy is not possible in patients who are transfusion dependent. Che‐
lation may be preferred for iron depletion [9]. There are limited data on the pharmacological
chelation of iron during the post–transplant period including the safety, optimal dose, time
for initiation of treatment and duration of therapy [51, 80, 81].
Deferoxamine, the first available iron chelator, has a proven efficacy and safety with dec‐
ades  of  experience  and has  also  been  studied in  HSCT recipients.  Recommended treat‐
ment schedule is at least 5 nights per week subcutaneous delivered via a pump for 8-12
hours [4,  9].  It  is effective in lowering serum ferritin levels and LIC and prevents endo‐
crinological  complications.  Long  term  treatment  is  also  associated  with  a  reduction  in
cardiac complications and improved survival. Redness and induration at the infusion site
are the most common side effects. Audiological, ophthalmological, growth and bone tox‐
icities  may  be  minimized  by  avoiding  overchelation.  Deferoxamine  treatment  in  the
HSCT setting is complicated by the short half life and the ability to release iron to bacte‐
ria and fungi. Deferoxamine supports the growth of zygomycetes because it acts as xeno‐
sidephore  delivering  iron  to  iron  uptaking  molecules  of  the  species  [22,  51,  81].  The
greatest challenge with DFO is patient adherence with therapy because the need for pa‐
renteral administration is cumbersome, uncomfortable, inconvenient and time consuming
[51].  Cardiac  morbidity  and  mortality  continue  to  occur  in  patients  treated  with  DFO,
likely related to difficulties with adherence [4, 9, 22, 51, 81].
Deferiprone is an oral iron chelator which was first identified in 1980s and subsequently ap‐
proved for clinical use in Canada and Europe especially when DFO is contraindicated. Deferi‐
prone is not commercially available in all countries and has not been investigated in HSCT
recipients. It has a short half life of only 1, 5 hours and thus requires 3 times daily dosing. Un‐
fortunately, it does not control liver iron as effective as DFO even after years of continued treat‐
ment.  In contrast,  a recent study in patients with thalassemia showed better myocardial
function in those receiving Deferiprone. Retrospective studies have also demonstrated re‐
duced cardiac morbidity and mortality and lower myocardial iron deposition among patients
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overload should be treated by means of phlebotomy and/or chelation therapy especially
when IO coexists with chronic viral hepatitis. Phlebotomy has the advantage over chelation
of better compliance, fewer side effects and lower costs. The use of ESA may facilitate the
success of this strategy in patients with low hemoglobin levels [4, 19, 22, 26, 70].
After normalization of transaminases and serum ferritin with aggressive phlebotomy, main‐
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serum ferritin in a low normal range. The gradual rise in ferritin after successful iron deple‐
tion suggests that there is a signal for increased iron absorbtion and the signal persists well
beyond the peri–transplant period. It may be that post–transplant immunosuppressants re‐
duce the level of cytokines that normally stimulate hepcidin production and allow increased
absorbtion of dietary iron. In addition hepatic GVHD may result in disordered hepcidin reg‐
ulation, as it likely does in chronic viral hepatitis and might explain increased risk of IO and
the need for maintenance phlebotomy after successful iron depletion [23].
2.6.2. Iron chelation
Treatment with phlebotomy is not possible in patients who are transfusion dependent. Che‐
lation may be preferred for iron depletion [9]. There are limited data on the pharmacological
chelation of iron during the post–transplant period including the safety, optimal dose, time
for initiation of treatment and duration of therapy [51, 80, 81].
Deferoxamine, the first available iron chelator, has a proven efficacy and safety with dec‐
ades  of  experience  and has  also  been  studied in  HSCT recipients.  Recommended treat‐
ment schedule is at least 5 nights per week subcutaneous delivered via a pump for 8-12
hours [4,  9].  It  is effective in lowering serum ferritin levels and LIC and prevents endo‐
crinological  complications.  Long  term  treatment  is  also  associated  with  a  reduction  in
cardiac complications and improved survival. Redness and induration at the infusion site
are the most common side effects. Audiological, ophthalmological, growth and bone tox‐
icities  may  be  minimized  by  avoiding  overchelation.  Deferoxamine  treatment  in  the
HSCT setting is complicated by the short half life and the ability to release iron to bacte‐
ria and fungi. Deferoxamine supports the growth of zygomycetes because it acts as xeno‐
sidephore  delivering  iron  to  iron  uptaking  molecules  of  the  species  [22,  51,  81].  The
greatest challenge with DFO is patient adherence with therapy because the need for pa‐
renteral administration is cumbersome, uncomfortable, inconvenient and time consuming
[51].  Cardiac  morbidity  and  mortality  continue  to  occur  in  patients  treated  with  DFO,
likely related to difficulties with adherence [4, 9, 22, 51, 81].
Deferiprone is an oral iron chelator which was first identified in 1980s and subsequently ap‐
proved for clinical use in Canada and Europe especially when DFO is contraindicated. Deferi‐
prone is not commercially available in all countries and has not been investigated in HSCT
recipients. It has a short half life of only 1, 5 hours and thus requires 3 times daily dosing. Un‐
fortunately, it does not control liver iron as effective as DFO even after years of continued treat‐
ment.  In contrast,  a recent study in patients with thalassemia showed better myocardial
function in those receiving Deferiprone. Retrospective studies have also demonstrated re‐
duced cardiac morbidity and mortality and lower myocardial iron deposition among patients
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treated with Deferiprone compared with DFO and Deferasirox (DFX). A reduction or stabiliza‐
tion of serum ferritin levels and LIC in most patients with transfusional IO was demonstrated.
The high risk of agranulocytosis necessitates weekly blood monitoring. Thus, toxicity profile of
the drug may be inappropriate for transplant recipients [4, 9, 81].
A novel oral iron chelator, DFX was approved by the US Food and Drug Administration in
2005 and represents a significant advancement in the treatment of IO. It is a tridentate oral iron
chelator which is lipid soluble but highly protein bound. It has a plasma half life about 12 hours
and thus is ideal for once daily dosing. It binds iron in a 2/1 ratio. It is excreted by the hepatobili‐
ary system and the chelated iron is excreted via the feces. The effective dose is between 20-40
mg/kg. It is generally well tolerated by patients although some dose modifications may be nec‐
essary for diarrhea. Phase III trials demonstrated that DFX at 20-30 mg/kg/day led to the main‐
tenance or reduction of iron burden as measured by LIC in chronically transfused patients.
Reductions in LIC and serum ferritin are similar to those found in the subcutaneous use of
DFO. Commonly reported side effects include skin rash, nausea, vomiting and diarrhea and el‐
evations in serum creatinine levels, which may be important in patients treated with calcineur‐
in inhibitors. Gastrointestinal disturbances often improve with continued administration of
the drug. Elevations in serum creatinine occur in approximately 1/3 of subjects. Side effects as‐
sociated with DFX therapy may overlap or exacerbate early complications such as calcineurin
induced renal injury seen after allo–HSCT, which Mkes it complicated to use early after HSCT.
The availability of an oral iron chelator has simplified the treatment of IO, but more experience
with its use in HSCT recipients is needed [4, 9, 22, 80, 81].
3. Conclusion
The role of IO in HSCT recipients and guidelines for screening strategies warrants further stud‐
ies. The value of routine screening for IO, the method of determining it, whether it should be
with serum ferritin, by determining LIC with non invasive MRI or biopsy and identifying a sub‐
group of patients who might benefit from phlebotomy and/or iron chelating agents requires fu‐
ture prospective studies.  The possibility of IO should be considered in patients who are
candidates for HSCT. Red blood cell transfusion should be limited whenever possible and chela‐
tion and/or phlebothomy should be considered in the course of documented IO. pre–transplant
preventive measures should also be adopted to avoid IO and improve survival in these patients.
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treated with Deferiprone compared with DFO and Deferasirox (DFX). A reduction or stabiliza‐
tion of serum ferritin levels and LIC in most patients with transfusional IO was demonstrated.
The high risk of agranulocytosis necessitates weekly blood monitoring. Thus, toxicity profile of
the drug may be inappropriate for transplant recipients [4, 9, 81].
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the drug. Elevations in serum creatinine occur in approximately 1/3 of subjects. Side effects as‐
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induced renal injury seen after allo–HSCT, which Mkes it complicated to use early after HSCT.
The availability of an oral iron chelator has simplified the treatment of IO, but more experience
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The role of IO in HSCT recipients and guidelines for screening strategies warrants further stud‐
ies. The value of routine screening for IO, the method of determining it, whether it should be
with serum ferritin, by determining LIC with non invasive MRI or biopsy and identifying a sub‐
group of patients who might benefit from phlebotomy and/or iron chelating agents requires fu‐
ture prospective studies.  The possibility of IO should be considered in patients who are
candidates for HSCT. Red blood cell transfusion should be limited whenever possible and chela‐
tion and/or phlebothomy should be considered in the course of documented IO. pre–transplant
preventive measures should also be adopted to avoid IO and improve survival in these patients.
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1. Introduction
Sickle Cell Disorder (SCD) is an inherited disease of red blood cells which has no widely
available cure (Bernaudin, Socie, Kuentz, et al., 2007). While current medical therapies can
make a significant difference in short-term effects (i.e. to relieve pain symptoms, prevent in‐
fections and manage complications such as eye damage, and strokes; and control complica‐
tions), the progressive deterioration in organ function results in increased mortality and
decreased quality of life among affect persons in Nigeria. Presently, blood and bone marrow
stem cell transplant appear to be the only viable option for its eliminating. This option is
hugely expensive and unaffordable for the vast majority of the affected Nigerian families
since most of them could barely provide for the general routine medication therapies of the
patient. Little attention is being given to the management of this disorder in Nigeria as com‐
pared to diseases such as malaria and polio myelitis. Institutional research attention and in‐
ternational funding support towards the search for ways to predict the severity of and for
curative therapies of this disorder are also limited in Africa.
Globally, sickle cell disorders (SCD) affect millions of people of all races throughout the
world. About 80% of affected children are born in developing countries and about 50 – 80%
of children with SCD die each year in low – middle income countries. Nonetheless, its mag‐
nitude in Nigeria and Africa on the whole is alarming. Nigeria has the largest burden of
SCD in Africa (see table 1 for a presentation of the progress report). At least 40 million Nigerians
are carriers (AS) versus 2 million Americans. Over 150,000 Nigerians are born each year
with sickle cell anaemia (SS) versus 2,000 in America (Akinyanju, 2009). Numerous families
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in Nigeria have lost loved ones to this red blood cell disorder. About 80,000 people are liv‐
ing with SCD in USA versus estimated ±1,000,000 in Nigeria (Akinyanju, 2009).
1916 - 1945 Virtually nil > 4y
1946 – 1965 Virtually no adults. Known as paediatric disease
1966 – 1985 Many adolescents and young adults
1986 – 2010 Many adults as parents and in workforce
Table 1. Progress of Nigerians with SS
Molineaux et al (1979) noted that there is no other known inherited disorder present at such
high frequency in a large population and of comparable severity as sickle cell anaemia in
Africa. With rising standards of living and control of malaria, sickle cell anaemia may be‐
come an immense medical, social and economic problem all over Africa (see table 2 below).
Indigenous
• Sub Saharan countries north of Zambesi River
• Eastern Saudi Arabia
• Some States in India
Imported
• Mediterranean Basin e.g. Greece,Sardinia
• USA & Canada
• Brazil, Belize Columbia etc
• Cuba, Jamaica, Haiti, Barbados, Trinidad etc
• UK, France, Holland,
Distribution and Names of Indigenous Sickle Gene
Haplotypes
Region
• Western West Africa
• *Cameroon (Ekona)
• Central West Africa
• Central & East Africa
• East Saudi Arabia & India
Haplotype
• Senegal – 3
• Cameroon – 17
• Benin – 19
• Bantu – 20
• Arab/India – 31
Note: * Most Cameroonians have the Benin haplotype. The Ekona haplotype is a recent discovery among the small
population of the Ekona ethnic group
Table 2. Where SCD is Found
The symptoms of SCD are seen predominantly in one-third of all aboriginal inhabitants (or
their descendants) of parts of tropical and sub-tropical regions where malaria is or was com‐
mon and in people from parts of the Middle East, Central India, Spanish-speaking regions
(South America, Cuba, Central America); Saudi Arabia; and countries bordering the Medi‐
terranean Sea, especially Turkey, Greece, and Italy (Akinyanju, 2009). This is because in
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areas where malaria is common, there is a survival value in carrying only a single sickle-cell
gene (sickle cell trait) (Akinyanju, 2009).
In the US, SCD affects around 72,000 people, most of whose ancestors come from Africa
(Benjamin & Payne, 2007). It occurs in about 1:500 African-American births and 1:1000-1400
Hispanic-American births. About 2 million Americans, or 1:12 African Americans carry the
sickle cell trait. Its occurrence among the Hispanic-Americans is about 5%, their median sur‐
vival based on 1991 national data was 42 years for males, 48 years for females (California
Institute For Regenerative Medicine, 2009). By twenty years of age, about 15% of children
with SCD suffer major strokes and by 40 years of age, almost half of the patients have had
central nervous system damage leading to significant cognitive dysfunction. These patients
suffer significant damage to lungs and kidneys as well as severe chronic pain that impacts
on quality of life. In Brazil, SCD is considered the most common monogenic disease seen
predominantly in the black population as well as among individuals from parts of the Mid‐
dle East, Central India and countries bordering the Mediterranean Sea, especially Italy and
Greece.
2. What is Sickle Cell Disease (SCD)?
Sickle cell disorders (SCD) is a group of inherited autosomal recessive disorder character‐
ized by production of abnormal of haemoglobin (Hb), resulting in anemia, susceptibility to
pneumococcal and other infections, pain, stroke, and multiple organ dysfunctions. Normal
red blood cells are soft, smooth, round and flexible and last about 120 days. It flows easily
through blood vessels, but the abnormal hemoglobin which causes the red blood cells to be
hard and sticky looks like a C-shaped farm tool called a sickle under the microscope (see
figure 1).
Figure 1. Shapes of Red Blood Cells
Sickle cell disorders, there are two main types of heamoglobin S- fetal Hb (F) in the unborn
child (fetus) and adult Hb (A) after birth. It encompasses > 960 variants of sickling syn‐
dromes caused by abnormal sickle hemoglobin. Some are harmless; few are incompatible
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with life and some like Hb S can make life more challenging. The most common and most
severe variant of SCD is hemoglobin SS (homozygous) disease. Other forms include Sickle
cell/C disorder (Hb SC), Sickle cell/β thalassaemia (Hb Sβ+thal or Hb Sβ0thal), SD- Punjab,
SO Arab, S Lepore and SE disease (NIH, 2010a, b).
Sickle cell trait (also known as being a carrier) occurs when a person has one gene for sickle
hemoglobin and one gene for normal hemoglobin. Approximately one in ten African-Ameri‐
cans carries sickle cell trait. People who are carriers generally do not have any medical prob‐
lems and lead normal lives. If you are a carrier you cannot develop sickle cell disease.
Figure 2. Types of Genotype Status
3. Symptom of Sickle Cell Disease: Related to painful and painless
complication
Symptoms of sickle cell disease vary, ranging from mild to severe or life-threatening crises.
It may occur without warning, and may go away and then come back many times. The signs
and symptoms are linked to anaemia, pain and disease's complications. SCD anaemia relat‐
ed symptoms (lack of RBC) range from mild to very severe symptoms. The symptoms of
anemia are fatigue (feeling tired or weak), shortness of breath, dizziness, headaches, cold‐
ness in the hands and feet, and paler than normal skin or mucous membranes (the tissue
that lines your nose, mouth, and other organs and body cavities).
The pain related symptoms are debilitating pain episode or crisis which can affect bones,
lungs, abdomen, and joints; as well as damage organs and increase the risk of stroke. The
pain can be acute or chronic, but acute pain is more common. Acute pain is sudden and can
range from mild to very severe. The pain usually lasts from hours to as long as a week or
more. Chronic pain often lasts for weeks or months. Such pains can be limiting, unbearable
and mentally draining. The painful crises are the leading cause of emergency room visits
and hospital stays for people who have sickle cell anaemia.
Disease complication related of SCD crises are painful episodes (crises), acute chest syn‐
drome, anemia (low hemoglobin), organ damage due to iron overload, infections, lung
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problems, leg ulcers, bone damage, strokes, and premature death. It can cause hand-foot
syndrome which is a blockage of the small blood vessels in the hands and feet in children
(usually those younger than 4 years of age) leading to pain, swelling, and fever. SCD can
also initiate splenic crisis in the abdomen, and pulmonary hypertension.
4. Etiology of SCD crises
The exact cause of episodic painful crisis is unknown. However, more than one factor is in‐
volved. First, the crises can occur whenever sickled red blood cells form clumps or abnormal
curved shapes called sickles in the bloodstream. These clumps of cells stick to small blood
vessels and block blood flow and oxygen to the limbs and organs. This can result in pain
and damage to body organs, such as kidneys. It can trigger a stroke and other medical prob‐
lems. For instance, the Hand-Foot Syndrome usually occurs whenever sickled RBCs block
the small blood vessels in the hands and feet in children (usually those younger than 4 years
of age). It can lead to pain, swelling, and fever. Swelling often occurs on the back of the
hands and feet and moves into the fingers and toes. One or both hands and/or feet may be
affected at the same time.
Gallstones usually develop in the gallbladder whenever there is too much bilirubin in the
body. Gallstones may cause steady pain that lasts for 30 minutes or more in the upper right
side of the belly, under the right shoulder, or between the shoulder blades. The pain may
happen after eating fatty meals. People who have gallstones may have nausea (feeling sick
to the stomach), vomiting, fever, sweating, chills, clay-coloured stools, or jaundice (a yellow‐
ish colour of the skin or whiteness of the eyes).
Ulcers on the Legs (sores) usually begin as small, raised, crusted sores on the lower third of
the leg. Leg sores may occur more often in males than in females. These sores usually devel‐
op in people who are aged 10 years or older. The cause of sickle cell ulcers isn't clear. The
number of ulcers can vary from one to many. Some heal quickly, but others persist for years
or come back after healing.
Splenic Crisis can also occur whenever the spleen traps red blood cells that should be in the
bloodstream. This causes the spleen to grow large and leads to anaemia. Acute Chest Syn‐
drome may be caused by infection or sickle cells trapped in the lungs. People who have this
condition often have chest pain, shortness of breath, and fever. They also often have low
oxygen levels and abnormal chest x- ray results. Pulmonary Hypertension occurs as a result
of damage to the small blood vessels in the lungs which make it hard for the heart to pump
blood through the lungs. This causes blood pressure in the lungs to rise. Increased blood
pressure in the lungs is called pulmonary hypertension (PH). Shortness of breath and fati‐
gue are the main symptoms of PH. Priapism which is painful, unwanted erections may oc‐
cur whenever sickle cells block blood flow out of an erect penis. Over time, priapism can
damage the penis and lead to impotence.
SCD crises may also be caused by factors such as dehydration, infections, hypoxia, cold tem‐
perature, surgery and emotional stress. Dehydration often increases the risk of a sickle cell
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with life and some like Hb S can make life more challenging. The most common and most
severe variant of SCD is hemoglobin SS (homozygous) disease. Other forms include Sickle
cell/C disorder (Hb SC), Sickle cell/β thalassaemia (Hb Sβ+thal or Hb Sβ0thal), SD- Punjab,
SO Arab, S Lepore and SE disease (NIH, 2010a, b).
Sickle cell trait (also known as being a carrier) occurs when a person has one gene for sickle
hemoglobin and one gene for normal hemoglobin. Approximately one in ten African-Ameri‐
cans carries sickle cell trait. People who are carriers generally do not have any medical prob‐
lems and lead normal lives. If you are a carrier you cannot develop sickle cell disease.
Figure 2. Types of Genotype Status
3. Symptom of Sickle Cell Disease: Related to painful and painless
complication
Symptoms of sickle cell disease vary, ranging from mild to severe or life-threatening crises.
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that lines your nose, mouth, and other organs and body cavities).
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lungs, abdomen, and joints; as well as damage organs and increase the risk of stroke. The
pain can be acute or chronic, but acute pain is more common. Acute pain is sudden and can
range from mild to very severe. The pain usually lasts from hours to as long as a week or
more. Chronic pain often lasts for weeks or months. Such pains can be limiting, unbearable
and mentally draining. The painful crises are the leading cause of emergency room visits
and hospital stays for people who have sickle cell anaemia.
Disease complication related of SCD crises are painful episodes (crises), acute chest syn‐
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curved shapes called sickles in the bloodstream. These clumps of cells stick to small blood
vessels and block blood flow and oxygen to the limbs and organs. This can result in pain
and damage to body organs, such as kidneys. It can trigger a stroke and other medical prob‐
lems. For instance, the Hand-Foot Syndrome usually occurs whenever sickled RBCs block
the small blood vessels in the hands and feet in children (usually those younger than 4 years
of age). It can lead to pain, swelling, and fever. Swelling often occurs on the back of the
hands and feet and moves into the fingers and toes. One or both hands and/or feet may be
affected at the same time.
Gallstones usually develop in the gallbladder whenever there is too much bilirubin in the
body. Gallstones may cause steady pain that lasts for 30 minutes or more in the upper right
side of the belly, under the right shoulder, or between the shoulder blades. The pain may
happen after eating fatty meals. People who have gallstones may have nausea (feeling sick
to the stomach), vomiting, fever, sweating, chills, clay-coloured stools, or jaundice (a yellow‐
ish colour of the skin or whiteness of the eyes).
Ulcers on the Legs (sores) usually begin as small, raised, crusted sores on the lower third of
the leg. Leg sores may occur more often in males than in females. These sores usually devel‐
op in people who are aged 10 years or older. The cause of sickle cell ulcers isn't clear. The
number of ulcers can vary from one to many. Some heal quickly, but others persist for years
or come back after healing.
Splenic Crisis can also occur whenever the spleen traps red blood cells that should be in the
bloodstream. This causes the spleen to grow large and leads to anaemia. Acute Chest Syn‐
drome may be caused by infection or sickle cells trapped in the lungs. People who have this
condition often have chest pain, shortness of breath, and fever. They also often have low
oxygen levels and abnormal chest x- ray results. Pulmonary Hypertension occurs as a result
of damage to the small blood vessels in the lungs which make it hard for the heart to pump
blood through the lungs. This causes blood pressure in the lungs to rise. Increased blood
pressure in the lungs is called pulmonary hypertension (PH). Shortness of breath and fati‐
gue are the main symptoms of PH. Priapism which is painful, unwanted erections may oc‐
cur whenever sickle cells block blood flow out of an erect penis. Over time, priapism can
damage the penis and lead to impotence.
SCD crises may also be caused by factors such as dehydration, infections, hypoxia, cold tem‐
perature, surgery and emotional stress. Dehydration often increases the risk of a sickle cell
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crisis. Drinking plenty of fluids can lower the risk of a painful crisis. Other factors include
bacterial infections. Infants and young children with sickle cell disease are especially vulner‐
able to serious infections, such as those that cause meningitis (infection of the lining of the
brain) and blood infection.
5. Treatment goals
The goals of treatment options in SCD are symptom control; prevention of infections and
stroke; detection and management of disease complications such as vaso-occlusive crisis,
chronic pain syndromes, chronic hemolytic anemia, pulmonary hypertension, and the vari‐
ous organ damage syndromes. Accepted treatment options include narcotic pain killers,
drugs, chronic blood transfusions, hydroxyurea, and stem cell transplantation (SCT) for se‐
lected children and young adults. Narcotic pain killers are used to treat the severe pain.
Drugs are used to stimulate production of additional blood cells. Transfusions are used to
treat the anemia and to dilute the sickle cells with normal red blood cells.
6. Stem cell transplantation treatment for SCD
Stem cells are parent cells found in all tissues and organs of the body, such as the bone mar‐
row, skin, muscles, brain, peripheral blood, umbilical cord blood, and, rarely, fetal liver. The
early cells nurtured in the bone marrow or less frequently from umbilical cord blood that
mature into red and white blood cells and platelets are called multi-potent stem cells or im‐
mature cells. Stem cells produce erythroid cells, granulocytes, lymphoid cells, megacaryo‐
cytes and monocytes by a number of differentiation steps. Stem cells maintain normal cell
populations in a healthy bone marrow controlled by haemopoietic growth factors, and stem
cells have the capacity for self-renewal. Haemopoietic growth factors include erythropoietin,
interleukins, glucocorticoids, sex hormones and thyroid hormones.
Figure 3. Stem Cell
Stem cell transplantation (SCT) refers to transplantation of the hematopoietic stem cells
(HSCs) from a donor into an individual. Transplanted human bone marrow or stem cells are
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dynamic biological entities that interact intimately with—and are influenced by—the physi‐
ology of the recipient. It is a very risky procedure. Before they are transplanted, cultured hu‐
man stem cells are maintained under conditions that promote either the self-renewing
expansion of undifferentiated progenitors or the acquisition of differentiated properties in‐
dicative of the phenotype the cells will assume (The National Institutes of Health resource
for stem cell research, 2010). After incompletely differentiated human stem cells are trans‐
planted, additional fine-tuning occurs as a consequence of instructions received from the
cells' physiologic microenvironments within the recipient.
The goal of SCT is elimination of the sickle erythrocyte and its cellular progenitors and re‐
placement with donor hematopoietic pluripotent stem cells which give rise to erythrocytes
that express no sickle hemoglobin (HbS). This will eventually reduce Hb S levels to those
associated with the trait condition. It has the possibility of preventing serious complications
from SCD which can cause extensive morbidity and early death.
The donor sources of hematopoietic stem cells transplantation (HSCT) include cells obtained
from another person (sibling or unrelated donor), termed allogeneic transplant; an identical
twin, termed syngeneic transplant; or the patient, termed autologous transplant (Samavedi,
2011). The autologous HSCT (using the individual’s own stem cells) involves using periph‐
eral blood stem cell transplantation (PBSCT) to treat disorders such as multiple myeloma,
non-hodgkin lymphoma, hodgkin disease, acute myeloid leukemia, neuroblastoma, germ
cell tumors, autoimmune disorders (systemic lupus erythematosus [SLE], systemic sclerosis)
and amyloidosis (Samavedi, 2011). It has not been used in the treatment of SCD.
Myeloablative allogeneic hematopoietic stem-cell transplantation (HSCT) is the only poten‐
tially curative treatment option for selected individuals with sickle cell anemia or thalasse‐
mia major (Samavedi, 2011; Krishnamurti, 2008; Walters, 2004). According to Samavedi
(2011) and Doubek, Folber, Koristek, et al. (2009), it can also be used in the treatment of con‐
ditions such as, leukemia, myeloproliferative disorders and myelodysplastic syndromes.
Successful allogeneic SCT not only eliminates the sickle-cell-induced vaso-occlusive sympto‐
matology, but also leads to reversal of some of the end organ damage that occurred prior to
the procedure.
In allogeneic HSCT, it is preferable for donors to have a human leukocyte antigen (HLA)
type that is identical to the recipient. Matching is performed on the basis of variability at
three of more loci of the HLA gene (e.g., HLA-A, HLA-B, HLA-DRB1). Usage of a non-mye‐
loablative conditioning regimen prior to allogeneic SCT for transplantation of pediatric pa‐
tients with SCD have been largely unsuccessful due to high rates of graft rejection
(Bernaudin, Vannier, et al., 1997). Thus, current opinion is that children with high-risk SCD
and a suitably matched donor should be offered allogeneic SCT using a conventional mye‐
loablative conditioning regimen. To date, nearly all transplants have utilized HLA-identical
sibling donors, which have limited the number of eligible sickle cell patients.
With HLA variability and lack of appropriate donors, there are increases in transplant-relat‐
ed morbidity and mortality, including graft rejection and graft-versus-host disease (GVHD).
All donor-to-patient stem cell transplants use material which contains donor T-cells. These
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chronic pain syndromes, chronic hemolytic anemia, pulmonary hypertension, and the vari‐
ous organ damage syndromes. Accepted treatment options include narcotic pain killers,
drugs, chronic blood transfusions, hydroxyurea, and stem cell transplantation (SCT) for se‐
lected children and young adults. Narcotic pain killers are used to treat the severe pain.
Drugs are used to stimulate production of additional blood cells. Transfusions are used to
treat the anemia and to dilute the sickle cells with normal red blood cells.
6. Stem cell transplantation treatment for SCD
Stem cells are parent cells found in all tissues and organs of the body, such as the bone mar‐
row, skin, muscles, brain, peripheral blood, umbilical cord blood, and, rarely, fetal liver. The
early cells nurtured in the bone marrow or less frequently from umbilical cord blood that
mature into red and white blood cells and platelets are called multi-potent stem cells or im‐
mature cells. Stem cells produce erythroid cells, granulocytes, lymphoid cells, megacaryo‐
cytes and monocytes by a number of differentiation steps. Stem cells maintain normal cell
populations in a healthy bone marrow controlled by haemopoietic growth factors, and stem
cells have the capacity for self-renewal. Haemopoietic growth factors include erythropoietin,
interleukins, glucocorticoids, sex hormones and thyroid hormones.
Figure 3. Stem Cell
Stem cell transplantation (SCT) refers to transplantation of the hematopoietic stem cells
(HSCs) from a donor into an individual. Transplanted human bone marrow or stem cells are
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dynamic biological entities that interact intimately with—and are influenced by—the physi‐
ology of the recipient. It is a very risky procedure. Before they are transplanted, cultured hu‐
man stem cells are maintained under conditions that promote either the self-renewing
expansion of undifferentiated progenitors or the acquisition of differentiated properties in‐
dicative of the phenotype the cells will assume (The National Institutes of Health resource
for stem cell research, 2010). After incompletely differentiated human stem cells are trans‐
planted, additional fine-tuning occurs as a consequence of instructions received from the
cells' physiologic microenvironments within the recipient.
The goal of SCT is elimination of the sickle erythrocyte and its cellular progenitors and re‐
placement with donor hematopoietic pluripotent stem cells which give rise to erythrocytes
that express no sickle hemoglobin (HbS). This will eventually reduce Hb S levels to those
associated with the trait condition. It has the possibility of preventing serious complications
from SCD which can cause extensive morbidity and early death.
The donor sources of hematopoietic stem cells transplantation (HSCT) include cells obtained
from another person (sibling or unrelated donor), termed allogeneic transplant; an identical
twin, termed syngeneic transplant; or the patient, termed autologous transplant (Samavedi,
2011). The autologous HSCT (using the individual’s own stem cells) involves using periph‐
eral blood stem cell transplantation (PBSCT) to treat disorders such as multiple myeloma,
non-hodgkin lymphoma, hodgkin disease, acute myeloid leukemia, neuroblastoma, germ
cell tumors, autoimmune disorders (systemic lupus erythematosus [SLE], systemic sclerosis)
and amyloidosis (Samavedi, 2011). It has not been used in the treatment of SCD.
Myeloablative allogeneic hematopoietic stem-cell transplantation (HSCT) is the only poten‐
tially curative treatment option for selected individuals with sickle cell anemia or thalasse‐
mia major (Samavedi, 2011; Krishnamurti, 2008; Walters, 2004). According to Samavedi
(2011) and Doubek, Folber, Koristek, et al. (2009), it can also be used in the treatment of con‐
ditions such as, leukemia, myeloproliferative disorders and myelodysplastic syndromes.
Successful allogeneic SCT not only eliminates the sickle-cell-induced vaso-occlusive sympto‐
matology, but also leads to reversal of some of the end organ damage that occurred prior to
the procedure.
In allogeneic HSCT, it is preferable for donors to have a human leukocyte antigen (HLA)
type that is identical to the recipient. Matching is performed on the basis of variability at
three of more loci of the HLA gene (e.g., HLA-A, HLA-B, HLA-DRB1). Usage of a non-mye‐
loablative conditioning regimen prior to allogeneic SCT for transplantation of pediatric pa‐
tients with SCD have been largely unsuccessful due to high rates of graft rejection
(Bernaudin, Vannier, et al., 1997). Thus, current opinion is that children with high-risk SCD
and a suitably matched donor should be offered allogeneic SCT using a conventional mye‐
loablative conditioning regimen. To date, nearly all transplants have utilized HLA-identical
sibling donors, which have limited the number of eligible sickle cell patients.
With HLA variability and lack of appropriate donors, there are increases in transplant-relat‐
ed morbidity and mortality, including graft rejection and graft-versus-host disease (GVHD).
All donor-to-patient stem cell transplants use material which contains donor T-cells. These
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donor T-cells react to the patient's body as foreign and causes GVHD which is a significant
cause of illness and even death in stem cell transplants. It is generally avoided by using a
donor as closely matched to the patient as possible. Usage of closely matched donors reduce
will the risk of GVHD. In the normal population, a patient has about a 30% chance of having
a matched sibling donor. However, SCD is a genetic disease, passed on from parents to chil‐
dren. A brother or sister who is a close match to the patient is very likely to also have SCD,
making them inappropriate as a donor. The chance that an SCD patient has a matched sib‐
ling donor is less than 15%.
The optimal timing for marrow transplantation in the course of SCD remains uncertain be‐
cause of the unpredictable nature and clinical heterogeneity of the disease (Walters, 2005).
Selection criteria for optimal candidates continue to evolve; however, children and young
adults, generally before the age of 21 years are considered the most appropriate candidates.
Indications for HSCT have been empirically determined from prognostic factors derived
from studies of the natural history of SCD. The most common indications for which patients
with SCD have undergone HSCT are a history of stroke, recurrent acute chest syndrome, or
frequent vaso-occlusive episodes (Novelli, Kato, Ragni, Zhang, Hildesheim, Nouraie, Barge,
Meyer, Hassett, Gordeuk, Gladwin & Isenberg, 2012).Children and young adults who have
severe complications (e.g. stroke, recurrent acute coronary syndrome [ACS], refractory pain)
and have a human-leukocyte antigen (HLA)-matched donor are the best candidates for
transplantation (Panepinto, Walters, Carreras, Marsh, Bredeson, Gayle, et al 2007). Very few
adults are considered for transplantation due to existing comorbidities and toxicity of treat‐
ment (Walters, 2005).
7. Indications for stem cell transplantation
Sickle cell disorder (SCD) has no widely available cure. Its current medical therapies have
only being relieving pain symptoms, preventing infections and managing complications
such as eye damage, and strokes; and control complications. The progressive deterioration
in organ function has being resulting in increased mortality and decreased quality of life.
Some severe cases are resistant to existent therapies and can cut life even shorter.
Presently, Blood and Marrow Stem Cell Transplant appear to be the only viable option for
eliminating SCD, especially in high risk patients. Patients with SCD are characterized as
high-risk if they have central nervous system pathology (clinical or subclinical stroke, seiz‐
ures), recurrent severe acute chest syndrome, chronic unremitting pain, or early evidence of
end organ damage such as pulmonary hypertension. The appropriateness of SCT can be
more firmly established in the presence of these high-risk features.
The bone marrow nurtures stem cells, which are early cells that mature into red and white
blood cells and platelets. By destroying the sickle cell patient's diseased bone marrow and
stem cells and transplanting healthy bone marrow from a genetically-matched donor, nor‐
mal hemoglobin may be produced. Clinical studies using a few carefully selected patients
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have reported very successful results (Harvey Simon, 2009). Unfortunately, only about 7%
of patients with sickle cell meet the criteria for transplantation, including those who:
• Are age 16 or younger (generally considered the better candidates, but patients in their
20s have had successful transplants)
• Have severe symptoms but no long-term organ or neurologic damage
• Have a genetically matched brother or sister who will donate their marrow
The clinical indicator for stem cell application for SCD is based on stem cells’ biological
properties of self-renewal and their capability to give rise to differentiated cell progenies
that maintain tissue homeostasis in physiological and pathological conditions (Lindvalland
and Kokaia, 2010; Orlacchio et al., 2010; Sendtner, 2009; Yu and Silva, 2008). Thus, neural
stem cells in the subventricular zone of the lateral ventricles and the subgranular zone of the
dentate gyrus in the hippocampus of the mammalian brain maintain the capability to gener‐
ate new neural cells throughout the lifetime (Conti and Cattaneo, 2010; Ma et al., 2009; Galli
et al., 2008).
Figure 4. Stem cells replacement therapy for neurological diseases. Cartoon schematizes the different strategies for
stem cell delivery in order to repair the degenerated tissue.
8. Risks and benefits of stem cell transplantation for sickle cell disease
management in Nigeria
There are two major barriers to stem cell transplants to treat SCD. First is the risk of serious
illness associated with donor-to-patient stem cell transplant; and 2) the lack of appropriate
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donor T-cells react to the patient's body as foreign and causes GVHD which is a significant
cause of illness and even death in stem cell transplants. It is generally avoided by using a
donor as closely matched to the patient as possible. Usage of closely matched donors reduce
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dren. A brother or sister who is a close match to the patient is very likely to also have SCD,
making them inappropriate as a donor. The chance that an SCD patient has a matched sib‐
ling donor is less than 15%.
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adults, generally before the age of 21 years are considered the most appropriate candidates.
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and have a human-leukocyte antigen (HLA)-matched donor are the best candidates for
transplantation (Panepinto, Walters, Carreras, Marsh, Bredeson, Gayle, et al 2007). Very few
adults are considered for transplantation due to existing comorbidities and toxicity of treat‐
ment (Walters, 2005).
7. Indications for stem cell transplantation
Sickle cell disorder (SCD) has no widely available cure. Its current medical therapies have
only being relieving pain symptoms, preventing infections and managing complications
such as eye damage, and strokes; and control complications. The progressive deterioration
in organ function has being resulting in increased mortality and decreased quality of life.
Some severe cases are resistant to existent therapies and can cut life even shorter.
Presently, Blood and Marrow Stem Cell Transplant appear to be the only viable option for
eliminating SCD, especially in high risk patients. Patients with SCD are characterized as
high-risk if they have central nervous system pathology (clinical or subclinical stroke, seiz‐
ures), recurrent severe acute chest syndrome, chronic unremitting pain, or early evidence of
end organ damage such as pulmonary hypertension. The appropriateness of SCT can be
more firmly established in the presence of these high-risk features.
The bone marrow nurtures stem cells, which are early cells that mature into red and white
blood cells and platelets. By destroying the sickle cell patient's diseased bone marrow and
stem cells and transplanting healthy bone marrow from a genetically-matched donor, nor‐
mal hemoglobin may be produced. Clinical studies using a few carefully selected patients
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have reported very successful results (Harvey Simon, 2009). Unfortunately, only about 7%
of patients with sickle cell meet the criteria for transplantation, including those who:
• Are age 16 or younger (generally considered the better candidates, but patients in their
20s have had successful transplants)
• Have severe symptoms but no long-term organ or neurologic damage
• Have a genetically matched brother or sister who will donate their marrow
The clinical indicator for stem cell application for SCD is based on stem cells’ biological
properties of self-renewal and their capability to give rise to differentiated cell progenies
that maintain tissue homeostasis in physiological and pathological conditions (Lindvalland
and Kokaia, 2010; Orlacchio et al., 2010; Sendtner, 2009; Yu and Silva, 2008). Thus, neural
stem cells in the subventricular zone of the lateral ventricles and the subgranular zone of the
dentate gyrus in the hippocampus of the mammalian brain maintain the capability to gener‐
ate new neural cells throughout the lifetime (Conti and Cattaneo, 2010; Ma et al., 2009; Galli
et al., 2008).
Figure 4. Stem cells replacement therapy for neurological diseases. Cartoon schematizes the different strategies for
stem cell delivery in order to repair the degenerated tissue.
8. Risks and benefits of stem cell transplantation for sickle cell disease
management in Nigeria
There are two major barriers to stem cell transplants to treat SCD. First is the risk of serious
illness associated with donor-to-patient stem cell transplant; and 2) the lack of appropriate
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donors. For these reasons, only about 300 of these transplants have been performed to date.
All donor-to-patient stem cell transplants use material which contains donor T-cells. These
donor T-cells react to the patient's body as foreign, causing graft-versus-host disease
(GVHD). GVHD is a significant cause of illness and even death in stem cell transplants, and
is generally avoided by using a donor as closely matched to the patient as possible, and by
appropriate care after the transplant to quickly address symptoms of GVHD when they
arise.
Another problem with stem cell transplant for SCD is a lack of donors. Usually, a patient's
brother or sister who is a close genetic match to the patient is the preferred donor. Using
closely matched donors reduces the risk of GVHD: the closer the donor cells are to the pa‐
tient's cells, the less severe the immune reaction is likely to be.
9. Emerging therapies and promising research in Nigeria
In Sub-Saharan Africa, human stem cells offer new opportunities and promise of a remarka‐
ble array of novel therapeutics for the management of Sickle Cell Disorders (SCD) (The Na‐
tional Institutes of Health, 2009). In Nigeria, the conventional pharmacotherapeutic
treatment options for SCD have been extremely limited in part to the management of its
painless and painful crises. That is the current medical therapies for SCD only have signifi‐
cant short-term effects on affected persons in Nigeria. Nonetheless, recently a couple of
medical Scientists at the University of Benin Teaching Hospital (UBTH), Benin-City, led by
Nosakhare Bazuaye recorded a major scientific breakthrough in having a successful stem
cell transplant in October 2011 on a 7 year old patient with sickle cell anemia (who had suf‐
fered stroke) after an appropriate allogeneic 14-year sibling donor was identified. This feat
was the first of its kind in Nigeria and third in Africa. It came on the heels of earlier ones
carried out in Egypt and South Africa (Sun Editorial, 2011).
10. The silence of literature on stem cell therapy for SCD in Africa
Numerous reasons could be advance for the silence of literature in Africa on stem cell trans‐
plantation. Firstly, Africa is a continent consisting of many developing nations. In most of
these nations, particularly the tropic region, falciparum mosquito is highly endemic. The fo‐
cus of such nations like Nigeria and Kenya in research and governmental policies has been
on malaria. Although SCDs are highly prevalent in these nations, the attention of the gov‐
ernment and policy makers have not been fully gained for the management of SCDs. Even
among the medical practitioners, sheer magnitude of SCDs induces apathy and or feeling of
helplessness. The availability of limited resources for the management of sickle cell crises
and complications in these nations could also be attributable to the silence of literature in
Africa on stem cell therapy for the management of SCDs. Currently, in Nigeria, attention is
being drawn towards genetic counselling for affected individuals and their relations as well
as to those intending to marry each other.
Innovations in Stem Cell Transplantation340
The political instability in most African nations has made it difficult for policy makers to
present bills on the effective management of sickle cell disorders in Africa. The economic
and emotional burden of this disorder is huge on the affected individuals and families in Af‐
rica. Many of the affected families are poor. Poverty is another reason for the relative silence
of stem cell transplantation in Africa. This is coupled with the inequitable distribution of re‐
sources such as money, education, information and health care services in African nations.
There is also the issue of lack of Respect and Support for research - molecular, clinical and
operational- in Africa. The governments and corporate bodies in Africa do not fund re‐
search. There is usually low political will (conflict too) and no funding of research related to
SCD management in Africa.
11. Implications for psychotherapy and genetic counselling
Although stem cell transplant has curative potentials for sickle cell anaemia or thalassemia,
the physical side effects and psychological distress related to this treatment could be severe
and even life threatening for the patients, the donor, and family members. First, for the pa‐
tient, the transplant procedure is very risky and may be psychologically devastating and
traumatizing.It can lead to serious physical and psychological side effects or even death. Ap‐
proximately 5 percent of patients do not survive and it is used only in very severely affected
children and young adults for whom there is a donor who is an appropriate genetic match.
For instance, Greenfield (2007) in his eloquent essay and personal reflection as both a psy‐
chologist and transplant patient described the reality that the “powerful experience” of
transplant caused him to re-experience psychological vulnerabilities despite years of psy‐
choanalysis and therapy to address his past issues.
Scheme 1.
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donors. For these reasons, only about 300 of these transplants have been performed to date.
All donor-to-patient stem cell transplants use material which contains donor T-cells. These
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arise.
Another problem with stem cell transplant for SCD is a lack of donors. Usually, a patient's
brother or sister who is a close genetic match to the patient is the preferred donor. Using
closely matched donors reduces the risk of GVHD: the closer the donor cells are to the pa‐
tient's cells, the less severe the immune reaction is likely to be.
9. Emerging therapies and promising research in Nigeria
In Sub-Saharan Africa, human stem cells offer new opportunities and promise of a remarka‐
ble array of novel therapeutics for the management of Sickle Cell Disorders (SCD) (The Na‐
tional Institutes of Health, 2009). In Nigeria, the conventional pharmacotherapeutic
treatment options for SCD have been extremely limited in part to the management of its
painless and painful crises. That is the current medical therapies for SCD only have signifi‐
cant short-term effects on affected persons in Nigeria. Nonetheless, recently a couple of
medical Scientists at the University of Benin Teaching Hospital (UBTH), Benin-City, led by
Nosakhare Bazuaye recorded a major scientific breakthrough in having a successful stem
cell transplant in October 2011 on a 7 year old patient with sickle cell anemia (who had suf‐
fered stroke) after an appropriate allogeneic 14-year sibling donor was identified. This feat
was the first of its kind in Nigeria and third in Africa. It came on the heels of earlier ones
carried out in Egypt and South Africa (Sun Editorial, 2011).
10. The silence of literature on stem cell therapy for SCD in Africa
Numerous reasons could be advance for the silence of literature in Africa on stem cell trans‐
plantation. Firstly, Africa is a continent consisting of many developing nations. In most of
these nations, particularly the tropic region, falciparum mosquito is highly endemic. The fo‐
cus of such nations like Nigeria and Kenya in research and governmental policies has been
on malaria. Although SCDs are highly prevalent in these nations, the attention of the gov‐
ernment and policy makers have not been fully gained for the management of SCDs. Even
among the medical practitioners, sheer magnitude of SCDs induces apathy and or feeling of
helplessness. The availability of limited resources for the management of sickle cell crises
and complications in these nations could also be attributable to the silence of literature in
Africa on stem cell therapy for the management of SCDs. Currently, in Nigeria, attention is
being drawn towards genetic counselling for affected individuals and their relations as well
as to those intending to marry each other.
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search. There is usually low political will (conflict too) and no funding of research related to
SCD management in Africa.
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proximately 5 percent of patients do not survive and it is used only in very severely affected
children and young adults for whom there is a donor who is an appropriate genetic match.
For instance, Greenfield (2007) in his eloquent essay and personal reflection as both a psy‐
chologist and transplant patient described the reality that the “powerful experience” of
transplant caused him to re-experience psychological vulnerabilities despite years of psy‐
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Secondly, bone marrow transplant carries its own dangers and limitations, especially for pa‐
tients who do not receive a bone marrow transplant from a well-matched brother or sister
donor. About 10% of those who have bone marrow transplants die from the treatment. In
patients who do not receive a bone marrow donation from a matched sibling, the transplant‐
ed cells from a donor (called allogeneic grafts) may attack the patient's own tissues, a poten‐
tially fatal condition called graft-versus-host disease (GVHD). Drugs that destroy bone
marrow and suppress immunity must be administered before the procedure so that the
body's immune system does not attack the transplanted tissue. Still, this does not always
prevent the problem.
Other very serious complications include bleeding, pneumonia, and severe infection. Those
who live but are not cured face long-term problems caused by the drugs used in transplan‐
tation and by the disease itself. Even in those who are cured, long-term consequences may
include a higher risk for cancer and infertility.
Psychologically, all the physical complications that patients face after transplantation may
have significant impact on their daily and cognitive functioning. The patients may experi‐
ence significant global psychological distress encompassing areas of existential concerns, ob‐
sessive-compulsiveness, loneliness, and ongoing health concerns such as memory loss
(Rusiewitcz, et al, 2008). They may also experience post-traumatic depression as a result of
chronic graft versus host disease (cGVHD), long-term issues of ongoing medical appoint‐
ments, and side-effects of medications (Sherman, Cooke & Grant, 2005; Syrjala, Langer,
Abrams, et al., 2004). They may also experience challenging cognitive changes and post-
transplant sexual difficulties such as vaginal dryness for women and erectile dysfunction in
men (Sherman, Cooke & Grant, 2005). The patient may be unprepared for post-transplant
life. In line with the time trajectory of HSCT as indicated in the table below, the physical and
distressing psychological effects of stem cell transplantations have serious implications for
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Table 3. Time Trajectory of HSCT
For the psychotherapists, genetic counsellors, psychologist, (particularly clinical psycholo‐
gists) and informal help-givers including the spiritual help-givers., the pathological basis of
SCD and stem cell transplantation have generated such questions as: Are the psychothera‐
pists and genetic counselors in Nigeria sufficiently equipped to adequately meet the psycho‐
logical needs of the individuals living with SCD in Nigeria after stem cell transplantation?
Are the professionals (such as psychologists and counsellors) seeing the need to explore the
possibility of blending pharmacotherapy with culturally accepted psychotherapeutic inter‐
ventions for pain coping and increase of steady state among individuals living with SCD in
Innovations in Stem Cell Transplantation342
this part of the world? As a result, professionals should focus on the development of cross-
culturally relevant psychotherapeutic measures that will address specific needs of patients,
donors and their families prior to and after stem cell transplantation. Such cross-culturally
sensitive psychotherapeutic programmes will take into consideration the psychological, cul‐
tural and spiritual aspects of individuals living with SCD in order to provide them with ho‐
listic care. In other words an eclectic but harmonious combination of behavioural techniques
(therapeutic interventions) and cross-cultural therapeutic techniques could be more potent
in achieving desirable therapy- outcomes.
There is also the urgent need for research that would assess the level of genetic counselling
and psychotherapy being offered individuals living with SCD during their crisis state and
steady state whether they are appropriate and whether they are being implemented proper‐
ly. Appropriate psychological interventions can profoundly alter sets of beliefs, ways of
thinking, affective states and patterns behaviour.
Added to this is the urgent need to train enough genetic counselors and psychotherapists
with special focus on SCD and stem cell transplantation across sub-Saharan Africa where
the disorder is prevalent, and most especially Nigeria which has the largest burden of SCD
globally.
The hall mark of psychotherapy and genetic couselling in Nigeria for SCD and SCT shall be
meeting the psychosocial health needs of the patients, the donor and family members. Be‐
cause of the unique nature of the transplant experience, psychosocial assessment and inter‐
ventions should be a high priority. The transplant procedure itself is complex and although
the mortality has improved over the years since transplants began in the 1970’s it continues
to be a significant stressor. The recovery after transplant can come with prolonged physical
and psychological set-backs, and extreme social strain on the patient’s caregiver, friends and
family members. In addition, the transplant experience can include multiple hospital read‐
missions for acute complications, slow recovery and long-term issues (Eldredge, Nail, Ma‐
ziarz, Hansen, Ewing & Archbold, 2006).
12. Conclusion
Sickle Cell Disorder (SCD) is an inherited disease of red blood cells characterized by pain
episodes, anemia (shortage of red blood cells), serious infections and damage to vital organs
which vary greatly from one person to the next. This disorder has no widely available cure
in Nigeria. Allogenic stem cell transplantation is the only treatment option with curative po‐
tentials, but is not readily affordable to most SCD affected families in sub-Saharan Africa.
Generally, hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) has a
strong track record of efficacy and there is growing appreciation that its benefits exceed its
risks in selected individuals. The results of transplantation are best when performed in chil‐
dren with a sibling donor who is HLA-identical. Globally, Nigeria has the largest burden of
this disorder. Government’s commitment and strong political will are needed to support
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and fund all activities and research geared towards effective management of SCDs in Niger‐
ia so that stem cell transplantation can become a clinical curative and affordable reality for
patients with sickle cell disorders and their families.
While there appears to be a considerable benefit to those who survive with stable engraft‐
ment of donor cells, there are also significant health risks to those who undergo this treat‐
ment. Therefore, engagement of trained psychotherapists and genetic counselors with focus
on SCD and HCT with the patients, donors and their families should be conducted to ensure
informed consent for this procedure. Presently, HCT is reserved for patients who have expe‐
rienced significant complications of sickle cell disease, such as stroke, recurrent episodes of
acute chest syndrome or intractable vaso-occlusive pain. Consequently, Nigeria is in dire
need of strong institutional support for and training of psychotherapists and genetic counse‐
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1. Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) has become a common proce‐
dure for the therapy of hematologic malignancies, immune disorders and many other blood
related disorders. Over 18,000 procedures are performed yearly in the US and Europe. The
donor  of  choice  for  allogenictransplantation  is  a  fully  HLA  matched  sibling,  which  is
available for only 20 to 25% of patients. Alternate donor sources have been developed and
in the past few years transplant using these sources have surpassed the ones from sibling
donor. These alternate sources are: adult volunteer donors which have been organized in
large national registries; umbilical cord blood that is stored in blood banks worldwide; and
manipulated stem cells  grafts  from haploidentical  relatives.  There is  a wide variation in
the transplant procedures, complications and outcomes between these sources, as well as
debate  over  which  one  is  the  best  source  for  each  given  patient,  with  few prospective
comparative  trials  reported  or  in  progress  to  settle  this  issue.  We  review  the  develop‐
ment  and  present  status  of  each  alternate  source  along  with  reported  comparisons  of
properties and outcomes.
2. Hematopoietic stem cell transplantation: Purpose and indications
HSCT is a procedure where the entire hematopoiesis and immune system are replaced by the
donor’s cells [1]. HSCT can be classified according to its purpose, HSC donor type and HSC
origin
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The purposes of HSCT are:
1. Rescue a cancer patient from the effects of high dose chemotherapy and total body
radiation. The most common indications are leukemia and lymphomas, which account
for more than two thirds of transplants.
2. Correct a congenital or acquired cell disorder of the hematopoietic system (i.e., severe
aplastic anemia and immune deficiencies, some inborn errors of metabolism)
3. Control the proliferation of cancer cells through immune mediated mechanisms that from
part of the graft versus host reaction
4. Reset the immunological system, which had proven useful in patients with severe
autoimmune disorders
Donor types are autologous, where stem cells are obtained from the patient, and allogeneic
where stem cells are obtained form a donor. Autologous cells are only used in the treatment
of malignant disorders that do not involve the bone marrow and autoimmune diseases.
An ever growing list of malignant and nonmalignant disorders is treated with HSCT (Table
1). It has grown at a rapid pace in the past two decades. Annual procedures in the US and
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Figure 1. Transplant activity in the US, 1980 to 2010, by type of transplantation. Since 2005 unrelated donor trans‐
plants surpassed sibling donor procedures [2].
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Leukemia and lymphomas with specific clinical or biological characteristics, including:
∙ Acute high risk myelogenousleukemia (AML):
∙ Antecedent hematological disease (e.g., myelodysplasia (MDS))
∙ Treatment-related leukemia
∙ Induction failure
∙ First complete remission with intermediate- or poor-risk cytogenetics or
molecular markers
∙ AML after relapse
∙ Second complete remission and beyond
∙ Acute high risk lymphoblastic leukemiaincluding:
∙ Poor-risk cytogenetics (e.g., Philadelphia chromosome (t(9;22)) or 11q23
rearrangements)
∙ High White cell blood count ("/>30,000 - 50,000) at diagnosis in adults
∙ t(11;22) in infants
∙ Central Nervous system NS or testicular involvement
∙ No complete remission within 4 weeks of initial treatment
∙ Second complete remission and beyond
∙ Chronic myelogenousleukemia:
∙ No hematologic or response post-tyrosine kinase inhibitor (TKI) initiation
∙ Disease progression or intolerance to TKI
∙ Accelerated phase or blast crisis (myeloid or lymphoid)




Multiple myeloma and other plasma cell disorders
Severe aplastic anemia and other marrow failure states, including:
∙ Severe aplastic anemia
∙ Fanconianemia
∙ Paroxysmal nocturnal hemoglobinuria (PNH)
∙ Pure red cell aplasia
∙ Amegakaryocytosis / congenital thrombocytopenia
SCID and other inherited immune system disorders, including:
∙ Severe combined immunodeficiency (SCID, all sub-types)
∙ Wiskott-Aldrich syndrome
Hemoglobinopathies, including:
∙ Beta thalassemia major
∙ Sickle cell disease
Hurler's syndrome and other inherited metabolic disorders, including:
∙ Hurler's syndrome (MPS-IH)
∙ Adrenoleukodystrophy
∙ Metachromatic leukodystrophy
Myelodysplastic and myeloproliferative disorders, including:
∙ Refractory anemia (all types)
∙ Chronic myelomonocyticleukemia
∙ Agnogenic myeloid metaplasia (myelofibrosis)
Familial erythrophagocyticlymphohistiocytosis and other histiocytic disorders
Other malignancies
Table 1. Current indications of allogeneic stem cell transplantation
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3. Sources of hematopoietic stem cells
3.1. Bone marrow
Marrow tissue obtained by repeated bone punctures and filtered to eliminate bone particles
and fat was the original source of HSC. It contains 1 to 15 % of CD34+ cells, the marker by
which HSC are identified. Bone marrow transplantation was performed successfully as a result
of the studies done by Donnall Thomas and the group at the Fred Hutchinson Cancer Center
during the 1960s [4]. Early studies demonstrated the effect of high radiation therapy doses and
chemotherapy in the bone marrow as well as the capacity to regenerate the individual’s
hematopoietic function by reinfusion of stored bone marrow cells from himself or a donor.
Bone marrow as a source continues to be widely used but it has not increased due to the
inherent nature of the procedure that includes general anesthesia, results in considerable blood
loss and is often followed with significant donor discomfort.
3.2. Mobilized peripheral stem cells
Donors treated with hematopoietic colony stimulating factors, mainly G-CSF, will mobilize
large amounts of CD34+ cells to their peripheral blood. These cells can be recovered by
leucopheresis, a procedure that circulates the blood of the patient/donor through a centrifuge,
separates white blood cells and reinfuse the remaining blood back to the donor. This is the
preferred source today for adult donors, which results in the harvest of large quantities of both
CD34+ cells and other mononuclear cells, mainly T lymphocytes. Both hematopoietic and
immune reconstitution are faster with PBSC than with bone marrow and less opportunistic
infections have been reported in patients receiving them [5, 6]. In patients with leukemia, they
have also been associated with higher incidence of chronic graft versus host disease and
improvements in survival but direct comparisons in a single center have been few. In one of
the few randomized trials comparing both stem cell sources, Storek et al reported a fourfold
increase of post transplant circulating CD45RA (naïve T cell precursors) in recipients of PBSC,
as well as a significant decrease in fungal an bacterial infections. In this report survival was
improved in PBSC recipients. Although earlier reports found that the incidence of chronic graft
versus host disease in patients receiving higher doses of CD34+ in a PBSC graft more recent
studies in larger number of patients have shown an overall benefit of the CD34+ dose [7].
3.3. Umbilical cord blood
Blood obtained from the placenta at birth is rich in high quality HSCs and can reconstitute the
hematopoietic function in a patient just like bone marrow or mobilized peripheral stem cells
[8, 9]. These cells have to be cryopreserved right after collection and stored for latter use in
liquid nitrogen. Cord blood banks have been established worldwide to provide this stem cell
source (see below) Umbilical cord blood grafts contain fewer HSCs than other sources and
because of this its use was initially limited in adult patients [10, 11]. Ways to circumvent this
limitation have been developed using pooled cells from two cord blood units. This modality
was first done by the group in University of Minnesota looking to expand a cord blood unit
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while using a second one to increase the cell dose. Patients transplanted in this fashion had
quicker hematopoietic cell recovery compared to those who received a single cord blood unit
and transplant related mortality was greatly reduced [12]. An intriguing result was that only
one unit of cord blood was identified in the peripheral blood of the patient, a phenomenon yet
to be fully explained. These early results gave way to widespread use of two cord grafts in
adult patients [13, 14]
A second alternative to increase the cell dose content has been expanding the cells before use.
Many studies to accomplish this are on the way but it has not yet reached clinical use [15, 16]
3.4. Donor sources for allogeneic transplantation
Donors for allogeneic HSCT are matched in 3 to 6 loci of the human major histocompability
complex (HLA, see below). Matching criteria are very strict due to the risk of acute and chronic
graft versus host disease, the most common complication of HSCT, which can result in
significant morbidity and mortality. Based on their origin and match grade donors can be
divided into:
• Fully matched relative, almost always a sibling and rarely other family members. As HLA
loci are inherited in a Mendelian fashion, the chances of a patient having a matched sibling
are 25% with each sibling, which determines that only 20 to 25% of the patients have this
type of donor. The chances improve in larger families.
• Partially matched relative: the donor shares at least one haplotype with the patient (hap‐
loidentical). HSC grafts need to be manipulated either with positive selection of CD34+ cells
o negative selection of T lymphocytes.
• Matched or partially matched unrelated donor: presently there are more than 20 million
unrelated donors listed in registries worldwide (see below) which are accessible for patients
needing a transplant. These include adult volunteer donors and cord blood units stored in
public access blood banks. The match grade accepted for a transplant depends on the criteria
of the transplant center.
 Matched or partially matched unrelated donor: presently there are more than 20 million unrelated donors listed in 
registries worldwide (see below) which are accessible for patients needing a transplant. These include adult volunteer donors and 
cord blood units stored in public access blood banks.  The match grade accepted for a transplant depends on the criteria of the 
transplant center.  
 
Figure 2. Stem cells sources and donor types in the US allogeneic transplantation, 1992 to 2009.  
4. HLA typing in stem cell trasnplantation  
The HLA system, also referred to the major histocompatibility complex, is a series of genes that expressed in the surface of immune 
and non immune cells represent a keystone in immune regulation and mediate graft acceptance or rejection in human allogeneic 
transplantation.  First described in the 1950s as leukoagglutinin antibodies that appeared in the serum of pregnant women after 
blood transfusion, in 1967 the first nomenclature for HLA antigens was developed after initial efforts of systematization and 
standardization. Initially HLA antigens were described by serologic reaction with standard antibodies but as the genes encoding 
these antigens were sequenced, DNA techniques were adopted to increase the repertoire and further understand the polymorphic 
structure of the complex.   
The antigens of the HLA system are encoded in genes located in the short arm of chromosome 6 (6p21.3). Their mission is to 
orchestrate the humoral and cellular immune responses, a basic issue in self and non-self molecular recognition. HLA antigens are 
localized on cell surface membranes and they form part of the antigen presenting complex with T cells receptors.   The HLA/MHC 
region is inherited as a haplotype, which means that one person inherits 50% of the genetic information for MHC from the mother 
and the other half from the father, and shares a codominant expression. The most signicant characteristic of this zone is its high 
polymorphism, which confers a huge variation between individuals.  
 
Figure 3. A Inherited MHC I and II complex antigens expressed on leucocyte membrane B. HLA encoding regions in Cr6. 
There are two distinct classes of HLA molecules, named I and II; genes HLA-A, B and C encode homonym antigens (A, B and C) 
and conform class I molecules.  They are expressed in all cells and mediate antigen recognition which triggers activation of 
cytotoxic lymphocytes. Class II antigens are HLA-DR, DQ and DP and its corresponding antigens.  They are expressed in 
professional antigen presenting cells and together with the T cell receptor they form the complex that activates T helper cells.  
It has been widely described that the one of the main prognostic factors in HSCT is HLA matching, which plays a significant role in 
engraftment, overall survival, transplant related infections, and leukemia control[17]. 
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4. HLA typing in stem cell trasnplantation
The HLA system, also referred to the major histocompatibility complex, is a series of genes
that expressed in the surface of immune and non immune cells represent a keystone in immune
regulation and mediate graft acceptance or rejection in human allogeneic transplantation. First
described in the 1950s as leukoagglutinin antibodies that appeared in the serum of pregnant
women after blood transfusion, in 1967 the first nomenclature for HLA antigens was developed
after initial efforts of systematization and standardization. Initially HLA antigens were
described by serologic reaction with standard antibodies but as the genes encoding these
antigens were sequenced, DNA techniques were adopted to increase the repertoire and further
understand the polymorphic structure of the complex.
The antigens of the HLA system are encoded in genes located in the short arm of chromosome
6 (6p21.3). Their mission is to orchestrate the humoral and cellular immune responses, a basic
issue in self and non-self molecular recognition. HLA antigens are localized on cell surface
membranes and they form part of the antigen presenting complex with T cells receptors. The
HLA/MHC region is inherited as a haplotype, which means that one person inherits 50% of
the genetic information for MHC from the mother and the other half from the father, and shares
a codominant expression. The most significant characteristic of this zone is its high polymor‐
phism, which confers a huge variation between individuals.
Figure 3. A Inherited MHC I and II complex antigens expressed on leucocyte membrane B. HLA encoding regions in
Cr6.
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There are two distinct classes of HLA molecules, named I and II; genes HLA-A, B and C encode
homonym antigens (A, B and C) and conform class I molecules. They are expressed in all cells
and mediate antigen recognition which triggers activation of cytotoxic lymphocytes. Class II
antigens are HLA-DR, DQ and DP and its corresponding antigens. They are expressed in
professional antigen presenting cells and together with the T cell receptor they form the
complex that activates T helper cells.
It has been widely described that the one of the main prognostic factors in HSCT is HLA
matching, which plays a significant role in engraftment, overall survival, transplant related
infections, and leukemia control [17].
5. Development of donor registries and cord blood banks
Large registries of volunteer donors were the natural solution to the need of patients who
lacked a matched sibling for transplantation. Because of the highly polymorphic nature of
the HLA system, thousands of donors had to be recruited to find matches for a sizable
population of patients. This required the development of large organizations which recruit
donors, obtain all the necessary information along with blood samples for HLA typing and
enter all  this information in searchable registries that can identify and contact the donor
in case their stem cells are required. Registries work with donor centers which perform all
the necessary medical tests and, if the transplant goes through, harvest stem cells from the
bone marrow or peripheral blood.
Most  of  this  activity  started  around blood  banks  that  had  leucopheresis  programs  and
volunteer donors for platelets products with HLA typing done. Most registries are national,
government supported organizations that  work with their  transplant and donor centers.
Once  they  became  established  it  was  also  natural  that  international  collaboration  soon
commenced and stem cell  products traveled between countries and continents.  The first
successful unrelated donor transplant took place in 1973 in New York when a young boy
with an inherited immunodeficiency received multiple marrow transplants from a donor
identified as a match through a blood bank in Denmark. Driven by the need of a single
patient with Wiskott Aldrich disease, a congenital immune deficiency that could only be
cured with a transplant, the Anthony Nolan Registry was started in England in 1974. The
first unrelated donor transplant for a patient with advanced leukemia was done in 1979 in
Seattle  and spurred the formation of  the National  Bone Marrow Donor Registry,  which
later became the National Marrow Donor Program (www.nmdp.org).  NMDP has grown
to  recruit  over  5,000,000  volunteer  donors.  Their  vast  experience  in  donor  selection  is
summarized  in  periodical  guidelines  and  recommendations  [18].  The  first  transplants
facilitated through these registries were done in the mid 80´s. Soon many more registries
around the world would follow; increasing the donor pool from a few thousand in 1980
to over 20 million by 2012 (figure 4).
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Figure 4. Stem cell donors and cord blood units listed in BMDW (www.bmdw.org)
The largest donor registries are located in the US and Europe, accounting for more than 60%
of the donor pool. Based on the finding of large amounts of high quality HSC in newborn blood
the first HSCT with umbilical cord blood was done in France in 1988 in a child with Fanconi
Anemia who received the cord blood cells of his matched newborn sibling [19]. Since cord
blood cells can be frozen and stored in liquid nitrogen for very long periods of time without
losing their properties, cord blood Banks were established in the early 90s with blood units
collected from the placenta at birth. HLA typing is done in these units and the cord blood bank
acts as a donor registry, increasing furthermore the donor pool.
In 1988 the Europdonor Foundation was started in the Netherlands to facilitate access to donor
registries around the world in a single site. Their network site, Bone Marrow Donors World‐
wide (www.bmdw.org) works as a registry of registries and allows for search among all
available donors. Presently BMDW lists donors from 112 registries in 50 countries.
Their mission is listed as:
• To maximize the chance of finding a stem cell donor or cord blood unit by providing access
to all stem cell donors and cord blood units available in the world.
• To minimize the effort required for stem cell donor or cord blood unit searches: only
registries with potential stem cell donors or cord blood units need to be contacted.
Two consequences are derived from this significant increase in the donor pool:
• Unrelated donor transplant activity has increased at a parallel pace (figure 1). Annual
procedures in the US and Europe have gone from a few hundred in the early 90´2 to over
18,000 in 2011 (CIBMTR, EBMT) and in both cases have surpassed the number of sibling
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donor patients transplants, which have remained constant. Despite this, and taking into
account that needing a transplant and having a sibling donor are independent variables,
there is room for much improvement in making this therapy available to all who need it.
• The larger donor pool coupled to improvement in HLA typing with identification of a
growing number of alleles allow for much better matching between donor an patient and
this likely accounts for the improvement in transplant results. A recent CIBMTR report
showed that the difference in one year survival of patients transplanted for leukemia or
myelodysplasia comparing those with a sibling donor to an unrelated one was reduced from
20% to less than 10% in the past two decades [2, figure 4]. We cannot rule out an effect of
improved transplant center experience in this result, but other smaller reports have
confirmed that donor source (sibling vs. unrelated) is less relevant to outcome.
In 1990 the World Marrow Donor Association was born to help coordinate international
searches  and  transplant  of  hematopoietic  stem  cells,  keeping  track  of  all  the  products
facilitated inside participating countries and those exported to other countries. According
to their 2010 annual report [20], 15,256 patients were transplanted during that year with
stem cells form unrelated donors. Of those, 7183 stem cells products (45,7%) were imported
to the country where the patient received their transplant, that is, every day 20 stem cell
products  travel  from one country to another.  12,237 products were obtained from adult
donors and 3028 were cord blood grafts (19,4%) making cord blood the fastest  growing
stem  cell  source,  even  though  it  only  represents  2,5%  of  the  donor  pool.  The  reasons
favoring this are a shorter search time, immediate availability and less strict HLA match
requirements.  Also,  more  centers  are  become  familiarized  with  this  type  of  transplant
procedure, accounting for its increased use.
A general overview at the global map displayed by CIBMTR, EBMT and WMDA immedi‐
ately  highlights  the  large  difference  of  access  and  activity  of  stem  cell  transplantation
among different regions of the world. In general the size of the national registries mirrors
the transplant activity for each region. By far, Europe and North America have the larger
registries (16,2 million donors)  and account for the highest  transplant activity (18,500 in
2010), followed by some countries in Asia. South America and Africa lag behind. The top
5 countries shipping marrow or peripheral stem cells products are Germany, USA, Japan,
United Kingdom and China, accounting for 83% of shipments. The registries recruiting the
largest  amount  of  donors  in  that  year  were  REDOME  (Brazil),  NMDP  (USA),  ZKRD
(Germany), CMDP (China) and CRIR (USA), accounting for 79% of the donors recruited.
The five largest suppliers of cord blood units were USA, Japan, Spain, France and Italy.
6. Haploidentical stem cell transplantation
Haploidentical stem cell transplantation consists in the use of a graft from a related donor,
usually parents or siblings, with whom the patient shares at least 50% (up to 80%) of the MHC
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alleles. The graft itself can be collected by apheresis or bone marrow aspiration and it has to
be manipulated to allow for engraftment and prevent graft versus host disease.
Two main advantages of transplantation from a full haplotype mismatched family member
are evident:
1. Most, if not all, patients have an HLA-partially matched relative who is available to serve
as a donor. In fact most patients will have more than one donor, allowing the possibility
of switching to another relative if more than one graft is required [21, 22].
2. More frequent than not the best donor can be chosen between many candidates. The graft
is immediately available once the best candidate is chosen, as is the case in sibling
transplantation
Haploidenticaltransplantation has been limited by historically high rates of graft rejection,
GVHD, TRM, and poor immune reconstitution, resulting in a high incidence of serious
opportunistic infection. Both myeloablative and reduced intensity conditioning transplant
strategies have been attempted looking for better outcomes, with diverse results. The first
attempts of HLA-non identical stem cell transplantation were reported in 1985 by Beatty et al
[23], who described the problems and adverse effects derived from unmanipulatedhaploi‐
dentical grafts using myeloablative conditioning regimens. This study reported non permis‐
sive toxicity and mortality with type II HLA mismatch as well as higher rates of GVHD with
class I antigen mismatch. It also set the stage for graft manipulation, which has improved
outcomes. Some of the strategies involved are:
1. Ex vivo T cell depletion, that resulted in improving acute and chronic GVHD, overall and
event free survival [24].
2. Ex vivo positive selection of CD34+ cells resulting in a T cell reduced graft [25].
3. In vivo immune suppression with anthymocyte globulin and post transplant high dose
cyclophosphamide [26]
4. Ex vivo induction of alloantigen specific anergy by coculturing host and donor BM
mononuclear cells with either CTLA-4-IG or anti–B-7.1 and B7.2 antibodies [27]
Delayed immune reconstitution after haploidentical HSCT is the main contributor to morbid‐
ity and mortality of this technique. The reasons for this are T cell depletion of the graft, thymic
dysfunction induced by pretransplant chemotherapies and conditioning regimens, and GVHD
occurrence and its treatment [28].The other major challenge for haploidentical HSCT is the
high relapse rate, and several strategies are been developed like the use of tumor specific T
cells and the use of NK from the donor as shown below.
Intense pretransplant conditioning and graft manipulation to rid of T lymphocytes is associ‐
ated with delayed hematological and immune recovery, resulting in an increased rate of
infection. To circumvent this drawback, large doses of CD34+cells have been used to improve
the speed of hematological recovery with success [29]. To hasten immune recovery and also
make the procedure tolerable to older patients, less intense or reduced conditioning regimens
have been tried [30] but the effect on improving immune recovery have been modest.
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Perhaps the most disturbing side effect of T cell depletion to allow a haploidentical graft is the
abolition of the graft versus tumor effect with the increased rate of post transplant recurrence
of leukemia. This was observed in the first attempts with haploidentical grafts. Despite this a
substantial graft versus tumor effect has been attributed to the infusion of natural killer (NK)
cells, which are not depleted with T lymphocytes [31]. The best described element regarding
NK cell activity is the inhibitory killer cell immunoglobulin-like receptor (KIR), which helps
prevent NK cells from damaging host tissues, [32]. KIRs are expressed by NK cells from the
donor and interact with host HLA class I epitopes (HLA-C) in the recipient. If the KIR-HLAC
is mismatched, the inhibitory action of the receptor fails and the alloreactive NK cell is activated
against the host cell. KIR mismatch between donor and recipient has been associated with
improved survival after HSCT in AML, appearing to promote engraftment, reduce GVHD and
decrease leukemic relapse [33, 34].
Further attempts to “engineer” the graft has been made to improve results. Handgretinger [24]
developed a protocol based on animal models, using NK cell enriched CD3+ depleted stem
cells, with either myeloablative or reduced intensity conditioning regimens, plus anti CD-20
for in vivo B cell depletion. Assessment of immune reconstitution by flow cytometry showed
a faster recovery of CD4+, CD56+ and thymic precursors measured by TREC analysis. The
protocol reported significant reduction in transplant related mortality as well as incidence of
cytomegalovirus and adenoviral infections,
7. Donor search algorithms
It is widely recognized that the HLA matching level is the most important factor for transplant
outcome [16, 35, 36]. Thus, fully matched siblings are the best source of HSC for transplanta‐
tion, also due to their immediate availability, lower transplant related complications and
mortality, and reduced costs in obtaining stem cells. Nevertheless a fully matched HLA graft
also implies a reduced alloreactive effect of donor T cells against tumor cells in patients
transplanted for malignant diseases and this can reflect on a higher rate of relapse, which has
to be weighed against the reduced transplant related mortality.
Several aspects can be taken into consideration when choosing an unrelated donor among the
different alternatives and they all come into play simultaneously. A very important one is
center experience, which in itself accounts for most of the improvement in outcome [37]. Large
transplant programs usually have preferences regarding the donor chosen based in their
experience. The search process, stem cell procurement, and previous results weigh in their
policy. Some programs only use one source of stem cells (i.e. adult donor or cord blood) and
establish search and procurement protocols based on this choice. Programs with a preference
for cord blood grafts will consider using less compatible cord blood units (4/6 match) or
resource to double cord blood grafts for adult patients [11,12, 38, 39] before considering an
adult donor with a single high resolution HLA mismatch. Other programs with no cord blood
transplant experience will either resource to a partially matched donor or forfeit transplanta‐
tion altogether. Perhaps the most center-dependent modality is haploidentical transplantation.
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Few centers have the infrastructure and professional teams trained in T cell depletion or CD34+
enrichment and despite its obvious appeal and having been around for a long period of time
the procedure has not reached wide acceptance. The total number of haploidentical transplants
reported to EBMT in the past decade has remained almost unchanged [3].
Despite different preferences in donor selection some points are generally agreed upon in the
transplant community, which rely in overall experience and careful review of multiple
published reports [40].
1. The best alternate donor for unrelated transplantation in a patient who can wait for the
search process to be completed is a fully matched adult with at least 8 high resolution (i.e.
4 digit or similar) matched alleles [34, 41]. Some centers will require a 10/10 match, usually
including DQB1, for donor acceptance. Unfortunately, and despite the massive recruit‐
ment of donors worldwide, we are still far from securing a fully matched donor for every
patient. A 2004 report by the National Marrow Donor Program in the US, with over 4
million recruited donors, projected that only white and hispanic patients would have an
over 50% chance for a fully matched donor by 2007, with other ethnic groups faring much
worse [42]. When more than one fully matched donor is available other secondary aspects
can be taken into consideration: younger age, male sex, CMV serology referred to the
patient, ABO compatibility, larger weight and rapacity. Despite this, only HLA matching
and donor age affect patient survival [17].
2. If no such donor is available or the patient cannot wait, most centers will opt for fully
matched or single mismatched cord blood unit (6/6 or 5/6; HLA-A and B in low resolution
and DRB1 in high resolution), provided it reaches a total nucleated cell dose of at least 3,0
x 107 per kg of the patient [43]. This is readily available for most children up to 40 kg.
[44]but can be difficult for large adults. In this situation most programs recur to a double
cord blood unit graft, a modality that has gained wide acceptance [37,38]. If no highly
matched cord blood units are available the options mentioned are either an adult donor
with a single major locus mismatch or a single or double 2 mismatched cord blood unit
(4/6). This situation is generally decided upon center experience and bias towards one or
the other graft source.
3. It has been difficult to place haploidentical transplantation in donor selection algorithms
since most of these procedures are done in few highly specialized centers that have the
facilities and trained staff for it. Recently, new approaches to avoid graft rejection and
GVHD by in vivo T cell depletion with potent immune suppression and chemotherapy
have been tried with reported results that are similar to the use of double cord blood grafts
[45]. In general transplant related mortality in haploidentical transplantation has been
reportedly lower than using cord blood but this advantage has been offset with the higher
risk of relapse, which makes this source less recommendable for patients with high risk
disease. Longer follow up will be needed to address the question of which particular
patient benefits from which particular donor.
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Adult donor Cord blood Haploidentical
Donor availability adults Fully matched 50%
One mismatch 70%
5/6 or 6/6 : 85% *
4/6: 100% *
80%
Donor availability pediatric Fully matched 50%
One mismatch 70%
5/6 or 6/6: 90%
4/6: 100%
100%
Average time from search to
transplant
3 months (0,5-6) 21 days (7-60) 7 days
Target CD34+ dose /kg > 2 x 106 > 0,1 x106 >10x106
Graft manipulation Not required Not required Required
T cells in the graft Replete (PBSC "/> BM) Partially depleted Depleted
T cell immune reconstitution 3 months 6-9 months 6-9 months










Relapse risk Similar to less Similar to less Higher
CMV reactivation ** Similar Frequent Frequent
Post transplant cell infusion Possible Not possible Possible
*single or double unit graft
**depends on the donor and patient serology results
Table 2. Comparison between alternative donor sources
8. Transplant outcomes: Comparison among donor sources
Large registries have tracked the progress of HSCT results in the past decades. The information
obtained from them allows comparing in an extensive number of patients the impact of disease
type and stage, the donor source and donor type in transplant outcomes. Analysis of the data
from CIBMTR has shown that transplant results in young patients with hematological
malignancy in early stages of the disease comparing related unrelated donors have improved
consistently in the past 20 years, reducing a 20% difference in one year survival to less than
10% (figure 5). This data strongly supports the use of a matched adult volunteer donor as the
first choice when one is available, and this is something most centers will agree upon. The
challenge and controversy comes from selecting between a cord blood graft, a mismatched
unrelated adult donor or ahaploidentical donor [46]. Several studies have addressed this issue
for different graft sources in patients with different diseases, both in adults and in children,
based on registry data or comparing published reports using a single donor source. Very few
clinical trials have attempted to compare graft sources and none have been randomized [44].
Center preference and the difficulty involved in search logistics will make very unlikely that
a randomized trial will ever be accomplished.
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Figure 5. Improvement in one year survival of HSCT from related and unrelated donors in patients with hematological malignancies.  
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and cord blood banks will improve the chances of finding the best suited donor.  
Another study by Eapen et al in 2010 [49] reported the outcome on 1525 adult patients transplanted for acute leukemia with 
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cord blood transplantation.  The pattern of treatment failure differed by donor type. Whereas nonrelapse mortality was higher after 
unrelated donor transplantation, they observed a higher, but not statistically signicant, risk of relapse after HLA-matched sibling 
donor transplantation. A logical conclusion to this and other reports is that as transplant related mortality is curbed with better 
control on infections, a more mismatched graft may be better for high risk leukemia. Similar results were published previously by 
Minnesota group [51]comparing single center transplant outcomes by HSC source for children less than 18 years with ALL in 
second complete remission. In a more limited sample of patients, their results also suggest that transplant outcomes are remarkably 
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Very few studies have compared outcomes of unrelated donors with haploidentical transplantation. Most reports come from  
single center studies and they are difficult to interpret due to the different techniques employed for haploidentical donor selection 
and graft manipulation. A recent study compared the results of two large parallel clinical trials: one, using haploidentical donors 
with in vivo treatment of the recipient with post transplant high dose cyclophosphamide ; two, using a double 0 to 2 antigen 
mismatched  cord blood graft [44].  One year survival in both groups was similar around 50%. Nevertheless large differences in 
outcome were noted: non relapse mortality was higher in the cord blood group (24% vs. 7%) but relapse was lower (31% vs. 45%).   
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Several large studies have compared umbilical cord blood with mismatched unrelated donors
in patients with hematologic malignancies:
Laughlin et al compared results of a single cord blood unit graft versus a 7/8 HLA matched
unrelated donor in 233 patients from the databases of CIBMTR and the National Cord Blood
Program in New York and found similar outcomes when measuring transplant related
mortality, event free survival and overall survival. Survival was a sobering 26% to 20% in cord
blood versus mismatched donor, and did not reach significance [47].
Eapen published in 2007 the results in a large group of children with acute leukemia trans‐
planted with a single cord blood unit, a fully matched unrelated donor or a mismatched
unrelated do or [48]. The measur d outcome was leukemia free survival, also assessing the
relative effect of cell dose and HLA matching in the outcome of cord blood transplants. The
study included 785 patients younger than 16 years at transplantation with acute lymphoblastic
or acute myeloid leukemia who received either a single-unit cord-blood or a bone-marrow
graft from an HLA-matched or HLA-mismatched unrelated donor in the USA. The compari‐
sons were mad  between six groups: HLA-matched cord blood, one-antigen mismatched high-
cell-dose cord blood, one antigen mismatched low cell dose cord blood, two antigen
mismatched cord blood (any dose), allele-mismatched bone marrow, and allele-matched bone
marrow. Early transplant related mortality was significantly less in patients who received
fullymatched marrow and cord blood, or a high dose one antigen mismatched cord. This
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advantage was offset by a higher incidence of relapse in the first group with similar leukemia
free survival among all groups analyzed. These data support the use of HLA-matched and
one- or two-antigen HLA-mismatched umbilical cord blood in children with acute leukemia
who need transplantation. The higher risk of non-relapse mortality associated with unrelated
bone marrow and cord blood transplantation raises anxiety among pediatric oncologists when
considering these donor sources for their patients. Nevertheless, the ever growing number of
donor registries and cord blood banks will improve the chances of finding the best suited
donor.
Another study by Eapen et al in 2010 [49] reported the outcome on 1525 adult patients
transplanted for acute leukemia with unrelated matched or mismatched donors comparing
them to single cord blood unit recipients. Transplant related mortality, leukemia free survival
and overall survivals were almost identical among cord blood recipients and mismatched
unrelated donor recipients. Overall survival 43-44%, a significant improvement from previous
studies.
Trying to address the question whether a more mismatched stem-cell source will give better
disease control due to a potential increased graft versus leukemia effect, Zhang 50 et al
compared leukemia free and overall survival among 348 children with leukemia registered
with CIBMTR who were transplanted with unrelated donor bone marrow, unrelated cord
blood and HLA-matched sibling bone marrow. 3-year leukemia free survival was comparable
among all groups, despite higher risks of acute and chronic GVHD after unrelated donor
transplantation and higher non relapse mortality after mismatched unrelated donor BM and
cord blood transplantation. The pattern of treatment failure differed by donor type. Whereas
nonrelapse mortality was higher after unrelated donor transplantation, they observed a higher,
but not statistically significant, risk of relapse after HLA-matched sibling donor transplanta‐
tion. A logical conclusion to this and other reports is that as transplant related mortality is
curbed with better control on infections, a more mismatched graft may be better for high risk
leukemia. Similar results were published previously by Minnesota group [51]comparing single
center transplant outcomes by HSC source for children less than 18 years with ALL in second
complete remission. In a more limited sample of patients, their results also suggest that
transplant outcomes are remarkably similar in recipients of matched sibling, matched unre‐
lated or umbilical cord donor grafts.
Very few studies have compared outcomes of unrelated donors with haploidentical trans‐
plantation. Most reports come from single center studies and they are difficult to interpret due
to the different techniques employed for haploidentical donor selection and graft manipula‐
tion. A recent study compared the results of two large parallel clinical trials: one, using
haploidentical donors with in vivo treatment of the recipient with post transplant high dose
cyclophosphamide ; two, using a double 0 to 2 antigen mismatched cord blood graft [44]. One
year survival in both groups was similar around 50%. Nevertheless large differences in
outcome were noted: non relapse mortality was higher in the cord blood group (24% vs. 7%)
but relapse was lower (31% vs. 45%).
Different considerations apply for patients with nonmalignant disease. The emphasis is put
on engraftment, quick immune recovery and avoidance of graft versus host disease. In this
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them to single cord blood unit recipients. Transplant related mortality, leukemia free survival
and overall survivals were almost identical among cord blood recipients and mismatched
unrelated donor recipients. Overall survival 43-44%, a significant improvement from previous
studies.
Trying to address the question whether a more mismatched stem-cell source will give better
disease control due to a potential increased graft versus leukemia effect, Zhang 50 et al
compared leukemia free and overall survival among 348 children with leukemia registered
with CIBMTR who were transplanted with unrelated donor bone marrow, unrelated cord
blood and HLA-matched sibling bone marrow. 3-year leukemia free survival was comparable
among all groups, despite higher risks of acute and chronic GVHD after unrelated donor
transplantation and higher non relapse mortality after mismatched unrelated donor BM and
cord blood transplantation. The pattern of treatment failure differed by donor type. Whereas
nonrelapse mortality was higher after unrelated donor transplantation, they observed a higher,
but not statistically significant, risk of relapse after HLA-matched sibling donor transplanta‐
tion. A logical conclusion to this and other reports is that as transplant related mortality is
curbed with better control on infections, a more mismatched graft may be better for high risk
leukemia. Similar results were published previously by Minnesota group [51]comparing single
center transplant outcomes by HSC source for children less than 18 years with ALL in second
complete remission. In a more limited sample of patients, their results also suggest that
transplant outcomes are remarkably similar in recipients of matched sibling, matched unre‐
lated or umbilical cord donor grafts.
Very few studies have compared outcomes of unrelated donors with haploidentical trans‐
plantation. Most reports come from single center studies and they are difficult to interpret due
to the different techniques employed for haploidentical donor selection and graft manipula‐
tion. A recent study compared the results of two large parallel clinical trials: one, using
haploidentical donors with in vivo treatment of the recipient with post transplant high dose
cyclophosphamide ; two, using a double 0 to 2 antigen mismatched cord blood graft [44]. One
year survival in both groups was similar around 50%. Nevertheless large differences in
outcome were noted: non relapse mortality was higher in the cord blood group (24% vs. 7%)
but relapse was lower (31% vs. 45%).
Different considerations apply for patients with nonmalignant disease. The emphasis is put
on engraftment, quick immune recovery and avoidance of graft versus host disease. In this
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regard most patients can wait and receive alternative therapy until a suitable donor is found
and therefore the search process can be prolonged as much as needed. In some cases the
transplant has to proceed more urgently to avoid organ damage, chronic blood transfusion or
repeated infections. As most patients with nonmalignant diseases are children a well matched
cord blood unit is usually available for almost every patient. The challenge of cord blood
transplantation in children with nonmalignant diseases is that with the exception of severe
immune deficiencies, the rate of graft failure is much higher than those with leukemia, making
strict HLA matching more necessary [52]. A plausible explanation is that children with
leukemia almost always receive chemotherapy to induce a remission before transplantation
so their immune system is greatly impaired before they start the transplant conditioning
regimen. Total body radiation is also extensively used in transplantation for malignancy
resulting in complete lymphodepletion in this patient population. Moreover patients with
nonmalignant disease usually receive either anti thymocyte globulin or as part of their
conditioning regimen to prevent graft versus host procedure. An approach that would merit
consideration is the delivery of chemotherapy which in itself prolongs or hampers immune
reconstitution.
9. Donor search in Chile: Progress in a developing country
Several shortcomings apply to the development of transplant programs in developing
countries. Lack of resources, shortage of trained staff and poor understanding of the benefits
of transplantation by the medical community all play into this reality. In 2010 WMDA reported
that out of the 4054 unrelated cord blood units that were shipped worldwide, 2706 were
provided by Europe, Australia and North America, 1324 by all Asia, and only 24 by South
America and none by Africa. Only 206 were transplanted in South America, a continent that
harbors more than 300 million inhabitants.
In Chile our transplant program was started in 1989 with sibling donors. As we were able to
successfully treat patients, the problem of those without a family match became compelling.
Our initial efforts to conduct searches for unrelated donors in the international registries were
hampered by the difficulty of implementing high quality HLA typing in our country, the
relatively small size of the donor pool and the restrictive policy of most international registries
in Europe and the US to work with transplant centers outside their network. This reality
changed in 1996 when Cord Blood Banks were implemented and the first procedures using
this source were done worldwide. Despite the initial small number of cord units started at that
time, we were able to find one or two antigen mismatched cord blood units for most of our
patients and through collaboration with the National Cord Blood Program in New York the
first procedures were done in 1997. Discouraged by poor results and high transplant related
mortality mainly caused by infection we decided to consider 0 to 1 antigen mismatched cord
blood units only. Initially we could only find such a donor for 50% of our patients [53], but
that percentage increased steadily during the next years. Cord blood transplantation gave us
the initial experience we needed and in 2009 our program started to recur to unrelated adult
donors facilitated first through NMDP and latter by registries and cord blood banks in the US,
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Germany, Spain, France, Italy, Netherlands, Australia among others. In the last 4 years the
proportion of unrelated donor transplants doubled the matched sibling procedures. A recent
review of our data showed that out of 108 completed unrelated donor searches we were able
to identify a fully matched adult donor in 18 patients, and a 0 to 1 antigen mismatched cord
blood unit with > 3x 107 cells /kg in 73 patients (84% of the total). In only 9 patients we were
not able to find a suitable donor, most of them adults. In summary, despite our mixed native
American and Spanish ascent almost all our patients in Chile are able to identify an unrelated
donor for stem cell transplantation.
10. Conclusion
Substantial biases in donor selection are the result of center preference and it is not forthcoming
that controlled clinical trials will be conducted to demonstrate superiority of one source above
the other. On the other hand much work is being carried to improve the donor pool in all three
donor sources:
1. As registries continue to expand the chances for patients with uncommon HLA alleles to
find a donor will improve steadily, especially for those from ethnic communities under‐
represented in the registries
2. Work in expanding cord blood cells and understanding and manipulating their homing
properties will result in safer transplantation of larger amounts of cells and faster
hematopoietic reconstitution.
3. Groups developing haploidentical transplantation have worked hard in graft manipula‐
tion testing strategies of adding back alloreactive lymphocytes to reduce the risk of relapse
while maintaining a low incidence of graft versus host disease.
In this scenario transplant physicians will be confronted with multiple choices when they plan
a procedure in a patient lacking a sibling donor, especially when they are able to find highly
matched adult volunteers, cord blood units of high quality and ever better matched with the
patient, and the infrastructure and experience to perform haploidentical transplantation. In an
ideal world where all of them are available, the disease and stage, the age of the patient and
the perceived or proven risk for a prolonged or partial immune reconstitution will come into
play.
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regard most patients can wait and receive alternative therapy until a suitable donor is found
and therefore the search process can be prolonged as much as needed. In some cases the
transplant has to proceed more urgently to avoid organ damage, chronic blood transfusion or
repeated infections. As most patients with nonmalignant diseases are children a well matched
cord blood unit is usually available for almost every patient. The challenge of cord blood
transplantation in children with nonmalignant diseases is that with the exception of severe
immune deficiencies, the rate of graft failure is much higher than those with leukemia, making
strict HLA matching more necessary [52]. A plausible explanation is that children with
leukemia almost always receive chemotherapy to induce a remission before transplantation
so their immune system is greatly impaired before they start the transplant conditioning
regimen. Total body radiation is also extensively used in transplantation for malignancy
resulting in complete lymphodepletion in this patient population. Moreover patients with
nonmalignant disease usually receive either anti thymocyte globulin or as part of their
conditioning regimen to prevent graft versus host procedure. An approach that would merit
consideration is the delivery of chemotherapy which in itself prolongs or hampers immune
reconstitution.
9. Donor search in Chile: Progress in a developing country
Several shortcomings apply to the development of transplant programs in developing
countries. Lack of resources, shortage of trained staff and poor understanding of the benefits
of transplantation by the medical community all play into this reality. In 2010 WMDA reported
that out of the 4054 unrelated cord blood units that were shipped worldwide, 2706 were
provided by Europe, Australia and North America, 1324 by all Asia, and only 24 by South
America and none by Africa. Only 206 were transplanted in South America, a continent that
harbors more than 300 million inhabitants.
In Chile our transplant program was started in 1989 with sibling donors. As we were able to
successfully treat patients, the problem of those without a family match became compelling.
Our initial efforts to conduct searches for unrelated donors in the international registries were
hampered by the difficulty of implementing high quality HLA typing in our country, the
relatively small size of the donor pool and the restrictive policy of most international registries
in Europe and the US to work with transplant centers outside their network. This reality
changed in 1996 when Cord Blood Banks were implemented and the first procedures using
this source were done worldwide. Despite the initial small number of cord units started at that
time, we were able to find one or two antigen mismatched cord blood units for most of our
patients and through collaboration with the National Cord Blood Program in New York the
first procedures were done in 1997. Discouraged by poor results and high transplant related
mortality mainly caused by infection we decided to consider 0 to 1 antigen mismatched cord
blood units only. Initially we could only find such a donor for 50% of our patients [53], but
that percentage increased steadily during the next years. Cord blood transplantation gave us
the initial experience we needed and in 2009 our program started to recur to unrelated adult
donors facilitated first through NMDP and latter by registries and cord blood banks in the US,
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Germany, Spain, France, Italy, Netherlands, Australia among others. In the last 4 years the
proportion of unrelated donor transplants doubled the matched sibling procedures. A recent
review of our data showed that out of 108 completed unrelated donor searches we were able
to identify a fully matched adult donor in 18 patients, and a 0 to 1 antigen mismatched cord
blood unit with > 3x 107 cells /kg in 73 patients (84% of the total). In only 9 patients we were
not able to find a suitable donor, most of them adults. In summary, despite our mixed native
American and Spanish ascent almost all our patients in Chile are able to identify an unrelated
donor for stem cell transplantation.
10. Conclusion
Substantial biases in donor selection are the result of center preference and it is not forthcoming
that controlled clinical trials will be conducted to demonstrate superiority of one source above
the other. On the other hand much work is being carried to improve the donor pool in all three
donor sources:
1. As registries continue to expand the chances for patients with uncommon HLA alleles to
find a donor will improve steadily, especially for those from ethnic communities under‐
represented in the registries
2. Work in expanding cord blood cells and understanding and manipulating their homing
properties will result in safer transplantation of larger amounts of cells and faster
hematopoietic reconstitution.
3. Groups developing haploidentical transplantation have worked hard in graft manipula‐
tion testing strategies of adding back alloreactive lymphocytes to reduce the risk of relapse
while maintaining a low incidence of graft versus host disease.
In this scenario transplant physicians will be confronted with multiple choices when they plan
a procedure in a patient lacking a sibling donor, especially when they are able to find highly
matched adult volunteers, cord blood units of high quality and ever better matched with the
patient, and the infrastructure and experience to perform haploidentical transplantation. In an
ideal world where all of them are available, the disease and stage, the age of the patient and
the perceived or proven risk for a prolonged or partial immune reconstitution will come into
play.
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